1 	|BT| (S (ADVP (RB Intriguingly)) (, ,) (NP (NN ZKSCAN3) (NN protein)) (ADVP (RB also)) (VP (VBD expressed) (NP (NP (NP (NN tumor) (JJ wild-type) (NN gene)) (PRN (-LRB- -LRB-) (NP (NP (NN APC)) (, ,) (NP (NN p53)) (, ,) (NP (NN K-Ras))) (-RRB- -RRB-))) (RRC (ADVP (RB commonly)) (NP (VBN targeted) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 7:D12.776 8:C04|ES| 1:1 2:1 3:1 4:1 5:1 6:1 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 15:1 16:1 17:1 18:1 19:1
1 	|BT| (S (NP (NN Notch-1) (NN Notch-4) (JJ potent) (NN breast) (NN oncogene)) (VP (VBN overexpressed) (NP (JJ triple-negative) (NNS subtypes) (NN breast) (NN cancer)))) |ET| |BS|9:G05.360.340.024.340.375.500 10:A01.236|ES| 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1
1 	|BT| (S (NP (NP (ADVP (RB Surprisingly)) (, ,) (VBN given) (VBN proposed) (NN role) (NN loss) (NN function) (NN mutation) (NN p53) (NN gene) (NN development)) (NP (JJ human) (JJ colorectal) (NN cancer)) (, ,)) (VP (VBD found) (NP (NP (NN evidence)) (PP (CC either) (NP (NP (NN increase) (NN rate) (NN adenoma) (NN formation) (NN APC)) (CC +) (: /) (: -) (, ,) (NP (NN p53) (: -)) (: /) (FRAG (: -) (NP (NP (NN animal)) (, ,) (NP (NP (VBD increased) (NN rate) (NN progression) (NN malignancy)) (VP (VBN compared) (NP (NP (NN APC)) (NP (CC +) (: /) (: -) (NN p53) (CC +) (FRAG (: /) (CC +) (NP (NN mouse)))))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495|ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1
1 	|BT| (S (NP (NNS Tumors)) (VP (VBD graded) (NP (NP (NN histology) (JJ immunostained) (NN p53)) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli)) (, ,) (NP (NN beta-catenin)) (, ,) (NP (NP (NP (NN cyclooxygenase-2) (-LRB- -LRB-) (NN Cox-2) (-RRB- -RRB-) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-))) (VBN sequenced) (NN p53) (NN mutation))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 8:C04 18:G05.365.590 21:G05.360.340.024.340.375.249.050 22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 28:H01.158.100.656|ES| 2:1 10:1 12:1 14:1 19:1 34:1 53:1 54:1 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1
1 	|BT| (S (NP (DT A) (NN TRAMP/COX) (CD -2) (JJ knockout) (NN mouse) (NN model)) (ADVP (RB also)) (VP (VBD generated) (VP (VB determine) (NP (NN effect) (NN loss) (NN COX-2) (NN gene) (NN prostate) (NN tumorigenesis) (NN TRAMP) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 34:A05.360.444.575|ES| 5:1 9:1 19:1 32:1 52:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1
1 	|BT| (NP (NP (JJ Aberrant) (NN methylation) (NN SPARC) (NN gene) (NN promoter) (JJ clinical) (NN implication) (JJ gastric) (NN cancer))) |ET| |BS|35:G02.111.570.080.689.675 36:G02.111.087.029.538 37:D12.776.157.125.715|ES| 9:1 18:1 19:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1
1 	|BT| (NP (NP (NP (NN Activation) (JJ p53-dependent) (NN apoptosis) (JJ acute) (NN ablation) (NN glycogen) (NN synthase) (NN kinase-3beta)) (NP (JJ colorectal) (NN cancer) (NN cell)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11|ES| 17:1 18:1 19:1 66:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1
1 	|BT| (S (NP (JJ Aldo-keto) (NN reductase) (NN family) (CD 1) (NN B10) (NN gene) (NN silencing)) (VP (VBP result) (NP (NP (NN growth) (NN inhibition) (JJ colorectal) (NN cancer) (NN cell)) (: :) (NP (NP (NN Implication) (NN cancer)) (NN intervention))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 42:G05.355.315.203.374 43:F01.145.544 44:F01.829.263 45:G07.700.320.249|ES| 9:1 17:1 18:1 19:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1
1 	|BT| (FRAG (SBAR (IN Although) (S (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (ADVP (RB morphologically)) (VP (VBZ resembles) (NP (NP (NN colon)) (, ,) (NP (NN CDX2) (NN expression))) (NP (ADJP (RB apparently) (JJR lower)) (JJ normal) (NN colon)))))) |ET| |BS|46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589|ES| 2:1 19:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1
1 	|BT| (S (NP (NN Analysis) (JJ colorectal) (NN cancer) (NN patient) (NN cohort)) (VP (VBZ establishes) (SBAR (S (NP (NN HNF4alpha)) (ADVP (RB significantly)) (VP (VBD upregulated) (NP (VBN compared) (NP (JJ adjacent) (JJ normal) (JJ epithelial) (NN resection)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 49:E05.318.760.500.750 50:M01.643|ES| 17:1 18:1 19:1 50:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1
1 	|BT| (S (NP (NN Animal) (NN breast) (NN colon) (NN tumor) (NN therapy) (NN study)) (VP (VBD showed) (SBAR (S (NP (JJ 15-PGDH) (NN gene) (NN therapy)) (VP (VBD produced) (NP (JJ significant) (NN delay) (NN 2LMP) (NN LS174T) (NN tumor) (NN growth))))))) |ET| |BS|8:C04 10:A01.236 19:B01.050 45:G07.700.320.249 51:C04.588.274.476.411.307.180 52:E02|ES| 7:1 9:1 19:1 23:1 102:1 113:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1
1 	|BT| (S (NP (NN Antagonism) (NN miR-221) (NN miR-222)) (VP (VBZ reduces) (NP (NN growth) (NN colon) (NN tumor) (NN mouse) (NN colitis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 51:C04.588.274.476.411.307.180 53:C06.405.205.265|ES| 7:1 19:1 52:1 102:1 113:1 139:1 140:1 141:1 142:1 143:1
1 	|BT| (S (NP (NP (JJ Antisense) (NNS oligodeoxynucleotides) (JJ human) (NN superoxide) (NN dismutase) (CD 2)) (CC and/or) (NP (JJ ectopic) (NN bcl-2) (NN overexpression))) (VP (VBD avoided) (NP (NP (NNS polyphenols)) (SBAR (S (NP (JJ chemoradiotherapy-induced) (JJ colorectal) (NN cancer) (NN elimination)) (VP (VBD showed) (NP (NP (JJ mangano-type) (NN superoxide) (NN dismutase) (NN Bcl-2) (JJ key) (NN target) (JJ molecular) (NN mechanism)) (VP (VBN activated) (NP (JJ combined) (NN application) (NN t-PTER) (NNP QUER)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 57:D13.695.578.424.450 58:D08.811.682.881 59:E02.186.079|ES| 17:1 18:1 19:1 36:1 132:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1
1 	|BT| (FRAG (PP (IN As) (NP (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (VP (VBN associated) (NP (NP (JJR higher) (NN risk) (JJ gastric) (NN cancer)) (, ,) (NP (JJR lower) (NN CDX2) (NN expression)) (VP (VBD compared) (NP (NP (JJ complete) (JJ intestinal) (NN metaplasia) (JJ normal) (NN colon) (NN epithelium)) (VP (VBN resolved) (NP (NP (JJ current) (NN contradiction) (JJ tumor-suppressive) (NN role)) (NN CDX2) (NN colon) (JJ high) (NN prevalence) (NN CDX2) (JJ intestinal) (NN metaplasia)))))))))) |ET| |BS|8:C04 15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 60:E05.318.308.985.525.750 61:E05.318.740.600.800 62:A10.272|ES| 2:1 18:1 19:1 31:1 50:1 86:1 108:1 109:1 110:1 113:1 114:1 115:1 117:1 118:1 168:1 169:1 170:1 171:1 172:1 173:1 174:1 175:1 176:1 177:1 178:1 179:1
1 	|BT| (S (PP (IN As) (NP (JJ key) (NN molecule) (NN drive) (NN progression) (NN chemoresistance) (JJ gastrointestinal) (NN cancer))) (, ,) (NP (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN HER2)) (VP (VBP become) (NP (JJ efficacious) (NN drug) (NN target) (NN setting)))) |ET| |BS|16:C23.550.291.656 63:G05.360.340.024.340.375.500.791.295.305 64:D08.811.913.696.620.682.725.400.009.300 65:D08.811.913.696.620.682.725.400.009.400 66:F01.658.293 67:D26|ES| 2:1 10:1 14:1 18:1 19:1 48:1 102:1 159:1 160:1 168:1 180:1 181:1 182:1 183:1 184:1 185:1 186:1 187:1 188:1 189:1 190:1 191:1 192:1
1 	|BT| (S (NP (NP (NP (NN Beta-catenin/T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN Tcf)) (-RRB- -RRB-))) (NN signaling)) (NP (RB constitutively) (JJ active) (NN majority) (JJ human) (JJ colorectal) (NN cancer)) (, ,) (VP (VBG accompanying) (NP (NN change) (NN Bcl-2) (NN expression)))) |ET| |BS|4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800|ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1
1 	|BT| (S (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD decreased) (NP (NP (JJ human) (JJ gastric) (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN dysplasia) (NN cancer))))) |ET| |BS|47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 201:1 202:1 203:1
1 	|BT| (S (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD decreased) (NP (NP (JJ human) (JJ gastric) (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN dysplasia) (NN cancer))))) |ET| |BS|33:C04.697.098 47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 159:1 201:1 202:1 203:1 204:1 205:1 206:1 207:1
1 	|BT| (S (NP (NN CDX2) (NN expression)) (VP (ADVP (RB significantly)) (VBD decreased) (NP (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (, ,) (NP (VBP express) (NP (NP (JJ gastric) (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC5AC) (NN MUC6)) (-RRB- -RRB-))) (JJ intestinal) (NP (NP (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC2)) (-RRB- -RRB-)))) (, ,)) (VP (VBD compared) (NP (JJ complete) (JJ intestinal) (NN metaplasia))) (, ,) (S (VP (VBP express) (NP (NP (JJ intestinal) (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC2)) (-RRB- -RRB-))))))) |ET| |BS|47:A03.556.124 48:C23.550.589 71:D12.776.395.560.631 72:D12.776.395.560.631.100|ES| 2:1 10:1 14:1 19:1 50:1 86:1 108:1 109:1 110:1 114:1 115:1 124:1 172:1 202:1 208:1 209:1 210:1 211:1 212:1
1 	|BT| (S (S (NP (NN Cdx2)) (VP (VBZ induces) (NP (NN differentiation) (JJ intestinal) (JJ epithelial) (NN cell) (NN vitro)))) (: ;) (S (ADVP (RB therefore)) (, ,) (VP (VBD sought) (VP (VB establish) (SBAR (IN whether) (S (NP (JJ causal) (NN relationship)) (VP (VBZ exists) (NP (NN Cdx2) (NN activation) (JJ intestinal) (NN metaplasia))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 73:N05.715.350.200 74:G04.299.151 75:A11.436|ES| 2:1 19:1 94:1 109:1 110:1 127:1 213:1 214:1 215:1 216:1 217:1 218:1 219:1 220:1 221:1 222:1 223:1 224:1 225:1
1 	|BT| (NP (NP (NP (NN CDX2)) (, ,) (NP (NP (JJ human) (NN homologue)) (NP (FW Drosophila) (FW caudal))) (, ,)) (NP (VBN mutated) (NN allele) (NN replication) (NN error) (JJ positive) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 76:B01.050.500.131.617.289.310.250 77:G05.360.340.024.340.030 78:G02.111.087.222|ES| 2:1 17:1 18:1 19:1 36:1 114:1 226:1 227:1 228:1 229:1 230:1 231:1 232:1 233:1
1 	|BT| (S (NP (NP (NN CDX2)) (, ,) (NP (NN master) (NN regulator) (JJ intestinal) (NN phenotype)) (, ,)) (VP (VBN shown) (NP (NN play) (JJ tumor-suppressive) (NN role) (NN colon) (NN cancer)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 51:C04.588.274.476.411.307.180 79:I03.450.642.693 80:G05.695|ES| 2:1 18:1 19:1 31:1 109:1 113:1 114:1 177:1 234:1 235:1 236:1 237:1 238:1
1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (NP (NP (JJ Gastric) (NN expression) (NN Cdx2)) (ADJP (RB alone) (JJ sufficient))) (VP (VBP induce) (NP (JJ intestinal) (NN metaplasia) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 70:A03.556.875.875|ES| 19:1 52:1 104:1 109:1 110:1 115:1 213:1 239:1 240:1 241:1 242:1 243:1
1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN In) (NP (JJ human) (NN CRC) (NN cell))) (, ,) (NP (NN miR-221) (NN miR-222)) (VP (VBP act) (NP (JJ positive) (NN feedback) (NN loop) (NN increase) (NN expression) (NN level) (NN RelA) (NN STAT3)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 82:D12.644.360.024.342.300 83:L01.143.283.425|ES| 2:1 19:1 36:1 40:1 94:1 104:1 115:1 140:1 141:1 233:1 239:1 244:1 245:1 246:1 247:1 248:1 249:1 250:1 251:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (UCP (PP (IN In) (NP (NN mouse))) (, ,) (NP (NP (NN fucosylation) (NN deficiency) (NN lead) (NN colitis) (NN adenocarcinoma)) (, ,) (NP (NN loss) (NN Notch) (NN activation)) (, ,) (NP (NN down-regulation) (NN Hes1))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 84:C04.557.470.200.025 85:G02.111.087.225 86:D01.268.556.435 87:C18.654.521|ES| 2:1 19:1 32:1 52:1 104:1 143:1 225:1 239:1 244:1 252:1 253:1 254:1 255:1 256:1 257:1 258:1
1 	|BT| (S (NP (JJ Correlated) (NN pattern)) (VP (VBN observed) (NP (NP (NN HNF4alpha) (NN Cdx2) (JJ several) (JJ experimental) (NN model) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line)) (: :) (NP (NP (NN xenograft) (JJ nude) (NN mouse)) (, ,) (NP (NN wound) (NN healing) (NN glucose) (NN starvation)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 89:G16.100.856.891 90:C18.654.521.750 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 94:A11.251.210 95:E05.599|ES| 2:1 18:1 19:1 36:1 52:1 72:1 94:1 104:1 113:1 123:1 213:1 259:1 260:1 261:1 262:1 263:1 264:1 265:1 266:1 267:1 268:1 269:1 270:1
1 	|BT| (S (S (NP (NN CRC) (NN patient)) (VP (VBD decreased) (NP (NN level) (NN miR-195-5p) (NN tumor) (NN tissue))) (S (ADVP (RB significantly)) (VP (VBD shortened) (SBAR (S (NP (NN survival)) (VP (VBD revealed) (NP (NP (NP (NN TCGA) (NN colon) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NN COAD)) (-RRB- -RRB-))) (NN dataset) (NN CRC) (NN cohort))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 46:A03.556.124.526.356 50:M01.643 84:C04.557.470.200.025 96:I03.784 97:V02.302 98:A10|ES| 7:1 10:1 14:1 19:1 113:1 120:1 121:1 124:1 202:1 245:1 249:1 255:1 271:1 272:1 273:1 274:1 275:1 276:1 277:1 278:1
1 	|BT| (S (S (VP (VBG Crossing) (NP (NP (NP (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Delta14)) (: /) (CC +) (-RRB- -RRB-))) (NP (NP (NN mouse) (JJ prone) (JJ spontaneous) (JJ intestinal) (NN tumor) (NN development) (NN pCdx2-9LacZ)) (NP (JJ transgenic) (NN mouse) (S (VP (VBG containing) (NP (NN LacZ) (NN reporter) (NN control) (JJ 9.3-kb) (NN Cdx2) (NN promoter))))))))) (VP (VBD showed) (SBAR (S (NP (NN promoter) (NN segment)) (VP (VBZ contains) (NP (NP (NN sequence)) (VP (VBG recapitulating) (NP (NN decrease) (NN Cdx2) (NN expression) (JJ intestinal) (NN cancer))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 26:G02.111.570.080 99:B01.050.050.136.500 100:G05.360.340.024.686.545 101:C04.588.274.476.411 102:C04.588.274.476.411 103:G11.427.695.525|ES| 7:1 10:1 14:1 18:1 19:1 35:1 52:1 83:1 109:1 115:1 132:1 213:1 279:1 280:1 281:1 282:1 283:1 284:1 285:1 286:1 287:1 288:1 289:1 290:1 291:1 292:1 293:1 294:1 295:1
1 	|BT| (S (NP (NN Downregulation) (NN miR-610)) (VP (VBZ promotes) (SBAR (S (NP (NN proliferation) (NN tumorigenicity)) (VP (VBZ activates) (NP (NN Wnt/beta-catenin) (NN signaling) (JJ human) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 105:G02.149.115.800.925|ES| 19:1 36:1 195:1 296:1 297:1 298:1 299:1 300:1 301:1 302:1 303:1 304:1
1 	|BT| (S (NP (JJ Ectopic) (NN expression) (NN miR-139-5p) (NN colon) (NN cancer) (NN cell) (NN line)) (VP (ADVP (RB significantly)) (NP (VBD suppressed) (NP (NP (NN cell) (NN growth) (VBN evidenced) (NN cell) (NN viability) (NN assay)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.001)))) (-RRB- -RRB-))) (NP (NP (NP (NN colony) (NN formation) (NN assay)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))) (NP (NP (NN xenograft) (NN tumor) (NN growth) (JJ nude) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))))))) |ET| |BS|8:C04 20:G03.495 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 107:G05.355.315.202 108:G04.299.316 109:I01.696.116|ES| 7:1 10:1 14:1 18:1 19:1 43:1 52:1 94:1 102:1 113:1 115:1 124:1 264:1 265:1 266:1 305:1 306:1 307:1 308:1 309:1 310:1 311:1 312:1 313:1 314:1 315:1
1 	|BT| (NP (NP (NN Expression) (JJ gut-enriched) (JJ Kruppel-like) (NN factor)) (FRAG (-LRB- -LRB-) (NP (NP (JJ Kruppel-like) (NN factor) (CD 4) (-RRB- -RRB-) (NN gene)) (JJ human) (ADJP (NN colon) (NN cancer) (NN cell) (NN line) (NN RKO) (JJ dependent)) (NN CDX2)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210|ES| 9:1 10:1 14:1 18:1 19:1 36:1 94:1 113:1 114:1 185:1 264:1 316:1 317:1 318:1 319:1 320:1 321:1
1 	|BT| (S (NP (NN Expression) (NN KLK13) (NN KLK14) (NN gene)) (VP (VBN examined) (NP (NP (NN mRNA) (NN protein) (NN level) (NN cohort) (CD 57) (NN patient)) (NP (NP (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 110:C04.588.894.797.520.109.220.249 111:D13.444.735.544 112:D12.776.097.820|ES| 4:1 9:1 10:1 14:1 18:1 19:1 120:1 121:1 249:1 316:1 322:1 323:1 324:1 325:1 326:1 327:1 328:1 329:1
1 	|BT| (S (NP (JJ Further) (NN decrease) (NN CDX2) (NN expression) (JJ gastric) (NN dysplasia) (NN cancer)) (VP (VBZ suggests) (NP (NP (NN CDX2) (NN play) (JJ similar) (JJ anticarcinogenic) (NN role)) (JJ intestinal) (NN metaplasia) (NN colon)))) |ET| |BS|15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 70:A03.556.875.875 79:I03.450.642.693|ES| 18:1 19:1 31:1 86:1 109:1 110:1 113:1 114:1 115:1 203:1 238:1 295:1 330:1 331:1 332:1 333:1
1 	|BT| (FRAG (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ high) (NN uniform) (NN expression) (NN CDX2)) (NP (NP (JJ characteristic) (JJ metastatic) (JJ colorectal) (NN cancer)) (, ,) (NP (ADJP (ADJP (JJ weak)) (CC and/or) (ADJP (JJ focal))) (NN CDX2) (NN expression) (JJ alert) (JJ surgical) (NN pathologist) (NN possibility) (JJ primary) (NN lung) (NN adenocarcinoma)) (, ,) (NP (ADVP (RB especially)) (NN presence) (NN goblet) (NN cell) (NN morphology))))) |ET| |BS|113:C04.697.650 114:J01.637.215 115:E04|ES| 2:1 17:1 18:1 19:1 94:1 114:1 115:1 149:1 178:1 255:1 328:1 334:1 335:1 336:1 337:1 338:1 339:1 340:1 341:1 342:1 343:1 344:1 345:1 346:1 347:1 348:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN Cdx2)) (VP (VBD decreased) (S (VP (VBG knocking) (NP (NN HNF4alpha) (JJ human) (NN colon) (NN cancer) (NN cell)) (S (VP (VBG using) (NP (NN siRNA) (NN colon) (NN mouse))))))) (S (ADVP (RB conditionally)) (VP (VBD knocked) (NP (NN Hnf4alpha) (NN gene) (JJ adult) (NN intestine)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN Hnf4alpha)) (PRN (-LRB- -LRB-) (NP (NN f/f)) (-RRB- -RRB-))) (: ;) (NP (NNP VilCre) (-LRB- -LRB-) (NN ERT2) (-RRB- -RRB-) (NN mouse))) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 41:A11 46:A03.556.124.526.356 47:A03.556.124 55:B01.050.150.900.649.801.400.112.400.400 116:D08.811.913.696.620.682.700.567.249.750 117:D13.150.650.700 118:D01.248.497.158.380 119:M01.060.116|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 52:1 94:1 113:1 123:1 202:1 213:1 217:1 334:1 349:1 350:1 351:1 352:1 353:1 354:1 355:1 356:1 357:1 358:1 359:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ stable) (NN overexpression)) (VP (VBG using) (NP (JJ lentiviral) (NN vector) (NN NCI-H460) (NN A549) (NN cell)))) (VP (VBD inhibited) (NP (NN tumor) (NN xenograft) (NN growth) (JJ immunodeficient) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (ADJP (CD 50) (NN %)) (NN reduction)) (VP (VBN compared) (NP (NN control)) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))) (, ,) (PP (IN whereas) (NP (NP (NP (NN effect) (NN mir-660) (NN overexpression) (JJ absent) (NN H1299)) (, ,) (NP (NP (NN lung) (NN cancer) (NN cell) (NN line)) (VP (VBG lacking) (NP (NN p53) (NN locus))))) (, ,) (NP (ADJP (FW vitro) (FW vivo)) (NN assay))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 120:I01.409.418.750.600.480.150 121:B04.820.650.589 122:C14.280.383 123:G05.360.337 124:C20.673|ES| 2:1 7:1 10:1 12:1 14:1 18:1 19:1 50:1 52:1 75:1 94:1 102:1 152:1 216:1 264:1 265:1 289:1 310:1 328:1 334:1 350:1 360:1 361:1 362:1 363:1 364:1 365:1 366:1 367:1 368:1 369:1 370:1 371:1 372:1 373:1 374:1 375:1 376:1 377:1 378:1
1 	|BT| (S (NP (NN gamma-Secretase) (NN inhibitor)) (VP (VBP abrogate) (NP (NP (JJ oxaliplatin-induced) (NN activation) (NN Notch-1) (NN signaling) (NN pathway) (NN colon) (NN cancer) (NN cell)) (VP (VBG resulting) (NP (VBN enhanced) (NN chemosensitivity)))))) |ET| |BS|41:A11 69:G02.111.087.800 125:D08.811.277.656.300.032 126:G02.111.087.800|ES| 18:1 19:1 20:1 94:1 113:1 195:1 225:1 379:1 380:1 381:1 382:1 383:1 384:1 385:1 386:1
1 	|BT| (NP (NP (NP (NN Germline) (JJ somatic) (NN mutation) (NN BER) (NN gene)) (, ,) (NP (NP (NN MutY) (NN Homolog)) (PRN (-LRB- -LRB-) (NP (NN MUTYH/MYH)) (-RRB- -RRB-))) (NP (NP (JJ DNA-directed) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN POLB)) (-RRB- -RRB-))) (, ,)) (NP (VBN associated) (VBN increased) (NN risk) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 61:E05.318.740.600.800 127:D08.811.913.696.445.308.300 128:E02.095.301 129:G02.111.087.219 130:A05.360.490|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 34:1 47:1 169:1 171:1 387:1 388:1 389:1 390:1 391:1 392:1 393:1 394:1 395:1
1 	|BT| (S (NP (NN HDAC8) (NN STAT3)) (VP (VBP repress) (NP (NN BMF) (NN gene) (NN activity) (NN colon) (NN cancer) (NN cell)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 41:A11 46:A03.556.124.526.356 82:D12.644.360.024.342.300|ES| 9:1 18:1 19:1 94:1 113:1 251:1 396:1 397:1 398:1 399:1
1 	|BT| (NP (NP (ADJP (RB Here) (VBN studied)) (NN role) (NN HNF4alpha) (NN mechanism) (NN deregulation) (NN Cdx2) (NN colon) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1
1 	|BT| (S (NP (ADJP (RB Here) (VBN investigated)) (NP (NN role) (NN Bcl-3) (NN azoxymethane/dextran) (NN sulfate) (NN sodium)) (PRN (-LRB- -LRB-) (NP (NN AOM/DSS)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NP (NN colon) (NN tumor)) (, ,) (NP (NN mouse) (NN model) (JJ colitis-associated) (JJ colorectal) (NN cancer)) (JJ human)))) |ET| |BS|4:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 51:C04.588.274.476.411.307.180 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 131:D09.698.365.272.300 132:D02.172.080|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 52:1 72:1 113:1 400:1 403:1 404:1 405:1 406:1 407:1 408:1 409:1 410:1
1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBD investigated) (NP (NP (NN cell) (NN death) (NN signaling) (NN mechanism)) (VP (VBD induced) (NP (NN PGG) (JJ human) (NN prostate) (NN cancer) (NN cell) (JJ different) (NN p53) (JJ functional) (NN status)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 133:D01.248.497.158.685.750.744.600 134:G04.299.139 135:C23.550.260|ES| 2:1 12:1 18:1 19:1 36:1 77:1 94:1 162:1 195:1 400:1 403:1 411:1 412:1 413:1 414:1 415:1 416:1
1 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (NP (NN report) (ADJP (RB inversely) (JJ related)) (NN expression) (NN miR-137) (NN CAR) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell)) (, ,) (SBAR (WHADVP (WRB wherein)) (S (NP (NN miR-137)) (VP (VBD downregulated) (NP (JJ resistant) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100|ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1
1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBP show) (SBAR (S (NP (NNP NANOG)) (VP (VBD expressed) (NP (NP (NN NANOG1) (NN NANOGP8) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-)))))))) |ET| |BS|4:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 6:1 10:1 14:1 17:1 18:1 19:1 36:1 245:1 428:1 429:1 430:1 431:1 432:1
1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (JJ molecular) (NN detail)) (VP (VBG underlying) (NP (NP (NN miR-146a) (JJ mediated) (NN regulation) (NN target) (NN gene) (JJ precise) (JJ biological) (NN function) (NN cancer)) (, ,) (NP (NP (RB especially) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) (VP (VBZ remains) (ADJP (JJ unclear)))) |ET| |BS|104:C04.557.470.200.025.255 140:G05.355.315 141:G16.100|ES| 2:1 9:1 10:1 14:1 18:1 19:1 33:1 160:1 161:1 303:1 304:1 345:1 433:1 434:1 435:1 436:1 437:1 438:1 439:1 440:1 441:1 442:1 443:1
1 	|BT| (NP (NP (NP (NP (JJ Human) (NN CRC) (NN tissue)) (NP (JJR higher) (NN level) (NN miR-221) (NN miR-222) (JJ nontumor) (NN colon) (NN tissue))) (: ;) (NP (NN increase)) (VP (VBD correlated) (NP (VBN increased) (NN level) (NN RelA) (NN STAT3) (NNS mRNAs))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544|ES| 19:1 40:1 47:1 113:1 140:1 141:1 170:1 217:1 245:1 249:1 250:1 251:1 272:1 444:1 445:1 446:1 447:1
1 	|BT| (S (NP (NN Hypermethylation) (NN miR-137) (NN promoter) (JJ negative) (NN regulation) (NN miR-137) (NN CAR)) (VP (VP (VBP contribute) (NP (NP (NN part)) (VP (VBD reduced) (NP (NN miR-137) (NN expression))))) (VP (VBD increased) (NP (NN CAR) (NN MDR1) (NN expression) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 142:I01.880.604|ES| 19:1 47:1 83:1 94:1 115:1 420:1 421:1 423:1 424:1 438:1 448:1 449:1 450:1 451:1 452:1 453:1
1 	|BT| (NP (NP (NP (NN Immunohistochemistry) (NN beta-catenin)) (, ,) (NP (NN c-myc)) (, ,) (NP (NP (NN Ki-67) (NN TUNEL-staining)) (VP (VBN performed) (VP (VBP investigate) (NP (NP (NN TQ) (POS 's)) (NN effect) (JJ major) (JJ colorectal) (NN cancer) (NN pathway))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475|ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1
1 	|BT| (S (PP (IN In) (NP (JJ nude) (NN mouse) (NN xenograft) (NN model))) (, ,) (NP (NN overexpression) (NN miR-141) (NN knockdown) (NN MAP4K4)) (ADVP (RB significantly)) (VP (VBD repressed) (NP (JJ pancreatic) (NN cancer) (NN cell) (NN growth)))) |ET| |BS|41:A11 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875|ES| 2:1 18:1 19:1 52:1 72:1 94:1 102:1 124:1 152:1 244:1 265:1 266:1 463:1 464:1 465:1 466:1 467:1
1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN PIM) (NN kinase)) (VP (VBP activate) (S (NP (NN MYC) (NN signaling) (NN mRNA) (NN translation) (NN prostate) (NN cancer)) (VP (VBP cooperate) (S (NP (NN MYC)) (VP (VB accelerate) (NP (NN tumorigenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 69:G02.111.087.800 145:G02.111.087.675.871|ES| 2:1 18:1 19:1 77:1 78:1 195:1 244:1 325:1 468:1 469:1 470:1 471:1 472:1 473:1 474:1 475:1
1 	|BT| (S (PP (IN In) (NP (JJ current) (NN report))) (, ,) (VBN used) (S (NP (NN DLD-1) (JJ colorectal) (NN cancer) (NN cell)) (ADVP (RB stably)) (NP (VBN transfected) (NP (NN POX) (NN gene) (NN control) (JJ tetracycline-inducible) (NN promoter))) (VP (VBD found) (SBAR (S (NP (CD three) (NN pathway) (NN cross) (NN talk)) (VP (VBD downregulated) (NP (NP (NN POX)) (: :) (NP (NP (NP (NP (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NN pathway)) (, ,) (NP (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN pathway) (NN Wnt/beta-catenin) (NN pathway)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 23:D12.776.091.249 24:D08.811.600.720.750 41:A11 64:D08.811.913.696.620.682.725.400.009.300 146:D02.455.426.559.847.562.900.875 147:G02.149.115.800.925 148:G12.425.143.281|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 37:1 61:1 76:1 83:1 94:1 102:1 104:1 175:1 184:1 185:1 186:1 187:1 244:1 289:1 302:1 383:1 417:1 426:1 476:1 477:1 478:1 479:1 480:1 481:1 482:1 483:1 484:1
1 	|BT| (NP (NP (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (NN expression) (JJ intestine-specific) (NN transcription) (NN factor) (NN Cdx2)) (, ,) (NP (JJ key) (NN gene) (JJ intestinal) (NN identity)) (VP (VBD downregulated) (NP (NP (JJ invasive) (NN cancer) (NN cell)) (, ,) (VP (VBD reduced) (NP (NN wound) (NN healing) (NN vitro)))))))) |ET| |BS|41:A11 47:A03.556.124 89:G16.100.856.891 149:G05.360.340.024.340.364.875.890|ES| 2:1 9:1 18:1 19:1 94:1 109:1 115:1 159:1 185:1 213:1 216:1 244:1 267:1 268:1 426:1 452:1 485:1 486:1 487:1 488:1 489:1
1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NN colon) (NN cancer) (NN cell)) (VP (MD may) (VP (VB up-regulate) (NP (NN Notch-1) (JJ protective) (NN mechanism) (NN response) (NN chemotherapy))))) |ET| |BS|41:A11 150:Z01.542.248.960 151:E02.319|ES| 2:1 18:1 19:1 20:1 94:1 113:1 162:1 244:1 490:1 491:1 492:1 493:1 494:1 495:1
1 	|BT| (FRAG (PP (IN In) (NP (JJ adult))) (, ,) (NP (NP (JJ Cdx1) (NN Cdx2)) (, ,) (NP (NN Cdx4)) (, ,) (NP (ADJP (RB intensively) (VBN explored)) (NN function) (JJ intestinal) (NN tissue) (NN homeostasis) (NN pathogenesis) (JJ gastrointestinal) (NN cancer)))) |ET| |BS|47:A03.556.124 98:A10 119:M01.060.116 152:G07.700.345|ES| 2:1 18:1 19:1 33:1 109:1 183:1 213:1 244:1 272:1 355:1 496:1 497:1 498:1 499:1 500:1 501:1
1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBP demonstrate) (S (NP (NP (NP (NN histone) (NN deacetylase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN HDACi)) (-RRB- -RRB-))) (NN vorinostat) (NN LBH589)) (VP (ADVP (RB significantly)) (VBP downregulate) (NP (NN TS) (NN gene) (NN expression) (NN panel) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|94:A11.251.210 153:D27.505.519.389.360 154:Z01.058.266.887 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 113:1 115:1 124:1 131:1 244:1 264:1 380:1 502:1 503:1 504:1 505:1 506:1 507:1 508:1 509:1 510:1
1 	|BT| (FRAG (PP (IN In) (NP (NN study))) (, ,) (NP (VBN explored) (NN role) (NN miR-141) (JJ pancreatic) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 2:1 18:1 19:1 31:1 131:1 244:1 463:1 467:1 499:1
1 	|BT| (FRAG (NP (ADVP (FW In) (FW vitro)) (PRN (, ,) (NP (NP (VBN forced) (NN expression) (NN Cdx2) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line)) (SBAR (S (NP (VBN retarded) (NN wound) (NN repair)) (VP (VBD reduced) (NP (NN migration)))))) (, ,))) (SBAR (IN whereas) (S (NP (NN inhibition) (NN Cdx2) (NN expression) (NN RNA) (NN interference)) (VP (VBD enhanced) (NP (NN migration)))))) |ET| |BS|43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 89:G16.100.856.891 94:A11.251.210 122:C14.280.383 156:G05.355.315.203.374.790|ES| 2:1 18:1 19:1 36:1 94:1 103:1 113:1 115:1 213:1 216:1 244:1 264:1 267:1 372:1 385:1 452:1 511:1 512:1 513:1 514:1 515:1 516:1
1 	|BT| (NP (NP (NP (NN Incubation) (NN CRC) (NN cell) (NN miR-221) (NN miR-222) (NN inhibitor)) (SBAR (S (NP (VBD reduced) (NN proliferation) (NN colony) (NN formation)) (VP (VBN compared) (NP (NN control) (NN cell))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 109:I01.696.116|ES| 19:1 43:1 50:1 94:1 140:1 141:1 245:1 289:1 299:1 314:1 380:1 452:1 517:1
1 	|BT| (NP (NP (ADVP (RB Interestingly)) (, ,) (NP (NP (NP (JJ gastric) (NN adenocarcinoma)) (ADJP (RB significantly) (JJ frequent)) (NN Pdx-1-Cre)) (: ;) (NP (NN Smad4) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Trp53) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NP (NP (NN Cdh1) (-LRB- -LRB-) (NN F) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (: /) (CC +) (-RRB- -RRB-))) (NN mouse) (NN Pdx-1-Cre)) (: ;) (NP (NN Smad4) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Trp53) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Cdh1) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-)) (NN mouse)) (, ,) (S (NP (VBG demonstrating) (NN Cdh1) (NN heterozygosity)) (VP (VBZ accelerates) (NP (NN development) (NN progression) (JJ gastric) (NN adenocarcinoma)))) (, ,) (NP (NN combination) (NN loss) (NN Smad4) (NN p53))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 70:A03.556.875.875 84:C04.557.470.200.025 118:D01.248.497.158.380 157:G05.380.383|ES| 2:1 10:1 12:1 14:1 19:1 32:1 35:1 48:1 51:1 52:1 86:1 124:1 217:1 255:1 518:1 519:1 520:1 521:1 522:1 523:1 524:1 525:1 526:1 527:1 528:1 529:1 530:1
1 	|BT| (S (NP (JJ Intestinal) (NN metaplasia) (NN dysplasia) (JJ low) (NN expression) (NN CDX2)) (VP (MD may) (VP (VB serve) (NP (JJ predictive) (NN marker) (JJ gastric) (NN cancer))))) |ET| |BS|47:A03.556.124 48:C23.550.589 158:D23.101|ES| 18:1 19:1 86:1 110:1 114:1 115:1 203:1 204:1 491:1 531:1 532:1 533:1 534:1
1 	|BT| (NP (NP (NN INTRODUCTION)) (: :) (NP (NP (NP (NP (JJ Triple) (JJ negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN TNBC)) (-RRB- -RRB-))) (NP (JJ aggressive) (ADJP (RB currently) (JJ specific)) (JJ therapeutic) (NN target))) (, ,) (NP (NP (NN hormone) (NN receptor) (JJ human) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN type) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN HER2)) (-RRB- -RRB-)))) (: ;) (ADVP (RB therefore)) (, ,) (NP (NN prognosis) (JJ poor))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 159:I01.880.735.634 160:C04.588.180.788 161:D06.472 162:F01.145.126.125 163:E01.789|ES| 2:1 10:1 14:1 18:1 19:1 23:1 36:1 102:1 104:1 148:1 160:1 184:1 185:1 186:1 188:1 217:1 218:1 449:1 535:1 536:1 537:1 538:1 539:1 540:1 541:1 542:1 543:1 544:1 545:1
1 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
1 	|BT| (S (NP (NN LINE-1) (NN methylation)) (VP (VBD decreased) (SBAR (S (NP (NN transition) (JJ intestinal) (NN metaplasia) (JJ gastric) (NN adenoma) (NN decrease)) (VP (VBD occurred) (NP (NN transition) (JJ gastric) (NN adenoma) (NN GC))))))) |ET| |BS|17:C04.557.470.035 36:G02.111.087.029.538 47:A03.556.124 48:C23.550.589 70:A03.556.875.875|ES| 19:1 42:1 81:1 86:1 109:1 110:1 202:1 295:1 551:1 552:1 553:1 554:1
1 	|BT| (S (NP (NP (ADJP (RB Little) (VBN known)) (JJ biological) (NN significance) (NN ELK1)) (, ,) (NP (JJ transcriptional) (NN factor))) (VP (VBZ activates) (NP (NP (JJ downstream) (NN target)) (PP (VBG including) (NP (NP (NN c-fos) (NN proto-oncogene)) (, ,) (NP (NN bladder) (NN cancer))))))) |ET| |BS|165:G05.360.340.024.340.375.500.791.330 166:D12.776.930 167:H01.158.273|ES| 2:1 18:1 19:1 160:1 185:1 301:1 440:1 555:1 556:1 557:1 558:1 559:1 560:1 561:1 562:1 563:1 564:1
1 	|BT| (NP (NP (NNS METHODS) (: :)) (NP (NP (NP (NN CRC) (NN cell) (NN line)) (PRN (-LRB- -LRB-) (NP (NN HCT116) (NN RKO)) (-RRB- -RRB-))) (VP (VBN transfected) (S (NP (NN miR-221) (NN miR-222)) (VP (VBP mimic) (NP (NN inhibitor))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 94:A11.251.210 168:E05.581|ES| 10:1 14:1 19:1 94:1 104:1 140:1 141:1 245:1 264:1 320:1 380:1 479:1 565:1 566:1 567:1
1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (NN Notch) (NN status)) (VP (VBD analysed) (S (VP (VBG studying) (S (NP (NN expression) (NN Notch) (NN effector) (NN Hes1) (NN Notch) (NNS ligands/receptors)) (NP (JJ human) (JJ colorectal) (NP (NP (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NN mouse) (NN model) (NN Apc) (NN mutation)))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 169:D12.776.543.750.725 170:D27.720.470.480|ES| 10:1 14:1 17:1 18:1 19:1 34:1 36:1 52:1 72:1 104:1 115:1 245:1 256:1 258:1 280:1 416:1 565:1 568:1 569:1 570:1 571:1
1 	|BT| (NP (NP (NN Methylation) (NN rate) (NN SPARC) (NN gene)) (NP (NP (CD 80) (NN %)) (NP (CD ten) (JJ gastric) (NN cancer) (NN cell) (NN line)) (NP (NP (CD 74) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 163) (CD 220)) (-RRB- -RRB-))) (NP (JJ primary) (NN tumor))) (, ,) (NP (NP (ADJP (CD 5) (NN %)) (JJ normal) (JJ gastric) (NN mucosa)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 40)))) (-RRB- -RRB-)))) |ET| |BS|8:C04 36:G02.111.087.029.538 37:D12.776.157.125.715 94:A11.251.210 171:E05.318.308.985.775.500 172:A03.556.875.875.440 173:C07.465.864.500|ES| 2:1 7:1 9:1 10:1 14:1 18:1 19:1 41:1 82:1 86:1 94:1 118:1 264:1 344:1 369:1 572:1 573:1 574:1 575:1 576:1 577:1 578:1 579:1 580:1 581:1 582:1
1 	|BT| (FRAG (NP (S (NP (NP (NNS Mice) (NN mutation) (NN mismatch) (NN repair) (NN gene)) (, ,) (NP (NN Msh2) (NN Mlh1)) (, ,)) (VP (VBP exhibit) (S (NP (NN mismatch) (NN repair) (NN defect)) (VP (VBN predisposed) (S (VP (VBG developing) (NP (JJ gastrointestinal) (NN cancer)))))))) (, ,) (NN lymphoma) (NN tumor) (NN organ) (NN system))) |ET| |BS|6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 174:G02.111.087.219.220 175:J01.897.280.500.269 176:C04.557.386|ES| 2:1 7:1 9:1 18:1 19:1 34:1 183:1 513:1 583:1 584:1 585:1 586:1 587:1 588:1 589:1 590:1 591:1 592:1 593:1
1 	|BT| (S (S (NP (NN miR-137) (NN overexpression)) (VP (VBD resulted) (NP (NP (NN downregulation) (NN CAR) (NN protein) (NN mRNA)) (PRN (-LRB- -LRB-) (PP (IN via) (NP (NN mRNA) (NN degradation))) (-RRB- -RRB-))))) (: ;) (S (VBN sensitized) (NP (JJ doxorubicin-resistant) (NN cell) (NN doxorubicin)) (-LRB- -LRB-) (VP (VP (VBN shown) (S (VP (VBN reduced) (NP (NN proliferation))))) (, ,) (VP (VBD increased) (NP (NN apoptosis))) (VP (VBD increased) (NP (JJ G2-phase) (NN cell) (NN cycle) (NN arrest))) (SINV (-RRB- -RRB-) (NP (VBD reduced) (FW vivo) (NN growth) (NN rate) (NN neuroblastoma) (NN xenograft)))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 45:G07.700.320.249 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 111:D13.444.735.544 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 177:G04.299.134.109.500 178:G02.111.780|ES| 2:1 4:1 10:1 14:1 19:1 41:1 47:1 89:1 94:1 102:1 152:1 217:1 237:1 265:1 299:1 325:1 378:1 420:1 421:1 423:1 424:1 452:1 594:1 595:1 596:1 597:1 598:1 599:1 600:1 601:1 602:1
1 	|BT| (S (NP (NN miR-137)) (VP (VBZ regulates) (SBAR (S (NP (JJ constitutive) (NN androstane) (NN receptor)) (VP (VBZ modulates) (NP (NN doxorubicin) (NN sensitivity) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320|ES| 19:1 94:1 186:1 420:1 422:1 423:1 424:1 599:1 603:1 604:1 605:1 606:1 607:1
1 	|BT| (S (NP (NN miR-490-3p)) (VP (VBD exhibited) (NP (NP (JJ progressive) (NN downregulation) (NN gastritis)) (, ,) (NP (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN adenocarcinoma) (NN H))))) |ET| |BS|47:A03.556.124 48:C23.550.589 84:C04.557.470.200.025 85:G02.111.087.225 175:J01.897.280.500.269 179:D01.248.497.300.459.700 180:C06.405.205.697|ES| 2:1 19:1 109:1 110:1 255:1 595:1 608:1 609:1 610:1 611:1 612:1
1 	|BT| (S (NP (NN Mir-660)) (VP (VBD downregulated) (SBAR (S (NP (NN lung) (NN cancer) (NN patient) (NN replacement)) (VP (VBZ inhibits) (NP (NP (NN lung) (NN tumorigenesis)) (VP (VBG targeting) (NP (NN MDM2-p53) (NN interaction))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 50:M01.643 122:C14.280.383 181:E04.936.494 182:A04.411|ES| 18:1 19:1 78:1 120:1 328:1 426:1 613:1 614:1 615:1 616:1 617:1 618:1
1 	|BT| (S (NP (NP (NN miRNA-141)) (, ,) (VP (VBD downregulated) (NP (JJ pancreatic) (NN cancer))) (, ,)) (VP (VBZ inhibits) (NP (NN cell) (NN proliferation) (NN invasion)) (S (VP (ADVP (RB directly)) (VBG targeting) (NP (NN MAP4K4)))))) |ET| |BS|122:C14.280.383 183:G04.299.233.750 184:D13.150.650.319|ES| 2:1 18:1 19:1 94:1 299:1 426:1 465:1 467:1 615:1 616:1 619:1 620:1 621:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (VP (VBD identified) (SBAR (S (NP (NN Usp28) (NN c-MYC) (NN target) (NN gene)) (ADVP (RB highly)) (VBD expressed) (NP (JJ murine) (JJ human) (JJ intestinal) (NN cancer)) (, ,) (VP (VBZ indicates) (SBAR (S (NP (NN USP28) (NN c-MYC) (NN form) (JJ positive) (NN feedback) (NN loop)) (VP (VBZ maintains) (NP (JJ high) (NN c-MYC) (NN protein) (NN level) (NN tumor)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 83:L01.143.283.425 101:C04.588.274.476.411 185:G05.360.340.024.340.375.500.791.420 186:G05.360.340.024.340.375.500.791.420 187:D08.622.705 188:N02.628 189:V02.460|ES| 2:1 4:1 6:1 7:1 9:1 18:1 19:1 36:1 109:1 160:1 178:1 233:1 247:1 248:1 249:1 622:1 623:1 624:1 625:1 626:1 627:1 628:1 629:1 630:1 631:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (JJ gastric) (NN cancer) (JJ human)) (ADVP (RB often)) (VP (VBD preceded) (NP (NP (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN phenotype))) (S (VP (VBD described) (SBAR (S (ADVP (RB strongly)) (VP (VBZ suggests) (NP (NP (NN involvement) (NN Cdx2) (NN initiation) (NN process)) (VBG leading) (JJ intestinal) (NN neoplasia) (JJ gastric) (NN mucosa))))))))) |ET| |BS|47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 86:D01.268.556.435 190:C04.588.274.476.767 191:A03.556.124.369|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 213:1 236:1 331:1 579:1 622:1 632:1 633:1 634:1 635:1 636:1 637:1 638:1 639:1 640:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD reduced) (NP (JJ gastric) (NN dysplasia) (NN cancer)))) |ET| |BS|70:A03.556.875.875|ES| 2:1 18:1 19:1 86:1 114:1 115:1 201:1 203:1 452:1 622:1
1 	|BT| (S (NP (NP (NN Mutation) (NN Pla2g2a)) (, ,) (NP (JJ secretory) (NN phospholipase) (NN A) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (NP (NN gene)) (, ,)) (VP (VP (ADVP (RB dramatically)) (VB increase) (NP (NN number) (JJ intestinal) (NN polyp)) (VP (VB develop) (NP (NP (NP (JJ multiple) (JJ intestinal) (NN neoplasia)) (PRN (-LRB- -LRB-) (NP (NN Min)) (-RRB- -RRB-))) (NN mouse)))) (, ,) (NP (JJ murine) (ADJP (NN model) (JJ adenomatous) (NN polyposis) (NN coli) (JJ human))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411|ES| 2:1 9:1 10:1 14:1 19:1 36:1 40:1 52:1 57:1 58:1 59:1 69:1 72:1 109:1 148:1 627:1 640:1 641:1 642:1 643:1 644:1 645:1 646:1 647:1 648:1 649:1 650:1
1 	|BT| (S (NP (NN Notch1)) (ADVP (RB directly)) (VP (VBD induced) (NP (NN CD133) (NN expression) (JJ human) (JJ diffuse) (NN type) (JJ gastric) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 36:1 86:1 115:1 412:1 543:1 621:1 651:1 652:1 653:1
1 	|BT| (S (NP (NP (CD One) (JJ common) (JJ rate-limiting) (NN mutation)) (JJ human) (NN CRC)) (VP (VBZ occurs) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750|ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1
1 	|BT| (S (NP (PRP$ Our) (NP (NP (JJ recent) (JJ global) (NN analysis) (NN CpG) (NN island) (NN hypermethylation) (NN gene) (NN expression) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD revealed) (S (NP (NN SOX17) (NN gene) (NN silencing)) (NP (VBN associated) (NN DNA) (NN hypermethylation) (NN CpG) (NN island) (NN promoter) (NN region))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 94:A11.251.210 155:G05.355.310 195:G02.111.570.080.380.160 196:G02.111.570.080.689.675 197:A01.456.505.420 198:D13.444.308|ES| 9:1 10:1 14:1 17:1 18:1 19:1 83:1 94:1 100:1 115:1 169:1 245:1 264:1 275:1 658:1 659:1 660:1 661:1 662:1 663:1 664:1 665:1 666:1 667:1
1 	|BT| (NP (NP (NP (NN Overexpression) (NN miR-141) (JJ pancreatic) (NN cancer) (NN cell)) (VBD inhibited) (NP (NN cell) (NN proliferation)) (, ,) (NP (NP (NN clonogenicity)) (, ,) (NP (NN invasion)) (: ;) (NP (VBN induced) (NN G1) (NN arrest) (NN apoptosis)) (: ;) (NP (VBN enhanced) (NN chemosensitivity))))) |ET| |BS|39:G04.299.139.160 41:A11 122:C14.280.383 183:G04.299.233.750|ES| 2:1 18:1 19:1 89:1 94:1 217:1 299:1 365:1 385:1 386:1 412:1 463:1 467:1 602:1 620:1 668:1 669:1 670:1
1 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
1 	|BT| (S (NP (NN p53) (NN activation) (NN CRC) (NN cell)) (VP (VBD interfered) (NP (JJ IL-6-induced) (NN invasion) (NN migration)) (PP (IN via) (NP (JJ miR-34a-dependent) (NN downregulation) (NN IL6R) (NN expression))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 201:D12.644.276.374.465.224|ES| 12:1 19:1 94:1 115:1 225:1 245:1 514:1 595:1 596:1 620:1 681:1 682:1 683:1 684:1
1 	|BT| (S (NP (NN Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)) (VP (VP (VBZ induces) (SBAR (S (NP (NN p53)) (VP (VBZ inhibits) (NP (NN STAT3) (NN prostate) (NN cancer) (NN cell) (NN vitro)))))) (VP (VBZ suppresses) (NP (NN prostate) (NN xenograft) (NN tumor) (NN growth)) (FW vivo)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770|ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1
1 	|BT| (NP (NP (NN PURPOSE) (CC AND) (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (NP (NP (DT The) (JJ molecular) (NN mechanism) (NN p14ARF) (NN gene)) (ADJP (JJ altered) (SBAR (S (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (VP (NN complex) (ADJP (JJ unclear)))))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 204:E05.581.500 205:E05.581.500|ES| 9:1 10:1 14:1 18:1 19:1 94:1 104:1 161:1 162:1 328:1 329:1 443:1 687:1 688:1 689:1 690:1 691:1 692:1 693:1 694:1 695:1
1 	|BT| (NP (NP (NP (NN PURPOSE) (: :)) (NN IFITM3) (, ,) (JJ IFN-inducible) (NN gene)) (, ,) (NP (VBN overexpressed) (JJ human) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 9:1 17:1 18:1 19:1 25:1 36:1 104:1 687:1 696:1 697:1
1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (NN MYC) (NN oncogene)) (ADVP (RB frequently)) (VP (VBN overexpressed) (NP (NN prostate) (NN cancer)))) |ET| |BS||ES| 18:1 19:1 24:1 25:1 77:1 104:1 472:1 687:1 691:1 698:1
1 	|BT| (NP (NP (NN Regulation) (NN tumor) (NN suppressor) (NN homeogene) (NN Cdx2) (NN HNF4alpha) (JJ intestinal) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 101:C04.588.274.476.411 142:I01.880.604 206:G05.360.340.024.340.375.249|ES| 7:1 18:1 19:1 109:1 123:1 213:1 699:1 700:1 701:1
1 	|BT| (FRAG (NP (NNS Results)) (VBP show) (NP (NN KLF9) (JJ haploinsufficient) (NN suppressor) (NN colon) (NN tumorigenesis) (NN Apc)) (-LRB- -LRB-) (NP (NP (NP (NP (NN Min)) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN part)) (, ,) (NP (NP (NN repression) (NN ISG15) (NN latter) (POS 's)) (JJ antiapoptotic) (NN function))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 207:G05.365.590.029.530.587 208:F01.393.821|ES| 2:1 10:1 14:1 19:1 33:1 52:1 78:1 113:1 280:1 429:1 451:1 461:1 700:1 702:1 703:1 704:1 705:1 706:1 707:1 708:1 709:1
1 	|BT| (S (NP (NNS RESULTS) (: :)) (VP (ADVP (RB Herein)) (VB provide) (NP (JJ new) (NP (NN evidence) (JJ transcriptional) (NN regulation)) (NN Notch) (NN PEA3) (NN breast) (NN cancer)))) |ET| |BS|142:I01.880.604 209:G02.111.087.847|ES| 18:1 19:1 23:1 38:1 104:1 256:1 428:1 438:1 559:1 710:1 711:1 712:1 713:1
1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (PP (IN In) (NP (NN CRC) (NN cell) (NN line))) (, ,) (VP (VBP mimic) (NP (NN miR-221) (NN miR-222) (VBD activated) (NN NF-kappaB) (NN STAT3)) (, ,) (NP (VBG increasing) (NN expression) (NN miR-221) (NN miR-222))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 82:D12.644.360.024.342.300 94:A11.251.210 210:D12.776.260.600|ES| 2:1 19:1 94:1 104:1 115:1 140:1 141:1 163:1 244:1 245:1 251:1 264:1 567:1 710:1 714:1 715:1
1 	|BT| (S (NP (NN Sil) (NN gene) (NN expression) (NN lung) (NN cancer)) (VP (VBD correlated) (NP (NN expression) (JJ several) (NN kinetochore) (NN check-point) (NN gene) (JJ histopathologic) (JJ mitotic) (NN index)))) |ET| |BS|155:G05.355.310 211:A11.284.430.106.279.345.190.160.165.500 212:E01.370.225.500.385.500|ES| 9:1 18:1 19:1 115:1 262:1 328:1 446:1 716:1 717:1 718:1 719:1 720:1 721:1
1 	|BT| (S (NP (NN Silencing) (NN MLH1)) (VP (ADVP (RB frequently)) (VBN seen) (S (NP (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 213:F02.830.816.964|ES| 17:1 18:1 19:1 698:1 722:1 723:1 724:1 725:1
1 	|BT| (S (ADVP (RB Similarly)) (, ,) (NP (NN treatment) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line) (NN hypomethylating) (NN agent)) (VP (VBZ induces) (NP (NP (JJ differentiation-related) (NN gene)) (, ,) (PP (VBG including) (NP (NN CDX1)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 94:A11.251.210|ES| 2:1 9:1 18:1 19:1 36:1 94:1 113:1 214:1 264:1 546:1 561:1 726:1 727:1 728:1 729:1 730:1
1 	|BT| (S (NP (JJ Sonic) (NN hedgehog) (NN inhibitor)) (VP (VBP prevent) (NP (JJ colitis-associated) (NN cancer)) (FRAG (IN via) (NP (VBN orchestrated) (NN mechanism) (NN IL-6)) (: /) (NP (NP (NN gp130) (NN inhibition)) (, ,) (NP (NN 15-PGDH) (NN induction)) (, ,) (NP (NN Bcl-2) (NN abrogation)) (, ,) (NP (NN tumorsphere) (NN inhibition)))))) |ET| |BS|43:F01.145.544 53:C06.405.205.265 54:G05.360.340.024.340.375.500.791.150 201:D12.644.276.374.465.224 214:B01.050.150.900.649.473.376|ES| 2:1 18:1 19:1 103:1 133:1 158:1 162:1 380:1 410:1 596:1 731:1 732:1 733:1 734:1 735:1 736:1 737:1 738:1
1 	|BT| (S (NP (NN SPDEF)) (VP (VP (VBD inhibited) (NP (NN expression) (JJ beta-catenin-target) (NN gene) (NN mouse) (NN colon) (NN tumor))) (, ,) (VP (VBD interacted) (NP (NP (NN beta-catenin) (NN block) (JJ transcriptional) (NN activity)) (NP (NN CRC) (NN cell) (NN line))) (, ,) (S (VP (VBG resulting) (NP (JJR lower) (NN level) (NN cyclin) (NN D1) (NN c-MYC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 94:A11.251.210 122:C14.280.383 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100|ES| 2:1 7:1 9:1 19:1 52:1 60:1 94:1 113:1 115:1 117:1 245:1 249:1 264:1 365:1 384:1 399:1 559:1 625:1 739:1 740:1 741:1 742:1 743:1 744:1
1 	|BT| (S (NP (JJ Stable) (NN transfection) (NN Ha-ras) (JJ human) (NN colon) (NN cancer) (NN line) (NN CaCo2)) (VP (VBP result) (NP (JJ morphologic) (NN differentiation) (JJ small) (NN bowel) (NN phenotype)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 216:Z01.107.084.900.425 217:E05.393.350.810 218:A03.556.124.684|ES| 18:1 19:1 36:1 101:1 113:1 215:1 236:1 264:1 745:1 746:1 747:1 748:1 749:1 750:1 751:1
1 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1
1 	|BT| (S (NP (DT The) (NN adhesion) (NN molecule) (NN L1CAM)) (VP (VBZ mediates) (S (NP (NN chemoresistance) (NN migration) (NN tumor) (NN cell) (JJ elevated) (NN CRC) (NN tissue)) (NP (VBN associated) (JJ metastatic) (NN spread) (JJ poor) (NN prognosis) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 98:A10 113:C04.697.650 159:I01.880.735.634 163:E01.789 221:D12.776.395.550.200.250.520.578 222:D12.776.395.550.200|ES| 7:1 19:1 94:1 120:1 169:1 180:1 182:1 245:1 272:1 337:1 514:1 544:1 545:1 691:1 753:1 754:1 755:1 756:1 757:1
1 	|BT| (S (NP (DT The) (NN analysis) (JJ clinical) (JJ characteristic)) (VP (VBD showed) (SBAR (S (NP (NN miR-141)) (ADVP (RB significantly)) (VP (VBD downregulated) (NP (NN tissue) (NN cell) (NN line) (JJ pancreatic) (NN cancer))))))) |ET| |BS|94:A11.251.210 98:A10|ES| 18:1 19:1 84:1 94:1 124:1 132:1 264:1 272:1 336:1 426:1 463:1 467:1 661:1 691:1
1 	|BT| (S (NP (DT The) (JJ apoptosis-inducing) (NN effect) (NN gastrin) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ relates) (NP (NP (VBN increased) (NP (NN IEX-1)) (NN expression)) (VP (VBG mediating) (NP (NP (NN NF-kappa) (NN B)) (NN inhibition)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600|ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1
1 	|BT| (S (NP (DT The) (NN CDX2) (NN expression) (JJ gastric) (NN cancer)) (ADVP (RB also)) (ADVP (RB inversely)) (VP (VBD correlated) (NP (NN expression) (JJ gastric) (NN mucin)))) |ET| |BS|72:D12.776.395.560.631.100|ES| 5:1 18:1 19:1 86:1 114:1 115:1 209:1 418:1 446:1 691:1
1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
1 	|BT| (FRAG (NP (NP (DT The) (NN level) (NN miR-221) (NN miR-222)) (RRC (ADVP (RB well)) (NP (NP (NN RelA)) (, ,) (NP (NN STAT3)) (, ,) (NP (NP (NN PDLIM2) (NNS mRNAs)) (VP (VBN measured) (NP (CD 57) (JJ paired) (NN CRC) (JJ adjacent) (JJ nontumor) (NN tissue) (NN patient)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544 228:E05.978|ES| 2:1 19:1 120:1 126:1 140:1 141:1 245:1 249:1 250:1 251:1 272:1 326:1 445:1 447:1 691:1 787:1 788:1 789:1 790:1
1 	|BT| (NP (NP (DT The) (NN role) (NN KCNQ1) (NN mouse) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 31:1 36:1 52:1 183:1 691:1 791:1
1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (S (NP (NN K-sam) (NN overexpression)) (VP (VBN associated) (NP (JJ malignant) (NN phenotype) (JJ undifferentiated) (NN type) (NN stomach) (NN cancer)))) (, ,) (NP (JJ infiltrative) (NN growth) (NN metastasis)))))) |ET| |BS|45:G07.700.320.249 80:G05.695 113:C04.697.650 231:C04.557.465.625.600.380.590 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 101:1 102:1 152:1 169:1 236:1 543:1 792:1 796:1 801:1 802:1 803:1 804:1 805:1 806:1
1 	|BT| (S (S (NP (DT This) (JJ K-Ras) (NN tumor) (NN phenotype)) (VP (VBN associated) (VP (VBD attenuated) (NP (NN signaling) (NN MAPK) (NN pathway))))) (, ,) (NP (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBG expressing) (NP (NP (JJ mutant) (NN K-Ras) (JJ hypersensitive) (NN inhibition) (NN Raf)) (, ,) (NP (NN Mek))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 80:G05.695 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565|ES| 2:1 7:1 13:1 18:1 19:1 36:1 94:1 103:1 113:1 169:1 195:1 236:1 383:1 807:1 808:1 809:1 810:1 811:1 812:1 813:1 814:1
1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NP (JJ first) (JJ quantitative) (NN analysis) (JJ discrete) (NN CRKI) (NN CRKII) (NN protein) (NNS isoforms)) (SBAR (S (NP (JJ human) (NN lung) (NN tumor)) (VP (VBZ provides) (NP (NN evidence) (NN C-CRK) (NN proto-oncogene)))))) (VP (MD may) (VP (VB foment) (NP (JJ aggressive) (NN phenotype) (NN lung) (NN cancer)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 162:F01.145.126.125 235:G05.360.340.024.340.375.500.791 236:D12.644.360.024.318 237:C04.588.894.797.520 238:D12.776.800|ES| 4:1 7:1 18:1 19:1 36:1 38:1 131:1 236:1 328:1 491:1 538:1 563:1 661:1 807:1 815:1 816:1 817:1 818:1 819:1 820:1 821:1 822:1 823:1
1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
1 	|BT| (S (S (S (VP (TO To) (VP (VB understand) (NP (NN miR-141))))) (VP (VBZ mediates) (NP (NN phenotype) (JJ pancreatic) (NN cancer) (NN cell)))) (S (, ,) (NP (NNS bioinformatics) (NN tool)) (VP (VBN used) (VP (VBP identify) (NP (NN MAP4K4) (JJ potential) (NN target) (NN miR-141)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 80:G05.695 239:F02.463.188.357 240:H01.158.273.180|ES| 2:1 18:1 19:1 94:1 160:1 236:1 463:1 465:1 467:1 476:1 755:1 827:1 828:1 829:1 830:1 831:1 832:1
1 	|BT| (FRAG (PP (TO To) (NP (VB investigate) (NP (NP (NN role) (NN KCNQ1) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN measured) (NN protein) (NN level) (NN KCNQ1) (NN immunohistochemistry) (NN tissue) (NNS microarrays)) (VP (VBG containing) (NP (NP (NN sample) (NN CRC) (NN patient) (NN liver) (NN metastasis)) (VP (VBN undergone) (NP (JJ hepatic) (NN resection))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 228:E05.978 241:D12.776.157.530.400.600.900.124.249.500 242:A03.620|ES| 2:1 4:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 120:1 128:1 245:1 249:1 272:1 286:1 459:1 789:1 791:1 806:1 828:1 833:1 834:1 835:1 836:1 837:1 838:1
1 	|BT| (NP (NP (NP (JJ Transient) (JJ stable) (NN overexpression) (NN mir-660)) (S (VP (VBG using) (S (NP (NN miRNA)) (VP (VBP mimic) (SBAR (S (NP (VBN reduced) (NP (NN migration)) (, ,) (NP (NN invasion)) (, ,) (NP (NN proliferation) (NN property))) (VP (VBD increased) (NP (NP (NN apoptosis) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN cell)) (PRN (-LRB- -LRB-) (NP (NP (NN NCI-H460)) (, ,) (NP (NN LT73)) (, ,) (NP (NN A549))) (-RRB- -RRB-)))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 120:I01.409.418.750.600.480.150 184:D13.150.650.319|ES| 2:1 8:1 10:1 12:1 14:1 18:1 19:1 47:1 89:1 94:1 152:1 299:1 328:1 350:1 360:1 363:1 364:1 373:1 452:1 514:1 567:1 620:1 839:1 840:1 841:1 842:1
1 	|BT| (S (NP (PRP We)) (VP (VBD aimed) (VP (VB investigate) (SBAR (IN whether) (S (NP (NN Notch1) (NN signaling)) (VP (VBZ contributes) (NP (NN carcinogenesis) (JJ gastric) (NN cancer) (NN CD133) (NN induction)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 69:G02.111.087.800|ES| 18:1 19:1 86:1 195:1 207:1 221:1 459:1 651:1 652:1 736:1 843:1 844:1 845:1
1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (JJ biological) (NN function) (NP (NP (JJ related) (JJ molecular) (NN mechanism) (NN PAX5) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 141:G16.100 243:D12.776.260.645.500|ES| 10:1 14:1 19:1 33:1 161:1 162:1 303:1 304:1 324:1 419:1 440:1 441:1 843:1 846:1
1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NN apobec-1) (NN gene) (NN expression) (JJ human) (JJ gastrointestinal) (NN tumor) (NN colon) (JJ cancer-derived) (NN cell) (NN line)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 155:G05.355.310 244:C04.588.274.476|ES| 7:1 9:1 19:1 36:1 94:1 113:1 115:1 183:1 264:1 324:1 843:1 847:1 848:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NN rat) (NN model)) (VP (VBG carrying) (NP (JJ knockout) (NN allele) (NN gatekeeper) (NN gene) (NNP Adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN Apc) (-RRB- -RRB-)))) (VP (VBZ recapitulates) (NP (NP (JJ familial) (NN colon) (NN cancer)) (JJ human) (S (ADVP (RB closely)) (VP (VBG existing) (NP (JJ murine) (NN model)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 77:G05.360.340.024.340.030 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 247:G01.374.676.530 248:E05.393.335.750|ES| 9:1 10:1 14:1 18:1 19:1 36:1 58:1 59:1 71:1 72:1 113:1 221:1 230:1 280:1 403:1 627:1 843:1 849:1 850:1 851:1 852:1 853:1 854:1 855:1 856:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN microRNA) (NN miR-221) (NN miR-222)) (VP (VBP regulate) (NP (NP (NP (NN NF-kappaB) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (NN activation) (JJ human) (NN CRC) (NN cell) (NN line)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 184:D13.150.650.319 210:D12.776.260.600 249:G05.355.315.800 250:E07.305.812|ES| 10:1 14:1 19:1 36:1 94:1 140:1 141:1 221:1 225:1 245:1 251:1 264:1 403:1 487:1 714:1 843:1 857:1 858:1 859:1 860:1 861:1 862:1
1 	|BT| (S (NP (PRP We)) (VP (VBD wanted) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (JJ genetic) (NN defect) (JJ relevant) (JJ colorectal) (NN cancer)) (, ,) (NP (NN Msh2) (NN p53) (NN deficiency)) (, ,)) (VP (MD would) (VP (VB influence) (NP (NN efficiency) (NN sulindac) (NN chemoprevention) (NN increase) (NN side) (NN effect))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 87:C18.654.521 251:D02.455.426.559.847.486.875 252:F02.784.692.351 253:E02.319.162 254:C16.131|ES| 2:1 12:1 17:1 18:1 19:1 40:1 74:1 75:1 221:1 253:1 585:1 588:1 843:1 863:1 864:1 865:1 866:1 867:1 868:1 869:1 870:1 871:1
1 	|BT| (S (NP (NP (NP (NN Western) (NN blot) (JJ quantitative) (JJ real-time) (NN PCR)) (PRN (-LRB- -LRB-) (NP (NN qRT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NN MAP4K4) (NN expression)) (VP (ADVP (RB inversely)) (VBD correlated) (NP (NN miR-141) (NN expression) (JJ pancreatic) (NN cancer) (NN sample) (NN cell) (NN line))))))) |ET| |BS|94:A11.251.210 255:E05.196.401.143 256:E05.196.401.143 257:E05.393.620.500.706|ES| 10:1 14:1 18:1 19:1 94:1 115:1 264:1 275:1 418:1 446:1 463:1 465:1 467:1 661:1 817:1 835:1 872:1 873:1 874:1 875:1 876:1
1 	|BT| (S (NP (NN Western) (NN blot)) (VP (VBD revealed) (NP (NP (NN overexpression) (NN beta-catenin)) (, ,) (NP (NP (NN c-Myc)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (NP (NN cyclooxygenase-2) (NN colon) (NN tumor) (NN sample)))))) |ET| |BS|22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 51:C04.588.274.476.411.307.180 215:D12.644.360.262.150.100 255:E05.196.401.143|ES| 2:1 7:1 19:1 60:1 61:1 63:1 64:1 65:1 66:1 113:1 152:1 275:1 743:1 744:1 824:1 835:1 872:1 873:1
1 	|BT| (S (NP (NN Wnt/beta-catenin) (NN signaling) (JJ critical) (JJ intestinal) (NN cell) (NN proliferation)) (, ,) (VP (VBD decreased) (NP (NN CDX2) (NN expression) (NN influence) (NN Wnt) (JJ signaling-related) (NN gene) (NN progression) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 16:C23.550.291.656 47:A03.556.124 69:G02.111.087.800 105:G02.149.115.800.925 183:G04.299.233.750|ES| 2:1 9:1 17:1 18:1 19:1 48:1 94:1 109:1 114:1 115:1 195:1 202:1 299:1 302:1 825:1 867:1 877:1 878:1
1 	|BT| (S (NP (NN YY1)) (VP (VBZ promotes) (NP (NP (NN colon) (NN cancer) (NN growth)) (VP (VBG inhibiting) (NP (NP (NN p53)) (S (VP (VBG promoting) (NP (NN Wnt) (NN signaling) (NN pathway) (NN serf) (JJ independent) (JJ prognostic) (NN biomarker) (NN CRC) (NN patient))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 45:G07.700.320.249 50:M01.643 122:C14.280.383 147:G02.149.115.800.925 158:D23.101 258:D12.776.260.235.875|ES| 12:1 18:1 19:1 102:1 113:1 120:1 195:1 245:1 298:1 383:1 877:1 879:1 880:1 881:1 882:1 883:1 884:1 885:1
2 	|BT| (S (NP (JJ Genetic) (NN analysis) (NN C/EBPalpha) (NN gene) (NN progress)) (VP (ADVP (RB fully)) (VB evaluate) (NP (ADJP (NN role) (JJ novel)) (NN tumor) (NN suppressor) (NN lung) (NN cancer)))) |ET| |BS|15:F01.829.316.616 206:G05.360.340.024.340.375.249 225:E05.337 259:D12.776.395.240.150.500 260:E01.370.225.562|ES| 7:1 9:1 18:1 19:1 31:1 328:1 661:1 700:1 886:1 887:1 888:1 889:1 890:1 891:1
2 	|BT| (S (NP (JJ Preneoplastic) (JJ neoplastic) (NNS hepatocytes)) (VP (VBP undergo) (NP (NN c-Myc) (NN up-regulation) (NN overgrowth) (NN rat)) (NP (NP (RB genetically) (JJ susceptible) (NN hepatocarcinogenesis)) (, ,) (NP (JJ resistant) (NN rat))))) |ET| |BS|8:C04 142:I01.880.604 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 261:C23.550.291.687.500 262:A11.436.348|ES| 2:1 19:1 427:1 824:1 849:1 892:1 893:1 894:1 895:1 896:1 897:1 898:1 899:1 900:1
2 	|BT| (NP (NP (NP (DT The) (NN HER2/neu) (NN oncogene) (JJ important) (JJ diagnostic) (JJ prognostic) (NN factor)) (NP (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|9:G05.360.340.024.340.375.500 10:A01.236 52:E02 63:G05.360.340.024.340.375.500.791.295.305 263:E01|ES| 18:1 19:1 23:1 24:1 160:1 185:1 541:1 691:1 884:1 901:1 902:1 903:1
2 	|BT| (S (NP (DT A) (JJR better) (NN understanding) (NN mechanism) (NN Cby) (NN gene) (NN activation) (NN LSCC)) (VP (MD could) (VP (VB provide) (NP (JJ potential) (JJ novel) (JJ therapeutic) (NN target) (JJ human) (JJ laryngeal) (NN carcinoma))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 239:F02.463.188.357 259:D12.776.395.240.150.500 264:G05.355.315.800 265:C04.557.470.200 266:E07.695.450 267:A04.329|ES| 9:1 19:1 36:1 69:1 160:1 162:1 225:1 304:1 541:1 711:1 827:1 891:1 904:1 905:1 906:1 907:1 908:1 909:1
2 	|BT| (S (NP (NP (DT A) (JJ functional) (JJ genomic) (NN approach)) (VP (VBG integrating) (NP (NP (NN microarray) (JJ proteomic) (NN analysis)) (VP (VBN done) (NP (NN laboratory)))))) (VP (VBD identified) (NP (JJ 14-3-3zeta) (JJ putative) (NN oncogene)) (WHNP (WHNP (WP$ whose) (NN activation)) (NP (JJ common) (VBN driven) (JJ genomic) (NN amplification) (NN lung) (NN adenocarcinoma))))) |ET| |BS|9:G05.360.340.024.340.375.500 66:F01.658.293 268:H01.158.273.180.350 269:G05.360.340 270:H01.158.201.843 271:N02.278.487|ES| 19:1 24:1 69:1 225:1 255:1 328:1 415:1 623:1 655:1 661:1 910:1 911:1 912:1 913:1 914:1 915:1 916:1 917:1 918:1 919:1 920:1 921:1
2 	|BT| (S (NP (DT A) (NN relationship) (JJ renal) (NN tumor) (NN ASPS)) (ADVP (RB initially)) (VP (VBD suggested) (NP (JJ cytogenetic) (NN finding) (JJ balanced) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;)) (NP (CD q25)) (-RRB- -RRB-) (SBAR (S (NP (NP (CD two) (NN case)) (, ,) (NP (NN ASPL-TFE3) (NN fusion) (NN transcript))) (VP (VBD confirmed) (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction))))))) |ET| |BS|272:E05.393.620.500.725 273:H01.158.273.343.180 274:C04.588.945.947.535 275:C23.888|ES| 2:1 7:1 10:1 14:1 19:1 69:1 217:1 223:1 768:1 922:1 923:1 924:1 925:1 926:1 927:1 928:1 929:1 930:1 931:1 932:1 933:1 934:1 935:1 936:1 937:1 938:1 939:1 940:1 941:1
2 	|BT| (NP (NNS Aberrations) (NP (NP (NP (JJ fragile) (NN histidine) (NN triad)) (PRN (-LRB- -LRB-) (NP (NN FHIT)) (-RRB- -RRB-))) (NN gene) (JJ idiopathic) (JJ pulmonary) (NN fibrosis))) |ET| |BS|6:G05.360.340.024.340 276:C08.381.483.487.500 277:D12.125.072.329|ES| 9:1 10:1 14:1 19:1 942:1 943:1 944:1 945:1 946:1 947:1 948:1 949:1
2 	|BT| (S (NP (VBG Activating) (NP (NN alteration) (NN variety) (JJ potential) (JJ oncogenic) (NN driver) (NN gene))) (ADVP (RB also)) (VP (VBD identified) (NP (NP (NNP NSCLC)) (, ,) (PP (VBG including) (NP (NN ROS1))) (, ,) (NP (NNP RET)) (, ,) (NP (NN MET)) (, ,) (NP (NN HER2)) (, ,) (NP (NN BRAF))))) |ET| |BS|18:G05.365.590 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 110:C04.588.894.797.520.109.220.249 278:D08.811.913.696.620.682.700.559.842.374 279:D27.888.569.100|ES| 2:1 5:1 9:1 19:1 188:1 329:1 561:1 623:1 827:1 950:1 951:1 952:1 953:1 954:1 955:1 956:1 957:1 958:1
2 	|BT| (NP (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB examine) (NP (NN status) (NP (NP (JJ clinical) (NN significance) (JJ anaplastic) (NN lymphoma) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN ALK)) (-RRB- -RRB-))) (NN gene) (NP (NP (NN alteration) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN patient)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 104:C04.557.470.200.025.255|ES| 9:1 10:1 14:1 19:1 84:1 104:1 120:1 303:1 304:1 416:1 441:1 470:1 557:1 591:1 828:1 951:1 959:1 960:1 961:1 962:1
2 	|BT| (NP (NP (NN ALK) (NN gene) (NN copy) (NN number)) (NP (NN gain) (JJ clinical) (NN significance) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 280:G05.380.350|ES| 9:1 19:1 84:1 303:1 304:1 557:1 646:1 962:1 963:1 964:1
2 	|BT| (S (NP (DT All) (NN fusion)) (VP (VBD identified) (SBAR (S (NP (NP (NNP RET) (NN KIF5B) (NN gene)) (, ,) (NP (NP (NNP RET) (NN fusion) (NN CCDC6) (NN NCOA4) (NN gene)) (, ,) (NP (JJ characteristic) (NN thyroid) (NN cancer)) (, ,))) (VP (VBD identified) (NP (JJ irradiated) (NN lung) (NN cell))))))) |ET| |BS|6:G05.360.340.024.340 13:D01.339.387 41:A11 182:A04.411 281:E02.815|ES| 2:1 9:1 18:1 19:1 94:1 328:1 336:1 623:1 936:1 956:1 965:1 966:1 967:1 968:1 969:1 970:1
2 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 36:1 48:1 98:1 115:1 217:1 245:1 556:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1
2 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 15:F01.829.316.616 16:C23.550.291.656 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 239:F02.463.188.357 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 31:1 36:1 48:1 78:1 98:1 115:1 217:1 245:1 433:1 438:1 556:1 889:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1 979:1
2 	|BT| (FRAG (SBAR (IN Although) (S (NP (NP (NP (JJ additional) (NN study) (NN animal) (NN model)) (VP (VBN needed) (, ,))) (VP (VBG finding) (VP (VBP suggest) (S (VP (VBG targeting) (NP (NN HMGA2))))))) (VP (MD could) (SBAR (S (NP (RB therapeutically) (JJ beneficial) (NN lung) (NN cancer) (NN cancer)) (VP (VBD characterized) (NP (VBN increased) (NN HMGA2) (NN expression))))))))) |ET| |BS|283:D12.776.260.312.937 284:N03.349.380.420 285:E05.598|ES| 2:1 18:1 19:1 46:1 47:1 72:1 107:1 115:1 131:1 328:1 616:1 796:1 908:1 927:1 980:1 981:1 982:1 983:1 984:1 985:1
2 	|BT| (FRAG (SBAR (IN Although) (S (NP (NN CTCF)) (VP (VBD described) (NP (NP (NP (ADJP (RB significantly) (VBN mutated)) (NN gene) (JJ endometrial) (NN cancer) (NN TCGA)) (, ,) (NP (NN A) (-LRB- -LRB-) (CD 7) (-RRB- -RRB-) (NN track))) (SBAR (S (NP (JJ variant) (VBG leading) (NN T204) (NNS frameshifts)) (VP (VBD reported))))))))) |ET| |BS|6:G05.360.340.024.340 86:D01.268.556.435 286:C04.588.945.418.948.585 287:G05.365.590.265|ES| 2:1 9:1 10:1 14:1 18:1 19:1 69:1 107:1 124:1 229:1 276:1 634:1 639:1 986:1 987:1 988:1 989:1 990:1 991:1 992:1 993:1
2 	|BT| (S (SBAR (IN Although) (S (NP (NP (NN therapy)) (VP (VBG targeting) (NP (JJ high) (NN EphA1) (NN expression)))) (VP (VBP seem) (NP (JJ plausible) (NN CRC))))) (, ,) (S (NP (NN loss) (NN expression)) (VP (VBD advanced) (NP (NN disease)))) (VP (VBZ suggests) (SBAR (S (NP (NP (NP (JJ potential) (NN risk)) (VBN targeted) (NN therapy)) (, ,) (VP (VBG selecting) (NP (NN loss) (NN expression))) (, ,)) (VP (MD might) (VP (VB contribute) (NP (NN disease) (NN progression)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 61:E05.318.740.600.800 288:C23.550.288|ES| 2:1 16:1 19:1 32:1 48:1 107:1 115:1 130:1 171:1 178:1 245:1 331:1 450:1 616:1 798:1 827:1 994:1 995:1 996:1 997:1 998:1 999:1
2 	|BT| (S (PP (IN Among) (NP (ADJP (RB frequently) (VBN deleted)) (JJ chromosomal) (NN site))) (, ,) (NP (NN LOH) (NN chromosome) (NN 3p)) (VP (VBD detected) (NP (NN MM)) (, ,) (S (VP (VBG suggesting) (S (NP (NN presence)) (NP (CD one) (NP (JJ several) (NN tumour) (NN suppressor) (NN gene) (JJ important) (NN role)) (NN development) (NN disease))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 206:G05.360.340.024.340.375.249 289:A11.284.187 290:G05.365.590.029.530 291:F03.625.421|ES| 2:1 9:1 19:1 31:1 35:1 262:1 346:1 698:1 700:1 902:1 998:1 1000:1 1001:1 1002:1 1003:1 1004:1 1005:1 1006:1 1007:1 1008:1 1009:1 1010:1 1011:1
2 	|BT| (S (NP (NN Amplification) (NN over-expression) (NN MAP3K3) (NN gene) (JJ human) (NN breast) (NN cancer)) (VP (VBZ promotes) (NP (NN formation) (NN survival) (NN breast) (NN cancer) (NN cell)))) |ET| |BS|20:G03.495 55:B01.050.150.900.649.801.400.112.400.400 108:G04.299.316 155:G05.355.310|ES| 9:1 18:1 19:1 23:1 36:1 43:1 94:1 274:1 298:1 1012:1 1013:1 1014:1
2 	|BT| (S (NP (DT An) (JJ integrative) (NN bioinformatics) (NN analysis) (NN region)) (VP (VBN nominated) (NP (NN MAP3K3) (NN gene) (JJ potential) (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 10:A01.236 12:Z01.542.049 52:E02 240:H01.158.273.180 292:Z01|ES| 9:1 18:1 19:1 23:1 160:1 541:1 661:1 667:1 827:1 830:1 1014:1 1015:1 1016:1 1017:1
2 	|BT| (S (NP (NN Analysis) (NN TP53) (NN CTNNB1) (NN gene) (NN mutation)) (NP (NNP HG) (NN component) (NNS MASCs)) (ADVP (RB well)) (NP (NN detection) (NN copy) (NN number) (NN aberration) (NN EGFR) (NN CCND1) (NN gene)) (VP (VBP harbor) (NP (NN abnormality)))) |ET| |BS|6:G05.360.340.024.340 18:G05.365.590 23:D12.776.091.249 254:C16.131 293:D01.268.556.504 294:G05.360.340.024.340.137|ES| 9:1 19:1 34:1 119:1 187:1 646:1 787:1 963:1 1018:1 1019:1 1020:1 1021:1 1022:1 1023:1 1024:1 1025:1 1026:1 1027:1
2 	|BT| (NP (NP (PP (IN As) (NP (NN result))) (, ,) (NP (NP (NN CDCA1) (JJ novel) (NN cancer-testis) (NN antigen) (JJ overexpressed) (NN LC)) (, ,) (NP (JJ cholangiocellular) (NN cancer)) (, ,) (NP (JJ urinary) (NN bladder) (NN cancer) (JJ renal) (NN cell) (NN cancer)) (, ,) (NP (NN CDCA1)) (VP (MD may) (ADVP (RB therefore)) (NP (JJ ideal) (NN TAA) (JJ useful) (NN diagnosis) (NN immunotherapy) (NN cancer)))))) |ET| |BS|259:D12.776.395.240.150.500 263:E01 295:C04.557.470.200.025.390 296:D02.065.064.786 297:C14.907.055.239.125 298:E02.095.465.425 299:D23.050|ES| 2:1 18:1 19:1 25:1 94:1 101:1 168:1 218:1 491:1 564:1 891:1 922:1 1028:1 1029:1 1030:1 1031:1 1032:1 1033:1 1034:1 1035:1 1036:1 1037:1 1038:1
2 	|BT| (S (PP (IN As) (NP (NP (NN Bim) (NN expression) (JJ critical) (NN biomarker) (NN response)) (NP (JJ many) (VBN targeted) (NN therapy)))) (, ,) (NP (NN PTK6) (NN inhibition)) (VP (MD may) (VP (VB offer) (NP (NP (JJ therapeutic) (NN approach)) (VP (VBG treating) (NP (NN patient) (NN Her2) (VBN targeted) (JJ therapy-resistant) (NN breast) (NN cancer))))))) |ET| |BS|43:F01.145.544 50:M01.643 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 158:D23.101|ES| 2:1 16:1 18:1 19:1 23:1 103:1 115:1 120:1 130:1 168:1 491:1 494:1 541:1 825:1 885:1 911:1 1039:1 1040:1 1041:1 1042:1 1043:1 1044:1 1045:1
2 	|BT| (S (NP (NN BACKGROUND) (: :)) (NP (NN MUC4) (VBN cloned) (JJ tracheobronchial) (NN mucosa) (NN cDNA)) (ADVP (RB reportedly)) (ADVP (RB highly)) (VP (VBN expressed) (NP (NP (JJ human) (NN malignancy)) (, ,) (PP (VBG including) (NP (NN lung) (NN carcinoma)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 182:A04.411 265:C04.557.470.200 300:D13.444.308.497.220 301:A11.251.353 302:A10.615.550|ES| 2:1 6:1 19:1 36:1 49:1 104:1 304:1 328:1 561:1 579:1 626:1 1046:1 1047:1 1048:1 1049:1 1050:1 1051:1
2 	|BT| (NP (NP (NP (JJ Basal) (NN cell) (NN carcinosarcoma) (NN PTCH1) (NN mutation)) (NP (JJ epithelial) (JJ sarcomatoid) (JJ primary) (NN tumor) (NN component) (JJ sarcomatoid) (NN metastasis)))) |ET| |BS|8:C04 18:G05.365.590 41:A11 113:C04.697.650 303:C04.557.450.795 304:C04.557.435.290|ES| 7:1 19:1 34:1 94:1 127:1 344:1 806:1 1021:1 1052:1 1053:1 1054:1 1055:1
2 	|BT| (S (VP (JJ BCL2-like) (NP (NP (CD 11) (NN intron) (CD 2) (NN deletion) (NN polymorphism)) (VP (VBN associated) (NP (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN risk) (NN prognosis)))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 61:E05.318.740.600.800 110:C04.588.894.797.520.109.220.249 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795|ES| 18:1 19:1 94:1 148:1 169:1 171:1 328:1 544:1 694:1 1056:1 1057:1 1058:1 1059:1 1060:1
2 	|BT| (S (NP (NN CD133)) (VP (VBN considered) (S (NP (NP (JJ stem-like) (NN cell) (NN marker) (NN cancer)) (PP (VBG including) (NP (NP (JJ gastric) (NN cancer)) (, ,) (NP (NP (NN Notch1) (NN signaling)) (VP (VBN known) (NP (NN play) (JJ important) (NN role) (NN maintenance) (NN differentiation) (JJ stem-like) (NN cell)))))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 74:G04.299.151 79:I03.450.642.693 158:D23.101 188:N02.628 308:A11.872 309:A18.024.937|ES| 2:1 18:1 19:1 31:1 86:1 94:1 195:1 215:1 238:1 534:1 556:1 561:1 651:1 652:1 902:1 1061:1 1062:1 1063:1
2 	|BT| (NP (NP (NN Characterization) (JJ tumor-suppressive) (NN function) (NN SOX6) (JJ human) (NN esophageal) (JJ squamous) (NN cell) (NN carcinoma))) |ET| |BS|8:C04 55:B01.050.150.900.649.801.400.112.400.400|ES| 19:1 33:1 36:1 94:1 177:1 304:1 1064:1 1065:1 1066:1 1067:1
2 	|BT| (S (NP (NN Chemokine) (NN gene) (NN expression) (JJ clonal) (NN analysis) (NN B) (NN cell) (NN tissue)) (VP (VBN involved) (NP (JJ lymphoid) (JJ interstitial) (NN pneumonitis) (JJ HIV-infected) (JJ pediatric) (NN patient)))) |ET| |BS|50:M01.643 98:A10 155:G05.355.310 301:A11.251.353 310:A11.063.438 311:B04.820.650.589.650.350 312:C02.782.815.616.400.500 313:D12.644.276.374.200 314:C02.782.815.616.400 315:H02.403.670|ES| 9:1 19:1 94:1 115:1 120:1 272:1 661:1 763:1 774:1 1068:1 1069:1 1070:1 1071:1 1072:1 1073:1 1074:1
2 	|BT| (S (NP (JJ Chromosomal) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NP (JJ close) (JJ genetic) (NN relationship) (NN papillary) (JJ urothelial) (JJ choriocarcinomatous) (NN tumor) (NN component)) (, ,) (VP (VBG documenting) (NP (JJ first) (NN time) (NN choriocarcinoma) (JJ renal) (NN pelvis)))) (VP (VBP result) (NP (JJ clonal) (NN evolution) (JJ urothelial) (NN carcinoma) (NN acquisition) (JJ trophoblastic) (NN differentiation))))))) |ET| |BS|8:C04 74:G04.299.151 149:G05.360.340.024.340.364.875.890 289:A11.284.187 316:C04.557.465.955.207 317:C04.557.470.200.430 318:A05.810.453.537 319:A11.382.992 320:G04.299.350 321:A10.272.850 322:G01.910|ES| 2:1 7:1 19:1 101:1 215:1 223:1 275:1 304:1 661:1 816:1 864:1 922:1 1021:1 1069:1 1075:1 1076:1 1077:1 1078:1 1079:1 1080:1 1081:1 1082:1 1083:1 1084:1 1085:1 1086:1
2 	|BT| (S (VP (VBG Combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam) (NN treat) (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1
2 	|BT| (S (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root)))) (NP (VBD suggested) (NN B))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 272:1 412:1 534:1 661:1 763:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1
2 	|BT| (S (NP (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root))))))) (VP (VBD suggested) (SBAR (S (NP (NNP B.) (JJ thuringiensis-induced) (NN defense) (NN system)) (VP (VBD activated) (NP (NP (NN leaf)) (, ,) (NP (NN stem)) (, ,) (NP (JJ main) (NN root) (NN tissue)) (, ,) (NP (JJ lateral) (NN root) (NN tissue)))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 309:A18.024.937 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650 329:A14.549.167.900.750 330:A18.024.812|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 163:1 272:1 412:1 534:1 593:1 661:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1 1102:1 1103:1 1104:1 1105:1 1106:1 1107:1 1108:1
2 	|BT| (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (VP (NN DCAMKL-1) (NP (JJ negative) (NN regulator) (NN let-7a) (NN miRNA) (NN biogenesis) (JJ intestinal) (NN stem) (JJ colorectal) (NN cancer) (NN cell)))) (: ;)) (VP (MD could) (VP (VB represent) (NP (JJ novel) (NN target) (JJ anti-cancer) (NN stem) (JJ cell-based) (NN strategy))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 47:A03.556.124 184:D13.150.650.319 259:D12.776.395.240.150.500 309:A18.024.937 331:G16.595 332:A11.872.650 333:D01.045|ES| 17:1 18:1 19:1 94:1 104:1 109:1 160:1 217:1 235:1 239:1 449:1 799:1 840:1 891:1 908:1 1106:1 1109:1 1110:1 1111:1 1112:1 1113:1 1114:1
2 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Expression) (NN ra) (NN protein) (NN type) (CD II) (JJ alveolar) (NNS pneumocytes) (NN mutation) (NN codon) (CD 12) (JJ K-ras) (NN gene) (NN lung) (NN tissue)) (VP (MD may) (VP (VB contribute) (NP (NN induction) (NN lung) (NN carcinoma) (NN patient) (NN IPF)))))) |ET| |BS|18:G05.365.590 50:M01.643 98:A10 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 334:D08.811.277.040.330.300.400.500 335:D13.444.735.544.355 336:A04.411.715.512 337:C08.381.765|ES| 4:1 9:1 19:1 34:1 104:1 120:1 239:1 272:1 304:1 316:1 328:1 450:1 491:1 543:1 736:1 1115:1 1116:1 1117:1 1118:1 1119:1 1120:1 1121:1 1122:1
2 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (NN Jab1) (NN expression)) (, ,) (NP (ADVP (RB well)) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-))) (NN upregulation)) (, ,) (NP (JJ evident) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN Jab1)) (VP (MD could) (NP (JJ diagnostic) (NN marker) (NN treatment) (NN target) (JJ precancerous) (NN lesion) (JJ early) (NNS HCCs))))))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 158:D23.101 249:G05.355.315.800 263:E01 338:D12.644.360.225.600 339:G02.111.087.880 340:C17.800.229.400 341:C04.834|ES| 2:1 10:1 14:1 19:1 104:1 115:1 160:1 239:1 534:1 546:1 787:1 900:1 903:1 908:1 1009:1 1123:1 1124:1 1125:1 1126:1 1127:1 1128:1 1129:1 1130:1 1131:1 1132:1
2 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Reduction) (NN ING1b) (NN gene) (NN expression)) (VP (VBN associated) (VP (VBD reduced) (NP (NN p21) (NN bax) (NN gene) (NN expression) (NNS NSCLCs)))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 155:G05.355.310 342:D12.644.360.075.718.400|ES| 9:1 19:1 104:1 115:1 169:1 239:1 452:1 1133:1 1134:1 1135:1 1136:1 1137:1
2 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT The) (CD two) (NN library)) (ADVP (RB differentially)) (VP (VBD expressed) (SBAR (S (NP (NN gene)) (VP (MD may) (VP (VB provide) (NP (NN basis) (JJ new) (NN insight) (NN clue) (NN finding) (JJ novel) (NN lung) (JJ cancer-related) (NN gene)))))))) (: ;) (S (NP (JJ several) (NN gene)) (ADVP (RB newly)) (VP (VBD found) (NP (NP (NN lung) (NN cancer) (NN ERGIC3)) (VP (VBG seeming) (NP (JJ novel) (NN lung) (JJ cancer-related) (NN gene))))))) |ET| |BS|9:G05.360.340.024.340.375.500 182:A04.411 259:D12.776.395.240.150.500 275:C23.888 343:G05.360.325 344:M01.438|ES| 6:1 9:1 18:1 19:1 37:1 104:1 217:1 239:1 262:1 328:1 491:1 691:1 711:1 712:1 891:1 927:1 933:1 1138:1 1139:1 1140:1 1141:1 1142:1 1143:1 1144:1 1145:1 1146:1
2 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (DT This) (NN panel)) (SBAR (S (NP (JJ variant-specific) (, ,) (JJ quantitative) (NN RT-PCR) (NN assay)) (VP (VBZ detects) (NP (NP (JJ common) (NN EML4-ALK) (CC +) (JJ variant) (RB well) (NN ALK) (NN gene) (NN expression) (NN level)) (JJ archival) (JJ formalin-fixed) (JJ paraffin-embedded) (NN NSCLC) (NN specimen))))))) |ET| |BS|106:E05.091 110:C04.588.894.797.520.109.220.249 155:G05.355.310 272:E05.393.620.500.725 345:E01.370.225.500.620.720.610 346:E05.393.620.500.706 347:D02.047.407 348:K01.400.152|ES| 2:1 9:1 19:1 104:1 115:1 239:1 249:1 310:1 329:1 510:1 655:1 787:1 807:1 817:1 962:1 990:1 1147:1 1148:1 1149:1 1150:1 1151:1 1152:1 1153:1 1154:1
2 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (NP (PRP We)) (VP (VBD provided) (NP (JJ first) (NN evidence) (NN SOX6) (JJ novel) (JJ tumor-suppressor) (NN gene) (NN ESCC) (NN development) (JJ potential) (JJ prognostic) (NN marker) (NN ESCC)))) |ET| |BS|149:G05.360.340.024.340.364.875.890 158:D23.101 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500|ES| 9:1 19:1 35:1 38:1 104:1 239:1 534:1 816:1 827:1 843:1 884:1 891:1 1065:1 1155:1 1156:1 1157:1
2 	|BT| (S (NP (NN Cyclooxygenase-2) (NN inhibitor)) (VP (VBP down-regulate) (NP (NN osteopontin) (NN Nr4A2-new) (JJ therapeutic) (NN target) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360|ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1
2 	|BT| (S (NP (NP (NP (NN DDR2)) (PRN (-LRB- -LRB-) (NP (NN L63V)) (-RRB- -RRB-))) (: ;) (NP (NP (NN TP53)) (PRN (-LRB- -LRB-) (NP (NN L/L)) (-RRB- -RRB-))) (NP (NN mouse))) (VP (VBD developed) (NP (NP (ADJP (RB poorly) (VBN differentiated)) (NN lung) (NN adenocarcinoma) (JJ transgenic) (NN animal)) (VP (VBN analyzed) (NP (NN latency) (CD 40) (CD 50) (NN week) (NN median) (NN survival) (CD 67.5) (NN week)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 74:G04.299.151 96:I03.784 352:B01.050.050.136|ES| 10:1 14:1 19:1 46:1 52:1 217:1 255:1 274:1 285:1 328:1 368:1 582:1 783:1 1018:1 1162:1 1163:1 1164:1 1165:1 1166:1 1167:1 1168:1 1169:1 1170:1 1171:1
2 	|BT| (S (NP (NN DEP) (NN domain)) (VP (VP (VBG containing) (NP (CD 1) (-LRB- -LRB-) (NN DEPDC1) (-RRB- -RRB-))) (SBAR (S (NP (ADJP (RB newly) (VBN identified)) (NP (JJ cancer-related) (NN cell) (NN cycle)) (JJ related) (NN gene)) (VP (VBD demonstrated) (NP (JJ novel) (JJ therapeutic) (NN target) (NN bladder) (NN cancer))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 259:D12.776.395.240.150.500 353:G04.299.134|ES| 9:1 10:1 14:1 18:1 19:1 94:1 98:1 160:1 286:1 419:1 541:1 564:1 601:1 623:1 891:1 1143:1 1144:1 1172:1 1173:1 1174:1 1175:1
2 	|BT| (S (NP (NN DEPDC1)) (VP (VBD required) (NP (NN cell) (NN cycle) (NN progression) (NN motility) (JJ nasopharyngeal) (NN carcinoma)))) |ET| |BS|16:C23.550.291.656 353:G04.299.134|ES| 19:1 48:1 94:1 304:1 601:1 1174:1 1176:1 1177:1 1178:1
2 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN BCL6B)) (VP (MD may) (VP (VB serve) (NP (JJ independent) (NN biomarker) (NN prognosis) (NN GC))))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 491:1 532:1 544:1 554:1 883:1 885:1 1179:1 1180:1 1181:1
2 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN PAX5)) (VP (VBD utilized) (NP (JJ independent) (JJ prognostic) (NN factor) (NN GC)))))) |ET| |BS|36:G02.111.087.029.538 243:D12.776.260.645.500|ES| 19:1 185:1 554:1 846:1 883:1 884:1 1179:1 1180:1 1182:1
2 	|BT| (S (NP (NP (NN Detection)) (VP (VBN methylated) (NP (NN TBX5)))) (VP (MD may) (VP (VB serve) (NP (JJ potential) (NN biomarker) (NN prognosis) (NN malignancy))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 49:1 491:1 532:1 544:1 827:1 885:1 1179:1 1180:1 1183:1
2 	|BT| (S (NP (NN Detection) (NN TFPI2) (NN methylation) (NN stool) (NN DNA)) (VP (MD may) (VP (VB act) (NP (JJ useful) (NN adjunct) (JJ noninvasive) (NN strategy) (NN screening) (NNS CRCs) (NN future))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 81:E02.095.465.425.400.330.050.400 198:D13.444.308 354:I01.320 355:A12.459|ES| 19:1 81:1 246:1 491:1 666:1 1036:1 1114:1 1179:1 1184:1 1185:1 1186:1 1187:1 1188:1 1189:1 1190:1
2 	|BT| (NP (NP (NP (NN DLGAP5) (NN overexpression) (JJ evident) (CD 25) (NN %)) (PRN (-LRB- -LRB-) (NP (QP (CD 22) (CD 88))) (-RRB- -RRB-))) (NP (NP (NNP HCC) (NN specimen)) (PP (IN without) (NP (NN AFP) (NN expression)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN DLGAP5)) (VP (MD may) (NP (JJ novel) (NN biomarker) (NN HCC) (NN pathogenesis)))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 115:1 152:1 369:1 441:1 491:1 501:1 885:1 891:1 1009:1 1127:1 1154:1 1191:1 1192:1 1193:1 1194:1 1195:1 1196:1
2 	|BT| (NP (NP (JJ Dual) (JJ therapeutic) (NN effect) (NN interferon-alpha) (NN gene) (NN therapy) (NN rat) (JJ hepatocellular) (NN carcinoma) (NN model) (NN liver) (NN cirrhosis))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 356:D12.644.276.374.440.890.250 357:C06.552.630|ES| 9:1 19:1 72:1 75:1 130:1 303:1 304:1 541:1 836:1 849:1 1197:1 1198:1 1199:1
2 	|BT| (NP (NP (NN EGFR) (NN gene) (NN mutation) (NN ALK) (NN gene) (NN fusion) (JJ well-characterized) (JJ molecular) (NN target) (NN NSCLC))) |ET| |BS|18:G05.365.590 110:C04.588.894.797.520.109.220.249 358:G05.360.340.024.340.375.500.791.295.300 359:G05.355.760.385|ES| 9:1 19:1 34:1 160:1 161:1 187:1 329:1 936:1 962:1 1200:1
2 	|BT| (NP (NP (JJ Epigenetic) (NN dysregulation) (JJ leukaemic) (NN HOX) (NN code) (JJ MLL-rearranged) (NN leukaemia) (NN mouse) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 360:N04.452.758.708.200.400.500 361:C04.557.337|ES| 19:1 52:1 72:1 1201:1 1202:1 1203:1 1204:1 1205:1 1206:1 1207:1
2 	|BT| (S (NP (NN Evaluation) (NN RB) (NN status)) (VP (MD may) (NP (JJ useful) (JJ prognostic) (NN factor) (JJ human) (NN HCC)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 225:E05.337|ES| 19:1 36:1 185:1 416:1 441:1 491:1 884:1 1036:1 1208:1 1209:1
2 	|BT| (S (NP (NN Expression) (NN DRD2)) (VP (VBZ Is) (SBAR (S (NP (VBN Increased) (JJ Human) (JJ Pancreatic) (JJ Ductal) (NN Adenocarcinoma) (NNS Inhibitors)) (VP (VBP Slow) (NP (NN Tumor) (NN Growth) (NNS Mice))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 362:D12.776.543.750.069.300.400.500 363:C04.557.470.200.025.232.750 364:D27.505.696.377.450|ES| 19:1 316:1 444:1 583:1 1210:1 1211:1 1212:1 1213:1 1214:1 1215:1 1216:1 1217:1 1218:1 1219:1
2 	|BT| (S (NP (NP (NP (CD Fifty-four)) (PRN (-LRB- -LRB-) (NP (CD 73) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 74) (NN lesion) (NNS metaplasias) (JJ bronchiolar) (NN epithelium)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient) (NN lung) (NN carcinoma) (CD 8)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 46) (NN sample)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient)) (PP (IN without) (NP (NN lung) (NN carcinoma))))))))) (VP (VBD showed) (NP (NP (NNP LOH) (NNP FHIT) (NN gene)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.0001)))) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 48:C23.550.589 50:M01.643 62:A10.272 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500|ES| 9:1 10:1 14:1 19:1 120:1 132:1 173:1 304:1 311:1 312:1 328:1 369:1 575:1 781:1 835:1 930:1 946:1 1004:1 1122:1 1131:1 1195:1 1220:1 1221:1 1222:1 1223:1 1224:1 1225:1 1226:1
2 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN CD133) (NN DNA) (NN methylation)) (VP (VBZ seems) (VP (VBP constitute) (SBAR (S (NP (JJ abnormal) (NN promoter) (NN signature)) (VP (VBD found) (NP (NP (JJ normal) (NN brain) (NN colon)) (VP (VBN cultured) (NP (JJ primary) (NN tumor)))))))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 366:G02.111.087.029.538.161 367:A08.186.211|ES| 2:1 7:1 19:1 37:1 81:1 83:1 113:1 118:1 334:1 344:1 652:1 666:1 1227:1 1228:1 1229:1 1230:1 1231:1 1232:1
2 	|BT| (S (NP (NNP Gene) (NN amplification) (NN 17q) (JJ chromosomal) (NN region)) (VP (VBN observed) (ADVP (RB frequently)) (NP (NN breast) (NN cancer)))) |ET| |BS|292:Z01 368:C23.550.210.182|ES| 18:1 19:1 23:1 261:1 667:1 698:1 921:1 1002:1 1233:1 1234:1
2 	|BT| (S (NP (JJ Genomic) (NN Sequencing)) (VP (VBZ Identifies) (NP (NN ELF3) (NN Driver) (NNP Ampullary) (NNP Carcinoma)))) |ET| |BS|265:C04.557.470.200 268:H01.158.273.180.350 269:G05.360.340|ES| 19:1 1235:1 1236:1 1237:1 1238:1 1239:1 1240:1 1241:1
2 	|BT| (S (NP (NN HEF1)) (VP (MD may) (VP (VB represent) (NP (NP (JJ attractive) (NN candidate) (NN drug)) (VP (VBG targeting) (NP (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 369:E02.319.300|ES| 19:1 191:1 245:1 491:1 616:1 799:1 974:1 1242:1 1243:1
2 	|BT| (S (NP (ADJP (RB Here) (VBN investigated)) (NN prevalence) (NN pattern) (NN mutation)) (NP (NP (CD two) (NN gene)) (, ,) (NP (NN Ha-ras) (NN beta-catenin)) (, ,)) (VP (VBN known) (NP (JJ mutational) (NN target) (NN mouse) (NN hepatocarcinogenesis)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 60:E05.318.308.985.525.750 216:Z01.107.084.900.425|ES| 2:1 9:1 19:1 34:1 52:1 60:1 160:1 179:1 260:1 400:1 403:1 556:1 747:1 900:1 933:1 1244:1
2 	|BT| (S (ADVP (RB Here)) (, ,) (NP (VBD generated) (NN mouse) (NN model) (NN lung) (NN adenocarcinoma)) (VP (VBN driven) (NP (NP (NN mutation) (NN discoidin) (NN domain) (NN receptor) (CD 2) (-LRB- -LRB-) (NN DDR2) (-RRB- -RRB-) (NN gene)) (JJ combined) (NN loss) (NN TP53)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 66:F01.658.293|ES| 2:1 9:1 10:1 14:1 19:1 32:1 34:1 52:1 72:1 73:1 148:1 164:1 186:1 255:1 328:1 400:1 920:1 1018:1 1162:1 1173:1 1245:1
2 	|BT| (S (NP (JJR Higher) (NN frequency) (JJ inactive) (NN TP53) (NN mutation)) (ADVP (RB also)) (VP (VBN seen) (S (NP (NP (NP (JJ advanced) (NN stage) (NN tumour)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.0003)))) (-RRB- -RRB-))) (NN tumour) (JJ poor) (JJ prognostic) (NN feature)) (NP (ADJP (NP (JJ vascular)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.006)))) (-RRB- -RRB-))) (NP (NP (JJ lymphatic) (NN invasion)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))))))) |ET| |BS|8:C04 159:I01.880.735.634 194:G05.355.044.250.750 213:F02.830.816.964 370:A15.382.520.301 371:A07.231|ES| 5:1 10:1 14:1 19:1 34:1 311:1 545:1 581:1 620:1 724:1 884:1 997:1 1011:1 1018:1 1129:1 1246:1 1247:1 1248:1 1249:1 1250:1 1251:1 1252:1 1253:1 1254:1
2 	|BT| (S (ADVP (RB However)) (, ,) (NP (NN mutation) (NN exon) (CD 3) (NN beta-catenin) (NN gene)) (VP (VBD detected) (SBAR (S (NP (CD one) (NN tumour)) (VP (VBD expressed) (NP (JJ nuclear) (NN beta-catenin) (JJ lining) (JJ polygonal) (NN component))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 18:G05.365.590 23:D12.776.091.249 372:G05.360.340.024.340.137.232|ES| 2:1 6:1 9:1 19:1 34:1 60:1 433:1 862:1 1007:1 1010:1 1011:1 1021:1 1255:1 1256:1 1257:1 1258:1
2 	|BT| (S (NP (NN HOX) (NN gene)) (ADVP (RB frequently)) (VP (VBN dysregulated) (NP (NP (JJ human) (NN leukaemia) (NN gene) (NN rearrangement) (JJ mixed) (NN lineage) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN MLL)) (-RRB- -RRB-))) (NP (NN partner) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 229:G05.360.340.024.340.230.500 361:C04.557.337 373:G05.355.330|ES| 9:1 10:1 14:1 19:1 36:1 698:1 1204:1 1207:1 1259:1 1260:1 1261:1 1262:1 1263:1 1264:1
2 	|BT| (NP (NP (NP (NN Identification) (NN trophinin) (NN enhancer) (NN cell) (NN invasion) (JJ prognostic) (NN factor)) (JJ early) (NN stage) (NN lung) (NN cancer))) |ET| |BS|41:A11 374:F01.393.446 375:Z01.639.100|ES| 18:1 19:1 94:1 185:1 328:1 620:1 884:1 972:1 1128:1 1129:1 1265:1 1266:1
2 	|BT| (S (NP (NN IHH) (NN SMO)) (VP (MD may) (SBAR (S (NP (JJ useful) (NNS biomarkers) (JJ diffuse) (NN cancer)) (VP (MD may) (VP (VB show) (NP (NN growth) (NN inhibition) (NN Hh) (NN antagonist) (NN cyclopamine)))))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 376:D23.101.140|ES| 18:1 19:1 102:1 103:1 429:1 491:1 653:1 1036:1 1267:1 1268:1 1269:1 1270:1 1271:1 1272:1
2 	|BT| (FRAG (PP (IN In) (NP (JJ CF-treated) (JJ main) (NN root))) (, ,) (NP (NP (JJ CF-treated) (JJ lateral) (NN root)) (, ,) (NP (NP (NN expression) (JJ several) (JJ salicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP SA)) (-RRB- -RRB-))) (: -) (S (NP (JJ responsive) (JJ defense-related) (NN gene)) (ADVP (RB specifically)) (VP (VBD induced) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (JJ jasmonic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN JA)) (-RRB- -RRB-))) (: -) (NP (JJ related) (NN gene) (NN expression))) (VP (CC either) (VP (VBD down-regulated) (NP (JJ induced) (NN response) (NN CF)))))))))) |ET| |BS|52:E02 142:I01.880.604 155:G05.355.310 325:Z01.058.290.100.140 326:A18.400 351:A17.360 377:D02.241.223.100.300.595.608|ES| 2:1 9:1 10:1 14:1 19:1 39:1 115:1 244:1 262:1 372:1 412:1 494:1 1100:1 1101:1 1107:1 1108:1 1273:1 1274:1 1275:1 1276:1 1277:1 1278:1 1279:1 1280:1 1281:1 1282:1 1283:1
2 	|BT| (FRAG (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (VBN defined) (NN subset) (NN bone) (JJ soft) (NN tissue) (NN tumor)) (, ,) (PP (VBG including) (NP (JJ benign) (NN tumor))) (, ,) (S (NP (NN Akt)) (ADVP (RB frequently)) (VP (VBN overexpressed) (S (VP (VBN activated))))) (, ,) (NP (NP (NNP AKT1/2) (NN copy) (NN number)) (VP (VBN increased))))) |ET| |BS|378:D08.811.913.696.620.682.700.755 379:C04.588.839 380:A02.835.232 381:C04|ES| 2:1 7:1 19:1 25:1 47:1 163:1 244:1 272:1 561:1 646:1 680:1 698:1 963:1 1284:1 1285:1 1286:1 1287:1 1288:1 1289:1 1290:1
2 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN change) (NN level) (NN cdk4)) (VP (MD may) (NP (JJ useful) (NN biomarker) (NN detection) (NN HCC))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101|ES| 2:1 19:1 200:1 244:1 249:1 441:1 491:1 796:1 885:1 1023:1 1036:1 1284:1 1291:1
2 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN WT1)) (VP (VBD expressed) (NP (NP (JJ substantial) (NN proportion) (NN HCC)) (VP (VBG contributing) (NP (NN tumor) (NN progression) (NN resistance) (NN chemotherapy)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN WT1)) (VP (MD may) (NP (JJ important) (NN target) (NN HCC) (NN treatment))))))))) |ET| |BS|8:C04 12:Z01.542.049 16:C23.550.291.656 52:E02 104:C04.557.470.200.025.255 151:E02.319 382:C04.557.435.595|ES| 2:1 6:1 7:1 19:1 48:1 160:1 244:1 441:1 491:1 495:1 546:1 902:1 1009:1 1094:1 1284:1 1292:1 1293:1 1294:1 1295:1
2 	|BT| (S (PP (IN In) (NP (NN silico) (NN analysis))) (VP (VBD used) (SBAR (S (NP (NN probe) (NN association) (NN gene) (NN expression) (NN signature) (NN RB) (NN loss) (JJ chromosomal) (NN instability) (NN ability) (NN gene)) (VP (VBD up-regulated) (SBAR (S (NP (NN RB) (NN loss)) (VP (VBP predict) (NP (NN survival) (JJ human) (NN HCC) (NN patient)))))))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 96:I03.784 104:C04.557.470.200.025.255 142:I01.880.604 150:Z01.542.248.960 383:C23.550.210.110 384:G02.111.087.847.750 385:F02.784.629.131 386:F02.463.425.069 387:L01.224.160|ES| 9:1 19:1 32:1 36:1 115:1 120:1 244:1 274:1 441:1 476:1 661:1 1002:1 1209:1 1230:1 1296:1 1297:1 1298:1 1299:1 1300:1 1301:1 1302:1
2 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (VP (VBD found) (S (S (NP (NN EREG) (JJ overexpressed) (NNS NSCLCs)) (VP (VBG harboring) (NP (NNP KRAS)))) (, ,) (NP (NNP BRAF) (NN EGFR) (NN mutation)) (VP (VBN compared) (NP (NNS NSCLCs) (JJ wild-type) (NN KRAS/BRAF/EGFR)))))) |ET| |BS|18:G05.365.590 110:C04.588.894.797.520.109.220.249 278:D08.811.913.696.620.682.700.559.842.374 388:G05.360.340.024.340.375.500.791.550|ES| 2:1 8:1 19:1 25:1 34:1 37:1 50:1 131:1 175:1 187:1 244:1 958:1 1137:1 1303:1 1304:1 1305:1 1306:1
2 	|BT| (UCP (PP (IN In) (NP (JJ present) (NN study) (JJ novel) (JJ metastasis-related) (NN gene))) (, ,) (NP (NP (NP (JJ eukaryotic) (NN initiation) (NN factor) (NN 5A2)) (PRN (-LRB- -LRB-) (NP (NN EIF5A2)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN characterized) (NN role) (NN HCC) (NN metastasis)) (VP (VBG underlying) (NP (JJ molecular) (NN mechanism)))))) |ET| |BS|6:G05.360.340.024.340 15:F01.829.316.616 104:C04.557.470.200.025.255 113:C04.697.650 259:D12.776.395.240.150.500 389:D12.776.835.725.868|ES| 2:1 9:1 10:1 14:1 19:1 31:1 131:1 161:1 162:1 185:1 244:1 435:1 441:1 637:1 806:1 891:1 985:1 1307:1 1308:1 1309:1 1310:1 1311:1
2 	|BT| (NP (NP (NP (VBN Increased) (NN loss) (NN chromosome) (NN 9p21) (NN p16) (NN inactivation)) (NP (JJ primary) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN smoker)))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 289:A11.284.187|ES| 18:1 19:1 32:1 94:1 328:1 344:1 694:1 1005:1 1212:1 1312:1 1313:1 1314:1 1315:1
2 	|BT| (S (NP (NN ING5)) (VP (VP (VBZ suppresses) (NP (NP (NN proliferation)) (, ,) (NP (NN apoptosis)) (, ,) (NP (NN migration) (NN invasion)))) (, ,) (VP (VBZ induces) (NP (JJ autophagy) (NN differentiation) (JJ gastric) (NN cancer) (NN cell))) (: :) (NP (JJ good) (NN marker) (NN carcinogenesis) (JJ subsequent) (NN progression)))) |ET| |BS|16:C23.550.291.656 33:C04.697.098 39:G04.299.139.160 74:G04.299.151 158:D23.101 390:G04.299.139.399|ES| 2:1 18:1 19:1 48:1 86:1 89:1 94:1 104:1 207:1 214:1 215:1 299:1 514:1 534:1 620:1 686:1 1316:1 1317:1 1318:1 1319:1
2 	|BT| (NP (NP (JJ Irrespective) (NN protein) (NN overexpression)) (, ,) (S (NP (NN HER-2)) (: /) (NP (NP (NN neu) (NN gene) (NN amplification) (JJ rare) (NN lung) (NN cancer) (NN study) (NN prevalence) (JJ clinicopathological) (NN implication) (JJ early) (NN stage) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NCSLC)) (-RRB- -RRB-))) (NP (NP (JJ neuroendocrine) (NN tumour)) (PRN (-LRB- -LRB-) (NP (NN NET)) (-RRB- -RRB-))) (VP (NN lung) (S (VP (VBG lacking)))))) |ET| |BS|7:D12.776 63:G05.360.340.024.340.375.500.791.295.305 110:C04.588.894.797.520.109.220.249 237:C04.588.894.797.520 391:E05.318.760.500.875 392:G05.355.315.250 393:A06.688|ES| 2:1 4:1 9:1 10:1 14:1 18:1 19:1 85:1 94:1 131:1 152:1 179:1 328:1 376:1 694:1 921:1 1011:1 1128:1 1129:1 1320:1 1321:1 1322:1 1323:1 1324:1 1325:1 1326:1
2 	|BT| (S (NP (PRP It)) (ADJP (ADJP (RB likely) (JJ major)) (SBAR (S (NP (NN genotype) (JJ gastric) (NN carcinoma)) (VP (VBD placed) (NP (JJS least) (CD 4) (NN microsatellite) (NN category)) (, ,) (S (ADVP (RB thus)) (VP (VBG allowing) (NP (NP (NN construction) (JJ comprehensive) (JJ genetic) (NN classification)) (JJ useful) (NN prediction) (JJ diverse) (JJ clinical) (NN course))))))))) |ET| |BS|70:A03.556.875.875 265:C04.557.470.200 394:G02.111.570.080.708.800.500 395:L01.100 396:G05.380|ES| 2:1 19:1 84:1 86:1 304:1 319:1 462:1 864:1 1036:1 1327:1 1328:1 1329:1 1330:1 1331:1 1332:1 1333:1 1334:1 1335:1 1336:1 1337:1 1338:1 1339:1 1340:1 1341:1
2 	|BT| (S (NP (PRP It)) (VP (VBD suggested) (SBAR (S (NP (NN ING5) (NN expression)) (VP (MD might) (VP (VP (VBN employed) (S (NP (JJ good) (NN marker) (JJ gastric) (NN carcinogenesis) (JJ subsequent) (NN progression)) (VP (VBG inhibiting) (NP (NN proliferation))))) (, ,) (NP (NP (NN growth)) (, ,) (NP (NN migration)) (, ,) (NP (NN invasion) (NN metastasis))))))))) |ET| |BS|16:C23.550.291.656 33:C04.697.098 45:G07.700.320.249 70:A03.556.875.875 113:C04.697.650 122:C14.280.383 158:D23.101|ES| 2:1 19:1 48:1 86:1 102:1 115:1 207:1 299:1 514:1 534:1 620:1 798:1 806:1 880:1 925:1 1316:1 1318:1 1319:1 1327:1 1342:1
2 	|BT| (S (NP (JJ Knock-down) (NN Prmt1) (JJ insufficient) (JJ reverse) (JJ active) (NN chromatin) (NN status)) (VP (VBN hypomethylated) (NP (NN Hox) (NN locus)) (, ,) (S (VP (VBG suggesting) (S (NP (JJ Prmt1-mediated) (NN histone) (NN arginine) (NN methylation)) (VP (ADVP (RB partially)) (NP (VBN involved) (NP (NN maintenance) (NN Hox) (NN expression) (JJ leukaemic) (NN cell))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 41:A11 188:N02.628 351:A17.360 397:A11.284.430.106.279.345.190.160.180 398:D12.125.068.050 399:D12.776.660.470|ES| 2:1 19:1 81:1 94:1 115:1 197:1 377:1 416:1 503:1 774:1 939:1 1009:1 1063:1 1203:1 1343:1 1344:1 1345:1 1346:1 1347:1 1348:1 1349:1 1350:1 1351:1
2 	|BT| (S (NP (JJ Knock-down) (NN TnC) (NN gene)) (VP (VBD increased) (NP (NN susceptibility) (JJ DSS-induced) (NN colitis)) (, ,) (S (VP (VBN compared) (S (NP (NP (NN TnC)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NNS littermates))))))) |ET| |BS|53:C06.405.205.265 400:E05.393.335.500 401:C23.550.291.687|ES| 2:1 9:1 10:1 14:1 19:1 47:1 50:1 51:1 143:1 1343:1 1352:1 1353:1 1354:1 1355:1
2 	|BT| (NP (NP (S (NP (JJ K-ras) (NN gene) (NN mutation)) (VP (VBZ enhances) (NP (NN motility) (VBN immortalized) (NN airway) (NN cell) (NN lung) (NN adenocarcinoma) (NN cell)) (PP (IN via) (NP (NN Akt) (NN activation)))) (: :)) (NP (JJ possible) (NN contribution) (JJ non-invasive) (NN expansion) (NN lung) (NN adenocarcinoma)))) |ET| |BS|18:G05.365.590 41:A11 378:D08.811.913.696.620.682.700.755|ES| 9:1 19:1 34:1 94:1 104:1 225:1 255:1 328:1 596:1 1121:1 1177:1 1289:1 1356:1 1357:1 1358:1 1359:1 1360:1 1361:1 1362:1
2 	|BT| (S (NP (NNP KRAS) (NN gene) (NN mutation)) (VP (VBN linked) (NP (NP (JJ poor) (NN prognosis) (NN resistance)) (JJ therapeutic) (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|18:G05.365.590 52:E02 110:C04.588.894.797.520.109.220.249 159:I01.880.735.634 163:E01.789|ES| 9:1 10:1 14:1 18:1 19:1 34:1 94:1 328:1 329:1 541:1 544:1 545:1 694:1 1094:1 1305:1 1363:1
2 	|BT| (NP (NP (NP (JJ K-ras) (NN gene) (JJ mutational) (NN analysis)) (NN support) (JJ monoclonal) (NN origin) (JJ biphasic) (JJ pleomorphic) (NN carcinoma) (NN lung))) |ET| |BS|18:G05.365.590 149:G05.360.340.024.340.364.875.890 182:A04.411 265:C04.557.470.200|ES| 9:1 19:1 304:1 328:1 661:1 1121:1 1244:1 1364:1 1365:1 1366:1 1367:1 1368:1
2 	|BT| (NP (NP (NP (NP (NNP KRAS) (NN mutation) (CD one) (JJ common) (NN driver) (NN mutation) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (SBAR (S (NP (NN finding) (JJ druggable) (NN target) (NN molecule)) (VP (VBP inhibit) (NP (JJ oncogenic) (NNP KRAS) (NN signaling) (JJ significant) (NN challenge) (NN NSCLC) (NN therapy))))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 69:G02.111.087.800 110:C04.588.894.797.520.109.220.249 122:C14.280.383 275:C23.888 279:D27.888.569.100 388:G05.360.340.024.340.375.500.791.550|ES| 10:1 14:1 18:1 19:1 34:1 130:1 135:1 160:1 180:1 195:1 327:1 328:1 329:1 655:1 927:1 953:1 954:1 1010:1 1305:1 1369:1 1370:1 1371:1
2 	|BT| (S (NP (NNP LOH) (NNP FHIT) (NN locus)) (ADVP (RB frequently)) (VP (VBN found) (PP (IN among) (NP (NN lesion) (NNS metaplasias) (JJ bronchiolar) (NN epithelium) (NN patient) (NN IPF))) (PRN (-LRB- -LSB-) (NP (NP (CD 62) (PRN (-LRB- -LRB-) (NP (CD 52) (NN %)) (-RRB- -RRB-))) (NP (CD 119) (JJ informative) (NN lesion))) (-RRB- -RSB-)))) |ET| |BS|48:C23.550.589 50:M01.643 62:A10.272 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500|ES| 10:1 14:1 19:1 37:1 120:1 173:1 369:1 377:1 698:1 946:1 1004:1 1122:1 1131:1 1222:1 1223:1 1372:1 1373:1 1374:1 1375:1 1376:1 1377:1 1378:1
2 	|BT| (NP (NP (JJ Mammary) (NN analogue) (JJ secretory) (NN carcinoma) (JJ salivary) (NN gland) (JJ high-grade) (NN transformation)) (: :) (NP (NP (NN report) (ADJP (CD 3) (NN case)) (NN ETV6-NTRK3) (NN gene) (NN fusion) (NN analysis) (NN TP53)) (, ,) (NP (NN beta-catenin)) (, ,) (NP (NN EGFR)) (, ,) (NP (NN CCND1) (NN gene)))) |ET| |BS|23:D12.776.091.249 359:G05.355.760.385 402:G05.360.340.024.340.375.500.791.148 403:C04.557.470.200.588 404:A03.556.500.760 405:V03.100 406:V03.100|ES| 2:1 9:1 19:1 60:1 104:1 187:1 304:1 417:1 643:1 661:1 862:1 934:1 936:1 1018:1 1025:1 1379:1 1380:1 1381:1 1382:1 1383:1 1384:1 1385:1
2 	|BT| (NP (NP (NP (JJ Mammary) (NN tumour)) (NP (VBN observed) (NN EphB4) (JJ transgenic) (NN animal))) (: ;) (NP (ADVP (RB however)) (, ,) (NP (NP (JJ double) (JJ transgenic) (NN animal) (VBG expressing) (NN EphB4) (NN neuT) (NN gene)) (, ,) (NP (NN tumour) (NN appearance)) (S (S (ADVP (RB significantly)) (VP (VBD accelerated))) (, ,) (NP (NP (NN contrast) (JJ neuT-only) (NN animal)) (, ,) (NP (NN metastasis)) (NP (VBD observed) (NN lung))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 19:B01.050 113:C04.697.650 182:A04.411 352:B01.050.050.136 407:E01.370.225.812.735.550 408:C04.588.531|ES| 2:1 9:1 19:1 46:1 124:1 217:1 261:1 285:1 328:1 806:1 810:1 1011:1 1379:1 1386:1 1387:1 1388:1 1389:1 1390:1 1391:1 1392:1 1393:1
2 	|BT| (S (NP (JJ Maternal) (NN folate) (NN level) (NN polymorphism) (JJ folate-related) (NN gene)) (VP (VBN known) (NP (NP (NN risk) (NN factor) (JJ neural) (NN tube) (NN defect)) (PRN (-LRB- -LRB-) (NP (NNS NTDs)) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 224:D03.438.733.631.400 307:G05.365.795 409:E05.318.740.600.800.725 410:F01.829.263.500.320.200 411:C10.500.680|ES| 9:1 10:1 14:1 19:1 171:1 185:1 249:1 556:1 588:1 778:1 1060:1 1394:1 1395:1 1396:1 1397:1 1398:1
2 	|BT| (S (NP (NNS METHODS) (: :)) (NP (NP (JJ Aberrant) (NN methylation) (NN status) (NN p16) (NN promoter) (NN region)) (, ,) (NP (NN expression) (NN product)) (, ,) (NP (NP (NN loss) (NN heterozygosity)) (PRN (-LRB- -LRB-) (NP (NN LOH)) (-RRB- -RRB-))) (NP (NN 9p21))) (VP (VBD examined) (NP (NP (NP (ADJP (RB surgically) (JJ resected)) (NN lung) (NN specimen) (CD 57) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 28) (JJ male) (CD 29) (NN female)) (-RRB- -RRB-))) (S (NP (JJ peripheral-type) (NN lung) (NN adenocarcinoma)) (VP (VBG measuring) (NP (ADVP (JJR <) (: /)) (NP (JJ =) (CD 2) (NN cm) (NN diameter)))))))) |ET| |BS|36:G02.111.087.029.538 50:M01.643 115:E04 168:E05.581 182:A04.411 196:G02.111.570.080.689.675 203:G05.360.340.024.340.375.249.375 228:E05.978 290:G05.365.590.029.530|ES| 2:1 10:1 14:1 19:1 32:1 80:1 81:1 83:1 104:1 115:1 120:1 148:1 255:1 312:1 324:1 326:1 328:1 416:1 528:1 565:1 667:1 675:1 1004:1 1154:1 1312:1 1313:1 1399:1 1400:1 1401:1 1402:1 1403:1 1404:1 1405:1 1406:1 1407:1 1408:1 1409:1
2 	|BT| (NP (NP (NN Methylation) (NN TFPI2) (NN stool) (NN DNA)) (: :) (NP (JJ potential) (JJ novel) (NN biomarker) (NN detection) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 36:G02.111.087.029.538 158:D23.101 198:D13.444.308 259:D12.776.395.240.150.500 355:A12.459|ES| 17:1 18:1 19:1 104:1 572:1 666:1 827:1 885:1 891:1 1023:1 1184:1 1185:1
2 	|BT| (S (NP (NNS Mutations) (NN EGFR) (NN gene)) (VP (VBD detected) (NP (NP (JJ pulmonary) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NNS ADCs)) (-RRB- -RRB-))))) |ET| |BS|18:G05.365.590 358:G05.360.340.024.340.375.500.791.295.300|ES| 9:1 10:1 14:1 19:1 187:1 255:1 948:1 1007:1 1410:1 1411:1
2 	|BT| (NP (NP (NNP New) (NN aspect) (JJ clinicopathologic) (NN oncogene) (NN study)) (NP (CD 23) (JJ pulmonary) (JJ lymphoepithelioma-like) (NN carcinoma))) |ET| |BS|9:G05.360.340.024.340.375.500 182:A04.411 265:C04.557.470.200|ES| 19:1 24:1 131:1 304:1 948:1 1412:1 1413:1 1414:1 1415:1 1416:1
2 	|BT| (S (NP (NN OBJECTIVE) (: :)) (VP (TO To) (VP (VB test) (SBAR (IN whether) (S (NP (NP (NP (JJ brain-targeted) (NN gene) (NN therapy) (JJ recombinant) (JJ adeno-associated) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN rAAV5)) (-RRB- -RRB-))) (: -) (NP (NN IDUA) (NN vector) (NN MPS-I) (JJ transgenic) (NN mouse) (NN model))) (VP (MD would) (VP (VB reverse) (NP (JJ pathological) (NN hallmark))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 99:B01.050.050.136.500 367:A08.186.211 412:C16.320.565.202.715.640 413:B04.280.580.650.170 414:B04.280.580.650.170 415:F01.658.500 416:G05.360.337 417:H02.403.650|ES| 9:1 10:1 14:1 19:1 52:1 72:1 104:1 130:1 221:1 285:1 362:1 828:1 866:1 939:1 1417:1 1418:1 1419:1 1420:1 1421:1 1422:1 1423:1 1424:1 1425:1 1426:1 1427:1
2 	|BT| (NP (NP (NP (JJ Odd-skipped) (JJ related) (CD 1) (JJ novel) (NN tumour) (NN suppressor) (NN gene)) (JJ potential) (JJ prognostic) (NN biomarker) (JJ gastric) (NN cancer))) |ET| |BS|158:D23.101 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500|ES| 9:1 18:1 19:1 86:1 98:1 419:1 700:1 827:1 884:1 885:1 891:1 1011:1 1428:1
2 	|BT| (S (PP (IN Of) (NP (JJ acidophilic) (NN lesion))) (PRN (, ,) (NP (NP (NP (NN majority) (NN focus)) (PRN (-LRB- -LRB-) (NP (NP (CD 28/32)) (, ,) (NP (CD 88) (NN %))) (-RRB- -RRB-))) (NN adenoma) (-LRB- -LRB-) (CD 47/50) (, ,) (NP (CD 94) (NN %))) (-RRB- -RRB-)) (VP (VBD expressed) (NP (NP (VBN increased) (NN bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (VP (VBN increased) (SBAR (S (NP (NN bcl-2)) (VP (VBN observed) (NP (NP (ADJP (CD 12.5) (NN %)) (JJ acidophilic) (JJ preneoplastic) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 4/32)) (-RRB- -RRB-))) (NP (NP (ADJP (CD 14) (NN %)) (JJ acidophilic) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (CD 7/50)) (-RRB- -RRB-))))))))))) |ET| |BS|17:C04.557.470.035 54:G05.360.340.024.340.375.500.791.150 418:D12.644.360.075.718.937 419:C04.557.465.625.650.025|ES| 2:1 6:1 10:1 14:1 19:1 42:1 47:1 151:1 198:1 261:1 369:1 372:1 1131:1 1194:1 1429:1 1430:1 1431:1 1432:1 1433:1 1434:1 1435:1 1436:1 1437:1 1438:1 1439:1 1440:1 1441:1
2 	|BT| (SINV (PP (IN Of) (NP (JJ small-cell) (JJ heterogeneous) (JJ basophilic) (NN lesion))) (, ,) (CD 86) (VP (NN %) (VP (NN focus) (SBAR (S (-LRB- -LRB-) (S (S (NP (NP (QP (CD 31/36) (-RRB- -RRB-) (CD 85) (NN %)) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (CD 35/41)) (-RRB- -RRB-))) (VP (VBD exhibited) (NP (NP (VBN increased) (NN bcl-2) (NN protein) (NN level)) (PP (VBN compared) (S (VP (VBG surrounding) (NP (JJ normal) (NNS hepatocytes)))))))) (, ,) (IN whereas) (S (NP (NP (NP (ADJP (CD 12.5) (NN %)) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 4/36)) (-RRB- -RRB-))) (ADJP (CD 12) (NN %)) (NN adenoma) (PRN (-LRB- -LRB-) (NP (CD 5/41)) (-RRB- -RRB-))) (VP (VBD exhibited) (NP (NP (NP (VBN increased) (NN bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-))) (NN level)))))))))) |ET| |BS|7:D12.776 17:C04.557.470.035 41:A11 54:G05.360.340.024.340.375.500.791.150 175:J01.897.280.500.269 262:A11.436.348 418:D12.644.360.075.718.937 420:A11.118.637.415.120 421:G05.365.331 422:N01|ES| 2:1 4:1 10:1 14:1 19:1 42:1 47:1 50:1 118:1 151:1 249:1 369:1 372:1 609:1 894:1 1120:1 1131:1 1429:1 1431:1 1435:1 1436:1 1437:1 1442:1 1443:1 1444:1 1445:1 1446:1 1447:1 1448:1 1449:1 1450:1 1451:1
2 	|BT| (S (ADVP (NP (CD One) (NN year)) (RB later)) (, ,) (NP (JJ intra-abdominal) (JJ metastatic) (NN tumor)) (VP (VBD detected) (ADJP (JJ resected)))) |ET| |BS|8:C04 9:G05.360.340.024.340.375.500 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 30:Z01.058.290.190.800 31:D08.811.520.224.800 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 158:D23.101 198:D13.444.308 303:C04.557.450.795 372:G05.360.340.024.340.137.232 423:A01.923.047.025 424:L01.143.506.423.557 425:G01.358.500.505.650 426:E01.370.350.515 427:C04.588.033 428:D27.720.233|ES| 2:1 7:1 9:1 19:1 68:1 118:1 127:1 272:1 337:1 344:1 534:1 654:1 666:1 806:1 833:1 965:1 1007:1 1021:1 1055:1 1250:1 1255:1 1327:1 1400:1 1452:1 1453:1 1454:1 1455:1 1456:1 1457:1 1458:1 1459:1 1460:1 1461:1 1462:1 1463:1 1464:1 1465:1 1466:1 1467:1
2 	|BT| (S (NP (PRP$ Our) (NNS data)) (ADVP (RB firmly)) (VP (VBP establish) (NP (JJ unique) (JJ oncogenic) (NN capability) (NN DNp73) (NN drive)) (ADVP (FW hepatocarcinogenesis) (FW vivo)) (, ,) (S (VP (VBG supporting) (NP (NN significance) (NN marker) (NN disease) (NN severity) (NN patient) (NN target) (NN cancer) (NN prevention)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 66:F01.658.293 158:D23.101 279:D27.888.569.100 288:C23.550.288|ES| 2:1 18:1 19:1 120:1 160:1 181:1 220:1 378:1 534:1 557:1 658:1 793:1 900:1 953:1 998:1 1468:1 1469:1 1470:1 1471:1 1472:1 1473:1 1474:1
2 	|BT| (NP (NP (PRP$ Our) (S (VP (NN finding) (VP (VB identify) (NP (NN EphA1) (JJ potential) (JJ prognostic) (NN marker) (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 158:D23.101|ES| 19:1 245:1 534:1 658:1 827:1 832:1 884:1 927:1 994:1
2 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (JJ allelic) (NN loss) (NN FHIT) (NN gene)) (VP (MD may) (NP (VBN involved) (NN carcinogenesis) (JJ peripheral) (NN lung) (NN patient) (NN IPF))))))) |ET| |BS|6:G05.360.340.024.340 33:C04.697.098 50:M01.643 182:A04.411 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765|ES| 9:1 19:1 32:1 120:1 207:1 328:1 491:1 658:1 774:1 796:1 927:1 946:1 1122:1 1475:1 1476:1
2 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (SBAR (S (NP (NN KLLN)) (VP (MD might) (VP (VBN used) (NP (JJ potential) (JJ prognostic) (NN marker) (JJ novel) (NN therapy) (NN target) (NN breast) (NN carcinoma)))))))) |ET| |BS|52:E02 158:D23.101 259:D12.776.395.240.150.500 429:N04.761.559.590.900 430:E05.581.249|ES| 19:1 23:1 130:1 160:1 304:1 476:1 534:1 658:1 796:1 798:1 827:1 884:1 891:1 1477:1 1478:1
2 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (NP (S (NP (NN miR-9) (NN miR-197)) (VP (ADVP (RB specifically)) (VBP downregulate) (NP (NN MTHFD1L) (NN level) (NN HEK293) (NN MCF-7) (NN cell) (NN SNPrs7646)) (ADVP (RB significantly)) (VP (VBP affect) (NP (NP (NN miR-197) (NN binding) (NN affinity) (NN MTHFD1L) (CD 3)) ('' ') (NN UTR)) (, ,) (S (VP (VBG causing) (NP (NP (JJ efficient) (JJ posttranscriptional) (NN gene) (NN repression) (NN presence) (NN allele)) (VP (VBN associated)))))))) (NP (VBD increased) (NN risk) (NNS NTDs))))) |ET| |BS|6:G05.360.340.024.340 61:E05.318.740.600.800 77:G05.360.340.024.340.030 208:F01.393.821 252:F02.784.692.351 411:C10.500.680 431:D13.444.735.544.875 432:A11.251.210.190.630 433:F01.470.047|ES| 2:1 9:1 19:1 47:1 94:1 101:1 124:1 169:1 171:1 230:1 249:1 346:1 508:1 658:1 706:1 862:1 1279:1 1398:1 1479:1 1480:1 1481:1 1482:1 1483:1 1484:1 1485:1 1486:1 1487:1 1488:1 1489:1 1490:1 1491:1 1492:1 1493:1
2 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (S (NP (NN offer) (JJ preclinical) (NN rationale)) (VP (VBG warranting) (NP (NP (JJ clinical) (NN investigation)) (VP (VBG combining) (NP (NNS HDACi) (NN EGFR) (JJ HER2-targeted) (NN therapy) (NN CRC) (NN treatment))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 225:E05.337|ES| 19:1 84:1 101:1 130:1 187:1 245:1 505:1 546:1 658:1 1042:1 1494:1 1495:1 1496:1 1497:1 1498:1 1499:1
2 	|BT| (NP (NP (NN Overactivation) (NN Wnt-beta-catenin) (NN signaling)) (, ,) (PP (VBG including) (NP (NP (NN beta-catenin-TCF) (NN target) (NN gene) (NN expression)) (, ,) (NP (NP (NN hallmark) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NN development))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 105:G02.149.115.800.925 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 35:1 115:1 160:1 195:1 245:1 561:1 1427:1 1500:1 1501:1 1502:1
2 	|BT| (NP (NP (NN P53) (NN gene) (JJ deficient) (NN mouse)) (SBAR (-LRB- -LRB-) (S (S (NP (NN p53) (PRN (: -) (: /) (: -) (-RRB- -RRB-))) (VP (VBD found) (ADVP (RB spontaneously)) (VP (VB develop) (NP (JJ malignant) (NN lymphoma) (NN hemangiosarcoma))))) (, ,) (IN whereas) (FRAG (NP (NN heterozygote)) (-LRB- -LRB-) (NP (NP (NP (NN p53)) (CC +) (: /) (: -) (-RRB- -RRB-) (NN mouse) (NN display) (JJ high) (NN incidence) (NN tumor) (JJ urinary) (NN bladder)) (VP (VBN treated) (NP (NN N-butyl-N) (: -) (-LRB- -LRB-) (NN 4-hydroxybutyl) (-RRB- -RRB-) (NN nitrosamine)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 157:G05.380.383 176:C04.557.386 434:E05.318.308.985.525.375 435:C04.557.450.795.390 436:C04.588.945.947.960 437:D02.654.442|ES| 2:1 7:1 9:1 10:1 14:1 19:1 37:1 52:1 178:1 372:1 564:1 591:1 648:1 802:1 1033:1 1099:1 1503:1 1504:1 1505:1 1506:1 1507:1 1508:1 1509:1 1510:1 1511:1 1512:1 1513:1 1514:1
2 	|BT| (NP (NP (NN Pdcd4)) (S (-LRB- -LRB-) (NP (VBN programmed) (NP (NP (NN cell) (NN death) (CD 4) (-RRB- -RRB-) (NN gene)) (NN tumor) (NN suppressor) (NN expression))) (ADVP (RB frequently)) (VP (VBD down-regulated) (NP (NN tumor)) (, ,) (NP (NP (VBN considered) (JJ diagnostic) (JJ prognostic) (NN marker)) (NP (ADJP (RB well) (JJ promising)) (NN target) (JJ anti-cancer) (NN therapy)))))) |ET| |BS|6:G05.360.340.024.340 8:C04 39:G04.299.139.160 52:E02 142:I01.880.604 158:D23.101 206:G05.360.340.024.340.375.249 263:E01 351:A17.360|ES| 2:1 7:1 9:1 10:1 14:1 19:1 94:1 115:1 130:1 160:1 319:1 411:1 534:1 698:1 700:1 787:1 884:1 903:1 1061:1 1112:1 1283:1 1515:1 1516:1 1517:1
2 	|BT| (NP (NP (NP (NN Point) (NN mutation) (JJ K-ras) (NN gene)) (, ,) (VP (VBD found) (NP (NP (ADJP (QP (CD 10) (CD 30)) (NN %)) (NN lung) (NN adenocarcinoma)) (, ,) (NP (VBN regarded) (RB early) (NN event) (NN carcinogenesis)))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 438:G05.365.590.675|ES| 2:1 9:1 19:1 34:1 37:1 205:1 207:1 255:1 328:1 369:1 1121:1 1128:1 1518:1 1519:1 1520:1 1521:1
2 	|BT| (NP (NP (NP (JJ Primary) (JJ renal) (NN neoplasm) (NN ASPL-TFE3) (NN gene) (NN fusion) (JJ alveolar) (JJ soft) (NN part) (NN sarcoma)) (: :) (S (NP (JJ distinctive) (NN tumor) (NN entity)) (ADVP (RB previously)) (VP (VBD included) (PP (IN among) (NP (JJ renal) (NN cell) (NN carcinoma) (NN child))) (ADVP (JJ adolescent)))))) |ET| |BS|8:C04 274:C04.588.945.947.535 295:C04.557.470.200.025.390 359:G05.355.760.385 439:C04.557.450.590.775 440:M01.060.057 441:M01.060.406|ES| 7:1 9:1 19:1 94:1 104:1 304:1 451:1 922:1 935:1 936:1 1117:1 1287:1 1372:1 1522:1 1523:1 1524:1 1525:1 1526:1 1527:1 1528:1 1529:1 1530:1
2 	|BT| (S (NP (NN PURPOSE) (: :)) (VP (VBG Activating) (NP (NP (NP (NP (JJ somatic) (NN mutation) (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN gene)) (ADJP (ADJP (JJ present)) (ADJP (JJ small))) (NN subset) (NN lung) (NN adenocarcinoma)))) |ET| |BS|18:G05.365.590 442:G05.360.340.024.340.375.500.791.295.300 443:G05.700.264|ES| 9:1 10:1 14:1 19:1 34:1 102:1 104:1 184:1 185:1 186:1 187:1 255:1 328:1 388:1 687:1 750:1 950:1 1285:1 1307:1
2 	|BT| (S (NP (VBN Reduced) (NN ING1b) (NN gene) (NN expression)) (VP (VBP play) (NP (NP (JJ important) (NN role)) (NN carcinogenesis) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN patient)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 33:C04.697.098 50:M01.643 79:I03.450.642.693 110:C04.588.894.797.520.109.220.249 155:G05.355.310|ES| 9:1 18:1 19:1 31:1 94:1 115:1 120:1 207:1 238:1 328:1 694:1 902:1 1134:1 1531:1
2 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN EGFR) (NN gene) (NN mutation)) (VP (VBD identified) (NP (NP (CD 13) (NN %)) (NP (JJ primary) (NN tumor))))) |ET| |BS|8:C04 18:G05.365.590 358:G05.360.340.024.340.375.500.791.295.300|ES| 7:1 9:1 19:1 34:1 104:1 187:1 344:1 369:1 623:1 710:1 1532:1
2 	|BT| (S (NP (NN SMO)) (VP (MD might) (NP (NP (JJ good) (JJ therapeutic) (NN target) (NN patient)) (NP (JJ colorectal) (NN polyp) (NN carcinoma))) (, ,) (NP (RB even) (NN absence) (NN Hh) (NN signal) (NN activation)))) |ET| |BS|50:M01.643 52:E02 265:C04.557.470.200 444:C23.300.825|ES| 2:1 17:1 19:1 120:1 160:1 225:1 304:1 541:1 647:1 798:1 859:1 1268:1 1270:1 1318:1 1533:1 1534:1
2 	|BT| (S (NP (NN SPOCK1) (NN act) (NN oncogene)) (VP (MD may) (NP (NP (JJ prognostic) (NN factor) (JJ therapeutic) (NN target) (NN patient)) (NP (NNP GBC))))) |ET| |BS|9:G05.360.340.024.340.375.500 50:M01.643 52:E02 81:E02.095.465.425.400.330.050.400|ES| 19:1 24:1 120:1 160:1 185:1 246:1 491:1 541:1 884:1 1535:1 1536:1
2 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBD suggested) (SBAR (S (NP (NN ING5) (NN downregulation)) (VP (MD might) (VP (VBN involved) (SBAR (S (NP (NP (NN carcinogenesis)) (, ,) (NP (NN growth)) (, ,) (NP (NN invasion) (NN lung) (NN cancer))) (VP (MD could) (VP (VBN considered) (S (NP (JJ promising) (NN marker) (NN gauge) (NN aggressiveness) (NN lung) (NN cancer))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 45:G07.700.320.249 85:G02.111.087.225 158:D23.101 162:F01.145.126.125|ES| 2:1 18:1 19:1 102:1 207:1 328:1 534:1 595:1 620:1 774:1 793:1 798:1 908:1 925:1 1061:1 1316:1 1517:1 1537:1 1538:1 1539:1 1540:1
2 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBG finding) (SBAR (S (NP (JJ indicated) (NN PVT1/EZH2/LATS2) (NN interaction)) (VP (MD might) (VP (VB serve) (NP (JJ new) (NN target) (NN lung) (NN adenocarcinoma) (NN diagnosis) (NN therapy)))))))) |ET| |BS|52:E02 263:E01|ES| 2:1 19:1 130:1 160:1 255:1 328:1 532:1 618:1 712:1 798:1 927:1 1037:1 1537:1 1538:1 1541:1 1542:1
2 	|BT| (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (VBN demonstrated) (JJ first) (NN time) (NN miR-372)) (VP (VBZ suppresses) (NP (NN tumorigenesis) (NN development) (NN EC))))))) (: ;) (FRAG (NP (NP (NN RhoC)) (JJ new) (ADJP (RB potentially) (JJ important)) (JJ therapeutic) (NN target)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 52:E02 322:G01.910|ES| 2:1 19:1 35:1 78:1 101:1 160:1 217:1 541:1 686:1 712:1 773:1 816:1 902:1 1081:1 1175:1 1537:1 1538:1 1543:1 1544:1 1545:1
2 	|BT| (S (NP (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (JJ present) (NN work)) (VP (VBD revealed) (NP (JJ novel) (NN function) (NN TIP30)) (, ,) (VP (ADVP (RB possibly)) (VBN used) (S (NP (JJ independent) (ADJP (JJ prognostic) (NN factor) (JJ potential)) (JJ therapeutic) (NN target) (JJ gastric) (NN cancer)))))) |ET| |BS|52:E02 259:D12.776.395.240.150.500 445:I03.946|ES| 2:1 18:1 19:1 33:1 86:1 160:1 185:1 275:1 476:1 541:1 827:1 883:1 884:1 891:1 1307:1 1537:1 1538:1 1546:1 1547:1 1548:1
2 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN SRC-3)) (VP (MD may) (NP (JJ important) (NN oncogene) (JJ therapeutic) (NN target) (NN lung) (NN cancer))))))) |ET| |BS|9:G05.360.340.024.340.375.500 52:E02|ES| 2:1 18:1 19:1 24:1 160:1 328:1 491:1 541:1 793:1 796:1 902:1 1537:1 1538:1 1549:1
2 	|BT| (S (NP (NNP TaqMan) (NN PCR) (NN genotyping) (NN technology)) (VP (VBD used) (VP (VB detect) (NP (NP (NP (NN genotype) (NN ITGA3) (NN gene) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN rs2230392)) (, ,) (NP (NN rs2285524) (NN rs16948627))) (-RRB- -RRB-))) (NP (JJ peripheral) (NN blood)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 61:E05.318.740.600.800 225:E05.337 386:F02.463.425.069 396:G05.380 434:E05.318.308.985.525.375 446:G05.365.795.598 447:C04.557.450.565.575.650 448:E05.393.620.500 449:A12.207.152 450:J01.897|ES| 2:1 7:1 9:1 10:1 14:1 19:1 171:1 336:1 476:1 780:1 875:1 1298:1 1329:1 1476:1 1511:1 1550:1 1551:1 1552:1 1553:1 1554:1 1555:1 1556:1 1557:1 1558:1 1559:1 1560:1 1561:1 1562:1
2 	|BT| (S (NP (JJ Testis-specific) (NN Fank1) (NN gene) (JJ knockdown) (NN mouse)) (VP (VBP produce) (NP (NN oligospermia)) (PP (IN via) (NP (NN apoptosis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 400:E05.393.335.500 451:C12.294.365.700.508 452:A05.360.444.849|ES| 9:1 19:1 52:1 89:1 464:1 596:1 1563:1 1564:1 1565:1 1566:1
2 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBD determine) (SBAR (IN whether) (S (S (VP (VBG combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam)))) (VP (MD could) (VP (VB offer) (NP (ADJP (ADJP (JJR better)) (ADJP (JJ therapeutic))) (NN effect) (NN combat) (NN HCC) (NN mouse)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 74:1 75:1 130:1 131:1 221:1 441:1 541:1 691:1 904:1 908:1 1042:1 1088:1 1089:1 1498:1 1567:1 1568:1
2 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP evaluate) (NP (NN hypermethylation) (JJ spastic) (NN paraplegia-20) (NN promoter) (JJ potential) (NN biomarker) (JJ prognostic) (NN factor) (JJ gastric) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 158:D23.101 225:E05.337 453:C10.597.622.669|ES| 18:1 19:1 83:1 86:1 131:1 185:1 664:1 691:1 827:1 884:1 885:1 890:1 1567:1 1569:1 1570:1
2 	|BT| (S (S (NP (DT The) (NN aim) (NN work)) (VP (VP (VB evaluate) (SBAR (IN whether) (S (NP (NN TP53) (NN mutation)) (VP (VBN classified) (ADVP (RB functionally)) (ADJP (JJ inactive)))))) (PRN (-LRB- -LRB-) (NP (ADJP (ADJP (JJR <)) (CC or) (ADJP (JJ =))) (ADJP (CD 20) (NN %)) (JJ wildtype) (NN transactivation) (NN ability)) (-RRB- -RRB-))) (S (NP (NP (JJ different) (JJ prognostic) (JJ predictive) (NN value) (NN CRC)) (VBN compared) (NN mutation)) (VP (VBD retained) (NP (JJ significant) (NN activity)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 385:F02.784.629.131 395:L01.100 445:I03.946 454:G05.355.315.800|ES| 10:1 14:1 19:1 34:1 50:1 135:1 221:1 245:1 312:1 369:1 399:1 414:1 533:1 691:1 884:1 890:1 1018:1 1248:1 1300:1 1546:1 1567:1 1571:1 1572:1 1573:1 1574:1 1575:1 1576:1 1577:1
2 	|BT| (NP (NP (NP (DT The) (NN expression) (JJ gastric) (NN cancer) (NN marker) (NN MUC1)) (, ,) (NP (NN MUC2)) (, ,) (NP (NN MUC5AC)) (, ,) (NP (NN oncogene) (NN c-myc)) (, ,) (NP (NN c-met)) (, ,) (NP (NN cyclin) (NN E1)) (, ,) (NP (NN cancer) (NN stem) (NN cell) (NN marker) (NN CD44)) (VP (VBD determined) (NP (NN MGCC3I) (NN cell))))) |ET| |BS|41:A11 158:D23.101 332:A11.872.650|ES| 2:1 18:1 19:1 24:1 86:1 94:1 115:1 210:1 212:1 455:1 534:1 691:1 743:1 1106:1 1578:1 1579:1 1580:1 1581:1 1582:1 1583:1
2 	|BT| (S (NP (NP (DT The) (NN lung) (NN adenocarcinoma) (NN cell) (NN bearing) (JJ K-ras) (NN gene) (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN A549) (NN H820)) (-RRB- -RRB-))) (VP (VBD showed) (NP (ADJP (RB consistently) (JJR higher)) (NN level) (NN cell) (NN motility)) (S (PP (IN without) (NP (NP (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN TKB6) (NN TKB14)) (-RRB- -RRB-)))) (, ,) (NP (NN motility) (NN A549) (NN H820) (NN cell)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN dnAkt) (NN transfection)))))) |ET| |BS|18:G05.365.590 41:A11 122:C14.280.383 217:E05.393.350.810 455:B01.050.150.900.649.147.890|ES| 2:1 9:1 10:1 14:1 19:1 34:1 94:1 124:1 132:1 170:1 249:1 255:1 328:1 364:1 365:1 691:1 746:1 1121:1 1177:1 1195:1 1584:1 1585:1 1586:1 1587:1 1588:1 1589:1
2 	|BT| (FRAG (NP (DT The) (NN morphology) (CD eight) (NN ASPL-TFE3) (JJ fusion-positive) (JJ renal) (NN tumor)) (, ,) (PP (IN although) (NP (NP (VBG overlapping) (NN aspect) (JJ classic) (NNS ASPS)) (, ,) (VP (ADVP (RB closely)) (VBZ resembles) (NP (NP (JJ renal) (NN cell) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN RCC)) (-RRB- -RRB-)))) (, ,) (NP (FW priori) (NN diagnosis) (NN case))))) |ET| |BS|263:E01 274:C04.588.945.947.535 295:C04.557.470.200.025.390|ES| 2:1 7:1 10:1 14:1 19:1 94:1 112:1 304:1 348:1 691:1 855:1 922:1 923:1 934:1 935:1 1037:1 1413:1 1590:1 1591:1 1592:1 1593:1 1594:1 1595:1 1596:1
2 	|BT| (NP (NP (NP (DT The) (JJ recombinant) (NN plasmid)) (NP (VBN transfected) (JJ human) (ADJP (NN lung) (NN cancer) (NN A549) (NN cell) (JJ liposome-mediated)) (NN method)))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 456:D25.479.517 457:G05.360.600|ES| 18:1 19:1 36:1 94:1 328:1 364:1 479:1 691:1 1420:1 1597:1 1598:1 1599:1
2 	|BT| (S (NP (DT The) (JJ resultant) (NN MLL) (NN fusion) (NN protein)) (VP (VBN known) (VP (VBP mediate) (NP (NN leukaemia) (NN disruption) (JJ normal) (JJ epigenetic) (NN regulation) (NN target) (NN gene) (NN locus))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 142:I01.880.604 361:C04.557.337 458:G05.360.340.024.380|ES| 4:1 9:1 19:1 118:1 160:1 377:1 438:1 556:1 691:1 936:1 1207:1 1263:1 1600:1 1601:1 1602:1 1603:1
2 	|BT| (S (NP (NP (DT The) (JJ significant) (NN association) (NN SNIP1) (NN c-Myc) (NN staining) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN tissue) (NN array) (NN evidence) (NN activity)) (VP (MD might) (VP (VBN linked)))) (VP (VBZ suggests) (SBAR (S (NP (NN SNIP1)) (VP (MD might) (NP (JJ important) (NN modulator) (NN c-Myc) (NN activity) (NN carcinogenesis))))))) |ET| |BS|12:Z01.542.049 33:C04.697.098 98:A10 110:C04.588.894.797.520.109.220.249 386:F02.463.425.069|ES| 18:1 19:1 38:1 94:1 135:1 207:1 272:1 328:1 331:1 399:1 691:1 694:1 798:1 824:1 902:1 1298:1 1363:1 1604:1 1605:1 1606:1 1607:1
2 	|BT| (S (NP (DT The) (JJ significant) (NN link) (NN tobacco) (NN loss) (NN p16) (NN locus)) (VP (VBZ identifies) (NP (JJ additional) (JJ genetic) (NN target) (NN smoking) (NN pathogenesis) (NN lung) (NN cancer)))) |ET| |BS|203:G05.360.340.024.340.375.249.375 459:B01.650.940.800.575.100.905.900 460:B01.650.940.800.575.100.905.900 461:F01.145.958.500 462:J01.637.836|ES| 18:1 19:1 32:1 135:1 160:1 328:1 377:1 501:1 691:1 864:1 980:1 1313:1 1608:1 1609:1 1610:1 1611:1
2 	|BT| (S (NP (DT The) (JJ siRNA-mediated) (NN DEPDC1) (NN depletion)) (VP (VBD resulted) (NP (NP (JJ significant) (NN inhibition) (NN proliferation) (NN delay) (NN cell) (NN cycle) (NN progression) (NN NPC) (NN cell) (NN line)) (, ,) (NP (NN CNE-1) (NN HNE-1))))) |ET| |BS|16:C23.550.291.656 43:F01.145.544 117:D13.150.650.700 353:G04.299.134|ES| 2:1 19:1 48:1 94:1 103:1 135:1 136:1 264:1 299:1 594:1 601:1 691:1 1174:1 1612:1 1613:1 1614:1 1615:1 1616:1
2 	|BT| (NP (NP (DT The) (JJ unbalanced) (NN translocation)) (, ,) (NP (NN der) (-LRB- -LRB-) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;) (CD q25)) (-RRB- -RRB-) (, ,) (NP (NP (JJ characteristic) (JJ alveolar) (JJ soft) (NN part) (NN sarcoma)) (PRN (-LRB- -LRB-) (NP (NN ASPS)) (-RRB- -RRB-)))) |ET| |BS|439:C04.557.450.590.775 463:C23.550.210.870|ES| 2:1 10:1 14:1 19:1 217:1 336:1 451:1 691:1 923:1 929:1 930:1 931:1 932:1 1117:1 1287:1 1524:1 1617:1 1618:1 1619:1
2 	|BT| (S (ADVP (RB Therefore)) (NP (NN bile) (NN duct) (NN cancer) (NN patient)) (VP (MD may) (NP (VBN treated) (NN miR-34a) (NN inhibitor) (NN Per1) (NN stimulator) (NN future)))) |ET| |BS|50:M01.643 52:E02 354:I01.320|ES| 18:1 19:1 120:1 380:1 491:1 1099:1 1190:1 1620:1 1621:1 1622:1 1623:1 1624:1 1625:1
2 	|BT| (S (NP (DT These) (NNS data) (NN challenge) (NN view) (NN MYH11) (NN passive) (NN differentiation) (NN marker)) (VP (VBG functioning) (S (NP (NN muscle) (NN contraction)) (VP (VBP add) (S (VP (VBG understanding) (NP (JJ intestinal) (NN neoplasia)))))))) |ET| |BS|74:G04.299.151 102:C04.588.274.476.411 158:D23.101 239:F02.463.188.357 375:Z01.639.100 464:G11.427.590.540|ES| 19:1 109:1 215:1 534:1 640:1 792:1 793:1 905:1 1371:1 1626:1 1627:1 1628:1 1629:1 1630:1 1631:1 1632:1
2 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
2 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP indicate) (SBAR (S (NP (NNP BIM) (NN deletion) (NN polymorphism) (JJ common) (JJ Korean) (NN NSCLC) (NN patient)) (ADVP (RB significantly)) (VP (VBP affect) (NP (JJ intrinsic) (JJ biologic) (NN function) (JJ BH3-only) (NN protein)))))))) |ET| |BS|7:D12.776 50:M01.643 110:C04.588.894.797.520.109.220.249 306:G05.355.600.800 307:G05.365.795 433:F01.470.047 465:D23|ES| 4:1 19:1 33:1 120:1 124:1 329:1 655:1 792:1 927:1 1059:1 1060:1 1479:1 1486:1 1633:1 1634:1 1635:1 1636:1 1637:1
2 	|BT| (S (NP (DT These) (VBG finding) (NP (VBN suggested) (NN Notch1) (NN signaling))) (VP (VBP play) (NP (NP (NP (JJ important) (NN role) (NN maintenance) (NN cancer)) (JJ stem-like) (NN phenotype) (JJ diffuse) (NN type) (JJ gastric) (NN cancer) (NN RBP-Jkappa) (JJ dependent) (NN pathway)) (VP (VBG inhibiting) (NP (NN Notch1) (NN signaling)))) (VP (MD could) (NP (JJ effective) (NN therapy) (NN CD133) (JJ positive) (JJ diffuse) (NN type) (JJ gastric) (NN cancer))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 52:E02 69:G02.111.087.800 79:I03.450.642.693 80:G05.695 122:C14.280.383 188:N02.628 309:A18.024.937|ES| 18:1 19:1 31:1 86:1 130:1 195:1 233:1 236:1 238:1 321:1 383:1 543:1 651:1 652:1 653:1 792:1 880:1 902:1 908:1 925:1 927:1 1062:1 1063:1 1638:1 1639:1
2 	|BT| (NP (NP (DT These) (UCP (S (VP (VBG finding) (PP (VBN suggested) (NP (NN endostatin) (NN gene) (NN therapy))) (, ,) (S (VP (VBG using) (NP (JJ cationic) (JJ vector-mediated) (JJ intravenous) (NN gene) (NN transfer)))))) (, ,) (MD might) (NP (NP (JJ feasible) (NN strategy) (JJ organ-targeted) (NN prevention) (NN regulation)) (JJ possible) (VBN disseminated) (NN cancer))))) |ET| |BS|123:G05.360.337 142:I01.880.604 466:D12.644.276.100.450.750 467:D01.248.497.300|ES| 2:1 9:1 18:1 19:1 130:1 350:1 438:1 792:1 798:1 925:1 927:1 1114:1 1359:1 1474:1 1640:1 1641:1 1642:1 1643:1 1644:1 1645:1 1646:1 1647:1
2 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (NP (NP (NN favour) (ADJP (ADJP (JJ non-invasive)) (, ,) (ADJP (JJ ALK-gene))) (NN status)) (JJ pre-screening) (JJ routine) (NN basis) (NNS CTCs)) (VP (VBN isolated) (NP (NP (NN patient) (NN lung) (NN cancer)) (SBAR (S (NP (JJ open) (JJ new) (NN avenue) (JJ real-time) (NN monitoring)) (VP (VBD adapted) (NP (VBN targeted) (NN therapy)))))))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 52:E02 322:G01.910 468:G07.700.062.133|ES| 2:1 16:1 18:1 19:1 101:1 120:1 130:1 328:1 416:1 712:1 792:1 874:1 1140:1 1361:1 1648:1 1649:1 1650:1 1651:1 1652:1 1653:1 1654:1 1655:1 1656:1 1657:1
2 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP implicate) (S (NP (NN SPARC) (NN promoter) (NN methylation) (JJ important) (NN factor) (NN tumorigenesis) (JJ gastric) (NN carcinoma)) (VP (VB provide) (NP (NP (JJ new) (NN insight) (JJ potential) (NN use)) (NP (NNP SPARC) (JJ novel) (NN biomarker) (JJ potential) (JJ clinical) (NN importance) (JJ human) (JJ gastric) (NN cancer)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 36:G02.111.087.029.538 37:D12.776.157.125.715 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875 158:D23.101 259:D12.776.395.240.150.500 265:C04.557.470.200|ES| 18:1 19:1 36:1 78:1 81:1 82:1 83:1 84:1 86:1 101:1 185:1 304:1 711:1 712:1 792:1 827:1 885:1 891:1 902:1 1141:1 1658:1 1659:1 1660:1
2 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NP (JJ VES-induced) (NN expression) (NN NAG-1) (NN mRNA/protein)) (VP (VBN regulated) (NP (JJ transcriptional/post-transcriptional) (NN mechanism) (NN p38) (JJ kinase-dependent) (NN manner) (NN NAG-1) (JJ chemopreventive/therapeutic) (NN target) (NN prostate) (NN cancer)))))))) |ET| |BS|7:D12.776 52:E02 111:D13.444.735.544 142:I01.880.604 209:G02.111.087.847 469:D08.811.913.696 470:C02.782.160.927|ES| 18:1 19:1 77:1 101:1 115:1 160:1 162:1 792:1 1479:1 1661:1 1662:1 1663:1 1664:1 1665:1 1666:1 1667:1 1668:1 1669:1
2 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP reveal) (NP (NN association) (NN SNP) (NN rs7646) (NN NTD) (NN risk))) (VP (VBZ involves) (NP (NP (NN difference) (NN microRNA) (NN regulation)) (, ,) (NP (NN highlight) (NN importance) (JJ genotype-dependent) (JJ differential) (NN microRNA) (NN regulation) (NN relation) (JJ human) (NN disease) (NN risk)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 61:E05.318.740.600.800 142:I01.880.604 184:D13.150.650.319 288:C23.550.288 386:F02.463.425.069 396:G05.380 411:C10.500.680 446:G05.365.795.598|ES| 2:1 19:1 36:1 101:1 171:1 438:1 792:1 857:1 998:1 1298:1 1561:1 1660:1 1670:1 1671:1 1672:1 1673:1 1674:1 1675:1 1676:1 1677:1 1678:1
2 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (NN ERBB4) (ADJP (ADJP (JJ novel)) (ADJP (JJ therapeutic))) (NN target) (NN subset) (NN CRC))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 259:D12.776.395.240.150.500|ES| 19:1 101:1 160:1 245:1 541:1 792:1 796:1 891:1 1285:1 1679:1
2 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (NP (NN IFN-alpha) (NN gene) (NN therapy) (JJ promising) (NN strategy) (NN treat) (NNP HCC) (NN patient)) (JJ concomitant) (NN liver) (NN cirrhosis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 52:E02 104:C04.557.470.200.025.255 357:C06.552.630|ES| 9:1 19:1 101:1 120:1 130:1 441:1 792:1 796:1 836:1 1090:1 1114:1 1199:1 1517:1 1680:1 1681:1
2 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (VBN suggested) (NN PSMA6) (NN serf) (JJ attractive) (NN target) (JJ high) (JJ therapeutic) (NN index) (NN lung) (NN cancer)))) |ET| |BS|52:E02|ES| 18:1 19:1 101:1 160:1 178:1 328:1 541:1 721:1 792:1 882:1 925:1 1242:1 1682:1
2 	|BT| (S (NP (NP (DT This) (NN study)) (VP (VBN designed))) (VP (VBP identify) (SBAR (S (NP (JJ TLR4-mediated) (NN gene) (NN expression) (NN pathway)) (VP (MD may) (VP (VBN used) (SBAR (S (NP (JJ prognostic) (NP (NN indicator) (NN susceptibility) (NN lung) (NN tumorigenesis) (NN mouse))) (VP (VBP provide) (NP (NN insight) (NN mechanism))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 155:G05.355.310 182:A04.411 401:C23.550.291.687 471:D27.720.470.410|ES| 9:1 19:1 52:1 78:1 115:1 131:1 162:1 328:1 383:1 476:1 491:1 711:1 807:1 832:1 884:1 1141:1 1353:1 1683:1 1684:1 1685:1
2 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
2 	|BT| (S (NP (DT This)) (VP (VBZ suggests) (SBAR (S (NP (NN c-Jun) (NN inhibition)) (VP (MD may) (VP (VB serve) (NP (JJ therapeutic) (NN target) (NN liver) (NN cancer)))))))) |ET| |BS|43:F01.145.544 52:E02|ES| 18:1 19:1 103:1 160:1 331:1 491:1 532:1 541:1 807:1 836:1 1686:1
2 	|BT| (S (PP (IN Through) (NP (NN combination) (NNS data) (NN mining) (JJ biochemical) (NN assay))) (, ,) (VP (VBD identified) (NP (NP (NN trophinin)) (, ,) (VP (MD could) (VP (VB enhance) (NP (NP (NN cell) (NN invasion)) (, ,) (NP (NP (JJ novel) (JJ prognostic) (NN factor)) (JJ early) (NN stage) (NN lung) (NN cancer)))))))) |ET| |BS|41:A11 106:E05.091 182:A04.411 259:D12.776.395.240.150.500 472:L01.313.500.750.280.199 473:E01.789.625|ES| 2:1 18:1 19:1 94:1 185:1 310:1 328:1 530:1 620:1 623:1 793:1 884:1 891:1 908:1 1128:1 1129:1 1266:1 1687:1 1688:1 1689:1 1690:1
2 	|BT| (NP (NP (ADVP (RB Thus)) (, ,) (NP (NP (NN inactivation) (NN p16) (NN gene) (JJ common) (NN event) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (, ,) (NP (NN mechanism) (NN gene) (NN alteration)) (VP (VBZ differs) (NP (NN smoker) (NN nonsmoker)))))) |ET| |BS|18:G05.365.590 42:G05.355.315.203.374 110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375|ES| 2:1 9:1 18:1 19:1 94:1 162:1 205:1 328:1 655:1 694:1 951:1 1313:1 1314:1 1315:1 1691:1 1692:1 1693:1
2 	|BT| (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NN DAP) (NN kinase) (NN promoter)) (NN methylation)) (VP (VBZ contributes) (NP (NP (NN TRAIL) (NN resistance) (NN NSCLC) (NN cell)) (, ,) (NP (NP (VBN measured) (NN DAP) (NN kinase) (NN promoter) (NN methylation) (NN gene) (NN expression) (NN status)) (NP (CD 11) (NN NSCLC) (NN cell) (NN line)))))))))) (VP (VBD correlated) (NP (NN methylation/expression) (NN status) (NN sensitivity) (NN cell) (NN TRAIL)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 41:A11 94:A11.251.210 110:C04.588.894.797.520.109.220.249 155:G05.355.310 228:E05.978 474:D08.811.913.696.620.682.700.125.387|ES| 2:1 9:1 19:1 74:1 81:1 83:1 94:1 115:1 221:1 264:1 329:1 416:1 446:1 470:1 607:1 789:1 828:1 845:1 1057:1 1094:1 1694:1 1695:1 1696:1
2 	|BT| (S (S (VP (TO To) (VP (VB elucidate) (NP (JJ pathogenic) (NN role) (NN MLL) (NN fusion) (NN protein) (NN HOX) (NN dysregulation) (NN leukaemia))))) (, ,) (VP (VBD generated) (NP (JJ novel) (JJ haematopoietic) (JJ lineage-specific) (NN Mll-Een) (NN knock-in) (NN mouse) (NN model)) (S (VP (VBG using) (NP (JJ Cre-mediated) (NN inversion) (NN strategy)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 259:D12.776.395.240.150.500 327:G06.930 361:C04.557.337 475:C23.550.210.190 476:A15.378|ES| 2:1 4:1 19:1 31:1 52:1 72:1 73:1 350:1 828:1 891:1 936:1 1114:1 1202:1 1204:1 1207:1 1263:1 1697:1 1698:1 1699:1 1700:1 1701:1 1702:1 1703:1 1704:1
2 	|BT| (SINV (S (VP (TO To) (VP (VB determine) (NP (NP (JJ genetic) (JJ molecular) (JJ characteristic) (NN tumor)) (VP (VBG carrying) (NP (NN EGFR) (NN gene) (NN mutation))))))) (, ,) (VBD investigated) (S (S (NP (NN EGFR) (NN gene) (NN status) (NN lung) (NN adenocarcinoma)) (VP (VBD evaluated) (NP (NN association) (JJ specific) (JJ characteristic) (NN patient) (NN tumor)))) (, ,) (NP (NP (NP (NP (NX (NN mutation) (NNP KRAS) (NN p53)) (, ,) (NN EGFR) (NN ErbB2) (NN gene) (NN amplification)) (, ,) (NP (NN level) (NN EGFR) (NN HER2) (NN protein)) (, ,)) (NN level) (JJ downstream) (NN effector) (NN EGFR)) (, ,) (NP (JJ phospho-extracellular) (JJ signal-regulated) (NN kinase) (NN phospho-S6) (NN protein))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 8:C04 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 225:E05.337 247:G01.374.676.530 358:G05.360.340.024.340.375.500.791.295.300 386:F02.463.425.069 388:G05.360.340.024.340.375.500.791.550 392:G05.355.315.250 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567|ES| 2:1 4:1 7:1 9:1 12:1 19:1 34:1 74:1 120:1 161:1 187:1 188:1 249:1 255:1 328:1 336:1 403:1 416:1 470:1 540:1 560:1 570:1 780:1 828:1 850:1 864:1 921:1 1298:1 1305:1 1705:1 1706:1 1707:1 1708:1
2 	|BT| (S (NP (PP (TO To) (NP (NN knowledge))) (, ,) (JJ first) (NN study) (NN report) (NN change) (NN lncRNA) (NN expression) (NN profile)) (VP (VBD induced) (NP (NN resveratrol) (NN lung) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 479:G08.686.157.500 480:D13.444.735.790.375 481:D13.444.735.790.375 482:K01.468|ES| 2:1 18:1 19:1 115:1 131:1 200:1 328:1 412:1 417:1 816:1 828:1 1709:1 1710:1 1711:1 1712:1
2 	|BT| (NP (NP (JJ Tubular) (NN atrophy) (JJ low) (NN netrin-1) (NN gene) (NN expression)) (NP (VBN associated) (VBN delayed) (NN kidney) (NN allograft) (NN function))) |ET| |BS|155:G05.355.310 483:C23.300.070 484:A01.941.500 485:A05.810.453 486:E04.936.864|ES| 9:1 19:1 33:1 115:1 169:1 531:1 1713:1 1714:1 1715:1 1716:1 1717:1 1718:1
2 	|BT| (S (S (VP (VBG Using) (NP (NP (JJ Mll-Een-expressing) (JJ leukaemic) (NN cell) (NN line)) (VP (VBN derived) (S (NP (NP (NN bone) (NN marrow) (NN Mll) (-LRB- -LRB-) (NN Een) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (: /) (CC +) (-RRB- -RRB-))) (VP (JJ mutant) (NP (NN mouse)))))))) (, ,) (VP (VBD showed) (NP (NP (NN induction) (NN Hox) (NN gene) (JJ leukaemic) (NN cell)) (VP (VBN associated) (NP (NP (JJ hypomethylated) (NN promoter) (NN region)) (NP (JJ aberrant) (JJ active) (NN chromatin) (NN state) (NN Hox) (NN locus))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 41:A11 94:A11.251.210 196:G02.111.570.080.689.675 397:A11.284.430.106.279.345.190.160.180 487:G05.355.315.800 488:A15.382.216|ES| 2:1 9:1 10:1 14:1 19:1 52:1 83:1 94:1 132:1 169:1 197:1 264:1 377:1 526:1 667:1 736:1 811:1 1203:1 1286:1 1346:1 1347:1 1348:1 1719:1 1720:1 1721:1 1722:1 1723:1 1724:1 1725:1 1726:1
2 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBP demonstrate) (SBAR (S (NP (NN dysregulation) (NN HAO2) (JJ early) (NN event) (NN development) (NN HCC)) (VP (MD may) (VP (VB represent) (NP (ADJP (ADJP (JJ useful)) (ADJP (JJ diagnostic))) (JJ prognostic) (NN marker) (JJ human) (NN HCC)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 158:D23.101 263:E01|ES| 5:1 19:1 35:1 36:1 205:1 441:1 491:1 502:1 534:1 799:1 843:1 884:1 903:1 1036:1 1128:1 1202:1 1727:1
2 	|BT| (S (NP (PRP We)) (VP (VBD confirmed) (NP (NP (JJ allelic) (NN loss) (NNS metaplasias)) (NP (JJ bronchiolar) (NN epithelium) (NN IPF) (NN FISH) (NN analysis) (NN FHIT) (NN gene))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 48:C23.550.589 62:A10.272 260:E01.370.225.562 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500 489:B01.050.150.900.493|ES| 9:1 19:1 32:1 173:1 661:1 843:1 938:1 946:1 1122:1 1222:1 1223:1 1475:1 1728:1
2 	|BT| (S (NP (PRP We)) (VP (VBD confirmed) (S (NP (JJ balanced) (NN nature)) (-LRB- -LRB-) (NP (NP (NP (NP (NN X) (: ;) (CD 17) (-RRB- -RRB-) (NN translocation) (NN fluorescence) (FW situ) (NN hybridization)) (NP (CD seven) (JJ renal) (NN tumor)) (ADVP (RB thus)) (VP (VBN analyzed))) (, ,) (NP (NP (NN contrast)) (ADJP (RB sharply) (JJ unbalanced)) (NN nature) (NN translocation) (NNS ASPS))))))) |ET| |BS|274:C04.588.945.947.535 463:C23.550.210.870 490:E01.370.225.500.620.670.325.350 491:D27.505.259.500 492:K01.637|ES| 2:1 7:1 10:1 14:1 19:1 217:1 843:1 922:1 923:1 928:1 929:1 930:1 938:1 1168:1 1334:1 1392:1 1617:1 1618:1 1729:1 1730:1 1731:1 1732:1 1733:1 1734:1
2 	|BT| (S (NP (PRP We)) (VP (VBP describe) (ADVP (RB herein)) (SBAR (S (NP (NP (CD eight) (RB morphologically) (JJ distinctive) (JJ renal) (NN tumor)) (VP (VBG occurring) (NP (JJ young) (NNS people)))) (VP (VBP bear) (NP (NP (JJ identical) (NN ASPL-TFE3) (NN fusion) (NN transcript) (NN ASPS)) (, ,) (FRAG (NP (NN distinction)) (-LRB- -LRB-) (NP (NP (NN X) (: ;) (CD 17) (-RRB- -RRB-) (NN translocation)) (ADJP (RB cytogenetically) (JJ balanced)) (JJ renal) (NN tumor))))))))) |ET| |BS|274:C04.588.945.947.535 455:B01.050.150.900.649.147.890 463:C23.550.210.870 493:M01|ES| 2:1 7:1 10:1 14:1 19:1 111:1 217:1 843:1 922:1 923:1 928:1 929:1 930:1 935:1 936:1 937:1 1525:1 1590:1 1618:1 1735:1 1736:1 1737:1 1738:1 1739:1 1740:1 1741:1 1742:1 1743:1
2 	|BT| (S (NP (PRP We)) (VP (VBD explored) (NP (NP (JJ potential) (NN TFPI2) (NN biomarker) (JJ early) (NN detection) (NN CRC)) (VP (VBG using) (NP (NP (NN stool) (JJ DNA-based) (NN assay) (NN patient)) (JJ nonmetastatic) (NN CRC) (JJ average-risk) (NN noncancer) (NN control) (NN candidate) (NN screening)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 61:E05.318.740.600.800 106:E05.091 158:D23.101 198:D13.444.308 333:D01.045 355:A12.459 375:Z01.639.100 494:E01.390|ES| 19:1 120:1 245:1 289:1 310:1 350:1 499:1 827:1 843:1 885:1 1023:1 1128:1 1184:1 1185:1 1188:1 1243:1 1744:1 1745:1 1746:1 1747:1
2 	|BT| (S (NP (PRP We)) (VP (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NN kallistatin) (NN gene) (NN therapy)) (VP (VBD suppressed) (NP (NP (NN growth) (NN HCC) (NN tumor) (JJ anti-angiogenic) (NN activity)) (, ,) (NP (NN meloxicam)) (, ,) (NP (JJ selective) (NN COX-2) (NN inhibitor))))))) (, ,) (VP (VBD inhibited) (NP (NN proliferation) (JJ induced) (NN apoptosis) (JJ human) (NN HCC) (NN cell) (NN vitro))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 122:C14.280.383 349:D27.505.519.389.310.500|ES| 2:1 7:1 9:1 19:1 36:1 76:1 89:1 94:1 102:1 130:1 216:1 299:1 307:1 365:1 380:1 399:1 412:1 441:1 843:1 993:1 1088:1 1089:1 1527:1 1748:1 1749:1
2 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (S (NP (NNP BIM) (NN intron) (CD 2) (NN deletion) (NN polymorphism) (NN increase) (NN lung) (NN cancer) (NN risk)) (VP (VBZ predicts) (NP (NP (NP (JJ poor) (NN prognosis) (JJ non-small) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN patient))))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 159:I01.880.735.634 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795|ES| 10:1 14:1 18:1 19:1 40:1 120:1 148:1 171:1 328:1 329:1 544:1 545:1 694:1 843:1 1058:1 1059:1 1060:1 1633:1 1750:1 1751:1
2 	|BT| (S (NP (PRP We)) (VP (VBD identified) (NP (NP (NP (NP (NP (JJ multiple) (JJ somatic) (NN mutation) (NN CCPRCC) (NN case)) (, ,) (PP (VBG including) (ADJP (JJ recurrent)))) (PRN (-LRB- -LSB-) (NP (NP (CD 3/14) (NN case)) (PRN (-LRB- -LRB-) (NP (CD 21) (NN %)) (-RRB- -RRB-))) (-RRB- -RSB-))) (JJ non-synonymous) (NN T992I) (NN mutation) (NN MET) (NN proto-oncogene)) (, ,) (NP (NP (NN gene)) (VP (VBN associated) (NP (NP (JJ epithelial-to-mesenchymal) (NN transition)) (PRN (-LRB- -LRB-) (NP (NN EMT)) (-RRB- -RRB-)))))))) |ET| |BS|6:G05.360.340.024.340 18:G05.365.590 235:G05.360.340.024.340.375.500.791 443:G05.700.264 495:G04.299.335.500 496:C23.550.291.937 497:G05.365.590.650|ES| 2:1 9:1 10:1 14:1 19:1 34:1 169:1 369:1 388:1 552:1 561:1 563:1 623:1 649:1 843:1 934:1 957:1 1373:1 1378:1 1752:1 1753:1 1754:1 1755:1 1756:1 1757:1 1758:1 1759:1
2 	|BT| (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ autophagy) (VBN involved) (JJ NAC1-mediated) (NN resistance) (NN cisplatin)) (, ,) (NP (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN drug) (NN treatment) (JJ ovarian) (NN cancer))))) |ET| |BS|52:E02 67:D26 151:E02.319 390:G04.299.139.399 498:D01.210.375|ES| 2:1 15:1 18:1 19:1 191:1 417:1 476:1 546:1 774:1 843:1 1094:1 1317:1 1760:1 1761:1 1762:1 1763:1
2 	|BT| (NP (NP (NP (NP (NN Xeroderma) (NN pigmentosum) (NN variant)) (PRN (-LRB- -LRB-) (NP (NN XP-V)) (-RRB- -RRB-))) (NP (JJ rare) (JJ genetic) (NN disease)) (, ,) (NP (VBN characterized) (NN sunlight) (NN sensitivity) (NN predisposition) (JJ cutaneous) (NN malignancy)))) |ET| |BS|401:C23.550.291.687 499:G01.358.500.505.650.836 500:C23.550.291.906 501:C04.834.867 502:C16.320|ES| 2:1 10:1 14:1 19:1 49:1 607:1 864:1 985:1 990:1 998:1 1322:1 1764:1 1765:1 1766:1 1767:1 1768:1 1769:1
3 	|BT| (S (NP (NP (DT A) (NP (NP (JJ genetic) (NN basis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (JJ well-established) (JJ major) (NN signaling) (NN pathway)) (, ,) (NP (NP (NN p53)) (, ,) (NP (NN Wnt-signaling)) (, ,) (NP (NP (NP (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF-beta)) (-RRB- -RRB-))) (NN Ras) (NN pathway))) (, ,)) (VP (VBD identified) (NP (JJ essential) (NN HCC) (NN development)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 149:G05.360.340.024.340.364.875.890 503:D12.644.276.374.687|ES| 2:1 10:1 12:1 14:1 19:1 35:1 69:1 102:1 195:1 303:1 304:1 383:1 441:1 462:1 623:1 864:1 1140:1 1770:1 1771:1 1772:1 1773:1 1774:1 1775:1 1776:1
3 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (NP (NN p53) (NNS Mutations)) (JJ common) (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (NN induction) (JJ hepatic) (NN p53) (NN expression))) (VP (VBP cause) (SBAR (S (NP (NN lysis)) (VP (VBD implanted) (NP (NN hepatoblastoma) (NN cell) (JJ chimeric) (NN mouse)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 55:B01.050.150.900.649.801.400.112.400.400 73:N05.715.350.200 104:C04.557.470.200.025.255 504:C04.557.435.380 505:B05.200|ES| 2:1 12:1 19:1 36:1 52:1 94:1 104:1 115:1 303:1 304:1 655:1 736:1 838:1 1046:1 1410:1 1777:1 1778:1 1779:1 1780:1 1781:1 1782:1 1783:1
3 	|BT| (S (ADVP (RB Instead)) (, ,) (NP (NNS data)) (VP (VBD revealed) (NP (NP (NP (NN Skp2)) (VBN regulated) (NN Myc) (NN activity)) (, ,) (NP (JJ oncogenic) (JJ potential) (NN generation) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|104:C04.557.470.200.025.255 142:I01.880.604 279:D27.888.569.100 506:F01.829.263.315 507:D12.776.157.743|ES| 2:1 19:1 275:1 303:1 304:1 399:1 793:1 827:1 953:1 1664:1 1784:1 1785:1 1786:1 1787:1
3 	|BT| (NP (NP (NP (NN Loss) (NN miR-122) (NN cause) (JJ chronic) (NN steatohepatitis)) (NP (JJ spontaneous) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|73:N05.715.350.200 104:C04.557.470.200.025.255 508:C06.552.241|ES| 19:1 283:1 303:1 304:1 1779:1 1788:1 1789:1 1790:1 1791:1
3 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NN MAT1A)))) (VP (VBD reduced) (NP (JJ hepatic) (NN S-adenosylmethionine) (NN content) (NN hyperplasia)) (ADVP (RB spontaneously)) (VP (VB develop) (NP (JJ nonalcoholic) (NN steatohepatitis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 232:D02.886.030.676.180 509:C06.552.241.519 510:C23.550.444|ES| 19:1 376:1 452:1 583:1 648:1 838:1 1506:1 1791:1 1792:1 1793:1 1794:1 1795:1 1796:1
3 	|BT| (S (NP (NP (NP (NN MicroRNA-122)) (PRN (-LRB- -LRB-) (NP (NN miR-122)) (-RRB- -RRB-))) (, ,) (NP (ADJP (RB highly) (JJ abundant)) (JJ liver-specific) (NN miRNA)) (, ,)) (VP (VBP act) (NP (NP (NN tumor) (NN suppressor) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 104:C04.557.470.200.025.255 184:D13.150.650.319 206:G05.360.340.024.340.375.249 242:A03.620|ES| 2:1 7:1 10:1 14:1 19:1 246:1 303:1 304:1 441:1 626:1 700:1 840:1 1789:1 1797:1 1798:1 1799:1
3 	|BT| (S (NP (NP (NP (NN Peroxisome) (JJ proliferator-activated) (NN receptor-gamma1)) (PRN (-LRB- -LRB-) (NP (NN PPARgamma1)) (-RRB- -RRB-))) (JJ important) (NN transcription) (NN factor)) (VP (VBN involved) (NP (NN atherosclerosis) (NN progression)))) |ET| |BS|16:C23.550.291.656 166:D12.776.930 511:C14.907.137.126.307 512:D12.776.826.239 513:C14.907.137.126|ES| 10:1 14:1 19:1 48:1 185:1 487:1 774:1 902:1 1800:1 1801:1 1802:1 1803:1 1804:1
3 	|BT| (S (NP (NP (ADVP (RB Surprisingly)) (, ,) (VBN given) (VBN proposed) (NN role) (NN loss) (NN function) (NN mutation) (NN p53) (NN gene) (NN development)) (NP (JJ human) (JJ colorectal) (NN cancer)) (, ,)) (VP (VBD found) (NP (NP (NN evidence)) (PP (CC either) (NP (NP (NN increase) (NN rate) (NN adenoma) (NN formation) (NN APC)) (CC +) (: /) (: -) (, ,) (NP (NN p53) (: -)) (: /) (FRAG (: -) (NP (NP (NN animal)) (, ,) (NP (NP (VBD increased) (NN rate) (NN progression) (NN malignancy)) (VP (VBN compared) (NP (NP (NN APC)) (NP (CC +) (: /) (: -) (NN p53) (CC +) (FRAG (: /) (CC +) (NP (NN mouse)))))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495|ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1
3 	|BT| (S (NP (DT The) (NN Tg737) (NN gene)) (VP (VBD investigated) (NP (JJ gross) (NN alteration) (NN series) (NN rodent/human) (NN liver) (NN tumor) (JJ human) (JJ tumorigenic) (NN cell) (NN line)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 514:B01.050.150.900.649.865 515:C04.588.274.623|ES| 7:1 9:1 19:1 36:1 94:1 264:1 403:1 691:1 836:1 951:1 1805:1 1806:1 1807:1 1808:1 1809:1
3 	|BT| (S (NP (DT A) (NN Cox) (JJ proportional) (NN hazard) (NN model)) (VP (VBD showed) (NP (NP (NN IFITM3) (NN expression) (JJ independent) (JJ prognostic) (NN factor)) (NP (JJ disease-free) (NN survival) (NN patient) (NN colon) (NN cancer))))) |ET| |BS|12:Z01.542.049 50:M01.643 516:E05.318.740.500.700 517:E01.789.200|ES| 18:1 19:1 69:1 72:1 113:1 115:1 120:1 132:1 185:1 274:1 696:1 883:1 884:1 1810:1 1811:1 1812:1 1813:1
3 	|BT| (NP (NP (NP (DT A) (JJ novel) (NN GSK-3) (NN beta-C/EBP) (JJ alpha-miR-122-insulin-like) (NN growth) (NN factor) (CD 1) (NN receptor) (JJ regulatory) (NN circuitry)) (NP (JJ human) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 518:D08.811.913.696.620.682.725.400.185 519:D05.500.117.875|ES| 19:1 36:1 69:1 98:1 102:1 185:1 186:1 303:1 304:1 891:1 1814:1 1815:1 1816:1 1817:1 1818:1
3 	|BT| (S (NP (DT A) (JJ previous) (NN investigation)) (VP (VBD indicated) (NP (NP (NN ATA) (JJ effective) (VBG inhibiting) (NN growth) (NN breast) (NN cancer)) (NP (RB especially) (NN cell) (NN HER2) (NN overexpression))))) |ET| |BS|41:A11 45:G07.700.320.249 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 122:C14.280.383 225:E05.337 520:C10.228.140.252.190.530.060|ES| 18:1 19:1 23:1 69:1 94:1 102:1 152:1 188:1 345:1 880:1 1497:1 1541:1 1639:1 1819:1 1820:1
3 	|BT| (S (NP (JJ Additional) (NN qRT-PCR) (NN analysis)) (VP (VBD revealed) (S (NP (JJ gradual) (NN elevation) (VBG circulating) (NNS miRNAs)) (-LRB- -LRB-) (NP (FRAG (NP (FW i.e.) (, ,) (NN let-7a) (, ,) (NN let-7f) (, ,) (NN miR-34a) (, ,) (NN miR-98) (, ,) (NN miR-331) (, ,) (NN miR-338) (NN miR-652) (-RRB- -RRB-) (NN progress) (NN hepatocarcinogenesis))))))) |ET| |BS|184:D13.150.650.319 448:E05.393.620.500|ES| 2:1 10:1 14:1 19:1 275:1 661:1 876:1 888:1 900:1 1110:1 1623:1 1821:1 1822:1 1823:1 1824:1 1825:1 1826:1 1827:1 1828:1 1829:1 1830:1 1831:1
3 	|BT| (NP (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB define) (NP (NP (JJ biological) (NN contribution) (NNP Hras) (NN mouse) (NN hepatocarcinogenesis)) (, ,) (VP (VBN quantified) (S (FW vivo) (NP (NN interaction) (JJ mutant) (NNP Hras) (JJ genetic) (NN alteration)) (ADVP (RB frequently)) (VP (VBN associated) (NP (NP (NN liver) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (NN overexpression) (NP (NN transcription) (NN factor) (NN c-myc) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN ligand) (VBG transforming) (NN growth) (NN factor) (NN alpha))) (PRN (-LRB- -LRB-) (NP (NN TGFalpha)) (-RRB- -RRB-))))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 64:D08.811.913.696.620.682.725.400.009.300 167:H01.158.273 170:D27.720.470.480 521:D08.811.277.040.330.300.400.500.600 522:D12.644.276.382.750 523:D12.776.260.676|ES| 2:1 10:1 14:1 18:1 19:1 52:1 102:1 104:1 152:1 169:1 184:1 185:1 186:1 378:1 440:1 455:1 487:1 561:1 618:1 698:1 811:1 828:1 836:1 864:1 900:1 951:1 959:1 1360:1 1772:1 1832:1 1833:1 1834:1 1835:1 1836:1 1837:1
3 	|BT| (S (NP (NN Alteration) (NN Apc) (NN gene)) (VP (VBN shown) (NP (NP (NN play) (JJ important) (NN role)) (JJ PhIP-induced) (JJ IQ-induced) (NN rat) (NN colon) (NN carcinogenesis)))) |ET| |BS|3:C04.557.470.035.215.100 15:F01.829.316.616 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 9:1 19:1 31:1 113:1 207:1 237:1 238:1 280:1 849:1 902:1 1838:1 1839:1 1840:1
3 	|BT| (NP (NNS Alterations) (NP (NP (NN hMSH2) (NN gene)) (VP (VBN linked) (NP (ADJP (QP (RB approximately) (CD 60)) (NN %)) (JJ hereditary) (JJ nonpolyposis) (NN colon) (NN cancer) (NN case))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 524:C04.588.274.476.411.307.190|ES| 9:1 18:1 19:1 113:1 369:1 934:1 1363:1 1841:1 1842:1 1843:1 1844:1 1845:1 1846:1
3 	|BT| (FRAG (SBAR (IN Although) (NP (NP (NP (VBN induced) (NN cell) (NN death)) (VBN regarded) (JJ major) (NN component) (NN p53) (JJ tumor-suppressive) (NN activity)) (, ,) (S (ADVP (RB recently)) (VP (VBD found) (SBAR (S (NP (JJ sustained) (NN p53) (NN activation) (JJ subsequent) (NN DNA) (NN damage)) (VP (VBZ promotes) (NP (JJ inflammation-associated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 134:G04.299.139 525:C23.550.470 526:G05.355.180|ES| 2:1 12:1 19:1 37:1 94:1 107:1 177:1 225:1 298:1 399:1 411:1 412:1 462:1 666:1 772:1 900:1 1021:1 1319:1 1521:1 1847:1 1848:1 1849:1
3 	|BT| (NP (NP (NP (NN Amplification) (NN HER2)) (PRN (-LRB- -LRB-) (NP (NP (NN ErbB2)) (, ,) (NP (NN c-Neu))) (-RRB- -RRB-))) (NP (NP (NN proto-oncogene) (NN breast) (NN cancer)) (NP (VBN associated) (JJ poor) (NN prognosis) (JJ high) (NN relapse) (NN rate)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 159:I01.880.735.634 163:E01.789 235:G05.360.340.024.340.375.500.791 527:C23.550.291.937|ES| 2:1 10:1 14:1 18:1 19:1 23:1 41:1 169:1 178:1 188:1 544:1 545:1 563:1 1012:1 1705:1 1850:1 1851:1
3 	|BT| (S (NP (NP (NN Androgen) (JJ receptor-induced) (NN tumor) (NN suppressor)) (, ,) (NP (NN KLLN)) (, ,)) (VP (VBZ inhibits) (SBAR (S (NP (NN breast) (NN cancer) (NN growth)) (ADVP (RB transcriptionally)) (VP (VBZ activates) (NP (JJ p53/p73-mediated) (NN apoptosis) (NN breast) (NN carcinoma))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 45:G07.700.320.249 122:C14.280.383 206:G05.360.340.024.340.375.249 528:D12.776.826.750.150|ES| 2:1 7:1 18:1 19:1 23:1 89:1 102:1 301:1 304:1 615:1 700:1 1478:1 1852:1 1853:1 1854:1 1855:1
3 	|BT| (NP (NP (NN Antitumor) (NN function) (NN microRNA-122) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 184:D13.150.650.319|ES| 19:1 33:1 303:1 304:1 1856:1 1857:1
3 	|BT| (S (NP (NN Astrocyte) (JJ elevated) (NN gene-1) (NN c-Myc)) (VP (VBP cooperate) (VP (VBP promote) (NP (NN hepatocarcinogenesis) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 529:A08.637.200|ES| 19:1 52:1 474:1 679:1 756:1 824:1 900:1 1858:1 1859:1
3 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (SBAR (: :) (S (S (NP (NNS Mutations) (NN APC) (NN gene)) (VP (VBP result) (VP (VBN increased) (S (NP (NN propensity)) (VP (VB develop) (NP (JJ intestinal) (NN neoplasia))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (JJ complete) (NN understanding) (NN mechanism)) (VP (VBG resulting) (NP (NN tumor) (NN formation)))) (VP (VBD remained) (ADJP (JJ elusive))))))) |ET| |BS|8:C04 18:G05.365.590 20:G03.495 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 102:C04.588.274.476.411 239:F02.463.188.357|ES| 2:1 7:1 9:1 11:1 19:1 43:1 47:1 101:1 104:1 109:1 162:1 172:1 217:1 384:1 640:1 648:1 777:1 905:1 1046:1 1387:1 1410:1 1777:1 1778:1 1860:1 1861:1
3 	|BT| (S (SBAR (IN Because) (S (NP (NN Notch) (NN signaling) (VBN implicated) (NN colon) (NN cancer) (NN tumorigenesis)) (VP (VBZ protects) (NP (NP (NN cell) (NN apoptosis)) (VP (VBG inducing) (NP (JJ prosurvival) (NN target))))))) (, ,) (VP (VBD hypothesized) (SBAR (S (NP (NP (NN inhibition) (NN Notch) (NN signaling) (NN gamma-secretase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN GSI)) (-RRB- -RRB-))) (VP (MD may) (NP (VB enhance) (NP (NN chemosensitivity) (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 43:F01.145.544 69:G02.111.087.800 125:D08.811.277.656.300.032|ES| 2:1 10:1 14:1 18:1 19:1 78:1 89:1 94:1 103:1 113:1 160:1 195:1 256:1 380:1 386:1 491:1 977:1 1690:1 1750:1 1862:1 1863:1 1864:1 1865:1 1866:1 1867:1
3 	|BT| (S (PP (IN By) (NP (JJ immunohistochemical) (NN analysis))) (, ,) (NP (CD 20) (CD 38) (NN case) (JJ undifferentiated) (NN type)) (VP (VBD advanced) (NP (NP (NN stomach) (NN cancer) (NN K-sam)) (JJ positive)) (, ,) (PP (IN whereas) (NP (NP (NN none) (CD 11) (NN case)) (SBAR (S (NP (VBN differentiated) (JJ intestinal) (NN type)) (VP (VBD revealed) (NP (NN K-sam) (NN staining))))))))) |ET| |BS|47:A03.556.124 74:G04.299.151 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 109:1 233:1 275:1 372:1 543:1 661:1 782:1 801:1 803:1 804:1 934:1 997:1 1057:1 1167:1 1605:1 1868:1 1869:1 1870:1 1871:1
3 	|BT| (S (ADVP (RB Collectively)) (, ,) (NP (NN miR-122) (NN depletion)) (VP (VBZ facilitates) (NP (NP (NN cystogenesis) (NN hepatocarcinogenesis) (NN mouse) (NN DEN) (NN challenge)) (VP (VBG up-regulating) (NP (NP (JJ several) (NN gene)) (VP (VBN involved) (NP (NP (NN proliferation)) (, ,) (NP (NN growth) (NN factor) (NN signaling)) (, ,) (NP (NN neovascularization)) (, ,) (NP (NN metastasis))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 113:C04.697.650 150:Z01.542.248.960 344:M01.438 530:C23.550.589.500|ES| 2:1 9:1 19:1 52:1 102:1 185:1 195:1 262:1 299:1 774:1 806:1 900:1 1371:1 1613:1 1789:1 1872:1 1873:1 1874:1 1875:1 1876:1 1877:1
3 	|BT| (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN loss) (JJ multifunctional) (NN miR-122)) (VP (VBZ contributes) (NP (NP (JJ malignant) (NN phenotype) (NN HCC) (NN cell)) (, ,) (NP (NN miR-122) (JJ mimetic) (RB alone) (NP (NN combination) (JJ anticancer) (NN drug))) (NP (JJ promising) (JJ therapeutic) (NN regimen) (NN liver) (NN cancer))))))))) |ET| |BS|41:A11 52:E02 67:D26 80:G05.695 104:C04.557.470.200.025.255 231:C04.557.465.625.600.380.590 242:A03.620 531:E02.183.750 532:E02.183|ES| 2:1 18:1 19:1 32:1 94:1 101:1 191:1 236:1 241:1 441:1 530:1 541:1 796:1 802:1 836:1 845:1 1517:1 1789:1 1872:1 1878:1 1879:1 1880:1 1881:1
3 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NN outcome) (NN study)) (VP (VBP represent) (NP (JJ significant) (NN contribution) (JJ current) (NN understanding) (JJ preventive) (NN mechanism) (NN quercetin) (JJ early) (NN stage) (NN liver) (NN cancer) (NN development)) (, ,) (S (VP (VBG demonstrating) (NP (NP (NN addition)) (VP (VBN known) (VP (JJ proapoptotic) (ADJP (ADJP (JJ characteristic)) (, ,) (SBAR (S (NP (NN flavonoid)) (VP (VBZ modulates) (NP (NP (NN expression) (JJ critical) (NN cell) (NN cycle) (NN regulator)) (NN peroxisome) (NN proliferator) (VBD activated) (NN receptor-alpha) (NN activity)))))))))))))) |ET| |BS|239:F02.463.188.357 242:A03.620 353:G04.299.134 473:E01.789.625 533:D03.383.663.283.266.450.284.777 534:D03.383.663.283.266.450 535:H01.770.644.145.431 536:D12.776.826.239.500|ES| 2:1 18:1 19:1 35:1 94:1 104:1 115:1 131:1 135:1 162:1 163:1 175:1 235:1 336:1 399:1 468:1 527:1 547:1 556:1 601:1 606:1 691:1 799:1 825:1 836:1 905:1 1128:1 1129:1 1360:1 1882:1 1883:1 1884:1 1885:1 1886:1 1887:1 1888:1 1889:1
3 	|BT| (S (NP (NN CONCLUSION) (: :)) (NP (DT These) (JJ clinical) (JJ mechanistic) (NN finding)) (VP (VBP indicate) (SBAR (S (NP (NP (NN IFITM3) (JJ direct) (JJ transcriptional) (NN target) (NN KLF4)) (VBN dysregulated) (NP (NN KLF4)) (NN expression)) (VP (VBP lead) (NP (JJ aberrant) (NN IFITM3) (NN expression)) (, ,) (S (ADVP (RB thus)) (VP (VBG contributing) (NP (NN colon) (NN cancer) (NN progression) (NN metastasis))))))))) |ET| |BS|16:C23.550.291.656 86:D01.268.556.435 113:C04.697.650 209:G02.111.087.847|ES| 2:1 18:1 19:1 48:1 84:1 104:1 113:1 115:1 160:1 254:1 559:1 696:1 792:1 806:1 927:1 1259:1 1295:1 1334:1 1479:1 1725:1 1882:1 1890:1 1891:1 1892:1
3 	|BT| (NP (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (JJ Acute) (NN ablation) (NN GSK3beta) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ activates) (NP (JJ p53-dependent) (NN apoptosis)))) (SBAR (S (VP (VBZ antagonizes) (NP (NN tumor) (NN growth))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 45:G07.700.320.249|ES| 7:1 17:1 18:1 19:1 88:1 89:1 91:1 94:1 102:1 104:1 239:1 301:1 794:1 1893:1 1894:1
3 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VB identify) (NP (NP (NP (JJ novel) (NN candidate) (NN mouse) (NN gene)) (, ,) (NP (NN Zfp277)) (, ,)) (SBAR (WHNP (WP$ whose) (NN expression) (NN pattern)) (S (NP (JJ compatible) (NN role)) (VP (VBG mediating) (NP (JJ divergent) (NN effect) (NN Chrm3) (NN Chrm1) (NN gene) (NN ablation) (JJ murine) (JJ intestinal) (NN neoplasia))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 47:A03.556.124 102:C04.588.274.476.411 259:D12.776.395.240.150.500 537:G05.360.340.024.340.375|ES| 2:1 9:1 19:1 31:1 52:1 75:1 91:1 101:1 104:1 109:1 115:1 239:1 260:1 627:1 640:1 658:1 761:1 832:1 891:1 919:1 1243:1 1895:1 1896:1 1897:1 1898:1 1899:1
3 	|BT| (S (NP (NN CRC)) (VP (VBD initiated) (NP (NP (NN mutation) (NN tumor) (NN suppressor) (NN gene)) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-))) (, ,) (NP (NN beta-catenin) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 9:1 10:1 11:1 14:1 19:1 34:1 57:1 58:1 59:1 60:1 245:1 700:1 1900:1
3 	|BT| (S (NP (NN CRC) (NN xenograft)) (VP (VBD differed) (NP (NP (NP (NP (NN p53) (NN status)) (PRN (-LRB- -LRB-) (NP (JJ wt) (NN muf)) (-RRB- -RRB-))) (NN microsatellite) (NN instability) (NN phenotype)) (PRN (-LRB- -LRB-) (NP (NP (NN MSI)) (CC +) (NP (JJ altered))) (-RRB- -RRB-))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 80:G05.695 92:E04.936.764 93:A01.941.875 538:C23.550.362.590|ES| 10:1 12:1 14:1 19:1 236:1 245:1 265:1 416:1 693:1 1299:1 1332:1 1901:1 1902:1 1903:1 1904:1
3 	|BT| (NP (NP (JJ Differential) (NN effect) (JJ oncogenic) (NN K-Ras) (NN N-Ras) (NN proliferation)) (, ,) (NP (NN differentiation) (NN tumor) (NN progression) (NN colon))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 16:C23.550.291.656 51:C04.588.274.476.411.307.180 74:G04.299.151 279:D27.888.569.100|ES| 2:1 7:1 13:1 19:1 48:1 75:1 113:1 215:1 299:1 953:1 1905:1 1906:1
3 	|BT| (S (NP (NN Differentiation) (NN therapy) (JJ hepatocellular) (NN carcinoma) (NN mouse) (JJ recombinant) (NN adenovirus)) (VP (VBG carrying) (NP (NN hepatocyte) (JJ nuclear) (NN factor-4alpha) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 52:E02 74:G04.299.151 104:C04.557.470.200.025.255 247:G01.374.676.530 539:D20.215.894.899.024 540:D12.776.260.262 541:C02.256.076 542:B04.280.030|ES| 9:1 19:1 52:1 130:1 303:1 304:1 850:1 1256:1 1420:1 1907:1 1908:1 1909:1 1910:1
3 	|BT| (S (S (NP (JJ Ectopic) (NN expression) (NN miR-155)) (VP (VBD promoted) (NP (NP (NP (NN growth) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN cell)))) (, ,) (IN whereas) (S (NP (NN depletion)) (VP (VBD inhibited) (NP (NN cell) (NN growth))))) |ET| |BS|41:A11 45:G07.700.320.249 104:C04.557.470.200.025.255 107:G05.355.315.202 122:C14.280.383|ES| 2:1 10:1 14:1 19:1 94:1 102:1 115:1 303:1 304:1 305:1 365:1 372:1 441:1 1613:1 1911:1 1912:1
3 	|BT| (S (NP (JJ Ectopic) (NN reactivation) (NN miR-184)) (VP (VBD inhibited) (SBAR (S (NP (NP (NN proliferation) (NP (NP (JJ self-renewal) (JJ triple) (JJ negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN TNBC)) (-RRB- -RRB-))) (NN cell) (NN line) (NN vitro)) (VP (VBN delayed) (NP (JJ primary) (NN tumour) (NN formation)))) (VP (VBD reduced) (NP (JJ metastatic) (NN burden) (FW vivo))))))) |ET| |BS|8:C04 20:G03.495 122:C14.280.383 160:C04.588.180.788 543:G04.299.134.220.235|ES| 10:1 14:1 18:1 19:1 23:1 43:1 94:1 216:1 264:1 299:1 305:1 337:1 344:1 365:1 378:1 449:1 452:1 537:1 1011:1 1716:1 1913:1 1914:1 1915:1 1916:1 1917:1
3 	|BT| (NP (NP (JJ Epigenetic) (NN inactivation) (JJ paired) (NN box) (NN gene) (CD 5)) (, ,) (NP (JJ novel) (NN tumor) (NN suppressor) (NN gene)) (, ,) (NP (NP (JJ direct) (NN upregulation) (NN p53)) (NP (VBN associated) (NN prognosis) (JJ gastric) (NN cancer) (NN patient)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 42:G05.355.315.203.374 50:M01.643 163:E01.789 206:G05.360.340.024.340.375.249 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880|ES| 2:1 7:1 9:1 12:1 18:1 19:1 86:1 120:1 169:1 544:1 578:1 700:1 790:1 891:1 1126:1 1201:1 1314:1 1891:1 1918:1
3 	|BT| (NP (NP (NP (NN ERBB4) (NN alteration)) (NP (NP (NP (DT The) (NN Cancer) (NNP Genome) (NNP Atlas) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NP (NN data) (NN set) (JJ stratified) (NN survival)) (, ,) (VP (VBN combined) (S (NP (NNP Moffitt) (NNP Cancer) (NNP Center) (NNP Vanderbilt) (NNP Medical) (NNP Center) (NN CRC) (NN expression) (NNS data)) (VP (VBN set) (, ,) (SBAR (S (NP (NN ERBB4) (NN message) (NN level)) (VP (VBD increased) (NP (NN tumor) (NN stage)))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 96:I03.784 97:V02.302 269:G05.360.340 544:A02.835.232.834.151.500 545:F02.463.425.838 546:V02.150|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 47:1 115:1 164:1 245:1 249:1 274:1 691:1 793:1 951:1 1129:1 1679:1 1919:1 1920:1 1921:1 1922:1 1923:1 1924:1 1925:1 1926:1 1927:1 1928:1
3 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN Apo-FHL2) (NN mouse)) (VP (VBD developed) (SBAR (S (NP (NP (NN tumor)) (, ,) (NP (NN FHL2) (NN transgene))) (VP (VBD enhanced) (SBAR (S (NP (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ liver-specific) (NN deletion) (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (NN gene) (JJ aberrant) (NN Wnt/beta-catenin) (NN signaling) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN lox/lox)) (-RRB- -RRB-))) (NN animal)))))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 11:B01.050.150.900.649.865.635.505.500 19:B01.050 21:G05.360.340.024.340.375.249.050 105:G02.149.115.800.925 242:A03.620 547:G05.360.340.024.340.825 548:D08.811.682.664.500.848 549:G05.355.600.800.320|ES| 2:1 7:1 9:1 10:1 14:1 19:1 46:1 52:1 57:1 58:1 59:1 195:1 280:1 302:1 385:1 412:1 900:1 1059:1 1165:1 1725:1 1799:1 1929:1 1930:1 1931:1 1932:1 1933:1
3 	|BT| (S (NP (JJ Further) (NN study) (NN mechanism) (NN ADCY3) (NN tumorigenesis)) (VP (VBP provide) (NP (NN basis) (JJ new) (JJ molecular) (NN target) (JJ gastric) (NN cancer)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098|ES| 18:1 19:1 78:1 86:1 131:1 160:1 161:1 162:1 330:1 711:1 712:1 1140:1 1934:1
3 	|BT| (S (ADVP (RB Furthermore)) (NP (NP (NN strategy)) (VP (VBN designed) (VP (VB restore) (NP (NN expression) (NN PTEN))))) (VP (MD may) (S (VP (VBG promising) (NP (NP (NN therapy)) (VP (VBG preventing) (NP (NN HCV) (JJ dependent) (NN hepatocarcinogenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 550:B04.450.410|ES| 19:1 115:1 130:1 321:1 334:1 491:1 900:1 1114:1 1517:1 1683:1 1935:1 1936:1 1937:1 1938:1
3 	|BT| (S (NP (NN Germ-line) (NN mutation) (NN APC) (NN gene)) (VP (NN cause) (SBAR (S (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,) (NP (NN syndrome) (NN patient))) (VP (VBP develop) (NP (CD hundred) (CD thousand) (JJ precancerous) (JJ adenomatous) (JJ colorectal) (NN polyp))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 50:M01.643 341:C04.834 551:C04.557.470.035.215 552:G05.365.590.350 553:C23.550.288.500|ES| 2:1 9:1 10:1 11:1 14:1 17:1 19:1 34:1 57:1 58:1 59:1 120:1 647:1 648:1 1130:1 1779:1 1939:1 1940:1 1941:1 1942:1
3 	|BT| (S (S (ADVP (RB Hence)) (, ,) (NP (NN agent)) (VP (VBD prevented) (SBAR (S (NP (NN colon) (NN cancer)) (VP (VBD decreased) (NP (NP (JJ mitotic) (NN index)) (NP (VBN altered) (NN expression) (NN c-myc)))))))) (, ,) (NP (NN p16) (NN p27)) (VP (VBG suggesting) (NP (NP (NN modulation) (NN expression) (NN gene)) (JJ potential) (NNS biomarkers) (JJ chemopreventive) (NN activity)))) |ET| |BS|155:G05.355.310 158:D23.101 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500|ES| 2:1 9:1 18:1 19:1 113:1 115:1 202:1 399:1 455:1 693:1 720:1 721:1 728:1 827:1 1009:1 1124:1 1269:1 1313:1 1943:1 1944:1 1945:1 1946:1
3 	|BT| (S (NP (JJ Hepatic) (NN loss) (NN miR-122)) (VP (VBZ predisposes) (NP (NN mouse) (JJ hepatobiliary) (NN cyst) (JJ hepatocellular) (NN carcinoma)) (PP (IN upon) (NP (NN diethylnitrosamine) (NN exposure))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 554:D02.654.442.200 555:C04.182|ES| 19:1 32:1 52:1 303:1 304:1 1789:1 1947:1 1948:1 1949:1 1950:1 1951:1 1952:1 1953:1
3 	|BT| (S (NP (NNP Hepatitis) (NNP C) (JJ virus-induced) (NN up-regulation) (NN microRNA-155)) (VP (VBZ promotes) (NP (NN hepatocarcinogenesis) (VBG activating) (NN Wnt) (NN signaling)))) |ET| |BS|69:G02.111.087.800 184:D13.150.650.319 249:G05.355.315.800 339:G02.111.087.880 550:B04.450.410|ES| 19:1 195:1 298:1 877:1 896:1 900:1 1954:1 1955:1 1956:1 1957:1 1958:1
3 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NN diethylnitrosamine) (JJ hepatic) (NN deletion) (NN PTEN)))) |ET| |BS|306:G05.355.600.800 554:D02.654.442.200|ES| 19:1 412:1 838:1 1059:1 1936:1 1952:1 1959:1
3 	|BT| (NP (NP (ADJP (RB Here) (VBN studied)) (NN role) (NN HNF4alpha) (NN mechanism) (NN deregulation) (NN Cdx2) (NN colon) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1
3 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBD investigated) (NP (NP (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (JJ oncogenic) (NN cooperation) (NN c-Myc) (NN E2F1) (NN relationship) (JJ human) (NN liver) (NN cancer)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100|ES| 2:1 18:1 19:1 36:1 161:1 162:1 223:1 400:1 403:1 435:1 824:1 836:1 953:1 1960:1 1961:1
3 	|BT| (S (NP (JJ Heterozygous) (NN disruption) (NN PTEN)) (VP (VBZ promotes) (NP (NP (JJ intestinal) (NN neoplasia) (NN APCmin)) (: /) (NP (CC +) (NP (NN mouse)) (: :) (NP (NN role))) (NP (NN osteopontin))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 102:C04.588.274.476.411 157:G05.380.383 350:D12.644.276.374.625|ES| 19:1 31:1 52:1 104:1 109:1 298:1 640:1 1160:1 1602:1 1936:1 1962:1 1963:1
3 	|BT| (S (NP (NN HNF4alpha) (NN Cdx2)) (ADVP (RB also)) (VP (VBD exhibited) (NP (JJ comparable) (VBN deregulated) (NN pattern) (JJ human) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 175:J01.897.280.500.269|ES| 5:1 19:1 36:1 123:1 213:1 245:1 260:1 609:1 1964:1 1965:1
3 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (NP (NN effect) (NN HNF4alpha) (NN cancer) (NN stem) (NN cell)) (PRN (-LRB- -LRB-) (NP (NNS CSCs)) (-RRB- -RRB-))) (NP (NP (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN HNF4alpha)) (VP (VBD reported))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 332:A11.872.650 556:C11.768.175|ES| 2:1 10:1 14:1 18:1 19:1 75:1 94:1 123:1 303:1 304:1 433:1 441:1 546:1 993:1 1106:1 1966:1
3 	|BT| (S (ADVP (RB However)) (, ,) (SBAR (IN whether) (S (NP (NN up-regulation) (NN DLGAP5)) (VP (VBZ contributes) (NP (NN hepatocarcinogenesis))))) (VP (VBZ remains) (ADJP (JJ unclear)))) |ET| |BS|142:I01.880.604|ES| 2:1 19:1 221:1 433:1 442:1 443:1 845:1 896:1 900:1 1191:1
3 	|BT| (S (PP (IN In) (NP (NN aggregate))) (, ,) (VP (VBP conclude) (NP (NP (NP (NN Let-7) (NN depletion) (NN drive) (NN stem) (NN cell) (NN phenotype)) (NN development) (JJ intestinal) (NN cancer)) (, ,) (PP (ADVP (RB primarily)) (IN via) (NP (NN Hmga2)))))) |ET| |BS|66:F01.658.293 80:G05.695 101:C04.588.274.476.411 283:D12.776.260.312.937 308:A11.872 557:D02.241.081.069.600.150|ES| 2:1 18:1 19:1 35:1 94:1 109:1 181:1 236:1 244:1 596:1 1106:1 1613:1 1967:1 1968:1 1969:1 1970:1 1971:1
3 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN loss) (NN PTEN) (NN dysregulation)) (VP (VBG transforming) (NP (NP (NN growth) (NN factor) (NN beta) (NN signaling)) (VP (VBN considered) (S (NP (JJ involved) (NN rat) (NN hepatocarcinogenesis) (JJ early) (NN stage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 503:D12.644.276.374.687|ES| 2:1 19:1 32:1 102:1 185:1 195:1 244:1 774:1 849:1 900:1 1061:1 1128:1 1129:1 1202:1 1284:1 1772:1 1936:1 1972:1
3 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN MiR-7) (JJ novel) (NN miRNA) (NN tumor) (JJ suppressive) (NN function) (NN colon) (NN cancer)) (VP (VBG targeting) (NP (JJ oncogenic) (NN YY1)))) |ET| |BS|8:C04 184:D13.150.650.319 258:D12.776.260.235.875 259:D12.776.395.240.150.500 279:D27.888.569.100|ES| 2:1 7:1 18:1 19:1 33:1 113:1 244:1 616:1 840:1 879:1 891:1 953:1 1284:1 1973:1 1974:1
3 	|BT| (NP (NP (PP (IN In) (NP (NN conclusion))) (, ,) (NP (S (VP (VBG finding) (S (VP (VBP indicate) (SBAR (S (NP (NN miR-375) (NN target) (NN AEG-1) (NN HCC)) (VP (VBZ suppresses) (NP (NN liver) (NN cancer) (NN cell) (NN growth)) (ADVP (FW vitro) (FW vivo))))))))) (, ,) (NP (NN highlight) (JJ therapeutic) (JJ potential) (NN miR-375) (NN HCC) (NN treatment))))) |ET| |BS|41:A11 45:G07.700.320.249 52:E02 104:C04.557.470.200.025.255 262:A11.436.348|ES| 2:1 18:1 19:1 94:1 102:1 160:1 216:1 244:1 378:1 441:1 541:1 546:1 686:1 827:1 836:1 927:1 1284:1 1479:1 1675:1 1975:1 1976:1
3 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN overexpression) (NN PPARgamma1) (NN gene)) (VP (VBZ exerts) (NP (NP (JJ beneficial) (NN effect)) (VP (VBG attenuating) (NP (NN atherosclerosis) (NN progression))))) (VP (VBZ stabilizes) (NP (JJ vulnerable) (NN plaque)))) |ET| |BS|6:G05.360.340.024.340 16:C23.550.291.656 511:C14.907.137.126.307 513:C14.907.137.126 558:C23.300.821|ES| 2:1 9:1 19:1 48:1 75:1 152:1 244:1 984:1 1284:1 1803:1 1804:1 1977:1 1978:1 1979:1 1980:1 1981:1
3 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NNS data)) (VP (VBP indicate) (SBAR (S (NP (NN LHX4)) (VP (MD may) (VP (VB act) (NP (JJ potential) (NN tumor) (NN suppressor) (NN hepatocarcinogenesis)) (, ,) (S (VP (VBG suggesting) (S (VP (VBG targeting) (NP (NN LHX4))))))))))) (VP (VBP downregulate) (SBAR (S (NP (NN AFP)) (VP (MD might) (NP (JJ therapeutic) (NN implication))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 81:E02.095.465.425.400.330.050.400 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 19:1 85:1 244:1 246:1 491:1 508:1 541:1 616:1 700:1 793:1 798:1 827:1 900:1 1009:1 1196:1 1284:1 1479:1 1982:1
3 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN study)) (VP (VBP show) (SBAR (S (NP (NN TS) (NN gene) (NN expression) (NN pretreatment) (NN biopsy)) (VP (VBZ predicts) (NP (NN response) (JJ local) (JJ rectal) (NN cancer) (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy) (JJ high) (NN percentage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 154:Z01.058.266.887 155:G05.355.310 333:D01.045 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500|ES| 2:1 9:1 18:1 19:1 115:1 131:1 178:1 244:1 429:1 494:1 509:1 1284:1 1751:1 1983:1 1984:1 1985:1 1986:1 1987:1 1988:1 1989:1 1990:1
3 	|BT| (NP (NP (PP (IN In) (NP (VBN damaged) (NN tissue))) (, ,) (NP (NP (JJ combined) (NN loss) (NN RB) (NN p53)) (VBD resulted) (NP (JJ early) (NN lesion) (NN formation)) (, ,) (NP (NP (JJ aggressive) (NN tumor) (NN progression)) (, ,) (NP (NP (NN gene) (NN expression) (NN signature)) (NP (JJ histologic) (JJ characteristic) (JJ advanced) (JJ human) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 16:C23.550.291.656 20:G03.495 98:A10 104:C04.557.470.200.025.255 162:F01.145.126.125 384:G02.111.087.847.750 562:F01.510|ES| 2:1 7:1 9:1 12:1 19:1 32:1 36:1 43:1 48:1 115:1 164:1 244:1 272:1 303:1 304:1 336:1 538:1 594:1 997:1 1128:1 1131:1 1209:1 1230:1 1991:1 1992:1
3 	|BT| (FRAG (PP (IN In) (NP (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN model) (NN colon) (NN cancer))) (, ,) (NP (NP (NN addition) (NN K-ras) (NN mutation)) (, ,) (VP (VBN shown) (S (NP (ADJP (ADJP (JJ wild-type)) (PRN (-LRB- -LRB-) (ADJP (JJ WT)) (-RRB- -RRB-))) (NN Ras)) (VP (VBD activated) (NP (NP (JJ upstream) (NN pathway)) (, ,) (S (VBG including) (, ,) (PP (FW e.g.)) (, ,) (VP (VBG signaling) (NP (NN ErbB) (NN receptor)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 69:G02.111.087.800 132:D02.172.080 563:D08.811.913.696.620.682.725.400.009|ES| 2:1 8:1 10:1 14:1 18:1 19:1 34:1 72:1 113:1 163:1 186:1 195:1 237:1 244:1 383:1 468:1 561:1 1121:1 1775:1 1993:1 1994:1 1995:1 1996:1 1997:1 1998:1
3 	|BT| (FRAG (PP (IN In) (NP (NN context))) (, ,) (NP (NP (NP (NN study) (NN p53)) (NP (ADVP (RB therefore)) (NP (JJ obvious) (NN implication) (JJ human) (NN health) (NN performance)))) (, ,) (NP (NP (VBN given) (JJ impaired) (JJ mitochondrial) (NN content) (NN function)) (VBN associated) (NN pathology) (JJ many) (JJ metabolic) (NN disorder)) (NP (JJ ageing) (, ,) (NN type) (CD 2) (NN diabetes)) (, ,) (NP (NN obesity) (NN cancer)) (, ,) (NP (ADJP (RB well) (VBN reduced)) (NN exercise) (NN performance)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 564:C18.654.726.500 565:A11.284.430.214.190.875.564 566:G11.427.590.530.698.277 567:G05.360.340.024.340.365 568:C18.452.394.750.149 569:G07.700.320.124 570:C23.550 571:N01.400|ES| 2:1 12:1 18:1 19:1 29:1 33:1 36:1 85:1 131:1 148:1 169:1 218:1 244:1 452:1 543:1 787:1 1040:1 1794:1 1999:1 2000:1 2001:1 2002:1 2003:1 2004:1 2005:1 2006:1 2007:1 2008:1 2009:1 2010:1 2011:1
3 	|BT| (S (PP (IN In) (NP (NN report))) (, ,) (VP (VBP show) (NP (NP (NP (NP (JJ synergistic) (NN action) (NN HBx) (NN p53) (NN mutation) (NN trigger) (JJ progressive) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN formation)) (PP (IN via) (NP (NN src) (NN activation) (NN zebrafish)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 20:G03.495 104:C04.557.470.200.025.255 572:B01.050.150.900.493.200.244.828 573:N05.715.350.200.650|ES| 2:1 10:1 12:1 14:1 19:1 34:1 43:1 225:1 244:1 303:1 304:1 417:1 429:1 441:1 596:1 610:1 2012:1 2013:1 2014:1 2015:1 2016:1 2017:1
3 	|BT| (S (NP (NN Inactivation) (NN APC) (NN gene)) (VP (VBN considered) (S (VP (VBG initiating) (NP (NN event) (JJ human) (JJ colorectal) (NN cancer)))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 55:B01.050.150.900.649.801.400.112.400.400|ES| 9:1 11:1 17:1 18:1 19:1 36:1 205:1 1061:1 2018:1 2019:1
3 	|BT| (S (NP (NN Induction) (NN p53)) (VP (VBP render) (NP (JJ ATM-deficient) (NN mouse) (JJ refractory) (NN hepatocarcinogenesis)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500|ES| 12:1 19:1 52:1 900:1 2020:1 2021:1 2022:1 2023:1
3 	|BT| (S (NP (NNP Integrated) (JJ transcriptomic) (JJ genomic) (NN analysis)) (VP (VBN defined) (S (NP (NP (JJ distinct) (NN superenhancer) (NN CIMP)) (CC +) (NP (NN colon) (NN cancer))) (VP (VBZ regulates) (NP (NN cMYC) (NN transcription)))))) |ET| |BS|209:G02.111.087.847 268:H01.158.273.180.350 269:G05.360.340|ES| 18:1 19:1 113:1 487:1 603:1 661:1 680:1 910:1 2024:1 2025:1 2026:1 2027:1 2028:1 2029:1
3 	|BT| (S (NP (JJ Intestinal) (NN cancer)) (VP (VBN driven) (SBAR (S (NP (ADJP (RB purely) (NN PTEN-deficiency)) (JJ transgenic) (NN mouse)) (VP (VBD developed) (NP (NP (NN CM) (JJ human) (NN CRC)) (, ,) (NP (NP (NN CM)) (VP (VBN associated) (NP (NNP PTEN) (NNP PRKCZ) (NN readout)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 66:F01.658.293 87:C18.654.521 99:B01.050.050.136.500 101:C04.588.274.476.411|ES| 2:1 18:1 19:1 36:1 52:1 169:1 204:1 245:1 285:1 920:1 1165:1 1936:1 2030:1 2031:1 2032:1 2033:1 2034:1
3 	|BT| (S (NP (JJ Isogenic) (JJ LKB1-knockdown) (NN breast) (NN cancer) (NN cell) (NN line) (NN pair)) (VP (VBD developed))) |ET| |BS|94:A11.251.210|ES| 18:1 19:1 23:1 94:1 264:1 1165:1 2035:1 2036:1 2037:1
3 	|BT| (S (NP (NN ITF-2)) (VP (VP (VBD disrupted) (PP (IN via) (NP (JJ allelic) (NN loss) (NN chromosome) (NN 18q21)))) (, ,) (SBAR (S (NP (NN ITF-2B) (NN expression)) (VP (VBD lost) (NP (JJ adenoma-carcinoma) (NN transition))))))) |ET| |BS|17:C04.557.470.035 289:A11.284.187 290:G05.365.590.029.530 317:C04.557.470.200.430|ES| 2:1 19:1 32:1 115:1 552:1 596:1 1005:1 1475:1 2038:1 2039:1 2040:1 2041:1 2042:1 2043:1
3 	|BT| (S (NP (JJ K-ras) (NN mutation)) (VP (VBP occur) (ADVP (RB frequently)) (S (NP (NN colon) (NN cancer)) (VP (VBP contribute) (NP (JJ autonomous) (NN growth)))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 45:G07.700.320.249|ES| 18:1 19:1 34:1 102:1 113:1 450:1 698:1 1121:1 2044:1 2045:1
3 	|BT| (NP (NP (JJ Many) (JJ etiological) (NN factor)) (, ,) (PP (VBG including) (NP (NP (NP (NP (NN hepatitis) (NN B) (NN virus) (NN X) (NN antigen)) (PRN (-LRB- -LRB-) (NP (NN HBx)) (-RRB- -RRB-))) (NN p53) (NN mutation)) (, ,) (NP (VBN implicated) (NN hepatocarcinogenesis))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 73:N05.715.350.200|ES| 2:1 10:1 12:1 14:1 19:1 34:1 185:1 561:1 763:1 900:1 929:1 977:1 1030:1 1422:1 2014:1 2046:1 2047:1 2048:1
3 	|BT| (S (NP (NNS Mice)) (NP (JJ heterozygous) (JJ dominant) (NN Min) (NN mutation) (NN Apc) (NN gene)) (VP (VBP develop) (NP (JJ multiple) (JJ intestinal) (NN neoplasia)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 102:C04.588.274.476.411 157:G05.380.383|ES| 9:1 19:1 34:1 109:1 280:1 583:1 640:1 648:1 649:1 650:1 786:1 2049:1
3 	|BT| (NP (NP (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NP (NN methionine) (NN adenosyltransferase) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN MAT1A)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NN PHB1) (NN expression)))) (, ,) (JJ impaired) (JJ mitochondrial) (NN function)) (, ,) (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 574:D08.811.913.225.650|ES| 2:1 10:1 14:1 19:1 33:1 115:1 303:1 304:1 376:1 441:1 452:1 583:1 648:1 1506:1 1792:1 2003:1 2004:1 2050:1 2051:1 2052:1 2053:1
3 	|BT| (S (NP (NN MicroRNA) (NNP 301A)) (VP (VBZ Promotes) (NP (NP (JJ Intestinal) (NN Inflammation) (NNP Colitis-Associated) (NNP Cancer) (NNP Development)) (VP (VBG Inhibiting) (NP (NN BTG1)))))) |ET| |BS|47:A03.556.124 53:C06.405.205.265 122:C14.280.383 184:D13.150.650.319 525:C23.550.470|ES| 19:1 204:1 1919:1 2054:1 2055:1 2056:1 2057:1 2058:1 2059:1 2060:1 2061:1
3 	|BT| (S (NP (NN MicroRNA-122)) (VP (VBZ inhibits) (SBAR (S (NP (JJ tumorigenic) (NN property) (JJ hepatocellular) (NN carcinoma) (NN cell)) (VP (VBZ sensitizes) (NP (NN cell) (NN sorafenib))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 122:C14.280.383 184:D13.150.650.319 575:V02.050|ES| 19:1 94:1 303:1 304:1 615:1 841:1 1797:1 1809:1 2062:1 2063:1
3 	|BT| (S (NP (NN microRNA-146a)) (VP (VBZ inhibits) (NP (NP (NN cancer) (NN metastasis)) (VP (VBG downregulating) (NP (NN VEGF) (JJ dual) (NN pathway) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|104:C04.557.470.200.025.255 113:C04.697.650 122:C14.280.383 184:D13.150.650.319|ES| 18:1 19:1 303:1 304:1 383:1 615:1 806:1 2064:1 2065:1 2066:1 2067:1
3 	|BT| (NP (NP (NP (NN MicroRNA-21) (JJ potential) (NN link) (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (NN modulation) (NN HBP1-p53-Srebp1c) (NN pathway))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 104:C04.557.470.200.025.255 184:D13.150.650.319 576:D12.776.260.103.500.750.500 577:C06.552.241.519|ES| 19:1 303:1 304:1 383:1 596:1 827:1 836:1 998:1 1608:1 1945:1 2068:1 2069:1 2070:1 2071:1
3 	|BT| (S (NP (NN MicroRNA-221)) (VP (VBZ governs) (S (NP (NN tumor) (NN suppressor) (NN HDAC6)) (VP (VB potentiate) (NP (JJ malignant) (NN progression) (NN liver) (NN cancer)))))) |ET| |BS|16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 184:D13.150.650.319 206:G05.360.340.024.340.375.249 231:C04.557.465.625.600.380.590|ES| 7:1 18:1 19:1 48:1 700:1 802:1 836:1 2072:1 2073:1 2074:1 2075:1
3 	|BT| (S (NP (NN MicroRNA-375) (NN target) (NN AEG-1) (JJ hepatocellular) (NN carcinoma)) (VP (VBZ suppresses) (NP (NN liver) (NN cancer) (NN cell) (NN growth)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|41:A11 45:G07.700.320.249 104:C04.557.470.200.025.255 184:D13.150.650.319 262:A11.436.348|ES| 18:1 19:1 94:1 102:1 160:1 216:1 303:1 304:1 378:1 686:1 836:1 1976:1 2076:1
3 	|BT| (S (NP (NN MicroRNA-608)) (VP (VBZ inhibits) (NP (NN proliferation) (NN bladder) (NN cancer)) (PP (IN via) (NP (NP (NN AKT/FOXO3a)) (NN signaling) (NN pathway))))) |ET| |BS|69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 184:D13.150.650.319 378:D08.811.913.696.620.682.700.755|ES| 18:1 19:1 195:1 299:1 383:1 564:1 596:1 615:1 2077:1 2078:1
3 	|BT| (S (NP (NN MicroRNA-7)) (VP (VBZ inhibits) (NP (NP (NN tumor) (NN growth) (NN metastasis)) (VP (VBG targeting) (NP (NN phosphoinositide) (NN 3-kinase/Akt) (NN pathway) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|8:C04 45:G07.700.320.249 104:C04.557.470.200.025.255 113:C04.697.650 122:C14.280.383 184:D13.150.650.319 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 7:1 19:1 102:1 303:1 304:1 383:1 615:1 616:1 806:1 2079:1 2080:1 2081:1
3 	|BT| (NP (NP (NN Microsatellite) (NN instability) (NN tool) (NN classification) (JJ gastric) (NN cancer))) |ET| |BS|395:L01.100 538:C23.550.362.590|ES| 18:1 19:1 86:1 831:1 1299:1 1338:1 2082:1
3 	|BT| (S (NP (JJ Microsomal) (NN prostaglandin) (NN E) (NN synthase-1)) (VP (VBN involved) (NP (JJ multiple) (NN step) (NN colon) (NN carcinogenesis)))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356|ES| 19:1 113:1 207:1 649:1 774:1 2083:1 2084:1 2085:1 2086:1 2087:1
3 	|BT| (S (NP (JJ Microsomal) (NN prostaglandin) (NN E) (NN synthase-1)) (VP (VBZ promotes) (NP (NN hepatocarcinogenesis) (NN activation) (JJ novel) (NN EGR1/beta-catenin) (NN signaling) (NN axis)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 259:D12.776.395.240.150.500 579:A02.835.232.834.151.383 580:D12.776.260.158.500|ES| 19:1 195:1 225:1 298:1 891:1 900:1 2083:1 2084:1 2085:1 2086:1 2088:1 2089:1
3 	|BT| (S (NP (NN MiR-122)) (VP (VBZ inhibits) (NP (NP (NN cell) (NN proliferation) (NN tumorigenesis) (NN breast) (NN cancer)) (VP (VBG targeting) (NP (NN IGF1R)))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 122:C14.280.383 183:G04.299.233.750|ES| 18:1 19:1 23:1 78:1 94:1 299:1 615:1 616:1 2090:1 2091:1
3 	|BT| (S (NP (NN MiR-145)) (VP (VBZ modulates) (NP (JJ multiple) (NN component) (JJ insulin-like) (NN growth) (NN factor) (NN pathway) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|104:C04.557.470.200.025.255 581:D12.644.276.937|ES| 19:1 102:1 185:1 303:1 304:1 383:1 606:1 649:1 1021:1 2092:1 2093:1
3 	|BT| (S (NP (NN miR-185)) (VP (VBZ inhibits) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN growth)) (VP (VBG targeting) (NP (NN DNMT1/PTEN/Akt) (NN pathway)))))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383 378:D08.811.913.696.620.682.700.755|ES| 19:1 102:1 303:1 304:1 383:1 615:1 616:1 2094:1 2095:1
3 	|BT| (S (NP (NN miR-221)) (VP (VBZ Mediates) (NP (NNP Chemoresistance) (NNP Esophageal) (NNP Adenocarcinoma) (NNP Direct) (NN Targeting) (NN DKK2) (NN Expression)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700|ES| 19:1 140:1 316:1 1215:1 2096:1 2097:1 2098:1 2099:1 2100:1 2101:1
3 	|BT| (S (NP (NN miR-490-3p)) (VP (VBD exerted) (NP (NP (NN growth)) (: -) (NP (NP (JJ metastasis-suppressive) (NN effect) (JJ gastric) (NN cancer) (NN cell)) (VP (ADVP (RB directly)) (VBG targeting) (NP (NP (NN SMARCD1)) (, ,) (NP (NP (NN SWItch/Sucrose) (NN NonFermentable)) (PRN (-LRB- -LRB-) (NP (NN SWI/SNF)) (-RRB- -RRB-))) (NP (NN chromatin) (NN remodeling) (NN complex) (NN subunit)))))))) |ET| |BS|41:A11 45:G07.700.320.249 113:C04.697.650 582:D09.698.629.305.770 583:D12.776.813|ES| 2:1 10:1 14:1 18:1 19:1 75:1 86:1 94:1 608:1 616:1 621:1 695:1 1346:1 2102:1 2103:1 2104:1 2105:1 2106:1 2107:1 2108:1 2109:1 2110:1
3 	|BT| (S (NP (NN miRNA-548p)) (VP (VBZ suppresses) (NP (NP (NN hepatitis) (NN B) (NN virus) (NN X) (NN protein)) (VP (VBN associated) (NP (NP (JJ hepatocellular) (NN carcinoma)) (VP (VBG downregulating) (NP (NN oncoprotein) (NN hepatitis) (NN B) (JJ x-interacting) (NN protein)))))))) |ET| |BS|104:C04.557.470.200.025.255 184:D13.150.650.319 584:D12.776.624.664|ES| 4:1 19:1 169:1 303:1 304:1 686:1 763:1 929:1 1422:1 2048:1 2065:1 2111:1 2112:1 2113:1
3 	|BT| (FRAG (PP (JJ Molecular) (S (VP (VBG targeting) (NP (NP (NP (NN GSK3beta) (NN overexpression) (NN GSK3beta) (JJ dominant-negative) (NN mutant)) (, ,) (NP (JJ acute-silencing) (NN GSK3beta) (NN RNA) (NN interference)) (, ,)) (VBN reproduced) (NN induction)) (NP (ADJP (RB transcriptionally) (JJ active)) (NP (NN p53) (JJ colorectal) (NN cancer) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 156:G05.355.315.203.374.790|ES| 2:1 12:1 17:1 18:1 19:1 94:1 152:1 197:1 515:1 516:1 616:1 736:1 811:1 1854:1 1894:1 2114:1 2115:1 2116:1 2117:1
3 	|BT| (S (S (NP (JJS Most) (JJ human) (JJ colorectal) (NN cancer)) (VP (VB arise) (NP (NN accumulation) (NN series) (JJ genetic) (NN alteration) (NN point) (NN mutation)) (PP (IN within) (NP (JJ Ki-ras) (NN p53) (NN gene))))) (, ,) (NP (NN chemical) (NN carcinogen)) (VP (MD may) (VP (VBN implicated) (NP (NN event) (ADJP (RB still) (JJ unidentified)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 438:G05.365.590.675|ES| 2:1 9:1 12:1 17:1 18:1 19:1 34:1 36:1 205:1 491:1 776:1 864:1 951:1 977:1 1807:1 2118:1 2119:1 2120:1 2121:1 2122:1 2123:1 2124:1 2125:1 2126:1
3 	|BT| (S (S (NP (NN Mouse) (NN strain)) (VP (VBD disrupted) (S (NP (NP (NN sPLA)) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NN gene) (JJ susceptible) (NN Min) (NN phenotype)) (VP (VBP develop) (NP (JJ numerous) (JJ intestinal) (NN polyp))))) (, ,)) (IN whereas) (S (NP (NP (NN mouse) (JJ normal) (NN sPLA)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (VP (VBP develop) (NP (JJ limited) (NN number) (NN polyp))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 80:G05.695 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411 444:C23.300.825|ES| 2:1 9:1 10:1 14:1 19:1 52:1 109:1 118:1 148:1 236:1 372:1 646:1 647:1 648:1 650:1 899:1 2039:1 2127:1 2128:1 2129:1 2130:1 2131:1
3 	|BT| (NP (NP (NNS Mutations) (NP (NP (NN APC) (NN gene) (JJ responsible) (JJ familial) (JJ adenomatous) (NN polyposis)) (PRN (-LRB- -LRB-) (NP (NN FAP)) (-RRB- -RRB-))) (NN majority) (JJ sporadic) (JJ colorectal) (NN cancer))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 18:G05.365.590 21:G05.360.340.024.340.375.249.050|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 57:1 58:1 198:1 725:1 854:1 1410:1 2132:1 2133:1
3 	|BT| (NP (NP (NNS Mutations)) (NP (NP (NP (JJ human) (NN DNA) (NN mismatch) (NN repair)) (PRN (-LRB- -LRB-) (NP (NN MMR)) (-RRB- -RRB-))) (NP (NP (NP (NN gene) (NN MLH1) (VBN associated) (JJ hereditary) (JJ nonpolyposis) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NP (NNP Lynch) (NN syndrome)) (, ,) (NP (NN HNPCC))) (-RRB- -RRB-))) (NP (JJ significant) (NN proportion) (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 174:G02.111.087.219.220 524:C04.588.274.476.411.307.190|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 36:1 135:1 169:1 513:1 584:1 666:1 723:1 725:1 1294:1 1410:1 1845:1 1846:1 1940:1 2134:1 2135:1 2136:1
3 	|BT| (NP (NNS Mutations) (NP (NP (NN APC) (NN gene) (NN play) (JJ critical) (NN role)) (JJ sporadic) (JJ familial) (NN form) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 44:F01.829.263 79:I03.450.642.693 189:V02.460|ES| 9:1 11:1 17:1 18:1 19:1 31:1 238:1 630:1 725:1 825:1 854:1 1410:1
3 	|BT| (S (NP (NN NAC1)) (VP (VBZ modulates) (NP (NP (NN sensitivity) (JJ ovarian) (NN cancer) (NN cell) (NN cisplatin)) (VP (VBG altering) (NP (JJ HMGB1-mediated) (JJ autophagic) (NN response)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 390:G04.299.139.399 498:D01.210.375 585:D12.644.276.087.371|ES| 18:1 19:1 94:1 494:1 606:1 607:1 1761:1 1763:1 2137:1 2138:1 2139:1 2140:1
3 	|BT| (S (NP (NN Number) (NN size) (JJ intestinal) (NN tumor)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NN mouse) (NN bearing) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN PTEN) (NN mutation)))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 102:C04.588.274.476.411 455:B01.050.150.900.649.147.890|ES| 7:1 10:1 11:1 14:1 19:1 34:1 47:1 52:1 57:1 58:1 59:1 109:1 124:1 1584:1 1936:1 2141:1 2142:1
3 	|BT| (S (NP (JJ Oncogenic) (NN mutation) (NN K-ras) (NN gene)) (VP (VBP occur) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (NP (JJ human) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100|ES| 9:1 17:1 18:1 19:1 34:1 36:1 368:1 369:1 1121:1 1843:1 2044:1 2143:1
3 	|BT| (S (NP (NP (CD One) (JJ common) (JJ rate-limiting) (NN mutation)) (JJ human) (NN CRC)) (VP (VBZ occurs) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750|ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1
3 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (NP (JJ important) (NP (NN role) (NN beta2-AR/STAT3/miR) (CD -373) (NN signaling) (NN transformation) (JJ gastric) (NN cancer) (NN cell))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 41:A11 69:G02.111.087.800 82:D12.644.360.024.342.300|ES| 18:1 19:1 31:1 86:1 94:1 195:1 658:1 793:1 796:1 902:1 1384:1 2144:1
3 	|BT| (S (NP (PRP$ Our) (NN finding) (NN support) (JJ mir-660) (NN act) (NN tumor) (NN suppressor) (NN miRNA)) (VP (VBP suggest) (NP (NN replacement) (JJ mir-660) (JJ new) (JJ therapeutic) (NN approach) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN treatment)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 81:E02.095.465.425.400.330.050.400 181:E04.936.494 184:D13.150.650.319 206:G05.360.340.024.340.375.249 275:C23.888 375:Z01.639.100|ES| 7:1 8:1 12:1 18:1 19:1 246:1 328:1 373:1 541:1 546:1 614:1 658:1 700:1 712:1 796:1 840:1 911:1 927:1 1364:1
3 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (NN JNK/PTEN) (NN NF-kappaB/PTEN) (NN pathway)) (VP (VBP play) (NP (JJ critical) (NP (NN role) (JJ normal) (NP (JJ intestinal) (NN homeostasis) (NN colon) (NN carcinogenesis))))))))) |ET| |BS|15:F01.829.316.616 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 79:I03.450.642.693 152:G07.700.345 210:D12.776.260.600|ES| 19:1 31:1 109:1 113:1 118:1 207:1 238:1 383:1 500:1 658:1 796:1 825:1 927:1 2145:1 2146:1
3 	|BT| (S (NP (NP (PRP$ Our) (VBN integrated) (NN microRNA)) (VP (VBG profiling) (NP (NN approach)))) (VP (VBD identified) (S (NP (NN miR-195-5p)) (ADVP (RB independently)) (VP (VBN associated) (NP (NN prognosis) (NN CRC)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 163:E01.789 184:D13.150.650.319|ES| 19:1 169:1 245:1 271:1 544:1 623:1 658:1 857:1 911:1 2147:1 2148:1 2149:1
3 	|BT| (S (NP (PRP$ Our) (JJ recent) (NN study)) (VP (VB establish) (NP (JJ oncogenic) (NN role) (NP (NP (NNP LSF) (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 104:C04.557.470.200.025.255 279:D27.888.569.100|ES| 10:1 14:1 19:1 31:1 131:1 220:1 304:1 441:1 658:1 659:1 953:1 2150:1 2151:1
3 	|BT| (S (NP (PRP$ Our) (JJ recent) (NN study)) (VP (VBZ indicates) (SBAR (S (NP (NNS AR)) (VP (VBZ upregulates) (NP (NP (NN expression) (NN tumor) (NN suppressor) (NN gene) (NN PTEN) (NN promoter)) (NN activation) (NN breast) (NN cancer))))))) |ET| |BS|155:G05.355.310 206:G05.360.340.024.340.375.249|ES| 7:1 9:1 18:1 19:1 23:1 83:1 115:1 131:1 225:1 628:1 658:1 659:1 700:1 1936:1 2152:1 2153:1
3 	|BT| (S (NP (PRP$ Our) (NN study)) (VP (VBP identify) (NP (NP (NN network) (NN protein)) (, ,) (PP (VBG including) (NP (NP (NP (NN osteopontin)) (PRN (-LRB- -LRB-) (NP (NN OPN)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Matrix) (NN metalloproteinase-9)) (PRN (-LRB- -LRB-) (NP (NN MMP-9)) (-RRB- -RRB-))) (, ,) (NP (NP (NN c-Met) (NN complement) (NN factor) (NN H)) (PRN (-LRB- -LRB-) (NP (NN CFH)) (-RRB- -RRB-))) (, ,) (VP (ADVP (RB directly)) (VBN regulated) (NP (NP (NN LSF) (NN play) (JJ important) (NN role)) (JJ LSF-induced) (NN hepatocarcinogenesis)))))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 112:D12.776.097.820 142:I01.880.604 350:D12.644.276.374.625 586:D08.811.277.656.300.480.205.360 587:D12.776.124.486.274.920.325.200 588:I01.880.853.500.600|ES| 2:1 4:1 10:1 14:1 19:1 31:1 131:1 185:1 238:1 561:1 612:1 621:1 658:1 832:1 900:1 902:1 1160:1 1664:1 2150:1 2154:1 2155:1 2156:1 2157:1 2158:1 2159:1 2160:1 2161:1 2162:1
3 	|BT| (S (NP (NN Overexpression) (NN miR-375) (NN liver) (NN cancer) (NN cell)) (VP (VBD decreased) (NP (NP (NN cell) (NN proliferation)) (, ,) (NP (NN clonogenicity)) (, ,) (NP (NN migration/invasion))) (ADVP (RB also)) (VP (VBD induced) (NP (NN G1) (NN arrest) (NN apoptosis))))) |ET| |BS|39:G04.299.139.160 41:A11 183:G04.299.233.750 262:A11.436.348|ES| 2:1 5:1 18:1 19:1 89:1 94:1 202:1 299:1 412:1 602:1 668:1 669:1 670:1 836:1 1975:1 2163:1
3 	|BT| (S (NP (NN p53)) (VP (VBZ promotes) (NP (NP (JJ inflammation-associated) (NN hepatocarcinogenesis)) (VP (VBG inducing) (NP (NN HMGB1) (NN release)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 525:C23.550.470 585:D12.644.276.087.371 589:E02.204.125|ES| 12:1 19:1 298:1 900:1 1849:1 1864:1 2164:1 2165:1
3 	|BT| (NP (NP (JJ Paired) (NN box) (NN gene) (CD 5) (JJ novel) (NN tumor) (NN suppressor) (JJ hepatocellular) (NN carcinoma) (NN interaction) (NN p53) (NN signaling) (NN pathway))) |ET| |BS|2:G05.360.340.024.340.375.249.385 6:G05.360.340.024.340 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 206:G05.360.340.024.340.375.249 243:D12.776.260.645.500 259:D12.776.395.240.150.500|ES| 7:1 9:1 12:1 19:1 195:1 303:1 304:1 383:1 578:1 618:1 700:1 891:1 1918:1 2166:1
3 	|BT| (NP (NP (NNP Parkin) (NN tumor) (NN suppressor) (NN gene) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 206:G05.360.340.024.340.375.249|ES| 7:1 9:1 19:1 303:1 304:1 700:1 2167:1
3 	|BT| (S (NP (NP (NNP PIRC) (NN rat)) (PRN (-LRB- -LRB-) (NP (NP (NN F344/NTac-Apc)) (PRN (-LRB- -LRB-) (NP (NN am1137)) (-RRB- -RRB-))) (-RRB- -RRB-))) (NP (VBN mutated) (NN Apc) (NN gene)) (ADVP (RB spontaneously)) (VP (VB develop) (NP (NN colon)) (NP (NN tumor)) (ADVP (RB thus)) (VP (NP (VBG mimicking) (JJ familial) (NP (NP (JJ adenomatous) (NN polyposis) (-LRB- -LRB-) (NN FAP) (-RRB- -RRB-) (JJ sporadic) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (RB closely) (JJ Apc-based) (JJ rodent) (NN model)) (S (VP (VBG developing) (NP (NP (NN tumor)) (ADJP (RB mostly) (JJ small)) (NN intestine))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 21:G05.360.340.024.340.375.249.050 51:C04.588.274.476.411.307.180 102:C04.588.274.476.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 333:D01.045 514:B01.050.150.900.649.865 590:B01.050.050.199.520.760.200|ES| 7:1 9:1 10:1 14:1 17:1 18:1 19:1 57:1 58:1 72:1 113:1 229:1 245:1 280:1 356:1 590:1 648:1 725:1 750:1 849:1 854:1 855:1 1334:1 1506:1 2133:1 2168:1 2169:1 2170:1 2171:1 2172:1 2173:1 2174:1
3 	|BT| (S (NP (NP (NP (JJ Real-time) (JJ reverse) (NN transcription) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD demonstrated) (NP (NP (NN up-regulation) (JJ oncogenic) (NN miR-155)) (, ,) (NP (NP (NN miR-221)) (: /) (NP (CD 222))) (, ,) (NP (NP (NN miR-21) (NN down-regulation) (JJ abundant) (JJ liver-specific) (NN miR-122)) (JJ early) (NN stage) (NN hepatocarcinogenesis))))) |ET| |BS|85:G02.111.087.225 242:A03.620 249:G05.355.315.800 272:E05.393.620.500.725 279:D27.888.569.100 339:G02.111.087.880 346:E05.393.620.500.706 591:G02.111.087.847.500|ES| 2:1 10:1 14:1 19:1 257:1 394:1 487:1 661:1 768:1 896:1 900:1 939:1 941:1 953:1 1128:1 1129:1 1148:1 1175:1 1789:1 1798:1 1799:1 1911:1 2175:1 2176:1 2177:1
3 	|BT| (S (ADVP (RB Recently)) (, ,) (S (NP (NP (NN microRNA-122)) (PRN (-LRB- -LRB-) (NP (NN miR-122)) (-RRB- -RRB-))) (VP (VBD proved) (NP (NP (NN play) (JJ important) (NN role)) (NP (JJ hepatocellular) (NN carcinoma))))) (, ,) (NP (NP (NN function) (NN context) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN BC)) (-RRB- -RRB-))) (VP (VBP remain) (ADJP (JJ unknown)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 104:C04.557.470.200.025.255 184:D13.150.650.319|ES| 2:1 10:1 14:1 18:1 19:1 23:1 31:1 33:1 238:1 303:1 304:1 902:1 1789:1 1857:1 1999:1 2178:1 2179:1 2180:1 2181:1 2182:1
3 	|BT| (S (ADVP (RB Recently)) (, ,) (NP (NP (NP (NP (NN microRNA-7)) (PRN (-LRB- -LRB-) (NP (NN miR-7)) (-RRB- -RRB-))) (NP (NP (JJ proven) (NN play) (JJ substantial) (NN role)) (NP (NN glioblastoma) (NN breast) (NN cancer)))) (, ,) (NP (NN function) (NN context) (NNP HCC))) (VP (VBP remain) (ADJP (JJ unknown)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 104:C04.557.470.200.025.255 184:D13.150.650.319 592:C04.557.465.625.600.380.080.335|ES| 2:1 10:1 14:1 18:1 19:1 23:1 31:1 33:1 238:1 441:1 1293:1 1999:1 2178:1 2181:1 2182:1 2183:1 2184:1 2185:1 2186:1
3 	|BT| (S (NP (NN Role) (NN microRNA-155) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ choline-deficient) (NN amino) (JJ acid-defined) (NN diet) (NN C57BL/6) (NN mouse)))) |ET| |BS|15:F01.829.316.616 184:D13.150.650.319 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 19:1 52:1 412:1 900:1 1128:1 1129:1 1957:1 2187:1 2188:1 2189:1 2190:1 2191:1 2192:1
3 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN ATA)) (VP (MD may) (NP (JJ broad) (NN utility) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer))))))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 520:C10.228.140.252.190.530.060|ES| 2:1 18:1 19:1 23:1 491:1 546:1 793:1 796:1 1537:1 1538:1 1820:1 2193:1 2194:1 2195:1
3 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NN study) (VP (VBP indicate) (SBAR (S (NP (VBN upregulated) (NN BYSL) (NN expression)) (VP (VBP play) (NP (NN role) (NN hepatocarcinogenesis))))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693|ES| 2:1 19:1 31:1 115:1 125:1 131:1 238:1 900:1 1479:1 1537:1 1538:1 2196:1
3 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VB identify) (SBAR (S (NP (NN downregulation) (NN miR-497) (JJ important) (NN mechanism) (NN upregulation) (NN IGF1-R) (NN CRC) (NN cell)) (VP (VBZ contributes) (NP (NN malignancy) (NN CRC)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 249:G05.355.315.800 339:G02.111.087.880 375:Z01.639.100 598:D12.644.276.937.400 599:M01.526.799.500|ES| 2:1 19:1 49:1 94:1 101:1 162:1 245:1 595:1 832:1 845:1 902:1 1126:1 1537:1 1538:1 2197:1 2198:1
3 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1
3 	|BT| (NP (NP (NP (DT The) (NN APC) (NN gene) (NN play) (JJ major) (NN role)) (NP (JJ human) (NN colon) (NN carcinogenesis)))) |ET| |BS|15:F01.829.316.616 21:G05.360.340.024.340.375.249.050 33:C04.697.098 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693|ES| 9:1 11:1 19:1 31:1 36:1 113:1 207:1 238:1 462:1 691:1
3 	|BT| (NP (NP (NP (DT The) (NN B-cell) (NN tumor) (NN promoter)) (SBAR (S (NP (NN Bcl-3)) (VP (VBZ suppresses) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis) (JJ epithelial) (NN cell))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 53:C06.405.205.265 75:A11.436 310:A11.063.438 600:D27.888.569.100|ES| 7:1 19:1 78:1 83:1 94:1 113:1 127:1 404:1 686:1 691:1 1849:1 2199:1
3 	|BT| (S (NP (DT The) (NP (NN c-myc) (NN oncogene) (NN play) (JJ important) (NN role)) (NN tumorigenesis)) (ADVP (RB frequently)) (VP (VBD deregulated) (NP (NP (JJ many) (JJ human) (NN cancer)) (, ,) (PP (VBG including) (NP (JJ gastrointestinal) (NN cancer)))))) |ET| |BS|9:G05.360.340.024.340.375.500 12:Z01.542.049 15:F01.829.316.616 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693|ES| 2:1 18:1 19:1 24:1 31:1 36:1 78:1 183:1 238:1 455:1 561:1 691:1 698:1 902:1 1040:1 1965:1
3 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
3 	|BT| (S (NP (DT The) (NN finding) (JJ parkin-deficient) (NN mouse) (JJ susceptible) (NN hepatocarcinogenesis)) (VP (VBN provided) (VP (JJ first) (NP (NN evidence) (VP (VBG showing) (NP (JJ parkin) (ADVP (RB indeed)) (NP (NN tumor) (NN suppressor) (NN gene)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 206:G05.360.340.024.340.375.249 275:C23.888|ES| 7:1 9:1 19:1 38:1 52:1 691:1 700:1 816:1 899:1 900:1 927:1 1155:1 2200:1 2201:1 2202:1 2203:1
3 	|BT| (S (NP (DT The) (NN finding)) (VP (MD may) (VP (VB provide) (NP (NP (NN basis) (NN understanding) (JJR greater) (NN predisposition) (JJ intestinal) (NN cancer) (NN Mlh1)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 101:C04.588.274.476.411 239:F02.463.188.357 401:C23.550.291.687|ES| 10:1 14:1 18:1 19:1 45:1 52:1 109:1 491:1 586:1 691:1 711:1 905:1 927:1 1140:1 1768:1 2204:1
3 	|BT| (NP (NP (NP (DT The) (NP (NN ITF-2) (NN gene))) (JJ located) (JJ chromosomal) (NN region) (NN 18q21)) (: ;) (S (NP (JJ allelic) (NN loss) (NN locus)) (VP (VBZ occurs) (NP (ADJP (CD 70) (NN %)) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 6:G05.360.340.024.340 289:A11.284.187 290:G05.365.590.029.530 292:Z01|ES| 9:1 17:1 18:1 19:1 32:1 217:1 369:1 377:1 657:1 667:1 691:1 1002:1 1475:1 2038:1 2040:1 2205:1 2206:1
3 	|BT| (NP (NP (DT The) (NN K-sam) (NN gene)) (, ,) (VP (ADVP (RB originally)) (VBN isolated) (NP (NP (VBN amplified) (NN gene) (NN stomach) (NN cancer) (NN cell) (NN line) (NN KATO-III)) (, ,) (VP (VBN characterized) (S (NP (NP (NP (JJ preferential) (NN amplification) (JJ undifferentiated) (NN type)) (PRN (-LRB- -LRB-) (NP (JJ diffuse) (NN type)) (-RRB- -RRB-))) (NN stomach) (NN cancer)) (VP (VBZ encodes) (NP (CD one) (NN receptor) (JJ heparin-binding) (NN growth) (NN factor) (NN fibroblast) (NN growth) (NN factor)))))))) |ET| |BS|6:G05.360.340.024.340 94:A11.251.210 232:D02.886.030.676.180 601:D12.644.276.624 602:D09.698.373.400|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 102:1 185:1 186:1 264:1 543:1 653:1 691:1 801:1 803:1 804:1 921:1 985:1 1010:1 1653:1 2207:1 2208:1 2209:1 2210:1 2211:1 2212:1 2213:1
3 	|BT| (UCP (S (NP (DT The) (NN miR-122) (JJ regulatory) (NN circuitry) (NN implication) (NN hepatocarcinogenesis)) (VP (VBN identified) (S (VP (VBG using) (NP (NN liver) (JJ different) (NN development) (NN stage)))))) (, ,) (NP (NP (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NN tissue) (NN cell) (NN line)) (, ,) (NP (NP (NN aflatoxin) (NN B)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (-LRB- -LRB-) (NN AFB) (LST (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (-RRB- -RRB-)))) (: -) (NP (VBN transformed) (NN cell)))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 98:A10 104:C04.557.470.200.025.255 242:A03.620 603:D03.383.663.283.119.075|ES| 2:1 10:1 14:1 19:1 35:1 36:1 85:1 94:1 98:1 264:1 272:1 303:1 304:1 350:1 414:1 441:1 623:1 691:1 763:1 836:1 900:1 1129:1 1789:1 1817:1 1818:1 2214:1 2215:1 2216:1
3 	|BT| (S (NP (DT The) (NN orphan) (NN cotransport) (NN protein)) (VP (VBD expressed) (NP (NP (NP (NN SLC5A8) (NN gene) (VBN shown) (NN play) (NN role)) (NP (VBG controlling) (NN growth) (NN colon) (NN cancer))) (, ,) (NP (NN silencing) (NP (NN gene) (JJ common) (NP (JJ early) (NN event) (JJ human) (NN colon) (NN neoplasia))))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 42:G05.355.315.203.374 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 604:M01.108|ES| 2:1 4:1 6:1 9:1 18:1 19:1 31:1 36:1 100:1 102:1 113:1 205:1 237:1 238:1 640:1 655:1 691:1 1128:1 2217:1 2218:1 2219:1 2220:1
3 	|BT| (NP (NP (NP (DT The) (JJ potential) (NN utility) (NN acetyltanshinone) (NN IIA) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer)) (: :) (NP (NP (NN Induction) (NN cancer) (NN cell) (NN death)) (VP (VBG targeting) (NP (JJ apoptotic) (JJ metabolic) (NN signaling) (NN pathway)))))) |ET| |BS|33:C04.697.098 39:G04.299.139.160 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 126:G02.111.087.800 134:G04.299.139 605:G03.495.553|ES| 18:1 19:1 23:1 94:1 104:1 195:1 383:1 411:1 546:1 616:1 691:1 827:1 2006:1 2020:1 2194:1 2195:1 2221:1 2222:1 2223:1
3 	|BT| (S (NP (NP (DT The) (NN proliferation)) (NP (JJ certain) (NP (JJ human) (JJ HER2-positive) (NN breast) (NN cancer) (NN line)))) (ADVP (RB also)) (VP (VBZ requires) (SBAR (S (NP (NP (NN HSF1)) (, ,) (NP (NN knockdown))) (VP (VBD led) (NP (NP (NN upregulation) (NN p21)) (CC and/or) (NP (NN decrease) (NN survivin))) (, ,) (S (VP (VBG precipitating) (NP (NN growth) (NN arrest))))))))) |ET| |BS|45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 86:D01.268.556.435 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 5:1 18:1 19:1 23:1 36:1 102:1 149:1 264:1 295:1 299:1 464:1 602:1 691:1 1126:1 1135:1 2224:1 2225:1 2226:1 2227:1 2228:1 2229:1 2230:1
3 	|BT| (S (NP (DT The) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN MTHFR) (NN genotype) (JJ relevant) (JJ independent) (NN factor) (NN patient) (NN outcome) (JJ 5FU-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 333:D01.045 396:G05.380 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 17:1 18:1 19:1 101:1 120:1 185:1 546:1 547:1 691:1 796:1 865:1 883:1 997:1 1329:1 2231:1 2232:1
3 	|BT| (S (NP (DT The) (NN Tg737) (NN gene)) (VP (VBD found) (NP (NP (JJ altered) (ADJP (QP (RB approximately) (CD 40)) (NN %)) (JJ rodent) (JJ chemically-induced) (NN liver) (NN tumor)) (, ,) (NP (NP (CD 40) (NN %)) (JJ human) (NN liver) (NN tumor)) (, ,) (NP (NN liver)) (, ,) (NP (NN kidney) (JJ pancreatic) (JJ human) (NN tumor) (NN cell) (NN line))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 242:A03.620 485:A05.810.453 514:B01.050.150.900.649.865 515:C04.588.274.623 607:A11.251.210.190 608:A03.734|ES| 2:1 7:1 9:1 19:1 36:1 37:1 94:1 264:1 369:1 467:1 582:1 691:1 693:1 836:1 1717:1 1805:1 1843:1 2173:1 2233:1
3 	|BT| (NP (NP (NP (DT The) (NN transcription) (NN factor) (NNP LSF)) (: :) (NP (JJ novel) (NN oncogene) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|9:G05.360.340.024.340.375.500 104:C04.557.470.200.025.255 166:D12.776.930 259:D12.776.395.240.150.500|ES| 19:1 24:1 104:1 185:1 303:1 304:1 487:1 691:1 891:1 2150:1
3 	|BT| (S (ADVP (RB Therefore)) (NP (NN bile) (NN duct) (NN cancer) (NN patient)) (VP (MD may) (NP (VBN treated) (NN miR-34a) (NN inhibitor) (NN Per1) (NN stimulator) (NN future)))) |ET| |BS|50:M01.643 52:E02 354:I01.320|ES| 18:1 19:1 120:1 380:1 491:1 1099:1 1190:1 1620:1 1621:1 1622:1 1623:1 1624:1 1625:1
3 	|BT| (S (ADVP (RB Therefore)) (, ,) (VP (VBP conclude) (SBAR (S (NP (NP (NN miR-141) (NN target) (NN MAP4K4)) (, ,) (VP (VBP act) (NP (NN tumor) (NN suppressor) (JJ pancreatic) (NN cancer) (NN cell))) (, ,)) (VP (MD may) (VP (VB serve) (NP (ADJP (ADJP (JJ novel)) (ADJP (JJ therapeutic))) (NN agent) (JJ miRNA-based) (JJ pancreatic) (NN cancer) (NN therapy)))))))) |ET| |BS|41:A11 52:E02 81:E02.095.465.425.400.330.050.400 184:D13.150.650.319 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500 333:D01.045 557:D02.241.081.069.600.150|ES| 2:1 7:1 18:1 19:1 94:1 130:1 160:1 246:1 463:1 465:1 467:1 491:1 532:1 541:1 700:1 728:1 891:1 1620:1 1968:1 2234:1
3 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN HNF4alpha)) (VP (VBZ maintains) (NP (NP (NN hepatocyte) (NN differentiation) (JJ adult) (JJ healthy) (NN liver)) (, ,) (S (NP (NN loss)) (VP (MD may) (ADVP (RB directly)) (VP (VB contribute) (NP (JJ hepatocellular) (NN carcinoma) (NN development))) (, ,) (S (VP (ADVP (RB thus)) (VBG indicating) (NP (NN factor) (JJ possible) (NN liver) (NN tumor) (NN suppressor) (NN gene)))))))))))) |ET| |BS|74:G04.299.151 104:C04.557.470.200.025.255 119:M01.060.116 188:N02.628 206:G05.360.340.024.340.375.249 242:A03.620 262:A11.436.348 571:N01.400|ES| 2:1 7:1 9:1 19:1 32:1 35:1 123:1 185:1 215:1 303:1 304:1 355:1 450:1 491:1 621:1 631:1 700:1 792:1 793:1 796:1 836:1 1334:1 1359:1 1909:1 2235:1 2236:1
3 	|BT| (S (NP (DT These) (VBG finding) (NP (VBN suggested) (NN Notch1) (NN signaling))) (VP (VBP play) (NP (NP (NP (JJ important) (NN role) (NN maintenance) (NN cancer)) (JJ stem-like) (NN phenotype) (JJ diffuse) (NN type) (JJ gastric) (NN cancer) (NN RBP-Jkappa) (JJ dependent) (NN pathway)) (VP (VBG inhibiting) (NP (NN Notch1) (NN signaling)))) (VP (MD could) (NP (JJ effective) (NN therapy) (NN CD133) (JJ positive) (JJ diffuse) (NN type) (JJ gastric) (NN cancer))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 52:E02 69:G02.111.087.800 79:I03.450.642.693 80:G05.695 122:C14.280.383 188:N02.628 309:A18.024.937|ES| 18:1 19:1 31:1 86:1 130:1 195:1 233:1 236:1 238:1 321:1 383:1 543:1 651:1 652:1 653:1 792:1 880:1 902:1 908:1 925:1 927:1 1062:1 1063:1 1638:1 1639:1
3 	|BT| (S (NP (DT These) (NN study)) (VP (VB establish) (NP (NP (JJ key) (NN role) (NN LSF) (NN hepatocarcinogenesis) (NN usher) (JJ novel) (JJ therapeutic) (NN avenue)) (NP (NNP HCC))) (, ,) (NP (RB invariably) (JJ fatal) (NN disease)))) |ET| |BS|15:F01.829.316.616 52:E02 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 288:C23.550.288|ES| 2:1 19:1 31:1 131:1 159:1 220:1 441:1 541:1 792:1 891:1 900:1 998:1 1655:1 2150:1 2237:1 2238:1 2239:1
3 	|BT| (S (NP (NP (DT This) (JJ first) (NN study)) (VP (VBG showing) (NP (NN miR-205)))) (VP (VBZ inhibits) (NP (JJ proto-oncogenic) (NNS SFKs)) (, ,) (S (VP (VBG indicating) (NP (JJ therapeutic) (JJ potential) (NN miR-205) (NN treatment) (JJ renal) (NN cancer)))))) |ET| |BS|52:E02 122:C14.280.383 279:D27.888.569.100|ES| 2:1 18:1 19:1 131:1 541:1 546:1 615:1 807:1 816:1 827:1 922:1 2201:1 2236:1 2240:1 2241:1 2242:1
3 	|BT| (S (NP (DT This)) (VP (VBD led) (SBAR (S (NP (NN u)) (VP (VBP investigate) (SBAR (S (NP (NP (JJ antitumor) (NN growth)) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin) (JJ immunocompetent) (NN xenograft) (NN model) (NN mouse) (JJ metastatic) (JJ mammary) (NN cancer) (NN p53) (NN mutation))) (VP (VBZ induces) (NP (NP (JJ metastatic) (NN spectrum)) (NP (JJ similar) (VBN seen) (JJ human) (NN breast) (NN cancer))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 10:A01.236 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 113:C04.697.650 213:F02.830.816.964 609:A01.236.249 610:G12.460|ES| 12:1 18:1 19:1 23:1 34:1 36:1 52:1 72:1 102:1 214:1 265:1 332:1 337:1 399:1 459:1 724:1 807:1 2228:1 2243:1 2244:1 2245:1 2246:1 2247:1 2248:1 2249:1
3 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN inactivation) (NN TGF-beta) (NN signaling) (NN loss) (NN PTEN)) (VP (VBP cooperate) (NP (NP (NN drive) (JJ intestinal) (NN cancer) (NN formation) (NN progression)) (VP (VBG suppressing) (NP (NN cell) (NN cycle) (NN inhibitor)))))) |ET| |BS|16:C23.550.291.656 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 66:F01.658.293 69:G02.111.087.800 101:C04.588.274.476.411 353:G04.299.134 503:D12.644.276.374.687|ES| 2:1 18:1 19:1 32:1 43:1 48:1 94:1 109:1 181:1 195:1 380:1 474:1 601:1 1314:1 1691:1 1774:1 1936:1 2250:1
3 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN MYH11) (NN mutation)) (VP (VBP appear) (VP (VBP contribute) (ADVP (RB also)) (NP (JJ human) (JJ intestinal) (NN neoplasia))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411|ES| 2:1 5:1 19:1 34:1 36:1 109:1 450:1 640:1 1627:1 1691:1 2251:1
3 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN PPARgamma1)) (VP (MD might) (VP (VB offer) (NP (JJ promising) (NN gene) (JJ therapeutic) (NN target) (NN atherosclerosis))))) |ET| |BS|52:E02 149:G05.360.340.024.340.364.875.890 511:C14.907.137.126.307 513:C14.907.137.126|ES| 2:1 9:1 19:1 160:1 541:1 798:1 1042:1 1517:1 1691:1 1803:1 1804:1
3 	|BT| (S (S (VP (TO To) (VP (VB characterize) (NP (NN CC531) (NN model) (JJ molecular) (NN level))))) (, ,) (NP (VBN screened) (NN mutation) (NN gene)) (VP (VBG covering) (NP (NP (JJ important) (NN signal-transduction) (NN pathway)) (NP (NP (VBN known) (NN play) (JJ major) (NN role) (NN colon) (NN carcinogenesis)) (, ,) (NP (NN wnt) (JJ ki-ras) (NN signaling) (NN pathway)))))) |ET| |BS|6:G05.360.340.024.340 15:F01.829.316.616 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 126:G02.111.087.800 611:E05.599.595|ES| 2:1 9:1 19:1 31:1 34:1 72:1 113:1 161:1 195:1 207:1 238:1 249:1 383:1 462:1 556:1 828:1 902:1 2252:1 2253:1 2254:1 2255:1 2256:1 2257:1 2258:1
3 	|BT| (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (NN role) (NN APC) (NN gene) (NN microsatellite) (NN instability)) (PRN (-LRB- -LRB-) (NP (NN MI)) (-RRB- -RRB-))) (JJ PhIP-induced) (NN colon) (NN carcinogenesis))))) (, ,) (NP (NN mutation) (NN APC) (NN gene) (NN alteration) (NNS microsatellites)) (VP (VBN examined))) |ET| |BS|15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 394:G02.111.570.080.708.800.500 538:C23.550.362.590|ES| 2:1 9:1 10:1 11:1 14:1 19:1 31:1 34:1 113:1 207:1 324:1 459:1 828:1 951:1 1299:1 1332:1 1839:1 2259:1 2260:1
3 	|BT| (NP (NP (NP (NNS Tumors)) (VP (VBG lacking) (S (NP (NN DNA) (NN mismatch) (NN repair) (NN activity) (-LRB- -LRB-) (NN MMR) (-RRB- -RRB-) (NN patient)) (NP (NP (NP (JJ Hereditary) (NN Nonpolyposis) (JJ Colorectal) (NN Cancer)) (PRN (-LRB- -LRB-) (NP (NN HNPCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ sporadic) (JJ colorectal) (NN cancer)) (VP (VBD identified) (NP (NP (NN presence) (JJ high) (NN level) (NN instability) (JJ repetitive) (NN sequence)) (VP (VBN known) (NP (NP (NNS microsatellites)) (PRN (-LRB- -LRB-) (NP (NN MSI)) (-RRB- -RRB-))))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 50:M01.643 174:G02.111.087.219.220 394:G02.111.570.080.708.800.500 524:C04.588.274.476.411.307.190 538:C23.550.362.590 612:G02.111.570.080.708|ES| 10:1 14:1 17:1 18:1 19:1 53:1 120:1 178:1 249:1 293:1 346:1 376:1 399:1 513:1 556:1 584:1 623:1 666:1 725:1 1299:1 1919:1 2134:1 2136:1 2260:1 2261:1 2262:1 2263:1 2264:1 2265:1
3 	|BT| (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (NN Loss) (NN E-cadherin)) (PRN (-LRB- -LRB-) (NP (NN CDH1)) (-RRB- -RRB-))) (, ,) (NP (NN Smad4)) (, ,) (NP (NP (NN p53) (VBN shown) (NN play) (JJ integral) (NN role)) (ADJP (JJ gastric))) (, ,) (NP (JJ intestinal) (, ,) (NN breast) (NN cancer) (NN formation)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200|ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1
3 	|BT| (S (NP (NP (NN Up-regulation) (JJ several) (NN miR-1) (NN target)) (PP (VBG including) (NP (NP (NN FoxP1)) (, ,) (NP (NN MET)) (, ,) (NP (NN HDAC4) (JJ primary) (JJ human) (NNS HCCs) (NP (NN down-regulation) (NN expression) (JJ 5-AzaC-treated) (NN HCC) (NN cell)))))) (VP (VBP suggest) (NP (NN role) (NN hepatocarcinogenesis)))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 19:1 31:1 36:1 94:1 115:1 160:1 257:1 262:1 344:1 441:1 561:1 796:1 900:1 957:1 1132:1 2270:1 2271:1 2272:1 2273:1 2274:1
3 	|BT| (S (NP (PRP We)) (VP (VBD analyzed) (NP (NP (NN cooperation) (NN RB) (NN p53) (NN liver) (NN development) (NN pathogenesis)) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 104:C04.557.470.200.025.255 242:A03.620|ES| 12:1 19:1 35:1 303:1 304:1 501:1 836:1 843:1 1168:1 1209:1 1960:1
3 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (S (NN parkin) (: -) (: /) (: -) (NP (NN mouse) (VBD enhanced) (NN hepatocyte) (NN proliferation)) (VP (VBD developed) (NP (JJ macroscopic) (JJ hepatic) (NN tumor) (JJ characteristic) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 262:A11.436.348 515:C04.588.274.623|ES| 7:1 19:1 52:1 299:1 303:1 304:1 336:1 385:1 838:1 843:1 1165:1 1175:1 1909:1 2275:1 2276:1
3 	|BT| (S (NP (PRP We)) (ADVP (RB first)) (VP (VBP show) (SBAR (S (NP (NP (NN Notch-1) (NN receptor)) (, ,) (NP (ADJP (RB well) (JJ downstream)) (NN target) (NN Hes-1)) (, ,)) (VP (VBD up-regulated) (NP (NP (NN colon) (NN cancer) (NN progression)) (, ,) (NP (NP (JJ similar) (NN gene)) (VP (VBN involved) (S (NP (NN chemoresistance))))))))))) |ET| |BS|6:G05.360.340.024.340 16:C23.550.291.656 142:I01.880.604 150:Z01.542.248.960|ES| 2:1 9:1 18:1 19:1 20:1 48:1 113:1 160:1 182:1 186:1 332:1 429:1 560:1 774:1 787:1 816:1 843:1 1301:1 2277:1
3 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (NP (NP (NN enhancement) (NN Brf1) (NN Pol) (CD III) (NN gene) (NN expression)) (VBN associated) (NP (NP (NN occurrence) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 614:G05.360.340.024.340.364.875.667|ES| 9:1 10:1 14:1 19:1 52:1 115:1 169:1 303:1 304:1 441:1 843:1 1175:1 2278:1 2279:1 2280:1 2281:1 2282:1
3 	|BT| (S (NP (PRP We)) (VP (VBP document) (NP (NP (NN cooperation) (NN AEG-1) (NN c-Myc)) (VP (VBG promoting) (NP (NP (NN hepatocarcinogenesis) (VBG analyzing) (JJ hepatocyte-specific) (JJ transgenic) (NN mouse)) (VP (VBG expressing) (NP (CC either) (NP (NP (NN AEG-1)) (PRN (-LRB- -LRB-) (NP (NP (NN albumin)) (PRN (-LRB- -LSB-) (NP (NN Alb)) (-RRB- -RSB-))) (: /) (NP (NN AEG-1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN c-Myc)) (PRN (-LRB- -LRB-) (NP (NN Alb/c-Myc)) (-RRB- -RRB-))) (, ,)))))) (PRN (-LRB- -LRB-) (NP (NNP Alb/AEG) (CD -1) (: /) (NN c-Myc)) (-RRB- -RRB-)))) |ET| |BS|99:B01.050.050.136.500 262:A11.436.348 615:D12.776.034|ES| 2:1 10:1 14:1 19:1 39:1 52:1 285:1 810:1 824:1 843:1 881:1 900:1 1373:1 1378:1 1960:1 1976:1 2283:1 2284:1 2285:1 2286:1 2287:1 2288:1 2289:1 2290:1
3 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (NP (NP (JJ hepatic) (NN coexpression) (NN c-Myc) (NN E2F1)) (, ,) (NP (CD 2) (JJ key) (NN regulator) (NN proliferation) (NN apoptosis)) (, ,) (NP (VBD enhanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN development) (JJ transgenic) (NN mouse))))) |ET| |BS|39:G04.299.139.160 99:B01.050.050.136.500 104:C04.557.470.200.025.255|ES| 2:1 10:1 14:1 19:1 35:1 52:1 89:1 148:1 159:1 235:1 285:1 299:1 303:1 304:1 385:1 441:1 824:1 838:1 843:1 993:1 1527:1 1961:1 2291:1
3 	|BT| (NP (WHADVP (WRB When)) (NP (NP (NP (NN Apc) (NN gene) (NN knockout) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NN APC1309) (NN mouse)) (-RRB- -RRB-))) (VP (VBN given) (NP (CD 600) (CD 1200) (NN p.p.m))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 29:B01.050.050.136.500.500 193:C23.300.825.411 595:G07.203.650.240 596:E02.642.249 616:E05.318.780.074|ES| 2:1 5:1 9:1 10:1 14:1 19:1 29:1 52:1 71:1 109:1 170:1 202:1 280:1 289:1 369:1 370:1 646:1 647:1 781:1 783:1 2191:1 2292:1 2293:1 2294:1 2295:1 2296:1 2297:1 2298:1 2299:1 2300:1 2301:1
4 	|BT| (NP (NP (NN BACKGROUND/AIMS)) (: :) (NP (NP (JJ Several) (NN study)) (VP (VBD reported) (NP (NP (NP (NP (NP (NN efficacy) (NN combination) (NN therapy) (NN interferon)) (PRN (-LRB- -LRB-) (NP (NN IFN)) (-RRB- -RRB-))) (NN alpha) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 617:D12.644.276.374.440 618:E02.186|ES| 10:1 14:1 19:1 104:1 130:1 131:1 303:1 304:1 441:1 530:1 993:1 1836:1 2302:1 2303:1 2304:1 2305:1 2306:1 2307:1 2308:1
4 	|BT| (NP (NP (NP (NN BACKGROUND/AIMS)) (: :) (NP (NP (DT The) (NN success) (NN sorafenib) (NN treatment)) (VP (VBD advanced) (SBAR (S (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (VP (VBD focused) (NP (NN interest) (NN role) (NN Ras) (NN signaling) (NN malignancy))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 15:F01.829.316.616 52:E02 69:G02.111.087.800 104:C04.557.470.200.025.255|ES| 10:1 14:1 19:1 31:1 49:1 104:1 195:1 303:1 304:1 441:1 546:1 691:1 997:1 1775:1 2063:1 2302:1 2309:1 2310:1 2311:1
4 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (NP (NNP Magnolol) (, ,) (NN plant) (NN lignan)) (NP (VBN isolated) (NN bark) (NN seed) (NN cone) (NN Magnolia) (NN officinalis)) (, ,) (VP (VBN shown) (NP (JJ chemopreventive) (NN effect) (JJ chemically-induced) (NN skin) (NN cancer) (NN development))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 328:B01.650 619:D02.455.426.559.847.117.159.205 620:B01.650.940.800.575.100.680.500 621:D02.455.426.559.389.140.450 622:A08.675.650.850.625.670.100 623:A08.186.211.730.885.287.500 624:D27.505.696.706.018 625:A06.407.071.140 626:A05.810.453.324 627:A18.024.500.750|ES| 2:1 18:1 19:1 35:1 75:1 104:1 237:1 1046:1 1098:1 1653:1 1946:1 2233:1 2312:1 2313:1 2314:1 2315:1 2316:1 2317:1 2318:1 2319:1
4 	|BT| (NP (NP (NP (NNP Brucine) (NN alkaloid) (VBN derived) (NN seed) (NNS Strychnos)) (NP (JJ nux-vomica) (NNP Linn)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 627:A18.024.500.750 628:B01.650.940.800.575.100.638.750.500 629:E02.190.488 630:Z01.252.474.164 631:D03.132|ES| 10:1 14:1 19:1 303:1 304:1 441:1 476:1 546:1 1721:1 2315:1 2320:1 2321:1 2322:1 2323:1 2324:1 2325:1 2326:1 2327:1 2328:1
4 	|BT| (S (S (NP (NP (NP (JJ Caffeic) (NN acid) (NN phenethyl) (NN ester)) (PRN (-LRB- -LRB-) (NP (NN CAPE)) (-RRB- -RRB-))) (, ,) (NP (JJ natural) (NN component)) (NP (NN propolis)) (, ,)) (VP (VBP show) (S (NP (JJ anticarcinogenic) (NN property)) (VP (NP (VBN modified) (JJ resistant) (NN hepatocyte) (NN model)) (S (NP (VBN administered) (NN initiation) (NN promotion) (NN hepatocarcinogenesis) (NN process))))))) (: ;) (RB however) (, ,) (NP (NP (NN information) (NN mechanism)) (VP (VBG underlying) (S (NP (NN chemoprotection)) (ADJP (VBN limited)))))) |ET| |BS|262:A11.436.348 632:D05.750.078.840.762|ES| 2:1 10:1 14:1 19:1 72:1 162:1 217:1 333:1 427:1 429:1 435:1 637:1 638:1 841:1 900:1 1021:1 1275:1 1387:1 1909:1 2131:1 2329:1 2330:1 2331:1 2332:1 2333:1 2334:1 2335:1 2336:1 2337:1 2338:1 2339:1
4 	|BT| (S (NP (NP (NP (JJ Epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN tyrosine) (NN kinase) (NN inhibitor) (NN erlotinib)) (VP (VBP show) (SBAR (S (NP (JJ potent) (NP (NP (NN antitumor) (NN activity) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD approved) (NP (NNP Food) (NNP Drug) (NNP Administration) (JJ second) (JJ third) (NN line) (NN treatment) (NN NSCLC))))))) |ET| |BS|52:E02 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 113:C04.697.650 633:I01.409.418.750.600.650.760 634:D12.125.072.050.875|ES| 10:1 14:1 18:1 19:1 22:1 94:1 102:1 185:1 186:1 187:1 264:1 327:1 328:1 329:1 380:1 399:1 429:1 470:1 546:1 2244:1 2340:1 2341:1 2342:1 2343:1 2344:1 2345:1 2346:1 2347:1 2348:1
4 	|BT| (NP (NN Hepatocyte) (NP (NP (CD I) (NN kappaB) (NN kinase) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN IKK) (NN beta)) (-RRB- -RRB-))) (VBZ inhibits) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG suppressing) (NP (NP (NP (NN accumulation) (JJ reactive) (NN oxygen) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))) (NN liver) (NN damage)))) (, ,) (SBAR (IN whereas) (S (NP (NN JNK1) (NN activation)) (VP (VBZ promotes) (NP (NP (NN ROS) (NN accumulation)) (, ,) (NP (NN liver) (NN damage)) (, ,) (NP (NN carcinogenesis))))))) |ET| |BS|33:C04.697.098 122:C14.280.383 242:A03.620 262:A11.436.348 635:D08.811.913.696.620.682.700.494 636:D01.339.431|ES| 2:1 10:1 14:1 19:1 207:1 225:1 298:1 372:1 470:1 615:1 836:1 900:1 1848:1 1972:1 2120:1 2250:1 2349:1 2350:1 2351:1 2352:1 2353:1 2354:1 2355:1 2356:1 2357:1
4 	|BT| (NP (NP (NN PURPOSE)) (: :) (S (NP (JJ Recent) (NN study)) (VP (VBD revealed) (S (NP (NP (JJ branched-chain) (NN amino) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN BCAA)) (-RRB- -RRB-))) (VP (VB reduce) (NP (NP (NP (NN development) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN patient) (NN obesity) (NN hepatitis) (NN C) (NN virus) (NN infection) (S (VP (VBG improving) (NP (NP (NN insulin) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NN IR)) (-RRB- -RRB-))))))))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 550:B04.450.410 564:C18.654.726.500 637:D06.472.699.587.200.500.625 638:C02.440.440 639:D12.125.070|ES| 10:1 14:1 19:1 35:1 104:1 120:1 131:1 275:1 303:1 304:1 441:1 687:1 1094:1 1275:1 1422:1 1955:1 2010:1 2048:1 2189:1 2358:1 2359:1 2360:1 2361:1 2362:1 2363:1 2364:1 2365:1
4 	|BT| (NP (NP (NP (NN Tamoxifen) (JJ non-steroidal) (JJ anti-estrogenic) (NN drug)) (NP (ADJP (RB widely) (JJ used)) (NN treatment) (NN prevention) (NN breast) (NN cancer) (NN woman))) (: ;) (FRAG (ADVP (RB however)) (, ,) (NP (NP (NN evidence) (NN tamoxifen) (JJ hepatocarcinogenic) (NN rat)) (, ,) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 67:D26 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900 641:D27.505.696.399.472.277.540 642:M01.975|ES| 2:1 18:1 19:1 23:1 38:1 52:1 191:1 217:1 476:1 546:1 849:1 1387:1 1474:1 2366:1 2367:1 2368:1 2369:1 2370:1 2371:1 2372:1
4 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN inflexinol)) (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN cell) (NN growth)) (PP (IN via) (NP (NP (NN induction)) (NP (NP (JJ apoptotic) (NN cell) (NN death) (NN inactivation) (NN NF-kappaB)) (NP (NP (JJ direct) (NN modification) (NN cysteine) (NN residue)) (NP (NN p50) (NN subunit) (NN NF-kappaB)))))))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383 210:D12.776.260.600 583:D12.776.813 643:D02.886.030.230|ES| 18:1 19:1 94:1 101:1 102:1 113:1 411:1 596:1 615:1 714:1 736:1 792:1 796:1 1314:1 1891:1 2110:1 2223:1 2373:1 2374:1 2375:1 2376:1 2377:1
4 	|BT| (S (NP (DT This) (NN research)) (VP (VBZ provides) (NP (NN evidence) (NN tea)) (, ,) (NP (ADVP (RB particularly)) (NP (VBN administered) (NN combination) (NN sulindac)) (, ,) (NP (PP (ADJP (RB highly) (JJ effective)) (S (VP (VBG inhibiting) (NP (NP (NP (JJ intestinal) (NN neoplasia) (NN male) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN min)) (-RRB- -RRB-))) (NN mouse)) (PP (IN via) (NP (JJ direct) (JJ indirect) (NN effect) (NN beta-catenin/APC) (NN pathway)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 102:C04.588.274.476.411 122:C14.280.383 251:D02.455.426.559.847.486.875 644:H01.770.644 645:H01.770.644|ES| 2:1 10:1 14:1 19:1 38:1 52:1 75:1 109:1 280:1 383:1 530:1 596:1 626:1 640:1 807:1 815:1 869:1 880:1 1402:1 1639:1 1891:1 2336:1 2378:1 2379:1 2380:1 2381:1 2382:1 2383:1
4 	|BT| (S (NP (NP (NNP UNLABELLED)) (: :) (S (NP (JJ Epidemiological) (NNS data)) (VP (VBP associate) (NP (NP (NN coffee) (NN consumption)) (NP (JJR lower) (NN prevalence) (JJ chronic) (NN liver) (NN disease))) (VP (VBD reduced) (NP (NP (NN risk) (JJ elevated) (NN liver) (NN enzyme) (NN level)) (PRN (-LRB- -LRB-) (NP (NN gamma) (NN glutamyl) (NN transpeptidase) (NN alanine) (NN aminotransferase)) (-RRB- -RRB-)))))) (, ,)) (VP (VBD advanced) (NP (NP (NN liver) (NN disease) (NN complication)) (, ,) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|60:E05.318.308.985.525.750 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 646:D08.811.913.477.700.100 647:D08.811.913.477.700.347 648:D08.811.913.050.200.500 649:E01.370.225.124.200 650:C06.552 651:H02.403.720.500 652:D20.215.784.249|ES| 2:1 10:1 14:1 19:1 104:1 117:1 171:1 179:1 249:1 303:1 304:1 452:1 756:1 793:1 836:1 997:1 998:1 1790:1 2266:1 2384:1 2385:1 2386:1 2387:1 2388:1 2389:1 2390:1 2391:1 2392:1 2393:1 2394:1
4 	|BT| (S (NP (NN 5-aza-dC) (NN treatment)) (ADVP (RB markedly)) (VP (VBD decreased) (NP (NP (NN atherosclerosis) (NN development) (NN Ldlr)) (-LRB- -LRB-) (PRN (: -) (: /) (: -)) (-RRB- -RRB-) (NN mouse)) (NP (PP (IN without) (NP (NN change) (NN body) (NN weight))) (, ,) (NP (NN plasma) (NN lipid) (NN profile)) (, ,) (NP (NN macrophage) (NN cholesterol) (NN level) (NN plaque) (NN lipid) (NN content))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 511:C14.907.137.126.307 513:C14.907.137.126 558:C23.300.821 653:C23.888.144 654:D02.145.150 655:D04.808.247.222.284 656:C07.793.208.377 657:A12.207.152.693 658:A11.329.372 659:D10|ES| 2:1 10:1 14:1 19:1 35:1 45:1 52:1 200:1 202:1 249:1 546:1 1195:1 1711:1 1794:1 1804:1 1981:1 2395:1 2396:1 2397:1 2398:1 2399:1 2400:1 2401:1 2402:1 2403:1
4 	|BT| (NP (NP (NP (NP (NN 5-Fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NP (CD one) (JJ common) (JJ chemotherapeutic) (NN agent)) (VP (VBN used) (NP (NP (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 660:D27.505.954.248|ES| 10:1 14:1 19:1 303:1 304:1 441:1 476:1 546:1 655:1 728:1 1010:1 1762:1 2308:1 2404:1
4 	|BT| (NP (NP (NP (NP (NN 5-Fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NP (CD one) (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN agent) (NN colon) (NN cancer) (NN treatment)) (, ,) (NP (JJ narrow) (JJ therapeutic) (NN index) (JJ limited) (NN toxicity))))) |ET| |BS|46:A03.556.124.526.356 52:E02 560:D03.383.742.698.875.404 660:D27.505.954.248|ES| 2:1 10:1 14:1 15:1 18:1 19:1 113:1 476:1 541:1 546:1 721:1 728:1 1010:1 1762:1 2131:1 2308:1 2404:1 2405:1 2406:1
4 	|BT| (S (NP (NP (NP (NN 5-Fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ common) (JJ chemotherapeutic) (NN agent)) (VP (VBN used) (NP (NP (NP (NN treatment) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (, ,) (NP (JJ inadequate) (NN response) (NN rate)) (: ;) (VP (VBG highlighting) (NP (NN need) (NN novel))))))) (VP (VBD improved) (NP (NN treatment) (NNS regimen) (NN patient)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 259:D12.776.395.240.150.500 284:N03.349.380.420 532:E02.183 560:D03.383.742.698.875.404 660:D27.505.954.248|ES| 2:1 10:1 14:1 17:1 18:1 19:1 41:1 120:1 217:1 245:1 476:1 494:1 546:1 655:1 728:1 891:1 1762:1 1881:1 2308:1 2404:1 2407:1 2408:1 2409:1 2410:1
4 	|BT| (S (NP (NNP Administration) (NNP SP600125) (NN acetaminophen)) (VP (VBD protected) (NP (NP (NP (NN Jnk)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN control) (NN mouse) (NN liver) (NN injury)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 242:A03.620 661:D02.065.199.092.040|ES| 10:1 14:1 19:1 52:1 289:1 836:1 2346:1 2411:1 2412:1 2413:1 2414:1 2415:1 2416:1
4 	|BT| (S (NP (NNP Administration) (NN HMGB1) (NN release) (NN inhibitor) (NN ethyl) (NN pyruvate)) (, ,) (VP (VBP affect) (NP (NP (JJ p53-mediated) (JJ hepatic) (NN apoptosis)) (, ,) (VP (ADVP (RB substantially)) (VBD prevented) (NP (JJ carcinogen-induced) (NN cirrhosis) (NN tumorigenesis) (NN rat) (NN liver)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 357:C06.552.630 433:F01.470.047 585:D12.644.276.087.371 589:E02.204.125 662:C23.550.355|ES| 2:1 19:1 78:1 89:1 380:1 836:1 838:1 849:1 1199:1 1486:1 1944:1 2164:1 2165:1 2346:1 2417:1 2418:1 2419:1 2420:1 2421:1
4 	|BT| (S (NP (NNP Aliskiren)) (VP (VBZ attenuates) (NP (NN steatohepatitis) (NN increase) (NN turnover) (JJ hepatic) (JJ fat) (NN mouse) (NN fed) (NN methionine) (NN choline) (JJ deficient) (NN diet)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 664:D02.886.030.676 665:N04.452.677.680|ES| 19:1 40:1 52:1 838:1 1504:1 1791:1 2050:1 2191:1 2422:1 2423:1 2424:1 2425:1 2426:1 2427:1
4 	|BT| (S (NP (DT All) (NN result)) (VP (VBD revealed) (NP (NP (NN pterostilbene) (JJ effective) (NN antitumor) (NN agent)) (NP (RB well) (NP (JJ inhibitory) (NN effect) (NN down-regulation) (JJ inflammatory) (NN iNOS) (NN COX-2) (NN gene)) (NN expression) (NN up-regulation) (NN apoptosis) (NN mouse) (NN colon))) (, ,) (S (VP (VBG suggesting) (NP (NP (NP (NN pterostilbene)) (JJ novel) (JJ functional) (NN agent)) (ADJP (JJ capable) (S (VP (VBG preventing) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 46:A03.556.124.526.356 53:C06.405.205.265 85:G02.111.087.225 155:G05.355.310 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880 660:D27.505.954.248|ES| 2:1 9:1 19:1 52:1 67:1 75:1 76:1 78:1 89:1 101:1 113:1 115:1 257:1 275:1 415:1 728:1 787:1 891:1 896:1 965:1 1009:1 1639:1 1849:1 1937:1 2244:1 2428:1 2429:1 2430:1 2431:1
4 	|BT| (S (NP (NP (NNP Alternol)) (, ,) (NP (JJ natural) (NN compound)) (, ,)) (VP (VBZ exerts) (NP (NP (JJ anti-tumour) (NN effect) (NN osteosarcoma)) (VP (VBG modulating) (NP (NN STAT3) (NN ROS/MAPK) (NN signalling) (NN pathway)))))) |ET| |BS|12:Z01.542.049 38:Z01.058.290.120.180 40:Z01.542.248.700 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650 666:G02.111.087.800.560|ES| 2:1 19:1 75:1 251:1 383:1 1562:1 1977:1 2333:1 2432:1 2433:1 2434:1 2435:1 2436:1 2437:1
4 	|BT| (S (NP (JJ Anthocyanin-containing) (JJ purple-fleshed) (NN potato)) (VP (VBP suppress) (NP (NP (NN colon) (NN tumorigenesis)) (PP (IN via) (NP (NN elimination) (NN colon) (NN cancer) (NN stem) (NN cell)))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 308:A11.872 667:B01.650.940.800.575.100.905.725.777 668:B01.650.940.800.575.100.905.725.777 669:D03.383.663.283.266.450.087|ES| 18:1 19:1 78:1 94:1 113:1 156:1 596:1 1106:1 2438:1 2439:1 2440:1 2441:1
4 	|BT| (FRAG (NP (NP (JJ Anti-tumor) (NN effect)) (VBN pegylated) (NN interferon) (NN rat) (NN hepatocarcinogenesis) (NN model))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 617:D12.644.276.374.440|ES| 19:1 72:1 75:1 849:1 900:1 2305:1 2442:1 2443:1
4 	|BT| (SINV (PP (IN As) (NP (NN wogonin) (ADJP (JJ effective) (ADVP (FW vitro) (FW vivo))))) (, ,) (NP (JJ novel) (S (VP (VBG finding) (S (NP (JJ open) (NN possibility) (NN wogonin) (JJ effective) (ADJP (ADJP (JJ therapeutic)) (CC and/or) (ADJP (JJ chemopreventive))) (NN agent)) (ADJP (JJ ER-positive))) (: -) (NP (NP (JJ negative) (NN breast) (NN cancer)) (, ,) (NP (RB particularly) (JJ aggressive) (JJ hormonal) (JJ therapy-resistant) (JJ ER-negative) (NN type))))))) |ET| |BS|52:E02 162:F01.145.126.125 259:D12.776.395.240.150.500|ES| 2:1 18:1 19:1 23:1 149:1 168:1 216:1 343:1 378:1 538:1 541:1 543:1 728:1 891:1 927:1 1045:1 1639:1 1654:1 1946:1 2380:1 2444:1 2445:1 2446:1 2447:1 2448:1
4 	|BT| (NP (NP (NP (NP (NN Aspirin)) (PRN (-LRB- -LSB-) (NP (NP (JJ acetylsalicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN ASA)) (-RRB- -RRB-))) (-RRB- -RSB-))) (VP (VBN shown) (VP (VBP prevent) (NP (NN CRC))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ epigenetic) (NN mechanism) (NN action)) (VP (VBP remain) (ADJP (JJ unknown))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 670:D02.455.426.559.389.657.410.595.176 671:G05.355.315.203|ES| 2:1 10:1 14:1 19:1 162:1 217:1 237:1 245:1 733:1 1275:1 1373:1 1378:1 1387:1 1603:1 2013:1 2181:1 2182:1 2449:1 2450:1 2451:1
4 	|BT| (S (NP (NN AZD6244) (NN doxorubicin)) (VP (VBP induce) (NP (NN growth) (NN suppression) (NN apoptosis) (NN mouse) (NN model) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 45:G07.700.320.249 104:C04.557.470.200.025.255 136:D02.455.426.559.847.562.050.200.175|ES| 19:1 52:1 72:1 89:1 102:1 243:1 303:1 304:1 599:1 2452:1 2453:1
4 	|BT| (NP (NP (NP (NN Beta-ionone)) (, ,) (NP (JJ end-ring) (NN analogue) (NN beta-carotenoid)) (, ,) (NP (NN constituent) (NN vegetable) (NN fruit)) (, ,)) (NP (VBN analyzed) (NN colon) (NN cancer) (NN chemoprevention) (NN treatment))) |ET| |BS|12:Z01.542.049 52:E02 253:E02.319.162 672:D02.455.326.271.665.202 673:A18.024.500 674:B01.650.510.956|ES| 2:1 18:1 19:1 113:1 546:1 870:1 1168:1 1380:1 2454:1 2455:1 2456:1 2457:1 2458:1 2459:1
4 	|BT| (S (NP (NNP Bortezomib)) (ADVP (RB also)) (VP (VBD prevented) (SBAR (S (NP (NN activation) (JJ hepatic) (JJ stellate) (NN cell)) (VP (VBD inhibited) (NP (NN liver) (NN fibrosis) (NN DEN/CDAA) (NN model))))))) |ET| |BS|122:C14.280.383 675:D01.029.260.110.500 676:C06.552.630 677:A11.561|ES| 5:1 19:1 72:1 94:1 225:1 365:1 836:1 838:1 949:1 1944:1 2460:1 2461:1 2462:1
4 	|BT| (S (NP (NN Bortezomib)) (VP (VBZ induces) (SBAR (S (NP (NP (JJ tumor-specific) (NN cell) (NN death)) (NN growth) (NN inhibition) (JJ hepatocellular) (NN carcinoma)) (VP (VBZ improves) (NP (NN liver) (NN fibrosis))))))) |ET| |BS|8:C04 43:F01.145.544 45:G07.700.320.249 104:C04.557.470.200.025.255 134:G04.299.139 675:D01.029.260.110.500 676:C06.552.630|ES| 19:1 94:1 102:1 103:1 214:1 303:1 304:1 411:1 836:1 949:1 2460:1 2463:1 2464:1
4 	|BT| (S (NP (JJ Branched-chain) (NN amino) (NN acid) (-LRB- -LRB-) (NN BCAA) (-RRB- -RRB-)) (, ,) (S (VP (VB improve) (NP (NN insulin) (NN resistance)))) (, ,) (VP (VBD inhibited) (NP (NP (JJ obesity-related) (NN colon) (NN carcinogenesis) (JJ rodent) (NN model)) (, ,) (S (ADVP (RB also)) (VP (VBD reduced) (NP (NN incidence) (JJ hepatocellular) (NN carcinoma) (JJ obese) (NN patient) (NN liver) (NN cirrhosis))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 50:M01.643 104:C04.557.470.200.025.255 122:C14.280.383 357:C06.552.630 434:E05.318.308.985.525.375 514:B01.050.150.900.649.865 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500|ES| 2:1 5:1 10:1 14:1 19:1 72:1 113:1 120:1 207:1 303:1 304:1 365:1 452:1 836:1 1094:1 1199:1 1275:1 1511:1 2173:1 2189:1 2360:1 2364:1 2465:1 2466:1 2467:1 2468:1
4 	|BT| (S (NP (JJ Bromelain-containing) (NN food) (CC and/or) (NN bromelain)) (VP (MD may) (VP (VB represent) (NP (JJ good) (NN candidate) (JJ colorectal) (NN cancer) (NN chemoprevention))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 253:E02.319.162 679:D08.811.277.656.262.500.096 680:G07.203.300|ES| 17:1 18:1 19:1 149:1 491:1 799:1 870:1 1243:1 1318:1 2469:1 2470:1 2471:1
4 	|BT| (S (NP (NP (NNP Brucine)) (, ,) (NP (NN alkaloid) (NN seed))) (VP (VBZ Strychnos) (NP (JJ nux-vomica) (NNP Linn)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 104:C04.557.470.200.025.255 113:C04.697.650 627:A18.024.500.750 628:B01.650.940.800.575.100.638.750.500 631:D03.132 681:G04.299.283 682:D12.776.260.103.625|ES| 2:1 19:1 31:1 63:1 94:1 98:1 104:1 185:1 303:1 304:1 383:1 514:1 806:1 2315:1 2320:1 2321:1 2322:1 2323:1 2472:1 2473:1 2474:1
4 	|BT| (S (NP (NP (NNP Celecoxib)) (, ,) (NP (NP (JJ selective) (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NP (NN inhibitor)) (, ,)) (NP (JJ effective) (JJ chemopreventive) (NN colon) (NN cancer) (JJ nonsteoroidal) (JJ antiinflammatory) (NN drug)) (VP (VBD approved) (NP (NP (NNP FDA) (JJ adjuvant) (NN therapy) (NN patient)) (JJ familial) (JJ adenomatous) (NN polyposis)))) |ET| |BS|3:C04.557.470.035.215.100 50:M01.643 52:E02 349:D27.505.519.389.310.500 633:I01.409.418.750.600.650.760 683:D27.505.519.389.310 684:D02.065.884.247 685:D27.505.696.477.067 686:D27.505.954.158 687:D26.650.064|ES| 2:1 10:1 14:1 18:1 19:1 57:1 58:1 61:1 76:1 113:1 120:1 130:1 191:1 380:1 854:1 1639:1 1749:1 1946:1 2343:1 2475:1 2476:1 2477:1 2478:1 2479:1
4 	|BT| (S (NP (NNP Coffee)) (VP (VBZ reduces) (NP (NP (NN liver) (NN damage) (NN rat) (NN model) (NN steatohepatitis)) (: :) (NP (VBG underlying) (NN mechanism) (NN role) (NNS polyphenols) (NNS melanoidins))))) |ET| |BS|15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249|ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1
4 	|BT| (S (NP (NN Colon) (NN cancer) (NN cell) (JJ treated) (NNS SDs)) (VP (VBD exhibited) (NP (VBN reduced) (NN Wnt) (JJ transcriptional) (NN activity)) (, ,) (VP (ADVP (RB well)) (VBN reduced)) (NP (JJ nuclear) (NN beta-catenin) (NN localization) (JJ subsequent) (NN reduction) (NN active-beta-catenin) (NN level)))) |ET| |BS|23:D12.776.091.249 41:A11 52:E02 175:J01.897.280.500.269 209:G02.111.087.847|ES| 2:1 18:1 19:1 60:1 94:1 249:1 370:1 399:1 452:1 559:1 609:1 787:1 877:1 1099:1 1256:1 1319:1 2482:1 2483:1 2484:1 2485:1
4 	|BT| (S (NP (NN Combination) (NN aspirin) (NN sorafenib)) (VP (MD may) (NP (JJ effective) (NN regimen) (NN treat) (NN HCC) (NN colon) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255 532:E02.183 670:D02.455.426.559.389.657.410.595.176|ES| 18:1 19:1 113:1 441:1 491:1 1090:1 1639:1 1881:1 2063:1 2486:1 2487:1
4 	|BT| (S (NP (NP (JJ Combined) (NN treatment) (NN EPLE) (NN 5-fluorouracil)) (, ,) (NP (JJ first-line) (NN chemotherapy) (NN CRC) (NN patient)) (, ,)) (VP (VBD achieved) (NP (JJ synergistic) (NN effect)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 151:E02.319 560:D03.383.742.698.875.404 618:E02.186|ES| 2:1 19:1 75:1 120:1 245:1 495:1 546:1 2012:1 2307:1 2488:1 2489:1 2490:1 2491:1
4 	|BT| (S (VP (VBG Combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam) (NN treat) (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1
4 	|BT| (S (NP (NN Compound) (NN Astragalus)) (NP (FW Salvia) (FW miltiorrhiza) (NN extract)) (VP (VBZ suppresses) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN progression)) (VP (VBG inhibiting) (NP (NN fibrosis) (NN PAI-1) (NN mRNA) (NN transcription)))))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 111:D13.444.735.544 122:C14.280.383 209:G02.111.087.847 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780 690:D12.644.861.695.500 691:C23.550.355|ES| 19:1 48:1 303:1 304:1 325:1 487:1 686:1 880:1 949:1 2492:1 2493:1 2494:1 2495:1 2496:1 2497:1
4 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN curcumin)) (VP (VBZ potentiates) (NP (NP (JJ antitumor) (NN effect) (NN radiation) (NN therapy)) (JJ colorectal) (NN cancer) (VBG suppressing) (NP (NN NF-kappaB) (JJ NF-kappaB-regulated) (NN gene) (NN product))) (, ,) (NP (VBG leading) (NN inhibition) (NN proliferation) (NN angiogenesis))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 43:F01.145.544 52:E02 86:D01.268.556.435 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 693:G01.750.745|ES| 2:1 9:1 17:1 18:1 19:1 75:1 101:1 103:1 104:1 130:1 299:1 639:1 675:1 714:1 796:1 1872:1 1882:1 2244:1 2250:1 2498:1 2499:1 2500:1 2501:1 2502:1
4 	|BT| (S (NP (NN CONCLUSION) (: :)) (PP (IN In) (NP (NN summary))) (, ,) (S (VP (VBG finding) (VP (VB provide) (NP (NP (JJ preclinical) (NN evidence)) (VP (VBG supporting) (NP (NN evaluation) (NN agent) (NN DMAPT) (NN gemcitabine) (NN prevention) (NN treatment) (JJ pancreatic) (NN cancer)))))))) |ET| |BS|52:E02 225:E05.337|ES| 2:1 18:1 19:1 38:1 104:1 244:1 467:1 490:1 546:1 711:1 728:1 927:1 1472:1 1474:1 1494:1 1882:1 2503:1 2504:1 2505:1
4 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (SBAR (S (NP (NN coffee) (NN consumption)) (VP (VBZ protects) (SBAR (S (NP (NN liver) (NN damage)) (VP (VBD caused) (NP (JJ high-fat) (NN diet))))))))))) |ET| |BS|242:A03.620 652:D20.215.784.249 694:G07.203.650.240.267|ES| 19:1 104:1 502:1 658:1 793:1 836:1 1848:1 1863:1 1882:1 2191:1 2386:1 2387:1 2506:1 2507:1
4 	|BT| (NP (NP (NN CONCLUSION)) (: :) (NP (NP (JJ Regular) (NN aspirin) (NN use) (NN diagnosis) (JJ colorectal) (NN cancer)) (VP (VBD associated) (NP (NP (JJR lower) (NN risk) (JJ colorectal) (JJ cancer-specific) (JJ overall) (NN mortality)) (, ,) (PP (ADVP (RB especially)) (IN among) (NP (JJ individual) (NN tumor)))) (S (VP (VBP overexpress) (NP (NN COX-2))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 493:M01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 696:V02.270.500|ES| 2:1 7:1 17:1 18:1 19:1 76:1 104:1 117:1 169:1 171:1 345:1 1037:1 1372:1 1659:1 1882:1 2487:1 2508:1 2509:1 2510:1 2511:1 2512:1 2513:1
4 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (DT The) (JJ present) (NN work)) (VP (VBZ provides) (NP (NP (JJ novel) (NNS data)) (PP (VBG concerning) (NP (JJ preventive) (NN action) (NN glycerol) (NN development) (NN liver) (NN cancer)))))) (VP (VBZ represents) (NP (ADJP (RB economically) (JJ feasible)) (NN intervention) (NN treat) (JJ high-risk) (NN individual))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 61:E05.318.740.600.800 259:D12.776.395.240.150.500 445:I03.946 493:M01 697:D02.033.800.421 698:I01.261|ES| 18:1 19:1 35:1 104:1 106:1 691:1 793:1 815:1 836:1 891:1 1090:1 1307:1 1546:1 1645:1 1882:1 1883:1 2013:1 2512:1 2514:1 2515:1 2516:1 2517:1 2518:1
4 	|BT| (NP (NP (NN CONCLUSION) (: :)) (NP (DT These) (VBP result) (NP (VBN suggested) (NN TFA) (VBD protected) (ADJP (NN mouse) (JJ CCl4-induced) (ADJP (NN liver) (NN injury) (JJ antioxidant)) (NN stress) (JJ antiinflammatory)) (NN effect)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217|ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1
4 	|BT| (FRAG (NP (NN CONCLUSION)) (: :) (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NN evidence) (NN saffron)) (VP (VBZ exerts) (NP (JJ significant) (JJ chemopreventive) (NN effect) (NN liver) (NN cancer) (NN inhibition) (NN cell) (NN proliferation) (NN induction) (NN apoptosis)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 624:D27.505.696.706.018 701:B01.650.940.800.575.100.549.500|ES| 18:1 19:1 38:1 75:1 89:1 94:1 103:1 104:1 131:1 135:1 299:1 736:1 807:1 815:1 836:1 1882:1 1946:1 1977:1 2523:1
4 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (NP (NNP Aliskiren)) (VP (VBZ attenuates) (NP (NN steatohepatitis) (NN fibrosis) (NN mouse) (NN fed) (NN MCD) (NN diet)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 691:C23.550.355|ES| 19:1 52:1 104:1 239:1 949:1 1791:1 2191:1 2422:1 2423:1 2426:1 2524:1
4 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Magnolol) (NNS pretreatments)) (VP (VBP prevent) (S (NP (JJ UVB-induced) (NN skin) (NN cancer) (NN development)) (VP (VBG enhancing) (NP (NN apoptosis)) (, ,) (S (VP (VBG causing) (NP (NN cell) (NN cycle) (NN arrest) (NN G2/M) (NN phase)))))) (, ,) (S (VP (VBG affecting) (NP (JJ various) (NN signaling) (NN pathway))))))) |ET| |BS|39:G04.299.139.160 126:G02.111.087.800 702:G04.299.134.109.750|ES| 2:1 18:1 19:1 35:1 89:1 94:1 104:1 195:1 239:1 383:1 601:1 602:1 733:1 1096:1 1491:1 2312:1 2319:1 2525:1 2526:1 2527:1 2528:1 2529:1 2530:1
4 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NN Silibinin) (NN target) (NN beta-catenin) (NN IGF-1Rbeta) (NN pathway) (JJ chemopreventive) (NN efficacy) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 581:D12.644.276.937|ES| 19:1 52:1 60:1 104:1 113:1 160:1 207:1 239:1 383:1 1946:1 2304:1 2531:1 2532:1 2533:1 2534:1
4 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN Since) (NP (NN lymph) (NN node) (NN involvement) (JJ important) (JJ prognostic) (NN factor) (NN breast) (NN cancer) (NN patient))) (, ,) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin)) (VP (VBD detected) (NP (NP (JJ mammary) (NN cancer)) (VP (VBG carrying) (NP (NN p53) (NN mutation) (JJ present) (NN study)))) (VP (MD may) (NP (JJ specific) (JJ clinical) (NN application))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 50:M01.643 247:G01.374.676.530 703:A10.549.400|ES| 2:1 12:1 18:1 19:1 23:1 34:1 84:1 104:1 120:1 131:1 165:1 185:1 239:1 399:1 491:1 540:1 636:1 850:1 884:1 902:1 1007:1 1307:1 2245:1 2246:1 2248:1 2535:1 2536:1 2537:1
4 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (VP (VBN Taken) (ADVP (RB together)) (, ,) (S (VP (VBG finding) (VP (VB identify) (S (NP (NN mechanism) (NN ABT-100) (NN function)) (VP (VBP show) (NP (NP (NN efficacy) (NN ABT-100) (JJ chemopreventive) (NN agent)) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|104:C04.557.470.200.025.255 375:Z01.639.100|ES| 2:1 19:1 33:1 104:1 162:1 239:1 303:1 304:1 429:1 728:1 832:1 927:1 1537:1 1538:1 1946:1 2304:1 2538:1
4 	|BT| (FRAG (NP (NNS CONCLUSIONS) (: :)) (PP (DT These) (S (VP (VBG finding) (S (VP (VBP suggest) (NP (NP (NN MPT0E028) (NN combination) (NN sorafenib) (JJ significant) (JJ anti-hepatocellular) (NN carcinoma) (NN activity) (JJ preclinical) (NN model)) (, ,) (S (ADVP (RB potentially)) (VP (VBG suggesting) (SBAR (S (NP (JJ novel) (JJ therapeutic) (NN strategy) (NN patient)) (VP (VBD advanced) (NP (JJ hepatocellular) (NN carcinoma)))))))))))))) |ET| |BS|50:M01.643 52:E02 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500|ES| 2:1 19:1 72:1 104:1 120:1 135:1 239:1 303:1 304:1 399:1 530:1 541:1 773:1 792:1 796:1 891:1 927:1 997:1 1009:1 1114:1 1494:1 2063:1 2539:1 2540:1
4 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (NP (JJ synergistic) (NN antitumor) (NN activity) (NN combination) (NN dovitinib) (NN oxaliplatin) (NN colon) (NN cancer) (JJ different) (NN RAS-RAF) (NN status))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550|ES| 18:1 19:1 104:1 113:1 131:1 239:1 399:1 414:1 416:1 530:1 807:1 2012:1 2244:1 2541:1 2542:1 2543:1 2544:1
4 	|BT| (NP (NP (NP (NN Connexin) (CD 32) (NN luteolin) (NN play) (JJ protective) (NN role)) (JJ non-alcoholic) (NN steatohepatitis) (NN development) (JJ related) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 509:C06.552.241.519 704:D03.383.663.283.266.450.260.555|ES| 19:1 31:1 35:1 238:1 419:1 493:1 849:1 900:1 1791:1 2069:1 2545:1 2546:1 2547:1
4 	|BT| (S (NP (NN Cyclooxygenase-2) (NN inhibitor)) (VP (VBP down-regulate) (NP (NN osteopontin) (NN Nr4A2-new) (JJ therapeutic) (NN target) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360|ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1
4 	|BT| (S (NP (NN Cytochrome) (NN P450) (NN 1A2)) (VP (VBZ Metabolizes) (S (NP (NN 17beta-Estradiol)) (VP (VB Suppress) (NP (JJ Hepatocellular) (NN Carcinoma)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 705:D08.244.453.040.443 706:D04.808.365.415.248|ES| 19:1 1241:1 2151:1 2548:1 2549:1 2550:1 2551:1 2552:1 2553:1
4 	|BT| (S (NP (NP (NNS Data)) (VP (VBN obtained))) (VP (VBP suggest) (S (NP (NN contribution) (NN SphK/S1P) (NN system)) (NP (JJ related) (NN signaling) (NN pathway) (JJ protective) (NN effect) (NN melatonin) (NN hepatocarcinogenesis))))) |ET| |BS|126:G02.111.087.800 707:D03.438.473.914.481|ES| 19:1 75:1 195:1 383:1 419:1 493:1 593:1 796:1 900:1 1224:1 1360:1 2554:1 2555:1 2556:1
4 	|BT| (NP (NP (NP (JJ Decorin-mediated) (NN inhibition) (JJ colorectal) (NN cancer) (NN growth) (NN migration)) (NP (VBN associated) (NN E-cadherin) (NN vitro) (NN mouse)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625|ES| 17:1 18:1 19:1 52:1 102:1 103:1 169:1 216:1 514:1 2267:1 2557:1
4 	|BT| (S (PP (IN Despite) (NP (JJ recent) (JJ therapeutic) (NN advance))) (, ,) (NP (NP (NN response) (NN rate) (NN chemotherapy) (NN patient)) (JJ metastatic) (NN colon) (NN cancer)) (VP (VBP remain) (NP (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (NP (NN fluoropyrimidine))) (, ,) (NP (NN 5-fluorouracil) (-LRB- -LRB-) (NN 5-FU) (-RRB- -RRB-))) (, ,) (S (VP (VBG continuing) (VP (VB serve) (NP (NN foundation) (JJ chemotherapeutic) (NN agent) (NN treatment) (NN disease))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 50:M01.643 52:E02 113:C04.697.650 151:E02.319 288:C23.550.288 560:D03.383.742.698.875.404 660:D27.505.954.248 709:N03.219.483.311|ES| 2:1 10:1 14:1 18:1 19:1 41:1 113:1 120:1 337:1 368:1 369:1 494:1 495:1 532:1 541:1 546:1 550:1 659:1 728:1 998:1 1762:1 1843:1 2181:1 2307:1 2308:1 2558:1 2559:1 2560:1 2561:1
4 	|BT| (S (NP (NP (JJ Dietary) (NN intake) (NN pterostilbene)) (, ,) (NP (NN constituent) (NN blueberry)) (, ,)) (VP (VBZ inhibits) (NP (NN beta-catenin/p65) (JJ downstream) (NN signaling) (NN pathway) (NN colon) (NN carcinogenesis) (NN rat)))) |ET| |BS|23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 710:B01.650.940.800.575.100.343.774.249|ES| 2:1 19:1 113:1 195:1 207:1 383:1 560:1 615:1 849:1 2428:1 2457:1 2562:1 2563:1 2564:1 2565:1
4 	|BT| (S (NP (JJ Dietary) (NN lycopene) (NN tomato) (NN extract) (NN supplementation)) (VP (VBP inhibit) (NP (JJ nonalcoholic) (JJ steatohepatitis-promoted) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 509:C06.552.241.519 595:G07.203.650.240|ES| 19:1 849:1 900:1 1097:1 1370:1 1796:1 2496:1 2562:1 2566:1 2567:1 2568:1
4 	|BT| (S (S (NP (JJ Diethylnitrosamine-induced) (NN hepatocarcinogenesis)) (VP (VBD suppressed) (NP (NN lecithin)))) (: :) (S (NP (NN retinol) (JJ acyltransferase-deficient) (NN mouse)) (ADVP (RB primarily)) (NP (NP (JJ retinoid) (NN action)) (NP (ADVP (RB immediately)) (NP (NN carcinogen) (NN administration)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 554:D02.654.442.200 711:D02.455.326.271.665.202.495|ES| 19:1 52:1 104:1 307:1 900:1 1970:1 2013:1 2125:1 2569:1 2570:1 2571:1 2572:1 2573:1 2574:1 2575:1
4 	|BT| (S (VP (NP (NNP Digital)) (VBG karyotyping) (VP (VBZ identifies) (NP (NN thymidylate) (NN synthase) (NN amplification) (NN mechanism) (NN resistance) (NN 5-fluorouracil) (JJ metastatic) (JJ colorectal) (NN cancer) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430|ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1
4 	|BT| (S (NP (NNP Diosmin)) (VP (VBZ abrogates) (VP (ADVP (RB chemically)) (VBN induced) (NN hepatocarcinogenesis) (PP (IN via) (NP (NP (NN alleviation) (JJ oxidative) (NN stress)) (, ,) (NP (JJ hyperproliferative) (JJ inflammatory) (NN marker) (JJ murine) (NN model))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 158:D23.101 715:D03.383.663.283.266.450.260.222 716:G03.495.710|ES| 2:1 19:1 72:1 412:1 534:1 596:1 627:1 900:1 2430:1 2522:1 2579:1 2580:1 2581:1 2582:1 2583:1 2584:1
4 	|BT| (S (NP (NP (NN DNA) (NN microarray) (NN analysis)) (VP (VBN used))) (VP (VBP analyze) (NP (NP (JJ transcriptional) (NN profile) (NN HCT116) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBN treated) (NP (NP (NP (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NN oxaliplatin) (VBN selected) (NN resistance) (NN agent)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 198:D13.444.308 209:G02.111.087.847 560:D03.383.742.698.875.404 717:A11.251.210.190.380 718:E05.588.570|ES| 10:1 14:1 17:1 18:1 19:1 94:1 476:1 559:1 566:1 661:1 666:1 728:1 913:1 1094:1 1099:1 1711:1 2307:1 2308:1 2543:1 2585:1 2586:1
4 	|BT| (S (NP (NN Embelin)) (VP (VBZ inhibits) (NP (NP (NN chemical) (JJ carcinogen-induced) (NN colon) (NN carcinogenesis)) (, ,) (NP (NP (NN effect)) (ADJP (RB partially) (JJ dependent)) (NN presence) (JJ functional) (NN PPARgamma)) (, ,) (NP (NP (VBG indicating) (NN PPARgamma) (JJ necessary) (NN signaling) (NN pathway)) (VBN involved) (NN antitumor) (NN activity) (JJ normal) (NN organism))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 279:D27.888.569.100 719:D12.776.826.239.588|ES| 2:1 19:1 75:1 113:1 118:1 195:1 207:1 321:1 346:1 383:1 399:1 415:1 615:1 774:1 1351:1 2124:1 2236:1 2244:1 2421:1 2587:1 2588:1 2589:1 2590:1
4 	|BT| (S (NP (JJ Epidemiological) (NN evidence)) (VP (VBZ suggests) (S (NP (NN vitamin) (NN D)) (VP (MD may) (VP (VB play) (NP (NP (NN role)) (VP (VBG inhibiting) (NP (NN development) (NN colon) (NN prostate) (NN cancer))))))))) |ET| |BS|15:F01.829.316.616 46:A03.556.124.526.356 79:I03.450.642.693 122:C14.280.383 651:H02.403.720.500 720:D04.808.247.222.474 721:D04.808.812.768|ES| 18:1 19:1 31:1 35:1 38:1 77:1 113:1 238:1 331:1 491:1 880:1 2384:1 2591:1 2592:1
4 	|BT| (S (NP (JJ Epidemiological) (NN study)) (VP (VBP indicate) (NP (JJ adequate) (JJ dietary) (NN folate) (JJ protective) (NN colon) (NN cancer)) (, ,) (SBAR (IN although) (S (NP (NN mechanism)) (VP (VBP remain) (ADJP (RB largely) (JJ elusive))))))) |ET| |BS|224:D03.438.733.631.400 595:G07.203.650.240 722:E05.318.760.500|ES| 2:1 18:1 19:1 113:1 131:1 162:1 493:1 777:1 778:1 1479:1 1592:1 2181:1 2384:1 2593:1 2594:1 2595:1
4 	|BT| (S (NP (NNP Erlotinib)) (ADVP (RB also)) (VP (VBD decreased) (NP (NN hepatocyte) (NN proliferation) (NN liver) (NN injury)))) |ET| |BS|242:A03.620 262:A11.436.348|ES| 5:1 19:1 202:1 299:1 836:1 1909:1 2416:1 2596:1
4 	|BT| (S (NP (NN ESE-1) (: /) (NN EGR-1) (NN pathway)) (VP (VBP play) (NP (NN role)) (NP (ADJP (JJ tolfenamic) (JJ acid-induced)) (NP (NN apoptosis) (JJ colorectal) (NN cancer) (NN cell))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 39:G04.299.139.160 41:A11 79:I03.450.642.693|ES| 17:1 18:1 19:1 31:1 89:1 94:1 238:1 383:1 2597:1 2598:1 2599:1
4 	|BT| (NP (NP (NP (NN Evaluation) (JJ chemopreventive) (NN effect)) (NP (NNP Fumaria) (NN indica) (NN N-nitrosodiethylamine) (JJ CCl4-induced) (JJ hepatocellular) (NN carcinoma) (NNP Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 225:E05.337 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900 724:B01.650.940.800.575.100.443.750|ES| 19:1 75:1 303:1 304:1 849:1 1208:1 1946:1 2520:1 2600:1 2601:1 2602:1 2603:1
4 	|BT| (NP (NP (NP (NN Exenatide)) (PRN (-LRB- -LRB-) (NP (NN Ex-4)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ potent) (NN diabetes) (NN drug)) (VP (VBG targeting) (NP (NP (JJ glucagon-like) (NN peptide-1) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GLP-1R)) (-RRB- -RRB-))))) (, ,) (NP (NP (JJ protective) (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN NAFLD)) (-RRB- -RRB-)))) |ET| |BS|369:E02.319.300 577:C06.552.241.519 725:D12.776.543.750.100.021.500 726:C18.452.394.750|ES| 2:1 10:1 14:1 19:1 22:1 186:1 191:1 493:1 616:1 836:1 998:1 2009:1 2069:1 2070:1 2604:1 2605:1 2606:1 2607:1 2608:1 2609:1
4 	|BT| (SINV (ADVP (RB Furthermore)) (, ,) (NP (NN exposure) (JJ colorectal) (NN cancer) (NN cell) (JJ anti-periostin) (NN antibody)) (VP (VBZ activates) (NP (NN apoptosis))) (VP (VBZ potentiates) (NP (NN effect) (NN 5-fluorouracil) (NN chemotherapy)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 151:E02.319 560:D03.383.742.698.875.404 727:D12.776.124.486.485.114.071|ES| 2:1 17:1 18:1 19:1 75:1 89:1 94:1 301:1 334:1 495:1 1953:1 2307:1 2499:1 2610:1 2611:1
4 	|BT| (S (NP (NNP Garcinol)) (VP (VBZ suppresses) (NP (JJ inflammation-associated) (NN colon) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 53:C06.405.205.265|ES| 19:1 52:1 113:1 207:1 686:1 1849:1 2612:1
4 	|BT| (S (NP (JJ Garlic) (NN oil)) (VP (VBD attenuated) (NP (NP (JJ nitrosodiethylamine-induced) (NN hepatocarcinogenesis)) (VP (VBG modulating) (NP (JJ metabolic) (NN activation) (NN detoxification) (NN enzyme)))))) |ET| |BS|554:D02.654.442.200 728:G03.495.244.224 729:G03.495.244.450 730:D08.811|ES| 19:1 225:1 808:1 900:1 2006:1 2388:1 2435:1 2613:1 2614:1 2615:1 2616:1
4 	|BT| (NP (NP (NP (NNP Gemcitabine)) (, ,) (NP (JJ current) (JJ standard-of-care) (NN chemotherapy) (JJ pancreatic) (NN cancer)) (, ,) (NP (JJ limited) (JJ clinical) (NN benefit)))) |ET| |BS|151:E02.319|ES| 2:1 18:1 19:1 84:1 175:1 467:1 495:1 2131:1 2617:1 2618:1 2619:1
4 	|BT| (S (NP (NNS Glucans) (JJ edible) (NN mushroom) (NN Pleurotus) (NN pulmonarius)) (VP (VBP inhibit) (NP (JJ colitis-associated) (NN colon) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 53:C06.405.205.265 122:C14.280.383 731:B01.300.179.100.650 732:D05.750.078.562 733:B01.300.179.100|ES| 19:1 52:1 113:1 207:1 410:1 1370:1 2620:1 2621:1 2622:1 2623:1 2624:1
4 	|BT| (NP (NP (NP (JJ Glycyrrhizic) (NN Acid)) (NP (VBN used) (NN treat) (JJ chronic) (NN hepatitis))) (, ,) (S (VP (VBG inhibiting) (NP (NN penetration) (NN hepatitis) (NN A) (NN virus) (NNS hepatocytes))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 122:C14.280.383 262:A11.436.348 734:D02.455.849.919.530.466 735:B04.450.420.410 736:C06.552.380.350|ES| 2:1 19:1 69:1 476:1 880:1 894:1 1090:1 1422:1 1790:1 2048:1 2625:1 2626:1 2627:1
4 	|BT| (S (NP (JJ Great) (NN interest)) (VP (VBD focused) (NP (NN chemoprevention) (JJ colonic) (NN carcinogenesis) (JJ oral) (NN administration)) (NP (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (NN administration)) (VP (ADVP (RB reportedly)) (VBZ reduces) (NP (NN incidence) (NN colon) (NN cancer) (NN animal) (NN experiment))))) |ET| |BS|33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 253:E02.319.162 434:E05.318.308.985.525.375 737:D04.808.105.225.272.962 738:E05.017 739:E02.319.267.100|ES| 10:1 14:1 18:1 19:1 46:1 113:1 142:1 207:1 677:1 870:1 1051:1 1275:1 1511:1 2310:1 2311:1 2575:1 2628:1 2629:1 2630:1 2631:1 2632:1
4 	|BT| (SINV (ADVP (RB Here)) (VP (VBN aimed)) (VP (VBP determine) (NP (NP (NN mechanism) (NN action) (NN DHEA)) (, ,) (NP (NP (NN comparison) (NN vitamin) (NN E)) (, ,) (NP (JJ chemically-induced) (JJ hepatocellular) (NN carcinoma) (NN model) (NN rat)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 740:D04.808.054.079.429.625 741:D03.383.663.283.909 742:G03.787|ES| 2:1 19:1 72:1 74:1 162:1 303:1 304:1 400:1 844:1 849:1 2013:1 2085:1 2233:1 2591:1 2633:1 2634:1
4 	|BT| (S (NP (ADVP (RB Herein)) (, ,) (JJ first) (NN time)) (, ,) (VP (VBP investigate) (NP (FW vivo) (NN efficacy) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 322:G01.910|ES| 2:1 19:1 52:1 78:1 113:1 378:1 428:1 459:1 816:1 1081:1 2304:1 2533:1 2534:1 2635:1
4 	|BT| (NP (NP (ADVP (RB However)) (, ,) (NP (NN investigation) (JJ protective) (NN effect) (NN betaine) (NN hepatocarcinogenesis)))) |ET| |BS|225:E05.337 743:D02.092.877.883.077|ES| 2:1 19:1 75:1 433:1 493:1 900:1 1497:1 2636:1
4 	|BT| (S (NP (NN HTHQ)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN colon) (NN carcinogenesis) (CD two) (NN stage) (NN colon) (NN carcinogenesis) (NN model)) (S (VP (VBG using) (NP (NP (NP (NN 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-))) (NN initiator))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725|ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1
4 	|BT| (S (NP (JJ Hyperactive) (NN EGFR) (NN signaling) (NN Stat3) (NN Jak-Stat3) (NN activity)) (ADVP (RB together)) (VP (VBP promote) (SBAR (S (NP (NP (JJ ovarian) (NN cancer) (NN progression) (NN cisplatin) (NN resistance)) (ADVP (RB therefore))) (VP (VBP represent) (NP (NP (NN target)) (VP (VBG preventing) (NP (NN development) (NN cisplatin) (NN resistance) (JJ recurrent) (NN disease) (NN cisplatin) (NN therapy) (JJ ovarian) (NN cancer))))))))) |ET| |BS|16:C23.550.291.656 52:E02 69:G02.111.087.800 82:D12.644.360.024.342.300 288:C23.550.288 496:C23.550.291.937 498:D01.210.375 745:C10.597.350.350|ES| 18:1 19:1 35:1 48:1 130:1 160:1 187:1 195:1 218:1 399:1 679:1 799:1 998:1 1094:1 1538:1 1753:1 1761:1 1763:1 1937:1 2645:1 2646:1 2647:1
4 	|BT| (FRAG (NP (NP (JJ Immunohistochemical) (NN analysis)) (JJ late) (NN stage) (NN tumor) (NN promotion) (NN oxfendazole) (NN rat) (NN hepatocarcinogenesis) (NN model))) |ET| |BS|8:C04 38:Z01.058.290.120.180 40:Z01.542.248.700 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 7:1 19:1 72:1 661:1 849:1 900:1 1129:1 2337:1 2648:1 2649:1 2650:1
4 	|BT| (S (ADVP (RB Importantly)) (, ,) (NP (NN cotreatment) (JJ low) (NNS dos) (NP (NP (NNS oligoamines) (NN DNA) (NN methyltransferase) (NN inhibitor)) (ADVP (RB highly)))) (VP (VBZ induces) (SBAR (S (NP (NN reexpression)) (ADVP (RB aberrantly)) (VP (VBD silenced) (SBAR (S (NP (NN SFRP2) (NN gene)) (VP (VBP result) (NP (NP (JJ significant) (NN inhibition) (NN growth)) (VBN established) (NN tumor) (JJ human) (NN colon) (NN tumor) (NN model)) (FW vivo))))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240|ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1
4 	|BT| (S (PP (IN In) (NP (CD 2012) (NN case) (NN report))) (, ,) (VP (VBN described) (NP (NP (NN breakthrough)) (VP (VBG finding) (NP (NP (CD two) (JJ advanced) (NNP HCC) (NN patient)) (, ,) (NP (S (NP (CD one)) (VP (VBD achieved) (SBAR (S (NP (JJ complete) (NN remission) (NN liver) (NN tumor)) (VP (VBD normalized) (NP (NP (NN alpha-fetoprotein) (NN level)) (, ,) (PP (IN along) (NP (JJ complete) (NN remission) (NN lung) (NN metastasis))))))))) (, ,) (NP (JJ concomitant) (NN use) (NN thalidomide) (NN cyproheptadine)))))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 275:C23.888 405:V03.100 406:V03.100 515:C04.588.274.623 747:D02.455.426.559.847.181.384.340 748:D12.776.124.790.106.092 749:D02.241.223.805.810.800|ES| 2:1 7:1 19:1 120:1 172:1 244:1 249:1 328:1 417:1 441:1 634:1 806:1 836:1 927:1 933:1 934:1 997:1 1010:1 1659:1 1681:1 2491:1 2661:1 2662:1 2663:1 2664:1 2665:1 2666:1 2667:1 2668:1
4 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN alpha-mangostin)) (VP (MD may) (VP (VB chemopreventive) (NP (NP (NN benefit)) (CC and/or) (VP (VB prove) (NP (NP (JJ useful) (JJ adjuvant) (NN therapy)) (, ,) (NP (JJ complementary) (NN alternative) (NN medicine) (NN treatment) (NN breast) (NN cancer)))))))) |ET| |BS|52:E02 685:D27.505.696.477.067 687:D26.650.064 750:E02.190|ES| 2:1 18:1 19:1 23:1 130:1 149:1 244:1 468:1 491:1 546:1 1036:1 1946:1 2246:1 2327:1 2479:1 2619:1 2669:1 2670:1 2671:1
4 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NP (NN dioscin) (NN show) (JJ excellent) (JJ protective) (NN effect)) (JJ ethanol-induced) (NN liver) (NN injury)) (S (VP (VBG ameliorating) (NP (NP (JJ ethanol-induced) (JJ oxidative) (NN stress)) (, ,) (NP (JJ mitochondrial) (NN function)) (, ,)) (NP (NP (JJ inflammatory) (NP (NN cytokine)) (NN production)) (, ,) (NP (NN apoptosis) (NN liver) (NN steatosis)) (, ,))))) (VP (VBD developed) (NP (JJ new) (NN drug) (NN treatment) (JJ ethanol-induced) (NN liver) (NN injury) (NN future)))) |ET| |BS|39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241|ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1
4 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN simvastatin)) (VP (VBD inhibited) (NP (NP (NN colon) (NN cancer) (NN development) (NN induction)) (NN apoptosis) (NN suppression) (NN angiogenesis)))) |ET| |BS|39:G04.299.139.160 122:C14.280.383 754:D02.455.426.559.847.638.400.900|ES| 2:1 18:1 19:1 35:1 89:1 113:1 244:1 365:1 736:1 1284:1 2453:1 2502:1 2679:1
4 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (VP (VBP inhibit) (NP (NP (JJ colitis-related) (NN mouse) (NN colon) (NN carcinogenesis)) (VBN compared) (NN effect) (NN sulfasalazine))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 53:C06.405.205.265 122:C14.280.383 737:D04.808.105.225.272.962 755:D02.065.884.730|ES| 2:1 10:1 14:1 19:1 50:1 52:1 75:1 113:1 131:1 175:1 207:1 221:1 244:1 403:1 1275:1 1370:1 2630:1 2631:1 2680:1 2681:1
4 	|BT| (FRAG (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBD investigated) (NP (JJ anticancer) (NN activity) (JJ tolfenamic) (NN acid) (JJ human) (JJ colorectal) (NN cancer) (NN cell)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 17:1 18:1 19:1 36:1 94:1 131:1 244:1 399:1 403:1 1275:1 1307:1 1880:1 2598:1
4 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBN shown) (NP (NP (JJ myrtenal) (, ,) (JJ natural) (NN monoterpene)) (, ,) (NP (VP (VBP act) (SBAR (S (NP (JJ antineoplastic) (NN agent) (NN diethylnitrosamine)) (VP (VBD induced) (NP (JJ phenobarbital) (VBN promoted) (NP (JJ experimental) (JJ hepatocellular) (NN carcinoma))))))))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 554:D02.654.442.200 660:D27.505.954.248 756:D03.383.742.698.253.650 757:C04.588.274.623.460 758:D02.455.849.575|ES| 2:1 19:1 131:1 237:1 244:1 246:1 263:1 303:1 304:1 412:1 728:1 1307:1 1912:1 1952:1 2333:1 2682:1 2683:1 2684:1 2685:1
4 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD demonstrated) (NP (NP (NN alantolactone)) (, ,) (NP (NN sesquiterpene) (NN lactone)) (, ,) (NP (NP (JJ potential) (NN activity) (JJ triple-negative) (NN breast) (NN cancer) (NN MDA-MB-231) (NN cell) (JJ suppressing) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (NN signaling) (NN pathway))))) |ET| |BS|41:A11 69:G02.111.087.800 160:C04.588.180.788 209:G02.111.087.847 250:E07.305.812 759:D02.092.471.683.152.660 760:Z01.107.084.900.600 761:G02.111.087.800 762:D02.455.849.765 763:Z01.542.248.540 764:D02.540|ES| 2:1 10:1 14:1 18:1 19:1 23:1 26:1 94:1 131:1 195:1 244:1 251:1 383:1 399:1 487:1 827:1 859:1 860:1 861:1 862:1 1175:1 1307:1 2250:1 2686:1 2687:1 2688:1 2689:1
4 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBN examined) (NN effect) (NN pitavastatin) (: -) (NN drug)) (VP (VBD used) (S (NP (NN treatment) (NN hyperlipidemia)) (: -) (NP (NP (NN development) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (S (NP (NP (NN liver) (JJ preneoplastic) (NN lesion) (NN C57BL/KsJ-db/db)) (PRN (-LRB- -LRB-) (NP (NN db/db)) (-RRB- -RRB-))) (NP (JJ obese) (NN mouse))))))) |ET| |BS|52:E02 67:D26 242:A03.620 554:D02.654.442.200 593:B01.050.050.199.520.520.420 765:B01.050.150.900.649.865.635.505.500.550.530 766:C18.452.584.500.500|ES| 2:1 10:1 14:1 19:1 35:1 52:1 75:1 131:1 191:1 244:1 324:1 409:1 476:1 546:1 836:1 1131:1 1307:1 1438:1 1875:1 1952:1 2468:1 2690:1 2691:1 2692:1 2693:1 2694:1
4 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBN shown) (NN diosmin)) (VP (VBZ attenuates) (SBAR (S (NP (NP (NN 2-AAF)) (VP (VBD induced) (NP (NP (NP (JJ hepatic) (NN toxicity) (JJ early) (NN tumor) (NN promotion) (NN marker)) (PRN (-LRB- -LRB-) (NP (NP (NN ODC)) (, ,) (NP (NN PCNA) (NN Ki67))) (-RRB- -RRB-))) (, ,) (NP (JJ chemopreventive) (NN efficacy) (NN DEN))))) (VP (VBD initiated) (NP (JJ 2-AAF) (VBN promoted) (NN hyper-proliferation) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))))))) |ET| |BS|376:D23.101.140 715:D03.383.663.283.266.450.260.222 723:B01.050.150.900.649.865.635.505.700.900 745:C10.597.350.350 767:D02.065.064.150 768:D12.776.660.740|ES| 2:1 7:1 10:1 14:1 19:1 131:1 237:1 244:1 412:1 534:1 838:1 849:1 900:1 1128:1 1307:1 1875:1 1900:1 1912:1 1946:1 2304:1 2337:1 2406:1 2423:1 2603:1 2695:1 2696:1 2697:1 2698:1 2699:1 2700:1
4 	|BT| (NP (NP (PP (IN In) (NP (NN study))) (, ,) (NP (NP (NP (NN report) (NN effect) (NN resveratrol) (JJ early) (JJ advanced) (NN stage) (NN hepatocarcinogenesis) (NN model) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VBN induced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (JJ male) (NNP Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900|ES| 2:1 10:1 14:1 19:1 72:1 75:1 131:1 244:1 303:1 304:1 409:1 417:1 441:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1712:1 1875:1 2602:1 2603:1
4 	|BT| (S (NP (NN Inflexinol)) (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN cell) (NN growth) (NN inhibition) (JJ nuclear) (NN factor-kappaB) (NN activity)) (PP (IN via) (NP (JJ direct) (NN interaction) (NN p50))))) |ET| |BS|41:A11 43:F01.145.544 45:G07.700.320.249 122:C14.280.383 210:D12.776.260.600|ES| 18:1 19:1 94:1 102:1 103:1 113:1 399:1 596:1 615:1 618:1 1256:1 1891:1 2377:1 2701:1 2702:1
4 	|BT| (S (NP (NN Inhibition) (JJ retinoic) (NN acid) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NN N-nitrosomorpholine) (NN expression) (NN myc) (NN oncogene) (NN protein) (JJ Sprague-Dawley) (NN rat)))) |ET| |BS|43:F01.145.544 584:D12.776.624.664 769:B01.050.150.900.649.865.635.505.700.750 770:D02.455.326.271.665.202.495.818.500|ES| 4:1 19:1 24:1 115:1 412:1 849:1 900:1 1275:1 2703:1 2704:1 2705:1 2706:1 2707:1
4 	|BT| (NP (NP (NN Inhibition) (NP (NN c-Jun) (JJ NH2-terminal) (NN kinase) (NN switch)) (NN Smad3) (NN signaling) (NN oncogenesis) (NN tumor)) (: -) (NP (NN suppression) (NN rat) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 43:F01.145.544 69:G02.111.087.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 771:D08.811.913.696.620.682.700.567.374|ES| 19:1 195:1 303:1 304:1 470:1 849:1 1686:1 2453:1 2703:1 2708:1 2709:1 2710:1 2711:1 2712:1
4 	|BT| (NP (NP (NP (JJ Inhibitory) (NN effect) (JJ oleanolic) (NN acid) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (NP (JJ ERK-p53-mediated) (NN cell) (NN cycle) (NN arrest)) (NP (JJ mitochondrial-dependent) (NN apoptosis)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 772:D02.455.849.919.530.733 773:G04.299.134.109|ES| 19:1 75:1 89:1 94:1 303:1 304:1 596:1 601:1 602:1 1275:1 2713:1 2714:1 2715:1 2716:1
4 	|BT| (NP (NP (JJ Inhibitory) (NN effect) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 75:1 78:1 113:1 2533:1 2534:1 2635:1 2713:1
4 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
4 	|BT| (S (NP (NP (JJ Kruppel-like) (NN factor) (CD 9)) (PRN (-LRB- -LRB-) (NP (NN KLF9)) (-RRB- -RRB-))) (VP (VBZ prevents) (NP (JJ colorectal) (NN cancer) (NN inhibition) (JJ interferon-related) (NN signaling)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 69:G02.111.087.800 617:D12.644.276.374.440 774:D12.776.124.125.375|ES| 10:1 14:1 17:1 18:1 19:1 103:1 185:1 195:1 318:1 703:1 2717:1 2718:1 2719:1
4 	|BT| (S (NP (NN Latexin)) (VP (VBP exhibit) (NP (NN tumor) (NN suppressor) (JJ potential) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|104:C04.557.470.200.025.255 175:J01.897.280.500.269 206:G05.360.340.024.340.375.249|ES| 7:1 19:1 303:1 304:1 587:1 700:1 827:1 2720:1
4 	|BT| (S (NP (NN Liver) (NN cell) (NN proliferation)) (VP (VBD increased) (ADVP (RB significantly)) (NP (NP (NN liver) (NN tumor) (JJ tamoxifen-treated) (NN rat)) (NP (ADJP (CD 12) (NN month)) (NN treatment) (NN recovery) (NN period))))) |ET| |BS|52:E02 183:G04.299.233.750 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 775:E02.760.058 776:G01.910.645|ES| 7:1 19:1 47:1 94:1 124:1 299:1 546:1 836:1 849:1 1120:1 2721:1 2722:1 2723:1 2724:1 2725:1
4 	|BT| (S (S (NP (JJ Liver-specific) (NN deletion) (NN prohibitin) (CD 1)) (VP (VBP result) (NP (JJ spontaneous) (NN liver) (NN injury)))) (, ,) (NP (NP (NN fibrosis)) (, ,) (NP (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 242:A03.620 306:G05.355.600.800 691:C23.550.355|ES| 2:1 19:1 52:1 98:1 101:1 283:1 303:1 304:1 836:1 949:1 1059:1 2416:1 2726:1 2727:1
4 	|BT| (S (NP (NN Loss) (NN Dicer)) (ADVP (RB primarily)) (VP (VBZ impairs) (SBAR (S (NP (NN hepatocyte) (NN survival)) (VP (VBP promote) (NP (NN hepatocarcinogenesis) (NN cooperation) (JJ additional) (JJ oncogenic) (NN stimulus))))))) |ET| |BS|96:I03.784 262:A11.436.348 279:D27.888.569.100|ES| 19:1 274:1 679:1 900:1 953:1 980:1 1788:1 1909:1 1960:1 1970:1 2728:1 2729:1 2730:1
4 	|BT| (S (NP (NN Loss) (NN metallothionein)) (VP (VBZ predisposes) (NP (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (VBG activating) (NN NF-kappaB) (NN target) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670|ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1
4 	|BT| (S (NP (NNP Lycopene) (JJ active) (JJ chemopreventive) (NN agent) (NN offer) (NN protection) (JJ DEN-induced) (NN hepatocarcinogenesis)) (VP (VBG inhibiting) (NP (NN NF-kappaB) (NN mTOR) (NN pathway)))) |ET| |BS|122:C14.280.383 210:D12.776.260.600|ES| 19:1 197:1 383:1 714:1 728:1 880:1 900:1 1042:1 1946:1 2733:1 2734:1 2735:1 2736:1
4 	|BT| (S (NP (NN Magnolol)) (VP (MD could) (ADVP (RB potentially)) (NP (JJ safe) (JJ potent) (JJ anticarcinogenic) (NN agent) (NN skin) (NN cancer)))) |ET| |BS|778:D27.505.954.444|ES| 18:1 19:1 22:1 333:1 728:1 773:1 908:1 2312:1 2319:1 2737:1
4 	|BT| (S (NP (NN Melatonin)) (VP (VBD improved) (SBAR (S (NP (NN survival) (NN rate)) (VP (ADVP (RB successfully)) (VBD attenuated) (NP (NN liver) (NN injury))))) (, ,) (VP (VBN shown) (NP (NN histopathology))) (, ,) (VP (VBD decreased) (NP (NP (NN level) (NN serum) (NN transaminase)) (NP (VBN reduced) (NN expression) (JJ placental) (NN glutathione) (NN S-transferase)))))) |ET| |BS|242:A03.620 707:D03.438.473.914.481 779:E05.318.308.985.550.900 780:D08.811.913.225.500 781:D08.811.913.477.700 782:A12.207.152.846 783:A16.710|ES| 2:1 19:1 41:1 115:1 202:1 237:1 249:1 274:1 452:1 808:1 836:1 2410:1 2416:1 2738:1 2739:1 2740:1 2741:1 2742:1 2743:1 2744:1 2745:1
4 	|BT| (S (NP (NN Metformin)) (VP (VBZ inhibits) (NP (JJ early) (NN stage) (JJ diethylnitrosamineinduced) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 784:D02.078.370.141.450|ES| 19:1 615:1 849:1 900:1 1128:1 1129:1 2746:1 2747:1
4 	|BT| (NP (NP (NP (NN METHODOLOGY/PRINCIPAL) (NNS FINDINGS)) (: :) (NP (NP (JJ Pancreatic) (NN cancer) (NN cell) (NN line)) (VP (VBN treated) (NP (NN resveratrol)))))) |ET| |BS|52:E02 94:A11.251.210|ES| 18:1 19:1 94:1 104:1 264:1 1099:1 1213:1 1712:1 2748:1 2749:1
4 	|BT| (NP (NP (NNS METHODS) (: :)) (NP (NP (JJ UVB-induced) (NN skin) (NN carcinogenesis) (NN model) (NN SKH-1) (NN mouse)) (VP (VBN used) (S (VP (VBG determining) (NP (JJ preventive) (NN effect) (NN magnolol) (NN skin) (NN cancer) (NN development))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 168:E05.581 785:A17.815|ES| 18:1 19:1 35:1 52:1 72:1 75:1 104:1 207:1 476:1 565:1 1883:1 2319:1 2526:1 2750:1 2751:1 2752:1
4 	|BT| (S (NP (NN Methyl) (NN antcinate) (NN A) (NN Antrodia) (NN camphorata)) (VP (VBZ induces) (NP (NP (NN apoptosis) (JJ human) (NN liver) (NN cancer) (NN cell) (JJ oxidant-mediated) (NN cofilin)) (: -) (NP (JJ Bax-triggered) (JJ mitochondrial) (NN pathway))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 573:N05.715.350.200.650 786:B01.300.179.120.174.070 787:D27.720.642|ES| 18:1 19:1 36:1 69:1 89:1 94:1 214:1 383:1 836:1 2004:1 2753:1 2754:1 2755:1 2756:1 2757:1 2758:1 2759:1
4 	|BT| (NP (NP (NN Modulation) (NN energy) (JJ metabolic) (NN enzyme) (NN expression) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (JJ Chinese) (NN herb)) (, ,) (NP (NNP Huqi) (NNP San))) |ET| |BS|554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500|ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1
4 	|BT| (FRAG (ADVP (RBR More) (RB importantly)) (, ,) (NP (NP (NN EPLE)) (VBN hampered) (NN tumor) (NN development) (NN CRC) (NN xenograft) (NN model))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 92:E04.936.764 93:A01.941.875|ES| 2:1 7:1 19:1 35:1 72:1 245:1 265:1 2489:1 2767:1 2768:1 2769:1
4 	|BT| (S (ADVP (RB Moreover)) (, ,) (S (VP (VBG using) (NP (NP (NN mouse) (NN xenograft) (NN model)) (, ,) (NP (NN show) (NN treatment) (JJ specific) (NNP PPOX) (NN inhibitor) (NN acifluorfen))))) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NP (NP (NN growth) (CD three) (CD seven)) (PRN (-LRB- -LRB-) (NP (CD 42.8) (NN %)) (-RRB- -RRB-))) (NN colon) (NN cancer) (NN line)) (NP (VBN investigated))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875|ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 102:1 113:1 124:1 264:1 265:1 350:1 369:1 380:1 403:1 429:1 452:1 482:1 540:1 546:1 622:1 1733:1 2770:1 2771:1 2772:1
4 	|BT| (S (NP (NP (NNP Myrtenal)) (, ,) (NP (JJ natural) (NN monoterpene)) (, ,)) (VP (VBZ down-regulates) (SBAR (S (NP (NN TNF-alpha) (NN expression)) (VP (VBZ suppresses) (NP (JJ carcinogen-induced) (JJ hepatocellular) (NN carcinoma) (NN rat))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 351:A17.360 758:D02.455.849.575 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 19:1 115:1 303:1 304:1 686:1 849:1 2333:1 2421:1 2683:1 2773:1 2774:1 2775:1
4 	|BT| (S (NP (NN N-acetyl-L-cysteine)) (VP (VBD blocked) (SBAR (S (NP (NN EGFR) (NN activation)) (VP (VBD reduced) (NP (JJ N-nitrosodiethylamine-initiated) (NN hepatocarcinogenesis) (NN level) (NNP Cre-Ctrl) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 554:D02.654.442.200 791:D02.886.030.230.259|ES| 19:1 52:1 187:1 225:1 249:1 452:1 900:1 2776:1 2777:1 2778:1 2779:1
4 	|BT| (S (NP (JJ Natural) (NNS polyphenols)) (VP (VBP facilitate) (NP (NP (NN elimination) (NN HT-29) (JJ colorectal) (NN cancer) (NN xenograft) (NN chemoradiotherapy)) (: :) (NP (NP (NN Bcl-2)) (: -) (NP (NN superoxide) (NN dismutase) (JJ 2-dependent) (NN mechanism)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 56:D02.455.426.559.389.657.715 59:E02.186.079 92:E04.936.764 93:A01.941.875 792:A11.251.210.190.475|ES| 17:1 18:1 19:1 104:1 146:1 147:1 154:1 156:1 162:1 265:1 1989:1 2780:1 2781:1 2782:1 2783:1 2784:1
4 	|BT| (S (NP (JJ Natural) (NN product) (NN pectolinarigenin)) (VP (VBZ inhibits) (NP (NN osteosarcoma) (NN growth) (NN metastasis)) (PP (IN via) (NP (JJ SHP-1-mediated) (NN STAT3) (NN signaling) (NN inhibition))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383 447:C04.557.450.565.575.650 793:D20.215|ES| 19:1 102:1 103:1 195:1 251:1 596:1 615:1 675:1 806:1 1562:1 2780:1 2785:1 2786:1
4 	|BT| (S (NP (NN Nitidine) (NN chloride)) (VP (VBZ inhibits) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN cell)) (NN growth)) (NP (FW vivo) (NN suppression) (NN JAK1/STAT3) (NN signaling) (NN pathway)))) |ET| |BS|41:A11 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 104:C04.557.470.200.025.255 122:C14.280.383 126:G02.111.087.800 794:D08.811.913.696.620.682.725.124.100|ES| 19:1 94:1 102:1 195:1 303:1 304:1 378:1 383:1 615:1 2453:1 2787:1 2788:1 2789:1
4 	|BT| (NP (NP (NP (JJ Nitric) (JJ oxide-releasing) (NN aspirin) (NN indomethacin) (JJ potent) (NN inhibitor) (NN colon) (NN cancer) (JJ azoxymethane-treated) (NN rat)) (: :) (NP (NN effect) (JJ molecular) (NN target)))) |ET| |BS|52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420|ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1
4 	|BT| (NP (NP (JJ Non-steroidal) (JJ anti-inflammatory) (NN drug) (NN sulindac) (JJ promising) (NN chemoprevention) (NN agent) (NN colon) (NN cancer)) (, ,) (NP (JJ weak) (NN potency) (NN side) (NN effect) (NN limit) (NN use) (NN chemoprevention) (NN chemotherapy))) |ET| |BS|151:E02.319 251:D02.455.426.559.847.486.875 253:E02.319.162 796:D27.505.696.663.850.014.040.500|ES| 2:1 18:1 19:1 75:1 113:1 191:1 338:1 495:1 728:1 869:1 870:1 871:1 1517:1 1659:1 2794:1 2795:1 2796:1 2797:1
4 	|BT| (S (S (ADVP (RB Notably)) (, ,) (NP (JJ adeno-XAF1) (NN treatment)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN tumor) (NN growth)) (, ,) (ADVP (NP (ADJP (RB strongly) (VBN enhanced)) (NN antitumor) (NN activity) (NN TRAIL) (JJ gastric) (NN cancer) (NN xenograft) (NN model)) (FW vivo)) (, ,) (NP (RB significantly) (JJ prolonged) (NN survival) (NN time) (JJ animal) (NN bearing) (NN tumor) (NN xenograft))))) |ET| |BS|8:C04 19:B01.050 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875 96:I03.784 122:C14.280.383 322:G01.910 455:B01.050.150.900.649.147.890|ES| 2:1 7:1 18:1 19:1 46:1 72:1 86:1 102:1 124:1 265:1 274:1 365:1 378:1 385:1 399:1 546:1 635:1 1081:1 1584:1 1695:1 2244:1 2798:1 2799:1 2800:1
4 	|BT| (S (ADVP (RB Notably)) (, ,) (NP (NN colon) (NN tumor) (NN prevention) (NN activity) (NN sulindac)) (VP (VP (VBN accompanied) (NP (NP (JJ marked) (NN induction) (JJ lymphoid) (NN aggregate)) (NP (JJ proximal) (JJ colonic) (JJ inflammatory) (NN mass) (NN lesion)))) (, ,) (VP (S (NP (JJ side) (NN effect)) (VP (VBN seen) (NP (JJR lesser) (NN degree) (NN celecoxib)))) (, ,) (NP (NN aspirin))))) |ET| |BS|51:C04.588.274.476.411.307.180 213:F02.830.816.964 251:D02.455.426.559.847.486.875 670:D02.455.426.559.389.657.410.595.176 684:D02.065.884.247 797:A10.549.600|ES| 2:1 7:1 19:1 75:1 113:1 399:1 677:1 724:1 736:1 869:1 871:1 1070:1 1131:1 1474:1 1967:1 2430:1 2487:1 2798:1 2801:1 2802:1 2803:1 2804:1 2805:1 2806:1 2807:1
4 	|BT| (S (NP (JJ Nuclear) (NN Maspin) (NN expression)) (NP (ADJP (RB highly) (JJ predictive)) (NN 5-FU) (NN chemotherapy) (NN response) (NN patient)) (VP (VBD advanced) (NP (NN stage) (NN colon) (NN cancer)))) |ET| |BS|50:M01.643 151:E02.319 560:D03.383.742.698.875.404|ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1
4 	|BT| (FRAG (PP (IN On) (NP (NN basis) (NN finding) (, ,) (NN development) (NN 2-aryl) (NN benzimidazole) (NN derivative))) (, ,) (NP (NP (JJ new) (NN class) (JJ multitarget) (JJ anticancer) (NN agent)) (, ,) (VP (VBD warranted) (VP (VBZ represents) (NP (NP (JJ novel) (NN strategy)) (VP (VBG improving) (NP (NN breast) (NN cancer) (NN treatment)))))))) |ET| |BS|52:E02 259:D12.776.395.240.150.500 660:D27.505.954.248 798:D03.438.103|ES| 2:1 18:1 19:1 23:1 35:1 546:1 712:1 728:1 891:1 927:1 1114:1 1140:1 1880:1 2363:1 2516:1 2810:1 2811:1 2812:1 2813:1 2814:1 2815:1 2816:1
4 	|BT| (S (NP (ADJP (RB Orally) (VBN administered)) (NN lycopene)) (VP (VBZ attenuates) (NP (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN rat)) (VP (VBG modulating) (NP (NP (NN Nrf-2)) (: /) (NP (NN HO-1) (NN Akt/mTOR) (NN pathway))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534|ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1
4 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD indicated) (SBAR (S (NP (NN nifuroxazide)) (VP (MD may) (ADVP (RB potentially)) (NP (JJ therapeutic) (NN agent) (NN growth) (NN metastasis) (NN breast) (NN cancer))))))) |ET| |BS|52:E02 113:C04.697.650|ES| 18:1 19:1 23:1 102:1 491:1 541:1 658:1 728:1 773:1 793:1 806:1 1541:1 2820:1
4 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD indicated) (NP (NP (NN silymarin) (JJ therapeutic) (NN effect)) (NP (JJ early) (NN stage) (NN liver) (NN damage))) (, ,) (S (VP (VBG reversing) (NP (NP (JJ fatty) (NN change)) (VP (VBG recovering) (NP (NN liver) (NN histopathology) (JJ dose-dependent) (NN manner)))))))) |ET| |BS|242:A03.620 801:D03.383.663.283.266.450.268.777|ES| 2:1 19:1 75:1 200:1 541:1 658:1 793:1 836:1 1128:1 1129:1 1541:1 1668:1 1848:1 2070:1 2740:1 2821:1 2822:1 2823:1 2824:1
4 	|BT| (S (NP (PRP$ Our) (NNS data)) (ADVP (RB thus)) (VP (VBP establish) (SBAR (S (NP (NN EPLE) (JJ novel) (NN inhibitor) (NN Wnt) (NN signaling)) (VP (VBP hold) (NP (JJ great) (NN promise) (JJ potential) (NN candidate) (JJ preclinical) (NN evaluation) (NN CRC) (NN treatment))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 69:G02.111.087.800 225:E05.337 259:D12.776.395.240.150.500|ES| 19:1 195:1 220:1 245:1 380:1 546:1 658:1 793:1 827:1 877:1 891:1 1243:1 1334:1 1494:1 2489:1 2503:1 2825:1 2826:1 2827:1
4 	|BT| (S (NP (PRP$ Our) (NNS data) (NN pterostilbene)) (VP (VBG suppressing) (NP (NP (NN colon) (NN tumorigenesis)) (, ,) (NP (NN cell) (NN proliferation)) (NP (ADJP (RB well) (JJ key)) (JJ inflammatory) (NN marker))) (ADVP (FW vivo) (FW vitro)) (VP (VBP suggest) (NP (JJ potential) (NN use) (NN pterostilbene) (NN colon) (NN cancer) (NN prevention))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 158:D23.101 183:G04.299.233.750|ES| 2:1 18:1 19:1 78:1 94:1 113:1 159:1 216:1 299:1 378:1 534:1 658:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1
4 	|BT| (S (NP (PRP$ Our) (NN finding)) (ADVP (RB also)) (VP (VBD showed) (SBAR (S (NP (NP (JJ myrtenal) (NNS restrains) (NN liver) (NN cancer)) (VP (VBG preventing) (NP (NN DEN-PB)))) (VP (VBD induced) (NP (NN up-regulation) (NN TNF-alpha) (NN protein) (NN expression) (NN immunoblot))))))) |ET| |BS|7:D12.776 122:C14.280.383 142:I01.880.604 789:D12.644.276.374.500.800 790:D12.644.276.374.750 802:E05.478.566.320|ES| 4:1 5:1 18:1 19:1 115:1 132:1 412:1 658:1 836:1 896:1 927:1 1937:1 2682:1 2775:1 2828:1 2829:1 2830:1
4 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (NP (NN rimonabant) (ADJP (JJ able) (S (VP (VBP inhibit) (NP (NP (JJ colorectal) (NN cancer) (NN cell) (NN growth) (JJ different) (NN stage) (NN colon) (NN cancer) (NN pathogenesis)) (VP (VBG inducing) (NP (JJ mitotic) (NN catastrophe) (NN vitro)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 122:C14.280.383 385:F02.784.629.131|ES| 17:1 18:1 19:1 94:1 102:1 113:1 216:1 414:1 501:1 658:1 720:1 796:1 927:1 1129:1 1370:1 1864:1 2831:1 2832:1 2833:1
4 	|BT| (S (NP (PRP$ Our) (JJ present) (NN study)) (VP (VBP identify) (S (NP (NP (JJ chemopreventive) (JJ potential) (NN pterostilbene) (JJ colonic) (NN tumor) (NN formation)) (NN end) (NN point)) (VP (VB evaluate) (NP (JJ mechanistic) (NN action) (NN pterostilbene) (NN colon) (NN carcinogenesis)))))) |ET| |BS|20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 51:C04.588.274.476.411.307.180 225:E05.337 742:G03.787|ES| 7:1 19:1 43:1 113:1 131:1 207:1 658:1 677:1 827:1 832:1 890:1 1307:1 1890:1 1946:1 2013:1 2121:1 2428:1 2834:1
4 	|BT| (S (NP (PRP$ Our) (JJ previous) (NN study)) (VP (VBD demonstrated) (SBAR (S (NP (NP (JJ garlic) (NN oil)) (PRN (-LRB- -LRB-) (NP (NN GO)) (-RRB- -RRB-))) (VP (MD could) (VP (VB prevent) (NP (JJ NDEA-induced) (NN hepatocarcinogenesis) (NN rat)) (, ,) (NP (NP (VBG underlying) (NN mechanism)) (VP (ADVP (RB fully)) (VBN understood))))))))) |ET| |BS|239:F02.463.188.357 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 131:1 162:1 435:1 658:1 733:1 849:1 889:1 900:1 908:1 979:1 1175:1 1819:1 2614:1 2835:1 2836:1 2837:1
4 	|BT| (S (PRP$ Our) (VP (VBP result) (ADVP (RB clearly)) (VP (VBP indicate) (SBAR (S (NP (JJ sulfated) (NN polysaccharide) (NNP U.) (NN lactuca)) (VP (VBD exert) (NP (JJ marked) (NN chemoprevention) (JJ DENA-initiated) (NN hepatocarcinogenesis) (NN inhibition) (JJ abnormal) (NN cell) (NN proliferation) (NN induction) (NN apoptosis)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 253:E02.319.162 554:D02.654.442.200 803:D01.248.497.158.845 804:D09.698|ES| 19:1 89:1 94:1 101:1 103:1 299:1 658:1 736:1 870:1 900:1 1229:1 1479:1 2802:1 2838:1 2839:1 2840:1 2841:1 2842:1 2843:1 2844:1
4 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP demonstrate)) (, ,) (NP (ADVP (JJ first) (NN time)) (, ,) (NP (NP (NP (ADJP (NN elaiophylin) (JJ novel)) (NN autophagy) (NN inhibitor)) (, ,) (NP (NP (JJ significant) (NN antitumor) (NN efficacy)) (JJ single) (NP (NN agent) (NN combination) (JJ human) (JJ ovarian) (NN cancer) (NN cell)))) (, ,) (VP (VBG establishing) (NP (JJ potential) (NN treatment) (JJ ovarian) (NN cancer) (NN compound)))))))) |ET| |BS|41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 259:D12.776.395.240.150.500 322:G01.910 390:G04.299.139.399 660:D27.505.954.248 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 2:1 18:1 19:1 36:1 94:1 101:1 135:1 380:1 502:1 530:1 546:1 658:1 728:1 816:1 827:1 891:1 1081:1 1317:1 1763:1 2244:1 2304:1 2433:1 2845:1 2846:1 2847:1
4 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (SBAR (S (NP (NNP Lrat) (NNP KO) (NN mouse)) (NP (DT le) (JJ susceptible) (JJ DEN-induced) (NN hepatocarcinogenesis)) (ADVP (RB due)) (VP (VBD increased) (NP (ADJP (NP (NN retinoid) (NN signaling)) (JJR higher)) (NN expression) (NN p21)) (, ,) (SBAR (S (NP (NP (VBN accompanied) (JJ altered) (JJ hepatic) (NN level)) (JJ DEN-activating) (NN enzyme) (NNP MGMT) (NNP Lrat) (NNP KO) (NN mouse)) (ADVP (RB also)) (VP (VBP contribute) (SBAR (S (NP (VBN decreased) (NN cancer) (NN initiation)) (VP (VBD suppressed) (NP (NN liver) (NN tumor) (NN development))))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 515:C04.588.274.623 649:E01.370.225.124.200 711:D02.455.326.271.665.202.495 807:D08.811.913.555.500.800.650|ES| 2:1 5:1 7:1 18:1 19:1 35:1 47:1 52:1 101:1 115:1 170:1 195:1 202:1 249:1 307:1 450:1 637:1 658:1 693:1 836:1 838:1 899:1 900:1 1135:1 1479:1 2388:1 2573:1 2735:1 2801:1 2848:1 2849:1 2850:1 2851:1 2852:1 2853:1
4 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (SBAR (S (NP (NP (NN administration) (NN resveratrol)) (UCP (CC either) (NP (JJ early) (JJ advanced) (NN stage) (NN hepatocarcinogenesis)) (ADJP (RB equally) (JJ effective)))) (VP (VBZ involves) (NP (NP (NN activation)) (NP (JJ apoptotic) (NN pathway) (NN male) (NNP Wistar) (NN rat)))))))) |ET| |BS|39:G04.299.139.160 723:B01.050.150.900.649.865.635.505.700.900|ES| 19:1 39:1 101:1 225:1 383:1 658:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1479:1 1639:1 1673:1 1712:1 2223:1 2575:1 2603:1 2854:1
4 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (NP (NN show) (NN enzastaurin) (JJ effective) (JJ chemopreventive) (NN agent) (NN mouse) (NN model) (JJ sporadic) (NN colon) (NN cancer)) (SBAR (S (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (NN expression) (JJ proproliferative) (NN gene)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 16:C23.550.291.656 122:C14.280.383 155:G05.355.310|ES| 7:1 9:1 18:1 19:1 48:1 52:1 72:1 101:1 113:1 115:1 124:1 142:1 429:1 637:1 658:1 725:1 728:1 880:1 1639:1 1946:1 2855:1 2856:1
4 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (NP (NN cimetidine) (VBG inhibiting) (NN effect) (NN hepatocarcinogenesis)))) |ET| |BS|12:Z01.542.049 122:C14.280.383 808:D02.078.370.200|ES| 19:1 75:1 101:1 132:1 658:1 880:1 900:1 2857:1
4 	|BT| (S (NP (PRP$ Our) (NN study)) (VP (VBZ demonstrates) (NP (NP (NN inhibition) (NN cell) (NN proliferation) (NN regulation)) (SBAR (S (NP (JJ inflammatory) (NN marker)) (VP (MD may) (, ,) (ADVP (JJS least) (NN part)) (, ,) (S (VP (VBG underlying) (NP (NN mechanism) (JJ related) (NN liver) (NN tumor) (NN inhibition) (NN diosmin)))))))))) |ET| |BS|41:A11 43:F01.145.544 85:G02.111.087.225 158:D23.101 183:G04.299.233.750 515:C04.588.274.623 715:D03.383.663.283.266.450.260.222|ES| 2:1 7:1 19:1 94:1 103:1 131:1 162:1 299:1 419:1 435:1 438:1 451:1 491:1 534:1 658:1 836:1 1331:1 2430:1 2541:1 2695:1
4 	|BT| (S (NP (JJ Overall) (NN finding)) (VP (VBP substantiate) (SBAR (S (NP (NN artesunate)) (VP (VBZ promotes) (SBAR (S (NP (JJ anti-tumour) (, ,) (JJ anti-proliferation) (NN apoptosis) (NN nitrosodiethylamine)) (VP (VBD mediated) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500|ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1
4 	|BT| (SINV (S (NP (JJ Overall) (NN analysis)) (VP (VBD indicated) (SBAR (S (NP (NN pterostilbene)) (VP (VBD reduced) (NP (NN colon) (NN tumor) (NN multiplicity) (JJ non-invasive) (NN adenocarcinoma))))))) (, ,) (VP (VBD lowered) (S (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen))))) (VP (VBD downregulated) (NP (NN expression) (NN beta-catenin) (NN cyclin) (NN D1)))) |ET| |BS|23:D12.776.091.249 51:C04.588.274.476.411.307.180 84:C04.557.470.200.025 215:D12.644.360.262.150.100 696:V02.270.500 768:D12.776.660.740|ES| 2:1 7:1 19:1 60:1 94:1 113:1 115:1 255:1 426:1 452:1 661:1 743:1 744:1 1030:1 1256:1 1361:1 1541:1 2428:1 2858:1 2863:1 2864:1 2865:1
4 	|BT| (S (ADVP (RB Overall)) (, ,) (VP (VBP result) (NP (NN support) (JJ translational) (JJ potential) (NN silibinin) (JJ colorectal) (NN cancer) (NN chemoprevention)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 145:G02.111.087.675.871 253:E02.319.162 696:V02.270.500 809:L01.178.682.920|ES| 2:1 17:1 18:1 19:1 101:1 827:1 870:1 1364:1 2635:1 2858:1 2866:1
4 	|BT| (S (NP (NN Overexpression) (NN Klotho)) (VP (VBZ suppresses) (SBAR (S (NP (NN liver) (NN cancer) (NN progression)) (VP (VBZ induces) (S (NP (NN cell) (NN apoptosis)) (ADVP (RB negatively)) (VP (VBG regulating) (NP (JJ wnt/beta-catenin) (NN signaling) (NN pathway))))))))) |ET| |BS|16:C23.550.291.656 39:G04.299.139.160 41:A11 105:G02.149.115.800.925|ES| 18:1 19:1 48:1 89:1 94:1 195:1 214:1 383:1 668:1 686:1 836:1 2867:1 2868:1 2869:1 2870:1
4 	|BT| (S (NP (NN Peroxisome) (JJ proliferator-activated) (NN receptor-gamma)) (VP (VBZ contributes) (NP (JJ inhibitory) (NN effect) (NN Embelin) (NN colon) (NN carcinogenesis)))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 719:D12.776.826.239.588|ES| 19:1 75:1 113:1 207:1 845:1 1800:1 1801:1 2429:1 2587:1 2871:1
4 	|BT| (NP (NP (NP (JJ Pharmacogenetic) (NN approach) (NN capecitabine) (NN 5-fluorouracil) (NN selection)) (SBAR (S (NP (VBN combined) (NN oxaliplatin) (JJ first-line) (NN chemotherapy)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 151:E02.319 375:Z01.639.100 560:D03.383.742.698.875.404 810:D03.383.742.680.245.500.425 811:H01.158.273.343.750 812:G05.355.800|ES| 17:1 18:1 19:1 164:1 495:1 911:1 997:1 2307:1 2490:1 2543:1 2872:1 2873:1 2874:1
4 	|BT| (S (NP (NN Phyllanthus) (NN urinaria)) (VP (VBZ ameliorates) (NP (NN severity) (JJ nutritional) (FW steatohepatitis) (FW vitro) (FW vivo)))) |ET| |BS|508:C06.552.241 813:B01.650.940.800.575.100.350.622|ES| 19:1 216:1 378:1 1473:1 1791:1 2875:1 2876:1 2877:1 2878:1
4 	|BT| (S (NP (NN Polyenephosphatidylcholine)) (VP (VBZ prevents) (NP (NP (JJ alcoholic) (NN liver) (NN disease) (NN PPARalpha-null) (NN mouse) (NN attenuation) (NN increase)) (JJ oxidative) (NN stress)))) |ET| |BS|29:B01.050.050.136.500.500 536:D12.776.826.239.500 716:G03.495.710 814:C06.552.645|ES| 19:1 40:1 52:1 836:1 998:1 2522:1 2583:1 2718:1 2879:1 2880:1 2881:1 2882:1
4 	|BT| (S (NP (NP (NP (JJ Polyinosinic-polycytidylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN Poly) (NN I) (: :) (NN C)) (-RRB- -RRB-))) (NN IFN-gamma) (NN treatment)) (VP (VBD inhibited) (NP (NN liver) (NN fibrosis) (JJ pair-fed) (JJ ethanol-fed) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 122:C14.280.383 663:C16.320.565.398.500.330.500 676:C06.552.630 751:D02.033.375 815:D13.695.578.550.560.600 816:G01.358.500.505.300|ES| 10:1 14:1 19:1 52:1 104:1 365:1 546:1 836:1 949:1 1275:1 1955:1 2350:1 2883:1 2884:1 2885:1 2886:1 2887:1
4 	|BT| (NP (NP (NP (NP (NP (NP (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (: -))) (-RRB- -RRB-) (NN mouse) (JJ susceptible) (JJ DMH-induced) (NN colon) (NN carcinogenesis) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NN mouse))) (, ,) (S (NP (NN embelin)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NP (NN incidence) (NN colon) (NN cancer) (NN PPARgamma)) (PRN (-LRB- -LRB-) (NP (NP (CC +) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (: -))) (-RRB- -RRB-))) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 434:E05.318.308.985.525.375 719:D12.776.826.239.588|ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 124:1 207:1 452:1 899:1 1511:1 2588:1 2888:1 2889:1
4 	|BT| (S (NP (NNP Pravastatin)) (VP (VBZ reduces) (NP (NN lung) (NN metastasis) (NN rat) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (VBN coordinated) (NN decrease) (NN MMP) (NN expression) (NN activity))))) |ET| |BS|104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 817:D02.455.426.559.847.638.930 818:D08.811.277.656.300.480.525|ES| 19:1 115:1 142:1 295:1 303:1 304:1 328:1 399:1 596:1 806:1 849:1 2890:1 2891:1 2892:1
4 	|BT| (S (NP (JJ Preclinical) (JJ clinical) (NN investigation)) (VP (VBP demonstrate) (SBAR (S (NP (NN aspirin)) (VP (VBP inhibit) (NP (NP (JJ several) (NN type) (NN cancer) (JJ colorectal) (NN adenoma) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))))) |ET| |BS|17:C04.557.470.035 104:C04.557.470.200.025.255 122:C14.280.383 225:E05.337 670:D02.455.426.559.389.657.410.595.176|ES| 10:1 14:1 17:1 18:1 19:1 42:1 84:1 262:1 303:1 304:1 441:1 502:1 543:1 1370:1 1497:1 2487:1 2893:1
4 	|BT| (S (NP (NP (JJ Pre-operative) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (: -) (NP (VBN based) (NN chemoradiotherapy)) (ADVP (RB locally)) (VP (VBD advanced) (SBAR (S (NP (NP (JJ rectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN UICC-II/III)) (-RRB- -RRB-))) (VP (MD may) (ADVP (RB significantly)) (VP (VB reduce) (NP (JJ local) (NN tumour) (NN mass)))))))) |ET| |BS|8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404|ES| 10:1 14:1 18:1 19:1 124:1 491:1 997:1 1011:1 1985:1 1986:1 1989:1 2307:1 2308:1 2361:1 2804:1 2894:1 2895:1 2896:1 2897:1
4 	|BT| (NP (NP (NNP Prevention) (NN rat) (NN liver) (NN fibrosis) (NN carcinogenesis) (NN coffee) (NN caffeine))) |ET| |BS|33:C04.697.098 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 652:D20.215.784.249 676:C06.552.630 819:D03.132.960.175|ES| 19:1 207:1 836:1 849:1 949:1 2386:1 2898:1 2899:1
4 	|BT| (NP (NP (JJ Previous) (NN study)) (VP (VBN shown) (S (NP (NN decorin) (NN expression)) (VP (ADVP (RB significantly)) (VBD reduced) (NP (NP (JJ colorectal) (NN cancer) (NN tissue) (NN cancer) (NN cell)) (, ,) (NP (JJ genetic) (NN deletion) (NN decorin) (NN gene) (JJ sufficient) (NN cause) (JJ intestinal) (NN tumor) (NN formation) (NN mouse)) (, ,) (VP (VBG resulting) (NP (NN downregulation) (NN p21))) (, ,) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN kip1)) (-RRB- -RRB-))) (FRAG (NP (NN E-cadherin) (NN upregulation) (NN beta-catenin) (NN signaling)) (-LRB- -LSB-) (NP (NP (NN Bi)) (, ,) (NP (NN X))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 20:G03.495 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 69:G02.111.087.800 85:G02.111.087.225 98:A10 102:C04.588.274.476.411 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 549:G05.355.600.800.320 708:D12.776.395.650.750.625 820:D12.776.395.550.200.200|ES| 2:1 7:1 9:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 60:1 94:1 109:1 115:1 124:1 131:1 195:1 237:1 242:1 272:1 384:1 452:1 595:1 864:1 929:1 1059:1 1124:1 1126:1 1135:1 1373:1 1779:1 2267:1 2900:1 2901:1 2902:1 2903:1
4 	|BT| (S (S (NP (JJ Previous) (NN work)) (VP (VBD showed) (NP (NN loss) (NN TIP30)))) (, ,) (ADVP (RB also)) (VP (VBN called) (S (NP (NN CC3))) (, ,) (NP (NP (JJ putative) (NN tumor) (NN suppressor)) (, ,) (NP (VBD increased) (NN incidence) (JJ hepatocellular) (NN carcinoma) (NN mouse)) (, ,) (NP (JJ clinical) (NN sample) (JJ human) (NN HCC) (NN tissue) (JJ aberrant) (NN expression) (NN TIP30))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 98:A10 104:C04.557.470.200.025.255 206:G05.360.340.024.340.375.249 434:E05.318.308.985.525.375 445:I03.946|ES| 2:1 5:1 7:1 19:1 32:1 36:1 47:1 52:1 84:1 115:1 132:1 272:1 303:1 304:1 441:1 700:1 835:1 918:1 1511:1 1546:1 1547:1 1725:1 2900:1 2904:1 2905:1
4 	|BT| (S (NP (NNP Progastrin) (VBG targeting) (NN strategy)) (VP (VBP provide) (NP (JJ exciting) (NN prospect) (NN differentiation) (NN therapy) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 52:E02 74:G04.299.151 821:E05.318.760.500.750.500|ES| 17:1 18:1 19:1 130:1 215:1 616:1 711:1 1114:1 2906:1 2907:1 2908:1
4 	|BT| (NP (NP (JJ Protective) (NN effect) (NN dioscin) (JJ alcohol-induced) (NN liver) (NN injury))) |ET| |BS|242:A03.620 751:D02.033.375 822:D02.033|ES| 19:1 75:1 836:1 2416:1 2672:1 2909:1 2910:1
4 	|BT| (NP (NP (NN Protein) (NN kinase) (JJ potential) (JJ chemotherapeutic) (NN target) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 151:E02.319 823:D08.811.913.696.620.682.700.150.125|ES| 17:1 18:1 19:1 160:1 470:1 827:1 1762:1 2911:1
4 	|BT| (S (NP (NN Pterostilbene)) (VP (VBZ inhibits) (NP (NP (NP (JJ colorectal) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NP (NP (NN colon) (NN carcinogenesis)) (PP (IN via) (NP (NN suppression) (JJ multiple) (NN signal) (NN transduction) (NN pathway) (JJ azoxymethane-treated) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 52:E02 122:C14.280.383 126:G02.111.087.800 132:D02.172.080 824:C04.834.020|ES| 10:1 14:1 17:1 19:1 52:1 113:1 207:1 383:1 596:1 615:1 649:1 859:1 1431:1 1725:1 2453:1 2793:1 2912:1 2913:1 2914:1 2915:1
4 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (JJ objective)) (VP (VBP investigate) (SBAR (IN whether) (S (NP (NP (NN polymorphism) (JJ putative) (NN influence) (NN fluorouracil/oxaliplatin) (NN activity)) (VBN associated) (JJ clinical) (NN outcome) (NN patient)) (VP (VBD advanced) (NP (NP (JJ colorectal) (NN cancer)) (VP (VBN treated) (NP (NP (JJ first-line) (NN oxaliplatin)) (, ,) (NP (JJ folinic) (NN acid)) (, ,) (NP (NN fluorouracil) (JJ palliative) (NN chemotherapy)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 52:E02 151:E02.319 307:G05.365.795 415:F01.658.500 560:D03.383.742.698.875.404 825:D03.438.733.631.400.800.350.450 826:F01.752.609|ES| 2:1 17:1 18:1 19:1 84:1 104:1 120:1 169:1 221:1 399:1 459:1 495:1 547:1 687:1 691:1 867:1 918:1 997:1 1060:1 1099:1 1275:1 2490:1 2543:1 2916:1 2917:1 2918:1 2919:1 2920:1
4 	|BT| (NP (NP (NP (NN Ras) (NN pathway) (NN activation) (JJ hepatocellular) (NN carcinoma) (JJ anti-tumoral) (NN effect)) (NP (VBN combined) (JJ sorafenib) (NN rapamycin) (FW vivo)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 104:C04.557.470.200.025.255 827:D02.540.505.760|ES| 19:1 75:1 164:1 225:1 303:1 304:1 378:1 383:1 1775:1 2063:1 2921:1 2922:1
4 	|BT| (S (S (NP (JJ Regular) (NN aspirin) (NN use) (NN diagnosis)) (VP (VBD associated) (NP (JJR lower) (NN risk) (JJ colorectal) (JJ cancer-specific) (NN mortality)) (PP (IN among) (NP (NP (NN participant) (JJ primary) (NN tumor) (JJ overexpressed) (NN COX-2)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 0.39)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.20-0.76)))) (-RRB- -RRB-)))))) (, ,) (IN whereas) (S (NP (NN aspirin) (NN use)) (VP (VBD associated) (NP (JJR lower) (NN risk)) (PP (IN among) (NP (NP (JJ primary) (NN tumor) (JJ weak) (JJ absent) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 1.22)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.36-4.18)))) (-RRB- -RRB-))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 828:Z01.107.757.235|ES| 2:1 7:1 10:1 14:1 17:1 19:1 25:1 76:1 115:1 117:1 169:1 171:1 217:1 338:1 344:1 367:1 369:1 372:1 374:1 1037:1 1372:1 1659:1 2487:1 2508:1 2509:1 2511:1 2923:1 2924:1 2925:1 2926:1 2927:1 2928:1 2929:1 2930:1
4 	|BT| (S (NP (NNS Results)) (NP (ADJP (FW vitro) (FW vivo)) (NN bioassay)) (ADVP (RB clearly)) (VP (VBP suggest) (SBAR (S (NP (NN beta-ionone)) (VP (MD could) (VP (VBD developed) (NP (NN prevention) (NN treatment) (NN colon) (NN cancer)))))))) |ET| |BS|52:E02 106:E05.091|ES| 18:1 19:1 113:1 216:1 378:1 546:1 702:1 796:1 908:1 1165:1 1474:1 2838:1 2931:1 2932:1
4 	|BT| (FRAG (NP (NNS RESULTS)) (: :) (NP (NP (NN Liver) (NN tumor) (NN mass)) (NP (NP (NP (JJR lower) (NN pravastatin) (NN group)) (PRN (-LRB- -LRB-) (NP (NN PG)) (-RRB- -RRB-))) (NP (NP (NP (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NN CG)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN estimated) (NN number) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR <) (NP (CD 0.004)))) (-RRB- -RRB-))) (NP (NP (NN liver) (NN weight/body) (NN weight) (NN ratio)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (NP (QP (JJR <) (CD 0.04)))) (-RRB- -RRB-))))))) |ET| |BS|242:A03.620 515:C04.588.274.623 616:E05.318.780.074 653:C23.888.144 817:D02.455.426.559.847.638.930 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 104:1 117:1 289:1 312:1 646:1 710:1 836:1 2300:1 2399:1 2721:1 2804:1 2933:1 2934:1 2935:1 2936:1 2937:1 2938:1 2939:1 2940:1 2941:1
4 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN Silibinin) (NN feeding)) (VP (VBD showed) (NP (NP (ADJP (NP (JJ dose-dependent) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)) (JJR stronger)) (NN efficacy) (NN pretreatment)) (CC versus) (NP (NN posttreatment) (NNS regimen))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 532:E02.183|ES| 19:1 78:1 104:1 113:1 132:1 295:1 710:1 1881:1 1983:1 2304:1 2531:1 2533:1 2824:1 2942:1 2943:1 2944:1 2945:1
4 	|BT| (S (NP (NNP Resveratrol)) (VP (VBZ interferes) (NP (NP (JJ N-nitrosodiethylamine-induced) (JJ hepatocellular) (NN carcinoma)) (JJ early) (JJ advanced) (NN stage) (JJ male) (JJ Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900|ES| 19:1 303:1 304:1 849:1 997:1 1128:1 1129:1 1402:1 2603:1 2946:1 2947:1 2948:1
4 	|BT| (S (S (NP (NN Rimonabant)) (VP (VBZ inhibits) (NP (JJ human) (NN colon) (NN cancer) (NN cell) (NN growth)))) (VP (VBZ reduces) (NP (NN formation) (JJ precancerous) (NN lesion) (NN mouse) (NN colon)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 341:C04.834|ES| 18:1 19:1 36:1 43:1 52:1 94:1 102:1 113:1 142:1 615:1 1130:1 1131:1 2949:1
4 	|BT| (NP (NP (NN Role) (NN Fas/FasL) (NN pathway) (NN combination) (NN therapy) (NN interferon-alpha) (NN fluorouracil) (JJ hepatocellular) (NN carcinoma) (NN vitro))) |ET| |BS|15:F01.829.316.616 104:C04.557.470.200.025.255 356:D12.644.276.374.440.890.250 560:D03.383.742.698.875.404 618:E02.186|ES| 19:1 130:1 216:1 303:1 304:1 383:1 530:1 1198:1 2187:1 2919:1 2950:1
4 	|BT| (NP (NP (NNP Saffron)) (: :) (NP (JJ potential) (NN candidate) (JJ novel) (JJ anticancer) (NN drug) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|67:D26 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 701:B01.650.940.800.575.100.549.500|ES| 19:1 104:1 191:1 303:1 304:1 827:1 891:1 1243:1 1880:1 2951:1
4 	|BT| (NP (NP (NNP Sesamin)) (, ,) (NP (JJ lipid-soluble) (NN lignan)) (, ,) (S (NP (CD one) (NN agent)) (VP (VBZ belongs) (NP (SBAR (S (NP (NP (NN class) (NNS phytoestrogens)) (, ,) (NP (NP (VBN isolated) (NN sesame)) (PRN (-LRB- -LRB-) (NP (NN Sesamum) (NN indicum)) (-RRB- -RRB-))) (, ,)) (VP (VBN linked) (NP (NN prevention) (NN hyperlipidemia))))) (, ,) (NP (NP (NN hypertension)) (, ,) (NP (NN carcinogenesis) (JJ unknown) (NN mechanism))))))) |ET| |BS|33:C04.697.098 621:D02.455.426.559.389.140.450 659:D10 766:C18.452.584.500.500 830:B01.650.940.800.575.100.583.690.750 831:D27.505.696.399.472.277.540.500 832:C14.907.489|ES| 2:1 10:1 14:1 19:1 162:1 207:1 728:1 1010:1 1363:1 1474:1 1653:1 2182:1 2313:1 2692:1 2814:1 2952:1 2953:1 2954:1 2955:1 2956:1 2957:1 2958:1 2959:1
4 	|BT| (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3) (JJ molecular) (NN therapy) (JJ non-small-cell) (NN lung) (NN cancer))) |ET| |BS|52:E02 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 375:Z01.639.100|ES| 18:1 19:1 130:1 161:1 327:1 328:1 487:1 860:1 861:1 862:1 2960:1
4 	|BT| (S (NP (NN Simvastatin)) (VP (VP (VBZ induces) (NP (NN apoptosis) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft))) (, ,) (VP (VBZ attenuates) (NP (JJ colitis-associated) (NN colon) (NN cancer) (NN mouse))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 41:A11 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 754:D02.455.426.559.847.638.400.900|ES| 2:1 7:1 18:1 19:1 36:1 52:1 89:1 94:1 113:1 214:1 265:1 410:1 2423:1 2961:1
4 	|BT| (S (NP (NN Sodium) (NN alginate)) (VP (VBZ prevents) (NP (NN progression) (JJ non-alcoholic) (NN steatohepatitis) (NN liver) (NN carcinogenesis) (JJ obese) (JJ diabetic) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 33:C04.697.098 242:A03.620 509:C06.552.241.519 564:C18.654.726.500|ES| 19:1 48:1 52:1 207:1 836:1 1791:1 2069:1 2468:1 2718:1 2962:1 2963:1 2964:1
4 	|BT| (S (NP (NN Sulindac) (NNS NSAIDs)) (VP (ADVP (RB widely)) (NP (VBN studied) (NP (JJ potential) (JJ chemopreventive) (NN agent) (NN colon) (NN cancer))))) |ET| |BS|251:D02.455.426.559.847.486.875 796:D27.505.696.663.850.014.040.500 833:D27.505.696.706.018|ES| 18:1 19:1 113:1 401:1 728:1 827:1 1946:1 2369:1 2965:1 2966:1
4 	|BT| (S (NP (NP (NN Supplementation) (JJ branched-chain) (NN amino) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN BCAA)) (-RRB- -RRB-))) (VP (VBZ reduces) (NP (NP (NN risk) (NN liver) (NN cancer) (JJ cirrhotic) (NN patient)) (NP (JJ obese) (, ,) (NP (JJ associated) (NN improvement) (NN insulin) (NN resistance)))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500|ES| 2:1 10:1 14:1 18:1 19:1 120:1 142:1 169:1 171:1 836:1 1094:1 1275:1 2189:1 2359:1 2360:1 2364:1 2468:1 2967:1 2968:1 2969:1
4 	|BT| (S (NP (NP (NP (NN Suppression) (JJ early) (NN stage) (JJ neoplastic) (NN transformation)) (JJ two-stage) (NN chemical) (NN hepatocarcinogenesis) (NN model)) (: :) (S (NP (NP (NN supplementation) (NN vanadium)) (, ,) (NP (JJ dietary) (NN micronutrient)) (, ,) (NP (NN limit) (NN cell) (NN proliferation))) (VP (VBZ inhibits) (NP (NP (NN formation) (NN 8-hydroxy-2)) ('' ')))) (: -)) (VP (NNS deoxyguanosines) (NP (NN DNA) (NNS strand-breaks) (NN liver) (JJ sprague-dawley) (NN rat)))) |ET| |BS|20:G03.495 32:C04.697.098.500 122:C14.280.383 183:G04.299.233.750 242:A03.620 595:G07.203.650.240 769:B01.050.150.900.649.865.635.505.700.750 834:D27.505.696.377.605.555 835:D27.505.696.377.605 836:G05.355.180.210 837:D01.268.556.920 838:E05.599.495|ES| 2:1 19:1 43:1 72:1 94:1 104:1 299:1 615:1 666:1 836:1 849:1 893:1 900:1 1128:1 1129:1 1384:1 2124:1 2567:1 2594:1 2797:1 2970:1 2971:1 2972:1 2973:1 2974:1 2975:1 2976:1
4 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (NP (VBN indicated) (NN nifuroxazide)) (VP (MD could) (VP (ADVP (RB effectively)) (VB inhibit) (NP (NN tumor) (NN metastasis)) (S (VP (VBG mediating) (NP (NP (NN Stat3)) (NN pathway))))))) (VP (MD might) (NP (JJ therapeutic) (JJ potential) (NN treatment) (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383|ES| 2:1 7:1 19:1 101:1 245:1 383:1 541:1 546:1 761:1 798:1 806:1 827:1 908:1 1370:1 1537:1 1538:1 1541:1 2646:1 2820:1 2977:1
4 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP provide) (SBAR (S (NP (NP (NN evidence) (NN plant) (NN flavonoid) (NN fisetin)) (VP (VBP induce) (NP (NN apoptosis)))) (VP (VBP suppress) (NP (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN inhibition) (NN COX2)) (: -) (NP (NN Wnt/EGFR/NF-kappaB-signaling) (NN pathway)))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 43:F01.145.544 45:G07.700.320.249 147:G02.149.115.800.925 210:D12.776.260.600 328:B01.650 534:D03.383.663.283.266.450|ES| 2:1 18:1 19:1 38:1 89:1 94:1 102:1 103:1 113:1 243:1 383:1 711:1 1098:1 1537:1 1538:1 1886:1 2441:1 2978:1 2979:1 2980:1
4 	|BT| (S (NP (VBN Targeted) (NN disruption) (JJ Nemo-like) (NN kinase)) (VP (VBZ inhibits) (NP (NN tumor) (NN cell) (NN growth) (JJ simultaneous) (NN suppression) (NN cyclin) (NN D1) (NN CDK2) (JJ human) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|8:C04 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 122:C14.280.383 215:D12.644.360.262.150.100 469:D08.811.913.696|ES| 7:1 19:1 36:1 94:1 102:1 303:1 304:1 470:1 615:1 743:1 744:1 1602:1 2453:1 2981:1 2982:1 2983:1 2984:1
4 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP investigate) (NP (NP (NP (NP (JJ molecular) (NN mechanism) (JJ chemopreventive) (NN effect)) (JJ folic) (NN acid) (NN tributyrin)) (ADVP (RB alone))) (NN combination) (NN rat) (NN hepatocarcinogenesis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 624:D27.505.696.706.018 839:D03.438.733.631.400|ES| 19:1 75:1 131:1 161:1 162:1 241:1 459:1 530:1 691:1 849:1 900:1 1275:1 1567:1 1946:1 2985:1 2986:1
4 	|BT| (S (NP (DT The) (NN cyclooxygenase-2) (-LRB- -LRB-) (NN COX-2) (-RRB- -RRB-) (NN inhibitor) (NN celecoxib)) (VP (VBN approved) (NP (NP (NN drug) (NN clinic) (NN colon) (NN cancer) (NN chemoprevention)) (VP (VBN tested) (NP (NP (JJ chemopreventive) (JJ therapeutic) (NN efficacy)) (JJ various) (JJ clinical) (NN trial)))))) |ET| |BS|12:Z01.542.049 52:E02 67:D26 253:E02.319.162 349:D27.505.519.389.310.500 683:D27.505.519.389.310 684:D02.065.884.247 840:E01.789.800 841:E05.318.760.250.500 842:N02.278.035|ES| 10:1 14:1 18:1 19:1 61:1 76:1 84:1 113:1 191:1 380:1 541:1 691:1 870:1 1096:1 1946:1 2304:1 2343:1 2807:1 2987:1 2988:1 2989:1
4 	|BT| (S (NP (DT The) (NNS data)) (VP (VBP provide) (NP (JJ additional) (NN evidence) (JJ potential) (NN use) (NN roxithromycin) (NN treatment) (JJ hepatocellular) (NN carcinoma) (NN prevention)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 843:D02.540.576.500.992.630|ES| 19:1 38:1 303:1 304:1 546:1 691:1 711:1 793:1 827:1 980:1 1474:1 1659:1 2990:1
4 	|BT| (NP (NP (NP (DT The) (JJ Dual) (NN Inhibition) (NN RNA) (NN Pol)) (SBAR (S (NP (PRP I)) (NP (NN Transcription) (NNP PIM) (NN Kinase) (NNP New) (JJ Therapeutic) (NNP Approach) (NNP Treat) (NNP Advanced) (NNP Prostate) (NNP Cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 52:E02 209:G02.111.087.847 844:D08.811.913.696.445.735.270.750|ES| 19:1 469:1 515:1 691:1 1197:1 1412:1 1919:1 2280:1 2350:1 2703:1 2991:1 2992:1 2993:1 2994:1 2995:1 2996:1 2997:1
4 	|BT| (S (NP (DT The) (JJ oncogenic) (NN kinase) (NN inhibitor) (NN sorafenib)) (ADVP (RB significantly)) (VP (VB prolong) (SBAR (S (NP (JJ median) (NN survival) (NN patient)) (VP (VBD advanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (, ,) (SBAR (IN although) (S (NP (NN response) (JJ disease-stabilizing) (JJ cytostatic)) (NP (QP (RB rather) (CD one)) (NN tumor) (NN regression))))))))) |ET| |BS|8:C04 50:M01.643 96:I03.784 104:C04.557.470.200.025.255 279:D27.888.569.100 288:C23.550.288 469:D08.811.913.696 845:D27.888.569.199 846:F01.393.784|ES| 2:1 7:1 10:1 14:1 19:1 120:1 124:1 274:1 303:1 304:1 380:1 441:1 470:1 494:1 691:1 953:1 997:1 1010:1 1170:1 1592:1 2063:1 2998:1 2999:1 3000:1 3001:1 3002:1
4 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ allows) (SBAR (S (NP (NN u)) (VP (VBP conclude) (SBAR (S (NP (JJ diosmin) (JJ dietary) (NN supplement)) (, ,) (VP (MD could) (VP (VBN used) (S (NP (JJ chemopreventive) (NN agent)) (VP (VBP prevent) (NP (NN hepatocarcinogenesis))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 557:D02.241.081.069.600.150 715:D03.383.663.283.266.450.260.222 847:G07.203.300.456|ES| 2:1 19:1 131:1 476:1 691:1 728:1 733:1 900:1 908:1 1307:1 1946:1 1968:1 2243:1 2594:1 2695:1 3003:1 3004:1
4 	|BT| (NP (NP (NP (DT The) (JJ present) (NN study) (NN offer) (NN strategy) (JJ novel) (NN CUR) (NN analogue)) (, ,) (PRN (-LRB- -LRB-) (NP (NN 1E) (CD ,4) (NN E)) (-RRB- -RRB-)) (NP (NP (NP (NN -1,5-bis) (-LRB- -LRB-) (NN 2-bromophenyl) (-RRB- -RRB-) (NN penta-1,4-dien-3-one)) (PRN (-LRB- -LRB-) (NP (NN GL63)) (-RRB- -RRB-))) (, ,) (NP (VBN used) (JJ potential) (NP (NP (JJ therapeutic) (NN agent) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (ADVP (FW vitro) (FW vivo))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 131:1 216:1 303:1 304:1 378:1 441:1 476:1 541:1 691:1 728:1 827:1 891:1 1042:1 1114:1 1307:1 1380:1 3005:1 3006:1 3007:1 3008:1 3009:1 3010:1
4 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VBP investigate) (FRAG (NP (NP (JJ chemopreventive) (NN action) (JJ possible) (NN mechanism) (NN saffron) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN liver) (NN cancer) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 701:B01.650.940.800.575.100.549.500|ES| 10:1 14:1 18:1 19:1 162:1 409:1 459:1 691:1 836:1 849:1 1359:1 1497:1 1875:1 1946:1 1952:1 2013:1 2523:1 3011:1
4 	|BT| (S (NP (DT The) (NN purpose) (NN study)) (VP (VBP evaluate) (NP (NP (NP (JJ anticancer) (NN potency) (NN mechanism) (JJ novel) (NN difluorodiarylidenyl) (NN piperidone)) (PRN (-LRB- -LRB-) (NP (NN H-4073)) (-RRB- -RRB-))) (S (NP (NP (NN N-hydroxypyrroline) (NN modification)) (PRN (-LRB- -LRB-) (NP (NN HO-3867)) (-RRB- -RRB-))) (NP (JJ human) (JJ ovarian) (NN cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 179:D01.248.497.300.459.700 225:E05.337 259:D12.776.395.240.150.500 848:D03.383.621.808|ES| 10:1 14:1 18:1 19:1 36:1 131:1 162:1 691:1 890:1 891:1 1763:1 1880:1 2374:1 2796:1 3011:1 3012:1 3013:1 3014:1 3015:1 3016:1
4 	|BT| (NP (NP (NP (DT The) (NN rate) (NN proliferation) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN reduced) (JJ treated) (NN gamma-secretase) (NN inhibitor) (NN dibenzazepine)) (VP (VBP inhibit) (NP (NP (NN Notch) (NN signaling) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD directed) (NP (NN Notch))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 117:D13.150.650.700 122:C14.280.383 125:D08.811.277.656.300.032 212:E01.370.225.500.385.500 792:A11.251.210.190.475|ES| 18:1 19:1 36:1 41:1 94:1 113:1 195:1 256:1 299:1 380:1 452:1 515:1 691:1 750:1 1099:1 1370:1 1866:1 3017:1 3018:1 3019:1 3020:1
4 	|BT| (S (NP (DT The) (NN result)) (VP (VBD indicated) (SBAR (S (NP (NN 6-MSITC)) (VP (VBD exerted) (NP (NP (NP (JJ chemopreventive) (NN effect)) (JJ present) (JJ short-term) (NN colon) (NN carcinogenesis) (NN bioassay)) (, ,) (NP (NP (NN alteration) (NN cell) (NN proliferation) (NN activity) (NN drug)) (VP (VBG metabolizing) (NP (NN enzyme) (NN level)))))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 67:D26 106:E05.091 212:E01.370.225.500.385.500 624:D27.505.696.706.018 649:E01.370.225.124.200 849:G08.686.785.760.769.490.500|ES| 2:1 19:1 75:1 94:1 101:1 113:1 191:1 207:1 249:1 299:1 399:1 691:1 951:1 1307:1 1541:1 1946:1 2102:1 2388:1 2931:1 3021:1 3022:1 3023:1
4 	|BT| (S (NP (DT The) (JJ selective) (NN EGFR) (NN inhibitor) (NN Gefitinib)) (VP (VBD found) (S (VP (VBP prevent) (NP (NN hepatocarcinogenesis) (NN rat) (JJ cirrhotic) (NN liver)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 19:1 37:1 187:1 380:1 691:1 733:1 836:1 849:1 900:1 1749:1 2968:1 3024:1
4 	|BT| (S (NP (DT The) (NN study)) (VP (VBD suggested) (SBAR (S (NP (NN HO-3867)) (VP (MD may) (NP (NP (JJ useful) (JJ safe) (JJ effective) (JJ anticancer) (NN agent)) (JJ ovarian) (NN cancer) (NN therapy))))))) |ET| |BS|52:E02|ES| 18:1 19:1 130:1 131:1 491:1 691:1 728:1 925:1 1036:1 1639:1 1763:1 1880:1 2737:1 3016:1
4 	|BT| (S (NP (DT The) (JJ sulfated) (NN polysaccharide) (NNP U.) (NN lactuca)) (VP (MD may) (SBAR (S (NP (JJ unique) (NN property) (VBG providing) (NN protection) (JJ DENA-induced) (JJ oxidative) (NN stress)) (VP (MD could) (VP (VB contribute) (NP (NN chemoprevention) (JJ experimental) (NN hepatocarcinogenesis)))))))) |ET| |BS|253:E02.319.162 554:D02.654.442.200 716:G03.495.710 803:D01.248.497.158.845 804:D09.698|ES| 19:1 263:1 450:1 491:1 691:1 841:1 870:1 900:1 908:1 1469:1 2522:1 2583:1 2734:1 2839:1 2840:1 2841:1 2842:1 3025:1 3026:1
4 	|BT| (S (NP (DT The) (NN theme) (NN study)) (VP (VBP evaluate) (SBAR (S (NP (JJ therapeutic) (NN efficacy)) (VP (VBD nanoencapsulated) (FRAG (NP (JJ flavonoidal) (NN quercetin)) (-LRB- -LRB-) (NP (NP (NP (CD 3,5,7,3) ('' ') (NN ,4)) ('' ') (PRN (: -) (NP (NP (NN pentahydroxy) (NN flavone)) (, ,) (NP (NN QC))) (-RRB- -RRB-))) (S (VP (VBG combating) (NP (JJ DEN-induced) (NN hepatocarcinogenesis) (NN rat))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 533:D03.383.663.283.266.450.284.777 850:D03.383.663.283.266.450.260 851:J01.897.608|ES| 2:1 10:1 14:1 19:1 131:1 541:1 691:1 849:1 890:1 900:1 1884:1 2304:1 2735:1 3027:1 3028:1 3029:1 3030:1 3031:1 3032:1 3033:1
4 	|BT| (NP (NP (JJ Therapeutic) (NN effect) (JJ multi-targeted) (NN imidazolium) (NN compound) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255|ES| 19:1 75:1 303:1 304:1 2433:1 2993:1 3034:1 3035:1
4 	|BT| (S (NP (NP (NN Therapy)) (VP (VBG targeting) (NP (NN Vav3) (NN combination) (NN docetaxel)))) (VP (MD may) (NP (JJ practical) (NN implication) (NN managing) (JJ castration-resistant) (NN prostate) (NN cancer)))) |ET| |BS|618:E02.186 852:C04.588.945.440.770.500|ES| 18:1 19:1 77:1 85:1 491:1 530:1 616:1 3036:1 3037:1 3038:1 3039:1 3040:1 3041:1
4 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (JJ genetic) (NN amplification) (NN TYMS) (JJ major) (NN mechanism) (NN 5-FU) (NN resistance)) (PP (FW vivo) (NP (NP (JJ important) (NN implication) (NN management) (JJ colorectal) (NN cancer) (NN patient)) (JJ recurrent) (NN disease)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 288:C23.550.288 392:G05.355.315.250 496:C23.550.291.937 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 853:N04.590.607|ES| 17:1 18:1 19:1 85:1 120:1 162:1 378:1 462:1 792:1 793:1 796:1 864:1 902:1 921:1 998:1 1094:1 1753:1 2308:1 3042:1 3043:1
4 	|BT| (NP (DT These) (VBG finding) (S (VP (VBP confirm) (NP (NN hypothesis) (NN ODC) (NN polymorphism) (JJ genetic) (NN marker) (NN colon) (NN cancer) (NN risk))) (, ,) (NP (NP (NP (NN support) (NN use) (NN ODC) (NN inhibitor) (NN aspirin)) (, ,) (NP (NP (JJ nonsteroidal) (JJ antiinflammatory) (NN drug)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))) (, ,)) (NN combination) (NN strategy) (NN colon) (NN cancer) (NN prevention)))) |ET| |BS|61:E05.318.740.600.800 149:G05.360.340.024.340.364.875.890 158:D23.101 307:G05.365.795 670:D02.455.426.559.389.657.410.595.176 796:D27.505.696.663.850.014.040.500|ES| 2:1 10:1 14:1 18:1 19:1 113:1 171:1 191:1 380:1 530:1 534:1 792:1 864:1 927:1 1060:1 1114:1 1364:1 1474:1 1659:1 2477:1 2487:1 2697:1 2966:1 3044:1 3045:1 3046:1
4 	|BT| (PP (DT These) (S (VP (VBG finding) (S (VP (VBP suggest) (SBAR (S (NP (NN sulindac)) (VP (MD may) (NP (NP (JJ effective) (NN agent) (NN colon) (NN cancer) (NN prevention)) (NP (JJ human) (JJ low) (NN 15-PGDH)))))))) (, ,) (S (NP (NN use)) (MD may) (ADVP (RB also)) (VP (VBN associated) (NP (JJ inflammatory) (NN lesion) (NN colon))))))) |ET| |BS|46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 251:D02.455.426.559.847.486.875|ES| 2:1 5:1 18:1 19:1 36:1 113:1 133:1 169:1 491:1 531:1 728:1 792:1 796:1 869:1 927:1 1131:1 1474:1 1639:1 1659:1 2430:1
4 	|BT| (NP (NP (DT These) (NN observation) (NN show)) (, ,) (NP (JJ first) (NN time)) (, ,) (S (NP (NP (NN CP-31398) (NN posse) (JJ significant) (JJ dose-dependent) (JJ chemopreventive) (NN activity)) (JJ well-established) (NN colon) (NN cancer) (NN model) (NN combination) (JJ low-dose) (NN CP-31398) (NN celecoxib)) (ADVP (RB significantly)) (VP (VBD enhanced) (NP (NN colon) (NN cancer) (JJ chemopreventive) (NN efficacy))))) |ET| |BS|322:G01.910 429:N04.761.559.590.900 430:E05.581.249 684:D02.065.884.247|ES| 2:1 18:1 19:1 72:1 113:1 124:1 135:1 385:1 399:1 429:1 530:1 792:1 816:1 1081:1 1477:1 1770:1 1946:1 2304:1 2807:1 2824:1 3047:1 3048:1 3049:1
4 	|BT| (S (NP (DT These)) (VP (VBP result) (ADVP (RB also)) (VP (VBP support) (NP (NN role) (NNP BMX) (JJ potential) (NN drug) (NN candidate) (NN use) (NN combination) (NN cisplatin) (NN treatment) (JJ human) (NN lung) (NN cancer))))) |ET| |BS|15:F01.829.316.616 52:E02 55:B01.050.150.900.649.801.400.112.400.400 67:D26 375:Z01.639.100 498:D01.210.375|ES| 5:1 18:1 19:1 31:1 36:1 101:1 191:1 328:1 530:1 546:1 792:1 827:1 1243:1 1364:1 1659:1 1761:1 3050:1
4 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VP (VBP indicate) (SBAR (S (NP (NP (NN chitin)) (, ,) (NP (NN chitosan) (JJ related) (NN compound))) (VP (VBP exert) (NP (NP (JJ unequivocal) (JJ chemopreventive) (NN effect)) (NP (JJ heterocyclic) (JJ amine-induced) (NN hepatocarcinogenesis))))))) (, ,) (SBAR (S (NP (NN effect) (NN organ)) (VP (MD may) (SBAR (S (NP (NN tissue) (JJ specific) (JJ possible) (JJ inhibitory) (NN action) (JJ mammary) (NN gland)) (VP (VBD offset) (NP (NN promotion) (NN colon) (NN lesion) (NN development))))))))))) |ET| |BS|46:A03.556.124.526.356 98:A10 609:A01.236.249 624:D27.505.696.706.018 854:D05.750.078.139.500 855:D05.750.078.139 856:D02.092|ES| 2:1 19:1 35:1 75:1 101:1 113:1 272:1 419:1 491:1 540:1 592:1 792:1 900:1 1131:1 1359:1 1382:1 1479:1 1946:1 2013:1 2248:1 2337:1 2429:1 2433:1 2843:1 3051:1 3052:1 3053:1 3054:1 3055:1 3056:1
4 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NNP Valerian) (VP (VBP exhibit) (S (NP (JJ inhibitory) (NN effect) (NN rat) (NN hepatocarcinogenesis)) (VP (VBG inhibiting) (NP (JJ oxidative) (NN DNA) (NN damage)))) (, ,) (S (VP (VBG suppressing) (NP (NP (NN cell) (NN proliferation)) (VP (VBG inducing) (NP (NP (NP (NN apoptosis) (NN GST-P)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN focus) (VBG activating) (NN GABA) (-LRB- -LRB-) (NN A) (-RRB- -RRB-) (JJ R-mediated) (NN signaling)))))))))))) |ET| |BS|39:G04.299.139.160 69:G02.111.087.800 122:C14.280.383 175:J01.897.280.500.269 183:G04.299.233.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 526:G05.355.180 599:M01.526.799.500 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 859:D02.241.081.114.500.350|ES| 2:1 10:1 14:1 19:1 69:1 75:1 89:1 94:1 101:1 195:1 299:1 587:1 666:1 792:1 849:1 880:1 900:1 1431:1 1479:1 1848:1 1864:1 1958:1 2250:1 2429:1 2583:1 3057:1 3058:1 3059:1 3060:1 3061:1
4 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP provide) (SBAR (S (NP (JJ preclinical) (NN evidence)) (VP (VBP continue) (NP (NP (NN development) (NN alantolactone) (NN STAT3) (NN inhibitor)) (JJ potential) (JJ therapeutic) (NN agent) (NN breast) (NN cancer)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 82:D12.644.360.024.342.300|ES| 18:1 19:1 23:1 35:1 38:1 101:1 251:1 380:1 541:1 711:1 728:1 792:1 827:1 1494:1 2686:1 3062:1
4 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (NP (NN show) (NN Cx32) (NN luteolin) (JJ suppressive) (NN role)) (NN inflammation) (, ,) (NN fibrosis) (NN hepatocarcinogenesis) (NN NASH) (NN progression)) (, ,) (S (VP (VBG suggesting) (NP (JJ potential) (JJ therapeutic) (NN application) (NNP NASH)))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 52:E02 525:C23.550.470 691:C23.550.355 704:D03.383.663.283.266.450.260.555|ES| 2:1 19:1 31:1 48:1 101:1 165:1 429:1 541:1 792:1 827:1 900:1 949:1 1009:1 1974:1 2547:1 3063:1 3064:1 3065:1
4 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN simvastatin)) (VP (MD could) (NP (NP (JJ potential) (JJ chemopreventive) (JJ therapeutic) (NN agent)) (NP (NP (NNP CAC)) (NP (ADVP (RB well)) (NP (ADJP (FW de) (FW novo)) (NN colon) (NN cancer))))))))))) |ET| |BS|52:E02 754:D02.455.426.559.847.638.400.900 860:Z01.107.567.875.500.200 861:Z01.542.315|ES| 18:1 19:1 101:1 113:1 541:1 728:1 787:1 792:1 796:1 827:1 908:1 1946:1 2679:1 3066:1 3067:1 3068:1
4 	|BT| (S (NP (NNS Thiazolidinediones)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (NN hepatitis) (NN B) (JJ virus-transgenic) (NN mouse) (NN peroxisome) (JJ proliferator-activated) (NN receptor) (JJ gamma-independent) (NN regulation) (NN nucleophosmin)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 99:B01.050.050.136.500 122:C14.280.383 142:I01.880.604 719:D12.776.826.239.588 862:D02.886.675.933 863:B04.280.375.650.425|ES| 19:1 52:1 186:1 438:1 763:1 900:1 1370:1 1801:1 1887:1 2048:1 3069:1 3070:1 3071:1 3072:1
4 	|BT| (S (NP (NN Thioredoxin) (NN reductase) (CD 1)) (VP (VBZ protects) (VP (ADVP (RB chemically)) (VBN induced) (NN hepatocarcinogenesis) (PP (IN via) (NP (NN control) (JJ cellular) (NN redox) (NN homeostasis)))))) |ET| |BS|41:A11 152:G07.700.345 864:D08.811.682.667.750.500 865:G02.149.767.650|ES| 19:1 96:1 98:1 289:1 412:1 500:1 596:1 900:1 1863:1 2581:1 3073:1 3074:1 3075:1
4 	|BT| (S (ADVP (RB Thus)) (, ,) (VP (VBP result) (NP (NN support) (JJ future) (NN utilization) (NN decorin) (NN antitumor) (NN agent) (NN liver) (NN cancer)))) |ET| |BS|354:I01.320 375:Z01.639.100 660:D27.505.954.248 708:D12.776.395.650.750.625|ES| 2:1 18:1 19:1 101:1 728:1 836:1 1190:1 1364:1 1691:1 2244:1 2901:1 3076:1
4 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN PKCbetaII) (JJ important) (NN target) (NN colon) (NN cancer) (NN chemoprevention) (JJ PKCbeta-selective) (NN inhibitor) (NN enzastaurin)) (VP (MD may) (VP (VB represent) (NP (NP (JJ effective) (JJ chemopreventive) (NN agent) (NN patient)) (JJ high) (NN risk) (NN colon) (NN cancer))))) |ET| |BS|12:Z01.542.049 61:E05.318.740.600.800 253:E02.319.162 866:D08.811.913.696.620.682.700.725.049 867:D08.811.913.696.620.682.700.725.049 868:M01.380.600|ES| 2:1 18:1 19:1 113:1 120:1 160:1 171:1 178:1 380:1 491:1 728:1 799:1 870:1 902:1 1639:1 1691:1 1946:1 2855:1 3077:1 3078:1
4 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NP (NN combination) (NN As2O3) (NN Ad-PML) (JJ synergistic) (JJ inhibitory) (NN effect)) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (, ,) (S (VP (ADVP (RB possibly)) (VBG resulting) (NP (NN regulation) (JJ apoptotic) (NN gene) (NN expression)))) (VP (VBD enhanced) (NP (NNP HCC) (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255 140:G05.355.315|ES| 2:1 9:1 10:1 14:1 19:1 75:1 89:1 115:1 303:1 304:1 384:1 385:1 438:1 441:1 530:1 1548:1 1691:1 2012:1 2223:1 2429:1 3079:1 3080:1
4 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN study)) (VP (VBP show) (NP (JJ myrtenal) (NN ability) (VBP suppress) (JJ hepatocellular) (NN carcinoma) (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 385:F02.784.629.131|ES| 2:1 19:1 131:1 303:1 304:1 429:1 849:1 1300:1 1691:1 2441:1 2682:1
4 	|BT| (NP (NP (NNP Thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NN dihydropyrimidine) (NN dehydrogenase) (NN expression)) (, ,) (NP (JJ histological) (NN tumour) (NN regression) (JJ 5-FU-based) (JJ neo-adjuvant) (JJ chemoradiotherapy) (JJ rectal) (NN cancer))) |ET| |BS|8:C04 333:D01.045 560:D03.383.742.698.875.404 561:E02.186.079.500 713:D08.811.913.555.500.862 846:F01.393.784 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350|ES| 2:1 18:1 19:1 66:1 115:1 1011:1 1986:1 1987:1 1988:1 1989:1 3002:1 3081:1 3082:1 3083:1 3084:1 3085:1 3086:1
4 	|BT| (S (NP (NNP Thymoquinone)) (VP (VBZ reduces) (SBAR (S (NP (NN mouse) (NN colon) (NN tumor) (NN cell) (NN invasion)) (VP (VBZ inhibits) (NP (NN tumor) (NN growth) (JJ murine) (NN colon) (NN cancer) (NN model))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 51:C04.588.274.476.411.307.180 122:C14.280.383|ES| 7:1 18:1 19:1 52:1 72:1 94:1 102:1 113:1 142:1 615:1 620:1 627:1 3087:1
4 	|BT| (NP (NP (S (VP (TO To) (ADVP (RBR better)) (VP (VB understand) (NP (NP (JJ anticancer) (NN activity) (NNP Levamisole)) (PRN (-LRB- -LRB-) (NP (NNP LMS)) (-RRB- -RRB-)))))) (, ,) (NP (NP (NN serf) (JJ adjuvant) (NN colon) (NN cancer) (NN therapy) (NN combination) (NN 5-Fluorouracil)) (, ,) (NP (NP (NN study) (NN analysis) (NNP LMS) (POS ')) (NN ability)) (S (VP (VBP induce) (NP (NP (NN apoptosis) (NN growth) (NN arrest)) (NP (VBN cultured) (JJ human) (JJ micro) (: -) (NP (JJ macrovascular) (JJ endothelial) (NN cell) (PRN (-LRB- -LRB-) (NP (NNS ECs)) (-RRB- -RRB-)) (NN fibroblast))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 239:F02.463.188.357 385:F02.784.629.131 560:D03.383.742.698.875.404 618:E02.186 685:D27.505.696.477.067 687:D26.650.064 871:D02.886.675.346 872:A11.329.228 873:A11.436.275|ES| 2:1 10:1 14:1 18:1 19:1 36:1 89:1 94:1 102:1 113:1 130:1 131:1 243:1 399:1 530:1 602:1 661:1 828:1 829:1 882:1 904:1 1232:1 1300:1 1489:1 1880:1 2213:1 2404:1 2479:1 3088:1 3089:1 3090:1 3091:1 3092:1 3093:1
4 	|BT| (S (S (VP (TO To) (VP (VB improve) (NP (JJ clinical) (NN outcome))))) (, ,) (NP (NN investigation) (JJ potential) (NN bortezomib) (NN therapy) (NN thyroid) (NN cancer)) (ADVP (RB clearly)) (VP (VBD warranted))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 225:E05.337 675:D01.029.260.110.500|ES| 2:1 18:1 19:1 84:1 130:1 547:1 827:1 828:1 969:1 1497:1 2466:1 2816:1 2838:1 3094:1
4 	|BT| (S (VP (ADVP (RB Together)) (, ,) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NN silibinin)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN SW480) (NN tumor)) (VP (VBG carrying) (NP (JJ mutant) (NN APC) (NN gene) (NN down-regulating) (NN CDK8) (NN beta-catenin) (NN signaling)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (NP (JJ effective) (NN agent) (NN CRC))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 247:G01.374.676.530 351:A17.360|ES| 2:1 7:1 9:1 11:1 19:1 60:1 102:1 195:1 218:1 245:1 615:1 728:1 796:1 811:1 850:1 908:1 927:1 1639:1 2635:1 3095:1 3096:1 3097:1 3098:1
4 	|BT| (S (NP (NN Tongue) (NN cancer) (NN prevention) (NN study)) (VP (VBD conducted) (NP (NP (JJ zinc-deficient) (NN rat)) (NP (ADJP (RB previously) (VBN exposed)) (NN tongue) (NN carcinogen) (NN celecoxib) (NN treatment))) (VP (PP (IN without) (NP (NN zinc) (NN replenishment))) (, ,) (NP (NP (NN zinc) (NN replenishment)) (ADVP (RB alone)))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 684:D02.065.884.247 874:D01.268.556.940 875:A03.556.500.885 876:F01.145|ES| 2:1 18:1 19:1 131:1 241:1 546:1 849:1 1195:1 1474:1 1527:1 2125:1 2807:1 3099:1 3100:1 3101:1 3102:1 3103:1 3104:1 3105:1
4 	|BT| (S (NP (NP (NP (NN Treatment) (NN mouse) (NN EGFR-inhibitor)) (PRN (-LRB- -LRB-) (NP (NN EGFRi)) (-RRB- -RRB-))) (, ,) (NP (NN Canertinib)) (, ,)) (VP (VBP 1h) (ADJP (JJ post-APAP)) (VP (VBD resulted) (NP (NP (JJ robust) (NN inhibition) (NN EGFR-activation) (JJ striking) (NN reduction)) (JJ APAP-induced) (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 52:E02 242:A03.620 661:D02.065.199.092.040 877:N03.540.571.608|ES| 2:1 10:1 14:1 19:1 52:1 103:1 370:1 594:1 836:1 2416:1 3106:1 3107:1 3108:1 3109:1 3110:1 3111:1 3112:1 3113:1 3114:1 3115:1
4 	|BT| (S (NP (NN Troglitazone)) (VP (VBZ inhibits) (NP (NN tumor) (NN growth) (JJ hepatocellular) (NN carcinoma)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|8:C04 45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383|ES| 7:1 19:1 102:1 216:1 303:1 304:1 378:1 615:1 3116:1
4 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (JJ Antidiabetic) (NNS thiazolidinediones)) (PRN (-LRB- -LRB-) (NP (NN TZD)) (-RRB- -RRB-))) (PP (FW vitro) (NP (NP (JJ antiproliferative) (NN effect) (JJ epithelial) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|104:C04.557.470.200.025.255 862:D02.886.675.933 878:D27.505.696.422|ES| 2:1 10:1 14:1 18:1 19:1 75:1 104:1 127:1 216:1 303:1 304:1 441:1 561:1 2266:1 3117:1 3118:1 3119:1 3120:1
4 	|BT| (NP (NP (NP (NP (JJ Ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (NP (NP (JJ known) (NN suppressor) (JJ cholestatic) (NN liver) (NN disease)) (JJ colorectal) (NN cancer) (NN development)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 650:C06.552 737:D04.808.105.225.272.962 879:C06.130.120.135|ES| 10:1 14:1 17:1 18:1 19:1 35:1 556:1 700:1 836:1 998:1 1275:1 2631:1 3121:1 3122:1
4 	|BT| (S (NP (NN Valerian)) (VP (VBZ inhibits) (NP (NP (NP (NN rat) (NN hepatocarcinogenesis) (VBG activating) (NN GABA)) (PRN (-LRB- -LRB-) (NP (NN A)) (-RRB- -RRB-))) (NP (JJ receptor-mediated) (NN signaling))))) |ET| |BS|69:G02.111.087.800 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 880:D12.776.157.530.400.175.562|ES| 10:1 14:1 19:1 69:1 195:1 615:1 849:1 900:1 1958:1 3057:1 3060:1 3123:1
4 	|BT| (NP (NP (NN Vanadium) (JJ chemopreventive) (JJ early) (NN stage) (JJ 2-AAF-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 837:D01.268.556.920 881:D02.065.064.150|ES| 19:1 849:1 900:1 1128:1 1129:1 1946:1 3124:1 3125:1
4 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (NP (JJ possible) (NP (NP (JJ beneficial) (NN use) (NN pamidronate) (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255|ES| 10:1 14:1 19:1 303:1 304:1 441:1 546:1 843:1 984:1 1175:1 1359:1 1659:1 3126:1
4 	|BT| (S (NP (PRP We)) (VP (VBP find) (SBAR (S (JJ enzastaurin) (ADVP (RB potently)) (VP (VBZ reduces) (NP (NP (JJ azoxymethane-induced) (NN colon) (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (JJ PKCbetaII-mediated) (NN tumor) (NN cell) (NN proliferation) (NN beta-catenin) (NN accumulation))))))))) |ET| |BS|8:C04 16:C23.550.291.656 23:D12.776.091.249 51:C04.588.274.476.411.307.180 122:C14.280.383 132:D02.172.080 183:G04.299.233.750 866:D08.811.913.696.620.682.700.725.049|ES| 7:1 19:1 48:1 60:1 94:1 113:1 142:1 299:1 637:1 843:1 880:1 2120:1 2533:1 2855:1 3127:1 3128:1 3129:1
4 	|BT| (S (S (S (NP (PRP We)) (VP (VBD found) (S (VP (VBG impairing) (NP (JJ autophagy) (NNS hepatocytes)))))) (VP (MD would) (VP (VB induce) (NP (JJ oxidative) (NN stress) (NN DNA) (NN damage))))) (, ,) (NP (VBD followed) (NN initiation) (NN hepatocarcinogenesis)) (, ,) (VP (MD could) (VP (VBD suppressed) (NP (NN antioxidant) (NN N-acetylcysteine))))) |ET| |BS|262:A11.436.348 390:G04.299.139.399 526:G05.355.180 700:D27.505.519.217 716:G03.495.710 791:D02.886.030.230.259|ES| 2:1 19:1 37:1 243:1 307:1 637:1 666:1 775:1 843:1 866:1 894:1 900:1 908:1 1317:1 1848:1 2521:1 2522:1 2583:1 3130:1 3131:1
4 	|BT| (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD demonstrated) (NP (NP (NP (JJ total) (NNP Astragalus) (NN saponin)) (PRN (-LRB- -LRB-) (NP (NNP AST)) (-RRB- -RRB-))) (NN posse) (JJ anticarcinogenic) (JJ proapoptotic) (NN property) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft)))) |ET| |BS|8:C04 41:A11 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780 882:D09.408.782|ES| 7:1 10:1 14:1 18:1 19:1 36:1 94:1 113:1 265:1 333:1 772:1 841:1 843:1 1175:1 1885:1 2493:1 3048:1 3132:1 3133:1 3134:1
4 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBN shown) (SBAR (S (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (VP (VBD prevented) (SBAR (S (NP (JJ AOM-induced) (NN colon) (NN cancer)) (VP (VBD suppressed) (NP (NN Cox-2) (NN induction)))))))))) |ET| |BS|132:D02.172.080 737:D04.808.105.225.272.962|ES| 5:1 10:1 14:1 18:1 19:1 62:1 113:1 237:1 307:1 736:1 843:1 1275:1 1944:1 2630:1 2631:1 3135:1
4 	|BT| (S (NP (PRP We)) (VP (VBD shown) (SBAR (S (NP (NP (JJ dietary) (NN fish) (NN oil) (NN pectin)) (PRN (-LRB- -LRB-) (NP (NN FP)) (-RRB- -RRB-))) (VP (VBZ protects) (NP (NP (JJ radiation-enhanced) (NN colon) (NN cancer)) (VP (VBG upregulating) (NP (NN apoptosis) (JJ colonic) (NN mucosa))))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 46:A03.556.124.526.356 281:E02.815 302:A10.615.550 489:B01.050.150.900.493 595:G07.203.650.240 883:D10.212.302.380 884:Z01.639.760.815 885:G01.358.500.505 886:D10.627.430 887:G01.750|ES| 10:1 14:1 18:1 19:1 89:1 113:1 237:1 579:1 677:1 843:1 1863:1 2594:1 2614:1 3136:1 3137:1 3138:1 3139:1 3140:1
4 	|BT| (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (S (NP (NP (NN NF-kappaB) (NN suppression) (JJ novel) (NN inhibitor) (NN dimethylaminoparthenolide)) (PRN (-LRB- -LRB-) (NP (NN DMAPT)) (-RRB- -RRB-))) (VP (MD may) (VP (VB enhance) (NP (NN effect) (NN gemcitabine) (JJ pancreatic) (NN cancer)))))))) |ET| |BS|210:D12.776.260.600 259:D12.776.395.240.150.500|ES| 10:1 14:1 18:1 19:1 75:1 380:1 467:1 491:1 714:1 843:1 891:1 1690:1 2453:1 2504:1 2505:1 3141:1 3142:1
4 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (NP (JJ significant) (NN reduction) (NN number) (NN size) (JJ small) (JJ intestinal) (NN polyp) (NN APC)) (PRN (-LRB- -LRB-) (NP (NP (NN min)) (CC +) (: /) (: -)) (-RRB- -RRB-))) (NN mouse) (VBN treated) (CC either) (NP (NP (NP (NP (NN celecoxib)) (PRN (-LRB- -LRB-) (NP (JJ selective) (NN COX-2) (NN inhibitor)) (-RRB- -RRB-))) (NN erlotinib)) (PRN (-LRB- -LRB-) (NP (NP (NN Tarceva)) (, ,) (NP (NN EGFR) (NN inhibitor))) (-RRB- -RRB-)))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 52:E02 193:C23.300.825.411 349:D27.505.519.389.310.500 684:D02.065.884.247 888:D03.438.786.375|ES| 2:1 10:1 11:1 14:1 19:1 39:1 52:1 76:1 109:1 135:1 187:1 261:1 370:1 380:1 646:1 647:1 750:1 843:1 1099:1 1749:1 2142:1 2342:1 2807:1 3143:1 3144:1
4 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NN embelin)) (VP (VBZ inhibits) (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN vitro))))) (, ,) (VP (ADVP (RB effectively)) (VBZ suppresses) (NP (JJ 1,2-dimethylhydrazine) (JJ dihydrochloride-induced) (NN colon) (NN carcinogenesis) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383|ES| 2:1 18:1 19:1 52:1 94:1 102:1 113:1 132:1 207:1 216:1 615:1 686:1 843:1 1527:1 2642:1 2889:1 2977:1 3145:1
4 	|BT| (S (NP (PRP We)) (VP (VP (VBP propose) (SBAR (S (NP (JJ estrogen-mediated) (NN inhibition) (NN IL-6) (NN production) (NNS KCs)) (VP (VBZ reduces) (NP (NP (NN liver) (NN cancer) (NN risk) (NN female)) (, ,) (NP (NP (NN finding)) (VP (MD may) (VP (VBN used))))))))) (VP (VBP prevent) (NP (NN HCC) (NN male))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 61:E05.318.740.600.800 104:C04.557.470.200.025.255 201:D12.644.276.374.465.224 889:D27.505.696.399.472.277|ES| 2:1 18:1 19:1 103:1 142:1 171:1 441:1 476:1 491:1 733:1 836:1 843:1 927:1 1402:1 1404:1 2677:1 3146:1 3147:1 3148:1 3149:1
4 	|BT| (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ autophagy) (VBN involved) (JJ NAC1-mediated) (NN resistance) (NN cisplatin)) (, ,) (NP (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN drug) (NN treatment) (JJ ovarian) (NN cancer))))) |ET| |BS|52:E02 67:D26 151:E02.319 390:G04.299.139.399 498:D01.210.375|ES| 2:1 15:1 18:1 19:1 191:1 417:1 476:1 546:1 774:1 843:1 1094:1 1317:1 1760:1 1761:1 1762:1 1763:1
4 	|BT| (S (NP (PRP We)) (VP (VBD studied) (NP (NP (NN mechanism) (VBG underlying) (NN inhibition) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NN lycopene) (NN rat)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 10:1 14:1 19:1 103:1 162:1 401:1 409:1 435:1 843:1 849:1 900:1 1875:1 1952:1 2566:1
4 	|BT| (S (NP (PRP We)) (VP (VBP suggest) (SBAR (S (NP (NN fisetin)) (VP (MD could) (NP (JJ useful) (NN agent) (NN prevention) (NN treatment) (NN colon) (NN cancer))))))) |ET| |BS|52:E02|ES| 18:1 19:1 113:1 546:1 728:1 796:1 843:1 908:1 1036:1 1474:1 2978:1
4 	|BT| (S (NP (NP (NNP Zerumbone)) (, ,) (NP (JJ tropical) (NN ginger) (NN sesquiterpene)) (, ,)) (VP (VBZ inhibits) (NP (NN colon) (NN lung) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 182:A04.411 762:D02.455.849.765 890:B01.650.940.800.575.100.975.900.444|ES| 2:1 19:1 52:1 113:1 207:1 328:1 615:1 2687:1 3150:1 3151:1 3152:1
5 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (NP (NN Androgen) (NN effect) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (VP (VBP remain) (SBAR (S (NP (JJ controversial) (NN androgen) (NN ablation) (NN therapy) (NN treat) (NNP HCC)) (ADVP (RB also)) (VP (VBP lead) (NP (JJ inconsistent) (NN result)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 86:D01.268.556.435 104:C04.557.470.200.025.255 891:D27.505.696.399.472.161 892:D27.505.696.399.472.161|ES| 5:1 10:1 14:1 19:1 75:1 91:1 101:1 104:1 130:1 254:1 303:1 304:1 441:1 1046:1 1090:1 1777:1 1778:1 1852:1 2181:1 3153:1 3154:1 3155:1
5 	|BT| (NP (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (NP (NP (NP (NN Chromodomain) (NN helicase/adenosine) (NN triphosphatase) (NN DNA) (NN binding) (NN protein)) (NP (ADJP (JJ 1-like) (-LRB- -LRB-) (NN CHD1L) (-RRB- -RRB-) (JJ SNF2-like)) (NN transcription) (NN factor))) (VP (VBN involved) (S (VP (NN development) (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|14:F01.525 104:C04.557.470.200.025.255 166:D12.776.930 893:D08.811.277.040.025 894:D08.811.277.040.025|ES| 4:1 10:1 14:1 19:1 35:1 36:1 104:1 185:1 303:1 304:1 441:1 487:1 666:1 774:1 1046:1 1487:1 1777:1 1778:1 3156:1 3157:1 3158:1 3159:1 3160:1 3161:1
5 	|BT| (NP (NP (NN BACKGROUND)) (: :) (S (NP (PRP It)) (VP (VBD suggested) (NP (NP (JJ altered) (NN iron) (NN metabolism) (NN liver) (NN tumor)) (, ,) (NP (VBN characterized) (JJ iron-deficient) (NN phenotype)) (, ,) (NP (NN importance) (NN tumor) (NN growth)))))) |ET| |BS|8:C04 45:G07.700.320.249 80:G05.695 515:C04.588.274.623 895:D01.490.600 896:D01.268.556.412 897:Z01.252.245.500.375 898:G03.495|ES| 2:1 7:1 19:1 102:1 104:1 236:1 693:1 836:1 925:1 985:1 1046:1 1327:1 1660:1 3162:1 3163:1 3164:1
5 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (DT The) (NP (NN ErbB2/Her2/Neu) (NN receptor) (NN tyrosine) (NN kinase))) (VP (VBD amplified) (NP (ADJP (QP (RB approximately) (CD 30)) (NN %)) (JJ human) (NN breast) (NN cancer))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400|ES| 18:1 19:1 23:1 36:1 104:1 186:1 369:1 470:1 691:1 1046:1 1520:1 1843:1 2208:1 2341:1 3165:1
5 	|BT| (NP (NP (NP (NP (NN Dehydroepiandrosterone)) (PRN (-LRB- -LRB-) (NP (NN DHEA)) (-RRB- -RRB-))) (, ,) (NP (JJ major) (NN precursor) (NN androgen) (NN estrogen)) (, ,)) (NP (NP (JJ several) (JJ beneficial) (NN effect) (JJ immune) (NN system)) (, ,) (NP (NN memory) (NN function)) (, ,) (S (VP (VBG modulating) (NP (NP (NN effect) (NN diabetes)) (, ,) (NP (NN obesity)) (, ,) (NP (NN chemical) (NN carcinogenesis))))))) |ET| |BS|33:C04.697.098 564:C18.654.726.500 726:C18.452.394.750 740:D04.808.054.079.429.625 889:D27.505.696.399.472.277 892:D27.505.696.399.472.161 899:F02.463.425.540 900:A15.382|ES| 2:1 10:1 14:1 19:1 33:1 75:1 207:1 262:1 462:1 593:1 984:1 2009:1 2010:1 2124:1 2435:1 2633:1 3154:1 3166:1 3167:1 3168:1 3169:1 3170:1
5 	|BT| (NP (NP (NP (NP (JJ Dimethylarsinic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN DMA)) (-RRB- -RRB-))) (JJ major) (NN metabolite) (JJ inorganic) (JJ arsenical)) (, ,) (NP (ADJP (RB epidemiologically) (JJ significant)) (NN chemical) (NN relation) (NN liver) (NN cancer) (NN mammal))) |ET| |BS|901:B01.050.150.900.649 902:D02.691.088.100 903:D01.075|ES| 2:1 10:1 14:1 18:1 19:1 135:1 462:1 836:1 1275:1 1678:1 2124:1 3171:1 3172:1 3173:1 3174:1 3175:1 3176:1 3177:1
5 	|BT| (NP (NP (NP (NN Ethanol) (NN consumption) (NN cause) (JJ serious) (NN liver) (NN injury)) (PP (VBG including) (NP (NN cirrhosis) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|73:N05.715.350.200 104:C04.557.470.200.025.255 242:A03.620 357:C06.552.630 662:C23.550.355 904:F01.145.317.269|ES| 19:1 303:1 304:1 561:1 836:1 1199:1 1779:1 2387:1 2416:1 3178:1 3179:1
5 	|BT| (S (NP (NP (NP (NN Expression) (NN cyclooxygenase)) (PRN (-LRB- -LRB-) (NP (NN COX)) (-RRB- -RRB-))) (CD -2) (NN protein) (NN rat) (NN hepatocarcinogenesis)) (VP (VBN associated) (NP (NP (JJ fatty) (NN change)) (, ,) (NP (NN fibrosis)) (, ,)) (NP (NP (NN cirrhosis) (JJ oxidative) (NN DNA) (NN damage)) (, ,) (VP (VBD caused) (SBAR (S (NP (ADJP (ADJP (JJ choline-deficient)) (, ,) (ADJP (ADJP (NN L-amino) (JJ acid-defined)) (PRN (-LRB- -LRB-) (ADJP (JJ CDAA)) (-RRB- -RRB-)))) (NN diet)) (VP (VBD investigated) (NP (NP (NN F344) (JJ male) (NN rat)) (, ,) (PP (IN along) (NP (NP (JJ chemopreventive) (NN efficacy) (JJ specific) (NN COX-2) (NN inhibitor)) (, ,) (NP (NP (NN nimesulide)) (PRN (-LRB- -LRB-) (NP (NN NIM)) (-RRB- -RRB-))))))))))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 349:D27.505.519.389.310.500 357:C06.552.630 526:G05.355.180 590:B01.050.050.199.520.760.200 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125 662:C23.550.355 691:C23.550.355|ES| 2:1 4:1 10:1 14:1 19:1 76:1 169:1 200:1 316:1 380:1 403:1 540:1 666:1 849:1 900:1 949:1 1199:1 1402:1 1848:1 1946:1 2070:1 2188:1 2190:1 2191:1 2304:1 2506:1 2583:1 2666:1 3180:1 3181:1 3182:1 3183:1 3184:1 3185:1 3186:1 3187:1
5 	|BT| (NP (NP (NNP Hepatitis) (NN B) (NN virus) (-LRB- -LRB-) (NN HBV) (-RRB- -RRB-) (: -)) (NP (VBN induced) (NN hepatitis) (NP (NP (JJ carcinogen-induced) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (JJ associated) (NN serum) (NN androgen) (NN concentration)))) |ET| |BS|104:C04.557.470.200.025.255 279:D27.888.569.100 782:A12.207.152.846 863:B04.280.375.650.425 892:D27.505.696.399.472.161 905:F02.830.104.214|ES| 10:1 14:1 19:1 169:1 303:1 304:1 409:1 441:1 763:1 1422:1 1954:1 2048:1 2421:1 2741:1 3154:1 3188:1 3189:1
5 	|BT| (S (PP (IN In) (NP (NN line) (NN observation))) (, ,) (NP (JJR lower) (NN serum) (NN level) (JJ active) (NN Caspase-3)) (VP (VBD found) (SBAR (S (NP (NN patient) (JJ metastasised) (NN CRC)) (VP (VBD revealed) (NP (NP (JJ stable) (NN disease) (NN tumour) (NN regression)) (VBN compared) (NN disease) (NN progression))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 50:M01.643 288:C23.550.288 429:N04.761.559.590.900 430:E05.581.249 782:A12.207.152.846 846:F01.393.784 906:D08.811.277.656.262.500.126.350.300|ES| 2:1 19:1 37:1 48:1 50:1 117:1 120:1 197:1 244:1 245:1 249:1 264:1 275:1 360:1 998:1 1011:1 1477:1 2741:1 3002:1 3190:1 3191:1
5 	|BT| (S (PP (IN In) (NP (NN order))) (VB clarify) (SBAR (IN whether) (S (NP (NP (JJ peroxisomal) (NN hydrogen) (NN peroxide)) (PRN (-LRB- -LRB-) (NP (NN H2O2)) (-RRB- -RRB-))) (VP (VBP play) (NP (JJ important) (NN role) (NN peroxisome) (JJ proliferator-induced) (NN hepatocarcinogenesis))))) (, ,) (NP (VBN examined) (NN change) (NN metabolism) (JJ peroxisomal) (NN H2O2)) (ADVP (FW vivo) (FW vitro)) (VP (VBG using) (NP (NP (JJ male) (NN Fischer-344) (NN rat) (NN fed) (NN clofibrate)) (, ,) (NP (NP (JJ bezafibrate) (FW di)) (PRN (-LRB- -LRB-) (NP (NN 2-ethylhexyl)) (-RRB- -RRB-))) (NP (NP (NN phthalate)) (PRN (-LRB- -LRB-) (NP (NN DEHP)) (-RRB- -RRB-)))) (NP (CD 78) (NN week)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 479:G08.686.157.500 590:B01.050.050.199.520.760.200 663:C16.320.565.398.500.330.500 898:G03.495 907:D01.248.497.158.685.750.424 908:A11.284.430.214.190.500.585.600 909:D02.065.277.067 910:D02.241.081.114.968.500.500.195 911:D02.241.223.805.250 912:D27.888.569.100.675|ES| 2:1 10:1 14:1 19:1 31:1 200:1 216:1 221:1 238:1 244:1 324:1 350:1 378:1 783:1 849:1 900:1 902:1 1402:1 1887:1 2426:1 3163:1 3192:1 3193:1 3194:1 3195:1 3196:1 3197:1 3198:1 3199:1 3200:1 3201:1 3202:1 3203:1 3204:1 3205:1 3206:1
5 	|BT| (S (S (VP (VBG Mounting) (NP (NN evidence)))) (VP (VBP underline) (NP (NP (NP (NP (NP (NP (NN role) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-))) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (NN development)) (, ,) (NP (JJ functional) (NN interaction) (NN pathway))) (VP (VBN involved) (NP (NNP HCC) (NN progression)))) (VP (VBP remain) (ADJP (JJ uninvestigated))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 22:D08.811.682.664.500.772.500 104:C04.557.470.200.025.255|ES| 2:1 10:1 14:1 19:1 31:1 35:1 38:1 48:1 63:1 64:1 65:1 66:1 67:1 303:1 304:1 383:1 415:1 441:1 618:1 774:1 2181:1 3207:1 3208:1 3209:1
5 	|BT| (S (NP (NNP Sorafenib) (NN increase) (NN survival) (NN rate) (NN patient)) (VP (VBD advanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 779:E05.318.308.985.550.900|ES| 10:1 14:1 19:1 40:1 41:1 120:1 274:1 303:1 304:1 441:1 997:1 3210:1
5 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN ADAM9)) (VP (VBZ contributes) (NP (NN pathogenesis) (NN prostate) (NN cancer)) (ADVP (RB potentially)) (ADVP (RB also)) (NP (NN carcinoma)) (, ,) (S (VP (VBG raising) (SBAR (S (NP (NN possibility) (NN ADAM9)) (VP (MD might) (NP (JJ good) (NN target) (NN antitumor) (NN drug))))))))))))) |ET| |BS|265:C04.557.470.200 369:E02.319.300|ES| 2:1 5:1 18:1 19:1 77:1 101:1 160:1 191:1 304:1 343:1 501:1 773:1 796:1 798:1 845:1 1318:1 1537:1 1538:1 2244:1 3211:1 3212:1
5 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VB evaluate) (NP (NP (JJ possible) (NN influence) (NN mixture) (NN pesticide) (JJ medium-term) (NN carcinogenesis)) (VP (VBG using) (NP (VBN improved) (NN hepatocarcinogenesis) (NN protocol)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 225:E05.337 826:F01.752.609 849:G08.686.785.760.769.490.500 913:D27.720.031.700 914:L01.178|ES| 19:1 207:1 350:1 691:1 867:1 890:1 900:1 1359:1 1497:1 2410:1 3011:1 3213:1 3214:1 3215:1 3216:1
5 	|BT| (S (NP (EX There)) (VP (VBG increasing) (NP (NN interest) (NP (NP (NNS phytoestrogens) (JJ potential) (JJ alternative) (JJ synthetic) (JJ selective) (NN estrogen) (NN receptor) (NNS modulators)) (PRN (-LRB- -LRB-) (NP (NNS SERMs)) (-RRB- -RRB-))) (NN prevention) (NN therapy) (NN breast) (NN cancer)))) |ET| |BS|52:E02 375:Z01.639.100 831:D27.505.696.399.472.277.540.500 915:D06.347.360.827|ES| 10:1 14:1 18:1 19:1 23:1 130:1 186:1 715:1 827:1 1474:1 1749:1 2311:1 2671:1 2955:1 3168:1 3217:1 3218:1 3219:1 3220:1
5 	|BT| (NP (NP (S (VP (TO To) (VP (VB clarify) (S (VP (VBG modifying) (NP (NP (NN effect) (NN N-Acetyl-L-Cysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (JJ antioxidative) (NN ability)) (, ,) (NP (NN hepatocarcinogenesis)) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN fenofibrate)) (PRN (-LRB- -LRB-) (NP (NN FF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PPAR)) (-RRB- -RRB-))) (NN alpha)) (NP (NN agonist))) (, ,) (NP (NP (JJ male) (NN F344/N) (NN rat)) (VP (VBN administered) (NP (NP (NP (ADJP (JJ single) (JJ intraperitoneal)) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN initiator))))) (VP (VBD followed) (NP (NN administration) (NN diet) (VBG containing) (CD 3,000) (NN ppm) (NN FF) (CD 16) (NN week))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 385:F02.784.629.131 536:D12.776.826.239.500 554:D02.654.442.200 590:B01.050.050.199.520.760.200 596:E02.642.249 791:D02.886.030.230.259 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 916:D02.241.081.114.968.500.625 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 75:1 186:1 286:1 783:1 785:1 828:1 849:1 900:1 1300:1 1402:1 1801:1 1836:1 1875:1 1887:1 1912:1 2191:1 2336:1 2575:1 2644:1 2846:1 3130:1 3193:1 3221:1 3222:1 3223:1 3224:1 3225:1 3226:1 3227:1 3228:1 3229:1 3230:1 3231:1 3232:1 3233:1 3234:1
5 	|BT| (NP (NP (NP (NNP UNLABELLED) (: :) (NN Activation) (NN beta-catenin)) (, ,) (NP (NP (JJ central) (NN effector) (JJ canonical) (NN Wnt) (NN pathway)) (VP (VBD recognized) (NP (NP (NN oncogene)) (, ,) (NP (VBN implicated) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|9:G05.360.340.024.340.375.500 23:D12.776.091.249 104:C04.557.470.200.025.255 105:G02.149.115.800.925|ES| 2:1 19:1 24:1 60:1 87:1 104:1 303:1 304:1 383:1 570:1 877:1 977:1 2266:1 3235:1 3236:1 3237:1
5 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (JJ Antidiabetic) (NNS thiazolidinediones)) (PRN (-LRB- -LRB-) (NP (NN TZD)) (-RRB- -RRB-))) (PP (FW vitro) (NP (NP (JJ antiproliferative) (NN effect) (JJ epithelial) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|104:C04.557.470.200.025.255 862:D02.886.675.933 878:D27.505.696.422|ES| 2:1 10:1 14:1 18:1 19:1 75:1 104:1 127:1 216:1 303:1 304:1 441:1 561:1 2266:1 3117:1 3118:1 3119:1 3120:1
5 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (DT The) (NN Wnt/beta-catenin) (NN pathway)) (VP (VBN implicated) (NP (NP (NN pathogenesis) (JJ hepatocellular) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|23:D12.776.091.249 147:G02.149.115.800.925|ES| 10:1 14:1 18:1 19:1 104:1 302:1 303:1 383:1 441:1 501:1 691:1 977:1 2266:1
5 	|BT| (S (NP (NN 17-Allylamino-17-demethoxygeldanamycin)) (VP (VBZ overcomes) (NP (NN TRAIL) (NN resistance) (NN colon) (NN cancer) (NN cell) (NN line)))) |ET| |BS|94:A11.251.210|ES| 18:1 19:1 94:1 113:1 264:1 1094:1 1695:1 3238:1 3239:1
5 	|BT| (S (NP (NN 5-Lipoxygenase)) (VP (VBZ contributes) (NP (NN progression) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 918:D08.811.682.690.416.583.500.055|ES| 19:1 48:1 303:1 304:1 845:1 3240:1
5 	|BT| (S (NP (DT A) (JJ novel) (JJ CYR61-triggered) (`` `) (NN CYR61-alphavbeta3) (NN integrin) (NN loop)) ('' ') (VP (VBZ regulates) (NP (NN breast) (NN cancer) (NN cell) (NN survival) (NN chemosensitivity) (NN activation) (NN ERK1/ERK2) (NN MAPK) (NN signaling) (NN pathway)))) |ET| |BS|69:G02.111.087.800 108:G04.299.316 116:D08.811.913.696.620.682.700.567.249.750 126:G02.111.087.800 259:D12.776.395.240.150.500 573:N05.715.350.200.650 919:D08.811.913.696.620.682.700.567.249.500 920:D12.776.543.750.705.408|ES| 18:1 19:1 23:1 69:1 94:1 195:1 225:1 248:1 274:1 383:1 386:1 603:1 809:1 891:1 1489:1 3241:1 3242:1 3243:1 3244:1
5 	|BT| (NP (NP (NP (DT A) (JJ novel) (NN inhibitor) (JJ fatty) (NN acid) (NN synthase) (NN show) (NN activity) (NN HER2)) (CC +) (NP (NN breast) (NN cancer) (NN xenograft) (JJ active) (JJ anti-HER2) (JJ drug-resistant) (NN cell) (NN line)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 67:D26 92:E04.936.764 93:A01.941.875 94:A11.251.210 259:D12.776.395.240.150.500 921:D08.811.682.664.500.772 922:D10.251|ES| 18:1 19:1 23:1 66:1 69:1 94:1 197:1 264:1 265:1 380:1 399:1 429:1 891:1 1275:1 2070:1 3245:1 3246:1 3247:1
5 	|BT| (S (NP (DT A) (NP (JJ pivotal) (NN signaling) (NN network) (JJ colorectal) (NN cancer) (NN cell))) (VP (VBZ involves) (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3beta)) (PRN (-LRB- -LRB-) (NP (NN GSK3beta)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ multifunctional) (NN kinase)) (SBAR (WHNP (WP$ whose) (NN role) (NN tumor) (NN cell) (NN survival)) (S (VP (VBN defined)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 69:G02.111.087.800 108:G04.299.316 469:D08.811.913.696 588:I01.880.853.500.600|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 66:1 69:1 92:1 93:1 94:1 195:1 274:1 470:1 680:1 919:1 1673:1 1878:1 1894:1 2154:1 3248:1
5 	|BT| (S (S (NP (DT A) (JJ potential) (VBG underlying) (NN mechanism) (NN role) (NN ADAM9) (NN prostate) (NN cancer)) (VP (VBD emerged) (NP (JJ cell-based) (NN assay)))) (: :) (S (NP (NN ADAM9)) (VP (VBP cleave) (NP (NP (NN release) (JJ epidermal) (NN growth) (NN factor) (NN FGFR2iiib) (NN cell)) (, ,) (NP (JJ pivotal) (NN function) (NN pathogenesis) (NN disease)))))) |ET| |BS|15:F01.829.316.616 41:A11 106:E05.091 288:C23.550.288 333:D01.045 589:E02.204.125 923:D06.472.317.350|ES| 2:1 18:1 19:1 31:1 33:1 69:1 77:1 94:1 102:1 104:1 162:1 184:1 185:1 310:1 435:1 501:1 827:1 998:1 1113:1 2165:1 3211:1 3248:1 3249:1 3250:1 3251:1
5 	|BT| (S (NP (JJ Aberrant) (NN beta-catenin) (JJ intracellular) (NN distribution)) (VP (VBD found) (NP (NP (JJ gastric) (NP (NN cancer)) (, ,) (NP (NN pattern) (NN Wnt) (NN expression) (JJ stepwise) (NN gastrocarcinogenesis) (JJ potential) (NN influence) (NN beta-catenin) (NN distribution)) (ADJP (RB still) (JJR lesser))) (VP (VBN known))))) |ET| |BS|23:D12.776.091.249 826:F01.752.609 924:A11.284.430.214|ES| 2:1 18:1 19:1 37:1 60:1 80:1 86:1 115:1 260:1 556:1 776:1 827:1 867:1 877:1 2805:1 3252:1 3253:1 3254:1 3255:1
5 	|BT| (NP (NP (JJ Aberrant) (NN methylation) (NN histone) (NN deacetylation) (NN cyclooxygenase) (CD 2) (JJ gastric) (NN cancer))) |ET| |BS|24:D08.811.600.720.750 36:G02.111.087.029.538 399:D12.776.660.470|ES| 18:1 19:1 80:1 81:1 86:1 148:1 503:1 3180:1 3256:1
5 	|BT| (S (NP (ADJP (QP (IN About) (CD 80)) (NN %)) (JJ gastric) (NN cancer)) (VP (VBD showed) (NP (JJ high) (NN level) (NN expression) (NN cyclooxygenase) (CD 2)) (, ,) (S (NP (NN subset) (NN case)) (VP (VBP express) (PP (IN without) (NP (JJ unknown) (NN reason))))))) |ET| |BS|24:D08.811.600.720.750|ES| 2:1 18:1 19:1 86:1 115:1 132:1 148:1 178:1 208:1 249:1 369:1 573:1 934:1 1195:1 1285:1 2182:1 3180:1 3257:1 3258:1
5 	|BT| (S (NP (VBN Accelerated) (NN liver) (NN regeneration) (NN hepatocarcinogenesis) (NN mouse)) (VP (VBG overexpressing) (NP (NN serine-45) (JJ mutant) (NN beta-catenin)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 925:G10.261.326.520 926:D12.125.154.800|ES| 19:1 52:1 60:1 811:1 836:1 900:1 3259:1 3260:1 3261:1 3262:1
5 	|BT| (S (NP (NN Acylglycerol) (NN kinase)) (VP (VBZ promotes) (NP (NN cell) (NN proliferation) (NN tumorigenicity) (NN breast) (NN cancer)) (PP (IN via) (NP (NN suppression) (NN FOXO1) (NN transcription) (NN factor))))) |ET| |BS|183:G04.299.233.750 209:G02.111.087.847|ES| 18:1 19:1 23:1 94:1 185:1 298:1 299:1 300:1 470:1 487:1 596:1 2453:1 3263:1 3264:1
5 	|BT| (S (PP (IN After) (NP (JJ 2-week) (NN treatment))) (, ,) (NP (NN animal)) (VP (VBN subjected) (SBAR (`` ``) (S (NP (NP (JJ resistant) (NN hepatocyte) ('' '') (NN model) (NN hepatocarcinogenesis)) (PRN (-LRB- -LRB-) (NP (NP (NN initiation) (NN diethylnitrosamine)) (, ,) (NP (NN selection/promotion) (JJ 2-acetylaminofluorene) (JJ partial) (NN hepatectomy))) (-RRB- -RRB-))) (VP (VBD euthanized) (NP (ADJP (CD 8) (NN week)) (NN treatment))))))) |ET| |BS|19:B01.050 52:E02 262:A11.436.348 554:D02.654.442.200 812:G05.355.800 881:D02.065.064.150 927:E02.760.905.850 928:E04.210.556|ES| 2:1 10:1 14:1 19:1 46:1 72:1 427:1 546:1 637:1 781:1 783:1 900:1 1909:1 1952:1 3265:1 3266:1 3267:1 3268:1 3269:1 3270:1 3271:1 3272:1 3273:1 3274:1
5 	|BT| (S (NP (NP (NP (JJ Aldo-keto) (NN reductase) (NN family) (CD 1) (NN B10)) (PRN (-LRB- -LRB-) (NP (NN AKR1B10)) (-RRB- -RRB-))) (, ,) (NP (NN member) (JJ aldo-keto) (NN reductase) (NN superfamily)) (, ,)) (VP (VP (VBN overexpressed) (NP (JJ human) (JJ hepatocellular) (NN carcinoma))) (, ,) (NP (NN lung) (JJ squamous) (NN cell) (NN carcinoma) (NN lung) (NN adenocarcinoma)))) |ET| |BS|44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 182:A04.411 929:C04.557.470.200.400|ES| 2:1 10:1 14:1 19:1 25:1 36:1 94:1 95:1 96:1 97:1 98:1 99:1 255:1 303:1 304:1 328:1 769:1 1067:1 3275:1 3276:1 3277:1
5 	|BT| (S (NP (DT All) (NN result)) (VP (VBP suggest) (SBAR (S (NP (JJ low) (NN concentration) (NN acrylamide)) (VP (MD may) (VP (VB contribute) (NP (NP (NN progression) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 905:F02.830.104.214 930:D02.065.122.015|ES| 10:1 14:1 19:1 48:1 101:1 303:1 304:1 441:1 450:1 491:1 531:1 796:1 965:1 3189:1 3278:1
5 	|BT| (FRAG (SBAR (IN Although) (S (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (NN liver) (NN tumor)) (, ,) (NP (NN IL-22TG) (NN mouse) (JJ susceptible) (JJ diethylnitrosamine-induced) (NN liver) (NN cancer))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 554:D02.654.442.200 897:Z01.252.245.500.375 931:Z01.107.567.875.350.350 932:D12.644.276.374.465|ES| 2:1 7:1 18:1 19:1 52:1 107:1 648:1 836:1 899:1 1506:1 2732:1 3279:1
5 	|BT| (S (IN Although) (, ,) (NP (NP (NN NLK) (VBN known) (NN tumor) (NN suppressor) (NN Wnt/beta-catenin) (NN signaling) (NN pathway) (NN colon) (NN cancer)) (, ,) (NP (NN event) (VBG occurring) (NP (JJ downstream) (NN NLK) (NN pathway) (NN type) (NN cancer)))) (VP (VBP remain) (ADJP (JJ unclear)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 18:1 19:1 107:1 113:1 195:1 205:1 302:1 383:1 443:1 543:1 556:1 560:1 700:1 1737:1 2181:1 3280:1
5 	|BT| (NP (NP (PP (IN Among) (NP (NNS others))) (, ,) (NP (NN bladder) (, ,) (NN lung) (, ,) (NN colon) (, ,) (NN breast) (NN cancer) (VBN associated) (NN 4-ABP)))) |ET| |BS|46:A03.556.124.526.356 182:A04.411 933:A05.810.890|ES| 2:1 18:1 19:1 23:1 113:1 169:1 328:1 564:1 1000:1 3281:1 3282:1
5 	|BT| (NP (NP (NP (JJ Antagonistic) (NN effect) (NN selenium) (NN lipid) (NN peroxide)) (NN growth) (NN control) (JJ early) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 934:D01.248.497.158.685.750.637 935:D01.268.185.850|ES| 19:1 75:1 102:1 289:1 303:1 304:1 1128:1 2401:1 3196:1 3283:1 3284:1
5 	|BT| (NP (NP (NP (JJ Anticancer) (NN effect) (NN wogonin) (NN estrogen) (JJ receptor-positive)) (: -) (NP (JJ negative) (JJ human) (NN breast) (NN cancer) (NN cell) (NN line) (NN vitro) (JJ nude) (NN mouse) (NN xenograft)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 936:D12.776.826.750.350|ES| 18:1 19:1 23:1 36:1 52:1 75:1 94:1 216:1 264:1 265:1 266:1 2444:1 2446:1 3168:1 3285:1 3286:1
5 	|BT| (S (NP (JJ Antisense) (NP (JJ E1AF-transfected) (NN MKN45) (JJ gastric) (NN cancer) (NN cell))) (VP (VBD expressed) (NP (VBN reduced) (NN level) (NN matrilysin)) (NP (DT le) (NP (JJ invasive) (NN vitro) (JJ mock-transfected) (NN MKN45) (NN cell))))) |ET| |BS|41:A11 937:D08.811.277.656.300.480.525.700.250|ES| 6:1 18:1 19:1 86:1 94:1 144:1 216:1 249:1 452:1 489:1 2850:1 3287:1 3288:1 3289:1 3290:1
5 	|BT| (S (NP (NN Apoptosis) (JJ signal-regulating) (NN kinase) (CD 1)) (VP (VBZ inhibits) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG controlling) (NP (JJ tumor-suppressing) (NN function) (JJ stress-activated) (JJ mitogen-activated) (NN protein) (NN kinase)))))) |ET| |BS|8:C04 122:C14.280.383 478:D08.811.913.696.620.682.700.567 938:D08.811.913.696.620.682.700.559.500|ES| 4:1 19:1 33:1 98:1 470:1 615:1 900:1 2220:1 3291:1 3292:1 3293:1 3294:1 3295:1
5 	|BT| (NP (NP (NN Aspirin) (NN use) (NN survival) (NN diagnosis) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 96:I03.784 263:E01 670:D02.455.426.559.389.657.410.595.176|ES| 17:1 18:1 19:1 274:1 1037:1 1659:1 2449:1
5 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (NP (NNP Drug) (NN combination) (NN therapy)) (VP (VBG using) (NP (NP (NN cisplatin) (JJ natural) (NN product)) (JJ common) (NN practice) (NN treatment) (JJ human) (NN lung) (NN cancer))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 498:D01.210.375 793:D20.215 939:E02.319.310|ES| 18:1 19:1 36:1 104:1 130:1 328:1 350:1 530:1 546:1 655:1 675:1 1046:1 1761:1 2333:1 2345:1 3296:1
5 	|BT| (S (NP (NN BACKGROUND) (: :)) (NP (NP (JJ Epidermal) (NN growth) (NN factor) (JJ receptor-tyrosine) (NN kinase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN EGFR-TKIs)) (-RRB- -RRB-))) (VP (VBD approved) (NP (NP (NN patient)) (JJ recurrent) (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|50:M01.643 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 496:C23.550.291.937 634:D12.125.072.050.875|ES| 10:1 14:1 18:1 19:1 94:1 102:1 104:1 120:1 185:1 328:1 329:1 380:1 470:1 694:1 1046:1 1753:1 2340:1 2343:1 3297:1 3298:1
5 	|BT| (S (NP (NP (NP (NN Balb/c) (NN mouse) (VBN treated) (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN dextran) (NN sulfate) (NN sodium)) (VP (VBP induce) (NP (NN colon) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 131:D09.698.365.272.300 132:D02.172.080 940:B01.050.050.199.520.520.338|ES| 10:1 14:1 18:1 19:1 52:1 113:1 243:1 406:1 407:1 1099:1 1993:1 1994:1 3299:1 3300:1
5 	|BT| (S (NP (NP (NP (NN Beta-catenin/T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN Tcf)) (-RRB- -RRB-))) (NN signaling)) (NP (RB constitutively) (JJ active) (NN majority) (JJ human) (JJ colorectal) (NN cancer)) (, ,) (VP (VBG accompanying) (NP (NN change) (NN Bcl-2) (NN expression)))) |ET| |BS|4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800|ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1
5 	|BT| (S (NP (NN Beta-ionone)) (VP (VP (VBZ inhibits) (NP (JJ colonic) (JJ aberrant) (NN crypt) (NN focus) (NN formation) (NN rat))) (, ,) (VP (VBZ suppresses) (NP (NN cell) (NN growth))) (, ,) (VP (VBZ induces) (NP (NN retinoid) (NN X) (NN receptor-alpha) (JJ human) (NN colon) (NN cancer) (NN cell))))) |ET| |BS|20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 824:C04.834.020 941:D12.776.826.701.500.500|ES| 2:1 18:1 19:1 36:1 43:1 94:1 102:1 113:1 214:1 615:1 677:1 686:1 849:1 929:1 1431:1 1725:1 1889:1 2454:1 2573:1 2913:1
5 	|BT| (FRAG (NP (NNP Boswellia) (NNP serrata) (NN resin) (NN extract)) (VBZ alleviates) (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (: /) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN colon) (NN tumorigenesis))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080 942:D05.750.078.840.490|ES| 10:1 14:1 19:1 78:1 113:1 406:1 407:1 409:1 1993:1 1994:1 2496:1 3301:1 3302:1 3303:1 3304:1 3305:1 3306:1
5 	|BT| (S (NP (JJ Branched-chain) (NN amino) (NN acid) (-LRB- -LRB-) (NN BCAA) (-RRB- -RRB-)) (, ,) (VP (VB improve) (NP (NP (NN protein) (NN malnutrition) (NN patient) (NN liver) (NN cirrhosis)) (, ,) (S (VP (VB reduce) (NP (NN risk) (JJ hepatocellular) (NN carcinoma) (NN patient) (NN obesity))))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 564:C18.654.726.500 639:D12.125.070 943:C18.654.521.719.500|ES| 2:1 4:1 10:1 14:1 19:1 120:1 171:1 303:1 304:1 836:1 1199:1 1275:1 2010:1 2189:1 2360:1 2361:1 2465:1 2466:1 3307:1
5 	|BT| (S (NP (NP (NN Breast) (NN cancer)) (VP (VBG expressing) (NP (VBN activated) (NN HER2/neu) (JJ sensitive) (FW gefitinib) (FW vitro) (FW vivo)))) (VP (VBZ acquires) (NP (NN resistance) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 259:D12.776.395.240.150.500 438:G05.365.590.675|ES| 18:1 19:1 34:1 163:1 216:1 378:1 810:1 891:1 901:1 1094:1 2121:1 3308:1 3309:1 3310:1 3311:1
5 	|BT| (NP (NP (NP (NN BTG3) (NN tumor) (NN suppressor) (NN gene) (NN promoter) (NN demethylation)) (, ,) (NP (NN histone) (NN modification) (NN cell) (NN cycle) (NN arrest)) (NP (NN genistein) (JJ renal) (NN cancer)))) |ET| |BS|206:G05.360.340.024.340.375.249 399:D12.776.660.470 773:G04.299.134.109 944:D03.383.663.283.266.450.400.375|ES| 2:1 7:1 9:1 18:1 19:1 83:1 94:1 503:1 601:1 602:1 700:1 922:1 2374:1 3312:1 3313:1 3314:1
5 	|BT| (S (NP (NN Caveolin-1)) (VP (VBZ enhances) (NP (JJ resveratrol-mediated) (NN cytotoxicity) (NN transport) (JJ hepatocellular) (NN carcinoma) (NN model)))) |ET| |BS|104:C04.557.470.200.025.255 945:D12.644.360.024.264 946:D27.888.569.213 947:G03.495.166|ES| 19:1 72:1 303:1 304:1 1356:1 3315:1 3316:1 3317:1 3318:1
5 	|BT| (S (NP (JJ Cellular) (JJ FLICE-inhibitory) (NN protein) (NN down-regulation)) (VP (VBZ contributes) (NP (JJ celecoxib-induced) (NN apoptosis) (JJ human) (NN lung) (NN cancer) (NN cell)))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 684:D02.065.884.247 948:D12.644.360.024.296.024|ES| 4:1 18:1 19:1 36:1 89:1 94:1 257:1 328:1 845:1 3319:1 3320:1 3321:1
5 	|BT| (NP (NP (NN Characterization) (JJ nuclear) (JJ receptor-mediated) (JJ murine) (NN hepatocarcinogenesis) (NN herbicide) (NN pronamide) (JJ human) (NN relevance))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 949:D27.720.031.700.366 950:D12.776.826|ES| 19:1 36:1 627:1 900:1 1064:1 1256:1 3123:1 3322:1 3323:1 3324:1
5 	|BT| (S (NP (NNP Chitinase) (JJ 3-like) (CD 1)) (VP (VBZ promotes) (NP (NN macrophage) (NN recruitment) (NN angiogenesis) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 658:A11.329.372 951:D08.811.277.450.207|ES| 17:1 18:1 19:1 98:1 298:1 2402:1 2502:1 3325:1 3326:1 3327:1
5 	|BT| (S (NP (NNP Chlorophyllin)) (VP (VP (VBN shown) (ADVP (RB significantly)) (VP (VB reduce) (S (NP (JJ genotoxic) (NN AFB) (NNS biomarkers)) (ADJP (JJ human))))) (, ,) (ADVP (RB therefore)) (VP (VBP hold) (NP (NP (NN promise) (JJ practical) (NN mean)) (VP (VBG reducing) (NP (NN incidence) (JJ AFB-induced) (NN liver) (NN cancer))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 158:D23.101 434:E05.318.308.985.525.375|ES| 2:1 18:1 19:1 36:1 124:1 218:1 237:1 836:1 1269:1 1511:1 2215:1 2361:1 2825:1 2827:1 3039:1 3328:1 3329:1 3330:1 3331:1 3332:1
5 	|BT| (S (NP (NN Claudin-1) (NN overexpression) (JJ intestinal) (JJ epithelial) (NN cell)) (VP (VBZ enhances) (NP (NN susceptibility) (JJ adenamatous) (NN polyposis) (JJ coli-mediated) (NN colon) (NN tumorigenesis)))) |ET| |BS|3:C04.557.470.035.215.100 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 75:A11.436 401:C23.550.291.687 952:D12.776.543.984.200.100|ES| 19:1 58:1 78:1 94:1 109:1 113:1 127:1 152:1 1353:1 1356:1 3333:1 3334:1 3335:1
5 	|BT| (S (NP (NNP Coffee)) (VP (VBZ reduces) (NP (NP (NN liver) (NN damage) (NN rat) (NN model) (NN steatohepatitis)) (: :) (NP (VBG underlying) (NN mechanism) (NN role) (NNS polyphenols) (NNS melanoidins))))) |ET| |BS|15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249|ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1
5 	|BT| (FRAG (ADVP (RB Collectively)) (, ,) (NP (NP (NNS data)) (SBAR (IN along) (S (NP (JJ negative) (NN genotoxicity)) (VP (VBP demonstrate) (SBAR (S (NP (NP (NN oxyfluorfen)) (PRN (-LRB- -LRB-) (NP (ADJP (QP (JJR >) (CD 98)) (NN %)) (NN purity)) (-RRB- -RRB-))) (ADJP (JJ potential)) (VP (VBP induce) (S (NP (NN mouse) (NN liver) (NN tumor)) (ADJP (JJ nongenotoxic)))))) (, ,) (NP (NP (JJ mitogenic) (NNP MOA) (JJ clear) (NN threshold)) (VP (VBD predicted) (NP (JJ carcinogenic) (JJ human) (JJ relevant) (NN exposure) (NN level))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 515:C04.588.274.623 575:V02.050 953:D27.505.519.593.624|ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 243:1 249:1 369:1 449:1 502:1 793:1 827:1 836:1 865:1 1466:1 1872:1 1953:1 2666:1 3336:1 3337:1 3338:1 3339:1 3340:1 3341:1 3342:1 3343:1 3344:1 3345:1 3346:1
5 	|BT| (S (NP (VBN Combined) (NN lapatinib) (NN panobinostat) (NN treatment)) (VP (VBD interacted) (ADVP (RB synergistically)) (VP (VB inhibit) (NP (NP (NN proliferation) (NN colony) (NN formation) (NN CRC) (NN cell) (NN line)) (VP (VBN tested)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 94:A11.251.210 109:I01.696.116 122:C14.280.383|ES| 19:1 43:1 94:1 245:1 264:1 299:1 314:1 546:1 741:1 1370:1 2488:1 2988:1 3347:1 3348:1 3349:1
5 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (PRP$ Our) (NNS data)) (VP (VBP indicate) (SBAR (S (NP (JJ sustained) (NN LPS) (NN accumulation)) (VP (VBZ represents) (NP (JJ pathological) (NN mediator) (NP (NP (JJ inflammation-associated) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN manipulation) (NN gut) (NN flora))))))) (VP (VBP prevent) (SBAR (S (NP (JJ pathogenic) (JJ bacterial) (NN translocation) (NN endotoxin) (NN absorption)) (VP (MD may) (ADVP (RB favorably)) (VP (VB influence) (NP (NP (NN liver) (NN function) (NN patient) (NN cirrhosis) (NN risk)) (VP (VBG developing) (NP (NNP HCC))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 327:G06.930 357:C06.552.630 417:H02.403.650 662:C23.550.355 954:G06.755.375 955:G06.755.375 956:D09.400.500 957:G06.099.112.105 958:G01.595.014 959:D23.946.123.329 960:D23.469|ES| 10:1 14:1 19:1 33:1 104:1 120:1 171:1 303:1 304:1 441:1 491:1 590:1 658:1 733:1 793:1 836:1 867:1 1199:1 1426:1 1479:1 1618:1 1698:1 1847:1 1849:1 1882:1 2120:1 2516:1 3350:1 3351:1 3352:1 3353:1 3354:1 3355:1 3356:1 3357:1 3358:1
5 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NNP Bromelain)) (VP (VBZ exerts) (NP (NP (JJ antiproliferative) (JJ proapoptotic) (NN effect)) (JJ colorectal) (NN carcinoma) (NN cell) (JJ chemopreventive) (NN action) (NN colon) (NN carcinogenesis)) (FW vivo)))) |ET| |BS|5:C04.588.274.476.411.307 33:C04.697.098 41:A11 46:A03.556.124.526.356 679:D08.811.277.656.262.500.096|ES| 17:1 19:1 75:1 94:1 104:1 113:1 207:1 304:1 378:1 1882:1 1885:1 1946:1 1977:1 2013:1 3120:1 3359:1
5 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (JJ Functional) (NN interaction) (NN FOXO3a) (NN ER)) (VP (VBP play) (NP (JJ critical) (NN role)) (S (VP (VBG suppressing) (ADVP (NP (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell) (NN growth) (NN tumorigenesis)) (FW vivo))))))) |ET| |BS|15:F01.829.316.616 32:C04.697.098.500 33:C04.697.098 41:A11 45:G07.700.320.249 79:I03.450.642.693 889:D27.505.696.399.472.277|ES| 18:1 19:1 23:1 31:1 78:1 94:1 102:1 104:1 238:1 378:1 618:1 825:1 1882:1 2250:1 3360:1 3361:1 3362:1 3363:1
5 	|BT| (NP (NP (NN CONCLUSION)) (: :) (NP (NP (NNP Metformin)) (, ,) (VP (ADVP (RB generally)) (VBN considered) (S (ADJP (JJ nontoxic) (SBAR (S (ADJP (RB remarkably) (JJ inexpensive)) (, ,) (VP (MD might) (NP (VBN used) (NN combination) (NNS TKIs) (NN patient) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (, ,) (S (VP (VBG harboring) (S (NP (NN EGFR) (NN mutation)) (VP (VBP overcome) (S (NP (NN TKI) (NN resistance)) (VP (VB prolong) (NP (NN survival)))))))))))))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 96:I03.784 110:C04.588.894.797.520.109.220.249 784:D02.078.370.141.450|ES| 2:1 18:1 19:1 34:1 94:1 104:1 120:1 187:1 274:1 328:1 476:1 530:1 694:1 798:1 1061:1 1094:1 1304:1 1882:1 2746:1 2998:1 3364:1 3365:1 3366:1 3367:1 3368:1 3369:1 3370:1
5 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN garcinol)) (VP (MD may) (VP (VB merit) (S (NP (JJ clinical) (NN investigation) (NN chemoprophylactic) (NN food) (NN help)) (VP (VB prevent) (NP (JJ colitis-associated) (NN colon) (NN cancer))))))))))) |ET| |BS|53:C06.405.205.265 225:E05.337 680:G07.203.300|ES| 18:1 19:1 84:1 101:1 104:1 113:1 410:1 491:1 658:1 733:1 796:1 1497:1 1882:1 2470:1 3371:1 3372:1 3373:1 3374:1
5 	|BT| (S (NP (NN CONCLUSION) (: :)) (VP (VP (VBN Taken) (ADVP (RB together))) (, ,) (SBAR (S (NP (NNS data) (VBP show) (NN Akt) (NN inhibitor) (NN AZD5363)) (VP (VBZ synergizes) (SBAR (S (NP (JJ lysosomotropic) (NN inhibitor) (NN autophagy) (NN chloroquine)) (VP (VBP induce) (NP (NN apoptosis) (NN delay) (NN tumor) (NN progression) (NN prostate) (NN cancer) (NN model) (JJ resistant) (NN monotherapy) (NN AZD5363)) (, ,) (S (VP (VBG providing) (NP (NP (JJ new) (JJ therapeutic) (NN approach)) (RRC (ADVP (RB potentially)) (NP (JJ translatable) (NN patient)))))))))))))) |ET| |BS|8:C04 16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 50:M01.643 52:E02 202:C04.588.945.440.770 390:G04.299.139.399 961:D03.438.810.050.180|ES| 2:1 7:1 18:1 19:1 48:1 72:1 77:1 89:1 104:1 120:1 136:1 243:1 380:1 427:1 429:1 541:1 712:1 773:1 793:1 911:1 1289:1 1317:1 1537:1 1538:1 1882:1 3025:1 3375:1 3376:1 3377:1 3378:1 3379:1 3380:1
5 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT The) (NN absence) (JJ retinoid-containing) (NN HSC) (NN lipid) (NN droplet)) (VP (VBP promote) (SBAR (S (NP (NN HSC) (NN activation)) (VP (VBZ reduces) (NP (NN hepatocarcinogenesis)))))))) |ET| |BS|711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393|ES| 19:1 104:1 142:1 225:1 239:1 679:1 691:1 900:1 1534:1 2401:1 3381:1 3382:1 3383:1
5 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN Raloxifene) (JJ potent) (NN IL-6) (: /) (NN GP130) (NN inhibitor)) (VP (MD may) (VP (VB chemoprevention) (NP (NP (NN agent) (NN liver) (NN cancer)) (VP (VBG targeting) (NP (JJ persistent) (NN STAT3) (NN signaling))))))))))) |ET| |BS|69:G02.111.087.800 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 253:E02.319.162 964:D02.455.426.559.389.150.700.900.775|ES| 18:1 19:1 22:1 101:1 104:1 195:1 239:1 251:1 380:1 491:1 616:1 658:1 728:1 796:1 836:1 870:1 3384:1 3385:1 3386:1
5 	|BT| (FRAG (NP (NNS CONCLUSIONS) (: :)) (NP (NN Pitavastatin) (JJ effective) (VBG inhibiting) (NP (JJ early) (NN phase) (JJ obesity-related) (NN liver) (NN tumorigenesis))) (, ,) (ADVP (RB therefore)) (, ,) (NP (MD may) (NP (JJ useful) (NN chemoprevention) (NN liver) (NN cancer) (JJ obese) (NN individual)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 122:C14.280.383 242:A03.620 253:E02.319.162 493:M01 564:C18.654.726.500|ES| 2:1 18:1 19:1 78:1 104:1 218:1 239:1 491:1 836:1 870:1 880:1 1036:1 1128:1 1639:1 2467:1 2468:1 2512:1 2529:1 3387:1
5 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (VP (VBN Taken) (ADVP (RB together))) (, ,) (S (NP (NNS data)) (VP (VBP provide) (NP (NP (JJ first) (ADJP (FW vitro) (FW vivo)) (NN evidence) (JJ integral) (NN role)) (NP (NN LKB1-AMPK) (NN axis) (JJ honokiol-mediated) (NN inhibition) (NN invasion) (NN migration) (NN breast) (NN cancer) (NN cell)))))) |ET| |BS|15:F01.829.316.616 43:F01.145.544 579:A02.835.232.834.151.383 681:G04.299.283|ES| 2:1 18:1 19:1 23:1 31:1 38:1 94:1 103:1 104:1 216:1 239:1 378:1 514:1 620:1 711:1 793:1 816:1 1537:1 1538:1 2089:1 2269:1 3388:1 3389:1
5 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (NP (DT This) (NN study)) (VP (VBD showed) (SBAR (S (NP (NN 5-LOX)) (VP (VBD up-regulated) (NP (NP (JJ adenomatous) (NN colon) (NN polyp) (NN cancer)) (NP (VBN compared) (JJ normal) (JJ colonic) (NN mucosa)))))))) |ET| |BS|46:A03.556.124.526.356 142:I01.880.604 150:Z01.542.248.960 302:A10.615.550 548:D08.811.682.664.500.848 551:C04.557.470.035.215|ES| 18:1 19:1 50:1 57:1 104:1 113:1 118:1 131:1 132:1 239:1 579:1 647:1 677:1 807:1 1301:1 3390:1
5 	|BT| (S (NP (JJ Conditional) (NN beta-catenin) (NN loss) (NN mouse)) (VP (VBZ promotes) (NP (NP (NN chemical) (NN hepatocarcinogenesis)) (: :) (NP (NN role) (NP (ADJP (JJ oxidative) (NN stress) (JJ platelet-derived)) (NN growth) (NN factor) (NN receptor) (NN alpha/phosphoinositide) (NN 3-kinase)) (NN signaling))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 23:D12.776.091.249 69:G02.111.087.800 578:D08.811.913.696.620.550 716:G03.495.710 965:D08.811.913.696.620.682.725.400.900|ES| 19:1 31:1 32:1 52:1 60:1 102:1 104:1 185:1 186:1 195:1 298:1 900:1 2124:1 2522:1 2583:1 3391:1 3392:1 3393:1 3394:1
5 	|BT| (NP (NP (NP (JJ Consistent) (NN finding) (, ,) (JJ ABCB5-expressing) (NN tumor) (NN cell) (NN population)) (RRC (ADVP (RB also)) (NP (NN treatment) (ADJP (JJ refractory) (S (VP (VBD exhibited) (NP (NN resistance) (JJ 5-FU-induced) (NN apoptosis) (JJ colorectal) (NN cancer) (NN xenograft) (NN model) (NN 5-FU) (NN monotherapy))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 52:E02 92:E04.936.764 93:A01.941.875 175:J01.897.280.500.269 275:C23.888 560:D03.383.742.698.875.404 829:M01.686 966:N01.600|ES| 2:1 5:1 7:1 17:1 18:1 19:1 72:1 89:1 94:1 265:1 546:1 609:1 927:1 1094:1 2023:1 2308:1 3379:1 3395:1 3396:1 3397:1 3398:1
5 	|BT| (NP (NP (NP (JJ Constitutive) (NN activation) (NN phosphoinositide) (NN 3-kinase)) (PRN (-LRB- -LRB-) (NP (NN PI3K)) (-RRB- -RRB-))) (: -) (S (NP (NN Akt) (NN pathway)) (VP (VBZ transmits) (NP (NP (JJ growth-regulatory) (NN signal) (NN play) (JJ central) (NN role)) (S (VP (VBG promoting) (NP (NP (NN survival)) (, ,) (NP (NN proliferation)) (, ,) (NP (NN angiogenesis) (JJ human) (NN prostate) (NN cancer) (NN cell))))))))) |ET| |BS|15:F01.829.316.616 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 96:I03.784 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 2:1 10:1 14:1 18:1 19:1 31:1 36:1 77:1 94:1 225:1 238:1 274:1 299:1 383:1 859:1 881:1 2080:1 2502:1 3235:1 3394:1 3399:1 3400:1 3401:1 3402:1 3403:1
5 	|BT| (S (NP (JJ Constitutive) (NN activation) (NN Wnt/beta-catenin) (NN pathway)) (VP (VBN implicated) (NP (JJ primary) (NN cause) (NN colon) (NN cancer)))) |ET| |BS|23:D12.776.091.249 147:G02.149.115.800.925|ES| 18:1 19:1 113:1 225:1 302:1 344:1 383:1 977:1 1779:1 3399:1
5 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NP (JJ partial) (NN loss) (NN A20)) (, ,) (NP (NN A20) (NN heterozygote) (NN mouse)) (, ,)) (ADVP (RB significantly)) (VP (VBZ impairs) (NP (NP (NN liver) (NN regeneration) (NN damage)) (, ,) (NP (VP (VBZ confers) (NP (JJ high) (NN lethality)) (S (VP (ADVP (RB otherwise)) (NP (JJ safe) (NN procedure))))) (NP (FW i.e.) (, ,) (CD 2/3) (JJ partial) (NN hepatectomy)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 157:G05.380.383 375:Z01.639.100 925:G10.261.326.520 928:E04.210.556 967:D01.248.497.158.490|ES| 2:1 19:1 32:1 52:1 124:1 178:1 836:1 1508:1 1826:1 1848:1 2729:1 2737:1 3260:1 3272:1 3273:1 3404:1 3405:1 3406:1 3407:1 3408:1 3409:1 3410:1
5 	|BT| (S (NP (NN Cooperativity) (NN E-cadherin) (NN Smad4) (NN loss)) (VP (VBP promote) (NP (JJ diffuse-type) (JJ gastric) (NN adenocarcinoma) (NN metastasis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 70:A03.556.875.875 84:C04.557.470.200.025 113:C04.697.650 613:D12.776.395.550.200.200 968:F01.145.813.115|ES| 19:1 32:1 86:1 255:1 521:1 679:1 806:1 2267:1 3411:1 3412:1
5 	|BT| (NP (NP (NN Correlation) (NN Wnt-2) (NN expression) (NN beta-catenin) (JJ intracellular) (NN accumulation) (JJ Chinese) (JJ gastric) (NN cancer)) (: :) (NP (NN relevance) (NN tumour) (NN dissemination))) |ET| |BS|8:C04 23:D12.776.091.249 924:A11.284.430.214|ES| 18:1 19:1 60:1 86:1 104:1 115:1 795:1 1011:1 2120:1 2763:1 3252:1 3324:1 3413:1 3414:1
5 	|BT| (NP (NP (JJ Critical) (NN function) (NN ADAM9) (NN mouse) (NN prostate) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500|ES| 18:1 19:1 33:1 52:1 77:1 3211:1 3415:1
5 	|BT| (NP (NP (NN Cross-talk) (NN aryl) (NN hydrocarbon) (NN receptor) (JJ mitogen-activated) (NN protein) (NN kinase) (NN signaling) (NN pathway) (NN liver) (NN cancer) (NN c-raf) (JJ transcriptional) (NN regulation))) |ET| |BS|69:G02.111.087.800 126:G02.111.087.800 142:I01.880.604 148:G12.425.143.281 209:G02.111.087.847 478:D08.811.913.696.620.682.700.567 969:D12.776.260.643.715|ES| 4:1 18:1 19:1 186:1 195:1 383:1 438:1 470:1 559:1 836:1 3295:1 3416:1 3417:1 3418:1 3419:1
5 	|BT| (S (NP (NN Cryptotanshinone)) (VP (VBZ inhibits) (NP (NP (JJ constitutive) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3) (NN function)) (VP (VBG blocking) (NP (NN dimerization) (NN DU145) (NN prostate) (NN cancer) (NN cell)))))) |ET| |BS|41:A11 122:C14.280.383 209:G02.111.087.847 250:E07.305.812 970:E06.658.453.560.100 971:G02.149.250|ES| 18:1 19:1 33:1 77:1 94:1 487:1 604:1 615:1 859:1 860:1 861:1 862:1 3420:1 3421:1 3422:1 3423:1
5 	|BT| (S (NP (NNP Cryptotanshinone)) (ADVP (RB rapidly)) (VP (VBD inhibited) (NP (NN STAT3) (NN Tyr705) (NN phosphorylation) (NN DU145) (NN prostate) (NN cancer) (NN cell) (NN growth) (NN cell)) (NP (CD 96) (NN hour) (NN treatment)))) |ET| |BS|41:A11 45:G07.700.320.249 52:E02 82:D12.644.360.024.342.300 122:C14.280.383 972:G02.111.087.677|ES| 18:1 19:1 77:1 94:1 102:1 251:1 365:1 546:1 3420:1 3423:1 3424:1 3425:1 3426:1 3427:1 3428:1
5 	|BT| (S (NP (NN Curcumin)) (VP (VBZ sensitizes) (NP (NP (JJ human) (JJ colorectal) (NN cancer) (NN xenograft) (JJ nude) (NN mouse) (NN gamma-radiation)) (VP (VBG targeting) (NP (JJ nuclear) (JJ factor-kappaB-regulated) (NN gene) (NN product)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335|ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1
5 	|BT| (NP (NP (NP (NN Cyclooxygenase) (CD 2) (NN play) (JJ critical) (NN role) (NN development) (JJ gastrointestinal) (NN cancer)) (NP (JJ human) (NN animal) (NN model)))) |ET| |BS|15:F01.829.316.616 24:D08.811.600.720.750 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 285:E05.598|ES| 18:1 19:1 31:1 35:1 36:1 46:1 72:1 148:1 183:1 238:1 825:1 3432:1
5 	|BT| (S (NP (NP (NN Cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (ADVP (RB constitutively)) (VP (VBD expressed) (NP (NP (NN variety) (NN tumor)) (PP (VBG including) (NP (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 24:D08.811.600.720.750|ES| 6:1 7:1 10:1 14:1 17:1 18:1 19:1 76:1 196:1 561:1 952:1 1158:1
5 	|BT| (S (NP (NN Decrease) (JJ hepatic) (JJ stellate) (NN cell) (NN rat)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ clofibrate-induced) (NN hepatocarcinogenesis)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 677:A11.561 910:D02.241.081.114.968.500.500.195|ES| 19:1 94:1 385:1 607:1 838:1 849:1 900:1 2461:1 3433:1 3434:1
5 	|BT| (FRAG (NP (NN Deficiency) (NN folate)) (, ,) (NP (S (VP (VBP play) (NP (NN role) (NN synthesis) (NNP SAM) (NN lead)))) (NP (VBD increased) (NN risk) (NN colon) (NN cancer)))) |ET| |BS|15:F01.829.316.616 20:G03.495 61:E05.318.740.600.800 79:I03.450.642.693 86:D01.268.556.435 232:D02.886.030.676.180 974:C18.654.521.500.133.699.308|ES| 2:1 18:1 19:1 31:1 47:1 113:1 171:1 238:1 254:1 778:1 3435:1 3436:1 3437:1
5 	|BT| (NP (NP (JJ Desmoplakin) (NN act) (NN tumor) (NN suppressor) (NN inhibition) (NN Wnt/beta-catenin) (NN signaling) (NN pathway) (JJ human) (NN lung) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249 975:D12.776.220.790.500|ES| 7:1 18:1 19:1 36:1 103:1 195:1 246:1 302:1 328:1 383:1 700:1 3438:1
5 	|BT| (S (NP (JJ Diet-induced) (NN obesity) (NN ethanol)) (VP (VBP impair) (NP (NN progression) (JJ hepatocellular) (NN carcinoma) (NN mouse) (JJ mesenteric) (NN vein) (NN injection) (NN model)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 226:E02.319.267.530 564:C18.654.726.500 595:G07.203.650.240 596:E02.642.249 751:D02.033.375 976:A07.231.908.670.385|ES| 19:1 48:1 52:1 72:1 303:1 304:1 785:1 2010:1 3439:1 3440:1 3441:1 3442:1 3443:1
5 	|BT| (S (VP (NP (NNP Digital)) (VBG karyotyping) (VP (VBZ identifies) (NP (NN thymidylate) (NN synthase) (NN amplification) (NN mechanism) (NN resistance) (NN 5-fluorouracil) (JJ metastatic) (JJ colorectal) (NN cancer) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430|ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1
5 	|BT| (NP (NP (NN Disruption) (NN Ptk6) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 78:1 113:1 295:1 2533:1 3444:1 3445:1
5 	|BT| (S (NP (NN DNA) (NN methylation) (NN alteration)) (VP (VBD detected) (SBAR (S (NP (NN zebrafish) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ environmental) (NN carcinogen) (CD 7)) (, ,) (NP (JJ 12-dimethylbenz) (-LRB- -LRB-) (-RRB- -RRB-) (NN anthracene)))))))) |ET| |BS|366:G02.111.087.029.538.161 515:C04.588.274.623 572:B01.050.150.900.493.200.244.828 977:D27.888.569.100.125|ES| 2:1 7:1 10:1 14:1 19:1 81:1 412:1 666:1 836:1 951:1 988:1 1007:1 2017:1 2125:1 3446:1 3447:1 3448:1
5 	|BT| (S (NP (NNP Dovitinib)) (ADVP (RB also)) (VP (VP (VBD caused) (NP (NP (NP (NN dephosphorylation) (NN retinoblastoma)) (, ,) (NP (NN upregulation) (NN p-histone) (NN H2A-X) (NN p27)) (, ,)) (NN downregulation) (NN p-cdk-2) (NN cyclin) (NN B1))) (, ,) (VP (VBD resulted) (NP (NN reduction) (JJ cellular) (NN proliferation) (NN induction) (NN tumor) (NN cell) (NN apoptosis))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 85:G02.111.087.225 183:G04.299.233.750 249:G05.355.315.800 339:G02.111.087.880 510:C23.550.444 978:D08.811.913.696.620.682.700.646.500 979:D12.644.360.262.120.100 980:C04.557.465.625.600.725|ES| 2:1 5:1 7:1 19:1 89:1 94:1 299:1 370:1 594:1 595:1 736:1 743:1 1124:1 1126:1 2506:1 3074:1 3449:1 3450:1 3451:1 3452:1 3453:1 3454:1 3455:1
5 	|BT| (S (NP (NNP Dovitinib)) (VP (VBZ demonstrates) (NP (JJ antitumor) (JJ antimetastatic) (NN activity) (NN xenograft) (NN model) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255|ES| 19:1 72:1 265:1 303:1 304:1 399:1 2244:1 2245:1 2541:1 3449:1
5 	|BT| (S (NP (NP (NN Downregulation) (JJ tumor-suppressor) (NN miR-16)) (PP (IN via) (NP (JJ progestin-mediated) (JJ oncogenic) (NN signaling)))) (VP (VBZ contributes) (NP (NN breast) (NN cancer) (NN development)))) |ET| |BS|69:G02.111.087.800 85:G02.111.087.225 206:G05.360.340.024.340.375.249 279:D27.888.569.100 981:D27.505.696.399.472.858|ES| 18:1 19:1 23:1 35:1 195:1 296:1 596:1 845:1 953:1 1156:1 3456:1 3457:1
5 	|BT| (NP (NP (NN Down-regulation) (NN tumor) (NN suppressor) (NN A) (NN kinase) (NN anchor) (NN protein) (CD 12) (JJ human) (NN hepatocarcinogenesis) (JJ epigenetic) (NN mechanism))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 206:G05.360.340.024.340.375.249 671:G05.355.315.203 823:D08.811.913.696.620.682.700.150.125|ES| 4:1 7:1 19:1 36:1 69:1 162:1 470:1 700:1 900:1 1120:1 1603:1 3458:1 3459:1
5 	|BT| (S (VP (VBN Dysregulated) (SBAR (S (NP (JJ Kruppel-like) (NN factor) (CD 4) (NN vitamin) (NN D) (NN receptor) (NN signaling)) (VP (VBP contribute) (NP (NN progression) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|16:C23.550.291.656 69:G02.111.087.800 104:C04.557.470.200.025.255 982:D12.776.826.535|ES| 19:1 48:1 185:1 186:1 195:1 303:1 304:1 318:1 319:1 450:1 2591:1 2592:1 3460:1
5 	|BT| (S (NP (NNS Effects)) (VP (VBP magnolol) (NP (NP (JJ UVB-induced) (NN skin) (NN cancer) (NN development) (NN mouse)) (JJ possible) (NN mechanism) (NN action)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 742:G03.787|ES| 18:1 19:1 35:1 52:1 162:1 1359:1 2013:1 2319:1 2526:1 2752:1 3461:1
5 	|BT| (NP (NP (NNS Effects) (JJ S-adenosylmethionine) (NN methylthioadenosine) (JJ inflammation-induced) (NN colon) (NN cancer) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 232:D02.886.030.676.180 525:C23.550.470|ES| 18:1 19:1 52:1 113:1 1793:1 3461:1 3462:1 3463:1
5 	|BT| (S (NP (JJ Elevated) (NN expression) (JJ coactivator-associated) (NN arginine) (NN methyltransferase) (CD 1)) (VP (VBN associated) (NP (JJ early) (NN hepatocarcinogenesis)))) |ET| |BS||ES| 19:1 98:1 115:1 169:1 900:1 1128:1 1350:1 2655:1 3464:1 3465:1
5 	|BT| (NP (NP (NP (VBN Enhanced) (NN liver) (NN tumor) (NN promotion) (NN liver) (NN initiation) (NN activity)) (NP (NN rat) (VBN subjected) (JJ combined) (NN administration) (NN omeprazole) (NN beta-naphthoflavone)))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 983:D03.383.663.283.266.450.175.100 984:D02.886.640.074.500|ES| 7:1 19:1 164:1 399:1 637:1 836:1 849:1 2337:1 2575:1 3267:1 3466:1 3467:1 3468:1
5 	|BT| (NP (NP (JJ Epigenetic) (NN identification) (NN ubiquitin) (JJ carboxyl-terminal) (NN hydrolase) (NN L1) (JJ functional) (NN tumor) (NN suppressor) (NN biomarker) (JJ hepatocellular) (NN carcinoma) (JJ digestive) (NN tumor))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101 206:G05.360.340.024.340.375.249 244:C04.588.274.476 374:F01.393.446 985:D08.811.277.352.897.850 986:C04.588.274|ES| 7:1 19:1 303:1 304:1 415:1 700:1 885:1 1201:1 3469:1 3470:1 3471:1 3472:1 3473:1 3474:1
5 	|BT| (FRAG (NP (NP (NN ErbB2) (NN ErbB3) (NN receptor) (NN tyrosine) (NN kinase)) (NP (VBN associated) (NN development) (JJ human) (NN colon) (NN cancer)) (, ,) (NP (NN expression) (NN receptor) (JJ high) (NN HT-29) (NN cell)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 792:A11.251.210.190.475 987:D08.811.913.696.620.682.725.400|ES| 2:1 18:1 19:1 35:1 36:1 94:1 113:1 115:1 169:1 178:1 186:1 470:1 1705:1 2341:1 2782:1 3475:1
5 	|BT| (NP (NP (JJ Essential) (NN contribution) (NN chemokine)) (, ,) (NP (NN CCL3)) (, ,) (NP (NN receptor)) (, ,) (NP (NN CCR1)) (, ,) (NP (JJ hepatocellular) (NN carcinoma) (NN progression))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 313:D12.644.276.374.200|ES| 2:1 19:1 48:1 186:1 303:1 304:1 1360:1 3476:1 3477:1 3478:1 3479:1
5 	|BT| (NP (NP (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD investigated) (NP (NP (NP (NN effect) (JJ novel) (NN farnesyltransferase) (NN inhibitor)) (, ,) (NP (NN ABT-100)) (, ,) (NP (JJ human) (NN liver) (NN cancer) (NN cell) (NN line))) (, ,) (NP (NN HepG2) (NN Huh7)) (, ,) (NP (NN animal) (NN model) (NN hepatocarcinogenesis)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 204:E05.581.500 205:E05.581.500 259:D12.776.395.240.150.500 285:E05.598 988:D08.811.913.225.431 989:D08.811.913.225.437 990:C22.232|ES| 2:1 18:1 19:1 36:1 46:1 72:1 75:1 94:1 104:1 131:1 244:1 264:1 380:1 403:1 689:1 690:1 836:1 891:1 900:1 1307:1 2538:1 3480:1 3481:1 3482:1
5 	|BT| (NP (NP (NP (NN Expression) (NP (JJ ets-related) (JJ transcriptional) (NN factor)) (NN E1AF) (VBN associated) (NN tumor) (NN progression) (NN over-expression) (NN matrilysin)) (NP (JJ human) (JJ gastric) (NN cancer)))) |ET| |BS|8:C04 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 166:D12.776.930 937:D08.811.277.656.300.480.525.700.250|ES| 7:1 18:1 19:1 36:1 48:1 86:1 169:1 185:1 316:1 559:1 1013:1 3289:1 3483:1 3484:1
5 	|BT| (S (NP (NN Expression) (NN glutathione) (NN peroxidase) (CD 2)) (VP (VBN associated) (NP (JJ early) (NN hepatocarcinogenesis)) (ADVP (RB also)) (NP (JJ late) (NN stage) (NN metastasis)))) |ET| |BS|113:C04.697.650 991:D08.811.682.732.500|ES| 5:1 19:1 148:1 169:1 316:1 806:1 900:1 1128:1 1129:1 2649:1 2744:1 3485:1
5 	|BT| (S (NP (NN Expression) (NN protein) (NN kinase) (NN C)) (VP (NNS isoenzymes) (NP (JJ colorectal) (NN cancer) (NN tissue) (JJ differential) (NN activation) (JJ different) (NN bile) (NN acid)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 98:A10 992:D08.811.913.696.620.682.700.725 993:D08.811.348 994:D04.808.105|ES| 4:1 17:1 18:1 19:1 225:1 272:1 316:1 414:1 470:1 1275:1 1621:1 1677:1 1955:1 3486:1
5 	|BT| (NP (NP (NP (NNP Farnesyltransferase) (NN inhibitor)) (, ,) (NP (NN ABT-100)) (, ,) (NP (JJ potent) (NN liver) (NN cancer) (JJ chemopreventive) (NN agent)))) |ET| |BS|988:D08.811.913.225.431 989:D08.811.913.225.437|ES| 2:1 18:1 19:1 22:1 380:1 728:1 836:1 1946:1 2538:1 3487:1
5 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN Apo-FHL2) (NN mouse)) (VP (VBD developed) (SBAR (S (NP (NP (NN tumor)) (, ,) (NP (NN FHL2) (NN transgene))) (VP (VBD enhanced) (SBAR (S (NP (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ liver-specific) (NN deletion) (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (NN gene) (JJ aberrant) (NN Wnt/beta-catenin) (NN signaling) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN lox/lox)) (-RRB- -RRB-))) (NN animal)))))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 11:B01.050.150.900.649.865.635.505.500 19:B01.050 21:G05.360.340.024.340.375.249.050 105:G02.149.115.800.925 242:A03.620 547:G05.360.340.024.340.825 548:D08.811.682.664.500.848 549:G05.355.600.800.320|ES| 2:1 7:1 9:1 10:1 14:1 19:1 46:1 52:1 57:1 58:1 59:1 195:1 280:1 302:1 385:1 412:1 900:1 1059:1 1165:1 1725:1 1799:1 1929:1 1930:1 1931:1 1932:1 1933:1
5 	|BT| (NP (NP (NNP Folate) (NN transport) (NN gene) (NN inactivation) (NN mouse) (NN increase) (NN sensitivity) (NN colon) (NN carcinogenesis))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 42:G05.355.315.203.374 46:A03.556.124.526.356 224:D03.438.733.631.400 947:G03.495.166|ES| 9:1 19:1 40:1 52:1 113:1 207:1 607:1 1314:1 3318:1 3488:1
5 	|BT| (S (PP (IN For) (NP (NN example))) (, ,) (NP (NP (NN gene) (VBN involved) (NN inflammation) (NN matrix) (NN protease) (NN cell) (NN cycle) (NN regulator) (NN gene)) (, ,) (NP (NN cyclin) (NN D2)) (, ,)) (ADVP (RB highly)) (VP (VBN expressed) (NP (NN colon) (NN cancer)))) |ET| |BS|6:G05.360.340.024.340 525:C23.550.470 995:D12.644.360.262.150.200 996:G05.360.340.024.340.220 997:D08.811.277.656.300 998:D08.811.277.656|ES| 2:1 6:1 9:1 18:1 19:1 94:1 113:1 235:1 601:1 626:1 743:1 774:1 3064:1 3489:1 3490:1 3491:1 3492:1 3493:1
5 	|BT| (S (NP (NN Forkhead) (NN box) (NN transcription) (NN factor) (NN FOXO3a)) (VP (VBZ suppresses) (NP (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell) (NN proliferation) (NN tumorigenesis)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 166:D12.776.930 183:G04.299.233.750 889:D27.505.696.399.472.277|ES| 18:1 19:1 23:1 78:1 94:1 185:1 299:1 487:1 686:1 1918:1 3361:1 3363:1 3494:1
5 	|BT| (S (NP (NP (NNP Gefitinib)) (, ,) (NP (NN EGFR) (NN inhibitor)) (, ,)) (VP (VBZ prevents) (NP (JJ hepatocellular) (NN carcinoma) (NN development) (NN rat) (NN liver) (NN cirrhosis)))) |ET| |BS|104:C04.557.470.200.025.255 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 662:C23.550.355|ES| 2:1 19:1 35:1 187:1 303:1 304:1 380:1 836:1 849:1 1199:1 2718:1 3024:1
5 	|BT| (S (NP (NNS Genes)) (VP (VBD expressed) (NP (NP (NN PB) (CD two) (NNS conazoles)) (RRC (ADVP (RB also)) (NP (VBN compared) (NP (NN gene) (VBN associated) (JJ human) (JJ hepatocellular) (NN cancer))))))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400|ES| 5:1 6:1 9:1 18:1 19:1 36:1 50:1 169:1 303:1 933:1 3495:1 3496:1 3497:1
5 	|BT| (SINV (NP (NP (NNP Geraniol)) (, ,) (NP (NN component) (NN plant) (JJ essential) (NN oil)) (, ,)) (VP (VBZ modulates) (NP (NN DNA) (NN synthesis))) (VP (VBZ potentiates) (NP (NN 5-fluorouracil) (NN efficacy) (JJ human) (NN colon) (NN tumor) (NN xenograft)))) |ET| |BS|51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 78:G02.111.087.222 92:E04.936.764 93:A01.941.875 560:D03.383.742.698.875.404 999:D10.627.675 1000:A18|ES| 2:1 7:1 19:1 36:1 113:1 265:1 606:1 666:1 1021:1 1098:1 1776:1 2304:1 2307:1 2499:1 2614:1 3436:1 3498:1
5 	|BT| (S (NP (NN Glycine) (NN soya) (NN diet)) (ADVP (RB synergistically)) (VP (VBZ enhances) (SBAR (S (NP (JJ suppressive) (NN effect) (NN tamoxifen)) (VP (VBZ inhibits) (NP (NP (JJ tamoxifen-promoted) (NN hepatocarcinogenesis)) (JJ 7,12-dimethylbenz) (PRN (-LRB- -LSB-) (NP (NN alpha)) (-RRB- -RSB-)) (JJ anthracene-induced) (NN rat) (JJ mammary) (NN tumor) (NN model))))))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 408:C04.588.531 595:G07.203.650.240 596:E02.642.249 640:D02.455.426.559.389.150.700.900 1001:B01.650.940.800.575.100.401.750 1002:C04.588.180 1003:D12.125.481|ES| 7:1 19:1 72:1 75:1 615:1 849:1 900:1 1356:1 1373:1 1378:1 1836:1 1974:1 2191:1 2248:1 2371:1 3349:1 3499:1 3500:1 3501:1 3502:1 3503:1
5 	|BT| (NP (NP (JJ Hepatoprotective) (NN effect) (NN tamoxifen) (NN steatosis) (JJ non-alcoholic) (NN steatohepatitis) (NN mouse) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 509:C06.552.241.519 640:D02.455.426.559.389.150.700.900|ES| 19:1 52:1 72:1 75:1 1791:1 2069:1 2371:1 2678:1 3504:1
5 	|BT| (S (VP (ADVP (RB Here)) (VBP show) (SBAR (S (NP (NP (JJ ATP-binding) (NN cassette) (NN member) (NN B5)) (PRN (-LRB- -LRB-) (NP (NN ABCB5)) (-RRB- -RRB-))) (VP (VBZ identifies) (NP (NP (JJ therapy-refractory) (NN tumor) (NN cell) (JJ colorectal) (NN cancer) (NN patient)) (PP (VBG following) (NP (NP (NN fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-)))))))) (: -) (S (NP (VBN based) (NN chemoradiation) (NN therapy)) (VP (VBP provide) (NP (NP (NN evidence)) (JJ functional) (NN role) (NN ABCB5) (JJ colorectal) (NN cancer) (NN 5-FU) (NN resistance)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 50:M01.643 52:E02 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 1004:E02.095.147|ES| 7:1 10:1 14:1 17:1 18:1 19:1 31:1 38:1 94:1 120:1 130:1 400:1 415:1 429:1 711:1 769:1 1094:1 1610:1 2308:1 2895:1 2919:1 3505:1 3506:1 3507:1 3508:1 3509:1 3510:1 3511:1
5 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBP provide) (NP (NP (NP (NN evidence) (NN periostin) (, ,) (NN protein) (JJ structural) (NN sequence) (NN homology) (JJ TGF-beta-inducible) (NN gene)) (, ,) (NP (NN beta) (NN ig-h3)) (, ,)) (VP (VBN upregulated) (NP (JJ colorectal) (NN cancer) (NN liver) (NN metastasis)))) (, ,) (VP (MD may) (VP (VB play) (NP (NN role)) (S (VP (VBG promoting) (NP (NN growth) (NN tumor)))))))) |ET| |BS|4:C04.588.274.476.411.307 6:G05.360.340.024.340 8:C04 15:F01.829.316.616 45:G07.700.320.249 79:I03.450.642.693 112:D12.776.097.820 113:C04.697.650 242:A03.620 503:D12.644.276.374.687 1005:G02.111.810|ES| 2:1 4:1 7:1 9:1 17:1 18:1 19:1 31:1 38:1 102:1 125:1 238:1 293:1 400:1 491:1 711:1 806:1 836:1 881:1 1972:1 3512:1 3513:1 3514:1 3515:1 3516:1
5 	|BT| (UCP (ADVP (RB Here)) (, ,) (NP (NP (NN report) (NN identification) (JJ hepatic) (NNS microRNAs)) (SBAR (S (NP (VBN dysregulated) (JJ early) (NN stage) (S (VP (VBG feeding) (NP (NP (NP (NN C57BL/6) (NN mouse) (JJ choline-deficient) (NN amino) (JJ acid-defined)) (-LRB- -LRB-) (JJ CDAA) (-RRB- -RRB-) (NN diet)) (ADJP (VBN known)))))) (VP (VBP promote) (FRAG (NP (NP (JJ nonalcoholic) (NN steatohepatitis)) (PRN (-LRB- -LRB-) (NP (NN NASH)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN hepatocarcinogenesis) (CD 84) (NN week)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 184:D13.150.650.319 374:F01.393.446 509:C06.552.241.519 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 2:1 10:1 14:1 19:1 52:1 400:1 409:1 417:1 556:1 679:1 783:1 838:1 900:1 1128:1 1129:1 1259:1 1791:1 1796:1 2188:1 2189:1 2190:1 2191:1 2192:1 2942:1 3065:1 3184:1 3469:1 3517:1 3518:1
5 	|BT| (S (ADVP (RB Here)) (, ,) (NP (NN report) (NNP MPA)) (ADVP (RB also)) (VP (VBZ induces) (NP (NP (NN differentiation) (JJ androgen-independent) (NN prostate) (NN cancer)) (NP (VBN derived) (NN cell) (NN line) (NN DU145))))) |ET| |BS|74:G04.299.151 94:A11.251.210 852:C04.588.945.440.770.500|ES| 2:1 5:1 18:1 19:1 77:1 94:1 214:1 215:1 264:1 400:1 417:1 1721:1 3423:1 3519:1 3520:1
5 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD found) (SBAR (IN whereas) (S (VP (VBG sparing) (NP (NP (JJ normal) (NP (JJ human) (NN colon) (JJ mucosal) (JJ epithelial) (NN cell))) (, ,) (NP (NN EPLE))) (VP (ADVP (RB selectively)) (VBD inhibited) (NP (NN proliferation) (NN CRC) (NN cell) (NN line)) (ADVP (RB well)) (NP (JJ primary) (NN tumor) (NN cell)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 41:A11 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 75:A11.436 122:C14.280.383 183:G04.299.233.750 302:A10.615.550|ES| 2:1 7:1 19:1 36:1 37:1 94:1 113:1 118:1 127:1 245:1 264:1 299:1 344:1 365:1 372:1 428:1 787:1 2489:1 3521:1 3522:1 3523:1
5 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD investigated) (NP (NP (NP (NN effect) (NN alpha-LA) (NN development) (NN rat)) (JJ pre-neoplastic) (NN lesion)) (VP (VBD generated) (NP (NN model) (NN hepatocarcinogenesis) (, ,) (NN similarity) (JJ histopathological) (NN sequence) (JJ human) (JJ hepatocellular) (NN carcinoma) (NN development) (NN cirrhosis)))))) |ET| |BS|8:C04 14:F01.525 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 662:C23.550.355 1006:D01.268.558.362.500|ES| 2:1 19:1 35:1 36:1 72:1 73:1 75:1 293:1 303:1 304:1 403:1 428:1 849:1 900:1 1131:1 1199:1 3524:1 3525:1 3526:1 3527:1
5 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD investigated) (NP (NP (ADJP (FW vitro) (FW vivo)) (JJ anticancer) (NN effect)) (NP (VBN associated) (NN mechanism) (NN wogonin) (JJ human) (NN breast) (NN cancer))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 18:1 19:1 23:1 36:1 75:1 162:1 169:1 216:1 378:1 403:1 428:1 1880:1 2444:1
5 	|BT| (S (NP (NN Histone) (NN deacetylase) (CD 6) (NN function) (NN tumor) (NN suppressor)) (VP (VBG activating) (NP (NN c-Jun) (JJ NH2-terminal) (JJ kinase-mediated) (NN beclin) (JJ 1-dependent) (JJ autophagic) (NN cell) (NN death) (NN liver) (NN cancer)))) |ET| |BS|206:G05.360.340.024.340.375.249 771:D08.811.913.696.620.682.700.567.374 1007:G04.299.139.399 1008:D08.811.277.087.520|ES| 7:1 18:1 19:1 33:1 94:1 411:1 504:1 700:1 836:1 1686:1 1958:1 2140:1 2708:1 3528:1 3529:1 3530:1 3531:1 3532:1
5 	|BT| (S (NP (NN Honokiol)) (VP (VP (VBZ activates) (NP (JJ AMP-activated) (NN protein) (NN kinase) (NN breast) (NN cancer) (NN cell)) (PP (IN via) (NP (JJ LKB1-dependent) (NN pathway)))) (VP (VBZ inhibits) (NP (NN breast) (NN carcinogenesis))))) |ET| |BS|10:A01.236 33:C04.697.098 41:A11 122:C14.280.383 1009:D08.811.913.696.620.682.700.085|ES| 4:1 18:1 19:1 23:1 94:1 207:1 301:1 383:1 470:1 596:1 615:1 3533:1 3534:1 3535:1
5 	|BT| (S (ADVP (RB However)) (, ,) (NP (JJ molecular) (NN mechanism) (NN progesterone) (NN action) (NN breast) (NN cancer)) (ADVP (RB still)) (VP (VBP remain) (ADJP (JJ elusive)))) |ET| |BS|742:G03.787 1010:D04.808.745.745.654.829|ES| 2:1 18:1 19:1 23:1 161:1 162:1 433:1 776:1 777:1 2013:1 2181:1 3536:1
5 	|BT| (S (NP (NP (JJ Hypoxia-inducible) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNS HIFs)) (-RRB- -RRB-))) (VP (VBP accumulate) (NP (NP (JJ neoplastic) (JJ inflammatory) (NN cell)) (PP (IN within) (NP (NN tumor) (NN microenvironment) (NN impact) (NN progression) (NN variety) (NN disease))) (, ,) (PP (VBG including) (NP (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 41:A11 1011:C23.888.852.079 1012:G04.366.500|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 48:1 94:1 185:1 561:1 893:1 952:1 998:1 2122:1 2430:1 3537:1 3538:1 3539:1 3540:1 3541:1
5 	|BT| (NP (NP (NP (JJ Immunohistochemical) (NN analysis) (NN thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NP (NN dihydropyrimidine) (NN dehydrogenase) (JJ rectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN cUICC) (NN II/III)) (-RRB- -RRB-))) (: :)) (NP (NP (NN correlation) (JJ histopathologic) (NN tumor) (NN regression)) (NP (JJ 5-fluorouracil-based) (JJ long-term) (NN neoadjuvant) (NN chemoradiotherapy)))) |ET| |BS|8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 846:F01.393.784 849:G08.686.785.760.769.490.500 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350 1013:E02.186.450|ES| 2:1 7:1 10:1 14:1 18:1 19:1 66:1 104:1 661:1 719:1 1986:1 1989:1 2578:1 2648:1 3002:1 3082:1 3083:1 3084:1 3085:1 3542:1 3543:1 3544:1 3545:1 3546:1 3547:1
5 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN Folbp1) (NN RFC1)) (ADVP (RB genetically)) (VP (NP (VBN modified) (NN mouse) (NN exhibit) (JJ distinct) (NN change) (NN colonocyte) (NN phenotype)) (ADVP (RB therefore)) (SBAR (S (NP (NN utility) (NN model)) (VP (VBP examine) (NP (NP (NN role)) (JJ folate) (NN homeostasis) (NN colon) (NN cancer) (NN development))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 80:G05.695 152:G07.700.345 175:J01.897.280.500.269 224:D03.438.733.631.400|ES| 2:1 18:1 19:1 31:1 35:1 52:1 72:1 113:1 200:1 218:1 236:1 244:1 500:1 587:1 778:1 898:1 960:1 1284:1 2026:1 2194:1 2335:1 3548:1 3549:1 3550:1
5 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NP (JJ insulin-independent) (NN liver) (NN tumor) (NN promotion)) (VP (VBD occurred) (NP (JJ diabetic) (NN mouse)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 637:D06.472.699.587.200.500.625|ES| 2:1 7:1 19:1 52:1 101:1 244:1 553:1 836:1 1284:1 1479:1 2337:1 2964:1 3551:1
5 	|BT| (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJ high) (NN level) (NN sPLA2) (NN expression)) (JJ likely) (VBG contributing) (JJ elevated) (NN level) (JJ arachidonic) (NN acid)) (VP (VBD found) (SBAR (S (NP (NP (JJ colorectal) (NN cancer)) (, ,) (NP (NN conjunction) (JJ elevated) (NN expression) (NN cyclooxygenase-2)) (, ,)) (VP (MD could) (NP (DT another) (NN factor) (NN tumor) (NN formation))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 20:G03.495 24:D08.811.600.720.750 491:D27.505.259.500 1014:D10.251.355.255.100.100|ES| 2:1 7:1 17:1 18:1 19:1 37:1 43:1 61:1 115:1 178:1 185:1 244:1 249:1 756:1 908:1 1275:1 1295:1 1328:1 1392:1 3552:1 3553:1 3554:1 3555:1
5 	|BT| (S (PP (IN In) (NP (NN HepG2) (NN cell))) (, ,) (S (S (NP (NN transfection) (NN RARgamma)) (VP (VBD enhanced))) (, ,) (IN whereas) (S (NP (NN downregulation) (NN RARgamma) (NN expression) (NN siRNA) (NN approach)) (VP (VBD impaired)))) (, ,) (NP (NN effect) (NN RA) (VBG inducing) (NN expression) (NN alpha-fetoprotein) (, ,) (NN protein) (NN marker) (NN hepatocarcinogenesis))) |ET| |BS|85:G02.111.087.225 112:D12.776.097.820 117:D13.150.650.700 158:D23.101 217:E05.393.350.810 748:D12.776.124.790.106.092 1015:A11.251.860.180.432|ES| 2:1 4:1 19:1 75:1 94:1 115:1 244:1 351:1 372:1 385:1 534:1 595:1 746:1 900:1 911:1 1864:1 2003:1 2665:1 3481:1 3556:1 3557:1
5 	|BT| (S (PP (IN In) (NP (JJ human) (JJ colorectal) (NN cancer))) (, ,) (NP (JJ arachidonic) (NN acid) (NN eicosanoid) (NN level)) (VP (VBD elevated))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 1014:D10.251.355.255.100.100 1016:D10.251.355.255|ES| 2:1 17:1 18:1 19:1 36:1 244:1 249:1 756:1 1275:1 3553:1 3558:1
5 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (NP (NN serial) (NN microPET) (NN imaging)) (VP (VBD used) (VP (VB evaluate) (NP (NP (JJ iodine-124-labeled) (NN iodo-azomycin-galactoside)) (PRN (-LRB- -LRB-) (NP (-LRB- -LRB-) (CD 124) (-RRB- -RRB-) (NN I-IAZG)) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (NP (JJ 4.2-day) (JJ physical) (NN half-life)) (-RRB- -RRB-)) (S (NP (NN hypoxia) (NN imaging) (NN agent)) (NP (CD 17) (NN MCa) (NN breast) (NN tumor) (CD six) (NN FSaII) (NNS fibrosarcomas)) (VP (VBN implanted) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 375:Z01.639.100 967:D01.248.497.158.490 1002:C04.588.180 1011:C23.888.852.079 1017:E01.370.350 1018:C04.557.450.565.590.350 1019:A07.231.114.228.550 1020:G01.910.405 1021:E01.370.600 1022:V02.690|ES| 2:1 7:1 10:1 14:1 19:1 23:1 52:1 131:1 175:1 244:1 476:1 728:1 890:1 930:1 1781:1 2474:1 3559:1 3560:1 3561:1 3562:1 3563:1 3564:1 3565:1 3566:1 3567:1 3568:1 3569:1 3570:1 3571:1 3572:1
5 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD sought) (VP (VB examine) (SBAR (S (NP (NN effectiveness) (NN honokiol) (VBG inhibiting) (NP (NN migration) (NN invasion) (NN breast) (NN cancer) (NN cell))) (VP (VBP elucidate) (S (VP (VBG underlying) (NP (JJ molecular) (NN mechanism)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 122:C14.280.383|ES| 2:1 18:1 19:1 23:1 94:1 131:1 161:1 162:1 219:1 244:1 435:1 514:1 620:1 880:1 960:1 1307:1 1697:1 3573:1 3574:1
5 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD determined) (NP (NP (JJ combined) (NN effect) (NN celecoxib)) (, ,) (NP (NN COX-2) (NN inhibitor)) (, ,)) (PP (IN along) (NP (NP (NP (NN exisulind)) (PRN (-LRB- -LRB-) (NP (NN sulindac) (NN sulfone/Aptosyn)) (-RRB- -RRB-))) (JJ low) (NNS dos) (NN prostate) (NN cancer))))) |ET| |BS|349:D27.505.519.389.310.500 684:D02.065.884.247|ES| 2:1 10:1 14:1 18:1 19:1 75:1 76:1 77:1 131:1 164:1 244:1 380:1 531:1 869:1 1582:1 2653:1 2666:1 2807:1 3575:1 3576:1
5 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (NP (NP (VBN investigated) (NN role) (NN progastrin)) (VP (VBG regulating) (NP (NNP CSC) (NN phenotype)))) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 80:G05.695 556:C11.768.175|ES| 2:1 17:1 18:1 19:1 31:1 131:1 236:1 244:1 403:1 671:1 997:1 2869:1 3577:1
5 	|BT| (S (PP (IN In) (NP (NN view) (JJ strong) (NN association) (NN estrogen))) (, ,) (NP (NP (NN progesterone)) (, ,) (NP (NN prolactin)) (, ,) (NP (NN breast) (NN cancer)) (, ,) (NP (NN PhIP) (NN repertoire)) (NP (JJ hormone-like) (NN activity))) (VP (VBZ provides) (NP (JJ mechanistic) (NN support) (JJ tissue-specific) (NN carcinogenicity) (NN chemical)))) |ET| |BS|98:A10 161:D06.472 279:D27.888.569.100 386:F02.463.425.069 889:D27.505.696.399.472.277 1010:D04.808.745.745.654.829 1023:D06.472.699.322.576.773|ES| 2:1 18:1 19:1 23:1 244:1 399:1 815:1 1298:1 1364:1 1626:1 1890:1 2124:1 2641:1 3168:1 3536:1 3578:1 3579:1 3580:1 3581:1 3582:1 3583:1
5 	|BT| (S (ADVP (FW In) (FW vivo)) (, ,) (NP (NP (NP (NN nimbolide)) (PRN (-LRB- -LRB-) (NP (CD 5) (CD 20) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-))) (, ,) (VP (VBN injected) (ADVP (RB intraperitoneally)) (NP (NN tumor) (NN inoculation))) (, ,)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN volume) (JJ colorectal) (NN cancer) (NN xenograft)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 92:E04.936.764 93:A01.941.875 653:C23.888.144 1024:D20.215.894.200 1025:Z01.252.100.450 1026:Z01.252.474.651|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 124:1 202:1 244:1 265:1 378:1 578:1 1870:1 2398:1 2399:1 3584:1 3585:1 3586:1 3587:1 3588:1 3589:1
5 	|BT| (S (NP (VBN Increased) (NN expression) (NN cyclooxygenase-2) (NN protein) (NN rat) (NN hepatocarcinogenesis)) (VP (VBD caused) (ADJP (ADJP (JJ choline-deficient)) (, ,) (NP (NP (NN L-amino) (JJ acid-defined) (NN diet) (JJ chemopreventive) (NN efficacy) (JJ specific) (NN inhibitor)) (, ,) (NP (NN nimesulide)))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 2:1 4:1 19:1 61:1 115:1 380:1 540:1 849:1 900:1 1212:1 1946:1 2188:1 2190:1 2191:1 2304:1 2506:1 3183:1 3186:1
5 	|BT| (NP (NP (NN Inhibition) (NN licorice) (NN flavonoid) (NN oil) (NN glutathione) (JJ S-transferase-positive) (NN focus) (JJ medium-term) (NN rat) (NN hepatocarcinogenesis) (NN bioassay))) |ET| |BS|43:F01.145.544 106:E05.091 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 534:D03.383.663.283.266.450 780:D08.811.913.225.500 849:G08.686.785.760.769.490.500 914:L01.178 1027:B01.650.940.800.575.100.401.300 1028:B01.650.940.800.575.100.401.300 1029:D10.627.700 1030:D10.627|ES| 19:1 849:1 900:1 1431:1 1886:1 2614:1 2703:1 2744:1 2931:1 3215:1 3590:1 3591:1
5 	|BT| (S (NP (NN Inhibition) (NN autophagy)) (VP (VBZ potentiates) (NP (JJ antitumor) (NN effect) (NN multikinase) (NN inhibitor) (NN sorafenib) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|43:F01.145.544 104:C04.557.470.200.025.255 390:G04.299.139.399|ES| 19:1 75:1 303:1 304:1 380:1 1317:1 2063:1 2244:1 2499:1 2703:1 3592:1
5 	|BT| (NP (NP (NN Inhibition) (JJ hypoxia-inducible) (NN factor) (NN limit) (NN tumor) (NN progression) (NN mouse) (NN model) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 43:F01.145.544 1011:C23.888.852.079 1031:C04.588.274.476.411.307|ES| 7:1 17:1 18:1 19:1 48:1 52:1 72:1 185:1 2703:1 2797:1 3593:1
5 	|BT| (S (NP (NN Inhibition) (NN STAT3) (NN signaling) (NN pathway) (NN nitidine) (NN chloride)) (VP (VBD suppressed) (NP (NN angiogenesis) (NN growth) (JJ human) (JJ gastric) (NN cancer)))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 82:D12.644.360.024.342.300 126:G02.111.087.800|ES| 18:1 19:1 36:1 86:1 102:1 195:1 251:1 307:1 383:1 2502:1 2703:1 2788:1 3594:1
5 	|BT| (S (NP (NP (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBP initiate) (NP (NN hepatocarcinogenesis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 554:D02.654.442.200|ES| 10:1 14:1 19:1 785:1 900:1 1875:1 3231:1 3595:1
5 	|BT| (FRAG (UCP (NP (JJ Insulin-independent) (NN promotion)) (ADVP (RB chemically)) (NP (VBN induced) (JJ hepatocellular) (NN tumor) (NN development)) (NP (ADJP (RB genetically) (JJ diabetic)) (NN mouse)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 637:D06.472.699.587.200.500.625|ES| 7:1 19:1 35:1 52:1 303:1 412:1 898:1 2337:1 2581:1 2964:1 3596:1
5 	|BT| (NP (NP (NP (NN Intake) (NNS isoflavones)) (SBAR (S (NP (VBN derived) (NN soybean) (NN product)) (VP (MD may) (VP (VB impact) (NP (NN prostate) (NN cancer) (NN risk)))))))) |ET| |BS|61:E05.318.740.600.800 1001:B01.650.940.800.575.100.401.750 1032:D03.383.663.283.266.450.400|ES| 18:1 19:1 77:1 171:1 491:1 675:1 1721:1 3541:1 3597:1 3598:1 3599:1
5 	|BT| (NP (NP (NP (JJ Interferon-gamma-mediated) (NN hepatocarcinogenesis) (NN mouse)) (VP (VBN treated) (NP (NN diethylnitrosamine))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 554:D02.654.442.200 1033:D12.644.276.374.440.893|ES| 19:1 52:1 900:1 1099:1 1952:1 3600:1
5 	|BT| (NP (NP (NN INTERPRETATION)) (: :) (S (S (NP (NN Stimulation) (NN survivin) (NN expression) (NN TCF/beta) (NN catenin)) (VP (MD might) (VP (VB impose) (NP (NN stem) (JJ cell-like) (NN phenotype)) (SBAR (S (NP (JJ colonic) (NN crypt) (NN epithelium) (NN coupling)) (VP (VBD enhanced) (NP (NN cell) (NN proliferation) (NN resistance) (NN apoptosis)))))))) (, ,) (VP (VBP contribute) (NP (JJ molecular) (NN pathogenesis) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 39:G04.299.139.160 46:A03.556.124.526.356 62:A10.272 80:G05.695 183:G04.299.233.750 308:A11.872|ES| 2:1 17:1 18:1 19:1 89:1 94:1 104:1 115:1 161:1 173:1 236:1 299:1 385:1 450:1 501:1 677:1 798:1 1094:1 1106:1 2229:1 2913:1 3601:1 3602:1 3603:1 3604:1 3605:1 3606:1 3607:1
5 	|BT| (NP (NP (NN INTRODUCTION)) (: :) (S (NP (NN Protein) (NN tyrosine) (NN kinase)) (NP (CD 6) (-LRB- -LRB-) (NN PTK6) (-RRB- -RRB-) (JJ non-receptor) (NN tyrosine) (NN kinase)) (ADVP (RB highly)) (VBD expressed) (NP (NP (JJ Human) (NNP Epidermal) (NN Growth) (NN Factor) (CD 2)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NP (NN Her2) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-) (-RRB- -RRB-)) (NN breast) (NN cancer))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 923:D06.472.317.350 987:D08.811.913.696.620.682.725.400|ES| 6:1 10:1 14:1 18:1 19:1 23:1 104:1 148:1 444:1 470:1 535:1 626:1 1041:1 1044:1 1219:1 2340:1 2341:1 2911:1 3059:1 3529:1 3608:1 3609:1
5 	|BT| (S (NP (NP (NNP Ling) (NN extract)) (, ,) (NP (JJ high) (NN furanodiene) (NN content)) (, ,)) (VP (VBD showed) (NP (JJ anti-cancer) (NN effect) (NN breast) (NN cancer) (NN cell) (NN vitro)))) |ET| |BS|41:A11|ES| 2:1 18:1 19:1 23:1 75:1 94:1 132:1 178:1 216:1 1112:1 1794:1 2496:1 3610:1 3611:1
5 	|BT| (S (NP (NN Loss) (NN caspase-8)) (VP (VBZ protects) (SBAR (S (NP (NN mouse) (JJ inflammation-related) (NN hepatocarcinogenesis)) (VP (VBZ induces) (NP (JJ non-apoptotic) (NN liver) (NN injury))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 242:A03.620 525:C23.550.470 1034:D08.811.277.656.262.500.126.550.800|ES| 19:1 52:1 214:1 836:1 900:1 1788:1 1863:1 2416:1 3612:1 3613:1 3614:1
5 	|BT| (S (NP (NN Loss) (NN metallothionein)) (VP (VBZ predisposes) (NP (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (VBG activating) (NN NF-kappaB) (NN target) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670|ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1
5 	|BT| (S (S (NP (JJ Low) (NN level) (NN Caspase-3)) (VP (VBP predict) (SBAR (S (NP (JJ favourable) (NN response) (JJ 5FU-based) (NN chemotherapy)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) (: :) (S (NP (NN Caspase-3) (NN inhibition) (JJ therapeutic) (NN approach)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 52:E02 151:E02.319 333:D01.045 560:D03.383.742.698.875.404 906:D08.811.277.656.262.500.126.350.300|ES| 17:1 18:1 19:1 103:1 104:1 249:1 494:1 495:1 541:1 911:1 997:1 1302:1 2232:1 3190:1 3615:1 3616:1
5 	|BT| (NP (NP (NNP Lupeol) (NN target) (NN liver) (JJ tumor-initiating) (NN cell) (NN phosphatase) (NN tensin) (NN homolog) (NN modulation))) |ET| |BS|242:A03.620 1035:D08.811.277.352.650 1036:A11.872.650|ES| 19:1 94:1 160:1 836:1 1945:1 3617:1 3618:1 3619:1 3620:1 3621:1
5 	|BT| (S (S (NP (NNP Lycopene)) (VP (VBZ modulates) (SBAR (S (NP (NN initiation) (NN N-nitrosodiethylamine)) (VP (VBD induced) (NP (NN hepatocarcinogenesis))))))) (: :) (S (NP (NP (NN study) (JJ chromosomal) (NN abnormality)) (, ,) (NP (NN membrane) (NN fluidity) (JJ antioxidant) (NN defense) (NN system))))) |ET| |BS|554:D02.654.442.200 700:D27.505.519.217 1037:C23.550.210 1038:G01.154.500 1039:C16.131.260|ES| 2:1 19:1 104:1 131:1 412:1 593:1 606:1 637:1 900:1 1002:1 1027:1 1104:1 2521:1 2602:1 2733:1 3622:1 3623:1
5 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (DT A) (JJ Solt-Farber) (JJ two-step) (NN test) (NN model) (NN hepatocarcino) (NN genesis)) (VP (VBD established) (S (NP (NP (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN AAF)) (-RRB- -RRB-))) (NN rat)) (VP (VBP investigate) (S (VP (VBG modifying) (NP (NP (NP (NN effect) (NN expression) (NN 6-glucosephosphatase)) (PRN (-LRB- -LRB-) (NP (NN G-6-Pase)) (-RRB- -RRB-))) (, ,) (NP (NN succinodehydrogenase) (-LRB- -LRB-) (NN SDH) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NN adenosine) (NN triphosphatase)) (PRN (-LRB- -LRB-) (NP (NN ATPase)) (-RRB- -RRB-))) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 506:F01.829.263.315 554:D02.654.442.200 767:D02.065.064.150 893:D08.811.277.040.025 894:D08.811.277.040.025 1040:D08.811.277.352.650.225 1041:E01.370.370.380.250|ES| 2:1 10:1 14:1 19:1 69:1 72:1 75:1 104:1 115:1 459:1 565:1 849:1 900:1 1418:1 1875:1 1952:1 2660:1 2762:1 3158:1 3221:1 3271:1 3624:1 3625:1 3626:1 3627:1 3628:1 3629:1 3630:1 3631:1 3632:1 3633:1 3634:1
5 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (JJ Male) (ADJP (ADJP (NN C57BL/6) (NN mouse) (NN fed) (NN methionine) (JJ choline-deficient)) (PRN (-LRB- -LRB-) (NP (NN MCD)) (-RRB- -RRB-))) (NN diet)) (VP (VBP induce) (NP (NN steatohepatitis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 508:C06.552.241 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 664:D02.886.030.676|ES| 10:1 14:1 19:1 52:1 104:1 243:1 565:1 1791:1 2050:1 2188:1 2191:1 2192:1 2426:1 2524:1 3635:1
5 	|BT| (S (NP (NNP Methylenetetrahydrofolate) (NN reductase) (NN gene) (NN polymorphism) (NN response) (JJ fluorouracil-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer) (NN patient)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 50:M01.643 52:E02 307:G05.365.795 333:D01.045 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 9:1 17:1 18:1 19:1 96:1 120:1 494:1 546:1 997:1 1060:1 3636:1 3637:1
5 	|BT| (NP (NP (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NP (NN methionine) (NN adenosyltransferase) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN MAT1A)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NN PHB1) (NN expression)))) (, ,) (JJ impaired) (JJ mitochondrial) (NN function)) (, ,) (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 574:D08.811.913.225.650|ES| 2:1 10:1 14:1 19:1 33:1 115:1 303:1 304:1 376:1 441:1 452:1 583:1 648:1 1506:1 1792:1 2003:1 2004:1 2050:1 2051:1 2052:1 2053:1
5 	|BT| (S (VP (VBG Modifying) (NP (NP (NN effect) (NN chitin) (, ,) (NN chitosan) (JJ related) (NN compound) (JJ 2-amino-3,8-dimethylimidazo)) (PRN (-LRB- -LSB-) (NP (NP (NP (NP (JJ 4,5-f) (-RRB- -RSB-) (NN quinoxaline)) (PRN (-LRB- -LRB-) (NP (NN MeIQx)) (-RRB- -RRB-))) (NN rat) (JJ medium-term) (NN hepatocarcinogenesis) (NN model)) (, ,) (NP (JJ post-initiation) (NN effect) (JJ female) (NN rat) (JJ 2-stage) (JJ multi-organ) (NN carcinogenesis) (NN model))))))) |ET| |BS|33:C04.697.098 118:D01.248.497.158.380 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 642:M01.975 849:G08.686.785.760.769.490.500 854:D05.750.078.139.500 855:D05.750.078.139 914:L01.178|ES| 2:1 10:1 14:1 19:1 72:1 75:1 207:1 419:1 849:1 900:1 1373:1 1378:1 1404:1 2433:1 3051:1 3052:1 3215:1 3638:1 3639:1 3640:1 3641:1 3642:1 3643:1 3644:1 3645:1
5 	|BT| (S (VP (VBG Modifying) (NP (NP (NN effect) (NN liver) (NN tumor) (NN promotion) (NN rat)) (VBN subjected) (NN co-administration) (NN indole-3-carbinol) (NN phenobarbital)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650 1042:Z01.107.757.284|ES| 7:1 19:1 75:1 836:1 849:1 2337:1 2685:1 3267:1 3638:1 3646:1 3647:1
5 	|BT| (S (NP (NN Monensin)) (VP (VBZ inhibits) (SBAR (S (NP (JJ canonical) (NP (NN Wnt) (NN signaling) (JJ human) (JJ colorectal) (NN cancer) (NN cell))) (VP (VBZ suppresses) (NP (NN tumor) (NN growth) (JJ multiple) (JJ intestinal) (NN neoplasia) (NN mouse))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 102:C04.588.274.476.411 122:C14.280.383 1043:D03.383.312.600|ES| 7:1 17:1 18:1 19:1 36:1 52:1 94:1 102:1 109:1 195:1 615:1 640:1 649:1 686:1 877:1 3236:1 3648:1
5 	|BT| (NP (NP (JJ Mycophenolic) (JJ acid-induced) (NN replication) (NN arrest)) (, ,) (NP (NN differentiation) (NN marker) (NN cell) (NN death) (JJ androgen-independent) (NN prostate) (NN cancer) (NN cell) (NN DU145))) |ET| |BS|41:A11 78:G02.111.087.222 134:G04.299.139 852:C04.588.945.440.770.500 1044:D02.241.081.193.678 1045:D23.050.301.264|ES| 2:1 18:1 19:1 77:1 94:1 215:1 231:1 411:1 534:1 602:1 2599:1 3423:1 3520:1 3649:1
5 	|BT| (S (NP (NNP Nestin) (NN silencing)) (VP (ADVP (RB also)) (VP (VBD upregulated) (NP (NP (NN Axin) (, ,) (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARa)) (-RRB- -RRB-))))) (, ,) (VP (VBD downregulated) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-Myc)) (, ,) (NP (NP (NN cyclin) (NN D)) (NN MMP-7) (NN expression) (NNP CSC)))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 536:D12.776.826.239.500 556:C11.768.175 937:D08.811.277.656.300.480.525.700.250 1046:D12.644.360.262.150 1047:D05.750.078.593.540|ES| 2:1 5:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 60:1 66:1 92:1 100:1 115:1 125:1 186:1 426:1 743:1 824:1 1801:1 1836:1 1887:1 1972:1 2592:1 3577:1 3650:1 3651:1 3652:1 3653:1 3654:1 3655:1
5 	|BT| (NP (NP (NP (NP (NNP Neurotensin) (NN receptor-1)) (PRN (-LRB- -LRB-) (NP (NN NTR-1)) (-RRB- -RRB-))) (NP (JJ overexpressed) (NN colon) (NN cancer) (NN colon) (NN cancer) (NN cell) (NN line)))) |ET| |BS|94:A11.251.210 1048:D12.776.543.750.100.550|ES| 10:1 14:1 18:1 19:1 25:1 94:1 113:1 264:1 3656:1 3657:1 3658:1
5 	|BT| (S (NP (NN Nifuroxazide)) (VP (VBZ induces) (SBAR (S (NP (NN apoptosis)) (VP (VBZ impairs) (NP (JJ pulmonary) (NN metastasis) (NN breast) (NN cancer) (NN model))))))) |ET| |BS|10:A01.236 39:G04.299.139.160 113:C04.697.650 182:A04.411|ES| 18:1 19:1 23:1 72:1 89:1 214:1 806:1 948:1 2729:1 3659:1
5 	|BT| (NP (NP (NP (JJ Nitric) (JJ oxide-releasing) (NN aspirin) (NN indomethacin) (JJ potent) (NN inhibitor) (NN colon) (NN cancer) (JJ azoxymethane-treated) (NN rat)) (: :) (NP (NN effect) (JJ molecular) (NN target)))) |ET| |BS|52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420|ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1
5 	|BT| (NP (NP (DT No) (VBG Modifying) (NP (NP (NN Effect) (JJ Antioxidant) (NN N-Acetyl-L-Cysteine)) (JJ Fenofibrate-induced) (NNP Hepatocarcinogenesis) (NNS Rats)))) |ET| |BS|13:D01.339.387 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 791:D02.886.030.230.259 916:D02.241.081.114.968.500.625 1049:D27.505.519.217|ES| 19:1 1959:1 3222:1 3638:1 3660:1 3661:1 3662:1 3663:1 3664:1
5 	|BT| (S (NP (JJ Nuclear) (NN Maspin) (NN expression)) (NP (ADJP (RB highly) (JJ predictive)) (NN 5-FU) (NN chemotherapy) (NN response) (NN patient)) (VP (VBD advanced) (NP (NN stage) (NN colon) (NN cancer)))) |ET| |BS|50:M01.643 151:E02.319 560:D03.383.742.698.875.404|ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1
5 	|BT| (S (NP (NN OBJECTIVE) (: :)) (NP (NP (NN Vitamin) (NN D)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (VP (VBN upregulated) (NP (NP (NN protein) (CD 1) (PRN (-LRB- -LRB-) (NP (NN VDUP1)) (-RRB- -RRB-))) (NP (NP (JJ potent) (NN tumour) (NN suppressor)) (SBAR (WHNP (WP$ whose) (NN expression)) (S (ADVP (RB dramatically)) (VP (VBD reduced) (NP (NP (JJ various) (NN type) (JJ human) (NN cancer)) (, ,) (PP (VBG including) (NP (JJ gastric) (NN cancer))))))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 206:G05.360.340.024.340.375.249 415:F01.658.500 1050:D12.776.157.125.050.060 1051:D04.808.247.222.159 1052:D12.776.641.750|ES| 2:1 4:1 10:1 14:1 18:1 19:1 22:1 36:1 86:1 98:1 104:1 115:1 125:1 452:1 543:1 561:1 645:1 700:1 862:1 919:1 1011:1 1096:1 1417:1 2592:1 3665:1 3666:1
5 	|BT| (NP (NP (JJ Oncogenic) (NN tumor) (JJ suppressive) (NN role)) (NP (JJ polo-like) (NN kinase) (JJ human) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|8:C04 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 279:D27.888.569.100|ES| 7:1 19:1 31:1 36:1 303:1 304:1 470:1 1974:1 2143:1 3667:1
5 	|BT| (NP (NP (CD One) (JJ reasonable) (NN possibility) (JJ attributable) (NN hyperinsulinemia) (JJ compensatory) (JJ obesity-related) (NN insulin) (NN resistance))) |ET| |BS|564:C18.654.726.500 678:C18.452.394.968.500 1053:C18.452.394.968|ES| 19:1 343:1 654:1 1094:1 2364:1 2467:1 3668:1 3669:1 3670:1 3671:1
5 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (NP (NP (JJ chemoprotective) (NN effect) (NN isorhamnetin) (NN colon) (NN cancer)) (VP (VBN linked) (NP (NP (JJ anti-inflammatory) (NN activity) (NN inhibition) (JJ oncogenic) (NN Src) (NN activity) (JJ consequential) (NN loss)) (VP (JJ nuclear) (NP (NP (NN beta-catenin)) (, ,) (NP (NN activity)) (NP (JJ dependent) (NN CSK) (NN expression))))))))) |ET| |BS|23:D12.776.091.249 43:F01.145.544 279:D27.888.569.100 429:N04.761.559.590.900 430:E05.581.249 686:D27.505.954.158|ES| 2:1 18:1 19:1 32:1 60:1 75:1 103:1 113:1 115:1 321:1 399:1 658:1 796:1 953:1 1256:1 1363:1 1477:1 2795:1 3672:1 3673:1 3674:1 3675:1 3676:1
5 	|BT| (S (VP (PRP$ Our) (S (VP (VBP result) (VP (VBP demonstrate) (S (NP (JJ potential) (JJ therapeutic) (NN role) (NN panobinostat)) (VP (VBG targeting) (NP (JJ aggressive) (JJ triple-negative) (NN breast) (NN cancer) (NN cell) (NN type))))))))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 160:C04.588.180.788 162:F01.145.126.125|ES| 18:1 19:1 23:1 26:1 31:1 94:1 101:1 502:1 538:1 541:1 543:1 616:1 658:1 827:1 3348:1
5 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP demonstrate) (S (VP (NN resveratrol) (VP (VB potentiate) (NP (JJ anti-tumor) (NN effect) (NN 5-FU) (NN CRC) (NN cell) (NN chemosensitizing)) (, ,) (S (VP (VBG inhibiting) (NP (NNP EMT) (NN phenotype)) (PP (IN via) (NP (NN up-regulation) (JJ intercellular) (NN junction) (NN down-regulation) (NN NF-kappaB) (NN pathway)))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 41:A11 80:G05.695 85:G02.111.087.225 122:C14.280.383 142:I01.880.604 210:D12.776.260.600 560:D03.383.742.698.875.404 1054:A11.284.149.165.420|ES| 2:1 19:1 75:1 94:1 101:1 236:1 245:1 257:1 383:1 502:1 596:1 658:1 714:1 880:1 896:1 1712:1 1759:1 2075:1 2308:1 3677:1 3678:1 3679:1 3680:1
5 	|BT| (FRAG (ADVP (RB Overall)) (, ,) (NP (NP (JJ 2-SeCD) (NNS sensitises) (JJ resistant) (NN breast) (NN cancer) (NN cell) (JJ TRAIL-based) (NN apoptosis)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|39:G04.299.139.160 41:A11 333:D01.045 696:V02.270.500|ES| 2:1 18:1 19:1 23:1 89:1 94:1 216:1 378:1 427:1 2858:1 3681:1 3682:1 3683:1
5 	|BT| (NP (NP (NN Overexpression) (NN 5-lipoxygenase) (NN colon) (NN polyp) (NN cancer) (NN effect) (NN 5-LOX) (NN inhibitor) (NN vitro) (JJ murine) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 548:D08.811.682.664.500.848 1055:D08.811.682.690.416.583.625 1056:C23.300.825.411.235|ES| 18:1 19:1 72:1 75:1 113:1 216:1 380:1 627:1 647:1 668:1 3390:1 3684:1
5 	|BT| (S (NP (NP (NN Overexpression) (NN cyclooxygenase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN COX2)) (-RRB- -RRB-))) (NP (NP (JJ uncontrolled) (JJ wingless) (NN Int) (-LRB- -LRB-) (NN Wnt) (-RRB- -RRB-) (: -)) (NN signaling) (NN pathway)) (ADVP (RB long)) (VP (VBD suggested) (NP (NP (NN play) (JJ crucial) (NN role)) (NP (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 24:D08.811.600.720.750 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 147:G02.149.115.800.925|ES| 10:1 14:1 17:1 18:1 19:1 31:1 148:1 238:1 383:1 668:1 877:1 925:1 2325:1 3180:1 3685:1 3686:1 3687:1 3688:1 3689:1 3690:1
5 	|BT| (S (NP (NP (NN Overexpression) (NN cyclooxygenase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (ADVP (RB frequently)) (VP (VBD found) (NP (JJ early) (JJ advanced) (NN lung) (NN cancer)))) |ET| |BS|24:D08.811.600.720.750|ES| 10:1 14:1 18:1 19:1 37:1 76:1 148:1 328:1 668:1 698:1 997:1 1128:1 3180:1
5 	|BT| (S (NP (NN Overexpression) (NN glutamine) (NN synthetase)) (VP (VBN associated) (NP (NNS beta-catenin-mutations) (NN mouse) (NN liver) (NN tumor) (NN promotion) (NN hepatocarcinogenesis) (NN phenobarbital)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 515:C04.588.274.623 756:D03.383.742.698.253.650 1057:D08.811.464.259.200.600|ES| 7:1 19:1 52:1 169:1 668:1 836:1 900:1 2337:1 2685:1 3691:1 3692:1 3693:1
5 	|BT| (S (NP (NN Pamidronate)) (VP (VBD induced) (NP (JJ anti-proliferative) (, ,) (NP (JJ apoptotic) (, ,) (NP (JJ anti-migratory) (NN effect) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255|ES| 2:1 19:1 75:1 303:1 304:1 412:1 2223:1 3694:1 3695:1 3696:1
5 	|BT| (S (NP (JJ Past) (NN study)) (VP (VBN shown) (VP (VBD amplified) (NP (NP (NP (JJ insulin-like) (NN growth) (NN factor) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN IGF1)) (-RRB- -RRB-))) (: /) (NP (NP (NP (NP (NN IGF1) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IGF1-R)) (-RRB- -RRB-))) (NN signalling) (JJ important) (NN role)) (NP (NP (NP (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NN development)))) (, ,) (NP (NN progression) (NN resistance) (NN treatment)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 15:F01.829.316.616 16:C23.550.291.656 52:E02 518:D08.811.913.696.620.682.725.400.185 598:D12.644.276.937.400 599:M01.526.799.500|ES| 2:1 10:1 14:1 17:1 18:1 19:1 31:1 35:1 48:1 98:1 102:1 131:1 185:1 186:1 237:1 245:1 546:1 902:1 1094:1 2093:1 2198:1 2208:1 2437:1 3697:1 3698:1 3699:1
5 	|BT| (NP (NP (NNS Polymorphisms) (NP (JJ estrogen-metabolizing) (NN gene) (NN risk) (JJ hepatocellular) (NN carcinoma)) (NNP Taiwan) (NN female))) |ET| |BS|6:G05.360.340.024.340 61:E05.318.740.600.800 104:C04.557.470.200.025.255 307:G05.365.795 889:D27.505.696.399.472.277 1058:Z01.252.474.872|ES| 9:1 19:1 171:1 303:1 304:1 1404:1 3700:1 3701:1 3702:1
5 	|BT| (NP (NP (NNP Prevention) (JJ upper) (JJ aerodigestive) (NN tract) (NN cancer) (JJ zinc-deficient) (JJ rodent)) (: :) (NP (NN inefficacy) (JJ genetic) (JJ pharmacological) (NN disruption) (NN COX-2))) |ET| |BS|514:B01.050.150.900.649.865 874:D01.268.556.940 1059:H01.158.703|ES| 18:1 19:1 76:1 104:1 864:1 1602:1 2173:1 2898:1 3101:1 3703:1 3704:1 3705:1 3706:1 3707:1
5 	|BT| (S (ADVP (RB Previously)) (, ,) (VP (VBD showed) (SBAR (S (NP (JJ habitual) (JJ heavy) (NN alcohol) (NN ingestion)) (VP (VBD amplified) (S (NP (NP (JJ age-related) (NN hepatocarcinogenesis) (NN P) (NN rat)) (, ,) (NP (NP (CD 80) (NN %)) (NP (JJ alcohol-consuming) (NP (NN P) (NN rat) (VBG developing) (NNS HCCs)) (NP (CD 18) (NN month) (NN alcohol) (NN exposure)))) (, ,)) (VP (VBN compared) (NP (ADJP (CD 5) (NN %)) (NN water-drinking) (NN control))))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 751:D02.033.375 822:D02.033 904:F01.145.317.269 1060:D01.045.250.875.300|ES| 2:1 19:1 50:1 132:1 289:1 311:1 369:1 573:1 578:1 590:1 767:1 849:1 900:1 1132:1 1953:1 2208:1 2723:1 3708:1 3709:1 3710:1 3711:1 3712:1 3713:1 3714:1 3715:1
5 	|BT| (NP (NP (JJ Prognostic) (NN significance) (NN metallothionein) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 777:D12.776.556.670|ES| 18:1 19:1 36:1 183:1 557:1 2731:1 3716:1
5 	|BT| (NP (NP (NNP Promotion) (NN hepatocarcinogenesis) (NN perfluoroalkyl) (NN acid) (NN rainbow) (NNS trout))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 1061:B01.050.150.900.493.817.750.825.580.600 1062:D01.029|ES| 19:1 900:1 1275:1 3717:1 3718:1 3719:1 3720:1
5 	|BT| (NP (NP (NP (NN Protein) (NN kinase) (NN Cbeta)) (NP (JJ effective) (NN target) (NN chemoprevention) (NN colon) (NN cancer)))) |ET| |BS|12:Z01.542.049 253:E02.319.162 867:D08.811.913.696.620.682.700.725.049|ES| 18:1 19:1 113:1 160:1 470:1 870:1 1639:1 2911:1 3721:1
5 	|BT| (S (NP (NP (NN Protein) (NN kinase) (NN CbetaII)) (PRN (-LRB- -LRB-) (NP (NN PKCbetaII)) (-RRB- -RRB-))) (VP (VP (VBP play) (NP (JJ requisite) (NN role) (NN initiation) (NN colon)) (NP (NP (NN carcinogenesis) (JJ preclinical) (NN mouse) (NN model)) (VP (VBG promoting) (NP (NN proliferation))))) (VP (VBD increased) (NP (NN beta-catenin) (NN accumulation))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 866:D08.811.913.696.620.682.700.725.049 1063:D08.811.913.696.620.682|ES| 10:1 14:1 19:1 31:1 47:1 52:1 60:1 72:1 113:1 207:1 238:1 299:1 470:1 637:1 881:1 1494:1 2120:1 2911:1 3077:1 3722:1 3723:1
5 	|BT| (S (NP (NN Protein) (NN kinase) (NN D1)) (VP (VBZ attenuates) (NP (NP (NN tumorigenesis) (NN colon) (NN cancer)) (VP (VBG modulating) (NP (NN beta-catenin/T) (NN cell) (NN factor) (NN activity)))))) |ET| |BS|23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 68:A11.118.637.555.567.569 1063:D08.811.913.696.620.682|ES| 18:1 19:1 78:1 94:1 113:1 185:1 399:1 470:1 744:1 2423:1 2435:1 2911:1 3724:1
5 	|BT| (NP (NP (NN PURPOSE) (: :)) (NP (NP (NP (NP (JJ Fatty) (NN acid) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN FAS)) (-RRB- -RRB-))) (NP (JJ overexpressed) (NN lung) (NN cancer))) (, ,) (VP (VBD investigated) (NP (JJ potential) (NN use) (NN FAS) (NN inhibitor) (NN chemoprevention) (NN lung) (NN cancer))))) |ET| |BS|253:E02.319.162 921:D08.811.682.664.500.772 922:D10.251|ES| 2:1 10:1 14:1 18:1 19:1 25:1 66:1 104:1 328:1 380:1 403:1 687:1 827:1 870:1 1275:1 1659:1 3725:1 3726:1
5 	|BT| (NP (NP (NP (NP (NN PURPOSE) (: :)) (NN Obesity) (JJ related) (JJ metabolic) (NN abnormality)) (, ,) (PP (VBG including) (NP (NP (NN insulin) (NN resistance)) (VP (NN activation) (NP (NP (NP (JJ insulin-like) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN IGF)) (-RRB- -RRB-))) (: /) (NP (NP (NP (NN IGF-I) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IGF-IR)) (-RRB- -RRB-))) (NN axis) (, ,) (NN risk) (NN factor) (NN colon) (NN cancer)))))))) |ET| |BS|254:C16.131 409:E05.318.740.600.800.725 518:D08.811.913.696.620.682.725.400.185 564:C18.654.726.500 579:A02.835.232.834.151.383 581:D12.644.276.937 678:C18.452.394.968.500 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 10:1 14:1 18:1 19:1 102:1 104:1 113:1 171:1 185:1 186:1 225:1 419:1 561:1 687:1 1027:1 1094:1 2006:1 2089:1 2093:1 2364:1 3727:1 3728:1 3729:1 3730:1
5 	|BT| (S (NP (NP (NN PURPOSE) (: :)) (NP (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription-3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (JJ downstream) (NN growth) (NN factor) (NN cytokine) (NN receptor))) (, ,)) (VP (VBZ regulates) (NP (NP (JJ key) (JJ oncogenic) (NN pathway) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))))) |ET| |BS|82:D12.644.360.024.342.300 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 279:D27.888.569.100 897:Z01.252.245.500.375 1066:D12.776.543.750.705.852|ES| 2:1 10:1 14:1 18:1 19:1 94:1 102:1 104:1 159:1 185:1 186:1 251:1 328:1 329:1 383:1 560:1 603:1 687:1 694:1 860:1 861:1 953:1 2676:1 2960:1 3731:1
5 	|BT| (NP (NP (NP (JJ Quantitative) (NN analysis) (JJ basic) (NN fibroblast) (NN growth) (NN factor) (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (NP (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 1067:D12.644.276.624.120|ES| 17:1 18:1 19:1 36:1 102:1 185:1 661:1 1251:1 2213:1 3092:1 3732:1 3733:1
5 	|BT| (NP (NP (NP (VBN Reduced) (NN expression) (NN cyclooxygenase) (CD 2) (NN protein) (JJ hereditary) (JJ nonpolyposis) (JJ colorectal) (NN cancer)) (JJ relative) (JJ sporadic) (NN cancer))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 524:C04.588.274.476.411.307.190|ES| 4:1 17:1 18:1 19:1 115:1 148:1 725:1 1531:1 1845:1 1846:1 3180:1 3734:1
5 	|BT| (S (NP (NN Regrowth) (JJ 5-fluorouracil-treated) (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBD prevented) (NP (NP (NN combination) (NN interferon) (NN gamma)) (, ,) (NP (NN indomethacin)) (, ,) (NP (NN phenylbutyrate))))) |ET| |BS|41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 560:D03.383.742.698.875.404 795:D03.438.473.420 1033:D12.644.276.374.440.893 1068:D02.241.223.651|ES| 2:1 18:1 19:1 36:1 94:1 113:1 530:1 1944:1 2305:1 2389:1 2792:1 3735:1 3736:1 3737:1
5 	|BT| (NP (NP (NNS RESULTS) (: :)) (NP (NP (NN 5-LOX) (VBN overexpressed) (JJ adenomatous) (NN polyp) (NN cancer)) (NP (VBN compared) (JJ normal) (JJ colonic) (NN mucosa)))) |ET| |BS|46:A03.556.124.526.356 302:A10.615.550 548:D08.811.682.664.500.848 551:C04.557.470.035.215|ES| 18:1 19:1 25:1 50:1 57:1 104:1 118:1 579:1 647:1 677:1 710:1 3390:1
5 	|BT| (S (NP (NNS RESULTS)) (: :) (S (NP (NN Microarray) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NP (NN osteopontin)) (, ,) (NP (NN marker) (NN colon) (NN cancer) (NN progression)) (, ,)) (VP (VBD down-regulated) (NP (NP (NP (NN polyp) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Delta14)) (: /) (CC +) (-RRB- -RRB-))) (NN mouse) (VBN given) (NN parecoxib)) (NP (VBN compared) (NN control)))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 142:I01.880.604 158:D23.101 350:D12.644.276.374.625 351:A17.360 444:C23.300.825 718:E05.588.570|ES| 2:1 10:1 14:1 18:1 19:1 29:1 48:1 50:1 52:1 104:1 113:1 275:1 280:1 281:1 289:1 534:1 647:1 661:1 710:1 1160:1 1283:1 3738:1 3739:1
5 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (NP (NN Nestin) (NN expression)) (ADVP (RB significantly)) (VP (VBD associated) (NP (NP (JJ poor) (NN survival) (NN patient) (JJ triple-negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.01)))) (-RRB- -RRB-)))))) |ET| |BS|50:M01.643 96:I03.784 159:I01.880.735.634 160:C04.588.180.788 1047:D05.750.078.593.540|ES| 10:1 14:1 18:1 19:1 23:1 26:1 104:1 115:1 120:1 124:1 169:1 274:1 311:1 315:1 545:1 581:1 710:1 3650:1
5 	|BT| (S (NP (NN Resveratrol)) (VP (VBZ induces) (NP (NP (NN chemosensitization) (NN 5-fluorouracil) (NN up-regulation) (JJ intercellular) (NN junction)) (, ,) (NP (JJ Epithelial-to-mesenchymal) (NN transition) (NN apoptosis) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 142:I01.880.604 495:G04.299.335.500 560:D03.383.742.698.875.404 1054:A11.284.149.165.420|ES| 2:1 17:1 18:1 19:1 89:1 214:1 552:1 896:1 2307:1 2946:1 3679:1 3680:1 3740:1 3741:1
5 	|BT| (S (S (NP (NP (NN RNA) (NN interference) (JJ knockdown) (NN DRD2) (NN inhibition) (JJ pharmacologic) (NN antagonist)) (PRN (-LRB- -LRB-) (NP (NN pimozide) (NN haloperidol)) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NN proliferation) (JJ pancreatic) (NN cancer) (NN cell)))) (, ,) (VP (VBD induced) (NP (NP (JJ endoplasmic) (NN reticulum) (NN stress) (NN apoptosis)) (, ,) (NP (VBN reduced) (NN cell) (NN migration))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 156:G05.355.315.203.374.790 183:G04.299.233.750 362:D12.776.543.750.069.300.400.500 681:G04.299.283 1059:H01.158.703 1069:D02.522.352.506 1070:D03.438.103.732 1071:G04.434|ES| 2:1 10:1 14:1 18:1 19:1 89:1 94:1 103:1 299:1 412:1 452:1 464:1 467:1 514:1 515:1 516:1 1210:1 1271:1 2522:1 3742:1 3743:1 3744:1 3745:1 3746:1
5 	|BT| (S (NP (NN Role) (NN microRNA-155) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ choline-deficient) (NN amino) (JJ acid-defined) (NN diet) (NN C57BL/6) (NN mouse)))) |ET| |BS|15:F01.829.316.616 184:D13.150.650.319 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 19:1 52:1 412:1 900:1 1128:1 1129:1 1957:1 2187:1 2188:1 2189:1 2190:1 2191:1 2192:1
5 	|BT| (NP (NP (NN Role) (JJ transcriptional) (JJ posttranscriptional) (NN regulation) (NN methionine) (NNS adenosyltransferases) (NN liver) (NN cancer) (NN progression))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 142:I01.880.604 209:G02.111.087.847 574:D08.811.913.225.650|ES| 18:1 19:1 48:1 438:1 559:1 836:1 1493:1 2050:1 2187:1 3747:1
5 	|BT| (S (NP (NN Roxithromycin)) (VP (VBZ inhibits) (S (NP (NP (JJ constitutive) (NN activation) (JJ nuclear) (NN factor)) (-LRB- -LCB-) (NN kappa) (-RRB- -RCB-) (NN B)) (VP (VBG diminishing) (NP (JJ oxidative) (NN stress) (NN rat) (NN model) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 104:C04.557.470.200.025.255 122:C14.280.383 210:D12.776.260.600 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 843:D02.540.576.500.992.630|ES| 19:1 72:1 185:1 225:1 303:1 304:1 604:1 615:1 763:1 849:1 1256:1 2522:1 2583:1 3748:1 3749:1 3750:1 3751:1 3752:1
5 	|BT| (NP (NP (JJ Seleno-cyclodextrin) (NNS sensitises) (JJ human) (NN breast) (NN cancer) (NN cell) (JJ TRAIL-induced) (NN apoptosis) (NN DR5) (NN induction) (NN NF-kappaB) (NN suppression))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 210:D12.776.260.600 1072:D04.345.103|ES| 18:1 19:1 23:1 36:1 89:1 94:1 714:1 736:1 2453:1 3682:1 3753:1 3754:1 3755:1
5 	|BT| (S (NP (NN Selenoprotein) (NN deficiency) (JJ high) (NN level) (NN selenium) (NN compound)) (ADVP (RB effectively)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (JJ transgenic) (NN mouse)))) |ET| |BS|87:C18.654.521 99:B01.050.050.136.500 122:C14.280.383 1073:D12.776.864 1074:D01.810|ES| 19:1 52:1 178:1 249:1 253:1 285:1 900:1 1370:1 2433:1 2977:1 3284:1 3756:1
5 	|BT| (S (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (VP (VBZ mediates) (NP (NN pathogenesis) (NN colon) (NN cancer) (NN substrate) (NN PTK6)))) |ET| |BS|209:G02.111.087.847 250:E07.305.812|ES| 10:1 14:1 18:1 19:1 113:1 251:1 487:1 501:1 755:1 860:1 861:1 862:1 1041:1 2960:1 3757:1
5 	|BT| (S (NP (NN Simvastatin)) (VP (VP (VBZ induces) (NP (NN apoptosis) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft))) (, ,) (VP (VBZ attenuates) (NP (JJ colitis-associated) (NN colon) (NN cancer) (NN mouse))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 41:A11 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 754:D02.455.426.559.847.638.400.900|ES| 2:1 7:1 18:1 19:1 36:1 52:1 89:1 94:1 113:1 214:1 265:1 410:1 2423:1 2961:1
5 	|BT| (S (NP (NP (NN Sodium) (NN butyrate)) (PRN (-LRB- -LRB-) (NP (NN NaB)) (-RRB- -RRB-))) (VP (VP (VBZ inhibits) (NP (NN proliferation))) (, ,) (VP (VBZ stimulates) (NP (NN apoptosis))) (, ,) (VP (VBZ promotes) (NP (NN differentiation) (JJ human) (NN colon) (NN cancer) (NN cell)) (PP (IN along) (NP (JJ absorptive) (NN phenotype)))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 122:C14.280.383 1075:D02.241.081.114.750|ES| 2:1 10:1 14:1 18:1 19:1 36:1 89:1 94:1 113:1 215:1 236:1 298:1 299:1 615:1 2666:1 2962:1 3758:1 3759:1 3760:1 3761:1
5 	|BT| (S (NP (NNP Sorafenib)) (VP (VBZ sensitizes) (NP (JJ hepatocellular) (ADJP (NN carcinoma) (NN cell) (JJ physiological)) (JJ apoptotic) (NN stimulus)))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255 230:G04|ES| 19:1 94:1 303:1 304:1 2062:1 2223:1 2730:1 3210:1 3762:1
5 	|BT| (NP (NP (NP (NN SRJ09)) (PRN (-LRB- -LRB-) (NP (CD 3,19) (: -) (-LRB- -LRB-) (NN 2-bromobenzylidene) (-RRB- -RRB-) (NN andrographolide)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ semisynthetic) (NN andrographolide)) (PRN (-LRB- -LRB-) (NP (NN AGP)) (-RRB- -RRB-))) (NP (NN derivative)) (, ,) (VP (VBN shown) (VP (VBP induce) (NP (NN G1) (NN cell) (NN cycle) (NN arrest)) (NP (ADVP (RB eventually)) (NP (NN apoptosis) (NN breast) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|10:A01.236 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 94:A11.251.210 1076:G04.299.134.109.249|ES| 2:1 10:1 14:1 18:1 19:1 23:1 89:1 94:1 113:1 237:1 243:1 264:1 601:1 602:1 670:1 2813:1 3763:1 3764:1 3765:1 3766:1 3767:1 3768:1 3769:1
5 	|BT| (NP (NP (NN Sulindac) (NN reversal) (JJ 15-PGDH-mediated) (NN resistance) (NN colon) (NN tumor) (NN chemoprevention) (NNS NSAIDs))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 251:D02.455.426.559.847.486.875 253:E02.319.162 796:D27.505.696.663.850.014.040.500|ES| 7:1 19:1 113:1 870:1 1094:1 2965:1 2966:1 3770:1 3771:1
5 	|BT| (NP (NP (NP (JJ Suppressive) (NN effect)) (NP (ADJP (RB enzymatically) (VBN modified)) (NN isoquercitrin) (JJ phenobarbital-induced) (NN liver) (NN tumor) (NN promotion) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650|ES| 7:1 19:1 75:1 836:1 849:1 2335:1 2337:1 3772:1 3773:1 3774:1 3775:1
5 	|BT| (S (NP (JJ Suppressive) (NN effect) (NN liver) (JJ tumor-promoting) (NN activity) (NN rat)) (VP (VBN subjected) (NP (JJ combined) (NN administration) (JJ phenobarbital) (NN piperonyl) (NN butoxide)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 756:D03.383.742.698.253.650 1077:D03.383.246.118.600|ES| 19:1 75:1 164:1 399:1 836:1 849:1 2575:1 2685:1 3267:1 3772:1 3776:1 3777:1 3778:1
5 	|BT| (S (NP (NN Survivin) (NN overexpression)) (VP (VBN associated) (NP (NP (JJ poor) (NN prognosis) (JJ human) (JJ gastric) (NN cancer)) (, ,) (NP (NN target) (JJ gastric) (NN cancer) (NN therapy))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 159:I01.880.735.634 163:E01.789|ES| 2:1 18:1 19:1 36:1 86:1 130:1 152:1 160:1 169:1 544:1 545:1 3779:1
5 	|BT| (NP (NP (NP (NN Susceptibility) (NN aflatoxin) (JJ B1-related) (JJ primary) (JJ hepatocellular) (NN carcinoma) (NN mouse)) (ADJP (JJ human)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 401:C23.550.291.687 1078:D03.383.663.283.119.075|ES| 19:1 36:1 52:1 303:1 304:1 344:1 2214:1 3780:1 3781:1
5 	|BT| (NP (NP (JJ Synergistic) (JJ chemopreventive) (NN effect) (NN nobiletin) (NN atorvastatin) (NN colon) (NN carcinogenesis))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 624:D27.505.696.706.018|ES| 19:1 75:1 113:1 207:1 1946:1 3782:1 3783:1 3784:1
5 	|BT| (SINV (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (VP (VBG finding) (VP (VBP demonstrate) (SBAR (S (NP (NN pectolinarigenin)) (VP (MD may) (NP (NP (NN candidate) (NN osteosarcoma) (NN intervention)) (VP (VBN linked) (NP (NP (NN STAT3)) (NN signaling) (JJ inhibitory) (NN activity))))))))))) |ET| |BS|69:G02.111.087.800 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650|ES| 2:1 19:1 106:1 195:1 251:1 399:1 491:1 502:1 927:1 1243:1 1363:1 1537:1 1538:1 1562:1 2429:1 2785:1
5 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VBP provide) (NP (JJ direct) (NN evidence) (JJ decorin-mediated) (NN inhibition) (JJ colorectal) (NN cancer) (NN growth) (NN migration) (NN interaction) (NN stabilization) (NN E-cadherin))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625|ES| 2:1 17:1 18:1 19:1 38:1 101:1 102:1 103:1 514:1 618:1 711:1 1537:1 1538:1 1891:1 2267:1 3785:1 3786:1
5 	|BT| (S (NP (NN Tandutinib)) (VP (VBZ inhibits) (S (NP (NN Akt/mTOR) (NN signaling) (NN pathway)) (VP (VBP inhibit) (NP (NN colon) (NN cancer) (NN growth)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 378:D08.811.913.696.620.682.700.755|ES| 18:1 19:1 102:1 113:1 195:1 383:1 615:1 1370:1 2819:1 3787:1
5 	|BT| (NP (NP (NP (NN Targeting) (NN cyclooxygenase-2) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN prevention) (NN treatment)) (JJ intestinal) (NP (NN cancer)))) |ET| |BS|24:D08.811.600.720.750 52:E02 64:D08.811.913.696.620.682.725.400.009.300 101:C04.588.274.476.411|ES| 18:1 19:1 61:1 102:1 109:1 184:1 185:1 186:1 546:1 1474:1 2100:1
5 	|BT| (FRAG (NP (NP (DT The) (NN aim) (NN work)) (VBP characterize) (NP (NP (NN effect) (NN CAPE) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (VBN involved) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NP (NN metabolism) (NN initiation) (NN stage) (NN chemical) (NN hepatocarcinogenesis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 445:I03.946 554:D02.654.442.200 898:G03.495 1079:D08.244.453|ES| 2:1 10:1 14:1 19:1 75:1 637:1 691:1 774:1 900:1 1129:1 1546:1 1567:1 1875:1 1952:1 2124:1 2252:1 2332:1 2549:1 3163:1 3788:1 3789:1
5 	|BT| (FRAG (NP (NP (DT The) (JJ angiogenic) (NN inducer) (NN CYR61)) (PP (RB differentially) (NP (NP (NP (JJ overexpressed) (NN breast) (NN cancer) (NN cell)) (VP (VBG exhibiting) (NP (NP (JJ high) (NN level) (NN Heregulin)) (PRN (-LRB- -LRB-) (NP (NN HRG)) (-RRB- -RRB-))))) (, ,) (NP (NN growth) (NN factor)) (NP (ADVP (RB closely)) (NP (VBN associated) (JJ metastatic) (NN breast) (NN cancer) (NN phenotype))))))) |ET| |BS|10:A01.236 41:A11 80:G05.695 113:C04.697.650 175:J01.897.280.500.269 1080:D12.644.276.860.550.750 1081:D12.644.276.860.550|ES| 2:1 10:1 14:1 18:1 19:1 23:1 25:1 94:1 102:1 169:1 178:1 185:1 236:1 249:1 337:1 691:1 855:1 1139:1 3790:1 3791:1 3792:1 3793:1 3794:1 3795:1
5 	|BT| (S (NP (DT The) (JJ anti-tumor) (NN effect) (NN thymoquinone)) (ADVP (RB also)) (VP (VP (VBD investigated) (NP (NN tumor) (NN xenograft) (NN mouse) (NN model) (NN colon))) (, ,) (NP (NN prostate) (, ,) (JJ pancreatic) (NN lung) (NN cancer)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 34:A05.360.444.575 46:A03.556.124.526.356 92:E04.936.764 93:A01.941.875 608:A03.734|ES| 2:1 5:1 7:1 18:1 19:1 52:1 72:1 75:1 77:1 113:1 265:1 328:1 403:1 467:1 691:1 3677:1 3796:1
5 	|BT| (S (NP (DT The) (NN blockade) (NN 5-LOX)) (VP (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN cell) (NN proliferation)) (ADVP (FW vitro) (FW vivo))) (SBAR (S (VP (MD may) (VP (VB prove) (NP (JJ beneficial) (JJ chemopreventive) (NN therapy) (NN colon) (NN cancer)))))))) |ET| |BS|52:E02 122:C14.280.383 183:G04.299.233.750 548:D08.811.682.664.500.848|ES| 18:1 19:1 94:1 113:1 130:1 216:1 299:1 378:1 491:1 615:1 691:1 984:1 1946:1 2669:1 3390:1 3797:1
5 	|BT| (NP (NP (NP (DT The) (VBN cooked) (NN meat)) (VBN derived) (JJ genotoxic) (NN carcinogen) (JJ 2-amino-3-methylimidazo) (PRN (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-)) (NN pyridine) (JJ potent) (JJ hormone-like) (NN activity)) (: :) (NP (NP (JJ mechanistic) (NN support) (NN role)) (NN breast) (NN cancer))) |ET| |BS|15:F01.829.316.616 161:D06.472 279:D27.888.569.100 744:D03.383.725 1082:J01.576.423.200.200 1083:G07.203.300.600|ES| 18:1 19:1 22:1 23:1 31:1 104:1 399:1 691:1 1364:1 1373:1 1378:1 1721:1 1890:1 2125:1 2639:1 2640:1 3329:1 3581:1 3798:1 3799:1 3800:1
5 	|BT| (FRAG (NP (NP (DT The) (NN copper) (NN chelator) (NN trientine) (JJ antiangiogenic) (NN effect)) (NP (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (ADVP (RB possibly)) (NN inhibition) (NN interleukin-8) (NN production)))) |ET| |BS|12:Z01.542.049 43:F01.145.544 104:C04.557.470.200.025.255 1084:D12.644.276.374.200.120.800 1085:D02.092.782.258.368.880 1086:D27.505.696.377.077.099 1087:D27.505.519.914.500 1088:D01.268.556.195|ES| 2:1 19:1 75:1 103:1 303:1 304:1 691:1 1548:1 2677:1 3801:1 3802:1 3803:1 3804:1 3805:1
5 	|BT| (NP (NNS defensins) (NP (NP (NN matrilysin)) (, ,) (S (ADVP (RB highly)) (VP (VBN overexpressed) (NP (NN colon) (NN cancer)))))) |ET| |BS|937:D08.811.277.656.300.480.525.700.250 1089:D12.644.050.200|ES| 2:1 18:1 19:1 25:1 113:1 626:1 3289:1 3806:1
5 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
5 	|BT| (S (NP (DT The) (NN effect) (NN honokiol) (NN invasion) (NN migration) (NN breast) (NN cancer) (NN cell)) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (NNP Matrigel) (NN invasion)) (, ,) (NP (NN scratch-migration)) (, ,) (NP (NN spheroid-migration)) (, ,) (NP (NP (JJ electric) (JJ cell-substrate) (NN impedance)) (VP (VBG sensing) (NP (-LRB- -LRB-) (NP (NN ECIS) (-RRB- -RRB-) (: -)) (VBN based) (NN migration) (NN assay))))))))) |ET| |BS|225:E05.337 333:D01.045 681:G04.299.283 1090:G01.358.500.249.277.350 1091:E01.370.225.500.335 1092:G01.358.500.249 1093:F02.830.816|ES| 2:1 10:1 14:1 18:1 19:1 23:1 75:1 94:1 310:1 350:1 514:1 620:1 691:1 780:1 2895:1 3574:1 3807:1 3808:1 3809:1 3810:1 3811:1 3812:1 3813:1 3814:1
5 	|BT| (S (NP (DT The) (JJ monoclonal) (NN antibody) (NN CH12)) (VP (VBZ augments) (NP (NP (JJ 5-fluorouracil-induced) (NN growth) (NN suppression) (JJ hepatocellular) (NN carcinoma) (NN xenograft)) (VP (VBG expressing) (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN variant) (CD III)))))) |ET| |BS|45:G07.700.320.249 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 1094:D12.776.124.125.900 1095:A10.272.497|ES| 19:1 102:1 184:1 185:1 186:1 265:1 303:1 304:1 691:1 810:1 990:1 1365:1 2281:1 2453:1 2611:1 3815:1 3816:1 3817:1
5 	|BT| (S (NP (NP (DT The) (NP (JJ murine) (JJ non-pancreatic) (JJ secretory) (NN phospholipase) (NN A)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN sPLA) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (-RRB- -RRB-))) (VP (VBN proposed) (NP (NP (NN tumor) (NN modifier) (JJ multiple) (JJ intestinal) (NN neoplasia)) (PRN (-LRB- -LRB-) (NP (NN Min)) (-RRB- -RRB-))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 192:D08.811.277.352.100.680.750.937.750 608:A03.734|ES| 7:1 10:1 14:1 19:1 30:1 69:1 109:1 148:1 627:1 640:1 643:1 644:1 649:1 650:1 691:1 2129:1 3818:1 3819:1
5 	|BT| (S (NP (DT The) (NN neurotensin) (NN receptor-1)) (VP (VBZ promotes) (NP (NN tumor) (NN development) (JJ sporadic) (JJ inflammation-associated) (NN mouse) (NN model) (NN colon) (NN cancer)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 53:C06.405.205.265 525:C23.550.470 1048:D12.776.543.750.100.550|ES| 7:1 18:1 19:1 35:1 52:1 72:1 113:1 298:1 691:1 725:1 1849:1 3657:1 3820:1
5 	|BT| (S (NP (NP (DT The) (NN observation) (NN TKO) (NN mouse) (JJ resistant) (NN tumor)) (VP (VBG promoting) (NP (NN effect) (NN dioxin) (NN liver)))) (VP (VBZ suggests) (SBAR (S (NP (JJ inflammatory) (NN cytokine) (NN play) (JJ important) (NN step) (NN dioxin)) (VP (VBD mediated) (NP (NN liver) (NN tumor) (NN promotion) (NN mouse))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 79:I03.450.642.693 242:A03.620 429:N04.761.559.590.900 430:E05.581.249 515:C04.588.274.623 752:D12.644.276.374 1096:D03.383.231.900 1097:D03.383.231|ES| 7:1 19:1 52:1 75:1 238:1 331:1 427:1 437:1 691:1 836:1 881:1 902:1 1477:1 2087:1 2337:1 2430:1 2676:1 3821:1 3822:1
5 	|BT| (NP (NP (NP (DT The) (NN potency) (JJ nifuroxazide) (NN breast) (NN cancer)) (VP (VBN assessed) (ADVP (FW vitro) (FW vivo))))) |ET| |BS||ES| 18:1 19:1 23:1 216:1 378:1 691:1 2796:1 2820:1 3823:1
5 	|BT| (NP (NP (NP (DT The) (JJ potential) (NN utility) (NN acetyltanshinone) (NN IIA) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer)) (: :) (NP (NP (NN Induction) (NN cancer) (NN cell) (NN death)) (VP (VBG targeting) (NP (JJ apoptotic) (JJ metabolic) (NN signaling) (NN pathway)))))) |ET| |BS|33:C04.697.098 39:G04.299.139.160 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 126:G02.111.087.800 134:G04.299.139 605:G03.495.553|ES| 18:1 19:1 23:1 94:1 104:1 195:1 383:1 411:1 546:1 616:1 691:1 827:1 2006:1 2020:1 2194:1 2195:1 2221:1 2222:1 2223:1
5 	|BT| (S (NP (DT The) (JJ present) (NN work)) (VP (VBN conducted) (VP (VBP examine) (S (NP (NP (NN effect) (NN thymosin) (NN beta-4)) (PRN (-LRB- -LRB-) (NP (NN Tbeta4)) (-RRB- -RRB-))) (NP (NP (NN upregulation) (NN apoptosis) (NN SW480) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN induced) (NN T) (NN cell) (JJ various) (JJ chemotherapeutic) (NN agent)) (VP (VBD reduced) (NP (NP (NP (NN susceptibility) (NN cytotoxicity) (JJ anti-Fas) (NN IgM)) (PRN (-LRB- -LRB-) (NP (NN CH-11)) (-RRB- -RRB-))) (NP (JJ Tbeta4-overexpressing) (NN cell))) (ADVP (RB previously)) (VP (VBD reported) (NP (NN u))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 68:A11.118.637.555.567.569 249:G05.355.315.800 339:G02.111.087.880 401:C23.550.291.687 445:I03.946 660:D27.505.954.248 876:F01.145 946:D27.888.569.213|ES| 10:1 14:1 18:1 19:1 75:1 89:1 94:1 113:1 412:1 452:1 691:1 728:1 960:1 993:1 1096:1 1126:1 1307:1 1353:1 1527:1 1546:1 1762:1 2243:1 3096:1 3100:1 3317:1 3824:1 3825:1 3826:1 3827:1 3828:1 3829:1 3830:1 3831:1
5 	|BT| (S (NP (DT The) (NN result)) (VP (VBP demonstrate) (NP (NP (JJ growth-promoting) (NN property) (NN periostin)) (, ,) (NP (NP (JJ possible) (NN role)) (VP (VBG targeting) (NP (NN protein) (JJ therapeutic) (NN option) (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 15:F01.829.316.616 45:G07.700.320.249 52:E02 112:D12.776.097.820|ES| 2:1 4:1 17:1 18:1 19:1 31:1 101:1 502:1 541:1 616:1 691:1 841:1 1359:1 3512:1 3832:1 3833:1
5 	|BT| (S (NP (DT The) (NN result)) (VP (VBD demonstrated) (SBAR (S (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (NN Wnt2) (NN expression) (JJ cytoplasmic/nuclear) (NN beta-catenin) (NN accumulation)) (VP (VBD appeared) (NP (JJ gastric) (NN cancer) (JJ irrespective) (JJ morphological) (NN phenotype)))) (, ,) (FRAG (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (JJ over-expressed) (NN Wnt) (JJ nuclear) (NN translocalisation) (NN beta-catenin)) (VBD found) (NP (NP (ADJP (QP (CD 68) (CD 58)) (NN %)) (NN i-GCs) (CD 47) (ADJP (CD 47) (NN %)) (NN d-GCs)) (NP (ADJP (RB closely) (JJ related)) (NN pattern)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))) (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (NP (NN co-existence) (NN Wnt2) (NN up-regulation/beta-catenin) (JJ nuclear) (NN translocalisation)) (ADJP (NP (NP (ADJP (RB positively) (VBN associated)) (NN lymph) (NN node) (NN metastasis)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.05)))) (-RRB- -RRB-))) (ADJP (RB well) (JJ T-stage))))))))) |ET| |BS|23:D12.776.091.249 80:G05.695 113:C04.697.650 142:I01.880.604 703:A10.549.400 967:D01.248.497.158.490 1042:Z01.107.757.284 1098:A11.284.430.214|ES| 2:1 10:1 14:1 18:1 19:1 37:1 60:1 86:1 98:1 101:1 115:1 148:1 169:1 236:1 260:1 311:1 312:1 315:1 369:1 419:1 691:1 787:1 806:1 855:1 862:1 877:1 1175:1 1256:1 2120:1 2536:1 2537:1 3834:1 3835:1 3836:1 3837:1 3838:1 3839:1 3840:1 3841:1 3842:1 3843:1 3844:1 3845:1 3846:1 3847:1 3848:1 3849:1 3850:1
5 	|BT| (S (NP (DT The) (NN result) (NN study)) (VP (VBP suggest) (SBAR (S (S (NP (NP (NN E1AF)) (, ,) (NP (NP (NN expression)) (ADVP (RB closely)))) (VP (VBD correlated) (NP (NN expression) (NN matrilysin)))) (, ,) (VP (VBP play) (NP (JJ key) (NN role) (NN progression) (JJ gastric) (NN cancer))))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 79:I03.450.642.693 937:D08.811.277.656.300.480.525.700.250|ES| 2:1 18:1 19:1 31:1 48:1 86:1 101:1 115:1 131:1 159:1 238:1 446:1 691:1 796:1 855:1 3289:1 3484:1
5 	|BT| (S (NP (DT The) (NN result)) (VP (VBP provide) (SBAR (S (NP (NN evidence) (JJ major) (NN role) (NN beta-catenin/Apc) (NN pathway) (NN development) (JJ heterocyclic) (JJ amine-induced) (NN colon) (NN tumor)) (VP (VBP give) (NP (NN weight) (NN view) (NN regulation) (NN beta-catenin) (JJ critical) (NN tumor) (JJ suppressive) (NN effect) (NN Apc) (NN colon) (NN carcinogenesis))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 15:F01.829.316.616 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 51:C04.588.274.476.411.307.180 142:I01.880.604 653:C23.888.144 856:D02.092|ES| 7:1 19:1 31:1 35:1 38:1 60:1 75:1 101:1 113:1 207:1 280:1 383:1 438:1 462:1 691:1 711:1 825:1 1626:1 1974:1 2399:1 3054:1 3055:1 3851:1 3852:1
5 	|BT| (S (NP (DT The) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN MTHFR) (NN genotype) (JJ relevant) (JJ independent) (NN factor) (NN patient) (NN outcome) (JJ 5FU-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 333:D01.045 396:G05.380 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 17:1 18:1 19:1 101:1 120:1 185:1 546:1 547:1 691:1 796:1 865:1 883:1 997:1 1329:1 2231:1 2232:1
5 	|BT| (S (NP (DT The) (NNP Ron) (NN receptor) (NN tyrosine) (NN kinase)) (VP (VBD overexpressed) (NP (ADJP (RB approximately) (JJ half)) (JJ human) (NN colon) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 25:1 36:1 113:1 186:1 470:1 691:1 1843:1 2341:1 3853:1 3854:1
5 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP indicate) (SBAR (S (NP (NN Wnt/beta-catenin) (NN signalling) (NN pathway)) (VP (VBD activated) (NP (JJ gastric) (NN cancer)))))) (, ,) (VP (MD may) (VP (VB play) (NP (NP (JJ pivotal) (NN role)) (NP (CC either) (NP (JJ gastric) (NN cancer) (NN formation) (NN tumour) (NN invasion) (NN dissemination)))))))) |ET| |BS|8:C04 15:F01.829.316.616 20:G03.495 23:D12.776.091.249 69:G02.111.087.800 79:I03.450.642.693|ES| 2:1 18:1 19:1 31:1 39:1 43:1 86:1 163:1 238:1 302:1 383:1 491:1 620:1 792:1 793:1 795:1 1011:1 1479:1 2437:1 3248:1
5 	|BT| (NP (NP (DT These) (S (VP (VBG finding) (VP (VB provide) (NP (NP (JJ important) (NN information) (NN interaction)) (PP (IN among) (NP (NP (VBG transforming) (NN growth) (NN factor) (NN beta)) (, ,) (NP (NN BMP)) (, ,) (NP (NN Wnt) (NN signaling) (NN pathway) (NN progression) (NN CRC)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 147:G02.149.115.800.925 503:D12.644.276.374.687 1099:D12.644.276.954.200|ES| 2:1 19:1 48:1 102:1 185:1 195:1 245:1 383:1 618:1 711:1 792:1 877:1 902:1 927:1 1372:1 1772:1 1972:1 2338:1 3855:1
5 	|BT| (SINV (NP (DT These)) (VBG finding) (ADVP (RB strongly)) (VBP suggest) (NP (NP (NP (NN estrogen) (NN play) (JJ critical) (NN role)) (NP (JJ female) (NN hepatocarcinogenesis))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 642:M01.975 889:D27.505.696.399.472.277|ES| 19:1 31:1 238:1 635:1 792:1 796:1 825:1 900:1 927:1 1404:1 3168:1
5 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP suggest) (S (ADVP (RB aberrantly)) (VP (VBN expressed) (SBAR (S (NP (NN CARM1) (NN tumor) (JJ marker-positive) (NN cell)) (VP (VBZ promotes) (NP (NN tumorigenesis) (JJ early) (NN stage) (NN hepatocarcinogenesis)))))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 41:A11 376:D23.101.140|ES| 6:1 7:1 19:1 78:1 94:1 298:1 792:1 796:1 900:1 927:1 1128:1 1129:1 2657:1 3856:1 3857:1
5 	|BT| (S (NP (DT These) (NN observation)) (VP (VBP suggest) (SBAR (S (NP (JJR safer) (JJ efficacious) (NN sulindac) (NN derivative)) (VP (VBD developed) (NP (NP (JJ colorectal) (NN cancer) (NN chemoprevention)) (VP (VBG targeting) (NP (NN PDE5)) (VP (ADVP (RB possibly)) (NP (JJ cGMP-degrading) (NNS isozymes)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 251:D02.455.426.559.847.486.875 253:E02.319.162 429:N04.761.559.590.900 430:E05.581.249 993:D08.811.348 1100:D03.438.759.646.454.160 1101:N06.850.135.060.075|ES| 17:1 18:1 19:1 190:1 616:1 792:1 796:1 869:1 870:1 1165:1 1477:1 1548:1 2813:1 3858:1 3859:1 3860:1 3861:1
5 	|BT| (S (NP (NNS Thiazolidinediones)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (NN hepatitis) (NN B) (JJ virus-transgenic) (NN mouse) (NN peroxisome) (JJ proliferator-activated) (NN receptor) (JJ gamma-independent) (NN regulation) (NN nucleophosmin)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 99:B01.050.050.136.500 122:C14.280.383 142:I01.880.604 719:D12.776.826.239.588 862:D02.886.675.933 863:B04.280.375.650.425|ES| 19:1 52:1 186:1 438:1 763:1 900:1 1370:1 1801:1 1887:1 2048:1 3069:1 3070:1 3071:1 3072:1
5 	|BT| (S (NP (DT This)) (VP (VBZ indicates) (SBAR (S (S (NP (JJ low) (NN level) (JJ active) (NN Caspase-3)) (VP (MD may) (VP (VB represent) (S (NP (NP (JJ new) (NN predictor) (NN CT) (NN responsiveness)) (, ,) (NP (NN inhibition) (NN Caspase-3)) (, ,)) (VP (VBG antagonising) (NP (JJ downstream) (NN effector) (NN Caspase-3) (NN paracrine) (NN signalling))))))) (, ,) (NP (NN COX-2)) (VP (MD may) (VP (VB improve) (NP (NP (NN patient) (NN outcome)) (VP (VBG following) (SBAR (S (NP (NNP CT)) (VP (VBD advanced) (NP (NN CRC))))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 50:M01.643 906:D08.811.277.656.262.500.126.350.300 1102:Z01.058.290.100.120 1103:G04.299.122.600|ES| 2:1 19:1 76:1 103:1 120:1 197:1 245:1 249:1 491:1 531:1 547:1 560:1 570:1 628:1 712:1 799:1 807:1 997:1 2437:1 2466:1 3190:1 3510:1 3862:1 3863:1 3864:1 3865:1 3866:1
5 	|BT| (S (NP (DT This)) (VP (VBD led) (SBAR (S (NP (NN u)) (VP (VBP investigate) (SBAR (S (NP (NP (JJ antitumor) (NN growth)) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin) (JJ immunocompetent) (NN xenograft) (NN model) (NN mouse) (JJ metastatic) (JJ mammary) (NN cancer) (NN p53) (NN mutation))) (VP (VBZ induces) (NP (NP (JJ metastatic) (NN spectrum)) (NP (JJ similar) (VBN seen) (JJ human) (NN breast) (NN cancer))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 10:A01.236 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 113:C04.697.650 213:F02.830.816.964 609:A01.236.249 610:G12.460|ES| 12:1 18:1 19:1 23:1 34:1 36:1 52:1 72:1 102:1 214:1 265:1 332:1 337:1 399:1 459:1 724:1 807:1 2228:1 2243:1 2244:1 2245:1 2246:1 2247:1 2248:1 2249:1
5 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (JJ NAC1-mediated) (NN autophagy)) (VP (MD may) (VP (VBN exploited) (NP (JJ new) (NN target) (VBG enhancing) (NN efficacy) (NN cisplatin) (JJ ovarian) (NN cancer) (NN type) (NN malignancy))))) |ET| |BS|390:G04.299.139.399 498:D01.210.375|ES| 2:1 18:1 19:1 49:1 160:1 491:1 543:1 712:1 1317:1 1691:1 1760:1 1761:1 1763:1 2304:1 2527:1 3867:1
5 	|BT| (NP (NP (NNP Thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NN dihydropyrimidine) (NN dehydrogenase) (NN expression)) (, ,) (NP (JJ histological) (NN tumour) (NN regression) (JJ 5-FU-based) (JJ neo-adjuvant) (JJ chemoradiotherapy) (JJ rectal) (NN cancer))) |ET| |BS|8:C04 333:D01.045 560:D03.383.742.698.875.404 561:E02.186.079.500 713:D08.811.913.555.500.862 846:F01.393.784 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350|ES| 2:1 18:1 19:1 66:1 115:1 1011:1 1986:1 1987:1 1988:1 1989:1 3002:1 3081:1 3082:1 3083:1 3084:1 3085:1 3086:1
5 	|BT| (S (NP (JJ Tolfenamic) (NN acid)) (ADVP (RB also)) (VP (VP (VBD facilitated) (NP (NP (NN translocation) (JJ endogenous) (JJ exogenous) (NN ESE-1) (NN nucleus)) (JJ colorectal) (NN cancer) (NN cell) (, ,) (NN gene) (NN silencing)) (S (VP (VBG using) (NP (NN ESE-1) (JJ small) (VBG interfering) (NN RNA))))) (VP (VBD attenuated) (NP (ADJP (JJ tolfenamic) (JJ acid-induced)) (NN EGR-1) (NN expression) (NN apoptosis))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 42:G05.355.315.203.374 117:D13.150.650.700 463:C23.550.210.870 580:D12.776.260.158.500 1104:A11.284.430.106|ES| 2:1 5:1 9:1 17:1 18:1 19:1 89:1 94:1 100:1 115:1 350:1 515:1 750:1 808:1 1275:1 1618:1 2598:1 2599:1 3019:1 3868:1 3869:1 3870:1 3871:1 3872:1 3873:1 3874:1
5 	|BT| (NP (NP (NN Transcription) (NN coactivator) (JJ PBP/MED1-deficient) (NNS hepatocytes)) (NP (JJ susceptible) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 209:G02.111.087.847 262:A11.436.348 554:D02.654.442.200 1105:D05.500.374.750|ES| 19:1 52:1 894:1 899:1 900:1 2732:1 2991:1 3875:1 3876:1
5 	|BT| (S (NP (NP (VBG Transforming) (NN growth) (NN factor-beta) (NN adaptor)) (, ,) (NP (NN beta2-spectrin)) (, ,)) (VP (VBZ modulates) (S (NP (NN cyclin) (JJ dependent) (NN kinase) (CD 4)) (VP (VB reduce) (NP (NN development) (JJ hepatocellular) (NN cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 503:D12.644.276.374.687 1106:D08.811.913.696.620.682.700.646.500.875 1107:D12.776.124.875|ES| 2:1 18:1 19:1 35:1 102:1 303:1 319:1 321:1 470:1 606:1 743:1 1773:1 2361:1 3877:1 3878:1 3879:1
5 	|BT| (S (NP (JJ Transgenic) (NN mouse) (VBG expressing) (NN cyclooxygenase-2) (NNS hepatocytes)) (VP (VBP reveal) (NP (JJ minor) (NN contribution) (NN enzyme) (NN chemical) (NN hepatocarcinogenesis)))) |ET| |BS|24:D08.811.600.720.750 99:B01.050.050.136.500 262:A11.436.348 730:D08.811 1108:M01.416|ES| 19:1 52:1 61:1 810:1 894:1 900:1 1360:1 1670:1 2124:1 2388:1 3880:1 3881:1
5 	|BT| (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (NN Loss) (NN E-cadherin)) (PRN (-LRB- -LRB-) (NP (NN CDH1)) (-RRB- -RRB-))) (, ,) (NP (NN Smad4)) (, ,) (NP (NP (NN p53) (VBN shown) (NN play) (JJ integral) (NN role)) (ADJP (JJ gastric))) (, ,) (NP (JJ intestinal) (, ,) (NN breast) (NN cancer) (NN formation)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200|ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1
5 	|BT| (S (PP (IN Unlike) (NP (NN celecoxib))) (, ,) (NP (NN sulindac)) (VP (VBD proved) (NP (ADJP (RB highly) (JJ effective)) (NN colon) (NN tumor) (NN prevention) (NN 15-PGDH) (NN KO) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 51:C04.588.274.476.411.307.180 251:D02.455.426.559.847.486.875 684:D02.065.884.247|ES| 2:1 7:1 19:1 52:1 113:1 133:1 626:1 869:1 1474:1 1639:1 2179:1 2807:1 2849:1 3882:1
5 	|BT| (S (NP (NP (NN Up-regulation) (JJ several) (NN miR-1) (NN target)) (PP (VBG including) (NP (NP (NN FoxP1)) (, ,) (NP (NN MET)) (, ,) (NP (NN HDAC4) (JJ primary) (JJ human) (NNS HCCs) (NP (NN down-regulation) (NN expression) (JJ 5-AzaC-treated) (NN HCC) (NN cell)))))) (VP (VBP suggest) (NP (NN role) (NN hepatocarcinogenesis)))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 19:1 31:1 36:1 94:1 115:1 160:1 257:1 262:1 344:1 441:1 561:1 796:1 900:1 957:1 1132:1 2270:1 2271:1 2272:1 2273:1 2274:1
5 	|BT| (S (NP (JJ Ursodeoxycholic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN Ras) (NN mutation)) (, ,) (NP (NP (JJ wild-type) (NN Ras)) (NN activation)) (, ,) (NP (NN cyclooxygenase-2) (NN expression) (NN colon) (NN cancer))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 24:D08.811.600.720.750 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 8:1 18:1 19:1 34:1 61:1 113:1 115:1 225:1 615:1 1275:1 1775:1 3121:1
5 	|BT| (S (S (NP (JJ Ursolic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN metastasis) (JJ human) (JJ colorectal) (NN cancer) (JJ orthotopic) (JJ nude) (NN mouse) (NN model)) (VP (VBG targeting) (NP (JJ multiple) (NN cell) (NN signaling) (NN pathway)))))) (: :) (NP (NN chemosensitization) (NN capecitabine))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 113:C04.697.650 122:C14.280.383 126:G02.111.087.800 810:D03.383.742.680.245.500.425|ES| 17:1 18:1 19:1 36:1 52:1 72:1 94:1 102:1 104:1 195:1 266:1 383:1 615:1 616:1 649:1 806:1 1275:1 2873:1 3740:1 3883:1 3884:1
5 	|BT| (S (NP (NNP Use) (JJ novel) (JJ genetic) (NN mouse) (NN model)) (VP (VBP investigate) (NP (NN role) (NN folate) (JJ colitis-associated) (NN colon) (NN cancer)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 53:C06.405.205.265 224:D03.438.733.631.400 259:D12.776.395.240.150.500 1109:E05.599.395.397|ES| 18:1 19:1 31:1 52:1 72:1 113:1 410:1 459:1 778:1 864:1 891:1 3885:1
5 	|BT| (S (S (VP (VBG Using) (NP (JJ protein-protein) (NN interaction) (NN screening)))) (, ,) (VP (VBD found) (SBAR (S (NP (NN FOXO3a)) (VP (VBD interacted) (NP (NN ER-alpha) (NN ER-beta) (NN protein) (JJ human) (NN breast) (NN carcinoma) (NN cell) (NN line) (NN MCF-7)) (, ,) (S (VP (VBG suggesting) (VP (VBZ exists) (NP (NN crosstalk) (NN FOXO3a) (NN ER) (NN signaling) (NN pathway) (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell)))))))))) |ET| |BS|7:D12.776 126:G02.111.087.800 148:G12.425.143.281 432:A11.251.210.190.630 889:D27.505.696.399.472.277 1110:D12.776.826.750.350.174 1111:D12.776.826.750.350.262 1112:D23.125|ES| 2:1 4:1 18:1 19:1 23:1 36:1 37:1 94:1 195:1 224:1 264:1 304:1 383:1 618:1 741:1 1009:1 1188:1 1484:1 1719:1 3361:1 3362:1 3363:1 3886:1 3887:1 3888:1 3889:1
5 	|BT| (S (NP (PRP We)) (VP (VBD shown) (SBAR (S (NP (NN Hsp90) (NN inhibitor) (NN 17-AAG)) (VP (VBZ enhances) (NP (NN cytotoxicity) (NN oxaliplatin) (NN colon) (NN cancer) (NN cell) (NN line) (NN inhibition) (NN NF-kappaB))))))) |ET| |BS|43:F01.145.544 94:A11.251.210 210:D12.776.260.600 946:D27.888.569.213 1113:D12.776.580.216.380|ES| 18:1 19:1 94:1 103:1 113:1 237:1 264:1 380:1 714:1 843:1 1356:1 2543:1 3317:1 3890:1 3891:1
5 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (S (NP (NN HT-29) (JJ human) (NN colon) (NN adenocarcinoma) (NN cell) (NN effect)) (VP (NN NO-ASA) (NP (NP (JJ inducible) (NN form) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN NOS2)) (-RRB- -RRB-))))) (, ,) (NN enzyme) (VBN implicated) (NN colon) (NN carcinogenesis)))) |ET| |BS|22:D08.811.682.664.500.772.500 33:C04.697.098 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 84:C04.557.470.200.025 189:V02.460 670:D02.455.426.559.389.657.410.595.176 730:D08.811 792:A11.251.210.190.475 1114:D08.811.277.352.827.070.250|ES| 2:1 10:1 14:1 19:1 36:1 63:1 64:1 65:1 66:1 75:1 94:1 113:1 207:1 255:1 324:1 630:1 843:1 977:1 2388:1 2782:1 3892:1 3893:1
5 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NP (NP (NP (JJ antiangiogenic) (NN effect) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN copper) (NN chelator) (NN trientine)) (, ,) (S (VP (ADVP (RB especially)) (VBG focusing) (NP (NP (NN relationship) (NN copper) (NN interleukin-8)) (PRN (-LRB- -LRB-) (NP (NN IL-8)) (-RRB- -RRB-)))) (, ,) (NP (JJ potent) (JJ angiogenic) (NN factor)) (VP (VBN produced) (NP (NN hepatoma) (NN cell))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 515:C04.588.274.623 1084:D12.644.276.374.200.120.800 1085:D02.092.782.258.368.880 1086:D27.505.696.377.077.099 1087:D27.505.519.914.500 1088:D01.268.556.195 1115:D27.505.696.377.077.077 1116:G14.640.079|ES| 2:1 10:1 14:1 19:1 22:1 75:1 94:1 134:1 185:1 223:1 303:1 304:1 324:1 345:1 441:1 843:1 3790:1 3801:1 3802:1 3803:1 3804:1 3805:1 3894:1 3895:1 3896:1
5 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NN effect) (NN pioglitazone) (NN lung) (NN cancer) (NN development) (JJ carcinogen-induced) (NN lung) (NN adenocarcinoma) (NP (NP (JJ squamous) (NN cell) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN SCC)) (-RRB- -RRB-)))))) |ET| |BS|279:D27.888.569.100 929:C04.557.470.200.400|ES| 10:1 14:1 18:1 19:1 35:1 75:1 94:1 255:1 304:1 324:1 328:1 843:1 1067:1 2421:1 3897:1 3898:1
5 	|BT| (S (NP (PRP We)) (VP (VBD examined) (SBAR (S (NP (NP (NP (NN role) (NN Se) (NNS selenoproteins) (NN liver) (NN tumor) (NN formation)) (NN TGFalpha/c-Myc) (JJ transgenic) (NN mouse)) (, ,) (NP (VBN characterized) (VBN disrupted) (NN redox) (NN homeostasis))) (VP (VBP develop) (NP (NN liver) (NN cancer) (CD 6) (NN month) (NN age))))))) |ET| |BS|15:F01.829.316.616 20:G03.495 99:B01.050.050.136.500 152:G07.700.345 515:C04.588.274.623 522:D12.644.276.382.750 865:G02.149.767.650 1073:D12.776.864 1117:Z01.639.520.750|ES| 2:1 7:1 18:1 19:1 31:1 43:1 52:1 285:1 324:1 500:1 648:1 836:1 843:1 985:1 2039:1 2723:1 3075:1 3529:1 3899:1 3900:1 3901:1 3902:1
5 	|BT| (S (NP (PRP We)) (VP (VBD found) (FRAG (NP (NN melatonin)) (ADVP (RB significantly)) (NP (VBD enhanced) (NP (JJ 5-FU-mediated) (NN inhibition) (NN cell) (NN proliferation)) (, ,) (NP (NP (NN colony) (NN formation)) (, ,) (NP (NN cell) (NN migration) (NN invasion) (NN colon) (NN cancer) (NN cell))))))) |ET| |BS|20:G03.495 41:A11 43:F01.145.544 109:I01.696.116 183:G04.299.233.750 560:D03.383.742.698.875.404 681:G04.299.283 707:D03.438.473.914.481|ES| 2:1 18:1 19:1 37:1 43:1 94:1 103:1 113:1 124:1 299:1 314:1 385:1 514:1 620:1 843:1 2556:1 3903:1
5 	|BT| (S (NP (PRP We)) (VP (VBD found) (SBAR (S (NP (NP (NN treatment) (JJ COX2-overexpressing) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell) (NN fisetin)) (PRN (-LRB- -LRB-) (NP (CD 30-120) (NN microM)) (-RRB- -RRB-))) (VP (VBD resulted) (SBAR (S (NP (NP (NN induction) (NN apoptosis)) (, ,) (NP (NP (NN downregulation) (NN COX2) (NN protein) (NN expression)) (PP (IN without) (S (VP (VBG affecting) (NP (NN COX1))))))) (VP (VBD inhibited) (NP (NN secretion) (NN prostaglandin) (NN E2)))))))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 122:C14.280.383 792:A11.251.210.190.475 1118:D10.251.355.255.550.250.200 1119:D08.811.600.720.500 1120:A12.200|ES| 2:1 4:1 10:1 14:1 18:1 19:1 36:1 37:1 89:1 94:1 113:1 115:1 365:1 546:1 594:1 595:1 736:1 843:1 1195:1 2084:1 2530:1 2978:1 3017:1 3685:1 3904:1 3905:1 3906:1 3907:1 3908:1 3909:1
5 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD examined) (NP (NP (NP (NP (NP (NP (NN toxicity)) (FW vivo) (NP (NN efficacy) (NN lead) (NN diaminothiazole) (NN 4-Amino-5-benzoyl-2)) (: -)) (PRN (-LRB- -LRB-) (NP (JJ 4-methoxy) (NN phenylamino)) (-RRB- -RRB-))) (NN thiazole)) (PRN (-LRB- -LRB-) (NP (NN DAT1)) (-RRB- -RRB-))) (NN colon) (NN cancer) (NN xenograft)))) |ET| |BS|86:D01.268.556.435 92:E04.936.764 93:A01.941.875 1121:D02.886.675|ES| 5:1 10:1 14:1 18:1 19:1 113:1 254:1 265:1 324:1 378:1 843:1 2304:1 2406:1 3910:1 3911:1 3912:1 3913:1 3914:1 3915:1
5 	|BT| (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBN shown) (NP (NP (NN I3C) (JJ cyclic) (JJ tetrameric) (JJ derivative) (NN CTet)) (VP (VBN formulated) (NP (NP (NN gamma-cyclodextrin)) (PRN (-LRB- -LRB-) (NP (NN gamma-CD)) (-RRB- -RRB-))) (ADVP (RB efficiently)) (VP (VBD inhibited) (NP (JJ cellular) (NN proliferation) (NN breast) (NN cancer) (NN cell) (NN line))))))) |ET| |BS|41:A11 122:C14.280.383 776:G01.910.645 1122:B01.050.500.500.294.700.750.700.680|ES| 10:1 14:1 18:1 19:1 23:1 94:1 237:1 264:1 299:1 365:1 772:1 843:1 2813:1 3074:1 3916:1 3917:1 3918:1 3919:1 3920:1 3921:1 3922:1 3923:1
5 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (S (NP (NN PTK6) (NN inhibition) (JJ effective) (NN strategy)) (VP (VBP inhibit) (SBAR (S (NP (NP (NP (NP (NN growth) (NN survival) (NN Her2)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN breast) (NN cancer) (NN cell)) (, ,) (PP (VBG including) (NP (ADJP (RB relatively) (JJ resistant)) (NNP Lapatinib))) (, ,)) (VP (VBN targeted) (NP (NP (NP (NP (NN therapy) (NN Her2)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN breast) (NN cancer)) (, ,) (NP (CC either) (ADJP (RB intrinsically) (VBN acquired)) (JJ continuous) (NN drug) (NN exposure)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 43:F01.145.544 45:G07.700.320.249 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 67:D26 96:I03.784 122:C14.280.383|ES| 2:1 10:1 14:1 16:1 18:1 19:1 23:1 39:1 94:1 102:1 103:1 130:1 191:1 274:1 427:1 561:1 843:1 1041:1 1044:1 1114:1 1370:1 1639:1 1750:1 1953:1 3059:1 3924:1 3925:1 3926:1 3927:1 3928:1
5 	|BT| (S (NP (PRP We)) (VP (VP (VBD investigated) (NP (NP (NN colon) (NN cancer) (NN cell) (NN effect)) (NP (NN geraniol) (NN thymidylate) (NN synthase) (NN thymidine) (NN kinase) (NN expression)))) (, ,) (NP (CD two) (NN enzyme) (JJ related) (NN 5-fluorouracil) (NN cytotoxicity)))) |ET| |BS|41:A11 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 730:D08.811 946:D27.888.569.213 1123:D08.811.913.696.620.750|ES| 2:1 18:1 19:1 66:1 75:1 94:1 113:1 115:1 403:1 419:1 470:1 843:1 933:1 2307:1 2388:1 2578:1 3082:1 3317:1 3929:1
5 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NP (NN expression) (NN leptin) (NN receptor) (CD 171) (JJ consecutive) (NN patient)) (PRN (-LRB- -LRB-) (NP (NP (CD 78) (JJ female) (CD 93) (NN male)) (: ;) (NP (CD 71) (NN year))) (-RRB- -RRB-))) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 642:M01.975 1124:D06.472.699.042.500|ES| 10:1 14:1 19:1 115:1 120:1 186:1 217:1 245:1 403:1 843:1 1402:1 1404:1 1452:1 3206:1 3930:1 3931:1 3932:1 3933:1 3934:1
5 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (S (NP (JJ suppressive) (NN effect) (NN roxithromycin)) (VP (VBD accelerated) (NP (JJ hepatocellular) (NN carcinoma) (NN growth) (NN rat) (JJ hepatocarcinogenetic) (NN model)) (NP (VBN compared) (NN result) (NN effect) (NN TNP-470))))))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 843:D02.540.576.500.992.630|ES| 19:1 50:1 72:1 75:1 101:1 102:1 303:1 304:1 403:1 843:1 849:1 1391:1 1974:1 2990:1 3935:1 3936:1
5 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN lack) (NN fucosylation) (JJ consequent) (NN loss) (NN GDP-fucose) (NN synthesis)) (VP (VBZ contributes) (NP (NN colon) (NN carcinogenesis))))))) |ET| |BS|20:G03.495 33:C04.697.098 46:A03.556.124.526.356 1125:D03.438.759.646.454.340.350.400|ES| 19:1 32:1 113:1 207:1 221:1 252:1 403:1 843:1 845:1 3436:1 3937:1 3938:1 3939:1
5 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD demonstrated) (SBAR (S (NP (NN simvastatin)) (VP (VBZ inhibits) (NP (NP (NN NF-kappaB)) (SBAR (S (NP (NN signaling) (JJ human) (JJ intestinal) (JJ epithelial) (NN cell)) (VP (VBZ ameliorates) (NP (JJ acute) (JJ murine) (NN colitis))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 47:A03.556.124 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 75:A11.436 122:C14.280.383 210:D12.776.260.600 754:D02.455.426.559.847.638.400.900|ES| 19:1 36:1 90:1 94:1 109:1 127:1 143:1 195:1 615:1 627:1 714:1 843:1 1175:1 1527:1 2679:1 2877:1
5 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NP (NP (NP (JJ anthocyanin-containing) (JJ baked) (JJ purple-fleshed) (NN potato)) (PRN (-LRB- -LRB-) (NP (NN PP)) (-RRB- -RRB-))) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN PA)) (-RRB- -RRB-))) (VP (VBD suppressed) (SBAR (S (NP (JJ early) (JJ advanced) (JJ human) (NN colon) (NN cancer) (NN cell) (NN proliferation)) (VP (VBD induced) (NP (NP (NN apoptosis)) (, ,) (NP (NP (NN effect) (NN colon) (NNS CSCs)) (ADJP (VBN known)))))))))))) |ET| |BS|39:G04.299.139.160 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 183:G04.299.233.750 556:C11.768.175 667:B01.650.940.800.575.100.905.725.777 668:B01.650.940.800.575.100.905.725.777 669:D03.383.663.283.266.450.087 1126:Z01.639.760.590.715 1127:Z01.107.757.656|ES| 2:1 10:1 14:1 18:1 19:1 36:1 75:1 89:1 94:1 113:1 132:1 299:1 307:1 412:1 556:1 843:1 997:1 1128:1 1527:1 1966:1 2439:1 2440:1 2496:1 3940:1 3941:1 3942:1 3943:1
5 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NN embelin)) (VP (VBZ inhibits) (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN vitro))))) (, ,) (VP (ADVP (RB effectively)) (VBZ suppresses) (NP (JJ 1,2-dimethylhydrazine) (JJ dihydrochloride-induced) (NN colon) (NN carcinogenesis) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383|ES| 2:1 18:1 19:1 52:1 94:1 102:1 113:1 132:1 207:1 216:1 615:1 686:1 843:1 1527:1 2642:1 2889:1 2977:1 3145:1
5 	|BT| (S (NP (PRP We)) (VBP suggest) (NP (NN inosine) (CD 5)) ('' ') (: -) (NP (NP (NN monophosphate) (NN dehydrogenase) (NN inhibitor)) (, ,) (VP (ADVP (RB already)) (VBN used) (NP (NN treatment) (NN disease)))) (, ,) (VP (MD may) (NP (VBN used) (JJ potential) (NN differentiation) (NN therapy) (NN drug) (NN control) (NN prostate) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 74:G04.299.151 288:C23.550.288 1128:D08.811.682.047.820.450 1129:E02.319|ES| 2:1 18:1 19:1 77:1 130:1 191:1 215:1 289:1 380:1 476:1 491:1 546:1 796:1 827:1 843:1 998:1 3085:1 3944:1 3945:1 3946:1
5 	|BT| (S (NP (PRP We)) (VP (VBD tested) (S (NP (NP (NP (NN role) (JJ basic) (NN fibroblast) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN bFGF)) (-RRB- -RRB-))) (NP (JJ vascular) (NP (NP (JJ endothelial) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-))))) (VP (VBP switch) (NP (JJ angiogenic) (NN phenotype)) (NP (CD 35) (NN patient) (JJ colorectal) (NN cancer) (JJ different) (NN stage) (NN disease)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 80:G05.695 288:C23.550.288 371:A07.231 1067:D12.644.276.624.120 1130:D12.644.276.390|ES| 10:1 14:1 17:1 18:1 19:1 31:1 102:1 120:1 185:1 236:1 414:1 843:1 998:1 1129:1 1251:1 2066:1 2213:1 2709:1 2988:1 3092:1 3733:1 3790:1 3947:1 3948:1
5 	|BT| (SINV (IN While) (NP (JJ exact) (NN mechanism)) (-LRB- -LRB-) (S (NP (-RRB- -RRB-) (NN antitumor) (NN activity) (NN p-XSC)) (VP (VBZ remains) (VP (VBN elucidated)))) (, ,) (VP (VBZ appears)) (NP (NP (NN modulation) (NN beta-catenin) (NN expression) (NN COX-2) (NN activity)) (VBN associated) (NN inhibition) (JJ intestinal) (NN polyp))) |ET| |BS|23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 193:C23.300.825.411|ES| 2:1 10:1 14:1 19:1 60:1 76:1 103:1 109:1 115:1 162:1 169:1 399:1 442:1 647:1 1945:1 2244:1 3949:1 3950:1 3951:1 3952:1 3953:1
5 	|BT| (S (NP (NP (NN Zinc-finger) (NN protein) (CD 331)) (, ,) (NP (JJ novel) (JJ putative) (NN tumor) (NN suppressor)) (, ,)) (VP (VBZ suppresses) (NP (NN growth) (NN invasiveness) (JJ gastric) (NN cancer)))) |ET| |BS|7:D12.776 45:G07.700.320.249 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500 1131:G02.111.570.820.709.600.040.985|ES| 2:1 4:1 7:1 18:1 19:1 86:1 102:1 686:1 700:1 891:1 918:1 3954:1 3955:1 3956:1
6 	|BT| (NP (NP (NN AIM) (: :)) (S (S (VP (TO To) (VP (VB elucidate) (S (NP (JJ anticancer) (NN mechanism) (NNP Huqi) (NNP San)) (VP (VBG assessing) (NP (NN expression) (NN G-6-Pase))))))) (, ,) (NP (NP (NN SDH)) (, ,) (NP (NN ATPase) (NN AFP) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 893:D08.811.277.040.025 894:D08.811.277.040.025|ES| 2:1 19:1 104:1 115:1 162:1 828:1 849:1 900:1 959:1 1196:1 1697:1 1880:1 2762:1 2765:1 2766:1 3630:1 3632:1 3634:1 3957:1
6 	|BT| (S (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (JJ therapeutic) (NN effect) (JJ potential) (NN mechanism) (JJ natural) (NN flavonoid) (NN quercetin-3-O-beta-D-glucuronide)) (PRN (-LRB- -LRB-) (NP (NN Q3GA)) (-RRB- -RRB-))) (VP (NN lipid) (NP (NP (NN metabolism) (NN disorder) (JJ free) (JJ fatty) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FFA)) (-RRB- -RRB-)))))))) (: -) (VP (VBN induced) (NP (NN fatty) (NN liver)) (ADVP (FW vivo) (FW vitro)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 533:D03.383.663.283.266.450.284.777 534:D03.383.663.283.266.450 1132:C18.452.584 1133:D10.251.310|ES| 10:1 14:1 19:1 75:1 104:1 162:1 216:1 378:1 409:1 459:1 541:1 827:1 828:1 836:1 959:1 1275:1 1886:1 2007:1 2070:1 2333:1 2401:1 3163:1 3958:1 3959:1 3960:1 3961:1
6 	|BT| (NP (NP (NN Alcohol) (JJ well-established) (NN risk) (NN factor) (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (NN mechanism) (NN alcohol) (NN liver) (NN cancer) (NN complex))) |ET| |BS|104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 751:D02.033.375 822:D02.033|ES| 2:1 18:1 19:1 162:1 171:1 185:1 303:1 304:1 695:1 836:1 1770:1 3710:1 3962:1
6 	|BT| (NP (NP (NP (JJ Altered) (NN gene) (NN expression) (NN DNA) (NN repair)) (: -) (NP (NP (NN cell) (JJ proliferation-associated) (NNS proteins/enzymes)) (VP (VBN examined) (NP (NN process) (JJ tamoxifen-induced) (NN hepatocarcinogenesis) (JJ female) (JJ Sprague-Dawley) (NN rat)))))) |ET| |BS|155:G05.355.310 640:D02.455.426.559.389.150.700.900 642:M01.975 730:D08.811 769:B01.050.150.900.649.865.635.505.700.750 1134:G02.111.087.219 1135:D12.776.543|ES| 9:1 19:1 94:1 115:1 324:1 638:1 666:1 849:1 900:1 971:1 1404:1 2707:1 3963:1 3964:1 3965:1 3966:1
6 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (JJ Chronic) (NN alcohol) (NN drinking)) (VP (VBZ accelerates) (NP (NP (NN liver) (NN fibrosis) (NN patient)) (JJ viral) (NN hepatitis)) (VP (ADVP (RB fully)) (VBD explained) (NP (JJ ethanol-enhanced) (NN liver) (NN damage)))))) |ET| |BS|50:M01.643 242:A03.620 676:C06.552.630 751:D02.033.375 904:F01.145.317.269 1136:B04.450|ES| 19:1 104:1 120:1 529:1 836:1 889:1 949:1 1046:1 1777:1 1778:1 1848:1 2048:1 3710:1 3967:1 3968:1 3969:1 3970:1 3971:1
6 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (NN Alcohol) (NN consumption)) (VP (VBZ promotes) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 904:F01.145.317.269|ES| 10:1 14:1 19:1 104:1 298:1 303:1 304:1 441:1 1046:1 2387:1 3962:1
6 	|BT| (S (NP (NP (NP (NN BACKGROUND) (: :)) (NP (NP (JJ Chemopreventive) (NN effect) (JJ selective) (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NN inhibitor) (NN JTE-522) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis)) (VP (VBD evaluated) (NP (NNP Wistar) (NN rat)))) |ET| |BS|225:E05.337 349:D27.505.519.389.310.500 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900|ES| 10:1 14:1 19:1 61:1 75:1 76:1 104:1 380:1 409:1 780:1 849:1 900:1 1046:1 1749:1 1875:1 1952:1 2603:1 3972:1 3973:1
6 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (JJ Chronic) (NP (NP (NN ethanol) (NN consumption) (NN increase) (NN risk) (JJ hepatic) (NN cirrhosis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 904:F01.145.317.269|ES| 10:1 14:1 19:1 40:1 104:1 171:1 303:1 304:1 441:1 838:1 1046:1 1199:1 2387:1 3440:1 3967:1
6 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (NP (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (ADVP (RB rapidly)) (VP (VBG increasing) (NP (NP (NN cancer)) (WHNP (WHNP (WP$ whose) (JJ known) (NN risk) (NN factor)) (NP (JJ chronic) (NN ethanol) (NN abuse))) (, ,) (NP (JJ viral) (NN hepatitis) (NN infection)) (, ,) (NP (NN aflatoxin) (NN exposure)))))) |ET| |BS|104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 1137:D03.383.663.283.119 1138:C02.440.420 1139:C25.775.100.250 1140:C06.552.380 1141:C02|ES| 2:1 10:1 14:1 18:1 19:1 104:1 171:1 185:1 304:1 441:1 556:1 715:1 919:1 1046:1 1790:1 1953:1 2048:1 2151:1 2214:1 2362:1 3424:1 3440:1 3969:1 3974:1
6 	|BT| (NP (NP (NP (NN BACKGROUND)) (: :) (NP (NP (JJ Prolonged) (JJ high) (NN intake) (JJ dietary) (NN selenium)) (VP (VBN shown) (VP (VBP induce) (NP (JJ gestational) (NN diabetes) (NN rat) (NN hyperinsulinemia) (NN pig))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 935:D01.268.185.850 1053:C18.452.394.968 1142:B01.050.150.900.649.077.880.399 1143:B01.050.150.900.649.077.880 1144:C13.703.170|ES| 19:1 104:1 178:1 237:1 243:1 849:1 1046:1 2009:1 2563:1 2594:1 3284:1 3670:1 3975:1 3976:1 3977:1
6 	|BT| (S (NP (NP (NP (JJ Carcinogenic) (NN risk) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (NP (NN liver) (JJ tumor-promoting) (NN activity)) (NN copper) (NN gluconate)))) (, ,) (NP (JJ additive) (JJ functional) (NN food)) (, ,)) (VP (VBN investigated) (S (VP (VBG using) (NP (NP (NP (NN rat) (JJ medium-term) (NN liver) (NN carcinogenicity) (NN bioassay) (NN protocol)) (PRN (-LRB- -LRB-) (NP (NN Ito) (NN test)) (-RRB- -RRB-))) (ADJP (ADJP (JJ 2-week)) (ADJP (JJ short-term))) (NN administration) (NN experiment)))))) |ET| |BS|12:Z01.542.049 61:E05.318.740.600.800 106:E05.091 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 515:C04.588.274.623 849:G08.686.785.760.769.490.500 914:L01.178 1145:D02.241.081.844.322 1146:D27.720.368 1147:C17.800.621|ES| 2:1 10:1 14:1 19:1 161:1 162:1 171:1 350:1 399:1 403:1 415:1 435:1 836:1 849:1 1418:1 2470:1 2575:1 2632:1 2931:1 3022:1 3215:1 3216:1 3266:1 3583:1 3776:1 3801:1 3978:1 3979:1 3980:1 3981:1
6 	|BT| (NP (NP (JJ Chronic) (JJ excessive) (NN alcohol) (NN consumption) (NN lead) (NN development)) (NP (NP (JJ alcoholic) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN ALD)) (-RRB- -RRB-))) (S (VP (ADVP (RB greatly)) (VB increase) (NP (NN risk) (NN liver) (NN cancer))))) |ET| |BS|61:E05.318.740.600.800 86:D01.268.556.435 650:C06.552 904:F01.145.317.269 1148:M01.066|ES| 10:1 14:1 18:1 19:1 35:1 40:1 171:1 254:1 836:1 998:1 2387:1 2880:1 3710:1 3967:1 3982:1 3983:1 3984:1
6 	|BT| (S (NP (JJ Chronic) (NN exposure) (NN toxaphene)) (VP (VBD resulted) (NP (NN increase) (NN liver) (NN tumor) (NN B6C3F1) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 7:1 19:1 40:1 52:1 594:1 836:1 1953:1 3967:1 3985:1 3986:1
6 	|BT| (SINV (NP (NP (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (CD one) (JJ common) (NN cancer)) (ADVP (RB worldwide)) (, ,) (VP (VBD caused)) (NP (NP (NP (NNP Hepatitis) (NNP C) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HCV)) (-RRB- -RRB-))) (NN hepatotoxin))) |ET| |BS|104:C04.557.470.200.025.255 550:B04.450.410|ES| 2:1 10:1 14:1 18:1 19:1 304:1 441:1 655:1 1010:1 1422:1 1938:1 1954:1 1955:1 2151:1 2506:1 3987:1 3988:1
6 	|BT| (NP (NP (NP (NN Mouse) (JJ nongenotoxic) (NNS hepatocarcinogens)) (SBAR (S (NP (JJ phenobarbital) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-)) (NN chlordane)) (VP (VBP induce) (ADVP (RB hepatomegaly)) (VP (VBN characterized) (NP (NN hypertrophy) (NN hyperplasia)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 510:C23.550.444 756:D03.383.742.698.253.650 1150:D02.455.526.439.180 1151:C06.552.416 1152:C23.300.775|ES| 10:1 14:1 19:1 243:1 985:1 1795:1 2127:1 2685:1 3340:1 3496:1 3989:1 3990:1 3991:1 3992:1
6 	|BT| (NP (NP (NP (NNS OBJECTIVES)) (: :) (NP (NP (NP (NP (DT The) (JJ chemopreventive) (JJ potential) (NN Tephrosia) (NN purpurea) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN TPE)) (-RRB- -RRB-))) (NN N-nitrosodiethylamine) (-LRB- -LRB-) (NN NDEA) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ Wistar) (NN rat)) (VP (VBN assessed))))))))) |ET| |BS|104:C04.557.470.200.025.255 415:F01.658.500 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1153:B01.650.940.800.575.100.401.890|ES| 10:1 14:1 19:1 104:1 303:1 304:1 409:1 441:1 691:1 827:1 849:1 1946:1 2496:1 2602:1 2603:1 3823:1 3993:1 3994:1 3995:1 3996:1 3997:1
6 	|BT| (S (NP (PRP$ Our) (JJ prior) (NN work)) (VP (VBD showed) (NP (NP (NP (JJ brief) (NN exposure) (JJ pregnant) (NN C3H) (NN mouse) (JJ inorganic) (JJ arsenic-induced) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NN formation) (JJ adult) (JJ male) (NN offspring))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 445:I03.946 1154:B01.050.050.199.520.520.388 1155:G08.686.340 1156:F01.829.263.065 1157:E05.916.039 1158:D01.268.513.249|ES| 10:1 14:1 19:1 43:1 52:1 132:1 303:1 304:1 355:1 441:1 658:1 1402:1 1546:1 1953:1 3174:1 3998:1 3999:1 4000:1 4001:1 4002:1 4003:1
6 	|BT| (NP (NP (NP (NNP Phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (NP (NP (NP (NN orphenadrine) (-LRB- -LRB-) (NN ORPH) (-RRB- -RRB-) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NP (NN 2B) (NN inducer) (NN liver) (JJ tumor-promoting) (NN effect) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650 1159:D02.092.471.600 1160:D27.505.389.249|ES| 10:1 14:1 19:1 75:1 836:1 849:1 2549:1 3496:1 3776:1 3788:1 3789:1 3791:1 4004:1 4005:1 4006:1 4007:1
6 	|BT| (S (NP (NN Rat) (NN liver) (NN tumor)) (VP (VBD initiated) (NP (NP (NP (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD followed) (S (NP (NP (NN promotion) (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (NP (NP (NP (VBN examined) (NN expression) (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF) (NN beta)) (-RRB- -RRB-))) (NP (NN type) (CD I) (, ,) (NP (QP (CD II) (CD III))) (NP (NN receptor))))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 554:D02.654.442.200 756:D03.383.742.698.253.650 1161:D12.644.276.374.687.100|ES| 2:1 7:1 10:1 14:1 19:1 102:1 115:1 186:1 324:1 543:1 836:1 1116:1 1772:1 1773:1 1875:1 1900:1 1972:1 2281:1 2337:1 2350:1 2602:1 2685:1 3130:1 3496:1 4008:1 4009:1
6 	|BT| (S (NP (NP (DT The) (JJ key) (NN event) (JJ responsible) (NN mouse) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (NN pesticide)) (PRN (-LRB- -LRB-) (NP (NP (NN viz.)) (, ,) (NP (NN pronamide))) (-RRB- -RRB-))))) (VP (VBD investigated) (NP (S (NP (NN series) (NN study)) (VP (VBG employing) (ADJP (ADJP (JJ molecular)) (, ,) (ADJP (JJ biochemical)) (, ,) (ADJP (JJ cellular))))) (, ,) (NP (JJ apical) (NN endpoint))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 515:C04.588.274.623 913:D27.720.031.700|ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 159:1 161:1 205:1 403:1 412:1 691:1 836:1 1689:1 1807:1 2132:1 3074:1 3214:1 3323:1 4010:1 4011:1 4012:1 4013:1
6 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBD determine) (SBAR (S (NP (NP (NP (NP (JJ chemopreventive) (NN activity) (JJ Korean) (JJ red) (NN ginseng) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN KRG)) (-RRB- -RRB-))) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD induced) (NP (NN hepatocarcinogenesis) (NN rat))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 415:F01.658.500 554:D02.654.442.200 1162:B01.650.940.800.575.100.087.500|ES| 10:1 14:1 19:1 74:1 131:1 399:1 412:1 691:1 849:1 900:1 1634:1 1875:1 1946:1 1952:1 2496:1 2916:1 4014:1 4015:1 4016:1
6 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBN designed) (VP (VB determine) (SBAR (IN whether) (S (NP (NN alteration) (NN expression) (NN RXRalpha) (NN retinoid) (NN receptor) (NN RARalpha) (NN RARbeta)) (VP (VBN involved) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG using) (NP (NP (NP (CD 3) ('' ') (: -) (NN methyl-4-dimethylaminoazobenzene) (-LRB- -LRB-) (CD 3) ('' ') (: -)) (NP (NN MeDAB) (-RRB- -RRB-) (: -))) (VP (VBN induced) (NP (NN rat) (NN liver) (NN carcinogenesis) (NN model)))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 1163:D02.092.146.325.500 1164:D12.776.826.701|ES| 10:1 14:1 19:1 72:1 74:1 115:1 131:1 186:1 207:1 221:1 350:1 409:1 691:1 774:1 836:1 849:1 900:1 951:1 1307:1 1683:1 2573:1 4017:1 4018:1 4019:1 4020:1 4021:1
6 	|BT| (S (NP (NP (DT The) (JJ present) (NN study)) (VP (VBN undertaken))) (VBP investigate) (NP (NP (NN effect) (JJ dietary) (NN supplementation) (NN nimesulide) (NN eugenol) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN initiated) (NP (JJ early) (NN hepatocarcinogenesis) (NN F344) (JJ male) (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 554:D02.654.442.200 590:B01.050.050.199.520.760.200 595:G07.203.650.240 1165:D02.241.223.200.054.500|ES| 10:1 14:1 19:1 75:1 131:1 459:1 691:1 849:1 900:1 1128:1 1307:1 1402:1 1875:1 2567:1 2594:1 2602:1 3185:1 3186:1 4022:1 4023:1 4024:1
6 	|BT| (S (NP (NP (DT The) (JJ preventive) (NN effect)) (VP (VP (VBN processed) (NP (NP (NP (NP (NNP Aloe) (NN vera) (NN gel)) (PRN (-LRB- -LRB-) (NP (NN PAG)) (-RRB- -RRB-))) (NN colon) (NN carcinogenesis)) (VP (VBN examined) (S (VP (VBG using) (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-)))))))) (: -) (VP (VBN initiated) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))))) (: -) (VP (VBD promoted) (NP (NN mouse) (NN colon) (NN carcinogenesis) (NN model)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080|ES| 10:1 14:1 19:1 52:1 72:1 75:1 113:1 207:1 324:1 350:1 406:1 407:1 674:1 691:1 1883:1 1993:1 1994:1 3300:1 3306:1 4024:1 4025:1 4026:1 4027:1 4028:1 4029:1
6 	|BT| (S (NP (NP (NP (DT The) (NN process) (NN hepatocarcinogenesis) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (JJ initiation/phenobarbital) (-LRB- -LRB-) (NN PB) (-RRB- -RRB-) (NN promotion) (NN mouse) (NN model)) (VP (VBZ involves) (NP (NP (JJ selective) (JJ clonal) (NN outgrowth) (NN cell) (NN harboring) (NN oncogene) (NN mutation) (NN Ctnnb1)) (, ,) (S (NP (JJ spontaneous) (JJ DEN-only-induced) (NN tumor)) (ADVP (RB often)) (NP (NP (NN Ha-ras)) (: -) (NP (JJ B-raf-mutated))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 9:G05.360.340.024.340.375.500 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 41:A11 216:Z01.107.084.900.425 278:D08.811.913.696.620.682.700.559.842.374 301:A11.251.353 554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 2:1 7:1 10:1 14:1 19:1 24:1 34:1 52:1 72:1 94:1 283:1 632:1 638:1 691:1 900:1 1069:1 1304:1 1673:1 1749:1 1875:1 1952:1 2337:1 3496:1 4030:1 4031:1 4032:1 4033:1 4034:1 4035:1
6 	|BT| (S (NP (NP (NP (DT The) (JJ tumour-promoting) (NN effect) (NN beta-naphthoflavone)) (PRN (-LRB- -LRB-) (NP (NN BNF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (JJ novel) (NN aryl) (NN hydrocarbon) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN AhR)) (-RRB- -RRB-))) (NN agonist)) (, ,)) (VP (VBN investigated) (S (VP (VBG using) (NP (JJ medium-term) (NN hepatocarcinogenesis) (NN model) (NN rat)))))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 259:D12.776.395.240.150.500 849:G08.686.785.760.769.490.500 914:L01.178 969:D12.776.260.643.715 983:D03.383.663.283.266.450.175.100|ES| 2:1 10:1 14:1 19:1 72:1 75:1 186:1 350:1 403:1 691:1 849:1 891:1 900:1 3215:1 3228:1 3417:1 3418:1 3468:1 4036:1 4037:1 4038:1
6 	|BT| (S (NP (EX There)) (NP (JJ abundant) (JJ epidemiological) (NN evidence) (JJ heavy) (NN alcohol) (NN intake)) (VP (VBZ contributes) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN development)))) |ET| |BS|104:C04.557.470.200.025.255 651:H02.403.720.500 904:F01.145.317.269|ES| 10:1 14:1 19:1 35:1 38:1 303:1 304:1 441:1 767:1 845:1 1798:1 2563:1 3217:1 3710:1 4039:1
6 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ validates) (NP (NP (NP (NN utility) (NN Gum) (JJ Arabic-conjugated) (NN gold) (NNS nanoparticles)) (PRN (-LRB- -LRB-) (NP (NNS GA-AuNPs)) (-RRB- -RRB-))) (SBAR (S (NP (NN laser)) (VP (VBP induce) (NP (JJ photothermal) (NN inhibition) (NN hepatocarcinogenesis)))))) (, ,) (PP (IN via) (S (VP (VBG employing) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (FRAG (: -) (NP (VBN mediated) (JJ hepatocellular) (NN carcinoma) (NN model))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 104:C04.557.470.200.025.255 554:D02.654.442.200 1166:Z01.058.290.190.300 1167:D05.750.078.739.500 1168:J01.637.512.600 1169:D01.268.556.322 1170:E07.632.490|ES| 2:1 10:1 14:1 19:1 72:1 103:1 131:1 243:1 303:1 304:1 596:1 807:1 900:1 1875:1 1952:1 2194:1 4011:1 4040:1 4041:1 4042:1 4043:1 4044:1 4045:1 4046:1 4047:1 4048:1
6 	|BT| (NP (NP (S (VP (TO To) (VP (VB clarify) (S (VP (VBG modifying) (NP (NP (NN effect) (NN N-Acetyl-L-Cysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (JJ antioxidative) (NN ability)) (, ,) (NP (NN hepatocarcinogenesis)) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN fenofibrate)) (PRN (-LRB- -LRB-) (NP (NN FF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PPAR)) (-RRB- -RRB-))) (NN alpha)) (NP (NN agonist))) (, ,) (NP (NP (JJ male) (NN F344/N) (NN rat)) (VP (VBN administered) (NP (NP (NP (ADJP (JJ single) (JJ intraperitoneal)) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN initiator))))) (VP (VBD followed) (NP (NN administration) (NN diet) (VBG containing) (CD 3,000) (NN ppm) (NN FF) (CD 16) (NN week))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 385:F02.784.629.131 536:D12.776.826.239.500 554:D02.654.442.200 590:B01.050.050.199.520.760.200 596:E02.642.249 791:D02.886.030.230.259 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 916:D02.241.081.114.968.500.625 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 75:1 186:1 286:1 783:1 785:1 828:1 849:1 900:1 1300:1 1402:1 1801:1 1836:1 1875:1 1887:1 1912:1 2191:1 2336:1 2575:1 2644:1 2846:1 3130:1 3193:1 3221:1 3222:1 3223:1 3224:1 3225:1 3226:1 3227:1 3228:1 3229:1 3230:1 3231:1 3232:1 3233:1 3234:1
6 	|BT| (S (VP (TO To) (VP (VB clarify) (NP (NP (JJ possible) (NN mechanism) (JJ non-genotoxic) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (NP (NN piperonyl) (NN butoxide)) (PRN (-LRB- -LRB-) (NP (NN PBO)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ male) (NN F344) (NN rat)) (VP (VBN administered) (S (NP (NN i.p))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 590:B01.050.050.199.520.760.200 967:D01.248.497.158.490 1077:D03.383.246.118.600|ES| 2:1 10:1 14:1 19:1 162:1 412:1 828:1 849:1 900:1 1359:1 1402:1 2336:1 3185:1 3193:1 3777:1 3778:1 4049:1 4050:1 4051:1
6 	|BT| (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (JJ protective) (NN effect) (NN bilberry) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN BBE)) (-RRB- -RRB-))) (NP (NP (NP (ADJP (RB enzymatically) (VBN modified)) (NN isoquercitrin)) (PRN (-LRB- -LRB-) (NP (NN EMIQ)) (-RRB- -RRB-))) (NP (NP (JJ hepatocarcinogenic) (NN process)) (VP (VBG involving) (NP (NP (JJ oxidative) (NN stress) (NN response)) (, ,) (VP (VBN used) (S (NP (NP (JJ two-stage) (NN hepatocarcinogenesis) (NN model) (JJ N-diethylnitrosamine-initiated) (NN piperonyl) (NN butoxide)) (PRN (-LRB- -LRB-) (NP (NN PBO)) (-RRB- -RRB-))))))))))))) (: -) (VP (VBD promoted) (NP (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 716:G03.495.710 1077:D03.383.246.118.600|ES| 2:1 10:1 14:1 19:1 72:1 75:1 459:1 476:1 493:1 494:1 638:1 828:1 849:1 900:1 2335:1 2372:1 2496:1 2522:1 2583:1 2971:1 3773:1 3774:1 3777:1 3778:1 4029:1 4050:1 4052:1 4053:1 4054:1 4055:1 4056:1
6 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (S (NP (NN effect) (NN liver) (NN damage)) (VP (VBD induced) (NP (NN flutamide) (JJ primary) (NN rat) (NNS hepatocytes)) (S (VP (VBG using) (NP (NP (NN liver)) (NP (JJ microfluidic) (NN biochip)))))))))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 1171:E05.830.666 1172:D02.065.199.420|ES| 19:1 75:1 344:1 350:1 403:1 412:1 836:1 843:1 849:1 894:1 1848:1 4057:1 4058:1 4059:1
6 	|BT| (NP (NP (JJ 2-Amino-1-methyl-6-phenylimidazo) (PRN (-LRB- -LSB-) (ADJP (JJ 4,5-b)) (-RRB- -RSB-)) (NN pyridine) (NN increase) (NN number) (NN tumor)) (, ,) (NP (JJ cystic) (NN crypt) (JJ aberrant) (NN crypt) (NN focus) (JJ multiple) (JJ intestinal) (NN neoplasia) (NN mouse))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 555:C04.182 744:D03.383.725 824:C04.834.020|ES| 2:1 7:1 19:1 40:1 52:1 109:1 640:1 646:1 649:1 1373:1 1378:1 1431:1 1725:1 2639:1 2640:1 2913:1 4060:1 4061:1
6 	|BT| (S (NP (NP (JJ 2-Nitrobenzo) (-LRB- -LSB-) (-RRB- -RSB-) (NN pyrene) (NN 6-nitrochrysene)) (VP (VBD induced) (NP (NP (JJ high) (NN incidence) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (CD 91-100) (NN %)) (-RRB- -RRB-))) (, ,) (PP (VBG remaining) (NP (NN test) (NN compound))))) (VP (VBP induce) (NP (NN tumor) (NN rate)) (NP (RB significantly) (JJR higher) (JJ solvent) (NN control)))) |ET| |BS|8:C04 434:E05.318.308.985.525.375 515:C04.588.274.623 1173:D02.455.426.559.847.799 1174:D27.720.844|ES| 2:1 7:1 10:1 14:1 19:1 41:1 124:1 170:1 178:1 243:1 289:1 369:1 412:1 836:1 1373:1 1378:1 1418:1 1511:1 2433:1 4062:1 4063:1 4064:1 4065:1 4066:1 4067:1
6 	|BT| (S (NP (DT A) (JJ diethylnitrosamine-induced) (NN liver) (NN cancer) (NN model)) (VP (VBD used) (VP (VB evaluate) (NP (NN role) (NN Myc) (NN hepatocarcinogenesis))))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 554:D02.654.442.200|ES| 18:1 19:1 31:1 69:1 72:1 476:1 836:1 890:1 900:1 1786:1 2732:1
6 	|BT| (S (ADVP (RB Additionally)) (, ,) (VP (VBD reported) (SBAR (S (NP (NN tamoxifen)) (VP (MD may) (VP (VB cause) (NP (NP (NP (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN NAFLD)) (-RRB- -RRB-))) (NP (JJ human) (JJ experimental) (NN animal))))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 577:C06.552.241.519 640:D02.455.426.559.389.150.700.900 1175:B01.050.050.199|ES| 2:1 10:1 14:1 19:1 36:1 46:1 263:1 491:1 836:1 993:1 998:1 1779:1 2069:1 2070:1 2371:1 2609:1 4068:1
6 	|BT| (S (NP (NP (NP (NNP Administration) (NN acetaminophen) (NN Jnk)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN mouse)) (VP (VBD produced) (NP (NP (JJR greater) (NN level) (NN liver) (NN injury)) (VBN observed) (NP (NP (NN Jnk1)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN control) (NN mouse)) (, ,) (NP (VBN based) (NN level) (NN serum) (NN marker) (JJ microscopic) (JJ histologic) (NN analysis) (NN liver) (NN tissue)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 98:A10 242:A03.620 333:D01.045 426:E01.370.350.515 661:D02.065.199.092.040 1176:D23.101|ES| 2:1 10:1 14:1 19:1 52:1 134:1 249:1 261:1 272:1 289:1 534:1 661:1 836:1 1992:1 2204:1 2346:1 2412:1 2414:1 2415:1 2416:1 2741:1 4069:1 4070:1 4071:1
6 	|BT| (FRAG (PP (IN After) (NP (NP (JJ 3-month) (NN recovery) (NN period) (JJ tamoxifen-treated) (NN rat) (JJ large) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN diameter) (CD 3) (NN cm)) (-RRB- -RRB-))))) |ET| |BS|8:C04 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 776:G01.910.645 1151:C06.552.416|ES| 7:1 10:1 14:1 19:1 836:1 849:1 862:1 1408:1 1409:1 2722:1 2724:1 2725:1 3265:1 4072:1 4073:1
6 	|BT| (S (NP (NN AIRmax)) (ADVP (RB also)) (NP (JJ susceptible) (NN AIRmin) (NN colon) (NN cancer)) (VP (VP (VBD induced) (NP (NP (QP (CD 2) (CD 7)) (JJ weekly) (NNS dos)) (ADJP (ADJP (JJ 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG showing) (NP (NP (ADJP (RB significantly) (JJR higher)) (NN number) (JJ colonic) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NP (CD 150) (NN day) (NN DMH) (NN treatment))))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.01)))) (-RRB- -RRB-))) (NP (ADJP (RB significantly) (JJR higher)) (NN number) (NN tumor) (VBG affecting) (NP (NP (JJR larger) (JJ intestinal) (NN area)) (CD 300-475) (NN day)))) |ET| |BS|8:C04 46:A03.556.124.526.356 52:E02 292:Z01 433:F01.470.047 824:C04.834.020 1177:A03.556.124.526|ES| 2:1 5:1 7:1 10:1 14:1 18:1 19:1 109:1 113:1 124:1 148:1 170:1 311:1 315:1 412:1 546:1 581:1 646:1 677:1 899:1 988:1 1431:1 1725:1 2201:1 2530:1 2642:1 2643:1 2653:1 2913:1 2914:1 4074:1 4075:1 4076:1 4077:1 4078:1 4079:1 4080:1 4081:1
6 	|BT| (NP (NP (NN Amelioration) (JJ free) (NN fatty) (JJ acid-induced) (NN fatty) (NN liver) (NN quercetin-3-O-beta-D-glucuronide) (NN modulation) (NN peroxisome) (JJ proliferator-activated) (JJ receptor-alpha/sterol) (JJ regulatory) (JJ element-binding) (JJ protein-1c) (NN signaling))) |ET| |BS|69:G02.111.087.800 242:A03.620 533:D03.383.663.283.266.450.284.777 536:D12.776.826.239.500 576:D12.776.260.103.500.750.500 1133:D10.251.310|ES| 19:1 195:1 836:1 1801:1 1817:1 1887:1 1945:1 2070:1 2599:1 3958:1 3960:1 4082:1 4083:1 4084:1 4085:1
6 	|BT| (NP (JJ Arsenic) (VP (VBN induced) (NP (NP (NP (JJ dose-related) (NN increase) (NN lung) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NN sex)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN sex)) (-RRB- -RRB-))) (, ,) (NP (NP (NN gallbladder) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN male)) (-RRB- -RRB-))) (, ,) (NP (JJ uterine) (NN carcinoma))))) |ET| |BS|104:C04.557.470.200.025.255 265:C04.557.470.200 1158:D01.268.513.249 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810 1182:C04.588.274.120.401 1183:A05.360.319.679|ES| 2:1 7:1 10:1 14:1 19:1 40:1 255:1 303:1 304:1 328:1 412:1 1402:1 4086:1 4087:1 4088:1 4089:1 4090:1
6 	|BT| (S (NP (NN beta-Naphthoflavone)) (VP (VBZ enhances) (NP (NP (JJ oxidative) (NN stress) (NN response)) (NN induction) (JJ preneoplastic) (NN lesion) (JJ diethylnitrosamine-initiated) (NN hepatocarcinogenesis) (NN model)) (ADVP (RB partially)) (VP (VBD hepatectomized) (NP (NN rat))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 716:G03.495.710 983:D03.383.663.283.266.450.175.100|ES| 19:1 72:1 494:1 736:1 849:1 900:1 1131:1 1351:1 1356:1 1438:1 2522:1 2583:1 4091:1 4092:1 4093:1
6 	|BT| (NP (NP (NN Cell) (NN expression) (NN pattern) (NN CD147) (JJ N-diethylnitrosamine/phenobarbital-induced) (NN mouse) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 104:C04.557.470.200.025.255 554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 19:1 52:1 115:1 260:1 303:1 304:1 4094:1 4095:1 4096:1
6 	|BT| (S (S (NP (NN Cell) (NN proliferation) (NN hepatocarcinogenesis) (NN rat)) (VP (VBD initiated) (SBAR (S (NP (NN diethylnitrosamine)) (VP (VBD promoted) (NP (NN phenobarbital))))))) (: :) (NP (NP (JJ potential) (NN role) (JJ early) (NN DNA) (NN damage) (NN liver) (NN metallothionein) (NN expression)))) |ET| |BS|15:F01.829.316.616 183:G04.299.233.750 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 526:G05.355.180 554:D02.654.442.200 756:D03.383.742.698.253.650 777:D12.776.556.670|ES| 19:1 31:1 104:1 115:1 299:1 666:1 827:1 836:1 849:1 900:1 1128:1 1848:1 1900:1 1912:1 1952:1 2685:1 2731:1 4094:1
6 	|BT| (NP (NP (NNP Chemoprevention) (NNP Diethylnitrosamine-Initiated) (NNP Phenobarbital-Promoted) (NNP Hepatocarcinogenesis) (NNP Rats) (NNP Sulfated) (NNP Polysaccharides) (NNP Aqueous) (NN Extract) (NNP Ulva) (NN lactuca))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 253:E02.319.162 554:D02.654.442.200 756:D03.383.742.698.253.650 803:D01.248.497.158.845 804:D09.698 1184:B01.650.940.150.900|ES| 19:1 1959:1 2842:1 3664:1 4097:1 4098:1 4099:1 4100:1 4101:1 4102:1 4103:1 4104:1
6 	|BT| (NP (NP (JJ Chemopreventive) (NN evaluation) (NN Tephrosia) (NN purpurea) (JJ N-nitrosodiethylamine-induced) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))) |ET| |BS|225:E05.337 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1153:B01.650.940.800.575.100.401.890|ES| 19:1 849:1 900:1 2503:1 2603:1 2948:1 3972:1 3994:1 3995:1
6 	|BT| (S (NP (JJ Chronic) (NN ethanol) (NN feeding)) (VP (VBZ accelerates) (NP (JJ hepatocellular) (NN carcinoma) (NN progression) (JJ sex-dependent) (NN manner)) (NP (NN mouse) (NN model) (NN hepatocarcinogenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 751:D02.033.375 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810|ES| 19:1 48:1 52:1 72:1 303:1 304:1 529:1 900:1 1668:1 2942:1 3440:1 3967:1 4105:1
6 	|BT| (S (S (NP (JJ Chronic) (JJ inorganic) (JJ arsenic) (NN exposure)) (VP (VBZ induces) (NP (JJ hepatic) (JJ global) (JJ individual) (NN gene) (NN hypomethylation)))) (: :) (NP (NN implication) (JJ arsenic) (NN hepatocarcinogenesis))) |ET| |BS|6:G05.360.340.024.340 197:A01.456.505.420 493:M01 1158:D01.268.513.249|ES| 9:1 19:1 85:1 104:1 214:1 660:1 838:1 900:1 1953:1 2512:1 3174:1 3967:1 4106:1 4107:1
6 	|BT| (S (NP (NN Colitis)) (VP (VBD induced) (NP (NP (NN knockout)) (, ,) (NP (NP (NP (JJ transgenic) (, ,) (NN control)) (PRN (-LRB- -LRB-) (NP (NN C57BL/B6)) (-RRB- -RRB-))) (NP (NP (NN mouse) (NN administration) (NN dextran) (NN sulfate) (NN sodium)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN mouse)) (VP (VBN given) (NP (NN azoxymethane))))) (VP (VBP induce) (NP (JJ colorectal) (NN carcinogenesis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 53:C06.405.205.265 131:D09.698.365.272.300 132:D02.172.080 352:B01.050.050.136 593:B01.050.050.199.520.520.420|ES| 2:1 10:1 14:1 17:1 19:1 29:1 52:1 71:1 207:1 243:1 285:1 289:1 406:1 407:1 412:1 1993:1 2575:1 3300:1 3306:1 4108:1 4109:1
6 	|BT| (NP (NP (NN CONCLUSION) (: :)) (NP (DT These) (VBP result) (NP (VBN suggested) (NN TFA) (VBD protected) (ADJP (NN mouse) (JJ CCl4-induced) (ADJP (NN liver) (NN injury) (JJ antioxidant)) (NN stress) (JJ antiinflammatory)) (NN effect)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217|ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1
6 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN In) (NP (NNS hepatocytes))) (, ,) (NP (NN JNK1) (NN JNK2)) (VP (VP (VBP appear) (NP (NP (JJ combined) (NN effect)) (VP (VBG protecting) (NP (NN mouse) (NN CCl4))))) (: -) (NP (JJ acetaminophen-induced) (NN liver) (NN injury)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 262:A11.436.348 661:D02.065.199.092.040|ES| 2:1 19:1 52:1 75:1 104:1 164:1 239:1 244:1 836:1 894:1 2251:1 2357:1 2416:1 4110:1 4111:1 4112:1 4113:1
6 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (S (NP (VBN truncated) (NN PPARalpha) (NN splice) (JJ variant) (NN function)) (NP (NP (JJ endogenous) (NN inhibitor) (JJ proliferative) (JJ pro-inflammatory) (NN gene)) (SBAR (S (NP (JJ human) (NN cell) (NN absence) (NN mouse)) (VP (MD may) (VP (VB explain) (NP (JJ species-specific) (NN difference) (JJ fibrate-induced) (NN hepatocarcinogenesis))))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 41:A11 55:B01.050.150.900.649.801.400.112.400.400 536:D12.776.826.239.500 1185:D12.125.072.401.623 1186:G16.824|ES| 9:1 19:1 33:1 36:1 52:1 94:1 104:1 239:1 380:1 491:1 658:1 793:1 796:1 900:1 990:1 1534:1 1674:1 3870:1 4114:1 4115:1 4116:1 4117:1 4118:1 4119:1 4120:1 4121:1
6 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NN Silibinin) (NN target) (NN beta-catenin) (NN IGF-1Rbeta) (NN pathway) (JJ chemopreventive) (NN efficacy) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 581:D12.644.276.937|ES| 19:1 52:1 60:1 104:1 113:1 160:1 207:1 239:1 383:1 1946:1 2304:1 2531:1 2532:1 2533:1 2534:1
6 	|BT| (S (NP (JJ Concurrent) (NN administration) (JJ ascorbic) (NN acid)) (VP (VBZ enhances) (NP (NP (NN liver) (JJ tumor-promoting) (NN activity)) (JJ kojic) (NN acid) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1187:D02.241.081.844.107|ES| 19:1 399:1 836:1 849:1 1275:1 1356:1 2575:1 3776:1 4122:1 4123:1 4124:1
6 	|BT| (S (NP (JJ Considerable) (NN attention)) (VP (VBD focused) (NP (NP (JJ peroxisome) (JJ proliferator-induced) (JJ hepatocellular) (NN carcinoma)) (, ,) (SBAR (S (NP (NN phenomenon)) (VP (VBD noted) (NP (NN man)))))) (, ,) (SBAR (IN whereas) (S (NP (JJ limited) (NN study)) (VP (VBP examine) (VP (VBZ fibrates) (SBAR (S (NP (JJ therapeutic) (NN drug)) (VP (VBP induce) (NP (NP (NN cholestasis)) (, ,) (NP (JJ common) (NN finding) (JJ human)))))))))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 67:D26 104:C04.557.470.200.025.255 275:C23.888 879:C06.130.120.135 905:F02.830.104.214 912:D27.888.569.100.675 1188:D02.241.081.114.968.500 1189:M01.390|ES| 2:1 19:1 36:1 131:1 191:1 243:1 303:1 304:1 372:1 541:1 655:1 927:1 960:1 1887:1 2131:1 2310:1 3198:1 4125:1 4126:1 4127:1 4128:1 4129:1 4130:1 4131:1
6 	|BT| (S (NP (NNP Cyclooxygenase) (CD 2) (NN Prostaglandin) (NN E2)) (VP (VBN Involved) (NP (JJ N-Nitrosodiethylamine-Initiated) (JJ Early) (NN Rat) (NN Hepatocarcinogenesis)))) |ET| |BS|24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1118:D10.251.355.255.550.250.200|ES| 19:1 148:1 1959:1 3432:1 3909:1 4008:1 4132:1 4133:1 4134:1 4135:1
6 	|BT| (NP (NP (NN DESIGN) (: :)) (NP (NP (NP (JJ Spontaneous) (JJ experimental) (NN fibrogenesis)) (SBAR (S (NP (ADJP (RB well) (JJ diethylnitrosamine-induced)) (NN hepatocarcinogenesis)) (VP (VBD investigated) (NP (NP (JJ lecithin-retinol) (NN acyltransferase)) (PRN (-LRB- -LRB-) (NP (NN LRAT)) (-RRB- -RRB-))))))) (: -) (NP (JJ deficient) (NN mouse) (NN lack) (JJ retinoid-containing) (NN lipid) (NN droplet) (NNS HSCs)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393|ES| 10:1 14:1 19:1 52:1 104:1 263:1 403:1 690:1 787:1 900:1 2401:1 2732:1 3381:1 3383:1 3937:1 4136:1 4137:1 4138:1 4139:1 4140:1 4141:1 4142:1
6 	|BT| (S (NP (NP (NN Dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (VP (VBN given) (S (VP (VBP induce) (NP (NP (NP (NN colitis) (NN C57/BL6)) (PRN (-LRB- -LRB-) (NP (NN control)) (-RRB- -RRB-))) (NN mouse)))) (, ,) (NP (ADVP (RB well)) (NP (NP (NN mouse) (NN disruption) (NN hydroxyprostaglandin) (NN dehydrogenase) (CD 15) (NN gene)) (PRN (-LRB- -LRB-) (NP (JJ 15-PGDH-knockout) (NN mouse)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Yap1) (NN gene)) (PRN (-LRB- -LRB-) (NP (JJ YAP-knockout) (NN mouse)) (-RRB- -RRB-))) (, ,) (NP (JJ double-knockout) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 53:C06.405.205.265 131:D09.698.365.272.300|ES| 2:1 9:1 10:1 14:1 19:1 29:1 52:1 143:1 243:1 289:1 406:1 407:1 787:1 1602:1 3085:1 3306:1 4143:1 4144:1 4145:1 4146:1 4147:1 4148:1 4149:1 4150:1
6 	|BT| (S (NP (NN Diethylnitrosamine) (NN initiation)) (VP (VBP alter) (NP (ADJP (JJ clofibric) (JJ acid-induced)) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1190:D02.241.081.114.968.500.500|ES| 19:1 637:1 849:1 900:1 2599:1 4151:1 4152:1 4153:1
6 	|BT| (S (NP (JJ Diethylnitrosamine-induced) (NN hepatocarcinogenesis)) (VP (VBD suppressed) (NP (NP (JJ heterozygous) (JJ NRDC-deficient) (NN mouse)) (VP (VBN compared) (NP (JJ wild-type) (NNS littermates)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 157:G05.380.383 554:D02.654.442.200|ES| 8:1 19:1 50:1 52:1 307:1 786:1 900:1 1355:1 2569:1 4154:1
6 	|BT| (S (NP (NNS Effects)) (VP (VBD baked) (S (NP (NP (NP (NN PP)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 20) (NN %)) (NN wt/wt)) (-RRB- -RRB-))) (NN colon) (NNS CSCs)) (ADVP (RB also)) (VP (VBN tested) (NP (FW vivo) (NN mouse) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 556:C11.768.175 1126:Z01.639.760.590.715|ES| 5:1 10:1 14:1 19:1 52:1 78:1 113:1 369:1 378:1 1870:1 1966:1 2533:1 2988:1 3461:1 3941:1 3942:1 4155:1
6 	|BT| (S (NP (VBN Enhanced) (NP (NN liver)) (NN tumor) (NN promotion) (NN activity) (NN rat)) (VP (VBN subjected) (NP (JJ combined) (NN administration) (JJ phenobarbital) (NN orphenadrine)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 756:D03.383.742.698.253.650 1159:D02.092.471.600|ES| 7:1 19:1 164:1 399:1 836:1 849:1 2337:1 2575:1 2685:1 3267:1 3466:1 4005:1
6 	|BT| (S (S (NP (NP (NN Ethanol)) (VBD diminished) (JJ hepatic) (NN function)) (VP (VBD increased) (NP (NN liver) (NN damage)))) (, ,) (S (NP (NP (NN ethanol)) (ADVP (RB alone))) (VP (VBP induce) (NP (JJ hepatic) (NN foci/HCC) (NN formation))))) |ET| |BS|20:G03.495 104:C04.557.470.200.025.255 242:A03.620 751:D02.033.375|ES| 2:1 19:1 33:1 43:1 47:1 241:1 243:1 836:1 838:1 1848:1 3178:1 3440:1 4156:1 4157:1
6 	|BT| (NP (NP (NP (NN Evaluation) (JJ chemopreventive) (NN effect)) (NP (NNP Fumaria) (NN indica) (NN N-nitrosodiethylamine) (JJ CCl4-induced) (JJ hepatocellular) (NN carcinoma) (NNP Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 225:E05.337 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900 724:B01.650.940.800.575.100.443.750|ES| 19:1 75:1 303:1 304:1 849:1 1208:1 1946:1 2520:1 2600:1 2601:1 2602:1 2603:1
6 	|BT| (NP (NP (NN Evolution) (JJ genomic) (NN instability) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 1191:C23.550.362 1192:G05.355.044|ES| 19:1 52:1 900:1 910:1 1299:1 2732:1 4158:1
6 	|BT| (NP (NP (NP (NP (NN Expression) (NN analysis) (NN group) (NN IIA) (JJ secretory) (NN phospholipase) (NN A)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (NN mouse) (JJ differential) (NN susceptibility) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 192:D08.811.277.352.100.680.750.937.750 401:C23.550.291.687 829:M01.686|ES| 10:1 14:1 19:1 52:1 69:1 78:1 113:1 148:1 316:1 643:1 644:1 661:1 1353:1 1677:1 2222:1 2300:1 2533:1
6 	|BT| (S (S (NP (NN Expression) (NN retinoid) (NN X) (NN receptor) (NN alpha)) (VP (VBD decreased) (NP (CD 3) ('' ')))) (: -) (FRAG (NP (JJ methyl-4-dimethylaminoazobenzene-induced) (JJ hepatocellular) (NN carcinoma) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 941:D12.776.826.701.500.500 1193:D02.092.146.325|ES| 19:1 186:1 202:1 303:1 304:1 316:1 849:1 929:1 1836:1 2573:1 4159:1
6 	|BT| (S (PP (VBG Following) (NP (NP (JJ initial) (CD 14) (NN day)) (JJ dietary) (NN dose) (NN range-finding) (NN study) (JJ male) (NN mouse))) (, ,) (ADJP (NP (NP (JJ mechanistic) (NN study)) (PRN (-LRB- -LRB-) (NP (NP (CD 0) (, ,) (CD 3) (, ,) (CD 32) (, ,) (CD 320) (NN ppm) (NN toxaphene) (NN diet) (CD 7)) (, ,) (NP (CD 14)) (, ,) (NP (ADJP (CD 28) (NN day)) (NN treatment))) (-RRB- -RRB-))) (VBN performed)) (VP (VBP examine) (SBAR (S (NP (JJ potential) (NN mechanism) (NN toxaphene)) (VP (VBD induced) (NP (NN mouse) (NN liver) (NN tumor))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 275:C23.888 515:C04.588.274.623 595:G07.203.650.240 596:E02.642.249 1149:D02.455.526.439.913|ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 162:1 412:1 458:1 546:1 827:1 836:1 862:1 960:1 988:1 1401:1 1402:1 1440:1 1890:1 2191:1 2301:1 2546:1 2594:1 3233:1 3985:1 4078:1 4160:1 4161:1 4162:1 4163:1 4164:1
6 	|BT| (S (PP (IN For) (NP (FW vivo) (NN study))) (, ,) (NP (JJ 1,2-dimethylhydrazine) (NN dihydrochloride) (-LRB- -LRB-) (NN DMH) (-RRB- -RRB-) (NN s.c.)) (VP (VBD injected) (VP (VBP induce) (NP (NP (NP (NN colon) (NN cancer) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NN PPARgamma) (PRN (-LRB- -LRB-) (CC +) (: /) (: -)))) (-RRB- -RRB-) (NP (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 719:D12.776.826.239.588|ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 131:1 243:1 378:1 2588:1 2642:1 2643:1 3489:1 3586:1 4165:1 4166:1
6 	|BT| (S (NP (JJ Garlic) (NN oil)) (VP (VBD attenuated) (NP (NP (JJ nitrosodiethylamine-induced) (NN hepatocarcinogenesis)) (VP (VBG modulating) (NP (JJ metabolic) (NN activation) (NN detoxification) (NN enzyme)))))) |ET| |BS|554:D02.654.442.200 728:G03.495.244.224 729:G03.495.244.450 730:D08.811|ES| 19:1 225:1 808:1 900:1 2006:1 2388:1 2435:1 2613:1 2614:1 2615:1 2616:1
6 	|BT| (NP (NP (NP (NN Glutathione) (NN S-transferase) (JJ placental) (-LRB- -LRB-) (NN GST-P) (-RRB- -RRB-)) (: -) (NP (NP (JJ negative) (JJ hepatocellular) (JJ altered) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN HAF)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (NN HCA)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (VP (VBD generated) (NP (NP (NP (NP (CD two) (JJ initiation-promotion) (NN model) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN NDEN)) (-RRB- -RRB-))) (NP (NN peroxisome) (NNS proliferators))) (, ,) (NP (NN Wy-14,643) (NN clofibrate)))))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 780:D08.811.913.225.500 783:A16.710 910:D02.241.081.114.968.500.500.195 912:D27.888.569.100.675 1194:C04.557.470.035.120|ES| 2:1 10:1 14:1 19:1 42:1 72:1 73:1 303:1 304:1 441:1 693:1 933:1 1431:1 1887:1 2446:1 2602:1 2743:1 2745:1 3058:1 3200:1 4167:1 4168:1 4169:1 4170:1 4171:1 4172:1 4173:1
6 	|BT| (NP (NP (NP (NN GP73)) (PRN (-LRB- -LRB-) (PRN (: -) (: /) (: -)) (-RRB- -RRB-))) (, ,) (NP (NN GP73) (PRN (-LRB- -LRB-) (CC +) (: /) (: -)) (-RRB- -RRB-) (, ,) (NP (NP (NN GP73) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-)) (NN mouse)) (VP (VBN given) (NP (NN injection) (NN diethylnitrosamine))))) (S (VP (VBP induce) (NP (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 242:A03.620 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 29:1 44:1 45:1 51:1 52:1 243:1 785:1 836:1 1952:1 2416:1 4174:1
6 	|BT| (S (NP (NN GT-094) (JJ first) (NN nitrate)) (VP (VBD reported) (VP (VB reduce) (NP (NP (NP (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 45) (NN %)) (-RRB- -RRB-))) (NP (VBN administered) (NN carcinogen) (NN standard) (NN azoxymethane) (NN rat) (NN model) (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 824:C04.834.020 1195:D01.248.497.158.606|ES| 10:1 14:1 17:1 18:1 19:1 72:1 369:1 816:1 849:1 993:1 1431:1 1725:1 1993:1 2125:1 2336:1 2361:1 2913:1 4175:1 4176:1 4177:1 4178:1
6 	|BT| (S (ADVP (RB Hence)) (, ,) (NP (NN chloroform)) (VP (VBD prevented) (SBAR (S (NP (NN hypomethylation)) (VP (VBD increased) (NP (NP (NN mRNA)) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN tumor) (NN DCA)) (, ,) (S (VP (VBG enhancing) (NP (JJ DCA-promotion) (NN kidney) (NN tumor))))))))) |ET| |BS|111:D13.444.735.544 155:G05.355.310 274:C04.588.945.947.535 515:C04.588.274.623 1196:D02.455.526.439.224|ES| 2:1 7:1 9:1 19:1 47:1 115:1 325:1 455:1 836:1 1717:1 1943:1 1944:1 2337:1 2527:1 4107:1 4179:1 4180:1 4181:1
6 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NN diethylnitrosamine) (JJ hepatic) (NN deletion) (NN PTEN)))) |ET| |BS|306:G05.355.600.800 554:D02.654.442.200|ES| 19:1 412:1 838:1 1059:1 1936:1 1952:1 1959:1
6 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (ADJP (JJ diethylnitrosamine/phenobarbital) (PRN (-LRB- -LRB-) (NP (NN DEN/PB)) (-RRB- -RRB-))))) |ET| |BS|554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 10:1 14:1 19:1 412:1 1959:1 4182:1 4183:1
6 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (JJ male) (NP (NP (JJ Sprague-Dawley) (NN rat) (JJ chronic) (NN feeding) (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN 2-AAF)) (-RRB- -RRB-))) (NN dose) (ADJP (CD 0.05) (NN %)) (JJ basal) (NN diet)) (NP (JJ daily) (CD 5) (NN day) (NN week))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 595:G07.203.650.240 596:E02.642.249 767:D02.065.064.150 769:B01.050.150.900.649.865.635.505.700.750 881:D02.065.064.150|ES| 10:1 14:1 19:1 369:1 412:1 578:1 783:1 849:1 1402:1 1790:1 1959:1 2191:1 2301:1 2696:1 2707:1 2942:1 3271:1 3849:1 4078:1 4184:1 4185:1
6 	|BT| (NP (NP (JJ Hepatocarcinogenic) (NN susceptibility) (NN fenofibrate) (JJ possible) (NN mechanism) (NN carcinogenicity) (JJ two-stage) (NN hepatocarcinogenesis) (NN model) (NN rasH2) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 401:C23.550.291.687 916:D02.241.081.114.968.500.625|ES| 19:1 52:1 72:1 162:1 900:1 1353:1 1359:1 2971:1 3225:1 3583:1 4186:1 4187:1
6 	|BT| (S (NP (JJ Hepatocellular) (NN carcinoma)) (VP (VBD found) (NP (CD four) (CD five) (NN rat) (CD 12) (NN month) (NN tamoxifen) (NN treatment)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900|ES| 19:1 37:1 304:1 546:1 770:1 849:1 1120:1 2151:1 2371:1 2723:1 4188:1
6 	|BT| (S (NP (NN Hepatocyte) (JJ nuclear) (NN factor) (CD 4) (NN alpha) (NN deletion)) (VP (VBZ promotes) (S (NP (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma)) (ADJP (JJ rodent))))) |ET| |BS|104:C04.557.470.200.025.255 306:G05.355.600.800 514:B01.050.150.900.649.865 554:D02.654.442.200 1197:D12.776.260.262.968|ES| 19:1 185:1 298:1 303:1 304:1 319:1 1059:1 1256:1 1836:1 2173:1 2349:1 2732:1
6 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBN conducted) (S (NP (NP (NP (CD two) (NN stage) (NN hepatocarcinogenesis) (NN study) (NN rat)) (VP (VBN exposed) (S (VP (VBG initiating) (NP (NP (NN agent) (NN nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))))))) (, ,) (NP (NP (JJ hepatotoxic) (NN compound) (NN thioacetamide)) (PRN (-LRB- -LRB-) (NP (NN TAA)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN methapyrilene)) (PRN (-LRB- -LRB-) (NP (NN MP)) (-RRB- -RRB-))) (VP (NN acetaminophen) (S (-LRB- -LRB-) (NP (NN APAP) (-RRB- -RRB-) (CD 1-2) (NP (NN week))) (VP (VBD followed) (NP (NP (NN liver) (NN tumor) (NN promoter) (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))))))))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 296:D02.065.064.786 554:D02.654.442.200 600:D27.888.569.100 661:D02.065.199.092.040 756:D03.383.742.698.253.650 876:F01.145 1198:D02.092.782.258.368.500|ES| 2:1 7:1 10:1 14:1 19:1 83:1 131:1 400:1 728:1 783:1 836:1 849:1 900:1 933:1 1035:1 1129:1 1875:1 2019:1 2412:1 2433:1 2685:1 2862:1 3100:1 3102:1 3130:1 3496:1 4189:1 4190:1 4191:1 4192:1 4193:1 4194:1
6 	|BT| (SINV (ADVP (RB Here)) (, ,) (VP (VBN examined) (NP (NP (NP (JJ chemopreventive) (JJ potential) (NN Acteoside)) (PRN (-LRB- -LRB-) (NP (NN ACT)) (-RRB- -RRB-))) (, ,) (NP (NP (NN plant)) (VP (VBN derived) (NP (NP (JJ phenylethanoid) (NN glycoside) (JJ environmental) (JJ dietary) (NN carcinogen)) (, ,) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (S (: -) (VP (VBN induced) (NP (NN rat) (NN hepatocarcinogenesis)))))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 328:B01.650 554:D02.654.442.200 595:G07.203.650.240 1199:D04.808.155.580 1200:G16.500.275 1201:D09.408|ES| 2:1 10:1 14:1 19:1 324:1 400:1 409:1 827:1 849:1 900:1 1098:1 1721:1 1875:1 1946:1 1952:1 2125:1 2594:1 3446:1 4195:1 4196:1 4197:1 4198:1
6 	|BT| (S (S (ADVP (RB Here)) (, ,) (VP (VBD identified) (SBAR (S (NP (JJ novel) (NN mechanism) (NN alcohol)) (VP (VBZ accelerates) (NP (NN liver) (NN fibrosis))))))) (: :) (NP (NP (NN inhibition) (JJ antifibrotic) (NN effect)) (SBAR (S (NP (NP (JJ natural) (NN killer)) (PRN (-LRB- -LRB-) (NP (NN NK)) (-RRB- -RRB-))) (VP (NN cell) (NP (NP (NN interferon-gamma)) (PRN (-LRB- -LRB-) (NP (NN IFN-gamma)) (-RRB- -RRB-)))))))) |ET| |BS|43:F01.145.544 259:D12.776.395.240.150.500 676:C06.552.630 751:D02.033.375 822:D02.033 1033:D12.644.276.374.440.893 1202:A11.118.637.555.567.537|ES| 2:1 10:1 14:1 19:1 75:1 94:1 103:1 104:1 162:1 400:1 529:1 623:1 836:1 891:1 949:1 2333:1 2885:1 3710:1 4199:1 4200:1 4201:1 4202:1
6 	|BT| (S (ADVP (RB Here)) (, ,) (NP (NN report) (NN level) (NN MT-1) (NN MT-2A)) (ADVP (RB drastically)) (VP (VBD reduced) (NP (JJ primary) (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NNS HCCs)) (-RRB- -RRB-))) (JJ diethylnitrosamine-induced) (NN liver) (NN tumor) (NN mouse)) (, ,) (NP (ADVP (RB primarily)) (JJ due) (NP (JJ transcriptional) (NN repression))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 208:F01.393.821 209:G02.111.087.847 515:C04.588.274.623 554:D02.654.442.200|ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 249:1 303:1 304:1 344:1 400:1 417:1 452:1 559:1 706:1 836:1 1132:1 1970:1 2732:1 2851:1 4203:1 4204:1 4205:1
6 	|BT| (S (ADVP (RB Herein)) (NP (ADJP (NN report) (JJ concurrent)) (NP (NN increase) (NN liver) (NN progenitor) (NN cell)) (PRN (-LRB- -LRB-) (NP (NNS LPCs)) (-RRB- -RRB-))) (NP (NP (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF-beta)) (-RRB- -RRB-))) (VP (NN diethylnitrosamine) (S (-LRB- -LRB-) (NP (NN DEN) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NN rat) (NN hepatocarcinogenesis) (JJ cirrhotic) (NN liver) (NN HCC) (NN patient)))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 503:D12.644.276.374.687 554:D02.654.442.200|ES| 10:1 14:1 19:1 40:1 94:1 102:1 120:1 409:1 417:1 428:1 441:1 836:1 849:1 900:1 1772:1 1773:1 1774:1 1875:1 1952:1 2968:1 4206:1 4207:1 4208:1
6 	|BT| (S (ADVP (RB Herein)) (VP (VBP show) (SBAR (S (NP (JJ global) (NN loss) (NN ERRalpha)) (VP (VBZ accelerates) (NP (NP (NN development) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (: -) (S (VP (VBN induced) (NP (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|104:C04.557.470.200.025.255 197:A01.456.505.420 554:D02.654.442.200|ES| 10:1 14:1 19:1 32:1 35:1 303:1 304:1 409:1 428:1 429:1 529:1 660:1 1875:1 1952:1 4209:1
6 	|BT| (S (NP (ADVP (RB Herein)) (, ,) (JJ first) (NN time)) (, ,) (VP (VBP investigate) (NP (FW vivo) (NN efficacy) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 322:G01.910|ES| 2:1 19:1 52:1 78:1 113:1 378:1 428:1 459:1 816:1 1081:1 2304:1 2533:1 2534:1 2635:1
6 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD investigated) (NP (NP (NP (NN MMP10) (NN expression) (NN function)) (JJ human) (JJ hepatocellular) (NN carcinoma) (-LRB- -LRB-) (NN HCC) (-RRB- -RRB-) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN mouse) (NN hepatocarcinogenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 33:1 36:1 52:1 115:1 303:1 304:1 403:1 409:1 428:1 441:1 900:1 1875:1 1952:1 4210:1
6 	|BT| (NP (NP (JJ High-saturate-fat) (NN diet) (NN delay) (NN initiation) (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 694:G07.203.650.240.267|ES| 19:1 136:1 303:1 304:1 637:1 2191:1 2732:1 4211:1
6 	|BT| (NP (NP (ADVP (RB However)) (PRN (, ,) (NP (JJ Ptk6-null) (NN mouse)) (ADVP (RB also)) (NP (JJ resistant) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis))))) |ET| |BS|29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 2:1 5:1 19:1 52:1 78:1 113:1 427:1 433:1 2533:1 4212:1
6 	|BT| (S (ADVP (RB However)) (, ,) (NP (NNP Sorafenib) (NN treatment)) (ADVP (RB transiently)) (VP (VBD inhibited) (SBAR (S (NP (NN cell) (NN cycle) (NN progression)) (VP (VBD resulted) (SBAR (S (NP (JJ mitotic) (NN catastrophe)) (VP (VBD enhanced) (NP (JJ non-apoptotic) (NN liver) (NN injury) (NN regeneration)))))))))) |ET| |BS|16:C23.550.291.656 39:G04.299.139.160 52:E02 122:C14.280.383 353:G04.299.134 925:G10.261.326.520|ES| 2:1 19:1 48:1 94:1 365:1 385:1 433:1 546:1 594:1 601:1 720:1 836:1 2416:1 2833:1 3210:1 3260:1 3614:1 4213:1
6 	|BT| (FRAG (ADVP (RB However)) (, ,) (NP (NP (NN action) (NN compound) (JJ ethanol-induced) (NN liver) (NN injury)) (ADJP (RB still) (JJ unknown)))) |ET| |BS|242:A03.620 751:D02.033.375|ES| 2:1 19:1 433:1 776:1 836:1 2013:1 2182:1 2416:1 2433:1 2674:1
6 	|BT| (S (NP (NN HTHQ)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN colon) (NN carcinogenesis) (CD two) (NN stage) (NN colon) (NN carcinogenesis) (NN model)) (S (VP (VBG using) (NP (NP (NP (NN 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-))) (NN initiator))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725|ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1
6 	|BT| (S (ADVP (RB Importantly)) (, ,) (NP (NN GEN-27)) (VP (VBD protected) (FRAG (NP (NP (NN mouse) (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (: /) (FRAG (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (: -) (NP (NP (VBN induced) (NN colon) (NN carcinogenesis)) (, ,) (NP (VBD reduced) (NN mortality)) (, ,) (NP (NN tumor) (NN number) (NN tumor) (NN volume))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080 695:E05.318.308.985.550 1203:E05.041.124.892|ES| 2:1 7:1 10:1 14:1 19:1 52:1 113:1 207:1 406:1 407:1 409:1 452:1 646:1 1993:1 1994:1 2413:1 2511:1 2651:1 3305:1 3306:1 3589:1 4214:1
6 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN mouse) (NNP Diethylnitrosamine) (NN model) (NN hepatocarcinogenesis)) (VP (VBN observed) (NP (JJ strong) (NN induction) (NN CXCR7) (NN CXCL11) (NN transcript)) (, ,) (S (VP (VBG confirming) (NP (NN CXCR7/CXCL11) (NN up-regulation) (VBN conserved) (JJ human) (NN mouse) (NN liver) (NN cancer)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 554:D02.654.442.200|ES| 2:1 18:1 19:1 36:1 52:1 72:1 244:1 261:1 468:1 736:1 836:1 896:1 900:1 937:1 3578:1 4151:1 4215:1 4216:1 4217:1 4218:1 4219:1
6 	|BT| (S (PP (IN In) (NP (NP (JJ experimental) (NN mouse) (NN model) (NN hepatocarcinogenesis)) (PRN (-LRB- -LRB-) (NP (JJ diethylnitrosamine-induced)) (-RRB- -RRB-)))) (, ,) (NP (NN tumor)) (VP (VBD showed) (NP (NP (VBN increased) (NN activation) (NN TGF-beta) (NN pathway)) (VBD enhanced) (NN CXCR4) (NN level)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 95:E05.599 503:D12.644.276.374.687 554:D02.654.442.200 1204:D12.776.543.750.100.160.500.400|ES| 2:1 7:1 10:1 14:1 19:1 47:1 52:1 72:1 132:1 225:1 244:1 249:1 263:1 383:1 385:1 900:1 1774:1 2732:1 4220:1
6 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NP (NN dioscin) (NN show) (JJ excellent) (JJ protective) (NN effect)) (JJ ethanol-induced) (NN liver) (NN injury)) (S (VP (VBG ameliorating) (NP (NP (JJ ethanol-induced) (JJ oxidative) (NN stress)) (, ,) (NP (JJ mitochondrial) (NN function)) (, ,)) (NP (NP (JJ inflammatory) (NP (NN cytokine)) (NN production)) (, ,) (NP (NN apoptosis) (NN liver) (NN steatosis)) (, ,))))) (VP (VBD developed) (NP (JJ new) (NN drug) (NN treatment) (JJ ethanol-induced) (NN liver) (NN injury) (NN future)))) |ET| |BS|39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241|ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1
6 	|BT| (FRAG (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (CD three) (CD 18) (NN vinyl) (JJ carbamate-induced) (NN liver) (NN tumor)) (, ,) (NP (CD one) (CD 18) (JJ TCDD-induced) (NN liver) (NN tumor)) (, ,) (NP (CD two) (CD 22) (JJ spontaneous) (NN liver) (NN neoplasm) (NN mutation) (NN beta-catenin)))) |ET| |BS|18:G05.365.590 23:D12.776.091.249 491:D27.505.259.500 515:C04.588.274.623 1096:D03.383.231.900|ES| 2:1 7:1 19:1 34:1 60:1 244:1 283:1 482:1 836:1 933:1 1010:1 1193:1 1392:1 1523:1 3714:1 4221:1 4222:1 4223:1
6 	|BT| (S (PP (IN In) (NP (JJ medium-term) (NN carcinogenesis) (NN test) (NN rat))) (, ,) (NP (NP (ADJP (CD 2.0) (NN %)) (NN KA)) (VP (ADVP (RB orally)) (VBN given) (NP (NN F344/DuCrj) (NN rat) (CD 4) (NN week) (NN initiation) (NN period))) (, ,)) (VP (VBD followed) (NP (NP (NN combination) (JJ partial) (NN hepatectomy) (NN treatment) (NN hepatocarcinogenesis) (NN promoter)) (, ,) (NP (NP (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-)))))) |ET| |BS|52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 590:B01.050.050.199.520.760.200 756:D03.383.742.698.253.650 776:G01.910.645 849:G08.686.785.760.769.490.500 914:L01.178 928:E04.210.556 1205:E05.940.150|ES| 2:1 10:1 14:1 19:1 29:1 83:1 207:1 244:1 319:1 369:1 530:1 546:1 637:1 783:1 849:1 900:1 1418:1 2685:1 2725:1 3130:1 3215:1 3272:1 3273:1 3496:1 4224:1 4225:1 4226:1 4227:1
6 	|BT| (FRAG (PP (IN In) (NP (NN mouse) (NN fed) (NN bezafibrate) (CD 1) (NN year))) (, ,) (NP (NP (JJ preneoplastic) (NN focus)) (, ,) (NP (NP (NP (NN adenoma) (JJ hepatocellular) (NN carcinoma)) (VP (VBN found))) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NN mouse)) (, ,) (NP (NP (JJ single) (JJ microscopic) (NN adenoma)) (VP (VBD found) (S (NP (NP (CD one)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 104:C04.557.470.200.025.255 426:E01.370.350.515 663:C16.320.565.398.500.330.500 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 909:D02.065.277.067|ES| 2:1 10:1 14:1 19:1 37:1 42:1 45:1 51:1 52:1 98:1 244:1 303:1 304:1 1010:1 1431:1 1438:1 1452:1 2426:1 2846:1 3201:1 4071:1
6 	|BT| (SINV (PP (IN In) (NP (NN order))) (VP (VBP prepare)) (NP (NP (JJ human) (NN trial) (NN inhibition) (NN colon) (NN carcinogenesis)) (, ,) (NP (NP (VBN conducted) (NN study) (JJ green) (NN tea) (NNS polyphenols)) (VP (JJ preventive) (VP (NN agent) (NP (NN azoxymethane) (S (-LRB- -LRB-) (NP (NN AOM) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NN rat) (NN colon) (NN cancer) (NN model)) (S (VP (VBG using) (NP (NP (NP (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NN end) (NN point)))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 43:F01.145.544 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 375:Z01.639.100 824:C04.834.020 841:E05.318.760.250.500 876:F01.145|ES| 2:1 10:1 14:1 18:1 19:1 36:1 72:1 103:1 113:1 131:1 154:1 207:1 244:1 350:1 409:1 728:1 849:1 1431:1 1725:1 1883:1 1993:1 1994:1 2121:1 2379:1 2834:1 2913:1 2914:1 2989:1 3100:1 3192:1 4228:1 4229:1
6 	|BT| (FRAG (PP (IN In) (NP (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN model) (NN colon) (NN cancer))) (, ,) (NP (NP (NN addition) (NN K-ras) (NN mutation)) (, ,) (VP (VBN shown) (S (NP (ADJP (ADJP (JJ wild-type)) (PRN (-LRB- -LRB-) (ADJP (JJ WT)) (-RRB- -RRB-))) (NN Ras)) (VP (VBD activated) (NP (NP (JJ upstream) (NN pathway)) (, ,) (S (VBG including) (, ,) (PP (FW e.g.)) (, ,) (VP (VBG signaling) (NP (NN ErbB) (NN receptor)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 69:G02.111.087.800 132:D02.172.080 563:D08.811.913.696.620.682.725.400.009|ES| 2:1 8:1 10:1 14:1 18:1 19:1 34:1 72:1 113:1 163:1 186:1 195:1 237:1 244:1 383:1 468:1 561:1 1121:1 1775:1 1993:1 1994:1 1995:1 1996:1 1997:1 1998:1
6 	|BT| (S (PP (IN In) (NP (JJ azoxymethane-treated) (NN rat) (NN model) (JJ experimental) (NN colon) (NN carcinogenesis))) (, ,) (NP (NN sulindac) (NN treatment)) (ADVP (RB markedly)) (VP (VBD induced) (NP (NP (NNP Csk) (JJ corresponding) (NN increase) (JJ inhibitory) (NN phosphorylation) (NN Src)) (PRN (-LRB- -LRB-) (NP (NN Tyr) (PRN (-LRB- -LRB-) (CD 527) (-RRB- -RRB-)) (-RRB- -RRB-)))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 52:E02 95:E05.599 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 634:D12.125.072.050.875 972:G02.111.087.677 1206:D08.811.682.690.708.125.500|ES| 2:1 10:1 14:1 19:1 40:1 72:1 113:1 207:1 244:1 263:1 412:1 546:1 849:1 869:1 2396:1 2429:1 2793:1 3426:1 3674:1 4230:1 4231:1 4232:1 4233:1
6 	|BT| (FRAG (PP (IN In) (ADJP (JJ present) (SBAR (S (NP (NP (NN paper)) (, ,) (NP (NP (JJ ethanol-induced) (JJ acute) (JJ chronic) (NN liver) (NN damage) (NN rat) (NN model)) (VP (VBN used))) (, ,)) (VP (VBP result) (VP (VBD showed) (SBAR (S (NP (NN dioscin)) (ADVP (RB significantly)) (VP (VBD alleviated) (SBAR (S (NP (NP (NN liver) (NN steatosis)) (, ,) (NP (VBN reduced) (NN level) (NN alanine) (NN aminotransferase)) (, ,) (NP (NN aspartate) (NN aminotransferase)) (, ,) (NP (NP (JJ total) (NN triglyceride)) (PRN (-LRB- -LRB-) (NP (NN TG)) (-RRB- -RRB-))) (, ,) (NP (JJ total) (NN cholesterol) (NN malondialdehyde)) (, ,)) (VP (VBD increased) (NP (NP (NN level) (JJ high-density) (NN lipoprotein)) (, ,) (NP (NN superoxide) (NN dismutase)) (, ,) (NP (NN glutathione) (NN glutathione) (NN peroxidase)))))))))))))))) |ET| |BS|58:D08.811.682.881 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 646:D08.811.913.477.700.100 647:D08.811.913.477.700.347 655:D04.808.247.222.284 751:D02.033.375 753:C06.552.241 991:D08.811.682.732.500 1207:D08.811.913.477.700.225 1208:D12.644.456.448 1209:D10.532.432 1210:D02.047.700 1211:J01.637.650 1212:D10.351.801|ES| 2:1 10:1 14:1 19:1 47:1 72:1 90:1 101:1 124:1 132:1 146:1 147:1 244:1 249:1 452:1 476:1 836:1 849:1 1307:1 1790:1 1848:1 2392:1 2393:1 2403:1 2672:1 2674:1 2678:1 2744:1 3132:1 3485:1 4234:1 4235:1 4236:1 4237:1 4238:1 4239:1 4240:1 4241:1
6 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBN shown) (NP (NP (JJ myrtenal) (, ,) (JJ natural) (NN monoterpene)) (, ,) (NP (VP (VBP act) (SBAR (S (NP (JJ antineoplastic) (NN agent) (NN diethylnitrosamine)) (VP (VBD induced) (NP (JJ phenobarbital) (VBN promoted) (NP (JJ experimental) (JJ hepatocellular) (NN carcinoma))))))))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 554:D02.654.442.200 660:D27.505.954.248 756:D03.383.742.698.253.650 757:C04.588.274.623.460 758:D02.455.849.575|ES| 2:1 19:1 131:1 237:1 244:1 246:1 263:1 303:1 304:1 412:1 728:1 1307:1 1912:1 1952:1 2333:1 2682:1 2683:1 2684:1 2685:1
6 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (S (VP (VBG using) (NP (FW vivo) (NN model) (NN rat) (NN hepatocarcinogenesis)))) (VP (VP (VBD induced) (NP (NN 2-acetylaminofluorene))) (, ,) (VP (VBD found) (NP (JJ extensive) (NN alteration) (JJ cellular) (NN iron) (NN metabolism) (JJ preneoplastic) (NN stage) (NN liver) (NN carcinogenesis))))) |ET| |BS|12:Z01.542.049 33:C04.697.098 41:A11 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 881:D02.065.064.150 895:D01.490.600 896:D01.268.556.412 898:G03.495|ES| 2:1 19:1 37:1 72:1 131:1 207:1 244:1 350:1 378:1 412:1 836:1 849:1 900:1 951:1 1129:1 1307:1 1438:1 3074:1 3162:1 3163:1 3271:1 4242:1
6 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBP demonstrate) (NP (NP (JJ altered) (NN gene) (NN expression) (JJ various) (NNS proteins/enzymes)) (VP (VBN involved) (NP (NP (NN DNA) (NN repair)) (, ,) (NP (NP (NN cell) (NN growth) (NN cell) (NN cycle) (NN process)) (JJ tamoxifen-induced) (NN hepatocarcinogenesis))))))) |ET| |BS|41:A11 45:G07.700.320.249 353:G04.299.134 640:D02.455.426.559.389.150.700.900 730:D08.811 1134:G02.111.087.219 1213:D12.776|ES| 2:1 9:1 19:1 94:1 102:1 115:1 131:1 244:1 502:1 513:1 601:1 638:1 666:1 693:1 774:1 900:1 1096:1 1307:1 3965:1 3966:1
6 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBN shown) (NN diosmin)) (VP (VBZ attenuates) (SBAR (S (NP (NP (NN 2-AAF)) (VP (VBD induced) (NP (NP (NP (JJ hepatic) (NN toxicity) (JJ early) (NN tumor) (NN promotion) (NN marker)) (PRN (-LRB- -LRB-) (NP (NP (NN ODC)) (, ,) (NP (NN PCNA) (NN Ki67))) (-RRB- -RRB-))) (, ,) (NP (JJ chemopreventive) (NN efficacy) (NN DEN))))) (VP (VBD initiated) (NP (JJ 2-AAF) (VBN promoted) (NN hyper-proliferation) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))))))) |ET| |BS|376:D23.101.140 715:D03.383.663.283.266.450.260.222 723:B01.050.150.900.649.865.635.505.700.900 745:C10.597.350.350 767:D02.065.064.150 768:D12.776.660.740|ES| 2:1 7:1 10:1 14:1 19:1 131:1 237:1 244:1 412:1 534:1 838:1 849:1 900:1 1128:1 1307:1 1875:1 1900:1 1912:1 1946:1 2304:1 2337:1 2406:1 2423:1 2603:1 2695:1 2696:1 2697:1 2698:1 2699:1 2700:1
6 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBN investigated) (S (NP (NP (NN role) (NN IDO) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NP (NP (NN IDO-knockout)) (PRN (-LRB- -LRB-) (NP (NN KO)) (-RRB- -RRB-))) (NN mouse)))))))) |ET| |BS|15:F01.829.316.616 29:B01.050.050.136.500.500 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 31:1 52:1 131:1 244:1 350:1 403:1 409:1 900:1 1307:1 1875:1 1952:1 2849:1 4243:1 4244:1
6 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD investigated) (SBAR (S (NP (NP (NP (JJ chemopreventive) (NN efficacy) (NN PEITC) (NN DBM) (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (PRN (: -) (VP (VBN initiated) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))) (: -))) (VP (VBD promoted) (SBAR (S (NP (NN colon) (NN cancer) (NN mouse) (NN model)) (VP (VBP compare) (NP (NP (JJ potential) (FW vivo) (NN mechanism)) (VP (VBG leading) (NP (NN chemoprevention)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 86:D01.268.556.435 131:D09.698.365.272.300 132:D02.172.080 253:E02.319.162|ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 113:1 131:1 162:1 244:1 378:1 403:1 406:1 407:1 639:1 827:1 870:1 1946:1 1993:1 1994:1 2304:1 3300:1 3306:1 4024:1 4029:1 4245:1 4246:1 4247:1
6 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (NP (VBN characterized) (NN cell) (NN signaling) (NN event)) (VP (VBD evoked) (NP (NN decorin) (NN deficiency) (CD two) (JJ experimental) (NN model) (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NN thioacetamide) (NN diethyl) (NN nitrosamine) (NN carcinogen)))))) |ET| |BS|69:G02.111.087.800 87:C18.654.521 95:E05.599 279:D27.888.569.100 296:D02.065.064.786 554:D02.654.442.200 708:D12.776.395.650.750.625|ES| 2:1 19:1 72:1 94:1 131:1 195:1 205:1 244:1 253:1 263:1 350:1 900:1 933:1 985:1 1514:1 2125:1 2901:1 4190:1 4248:1 4249:1
6 	|BT| (SINV (PP (IN In) (NP (NN study))) (, ,) (VBD evaluated) (FRAG (NP (NN susceptibility) (NNP Vparp)) (: -) (: /) (: -) (NP (NN Tep1) (: -) (: /) (: -) (NN mouse) (JJ dimethylhydrazine-induced) (NN colon) (NN tumorigenesis) (JJ urethane-induced) (NN lung) (NN tumorigenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 182:A04.411 225:E05.337 401:C23.550.291.687 1214:D02.241.081.251.944|ES| 2:1 19:1 52:1 78:1 113:1 131:1 244:1 328:1 780:1 1353:1 4250:1 4251:1 4252:1 4253:1
6 	|BT| (S (PP (IN In) (NP (JJ wild-type) (NN mouse))) (, ,) (NP (CD 200) (NN ppm) (NN cyproconazole)) (VP (VBD caused) (NP (NP (NP (NP (NN liver) (NN hypertrophy)) (, ,) (NP (VBD increased) (NN liver) (NN weight) (NN cell) (NN proliferation)) (, ,)) (JJ single-cell) (NN necrosis) (JJ fat) (NN vacuolation)) (, ,) (NP (NP (NP (NN effect)) (ADJP (RB generally) (JJ similar))) (VP (VBN caused) (NP (CD 850) (NN ppm) (NN phenobarbital))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 183:G04.299.233.750 242:A03.620 756:D03.383.742.698.253.650 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 1151:C06.552.416 1215:C23.888.144.243.926 1216:C23.550.717|ES| 2:1 8:1 19:1 47:1 52:1 75:1 94:1 244:1 299:1 332:1 836:1 2399:1 2425:1 2506:1 2685:1 3233:1 3364:1 3992:1 4254:1 4255:1 4256:1 4257:1 4258:1 4259:1
6 	|BT| (NP (NP (NN indica)) (NP (NP (-RRB- -RRB-) (NN extract) (-LRB- -LRB-) (NN FIE) (-RRB- -RRB-) (NN N-nitrosodiethylamine) (NN CCl)) (FRAG (-LRB- -LRB-) (NP (NP (CD 4) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))))) |ET| |BS|554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1217:A02.513.514.100|ES| 10:1 14:1 19:1 319:1 409:1 849:1 900:1 2496:1 2601:1 2602:1 2603:1 4260:1 4261:1
6 	|BT| (S (NP (NN Inhibition) (JJ retinoic) (NN acid) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NN N-nitrosomorpholine) (NN expression) (NN myc) (NN oncogene) (NN protein) (JJ Sprague-Dawley) (NN rat)))) |ET| |BS|43:F01.145.544 584:D12.776.624.664 769:B01.050.150.900.649.865.635.505.700.750 770:D02.455.326.271.665.202.495.818.500|ES| 4:1 19:1 24:1 115:1 412:1 849:1 900:1 1275:1 2703:1 2704:1 2705:1 2706:1 2707:1
6 	|BT| (S (NP (NP (NN Inhibition) (JJ azoxymethane-induced) (JJ colorectal) (NN cancer) (NN CP-31398)) (, ,) (NP (NN TP53) (NN modulator)) (, ,) (ADVP (RB alone)) (NP (NN combination) (JJ low) (NNS dos))) (VP (VBP celecoxib) (NP (JJ male) (NN F344) (NN rat)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 132:D02.172.080 590:B01.050.050.199.520.760.200 684:D02.065.884.247|ES| 2:1 17:1 18:1 19:1 241:1 530:1 531:1 849:1 1018:1 1402:1 1607:1 2533:1 2653:1 2703:1 2807:1 3047:1 3185:1
6 	|BT| (NP (NP (JJ Inhibitory) (NN effect) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 75:1 78:1 113:1 2533:1 2534:1 2635:1 2713:1
6 	|BT| (S (NP (NP (VBN injected) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBP induce) (NP (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 554:D02.654.442.200|ES| 10:1 14:1 19:1 243:1 303:1 304:1 1875:1 1952:1 3586:1
6 	|BT| (S (NP (NP (NN Injection) (NN carcinogen)) (, ,) (NP (NN diethylnitrosamine)) (, ,)) (VP (VBD induced) (SBAR (S (NP (ADJP (RB significantly) (JJR larger)) (NN liver) (NN tumor) (NN HCV) (JJ transgenic) (NN mouse)) (VP (VBP overexpress) (NP (NP (NN PP2Ac)) (VBN compared) (NN control) (NN mouse))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 99:B01.050.050.136.500 226:E02.319.267.530 279:D27.888.569.100 550:B04.450.410 554:D02.654.442.200 1151:C06.552.416|ES| 2:1 7:1 19:1 50:1 52:1 124:1 285:1 289:1 412:1 836:1 1938:1 1952:1 2125:1 2513:1 4079:1 4262:1 4263:1
6 	|BT| (NP (NP (NP (NN Involvement) (NN Mouse) (JJ Constitutive) (NN Androstane) (NN Receptor) (JJ Acifluorfen-Induced) (NN Liver)) (NP (NNP Injury) (JJ Subsequent) (NN Tumor) (NN Development)))) |ET| |BS|8:C04 242:A03.620|ES| 19:1 1218:1 2059:1 2127:1 2721:1 3399:1 4264:1 4265:1 4266:1 4267:1 4268:1 4269:1
6 	|BT| (S (NP (PRP It)) (VP (VBD suggested) (SBAR (S (NP (NN CYP2E1)) (ADVP (RB completely)) (VP (VBZ participates) (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis)) (, ,) (SBAR (S (NP (JJ high) (NP (NN frequency)) (NN tumor) (JJ wild-type) (NN mouse)) (VP (MD could) (VP (VBN associated) (NP (VBN increased) (NN apoptosis))))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 554:D02.654.442.200 1218:D08.244.453.300|ES| 2:1 7:1 8:1 19:1 47:1 52:1 89:1 169:1 178:1 900:1 908:1 925:1 1247:1 1327:1 2732:1 4270:1 4271:1 4272:1
6 	|BT| (S (NP (PRP It)) (ADVP (RB also)) (VP (VBD nominated) (NP (NP (JJ dichloroacetic) (NN acid)) (VP (VBN studied) (NP (NP (JJ representative) (NN class) (JJ haloacetic) (NN acid)) (NP (VBN shown) (NN cause) (NN liver) (NN tumor) (NN rat) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1062:D01.029 1219:D02.241.081.018.214.500|ES| 5:1 7:1 19:1 52:1 237:1 401:1 836:1 849:1 1017:1 1275:1 1327:1 1779:1 2814:1 4273:1 4274:1 4275:1
6 	|BT| (NP (NP (NN JNK) (NN protein)) (VP (VBN activated) (PP (IN via) (NP (NN phosphorylation) (NN response) (NN acetaminophen)))) (FRAG (: -) (NP (NP (NN carbon) (NN tetrachloride)) (PRN (-LRB- -LRB-) (NP (NN CCl4)) (-RRB- -RRB-))) (: -) (NP (NP (VBN induced) (NN liver) (NN damage)) (: ;) (S (NP (NN level) (NN activation)) (VP (VBP correlate) (NP (NN degree) (NN injury))))))) |ET| |BS|7:D12.776 242:A03.620 661:D02.065.199.092.040 972:G02.111.087.677 1220:D02.455.526.439.150|ES| 4:1 10:1 14:1 19:1 163:1 217:1 225:1 249:1 409:1 494:1 596:1 836:1 1848:1 2416:1 2806:1 3426:1 4276:1 4277:1 4278:1 4279:1 4280:1 4281:1
6 	|BT| (S (NP (NN Liver) (NN fibrosis)) (VP (VBD induced) (NP (NP (NN carbon) (NN tetrachloride)) (, ,) (NP (NN bile) (NN duct) (NN ligation)) (, ,) (NP (NP (NN disruption) (JJ multidrug-resistance) (NN transporter) (CD 2) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN Mdr2)) (-RRB- -RRB-)))))) |ET| |BS|227:D12.776.157.530 676:C06.552.630 1220:D02.455.526.439.150 1221:G05.360.340.024.340.361 1222:A03.159.183 1223:E04.426|ES| 2:1 9:1 10:1 14:1 19:1 148:1 412:1 779:1 949:1 1602:1 1621:1 1622:1 2721:1 4278:1 4279:1 4282:1 4283:1 4284:1
6 	|BT| (S (NP (NN Liver) (NN tumor) (NN formation) (JJ female) (NN rat)) (VP (VBD induced) (NP (NN fluopyram) (JJ mediated) (NN CAR/PXR) (JJ nuclear) (NN receptor) (NN activation)))) |ET| |BS|20:G03.495 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 642:M01.975|ES| 7:1 19:1 43:1 186:1 225:1 412:1 437:1 849:1 1256:1 1404:1 2721:1 4285:1 4286:1
6 	|BT| (S (NP (NN Liver) (NN tumor)) (VP (VBG promoting) (NP (NN effect) (NN etofenprox) (NN rat) (JJ possible) (NN mechanism) (NN action)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 742:G03.787|ES| 7:1 19:1 75:1 162:1 849:1 881:1 1359:1 2013:1 2721:1 4287:1
6 	|BT| (S (NP (NN Liver) (NN tumor)) (VP (VBG promoting) (NP (NP (NN effect) (NN orphenadrine) (NN rat) (JJ possible) (NN mechanism) (NN action)) (PP (VBG including) (NP (NN CAR) (NN activation) (JJ oxidative) (NN stress)))))) |ET| |BS|139:J01.937.500.100 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 716:G03.495.710 742:G03.787 1159:D02.092.471.600|ES| 7:1 19:1 75:1 162:1 225:1 421:1 561:1 849:1 881:1 1359:1 2013:1 2522:1 2583:1 2721:1 4005:1
6 	|BT| (S (NP (NN Liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ male) (NNP Fischer) (NN F344) (NN rat) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))))) |ET| |BS|515:C04.588.274.623 554:D02.654.442.200 590:B01.050.050.199.520.760.200|ES| 7:1 10:1 14:1 19:1 412:1 849:1 1402:1 1875:1 1952:1 2721:1 3185:1 4288:1
6 	|BT| (S (NP (NN Loss) (NN hepatocyte) (NN growth) (NN factor/c-Met) (NN signaling) (NN pathway)) (VP (VBZ accelerates) (SBAR (S (NP (JJ early) (NN stage) (NN N-nitrosodiethylamine)) (VP (VBD induced) (NP (NN hepatocarcinogenesis))))))) |ET| |BS|45:G07.700.320.249 69:G02.111.087.800 126:G02.111.087.800 262:A11.436.348 554:D02.654.442.200|ES| 19:1 102:1 195:1 383:1 412:1 529:1 900:1 1128:1 1129:1 1788:1 1909:1 2602:1 4289:1
6 	|BT| (S (S (NP (NP (JJ Low) (JJ dietary) (NN folate) (NN intake)) (VP (VBN associated))) (VP (VBD increased) (NP (NN risk) (NN colon) (NN cancer))) (: ;)) (S (ADVP (RB however)) (, ,) (NP (JJ relevant) (JJ genetic) (NN animal) (NN model)) (VP (VBG lacking)))) |ET| |BS|19:B01.050 61:E05.318.740.600.800 224:D03.438.733.631.400 285:E05.598 595:G07.203.650.240 1109:E05.599.395.397|ES| 2:1 18:1 19:1 46:1 47:1 72:1 113:1 169:1 171:1 217:1 376:1 778:1 864:1 865:1 1387:1 2563:1 2594:1 3615:1
6 	|BT| (S (S (NP (NNP Lycopene)) (VP (VBZ modulates) (SBAR (S (NP (NN initiation) (NN N-nitrosodiethylamine)) (VP (VBD induced) (NP (NN hepatocarcinogenesis))))))) (: :) (S (NP (NP (NN study) (JJ chromosomal) (NN abnormality)) (, ,) (NP (NN membrane) (NN fluidity) (JJ antioxidant) (NN defense) (NN system))))) |ET| |BS|554:D02.654.442.200 700:D27.505.519.217 1037:C23.550.210 1038:G01.154.500 1039:C16.131.260|ES| 2:1 19:1 104:1 131:1 412:1 593:1 606:1 637:1 900:1 1002:1 1027:1 1104:1 2521:1 2602:1 2733:1 3622:1 3623:1
6 	|BT| (S (NP (JJ Male) (NN F344) (NN rat)) (VP (VBN treated) (S (NP (NP (CD one) (JJ powerful) (NNP Valerian) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN Valeriana) (NN sitchensis)) (-RRB- -RRB-))) (VP (VBZ dos) (NP (CD 0) (, ,) (CD 50) (, ,) (NP (NP (CD 500) (CD 5000) (NN ppm) (NN drinking) (NN water) (NN initiation) (NN hepatocarcinogenesis) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))))) |ET| |BS|52:E02 554:D02.654.442.200 590:B01.050.050.199.520.760.200 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 1060:D01.045.250.875.300 1224:E05.318.740.872 1225:F01.658.780|ES| 2:1 10:1 14:1 19:1 368:1 637:1 849:1 900:1 1010:1 1099:1 1875:1 1952:1 2355:1 2653:1 3057:1 3185:1 3233:1 3635:1 3968:1 4163:1 4290:1 4291:1 4292:1 4293:1 4294:1 4295:1
6 	|BT| (NP (NP (NP (JJ Male) (NN Malat1)) (: -) (: /) (: -)) (NP (S (NP (NN mouse) (JJ wild-type) (-LRB- -LRB-) (JJ WT) (-RRB- -RRB-) (NNS littermates)) (VP (VBD studied) (NP (NP (CD one) (NN year)) (NP (NP (NN treatment) (JJ genotoxic) (NN agent) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (, ,) (NP (JJ potent) (NN inducer) (NN liver) (NN cancer)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 775:E02.760.058|ES| 2:1 8:1 10:1 14:1 18:1 19:1 22:1 52:1 401:1 546:1 728:1 836:1 1010:1 1355:1 1452:1 1875:1 1952:1 1995:1 3329:1 3635:1 3791:1 4296:1
6 	|BT| (NP (NP (NP (JJ Mechanistic) (NN Investigation) (NNP Toxaphene)) (NP (VBN Induced) (NN Mouse) (NN Liver) (NNS Tumors)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 225:E05.337 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 19:1 53:1 2127:1 2721:1 4297:1 4298:1 4299:1 4300:1
6 	|BT| (S (NP (JJ Mechanistic) (NN study) (NN liver) (NN tumor)) (VP (VBG promoting) (NP (NN effect) (NN flutamide) (NN rat)))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 1172:D02.065.199.420 1226:E01.370.372.460|ES| 7:1 19:1 75:1 131:1 836:1 849:1 881:1 4057:1 4297:1
6 	|BT| (S (NP (NNP Melatonin)) (VP (VBZ Activates) (NP (NP (JJ Endoplasmic) (NN Reticulum) (NN Stress) (NN Apoptosis) (NNS Rats)) (NP (JJ Diethylnitrosamine-Induced) (NN Hepatocarcinogenesis))))) |ET| |BS|39:G04.299.139.160 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 707:D03.438.473.914.481 1071:G04.434|ES| 19:1 1959:1 2738:1 3291:1 3664:1 4301:1 4302:1 4303:1 4304:1 4305:1
6 	|BT| (S (NP (NN Melatonin)) (VP (VBZ prevents) (NP (NN deregulation) (NN sphingosine) (NN kinase/sphingosine) (NN 1-phosphate) (NN signaling) (NN pathway) (NN mouse) (NN model) (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 469:D08.811.913.696 554:D02.654.442.200 707:D03.438.473.914.481 1227:D01.029.260.700.675.374 1228:D02.705.400|ES| 19:1 52:1 72:1 195:1 303:1 304:1 383:1 402:1 2718:1 2732:1 2738:1 4306:1 4307:1 4308:1
6 	|BT| (S (NP (NN Metformin)) (VP (VBZ inhibits) (NP (JJ early) (NN stage) (JJ diethylnitrosamineinduced) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 784:D02.078.370.141.450|ES| 19:1 615:1 849:1 900:1 1128:1 1129:1 2746:1 2747:1
6 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (DT A) (JJ Solt-Farber) (JJ two-step) (NN test) (NN model) (NN hepatocarcino) (NN genesis)) (VP (VBD established) (S (NP (NP (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN AAF)) (-RRB- -RRB-))) (NN rat)) (VP (VBP investigate) (S (VP (VBG modifying) (NP (NP (NP (NN effect) (NN expression) (NN 6-glucosephosphatase)) (PRN (-LRB- -LRB-) (NP (NN G-6-Pase)) (-RRB- -RRB-))) (, ,) (NP (NN succinodehydrogenase) (-LRB- -LRB-) (NN SDH) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NN adenosine) (NN triphosphatase)) (PRN (-LRB- -LRB-) (NP (NN ATPase)) (-RRB- -RRB-))) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 506:F01.829.263.315 554:D02.654.442.200 767:D02.065.064.150 893:D08.811.277.040.025 894:D08.811.277.040.025 1040:D08.811.277.352.650.225 1041:E01.370.370.380.250|ES| 2:1 10:1 14:1 19:1 69:1 72:1 75:1 104:1 115:1 459:1 565:1 849:1 900:1 1418:1 1875:1 1952:1 2660:1 2762:1 3158:1 3221:1 3271:1 3624:1 3625:1 3626:1 3627:1 3628:1 3629:1 3630:1 3631:1 3632:1 3633:1 3634:1
6 	|BT| (FRAG (NP (NNS METHODS) (: :)) (NP (NN Liver) (NN fibrosis)) (VBD induced) (NP (NN mouse)) (VBG receiving) (NP (NP (NN bile) (NN duct) (NN ligation)) (PRN (-LRB- -LRB-) (NP (NN BDL)) (-RRB- -RRB-))) (NP (NN carbon) (NN tetrachloride)) (-LRB- -LRB-) (NP (NP (NN CCl) (PRN (-LRB- -LRB-) (CD 4) (-RRB- -RRB-) (-RRB- -RRB-)) (NN administration)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 168:E05.581 676:C06.552.630 1217:A02.513.514.100 1220:D02.455.526.439.150 1222:A03.159.183 1223:E04.426|ES| 10:1 14:1 19:1 52:1 104:1 319:1 412:1 548:1 565:1 949:1 1621:1 1622:1 2575:1 2721:1 4261:1 4278:1 4279:1 4282:1 4309:1
6 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (CD Twenty-four) (JJ Sprague-Dawley) (NN rat) (VBN treated) (NN diethylnitrosamine) (NN phenobarbital)) (VP (VBP induce) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255 168:E05.581 554:D02.654.442.200 756:D03.383.742.698.253.650 769:B01.050.150.900.649.865.635.505.700.750|ES| 19:1 104:1 243:1 303:1 304:1 565:1 849:1 1099:1 1952:1 2685:1 2707:1 4310:1
6 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG developing) (NP (NP (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma)) (VP (VBN subjected) (NP (JJ hydrodynamic) (NN gene) (NN delivery)))))) (VP (VBP overexpress) (NP (NN Gas1) (NN liver)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 242:A03.620 554:D02.654.442.200 1229:E04.520.252 1230:G01.342|ES| 9:1 19:1 303:1 304:1 583:1 590:1 836:1 2513:1 2732:1 3267:1 4311:1 4312:1 4313:1
6 	|BT| (NP (NP (NNP Mode) (NN action) (NN analysis) (JJ synthetic) (NN pyrethroid) (JJ metofluthrin-induced) (NN rat) (NN liver) (NN tumor)) (: :) (NP (NN evidence) (JJ hepatic) (NN CYP2B) (NN induction) (NN hepatocyte) (NN proliferation))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 515:C04.588.274.623 1231:D02.455.849.575.812|ES| 7:1 19:1 38:1 104:1 299:1 661:1 736:1 836:1 838:1 849:1 1909:1 2013:1 3218:1 4314:1 4315:1 4316:1 4317:1
6 	|BT| (NP (NP (NN Modulation) (NN energy) (JJ metabolic) (NN enzyme) (NN expression) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (JJ Chinese) (NN herb)) (, ,) (NP (NNP Huqi) (NNP San))) |ET| |BS|554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500|ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1
6 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN mouse) (NN model) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis)) (, ,) (S (NP (NN rimonabant)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NN formation)))) (, ,)) (VP (VBZ precedes) (NP (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 20:G03.495 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 824:C04.834.020|ES| 2:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 72:1 113:1 124:1 202:1 207:1 622:1 1431:1 1725:1 2533:1 2831:1 2913:1 2914:1 4318:1
6 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN mechanism) (NNS fibrates)) (VP (VBP induce) (NP (NN hepatocyte) (NN proliferation) (NN cholestasis)) (ADVP (RB still)) (VP (ADVP (RB fully)) (VBN understood)))) |ET| |BS|239:F02.463.188.357 262:A11.436.348 879:C06.130.120.135 1188:D02.241.081.114.968.500|ES| 2:1 19:1 162:1 243:1 299:1 622:1 776:1 889:1 979:1 1909:1 4130:1 4131:1
6 	|BT| (S (NP (NN N-acetyl-L-cysteine)) (VP (VBD blocked) (SBAR (S (NP (NN EGFR) (NN activation)) (VP (VBD reduced) (NP (JJ N-nitrosodiethylamine-initiated) (NN hepatocarcinogenesis) (NN level) (NNP Cre-Ctrl) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 554:D02.654.442.200 791:D02.886.030.230.259|ES| 19:1 52:1 187:1 225:1 249:1 452:1 900:1 2776:1 2777:1 2778:1 2779:1
6 	|BT| (S (NP (JJ Nonalcoholic) (NN steatohepatitis)) (VP (VBD induced) (SBAR (S (NP (JJ high-fat) (NN diet)) (VP (VBZ promotes) (NP (JJ diethylnitrosamine-initiated) (JJ early) (NN hepatocarcinogenesis) (NN rat))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 509:C06.552.241.519 554:D02.654.442.200 694:G07.203.650.240.267|ES| 19:1 298:1 412:1 849:1 900:1 1128:1 1791:1 2191:1 2507:1 4092:1 4319:1
6 	|BT| (S (NP (ADJP (RB Orally) (VBN administered)) (NN lycopene)) (VP (VBZ attenuates) (NP (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN rat)) (VP (VBG modulating) (NP (NP (NN Nrf-2)) (: /) (NP (NN HO-1) (NN Akt/mTOR) (NN pathway))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534|ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1
6 	|BT| (NP (NP (PRP$ Our) (S (VP (VBP result) (S (VP (VBP provide) (NP (NP (ADJP (NN clue) (JJ molecular)) (NN event)) (VP (VBN involved) (NP (NN mechanism) (NN action) (JJ HCB-induced) (NN hepatocarcinogenesis)))))))))) |ET| |BS|742:G03.787 1232:D02.455.426.559.389.261.400|ES| 19:1 101:1 161:1 162:1 205:1 658:1 711:1 774:1 900:1 1142:1 2013:1 4320:1
6 	|BT| (NP (PRP$ Our) (VP (VBP result) (NP (NP (NN show) (NNS HCCs)) (VP (VBG developing) (FRAG (X (SYM AOX)) (: -) (NP (NP (: /) (: -) (NN mouse) (NN share) (NN number)) (VP (VBN deregulated) (FRAG (-LRB- -LRB-) (NP (RP up) (: -) (VBN down-regulated) (-RRB- -RRB-) (NN gene) (JJ ciprofibrate-induced) (NN liver) (NN tumor)))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 142:I01.880.604 351:A17.360 515:C04.588.274.623|ES| 7:1 9:1 10:1 14:1 19:1 52:1 101:1 429:1 590:1 646:1 658:1 836:1 1132:1 1283:1 1965:1 4321:1 4322:1 4323:1 4324:1
6 	|BT| (S (NP (JJ Overall) (NN finding)) (VP (VBP substantiate) (SBAR (S (NP (NN artesunate)) (VP (VBZ promotes) (SBAR (S (NP (JJ anti-tumour) (, ,) (JJ anti-proliferation) (NN apoptosis) (NN nitrosodiethylamine)) (VP (VBD mediated) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500|ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1
6 	|BT| (S (NP (NP (NN Overdose) (NN acetaminophen)) (PRN (-LRB- -LRB-) (NP (NN APAP)) (-RRB- -RRB-))) (VP (VBP cause) (NP (NN liver) (NN injury) (JJ human) (NN animal)))) |ET| |BS|19:B01.050 55:B01.050.150.900.649.801.400.112.400.400 73:N05.715.350.200 242:A03.620 661:D02.065.199.092.040 1233:C25.775.383|ES| 10:1 14:1 19:1 36:1 46:1 836:1 1779:1 2412:1 2416:1 4193:1 4325:1
6 	|BT| (NP (NP (NP (JJ Partial) (JJ hepatectomized) (NN rat)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (QP (CD 11) (CD 12))))) (-RRB- -RRB-))) (VP (VBN fed) (NP (NN diet) (VP (VBG containing) (S (CD 0) (, ,) (NP (CD 0.03) (, ,) (CD 0.06) (, ,) (CD 0.125) (ADJP (CD 0.25) (NN %)) (NN BNF)) (NP (NP (CD 6) (NN week) (JJ intraperitoneal) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBP initiate) (NP (NN hepatocarcinogenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 595:G07.203.650.240 663:C16.320.565.398.500.330.500 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 286:1 369:1 580:1 581:1 783:1 785:1 849:1 900:1 1057:1 1120:1 1875:1 2191:1 2426:1 3230:1 3231:1 3529:1 3595:1 4037:1 4093:1 4163:1 4326:1 4327:1 4328:1 4329:1 4330:1
6 	|BT| (S (NP (NP (NP (NNP Phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (JJ antiepileptic) (NN drug)) (VP (VBZ promotes) (NP (NP (NN hepatocarcinogenesis) (JJ rodent) (VBN administered) (JJ subsequent) (VBG initiating) (NN carcinogen)) (PP (IN like) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))))))) |ET| |BS|279:D27.888.569.100 514:B01.050.150.900.649.865 554:D02.654.442.200 756:D03.383.742.698.253.650 1234:D27.505.954.427.080|ES| 10:1 14:1 19:1 191:1 298:1 900:1 1319:1 1875:1 1952:1 2019:1 2125:1 2173:1 2336:1 3496:1 4004:1 4331:1 4332:1
6 	|BT| (NP (NP (JJ Possible) (NN involvement) (JJ oxidative) (NN stress) (JJ fenofibrate-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 916:D02.241.081.114.968.500.625|ES| 19:1 636:1 849:1 900:1 2522:1 2583:1 4333:1 4334:1
6 	|BT| (S (NP (JJ Possible) (NN involvement) (JJ oxidative) (NN stress) (NN piperonyl) (NN butoxide)) (VP (VBD induced) (NP (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 1077:D03.383.246.118.600|ES| 19:1 412:1 636:1 849:1 900:1 2522:1 2583:1 3777:1 3778:1 4333:1
6 	|BT| (S (NP (NNP Prevention) (JJ azoxymethane/dextran) (NN sodium) (JJ sulfate-induced) (NN mouse) (NN colon) (NN carcinogenesis)) (VP (VBN processed) (NP (NNP Aloe) (NN vera) (NN gel)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080|ES| 19:1 52:1 113:1 207:1 405:1 407:1 674:1 2898:1 4025:1 4026:1 4027:1 4335:1
6 	|BT| (NP (NP (JJ Protective) (NN effect) (NN dioscin) (JJ alcohol-induced) (NN liver) (NN injury))) |ET| |BS|242:A03.620 751:D02.033.375 822:D02.033|ES| 19:1 75:1 836:1 2416:1 2672:1 2909:1 2910:1
6 	|BT| (NP (NP (NP (NP (NN ra) (NN proto-oncogene) (NN activation) (JJ dichloroacetic) (NN acid)) (: -) (, ,) (NP (NN trichloroethylene)) (: -)) (JJ tetrachloroethylene-induced) (NN liver) (NN tumor) (NN B6C3F1) (NN mouse))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 11:B01.050.150.900.649.865.635.505.500 235:G05.360.340.024.340.375.500.791 515:C04.588.274.623 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939 1236:D02.455.526.439.880|ES| 2:1 7:1 19:1 52:1 225:1 563:1 836:1 1115:1 3986:1 4273:1 4336:1 4337:1 4338:1
6 	|BT| (S (NP (NNS Rats)) (VP (VBD received) (SBAR (S (NP (NP (JJ weekly) (JJ intraperitoneal) (NN injection) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD followed) (NP (NP (JJ 2-week) (JJ wash-out) (NN period)) (VP (VBD caused) (NP (NP (NN cirrhosis) (CD 14) (NN week)) (JJ multifocal) (NN HCC) (CD 18) (NN week))))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 554:D02.654.442.200 662:C23.550.355 776:G01.910.645 917:E02.319.267.530.490|ES| 10:1 14:1 19:1 441:1 783:1 785:1 1199:1 1440:1 1875:1 1952:1 2506:1 2725:1 3130:1 3230:1 3266:1 3664:1 3714:1 4076:1 4339:1 4340:1 4341:1
6 	|BT| (NP (NP (VBN Reduced) (NP (NN susceptibility) (JJ azoxymethane-induced) (JJ aberrant) (NN crypt) (NN focus) (NN formation) (NN colon) (NN cancer) (NN growth) (NN hormone) (JJ deficient) (NN rat)))) |ET| |BS|20:G03.495 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 401:C23.550.291.687 824:C04.834.020 1237:D06.472.699.631.525.425.875 1238:D06.472.699.631.525.425|ES| 18:1 19:1 43:1 102:1 113:1 542:1 849:1 1353:1 1431:1 1504:1 1531:1 1725:1 2533:1 2913:1
6 	|BT| (NP (NP (NN Regulation) (NN iron) (JJ metabolism-related) (NN gene) (JJ diethylnitrosamine-induced) (NN mouse) (NN liver) (NN tumor))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 140:G05.355.315 515:C04.588.274.623 554:D02.654.442.200 895:D01.490.600 896:D01.268.556.412 898:G03.495|ES| 7:1 9:1 19:1 52:1 699:1 836:1 2732:1 3162:1 4342:1
6 	|BT| (S (S (NP (NN Reporter) (NN mouse) (VBN given) (NN azoxymethane)) (VP (VBD followed) (S (NP (NN dextran) (NN sulfate) (NN sodium)) (VP (VBP induce) (NP (NN colitis) (NN colon) (NN tumor)))))) (: ;) (S (NP (NN mouse)) (VP (VBN given) (NP (NNP ROCK) (NN inhibitor) (NN fasudil)) (PP (IN along) (NP (NP (NN agent)) (PRN (-LRB- -LRB-) (NP (NN ROCK) (NN inhibitor) (NN increase) (NN miRNA) (NN function)) (-RRB- -RRB-))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 53:C06.405.205.265 131:D09.698.365.272.300 132:D02.172.080 184:D13.150.650.319|ES| 7:1 10:1 14:1 19:1 29:1 33:1 40:1 52:1 113:1 143:1 217:1 243:1 380:1 406:1 407:1 728:1 840:1 1993:1 2666:1 3130:1 3300:1 4343:1 4344:1 4345:1
6 	|BT| (S (NP (NNS Results) (NN study)) (VP (VBP demonstrate) (SBAR (S (NP (NP (NN PPARalpha)) (VP (VBN required))) (VP (VBP mediate) (NP (NP (NN hepatocarcinogenesis) (VBD induced) (NN bezafibrate)) (, ,) (S (NP (NN PPARalpha)) (VP (VBZ protects) (NP (JJ potential) (NN cholestasis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 535:H01.770.644.145.431 536:D12.776.826.239.500 879:C06.130.120.135 909:D02.065.277.067|ES| 2:1 19:1 131:1 412:1 502:1 702:1 827:1 900:1 1176:1 1601:1 1863:1 3201:1 4115:1 4131:1
6 	|BT| (NP (NP (NNS RESULTS) (: :)) (UCP (S (NP (NN Deletion) (NN Tgfbr2) (NN liver) (JJ epithelial) (NN cell)) (VP (VBP alter) (NP (NN liver) (NN injury)))) (, ,) (NP (NP (JJ toxin-induced) (JJ biliary) (NN fibrosis)) (, ,) (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis))))) |ET| |BS|242:A03.620 262:A11.436.348 306:G05.355.600.800 554:D02.654.442.200 691:C23.550.355 1239:A12.200.087 1240:D23.946|ES| 2:1 19:1 94:1 104:1 127:1 710:1 836:1 900:1 949:1 2416:1 2732:1 4152:1 4346:1 4347:1 4348:1 4349:1
6 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN Silibinin) (NN feeding)) (VP (VBD showed) (NP (NP (ADJP (NP (JJ dose-dependent) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)) (JJR stronger)) (NN efficacy) (NN pretreatment)) (CC versus) (NP (NN posttreatment) (NNS regimen))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 532:E02.183|ES| 19:1 78:1 104:1 113:1 132:1 295:1 710:1 1881:1 1983:1 2304:1 2531:1 2533:1 2824:1 2942:1 2943:1 2944:1 2945:1
6 	|BT| (S (NP (NNS RESULTS)) (: :) (S (NP (PRP We)) (VP (VBD uncovered) (SBAR (S (NP (NN adrenaline)) (VP (VBD promoted) (NP (JJ DEN-induced) (NN hepatocarcinogenesis))))))) (, ,) (VP (VBD reversed) (NP (NN ADRB2) (NN antagonist) (NN ICI118) (CD ,551)))) |ET| |BS|1241:D12.776.543.750.069.300.300.340.200 1242:D02.033.100.291.310|ES| 2:1 19:1 104:1 710:1 843:1 900:1 1271:1 1912:1 2735:1 4350:1 4351:1 4352:1 4353:1 4354:1
6 	|BT| (NP (NP (NN Role) (NN CYP2E1) (JJ diethylnitrosamine-induced) (FW hepatocarcinogenesis) (FW vivo))) |ET| |BS|15:F01.829.316.616 554:D02.654.442.200 1218:D08.244.453.300|ES| 19:1 378:1 900:1 2187:1 2732:1 4270:1
6 	|BT| (NP (NP (NN Role) (NN Nrf2) (JJ oxidative) (NN stress) (JJ fenofibrate-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|15:F01.829.316.616 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 799:D12.776.260.615.249 916:D02.241.081.114.968.500.625|ES| 19:1 849:1 900:1 2187:1 2522:1 2583:1 4334:1 4355:1
6 	|BT| (NP (NP (NN Role) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor-alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARalpha)) (-RRB- -RRB-))) (JJ bezafibrate-induced) (NN hepatocarcinogenesis) (NN cholestasis))) |ET| |BS|15:F01.829.316.616 536:D12.776.826.239.500 879:C06.130.120.135 909:D02.065.277.067|ES| 10:1 14:1 19:1 900:1 1801:1 1887:1 1889:1 2187:1 4115:1 4131:1 4356:1
6 	|BT| (NP (NP (NP (NP (NN Role) (NN life) (NN span) (NN determinant) (NN P66)) (PRN (-LRB- -LRB-) (NP (NN shcA)) (-RRB- -RRB-))) (JJ ethanol-induced) (NN liver) (NN damage))) |ET| |BS|15:F01.829.316.616 242:A03.620 751:D02.033.375 1243:K01.752.400|ES| 10:1 14:1 19:1 836:1 1848:1 2187:1 2674:1 4357:1 4358:1 4359:1 4360:1 4361:1
6 	|BT| (S (ADVP (RB Second)) (, ,) (NP (NN carbon) (NN tetrachloride)) (-LRB- -LRB-) (NP (NP (NP (NN CCl) (-LRB- -LRB-) (CD 4) (-RRB- -RRB-)) (: ;) (NP (NP (NP (CD 0.2) (NN ml/kg)) (, ,) (NP (JJ 2/week) (NN ip))) (VP (VBG starting) (NP (CD 8) (NN week) (NN age)))) (-RRB- -RRB-)) (VP (VBN administered) (NP (CD 9) (CD 14) (NN week)))) (VP (VBP develop) (NP (JJ advanced) (NN liver) (NN fibrosis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 113:C04.697.650 676:C06.552.630 1025:Z01.252.100.450 1217:A02.513.514.100 1220:D02.455.526.439.150|ES| 2:1 10:1 14:1 19:1 217:1 319:1 648:1 781:1 783:1 836:1 949:1 997:1 1440:1 2336:1 2717:1 3902:1 4261:1 4278:1 4279:1 4362:1 4363:1 4364:1 4365:1 4366:1
6 	|BT| (NP (NP (NP (JJ Selective) (NN pressure) (NN tumor) (NN promotion)) (NP (JJ phenobarbital) (NN lead) (JJ clonal) (NN outgrowth) (JJ beta-catenin-mutated) (NN mouse) (NN liver) (NN tumor)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 86:D01.268.556.435 301:A11.251.353 515:C04.588.274.623 756:D03.383.742.698.253.650 1244:G01.374.715|ES| 7:1 19:1 52:1 254:1 836:1 1069:1 2337:1 2685:1 4031:1 4367:1 4368:1 4369:1
6 	|BT| (S (NP (NP (CD SP600125)) (, ,) (NP (NN JNK) (NN inhibitor)) (, ,)) (VP (VBD reported) (NP (NN block) (JJ acetaminophen-induced) (NN liver) (NN injury)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 122:C14.280.383 242:A03.620 661:D02.065.199.092.040|ES| 2:1 19:1 380:1 742:1 836:1 993:1 2411:1 2416:1 4113:1 4276:1
6 	|BT| (S (NP (DT The) (NN parameter)) (NP (JJ related) (JJ key) (NN event) (JJ Metofluthrin-induced) (NN liver) (NN tumor)) (VP (VBD observed) (NP (JJ tumorigenic) (NN dose) (NN level)))) |ET| |BS|515:C04.588.274.623|ES| 7:1 19:1 159:1 205:1 249:1 261:1 419:1 691:1 836:1 1809:1 2301:1 4370:1 4371:1
6 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP examine) (NP (NP (NP (JJ anti-cancer) (JJ anti-fibrotic) (NN effect) (NN BCAA) (NN development) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VBN induced) (NN HCC) (NN liver) (NN cirrhosis) (NN rat) (NN model)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 554:D02.654.442.200 691:C23.550.355|ES| 10:1 14:1 19:1 35:1 72:1 75:1 131:1 409:1 441:1 691:1 836:1 849:1 960:1 1112:1 1199:1 1567:1 1875:1 1952:1 2360:1 4372:1
6 	|BT| (FRAG (NP (NP (DT The) (NN aim) (NN work)) (VBP characterize) (NP (NP (NN effect) (NN CAPE) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (VBN involved) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NP (NN metabolism) (NN initiation) (NN stage) (NN chemical) (NN hepatocarcinogenesis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 445:I03.946 554:D02.654.442.200 898:G03.495 1079:D08.244.453|ES| 2:1 10:1 14:1 19:1 75:1 637:1 691:1 774:1 900:1 1129:1 1546:1 1567:1 1875:1 1952:1 2124:1 2252:1 2332:1 2549:1 3163:1 3788:1 3789:1
6 	|BT| (S (NP (DT The) (NN conclusion) (NN evaluation) (JJ pronamide-induced) (NN mouse) (NN liver) (NN tumor)) (VP (VBP occur) (PP (IN via) (NP (NP (JJ NR-mediated) (NN MoA)) (VP (VBG involving) (NP (NP (NN CAR) (NN PPAR-alpha) (NN activation) (NN MoA) (JJ relevant) (JJ human) (VBN based) (JJ qualitative/quantitative) (NN difference) (NN mouse)) (ADJP (JJ human)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 139:J01.937.500.100 225:E05.337 333:D01.045 515:C04.588.274.623 536:D12.776.826.239.500 1245:Z01.639.760.680|ES| 7:1 19:1 36:1 52:1 225:1 421:1 596:1 691:1 836:1 865:1 1284:1 1674:1 2044:1 2503:1 4055:1 4070:1 4373:1 4374:1 4375:1 4376:1 4377:1
6 	|BT| (NP (NP (DT The) (NN correlation) (NN body) (NN growth) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN relation) (NN serum) (NN insulin) (NN somatomedin-C))) |ET| |BS|45:G07.700.320.249 554:D02.654.442.200 598:D12.644.276.937.400 637:D06.472.699.587.200.500.625 782:A12.207.152.846 1246:I01.076.201.450.560|ES| 19:1 102:1 691:1 900:1 1678:1 2364:1 2398:1 2732:1 2741:1 3544:1 4378:1
6 	|BT| (S (NP (NP (DT The) (NN effect) (NN D-allose) (NN diethyl) (NN nitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NP (NN hepatocarcinogenesis) (VBN examined) (JJ male) (NN F344) (NN rat) (NN rat) (JJ medium-term) (NN bioassay)) (VP (VBN based) (NP (NP (JJ two-step) (NN model) (NN hepatocarcinogenesis)) (PRN (-LRB- -LRB-) (NP (NN experiment) (CD 1)) (-RRB- -RRB-))))))) |ET| |BS|106:E05.091 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 333:D01.045 554:D02.654.442.200 590:B01.050.050.199.520.760.200 849:G08.686.785.760.769.490.500 914:L01.178|ES| 10:1 14:1 19:1 72:1 75:1 98:1 324:1 409:1 691:1 849:1 900:1 1402:1 1514:1 1875:1 2632:1 2931:1 3185:1 3215:1 3625:1 4070:1 4249:1 4379:1
6 	|BT| (NP (NP (DT The) (NN gene) (NN expression) (JJ hepatic) (NN protein) (JJ responsible) (NN DNA) (NN repair) (NN cell) (NN proliferation) (JJ tamoxifen-induced) (NN hepatocarcinogenesis))) |ET| |BS|183:G04.299.233.750 640:D02.455.426.559.389.150.700.900 1134:G02.111.087.219 1213:D12.776|ES| 4:1 9:1 19:1 94:1 115:1 299:1 513:1 666:1 691:1 838:1 900:1 2132:1 3966:1
6 	|BT| (S (S (NP (DT The) (NN goal) (JJ present) (NN study)) (-LRB- -LRB-) (-RRB- -RRB-) (VP (VBP investigate) (NP (NN mechanism) (NN resistance) (NN mouse) (JJ tamoxifen-induced) (NN hepatocarcinogenesis)))) (, ,) (S (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (VP (VB clarify) (NP (NN effect) (NN tamoxifen) (JJ NAFLD-associated) (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 415:F01.658.500 577:C06.552.241.519 640:D02.455.426.559.389.150.700.900 967:D01.248.497.158.490|ES| 2:1 10:1 14:1 19:1 52:1 75:1 131:1 162:1 459:1 691:1 836:1 900:1 1094:1 1307:1 2371:1 2416:1 3193:1 3966:1 4380:1 4381:1 4382:1
6 	|BT| (S (NP (NP (NP (DT The) (JJR higher) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 450) (NN ppm)) (-RRB- -RRB-))) (NN cyproconazole)) (VP (VBD caused) (NP (NP (JJ similar) (NN change)) (, ,) (NP (NP (JJR greater) (NN evidence) (NN liver) (NN damage)) (VP (VBN observed) (, ,) (PP (VBG including) (NP (JJ large) (NN increase) (NN plasma) (NN transaminase)))))))) |ET| |BS|242:A03.620 657:A12.207.152.693 781:D08.811.913.477.700|ES| 2:1 10:1 14:1 19:1 38:1 40:1 170:1 200:1 261:1 332:1 561:1 691:1 836:1 1848:1 2204:1 2301:1 2400:1 2506:1 2742:1 3233:1 4073:1 4255:1 4383:1
6 	|BT| (S (S (NP (DT The) (JJ knockout) (NN animal)) (VP (VBD increased) (NP (NP (NN lipid) (NN peroxidation)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ CCl4-induced) (NN liver) (NN damage)) (, ,) (PP (ADVP (RB largely)) (JJ due) (NP (NP (VBN increased) (NN CYP2E1) (NN expression) (NN diallyl) (NN sulfide)) (, ,) (NP (NN inhibitor) (NN CYP2E1)) (, ,))))))) (VP (VBD prevented) (NP (JJ CCl4-induced) (NN liver) (NN injury)))) |ET| |BS|12:Z01.542.049 19:B01.050 242:A03.620 1218:D08.244.453.300 1247:G02.111.087.520|ES| 2:1 19:1 46:1 47:1 71:1 115:1 380:1 385:1 607:1 691:1 836:1 1848:1 1944:1 2401:1 2416:1 2520:1 2595:1 2851:1 4270:1 4384:1 4385:1 4386:1
6 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBP examine) (SBAR (S (NP (NN effect) (NN pharmacology) (NN PARP-1) (NN inhibition) (NN reduction) (NN tumor) (NN volume) (NN HCC) (NN xenograft) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (NN diethyl-nitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 415:F01.658.500 554:D02.654.442.200 1059:H01.158.703 1203:E05.041.124.892 1248:D08.811.913.400.725.115.690|ES| 7:1 10:1 14:1 19:1 75:1 103:1 131:1 265:1 370:1 412:1 441:1 691:1 900:1 960:1 1875:1 2916:1 3589:1 4387:1 4388:1 4389:1
6 	|BT| (NP (NP (NP (DT The) (JJ orphan) (JJ nuclear) (NN receptor) (JJ constitutive) (NN active/androstane) (NN receptor)) (JJ essential) (NN liver) (NN tumor) (NN promotion) (JJ phenobarbital) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 38:Z01.058.290.120.180 40:Z01.542.248.700 515:C04.588.274.623 604:M01.108 756:D03.383.742.698.253.650 950:D12.776.826 1249:D04.808.054|ES| 7:1 19:1 52:1 186:1 604:1 691:1 836:1 1256:1 1776:1 2217:1 2337:1 2685:1 4390:1
6 	|BT| (S (NP (DT The) (JJ overall) (NN commonality) (NN expression)) (SYM AOX) (: -) (: /) (: -) (NP (JJ ciprofibrate-induced) (NN liver) (NN tumor) (JJ DENA-induced) (NN tumor)) (VP (ADVP (RB strongly)) (VBZ implicates) (NP (NP (NN activation) (NN PPARalpha) (JJ PPARalpha-regulated) (NN gene) (NN liver)) (, ,) (PP (VBG including) (S (VP (VBG participating) (NP (NN lipid) (NN catabolism)))))) (, ,) (FRAG (NP (JJ key) (NN factor) (NN development) (NN HCC)) (SYM AOX) (: -) (: /) (: -) (NP (JJ ciprofibrate-treated) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 52:E02 104:C04.557.470.200.025.255 142:I01.880.604 242:A03.620 515:C04.588.274.623 536:D12.776.826.239.500 554:D02.654.442.200 696:V02.270.500 1250:G02.111.087.530|ES| 2:1 7:1 9:1 19:1 35:1 52:1 115:1 159:1 185:1 225:1 441:1 561:1 635:1 691:1 836:1 2401:1 2510:1 3026:1 4115:1 4321:1 4324:1 4391:1 4392:1 4393:1 4394:1 4395:1 4396:1
6 	|BT| (NP (NP (DT The) (JJ present) (NN study)) (VP (VBN aimed) (VP (VBP investigate) (NP (NP (NP (NP (NN efficacy) (NN thymoquinone)) (PRN (-LRB- -LRB-) (NP (NN TQ)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ active) (NN compound)) (VP (VBN derived) (NP (JJ medicinal) (NN plant) (NNP Nigella) (NN sativa)))) (, ,) (NP (NP (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN NDEA)) (-RRB- -RRB-)))) (PRN (-LRB- -LSB-) (NP (ADJP (CD 0.01) (NN %)) (NN drinking) (NN water) (CD 16) (NN week)) (-RRB- -RSB-))))) (NP (: -) (VBN induced) (NN hepatocarcinogenesis) (JJ experimental) (NN rat))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1060:D01.045.250.875.300 1251:B01.650.940.800.575.100.838.518.750 1252:B01.650.560|ES| 2:1 10:1 14:1 19:1 131:1 197:1 263:1 315:1 369:1 409:1 459:1 460:1 691:1 783:1 844:1 849:1 900:1 1098:1 1307:1 1373:1 1378:1 1721:1 2304:1 2433:1 2602:1 3234:1 3796:1 3968:1 3997:1 4295:1 4397:1 4398:1 4399:1
6 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBN designed) (VP (VBP investigate) (SBAR (S (NP (NP (JJ hepatoprotective) (NN effect) (NN plant) (NN extract) (NN carbon) (NN tetrachloride)) (PRN (-LRB- -LRB-) (NP (NN CCl4)) (-RRB- -RRB-))) (VP (VBD induced) (NP (NN hepatocyte) (NN damage) (NN vitro) (NN liver) (NN injury)) (FW vivo))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 262:A11.436.348 328:B01.650 1220:D02.455.526.439.150|ES| 10:1 14:1 19:1 75:1 131:1 216:1 378:1 412:1 459:1 691:1 836:1 1098:1 1307:1 1683:1 1848:1 1909:1 2416:1 2496:1 4278:1 4279:1 4280:1 4400:1
6 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VBP investigate) (FRAG (NP (NP (JJ chemopreventive) (NN action) (JJ possible) (NN mechanism) (NN saffron) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN liver) (NN cancer) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 701:B01.650.940.800.575.100.549.500|ES| 10:1 14:1 18:1 19:1 162:1 409:1 459:1 691:1 836:1 849:1 1359:1 1497:1 1875:1 1946:1 1952:1 2013:1 2523:1 3011:1
6 	|BT| (NP (NP (DT The) (NN result) (NN show) (NN tamoxifen)) (, ,) (NP (NN toremifene)) (, ,) (NP (JJ potential) (S (VP (VBP induce) (VP (VBP promote) (NP (NN development) (NN rat) (NN hepatocarcinogenesis) (JJ experimental) (NN model))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 95:E05.599 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900 1253:D02.455.426.559.389.150.700.900.900|ES| 2:1 19:1 35:1 72:1 101:1 243:1 263:1 429:1 679:1 691:1 827:1 849:1 900:1 2371:1 4401:1
6 	|BT| (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN effect)) (NP (ADJP (RB orally) (JJ bioavailable)) (JJ synthetic) (NN triterpenoid) (NN 2-cyano-3,12-dioxooleana)) (: -) (NP (CD 1,9) (-LRB- -LRB-) (CD 11) (-RRB- -RRB-) (: -)) (NP (NP (NN dien-28-oate-ethyl) (NN amide)) (PRN (-LRB- -LRB-) (NP (NP (NN CDDO-EA)) (, ,) (NP (NN RTA) (CD 405))) (-RRB- -RRB-))) (, ,) (NP (JJ potent) (JJ antioxidative) (JJ antiinflammatory) (NN property))) (, ,) (VP (VBD evaluated) (S (NP (JJ chronic) (NN carbon) (NN tetrachloride)) (-LRB- -LRB-) (NP (NN CCl) (PRN (-LRB- -LRB-) (CD 4) (-RRB- -RRB-) (-RRB- -RRB-)) (: -)) (VP (VBN induced) (NP (NP (NN model) (NN liver) (NN cirrhosis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|104:C04.557.470.200.025.255 225:E05.337 357:C06.552.630 686:D27.505.954.158 1217:A02.513.514.100 1220:D02.455.526.439.150 1254:D02.241.081.018.386.682.300 1255:G03.787.151 1256:D02.065|ES| 2:1 10:1 14:1 19:1 22:1 72:1 75:1 303:1 304:1 319:1 409:1 441:1 780:1 836:1 841:1 1057:1 1199:1 1620:1 1790:1 2477:1 3218:1 3224:1 4226:1 4261:1 4278:1 4279:1 4402:1 4403:1 4404:1 4405:1 4406:1 4407:1 4408:1 4409:1 4410:1
6 	|BT| (S (ADVP (RB Therefore)) (, ,) (NP (NN study)) (VP (VBD initiated) (VP (VB investigate) (SBAR (IN whether) (S (NP (NP (NP (NN thymoquinone)) (PRN (-LRB- -LRB-) (NP (NN TQ)) (-RRB- -RRB-))) (, ,) (NP (NNP Nigella) (NN sativa) (NN derived-compound) (JJ strong) (JJ antioxidant) (NN property)) (, ,) (NP (NN supplementation))) (VP (MD could) (VP (VB prevent) (NP (NP (NP (NN initiation) (JJ hepatocarcinogenesis-induced) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DENA)) (-RRB- -RRB-))) (, ,) (NP (JJ potent) (NN initiator) (NN hepatocarcinogen)) (, ,) (NP (NN rat)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 700:D27.505.519.217 1251:B01.650.940.800.575.100.838.518.750 1257:G07.265.500|ES| 2:1 10:1 14:1 19:1 22:1 131:1 221:1 459:1 460:1 637:1 733:1 841:1 849:1 908:1 1620:1 1900:1 1952:1 2521:1 2567:1 2644:1 3578:1 3796:1 4398:1 4399:1 4411:1 4412:1 4413:1 4414:1
6 	|BT| (S (NP (NP (DT These) (NN alteration)) (, ,) (NP (NN hallmark) (JJ human) (NN colon) (NN cancer)) (, ,)) (ADVP (RB probably)) (VP (VBD contributed) (NP (NN pathogenesis) (JJ large) (JJ intestinal) (NN carcinoma) (NN mouse)) (PP (VBG following) (NP (JJ o-nitrotoluene) (NN exposure))))) |ET| |BS|5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 18:1 19:1 36:1 52:1 109:1 113:1 304:1 501:1 792:1 951:1 1427:1 1953:1 3510:1 4073:1 4415:1 4416:1 4417:1
6 	|BT| (S (NP (DT These) (NN finding) (, ,)) (S (VP (VP (VBN taken) (ADVP (RB together)) (ADVP (RB previously)) (VP (VBN reported) (S (VP (NN study))))) (, ,) (S (NP (NP (NN support) (NN mode) (NN action) (NN toxaphene)) (VP (VBD induced) (NP (NP (NN mouse) (NN liver) (NN tumor) (JJ nongenotoxic) (NN mechanism)) (VP (VBG involving) (NP (ADJP (RB primarily) (JJ CAR-mediated)) (NN process)))))) (VP (VBP result) (NP (NN increase) (NN cell) (NN proliferation) (NN liver)))))) (, ,) (VP (VBZ promotes) (NP (NP (JJ clonal) (NN expansion) (JJ preneoplastic) (NN lesion)) (VP (VBG leading) (NP (NN adenoma) (NN formation)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 20:G03.495 86:D01.268.556.435 139:J01.937.500.100 183:G04.299.233.750 242:A03.620 301:A11.251.353 515:C04.588.274.623 897:Z01.252.245.500.375 1149:D02.455.526.439.913|ES| 2:1 7:1 19:1 40:1 42:1 43:1 52:1 94:1 101:1 131:1 162:1 298:1 299:1 412:1 638:1 639:1 792:1 836:1 927:1 993:1 1069:1 1131:1 1362:1 1364:1 1438:1 1527:1 1538:1 1970:1 2013:1 3340:1 3985:1 4055:1 4418:1 4419:1 4420:1
6 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP argue) (S (NP (JJ intact) (NN HGF/c-Met) (NN signaling) (JJ essential)) (VP (VBG maintaining) (NP (NP (JJ normal) (NN redox) (NN homeostasis) (NN liver) (NN tumor) (NN suppressor) (NN effect)) (-LRB- -LRB-) (NP (-RRB- -RRB-) (JJ early) (NN stage) (JJ N-nitrosodiethylamine-induced) (NN hepatocarcinogenesis)))))))) |ET| |BS|69:G02.111.087.800 152:G07.700.345 188:N02.628 206:G05.360.340.024.340.375.249 242:A03.620 554:D02.654.442.200 865:G02.149.767.650|ES| 7:1 10:1 14:1 19:1 75:1 101:1 118:1 195:1 500:1 700:1 792:1 836:1 900:1 1128:1 1129:1 1776:1 2948:1 3075:1 4421:1 4422:1 4423:1 4424:1
6 	|BT| (S (NP (NN Thioacetamide)) (VP (VBZ accelerates) (NP (NP (NN steatohepatitis)) (, ,) (NP (NP (NN cirrhosis) (NN HCC)) (VP (VBG expressing) (NP (NN HCV) (NN core) (NN protein) (JJ transgenic) (NN zebrafish) (NN Danio) (NN rerio))))))) |ET| |BS|104:C04.557.470.200.025.255 296:D02.065.064.786 352:B01.050.050.136 357:C06.552.630 508:C06.552.241 572:B01.050.150.900.493.200.244.828 662:C23.550.355|ES| 2:1 4:1 19:1 285:1 441:1 529:1 810:1 1199:1 1791:1 1938:1 2017:1 4425:1 4426:1 4427:1 4428:1
6 	|BT| (S (NP (DT This) (NN study)) (VP (VBD evaluated) (SBAR (S (NP (JJ beneficial) (NN effect) (NN coffee) (NN caffeine) (JJ medium-term) (NN bioassay) (NN rat) (NN liver) (NN fibrosis/carcinogenesis)) (VP (VBD induced) (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NP (NP (NN carbon) (NN tetrachloride)) (PRN (-LRB- -LRB-) (NP (NN CCl4)) (-RRB- -RRB-))))))))) |ET| |BS|33:C04.697.098 106:E05.091 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 652:D20.215.784.249 676:C06.552.630 819:D03.132.960.175 849:G08.686.785.760.769.490.500 914:L01.178 1220:D02.455.526.439.150|ES| 10:1 14:1 19:1 75:1 131:1 412:1 780:1 807:1 836:1 849:1 984:1 1875:1 1952:1 2386:1 2899:1 2931:1 3215:1 4278:1 4279:1 4280:1 4429:1
6 	|BT| (S (NP (DT This) (NN study)) (VP (VBN tested) (NP (NP (NN effectiveness) (NN SAM) (NN supplementation)) (VP (VBG protecting) (NP (NP (NN azoxymethane) (-LRB- -LRB-) (NN AOM) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NN colon) (NN carcinogenesis) (JJ male) (NN F344) (NN rat)))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 232:D02.886.030.676.180 590:B01.050.050.199.520.760.200|ES| 10:1 14:1 19:1 113:1 131:1 207:1 409:1 807:1 849:1 1402:1 1993:1 1994:1 2567:1 2988:1 3185:1 3437:1 3573:1 4111:1
6 	|BT| (S (NP (DT This) (NN study)) (VP (VBD performed) (VP (VB investigate) (SBAR (S (NP (NN mode) (NN action) (NN toxaphene)) (VP (VBD induced) (NP (NN mouse) (NN liver) (NN tumor)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 7:1 19:1 52:1 131:1 412:1 458:1 459:1 807:1 836:1 2013:1 3985:1 4419:1
6 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (ADJP (RB highly) (JJ likely)) (NNP MOA) (JJ Metofluthrin-induced) (NN liver) (NN tumor) (NN rat) (NN CYP) (NN induction)) (VP (VBD increased) (NP (NN hepatocyte) (NN proliferation)) (, ,) (NP (JJ similar) (VBN seen) (NN phenobarbital)))) |ET| |BS|213:F02.830.816.964 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 515:C04.588.274.623 756:D03.383.742.698.253.650 897:Z01.252.245.500.375|ES| 2:1 7:1 19:1 47:1 299:1 332:1 626:1 724:1 736:1 836:1 849:1 1328:1 1691:1 1909:1 2685:1 3342:1 3789:1 4371:1
6 	|BT| (S (NP (NN Thymoquinone)) (VP (VBZ inhibits) (NP (NP (NN cell) (NN proliferation) (NN regulation) (NN G1/S) (NN phase) (NN cell) (NN cycle) (NN transition)) (NP (JJ N-nitrosodiethylamine-induced) (JJ experimental) (NN rat) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 757:C04.588.274.623.460 1258:G04.299.134.500.320 1259:G04.299.134.109|ES| 19:1 94:1 263:1 299:1 303:1 304:1 438:1 552:1 601:1 615:1 849:1 2529:1 2948:1 3087:1 4430:1
6 	|BT| (S (S (VP (TO To) (VP (VB approach) (NP (NN question))))) (, ,) (S (NP (JJ molecular) (JJ cellular) (NN response)) (VP (VBD monitored) (NP (NP (NP (NN development) (NN liver) (NN tumor) (NN mouse)) (VBN exposed) (NN chemical) (NN hepatocarcinogen)) (, ,) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drinking) (NN water)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN microg/l)) (-RRB- -RRB-))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 515:C04.588.274.623 554:D02.654.442.200 1060:D01.045.250.875.300 1260:E01.370.520|ES| 2:1 7:1 10:1 14:1 19:1 35:1 52:1 161:1 368:1 494:1 828:1 836:1 911:1 1875:1 1952:1 2124:1 3074:1 3102:1 3968:1 4295:1 4414:1 4431:1 4432:1 4433:1
6 	|BT| (S (S (VP (TO To) (VP (VB clarify) (NP (NN mechanism) (NN IFN-alpha))))) (VP (VBZ prevents) (NP (NN hepatocarcinogenesis)) (, ,) (NP (NP (VBN examined) (NN effect) (NN IFN-alpha)) (VP (ADVP (RB chemically)) (VBN induced) (S (NP (NN hepatocarcinogenesis) (NN model)) (VP (VBD initiated) (SBAR (S (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN 2-AAF)) (-RRB- -RRB-))) (NP (JJ partial) (NN hepatectomy))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (VP (VBZ arises) (NP (JJ pre-neoplastic) (NN focus)) (PP (IN without) (NP (NN inflammation) (NN fibrosis))))))))))))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 525:C23.550.470 554:D02.654.442.200 691:C23.550.355 767:D02.065.064.150 881:D02.065.064.150 928:E04.210.556|ES| 2:1 10:1 14:1 19:1 72:1 75:1 162:1 303:1 304:1 324:1 412:1 441:1 828:1 900:1 949:1 1195:1 1431:1 1680:1 1875:1 1900:1 1912:1 1952:1 2581:1 2696:1 2718:1 3064:1 3193:1 3271:1 3272:1 3273:1 3525:1 4434:1
6 	|BT| (S (S (VP (TO To) (VP (VB clarify)))) (, ,) (VP (VBD carried) (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN experiment)) (S (VP (VBG using) (NP (JJ Cyp2e1-null) (NN mouse)))))) |ET| |BS|29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 247:G01.374.676.530 554:D02.654.442.200 1218:D08.244.453.300|ES| 2:1 19:1 52:1 350:1 828:1 900:1 2632:1 2732:1 3193:1 4435:1 4436:1
6 	|BT| (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (JJ precise) (NN role) (NN UDCA) (NN chemoprevention) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis)) (, ,) (NP (VBN examined) (NN expression) (NN level) (NN group) (CD II) (NN phospholipase) (NN A2)) (NP (JJ colonic) (NN tissue) (JJ UDCA-treated) (JJ untreated) (NN rat)))))) (VP (VBD correlated) (NP (NN level) (NN finding) (JJ aberrant) (NN crypt) (NN focus)) (, ,) (NP (JJ putative) (JJ preneoplastic) (NN lesion)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 52:E02 98:A10 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 253:E02.319.162 737:D04.808.105.225.272.962 824:C04.834.020 829:M01.686 1261:D08.811.277.352.100.680.750.937.750.550|ES| 2:1 19:1 31:1 113:1 115:1 207:1 249:1 272:1 324:1 439:1 446:1 644:1 677:1 828:1 849:1 870:1 918:1 927:1 1116:1 1131:1 1431:1 1438:1 1697:1 1725:1 2300:1 2533:1 2631:1 2913:1 4437:1 4438:1 4439:1
6 	|BT| (S (S (VP (TO To) (VP (VB explore) (NP (NN role) (NN CHOP) (NN hepatocarcinogenesis))))) (, ,) (VP (VBD induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NP (NP (JJ wild) (NN type)) (PRN (-LRB- -LRB-) (NP (JJ wt)) (-RRB- -RRB-))) (NP (NP (NP (NP (NN CHOP) (NN knockout)) (PRN (-LRB- -LRB-) (NP (NN KO)) (-RRB- -RRB-))) (NP (NN mouse))) (S (VP (VBG using) (NP (NP (NN carcinogen) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))))))) |ET| |BS|15:F01.829.316.616 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 279:D27.888.569.100 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 31:1 52:1 71:1 303:1 304:1 350:1 412:1 441:1 543:1 828:1 900:1 1875:1 1902:1 2125:1 2849:1 3231:1 4440:1 4441:1 4442:1
6 	|BT| (S (VP (TO To) (FRAG (VB investigate) (NP (NP (NN effect) (NN Compound) (NN Astragalus)) (NP (FW Salvia) (FW miltiorrhiza) (NP (NP (NN Extract)) (PRN (-LRB- -LRB-) (NP (NN CASE)) (-RRB- -RRB-))) (NN diethylinitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN hepatocarcinogenesis) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780|ES| 10:1 14:1 19:1 75:1 409:1 459:1 828:1 849:1 900:1 1875:1 2492:1 2493:1 2494:1 2495:1 4103:1 4443:1 4444:1
6 	|BT| (S (VP (TO To) (VP (VB shed) (NP (NP (JJ light) (JJ global) (NN change) (NN gene) (NN expression) (NN colon) (NN cancer) (NN gain) (NN insight) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (NP (NN colon) (NN carcinogenesis)) (, ,) (NP (VBN conducted) (NP (JJ comprehensive) (NN microarray) (NN analysis) (NN mRNA))) (VP (VBG using) (NP (NP (NN rat) (NN colon) (NN cancer) (NN model) (JJ food-borne) (NN carcinogen)) (, ,) (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 111:D13.444.735.544 155:G05.355.310 197:A01.456.505.420 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 425:G01.358.500.505.650 455:B01.050.150.900.649.147.890 680:G07.203.300 718:E05.588.570 744:D03.383.725 876:F01.145|ES| 2:1 9:1 10:1 14:1 18:1 19:1 72:1 113:1 115:1 161:1 162:1 200:1 207:1 325:1 350:1 435:1 660:1 661:1 828:1 849:1 913:1 964:1 1141:1 1337:1 1373:1 1378:1 1455:1 2125:1 2638:1 2639:1 2640:1 2641:1 3100:1 4445:1 4446:1
6 	|BT| (S (S (VP (TO To) (VP (VB test) (NP (NN hypothesis))))) (, ,) (VP (VP (VBN studied) (NP (NP (NP (NP (NN effect) (NN Kupffer) (NN cell) (NN inhibition) (JJ dietary) (NN glycine)) (PRN (-LRB- -LRB-) (NP (NN inhibitor) (NN Kupffer) (NN cell) (JJ secretory) (NN activity)) (-RRB- -RRB-))) (NP (NN rat) (JJ two-stage) (NN hepatocarcinogenesis) (NN model))) (VP (VBG using) (NP (CD 2,2) ('' ')))) (NP (CD ,4,4) ('' ') (CD ,5,5) ('' '))) (: -) (PRN (NP (NN hexachlorobiphenyl) (-LRB- -LRB-) (NN PCB-153) (, ,) (JJ non-dioxin-like) (NN PCB)) (-RRB- -RRB-) (NP (NP (CD 3,3) ('' ') (CD ,4,4) ('' ')) (: -) (NP (NP (NP (NN tetrachlorobiphenyl)) (PRN (-LRB- -LRB-) (NP (NP (NN PCB-77)) (, ,) (NP (JJ dioxin-like) (NN PCB))) (-RRB- -RRB-))) (NN promoter)))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 1003:D12.125.481 1096:D03.383.231.900 1097:D03.383.231 1262:D02.065.277.727 1263:D02.455.426.559.389.185.698 1264:A11.329.372.588|ES| 2:1 10:1 14:1 19:1 72:1 75:1 83:1 94:1 103:1 350:1 380:1 399:1 401:1 643:1 828:1 849:1 900:1 1418:1 2594:1 2971:1 3045:1 4447:1 4448:1 4449:1 4450:1 4451:1 4452:1 4453:1 4454:1 4455:1
6 	|BT| (S (NP (NN Tomato) (NN oleoresin)) (VP (VBZ inhibits) (NP (NN DNA) (NN damage) (JJ diethylnitrosamine-induced) (NN rat) (NN hepatocarcinogenesis)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 526:G05.355.180 554:D02.654.442.200|ES| 19:1 615:1 666:1 849:1 900:1 1848:1 2732:1 4456:1 4457:1
6 	|BT| (NP (NP (NP (VBG Transforming) (NN growth) (NN factor-beta) (NN receptor) (NN type) (CD I)) (, ,) (NP (QP (CD II) (CD III)) (JJ phenobarbital-promoted) (NN rat) (NN liver) (NN tumor)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650|ES| 2:1 7:1 19:1 102:1 186:1 543:1 836:1 849:1 1116:1 1773:1 2281:1 2350:1 3877:1 4458:1
6 	|BT| (S (NP (NN Treatment) (NN HCC) (NN colon) (NN cancer) (NN xenograft) (NN aspirin) (NN sorafenib)) (VP (VBP result) (NP (JJ significant) (NN tumor) (NN suppression) (JJ single) (NN agent)))) |ET| |BS|8:C04 52:E02 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 670:D02.455.426.559.389.657.410.595.176 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 7:1 18:1 19:1 101:1 113:1 135:1 265:1 441:1 728:1 2063:1 2453:1 2487:1 2846:1 3106:1
6 	|BT| (NP (NP (NN Vanadium) (JJ chemopreventive) (JJ early) (NN stage) (JJ 2-AAF-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 837:D01.268.556.920 881:D02.065.064.150|ES| 19:1 849:1 900:1 1128:1 1129:1 1946:1 3124:1 3125:1
6 	|BT| (S (NP (PRP We)) (VP (VBD found) (SBAR (S (NP (NN panel) (CD 12) (NN gene)) (VP (VBD upregulated) (NP (NP (CD three) (NN class) (NN liver) (NN tumor)) (, ,) (ADJP (ADVP (RB namely)) (X (SYM AOX)) (: -) (: /) (: -) (, ,) (JJ ciprofibrate-induced) (JJ DENA-induced)))))))) |ET| |BS|149:G05.360.340.024.340.364.875.890 515:C04.588.274.623 554:D02.654.442.200|ES| 2:1 7:1 9:1 19:1 37:1 125:1 482:1 510:1 836:1 843:1 1120:1 2814:1 3026:1 4321:1 4324:1 4459:1
6 	|BT| (S (NP (PRP We)) (VP (VBD assessed) (NP (NP (NP (NP (NP (JJ chemopreventive) (NN property) (NN NO-indomethacin)) (PRN (-LRB- -LRB-) (NP (NN NCX) (CD 530)) (-RRB- -RRB-))) (NN NO-aspirin)) (PRN (-LRB- -LRB-) (NP (NN NCX) (CD 4016)) (-RRB- -RRB-))) (JJ azoxymethane-induced) (NN colon) (NN cancer)))) |ET| |BS|132:D02.172.080 795:D03.438.473.420|ES| 10:1 14:1 18:1 19:1 113:1 841:1 843:1 1946:1 2533:1 3823:1 4460:1 4461:1 4462:1 4463:1 4464:1
6 	|BT| (S (NP (PRP We)) (VP (VBP conclude) (SBAR (S (SBAR (IN although) (S (NP (NN PB) (CD 2) (NNS conazoles)) (VP (VBP induce) (NP (NN mouse) (NN liver) (NN tumor))))) (VP (VBP exhibit) (NP (NP (JJ similar) (JJ toxicological) (NN response)) (, ,) (NP (JJ transcriptional) (NN profile))) (ADJP (RB significantly) (JJ different)) (NP (ADVP (NP (RB thus) (NN mechanism) (JJ tumorigenic) (NN action)) (JJ likely)) (VBP differ))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 175:J01.897.280.500.269 209:G02.111.087.847 515:C04.588.274.623 557:D02.241.081.069.600.150 742:G03.787 1265:H01.158.891|ES| 2:1 7:1 19:1 52:1 124:1 148:1 162:1 243:1 332:1 414:1 494:1 559:1 587:1 836:1 843:1 1328:1 1334:1 1592:1 1711:1 1809:1 1968:1 2013:1 3496:1 3497:1 4465:1 4466:1
6 	|BT| (S (NP (PRP We)) (VP (VBP conclude) (SBAR (S (NP (JJ Cyp2e1-null) (NN mouse)) (VP (VBP show) (SBAR (S (NP (JJR lower) (NN tumor) (NN incidence) (NN multiplicity)) (VP (VBN compared) (NP (JJ wild-type) (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 434:E05.318.308.985.525.375 554:D02.654.442.200 557:D02.241.081.069.600.150 1218:D08.244.453.300|ES| 7:1 8:1 19:1 50:1 52:1 117:1 429:1 843:1 900:1 1511:1 1968:1 2732:1 2863:1 4436:1
6 	|BT| (S (NP (PRP We)) (VP (VBP find) (SBAR (S (JJ enzastaurin) (ADVP (RB potently)) (VP (VBZ reduces) (NP (NP (JJ azoxymethane-induced) (NN colon) (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (JJ PKCbetaII-mediated) (NN tumor) (NN cell) (NN proliferation) (NN beta-catenin) (NN accumulation))))))))) |ET| |BS|8:C04 16:C23.550.291.656 23:D12.776.091.249 51:C04.588.274.476.411.307.180 122:C14.280.383 132:D02.172.080 183:G04.299.233.750 866:D08.811.913.696.620.682.700.725.049|ES| 7:1 19:1 48:1 60:1 94:1 113:1 142:1 299:1 637:1 843:1 880:1 2120:1 2533:1 2855:1 3127:1 3128:1 3129:1
6 	|BT| (S (NP (PRP We)) (VP (VBD induced) (SBAR (S (NP (NN liver) (NN tumor) (NN mouse) (NN treatment) (NN liver) (NN carcinogen) (NN N-nitrosodiethylamine)) (VP (VBD followed) (NP (NP (JJ chronic) (NN treatment) (NN tumor) (NN promoter)) (NN phenobarbital))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 242:A03.620 279:D27.888.569.100 515:C04.588.274.623 554:D02.654.442.200 600:D27.888.569.100 756:D03.383.742.698.253.650|ES| 7:1 19:1 52:1 83:1 412:1 546:1 836:1 843:1 1790:1 2125:1 2602:1 2685:1 3130:1
6 	|BT| (S (NP (PRP We)) (VP (VBD reported) (SBAR (S (NP (JJ brief) (NN exposure) (JJ pregnant) (NN C3H) (NN mouse) (NN arsenite) (NN drinking) (NN water) (NN gestation)) (VP (VBD induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ male) (NN offspring)) (VP (VBD became) (ADJP (JJ adult))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 119:M01.060.116 1060:D01.045.250.875.300 1154:B01.050.050.199.520.520.388 1155:G08.686.340 1266:G08.686.785.760.769|ES| 10:1 14:1 19:1 52:1 303:1 304:1 355:1 412:1 441:1 843:1 993:1 1402:1 1953:1 3968:1 3999:1 4000:1 4001:1 4003:1 4295:1 4467:1 4468:1 4469:1
6 	|BT| (S (NP (PRP We)) (VP (VBD monitored) (SBAR (S (NP (JJ pre-neoplastic) (NN focus)) (VP (VBD induced) (NP (JJ two-stage) (NN initiation/promotion) (NN model) (NN hepatocarcinogenesis) (NN rat)) (, ,) (S (VP (VBG using) (NP (NN diethylnitrosamine) (NN acetylaminofluorene))))))))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 881:D02.065.064.150 1260:E01.370.520|ES| 2:1 19:1 72:1 350:1 412:1 843:1 849:1 900:1 1431:1 1952:1 2971:1 3525:1 4432:1 4470:1 4471:1
6 	|BT| (S (NP (PRP We)) (VP (VBD examined) (S (NP (NP (NN role) (NN PBP/MED1) (JJ genotoxic) (NN chemical) (NN carcinogen) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (JJ phenobarbital-promoted) (NN hepatocarcinogenesis)))))) |ET| |BS|15:F01.829.316.616 279:D27.888.569.100 554:D02.654.442.200 756:D03.383.742.698.253.650 1105:D05.500.374.750|ES| 10:1 14:1 19:1 31:1 324:1 409:1 843:1 900:1 1875:1 1952:1 2124:1 2125:1 3329:1 4458:1 4472:1
6 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (ADVP (RB strongly)) (VP (VBZ enhances) (SBAR (S (NP (NP (NP (NN colon) (NN carcinogenesis) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Min)) (: /) (CC +) (-RRB- -RRB-))) (NP (NP (NN mouse) (NN over-expression) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-)))) (VP (VBZ contributes) (NP (NN enhancement)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 22:D08.811.682.664.500.772.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300|ES| 10:1 14:1 19:1 52:1 63:1 64:1 65:1 66:1 67:1 113:1 207:1 280:1 406:1 407:1 635:1 705:1 843:1 845:1 993:1 1013:1 1356:1 1527:1 2278:1 3300:1 3306:1
6 	|BT| (FRAG (NP (PRP We)) (ADVP (RB recently)) (VBD showed) (NP (NP (JJ high-fat) (NN diet)) (PRN (-LRB- -LRB-) (NP (NN HFD)) (-RRB- -RRB-))) (: -) (VBN induced) (NP (NP (JJ nonalcoholic) (NN steatohepatitis)) (PRN (-LRB- -LRB-) (NP (NN NASH)) (-RRB- -RRB-))) (VBD promoted) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN initiated) (NN hepatocarcinogenesis) (NN rat) (NN model))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 554:D02.654.442.200 694:G07.203.650.240.267|ES| 10:1 14:1 19:1 72:1 132:1 409:1 772:1 843:1 849:1 900:1 1791:1 1796:1 1875:1 1912:1 1952:1 2191:1 2507:1 3065:1 4024:1 4473:1
6 	|BT| (S (NP (PRP We)) (VP (VBD studied) (NP (NP (NN mechanism) (VBG underlying) (NN inhibition) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NN lycopene) (NN rat)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 10:1 14:1 19:1 103:1 162:1 401:1 409:1 435:1 843:1 849:1 900:1 1875:1 1952:1 2566:1
6 	|BT| (S (NP (PRP We)) (VBD studied) (SBAR (IN whether) (S (NP (NP (JJ abundant) (JJ mutagenic) (JJ heterocyclic) (NN amine)) (VP (VBN isolated))) (VP (VBD cooked) (NP (NP (NN food)) (, ,) (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))) (, ,))))) (VP (MD could) (VP (VB influence) (NP (NP (JJ early) (JJ intestinal) (NN neoplasia) (NN C57BL/6J-Min)) (: /) (NP (CC +) (NN C57BL/6J) (: -) (CC +) (: /) (CC +) (PRN (-LRB- -LRB-) (ADJP (JJ wild-type)) (-RRB- -RRB-)) (NN mouse) (NN sex)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 593:B01.050.050.199.520.520.420 680:G07.203.300 744:D03.383.725 856:D02.092 1082:J01.576.423.200.200 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810 1267:D27.888.569.468|ES| 2:1 8:1 10:1 14:1 19:1 51:1 52:1 109:1 221:1 401:1 640:1 843:1 867:1 908:1 1128:1 1373:1 1378:1 1653:1 1798:1 2470:1 2638:1 2639:1 2640:1 2641:1 3054:1 3798:1 4088:1 4474:1 4475:1 4476:1 4477:1
6 	|BT| (S (NP (PRP We)) (VP (VBD compared) (SBAR (S (SYM AOX) (: -) (NP (: /) (: -) (NN liver) (NN tumor) (NN expression) (NN profile)) (VP (VBD induced) (SBAR (S (NP (NP (NN ciprofibrate)) (, ,) (NP (JJ non-genotoxic) (NN peroxisome) (NN proliferator)) (, ,) (NP (NP (JJ genotoxic) (NN carcinogen) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DENA)) (-RRB- -RRB-)))) (VP (VBP discern) (SBAR (S (NP (NN difference) (NN gene) (NN expression) (NN pattern)) (VP (MD may) (VP (VB predict) (VP (VB distinguish) (NP (JJ PPARalpha-mediated) (NN liver) (NN tumor)) (VP (ADVP (RB genotoxically)) (VBN derived) (S (NP (NN tumor))))))))))))))))) |ET| |BS|155:G05.355.310 279:D27.888.569.100 515:C04.588.274.623 536:D12.776.826.239.500 554:D02.654.442.200 912:D27.888.569.100.675|ES| 2:1 7:1 9:1 10:1 14:1 19:1 50:1 115:1 260:1 412:1 491:1 836:1 843:1 1302:1 1674:1 1711:1 1721:1 1887:1 1888:1 1952:1 2125:1 3329:1 4049:1 4321:1 4413:1 4478:1 4479:1 4480:1 4481:1 4482:1
6 	|BT| (S (NP (PRP We)) (RB thus) (NP (NP (NP (JJ treated) (JJ simple) (NN Tgfbr2)) (PRN (-LRB- -LRB-) (NP (NN DeltaIEC)) (-RRB- -RRB-))) (NP (NP (NN mouse) (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))) (VP (VBP cause) (NP (JJ ulcerative) (NN colitis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 73:N05.715.350.200 131:D09.698.365.272.300 1268:C06.405.205.265.231|ES| 10:1 14:1 19:1 52:1 143:1 406:1 407:1 843:1 1099:1 1334:1 1779:1 3300:1 3306:1 4347:1 4483:1 4484:1 4485:1
6 	|BT| (S (NP (PRP We)) (VP (VBD used) (S (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN injection) (NN initiate) (NN liver) (NN cancer) (NN mouse)) (NP (VBN assessed) (NN extent) (NN liver) (NN cancer) (JJ JDP2-transgenic) (JJ wild) (NN type) (NN control) (NN mouse) (JJ biochemical) (JJ molecular) (NN biology) (NN technique))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 352:B01.050.050.136 554:D02.654.442.200 1269:H01.158.201.636|ES| 10:1 14:1 18:1 19:1 52:1 161:1 289:1 476:1 543:1 785:1 836:1 843:1 1689:1 1875:1 1952:1 3595:1 3823:1 4442:1 4486:1 4487:1 4488:1 4489:1
6 	|BT| (S (NP (SBAR (WHADVP (WRB When)) (S (NP (NN goldenseal)) (VP (VBD evaluated) (NP (NNP National) (NNP Toxicology) (NNP Program))))) (PRN (-LRB- -LRB-) (NP (NNP NTP)) (-RRB- -RRB-)) (NP (JJ standard) (JJ 2-year) (NN bioassay)) (, ,) (NP (NP (NN goldenseal)) (VP (VBD induced) (NP (NN increase) (NN liver) (NN tumor) (NN rat) (NN mouse)))) (: ;)) (ADVP (RB however)) (, ,) (NP (NN mechanism) (JJ goldenseal-associated) (NN liver) (NN carcinogenicity)) (VP (VBZ remains) (ADJP (JJ unknown)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 106:E05.091 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 515:C04.588.274.623 1265:H01.158.891 1270:B01.650.940.800.575.100.838.397 1271:E05.337.820|ES| 2:1 7:1 10:1 14:1 19:1 40:1 52:1 162:1 217:1 412:1 442:1 780:1 836:1 849:1 1387:1 2182:1 2292:1 2931:1 3583:1 4178:1 4490:1 4491:1 4492:1 4493:1 4494:1 4495:1 4496:1
7 	|BT| (S (ADVP (RB Additionally)) (, ,) (NP (NP (NP (NN transcription) (NN factor) (JJ early) (NN growth) (NN response-1)) (PRN (-LRB- -LRB-) (NP (NN Egr-1)) (-RRB- -RRB-))) (NN gene) (ADJP (RB transcriptionally) (VBN activated)) (NN level) (NP (NP (JJ non-steroidal) (JJ anti-inflammatory) (NN drug)) (PRN (-LRB- -LRB-) (NP (NN NSAID)) (-RRB- -RRB-)))) (: -) (NP (NP (NP (VBN activated) (NN gene-1)) (PRN (-LRB- -LRB-) (NP (NN NAG-1)) (-RRB- -RRB-))) (NN protein)) (ADVP (RB also)) (VP (VBD elevated) (NP (JJ PTX-2-treated) (NN Hep3B) (NN cell)))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 41:A11 52:E02 580:D12.776.260.158.500 796:D27.505.696.663.850.014.040.500 1272:D03.438.759.758.824.651.700|ES| 2:1 4:1 5:1 9:1 10:1 14:1 19:1 94:1 102:1 163:1 185:1 191:1 249:1 487:1 756:1 1128:1 1662:1 1854:1 1859:1 2367:1 2795:1 4068:1 4497:1 4498:1 4499:1 4500:1 4501:1 4502:1
7 	|BT| (S (NP (NP (NP (JJ Epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN tyrosine) (NN kinase) (NN inhibitor) (NN erlotinib)) (VP (VBP show) (SBAR (S (NP (JJ potent) (NP (NP (NN antitumor) (NN activity) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD approved) (NP (NNP Food) (NNP Drug) (NNP Administration) (JJ second) (JJ third) (NN line) (NN treatment) (NN NSCLC))))))) |ET| |BS|52:E02 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 113:C04.697.650 633:I01.409.418.750.600.650.760 634:D12.125.072.050.875|ES| 10:1 14:1 18:1 19:1 22:1 94:1 102:1 185:1 186:1 187:1 264:1 327:1 328:1 329:1 380:1 399:1 429:1 470:1 546:1 2244:1 2340:1 2341:1 2342:1 2343:1 2344:1 2345:1 2346:1 2347:1 2348:1
7 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN ACR) (NN GW4064)) (ADVP (RB cooperatively)) (VP (VBP inhibit) (SBAR (S (NP (NN RXRalpha) (NN phosphorylation)) (, ,) (VP (VBP modulate) (NP (NP (NN expression) (JJ FXR-regulated) (NN gene)) (, ,) (S (ADVP (RB thus)) (VP (VBG resulting) (NP (NN induction) (NN apoptosis) (NN inhibition) (NN growth) (NN HCC) (NN cell))))))))))))))) |ET| |BS|39:G04.299.139.160 41:A11 43:F01.145.544 45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383 142:I01.880.604 155:G05.355.310 972:G02.111.087.677|ES| 2:1 9:1 19:1 89:1 94:1 101:1 102:1 103:1 115:1 384:1 441:1 658:1 736:1 796:1 1334:1 1370:1 3426:1 4017:1 4503:1 4504:1 4505:1 4506:1 4507:1
7 	|BT| (S (NP (JJ Quantitative) (JJ real-time) (NN RT-PCR) (NN analysis)) (VP (VBD showed) (SBAR (S (NP (NN troglitazone)) (VP (VBD down-regulated) (NP (NN Skp2) (NN mRNA) (NN level))))))) |ET| |BS|111:D13.444.735.544 142:I01.880.604 257:E05.393.620.500.706 351:A17.360 507:D12.776.157.743|ES| 19:1 132:1 249:1 325:1 661:1 874:1 1148:1 1283:1 1785:1 3732:1 4508:1
7 	|BT| (S (NP (DT This) (NN research)) (VP (VBZ provides) (NP (NN evidence) (NN tea)) (, ,) (NP (ADVP (RB particularly)) (NP (VBN administered) (NN combination) (NN sulindac)) (, ,) (NP (PP (ADJP (RB highly) (JJ effective)) (S (VP (VBG inhibiting) (NP (NP (NP (JJ intestinal) (NN neoplasia) (NN male) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN min)) (-RRB- -RRB-))) (NN mouse)) (PP (IN via) (NP (JJ direct) (JJ indirect) (NN effect) (NN beta-catenin/APC) (NN pathway)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 102:C04.588.274.476.411 122:C14.280.383 251:D02.455.426.559.847.486.875 644:H01.770.644 645:H01.770.644|ES| 2:1 10:1 14:1 19:1 38:1 52:1 75:1 109:1 280:1 383:1 530:1 596:1 626:1 640:1 807:1 815:1 869:1 880:1 1402:1 1639:1 1891:1 2336:1 2378:1 2379:1 2380:1 2381:1 2382:1 2383:1
7 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NP (VBN isolated) (NN colon) (NNS CSCs)) (PRN (-LRB- -LRB-) (NP (NP (JJ positive) (NN CD44)) (, ,) (NP (NN CD133) (NN ALDH1b1) (NN marker))) (-RRB- -RRB-))) (VP (VBG functioning) (NP (NP (NN p53) (JJ shRNA-attenuated) (NN p53)) (VBN treated) (NN PA) (CD 5.0) (NN mug/ml)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 46:A03.556.124.526.356 52:E02 158:D23.101 556:C11.768.175 1127:Z01.107.757.656 1273:D13.150.650.700|ES| 2:1 10:1 12:1 14:1 19:1 113:1 233:1 534:1 652:1 1099:1 1581:1 1629:1 1653:1 1691:1 1966:1 3943:1 4509:1 4510:1 4511:1 4512:1
7 	|BT| (S (NP (NNP UNLABELLED) (: :)) (S (VP (TO To) (VP (VB evaluate) (NP (NN possibility) (JJ radionuclide) (NN gene) (NN therapy) (NN imaging) (JJ hepatocellular) (NN carcinoma) (NN cancer))))) (, ,) (VP (VBD investigated) (NP (NP (NP (NN iodine) (NN accumulation) (JJ human) (JJ hepatocellular) (NN carcinoma) (NN cell) (NN line)) (, ,) (NP (NN SK-Hep1))) (, ,) (NP (NP (NN transfer) (JJ human) (NN sodium) (NN iodide) (NN symporter)) (PRN (-LRB- -LRB-) (NP (NN hNIS)) (-RRB- -RRB-))) (NP (NN gene))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 104:C04.557.470.200.025.255 225:E05.337 265:C04.557.470.200 967:D01.248.497.158.490 1017:E01.370.350 1274:D01.268.380.400 1275:D01.496.749|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 94:1 104:1 130:1 264:1 303:1 304:1 343:1 403:1 407:1 828:1 890:1 1644:1 2120:1 2266:1 3561:1 4513:1 4514:1 4515:1 4516:1 4517:1 4518:1
7 	|BT| (SINV (SBAR (IN Whether) (S (NP (NP (JJ single) (NN cell)) (NP (NP (ADJP (RB immunohistochemically) (JJ positive)) (NN glutathione) (NN S-transferase) (NN P1-1)) (PRN (-LRB- -LRB-) (NP (NN GSTP1-1)) (-RRB- -RRB-)))) (VP (VBD induced) (NP (JJ female) (NN mouse) (NN liver) (NN DEN))))) (PRN (-LRB- -LRB-) (NP (NP (NNP Hatayama) (FW et) (FW al.)) (, ,) (NP (NN Carcinogenesis)) (, ,) (CD 14) (, ,) (CD 537-538) (, ,) (NP (CD 1993))) (-RRB- -RRB-)) (NP (NP (NN precursor) (VBD initiated) (NN cell) (JJ preneoplastic) (NN focus)) (, ,) (NP (NN importance) (NN chemical) (NN hepatocarcinogenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 242:A03.620 642:M01.975 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 897:Z01.252.245.500.375 962:A11.148.378 1276:D08.811.913.225.500.500|ES| 2:1 10:1 14:1 19:1 52:1 94:1 233:1 412:1 836:1 900:1 1404:1 1431:1 1438:1 1440:1 1660:1 1875:1 1900:1 2124:1 2744:1 2745:1 2846:1 3167:1 4519:1 4520:1 4521:1 4522:1 4523:1 4524:1 4525:1 4526:1 4527:1 4528:1
7 	|BT| (S (NP (CD 1,25) (NN D)) (VP (VBD inhibited) (SBAR (S (NP (NN MYC) (NN gene) (NN expression)) (VP (VBD accelerated) (NP (NN protein) (NN turnover))))))) |ET| |BS|7:D12.776 122:C14.280.383 155:G05.355.310 185:G05.360.340.024.340.375.500.791.420 186:G05.360.340.024.340.375.500.791.420 665:N04.452.677.680|ES| 4:1 9:1 19:1 115:1 365:1 472:1 1391:1 2424:1 4529:1
7 	|BT| (S (S (NP (CD 1,25) (NN D)) (VP (VBD inhibited) (SBAR (S (NP (NP (NN transcription) (JJ c-MYC-regulated) (NN gene) (NN vitro)) (, ,) (NP (JJ topical) (CD 1,25) (NN D))) (VP (VBD suppressed) (NP (NN expression) (NN c-MYC) (NN target) (CD setd8) (NN mouse) (NN skin)))))) (, ,)) (IN whereas) (S (NP (NN MXD1) (NN level)) (VP (VBD increased)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 142:I01.880.604 185:G05.360.340.024.340.375.500.791.420 209:G02.111.087.847 785:A17.815|ES| 2:1 9:1 19:1 47:1 52:1 115:1 160:1 216:1 249:1 307:1 365:1 372:1 487:1 625:1 2319:1 4529:1 4530:1 4531:1 4532:1 4533:1
7 	|BT| (S (NP (DT A) (NN benzimidazole) (JJ derivative) (VBG exhibiting) (NN antitumor) (NN activity) (NN block) (NN EGFR) (NN HER2) (NN activity)) (VP (VBZ upregulates) (NP (NN DR5) (NN breast) (NN cancer) (NN cell)))) |ET| |BS|41:A11 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 122:C14.280.383 175:J01.897.280.500.269 798:D03.438.103|ES| 18:1 19:1 23:1 69:1 94:1 187:1 188:1 399:1 742:1 2153:1 2244:1 2812:1 2813:1 3755:1 3793:1
7 	|BT| (FRAG (NP (NP (DT A) (JJ critical) (NN threshold) (NN beta-catenin) (NN level) (JJ TCF-regulated) (NN transcription) (JJ uncovered) (NN Apc)) (JJ mutation-induced) (NN effect) (NN colon) (NN epithelium)) (, ,) (PP (IN along) (NP (NN evidence) (JJ feed-forward) (NN role) (NN beta-catenin) (NN Ctnnb1) (NN gene) (NN expression) (NN CTNNB1) (NN transcription)))) |ET| |BS|3:C04.557.470.035.215.100 15:F01.829.316.616 18:G05.365.590 23:D12.776.091.249 46:A03.556.124.526.356 62:A10.272 142:I01.880.604 155:G05.355.310 209:G02.111.087.847 1277:N03.219.442|ES| 2:1 9:1 19:1 31:1 38:1 60:1 69:1 75:1 113:1 115:1 173:1 249:1 280:1 487:1 825:1 1019:1 2666:1 3344:1 4032:1 4350:1 4534:1 4535:1 4536:1
7 	|BT| (S (NP (DT A) (VBN decreased) (NN protein) (NN level) (NN DAX-1) (NN APAP) (NN treatment)) (ADVP (RB also)) (VP (VBD enhanced) (SBAR (S (NP (NN miR-561)) (VP (VBP mimic) (NP (NN transfection) (NN HepG2) (NN cell) (JJ primary) (JJ human) (NNS hepatocytes))))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 112:D12.776.097.820 217:E05.393.350.810 262:A11.436.348 661:D02.065.199.092.040 1015:A11.251.860.180.432|ES| 4:1 5:1 19:1 36:1 69:1 94:1 202:1 249:1 344:1 385:1 546:1 567:1 746:1 894:1 3481:1 4193:1 4537:1 4538:1
7 	|BT| (S (NP (NN Activation) (NN RXRalpha) (JJ retinoic) (NN acid)) (VP (VBD increased) (NP (NP (NN cyclin) (NN E1) (NN promoter) (NN activity)) (VP (VBG indicating) (NP (ADJP (JJ retinoic) (JJ acid-mediated)) (NN signaling)))) (S (ADVP (RB positively)) (VP (VBP control) (NP (NN cyclin) (NN E1) (NN gene) (NN expression)))))) |ET| |BS|69:G02.111.087.800 155:G05.355.310 711:D02.455.326.271.665.202.495 770:D02.455.326.271.665.202.495.818.500|ES| 9:1 19:1 47:1 83:1 87:1 115:1 195:1 289:1 399:1 743:1 1275:1 1580:1 2236:1 2704:1 3848:1 4017:1 4539:1
7 	|BT| (S (S (NP (JJ Acute) (NN treatment) (NN B6C3F1) (NN mouse) (NN phenobarbital)) (VP (VBD resulted) (SBAR (S (NP (VBN increased) (NN level) (NN bcl-2)) (VP (VBD decreased) (NP (NN level) (NN bax) (NN protein))))))) (, ,) (NP (JJ acute) (NN treatment) (NN WY-14,643)) (VP (VBD resulted) (NP (VBN increased) (NN bcl-2) (NN BAG-1) (NN protein) (NN liver)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 54:G05.360.340.024.340.375.500.791.150 242:A03.620 342:D12.644.360.075.718.400 756:D03.383.742.698.253.650|ES| 2:1 4:1 19:1 47:1 52:1 90:1 151:1 202:1 249:1 546:1 594:1 836:1 1136:1 1893:1 2685:1 3986:1 4540:1 4541:1
7 	|BT| (S (ADVP (RB Additionally)) (, ,) (NP (NN DNA) (NN microarray) (NNS data)) (VP (VBD indicated) (SBAR (S (NP (NN cell) (JJ cycle-related) (NN gene) (NNS cyclins) (NN CCNB1) (NN CCNA2) (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN CDKN3)) (ADVP (RB also)) (VP (VBD down-regulated) (NP (NP (NN treatment)) (NP (CC either) (NP (NN PB) (NN CF) (CD 13) (NN week))))))))) |ET| |BS|52:E02 142:I01.880.604 325:Z01.058.290.100.140 351:A17.360 979:D12.644.360.262.120.100 996:G05.360.340.024.340.220 1278:D12.644.360.262.100.200 1279:D12.644.360.225 1280:D12.644.360.262|ES| 2:1 5:1 9:1 19:1 39:1 94:1 380:1 470:1 546:1 666:1 783:1 793:1 913:1 1100:1 1283:1 1532:1 1541:1 3496:1 4068:1 4542:1 4543:1 4544:1 4545:1 4546:1 4547:1
7 	|BT| (S (NP (NN AIMS/METHODS)) (: :) (NP (PRP We)) (VP (VBD evaluated) (NP (NP (FW vivo) (NN effect) (JJ intraperitoneal) (NN injection) (NN Ras) (NN inhibitor) (NN S-trans)) (, ,) (NP (NP (NP (JJ trans-farnesylthiosalicyclic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (S (NP (NN Ras) (NN activation) (NN development) (JJ preneoplastic) (NN liver) (NN lesion) (NN rat)) (VP (VBG receiving) (NP (NP (NP (JJ weekly) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN injection) (NNS 16weeks)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 168:E05.581 225:E05.337 226:E02.319.267.530 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 917:E02.319.267.530.490 1062:D01.029|ES| 2:1 10:1 14:1 19:1 35:1 75:1 104:1 225:1 378:1 380:1 548:1 780:1 785:1 836:1 843:1 849:1 1131:1 1275:1 1438:1 1775:1 1875:1 1952:1 3230:1 4076:1 4548:1 4549:1 4550:1 4551:1 4552:1
7 	|BT| (NP (NP (NNS AIMS)) (: :) (S (NP (DT The) (NN aim) (NN study)) (VP (VBP examine) (NP (NN effect) (NNS NSAIDs) (NP (NN mRNA) (NN expression) (NN tumour) (NN suppressor) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)) (NN rat) (NN colon) (NN mucosa))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 111:D13.444.735.544 155:G05.355.310 206:G05.360.340.024.340.375.249 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 302:A10.615.550 796:D27.505.696.663.850.014.040.500|ES| 9:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 75:1 104:1 113:1 115:1 131:1 325:1 579:1 691:1 700:1 849:1 960:1 1011:1 1567:1 1778:1 2966:1
7 	|BT| (S (NP (DT All) (NN result)) (VP (VBD revealed) (NP (NP (NN pterostilbene) (JJ effective) (NN antitumor) (NN agent)) (NP (RB well) (NP (JJ inhibitory) (NN effect) (NN down-regulation) (JJ inflammatory) (NN iNOS) (NN COX-2) (NN gene)) (NN expression) (NN up-regulation) (NN apoptosis) (NN mouse) (NN colon))) (, ,) (S (VP (VBG suggesting) (NP (NP (NP (NN pterostilbene)) (JJ novel) (JJ functional) (NN agent)) (ADJP (JJ capable) (S (VP (VBG preventing) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 46:A03.556.124.526.356 53:C06.405.205.265 85:G02.111.087.225 155:G05.355.310 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880 660:D27.505.954.248|ES| 2:1 9:1 19:1 52:1 67:1 75:1 76:1 78:1 89:1 101:1 113:1 115:1 257:1 275:1 415:1 728:1 787:1 891:1 896:1 965:1 1009:1 1639:1 1849:1 1937:1 2244:1 2428:1 2429:1 2430:1 2431:1
7 	|BT| (S (S (PP (IN Along) (NP (NN Nrf2) (NN inhibition))) (, ,) (NP (NN trig)) (VP (VBD blocked) (NP (NP (JJ Nrf2-dependent) (NN expression) (JJ proteasomal) (NN gene)) (PRN (-LRB- -LRB-) (NP (NP (NN example)) (, ,) (NP (NN s5a/psmd4) (NN alpha5/psma5))) (-RRB- -RRB-)))) (VP (VBD reduced) (NP (NP (NN proteasome) (NN activity) (NN cell) (NN line)) (VP (VBN tested)))))) |ET| |BS|43:F01.145.544 94:A11.251.210 122:C14.280.383 155:G05.355.310 799:D12.776.260.615.249 1281:D05.500.562.500|ES| 2:1 9:1 10:1 14:1 19:1 94:1 103:1 115:1 264:1 399:1 452:1 2777:1 2988:1 3490:1 4355:1 4553:1 4554:1 4555:1 4556:1 4557:1 4558:1 4559:1
7 	|BT| (S (SBAR (IN Although) (S (NP (NN study)) (VP (VBD needed) (VP (VB prove) (SBAR (S (NP (VBN increased) (NN expression) (NN Egr-1) (NN PTX-2)) (VP (ADVP (RB directly)) (VBP lead) (NP (NP (NN NAG-1) (NN induction) (NN apoptosis) (NN induction)) (NP (JJ p53-deficient) (NN Hep3B) (NN cell)))))))))) (, ,) (VP (VBP result) (SBAR (S (NP (NN study)) (VP (VBP suggest) (SBAR (S (NP (NN PTX-2)) (VP (MD may) (NP (JJ good) (NN candidate) (NN development) (JJ potential) (JJ anti-tumorigenic) (NN agent) (JJ p53-deficient) (NN tumor)))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 86:D01.268.556.435 284:N03.349.380.420 1272:D03.438.759.758.824.651.700|ES| 2:1 7:1 19:1 35:1 47:1 89:1 94:1 101:1 107:1 115:1 131:1 254:1 491:1 621:1 728:1 736:1 796:1 827:1 981:1 1243:1 1318:1 1662:1 2669:1 4498:1 4502:1 4560:1 4561:1 4562:1
7 	|BT| (S (SBAR (IN Although) (S (NP (NP (NP (NN Mlh1)) (PRN (-LRB- -LRB-) (NP (NN G67R)) (-RRB- -RRB-))) (NN mutation)) (VP (VBD resulted) (NP (NN DNA) (NN repair) (NN deficiency) (JJ homozygous) (JJ mutant) (NN mouse))))) (, ,) (VP (VBP affect) (SBAR (S (NP (NP (JJ MMR-mediated) (JJ cellular) (NN response) (NN DNA) (NN damage)) (, ,) (PP (VBG including) (NP (NP (JJ apoptotic) (NN response) (JJ epithelial) (NN cell) (JJ intestinal) (NN mucosa) (NN cisplatin)) (, ,) (NP (NP (JJ defective) (NN Mlh1)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))) (VP (VBD remained) (NP (NP (NP (JJ normal) (NN Mlh1)) (PRN (-LRB- -LRB-) (NP (NN G67R/G67R)) (-RRB- -RRB-))) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 39:G04.299.139.160 41:A11 191:A03.556.124.369 433:F01.470.047 498:D01.210.375 526:G05.355.180 1282:C18.452.284 1283:G05.380.554|ES| 2:1 10:1 14:1 19:1 34:1 45:1 52:1 94:1 107:1 109:1 118:1 127:1 253:1 494:1 513:1 561:1 579:1 586:1 594:1 666:1 811:1 1486:1 1761:1 1848:1 1861:1 2223:1 3074:1 4563:1 4564:1 4565:1 4566:1 4567:1
7 	|BT| (NP (NP (PP (IN Among) (NP (JJ different) (NNS chemotherapeutics))) (, ,) (NP (NN induction) (NN WT1) (NN transcription) (JJ restricted) (NN topoisomerase) (CD 2) (NN inhibitor)))) |ET| |BS|209:G02.111.087.847 382:C04.557.435.595 1284:D27.505.519.389.892.750|ES| 2:1 19:1 148:1 380:1 414:1 487:1 736:1 1000:1 1292:1 4568:1 4569:1 4570:1
7 	|BT| (S (NP (DT An) (JJ apoptosis-related) (NN gene) (NN expression) (NN profiling) (NN analysis)) (VP (VBD provided) (SBAR (S (NP (NP (NP (NN clue) (JJ death-associated) (NN protein) (NN kinase) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN dapk1)) (-RRB- -RRB-))) (NN gene)) (VP (VBN upregulated) (NP (ADJP (JJS least) (JJ twofold)) (NN response) (NN grifolin) (NN treatment) (JJ nasopharyngeal) (NN carcinoma) (NN cell) (NN CNE1))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 41:A11 52:E02 718:E05.588.570 1285:D08.811.913.696.620.682.700.125.387 1286:E05.393.332|ES| 4:1 9:1 10:1 14:1 19:1 94:1 98:1 115:1 125:1 304:1 470:1 494:1 546:1 661:1 1015:1 1142:1 1155:1 1178:1 1331:1 2148:1 4571:1 4572:1 4573:1 4574:1 4575:1 4576:1
7 	|BT| (VP (NP (NP (NP (NN Androgen)) (PRN (-LRB- -LRB-) (NP (NP (NN R1881)) (, ,) (NP (NN dihydrotestosterone))) (-RRB- -RRB-))) (NN treatment) (NP (NP (NN SVHUC) (VBN immortalized) (JJ normal) (JJ urothelial) (NN cell)) (ADVP (RB stably)) (VP (VBG expressing) (NP (NP (NN AR)) (PRN (-LRB- -LRB-) (NP (NN SVHUC-AR)) (-RRB- -RRB-)))))) (VP (VBD decreased) (NP (NN GATA3) (NN expression) (NN mRNA) (NN protein) (NN level))) (, ,) (VP (VBD abolished) (NP (NNS anti-androgens)))) |ET| |BS|7:D12.776 41:A11 52:E02 111:D13.444.735.544 321:A10.272.850 892:D27.505.696.399.472.161 1287:D04.808.054.040.248 1288:D06.347.065 1289:D04.808.365.415.550|ES| 2:1 4:1 10:1 14:1 19:1 94:1 115:1 118:1 202:1 249:1 325:1 478:1 546:1 810:1 1078:1 1357:1 1852:1 2152:1 4577:1 4578:1 4579:1 4580:1 4581:1 4582:1 4583:1
7 	|BT| (S (NP (NP (JJ Antisense) (NNS oligodeoxynucleotides) (JJ human) (NN superoxide) (NN dismutase) (CD 2)) (CC and/or) (NP (JJ ectopic) (NN bcl-2) (NN overexpression))) (VP (VBD avoided) (NP (NP (NNS polyphenols)) (SBAR (S (NP (JJ chemoradiotherapy-induced) (JJ colorectal) (NN cancer) (NN elimination)) (VP (VBD showed) (NP (NP (JJ mangano-type) (NN superoxide) (NN dismutase) (NN Bcl-2) (JJ key) (NN target) (JJ molecular) (NN mechanism)) (VP (VBN activated) (NP (JJ combined) (NN application) (NN t-PTER) (NNP QUER)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 57:D13.695.578.424.450 58:D08.811.682.881 59:E02.186.079|ES| 17:1 18:1 19:1 36:1 132:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1
7 	|BT| (S (NP (JJ Arsenic)) (VP (ADVP (RB also)) (NP (NP (ADVP (RB markedly)) (NP (VBN reduced) (NN methylation)) (PP (IN within) (NP (NN ER-alpha) (NN gene) (NN promoter) (NN region)))) (, ,) (NP (VBN assessed) (JJ methylation-specific) (NN PCR)) (, ,) (NP (NP (NN reduction)) (ADVP (RB statistically)) (NP (JJ significant) (CD 8) (CD 13) (NN CpG) (NN site))) (PP (IN within) (NP (NN promoter) (NN region)))))) |ET| |BS|6:G05.360.340.024.340 36:G02.111.087.029.538 196:G02.111.570.080.689.675 448:E05.393.620.500 1110:D12.776.826.750.350.174 1158:D01.268.513.249|ES| 2:1 5:1 9:1 19:1 81:1 83:1 135:1 370:1 452:1 662:1 667:1 781:1 875:1 1003:1 1532:1 2122:1 2396:1 3823:1 3887:1 4086:1 4584:1 4585:1
7 	|BT| (S (NP (JJ AST-induced) (NN NAG-1) (NN activation)) (VP (VBD intensified) (NP (NN PI3K) (NN inhibitor) (NN LY294002) (NN Akt) (NN inhibitor) (JJ co-treated) (JJ reversed) (NN NAG-1) (NN siRNA) (NN transfection)))) |ET| |BS|52:E02 117:D13.150.650.700 217:E05.393.350.810 378:D08.811.913.696.620.682.700.755 1042:Z01.107.757.284 1290:D08.811.913.696.620.500|ES| 19:1 225:1 351:1 380:1 746:1 1289:1 1662:1 3400:1 4352:1 4586:1 4587:1 4588:1 4589:1
7 	|BT| (S (PP (IN At) (NP (JJ molecular) (NN level))) (, ,) (NP (NN silibinin)) (VP (VBD increased) (NP (NP (NN IGFBP-3)) (, ,) (NP (NN Cip1/p21)) (, ,) (NP (NN Kip1/p27) (NN level) (NN ERK1/2) (NN activation))) (VP (VBD decreased) (NP (NN Bcl-2))) (, ,) (NP (JJ survivin) (NN VEGF) (NN level) (NN tumor)))) |ET| |BS|8:C04 54:G05.360.340.024.340.375.500.791.150 116:D08.811.913.696.620.682.700.567.249.750 1291:D12.776.157.420.270|ES| 2:1 7:1 19:1 47:1 158:1 161:1 202:1 225:1 249:1 2066:1 2229:1 2635:1 4590:1 4591:1 4592:1 4593:1 4594:1
7 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (NP (NP (DT The) (ADJP (RB ubiquitously) (VBN expressed)) (NP (JJ basic) (JJ helix-loop-helix) (NN transcription) (NN factor) (NN ITF-2B) (JJ important) (NN role)) (NN differentiation) (NN process)) (, ,) (S (NP (NN transcription)) (VP (VBD regulated) (NP (NN beta-catenin)))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 23:D12.776.091.249 74:G04.299.151 142:I01.880.604 166:D12.776.930 209:G02.111.087.847 1292:G02.111.570.820.709.600.040.360.360|ES| 2:1 6:1 19:1 31:1 60:1 104:1 185:1 215:1 487:1 638:1 691:1 902:1 1046:1 1664:1 1777:1 1778:1 2041:1 3733:1 4595:1 4596:1
7 	|BT| (NP (NP (NP (VBN Based) (NN finding)) (, ,) (VBP conclude) (NN matrilysin) (NN suppressor) (NN Min) (NN phenotype)) (, ,) (VP (ADVP (RB possibly)) (VBG functioning) (NP (NN capacity) (JJ independent) (NN matrix) (NN degradation)))) |ET| |BS|80:G05.695 333:D01.045 557:D02.241.081.069.600.150 937:D08.811.277.656.300.480.525.700.250 1293:G03.495|ES| 2:1 19:1 236:1 597:1 650:1 700:1 883:1 927:1 1548:1 1629:1 1968:1 3289:1 3491:1 4597:1 4598:1
7 	|BT| (S (SBAR (IN Because) (S (NP (NN Notch) (NN signaling) (VBN implicated) (NN colon) (NN cancer) (NN tumorigenesis)) (VP (VBZ protects) (NP (NP (NN cell) (NN apoptosis)) (VP (VBG inducing) (NP (JJ prosurvival) (NN target))))))) (, ,) (VP (VBD hypothesized) (SBAR (S (NP (NP (NN inhibition) (NN Notch) (NN signaling) (NN gamma-secretase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN GSI)) (-RRB- -RRB-))) (VP (MD may) (NP (VB enhance) (NP (NN chemosensitivity) (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 43:F01.145.544 69:G02.111.087.800 125:D08.811.277.656.300.032|ES| 2:1 10:1 14:1 18:1 19:1 78:1 89:1 94:1 103:1 113:1 160:1 195:1 256:1 380:1 386:1 491:1 977:1 1690:1 1750:1 1862:1 1863:1 1864:1 1865:1 1866:1 1867:1
7 	|BT| (S (NP (NNP Betaine) (NN supplementation)) (VP (VBD attenuated) (SBAR (S (NP (NN down-regulation) (NN p16)) (VP (VBD inhibited) (SBAR (S (NP (NN up-regulation) (NN c-myc)) (VP (VBD induced) (NP (NNP DEN) (JJ dose-dependent) (NN manner)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-)))))))))) |ET| |BS|85:G02.111.087.225 122:C14.280.383 142:I01.880.604 203:G05.360.340.024.340.375.249.375 743:D02.092.877.883.077|ES| 10:1 14:1 19:1 257:1 311:1 312:1 315:1 365:1 412:1 455:1 808:1 896:1 1313:1 1668:1 1875:1 2567:1 2824:1 4599:1
7 	|BT| (S (NP (JJ Biochemical) (NN analysis) (NN liver) (NN tissue)) (VP (VBD revealed) (NP (NN induction) (NN p66) (NN protein) (NN ethanol)) (, ,) (SBAR (IN whereas) (S (NP (JJ p66-deficient) (NN liver)) (VP (VBD responded) (NP (NP (NN alcohol) (JJ significant) (NN upregulation)) (NP (JJ mitochondrial) (JJ antioxidant) (NN enzyme) (NN MnSOD)))))) (, ,) (NP (ADJP (RB nearly) (JJ absent)) (NN control) (NN mouse)))) |ET| |BS|7:D12.776 11:B01.050.150.900.649.865.635.505.500 98:A10 242:A03.620 249:G05.355.315.800 339:G02.111.087.880 700:D27.505.519.217 730:D08.811 751:D02.033.375 822:D02.033|ES| 2:1 4:1 19:1 52:1 135:1 272:1 275:1 289:1 372:1 374:1 661:1 736:1 836:1 1126:1 2004:1 2388:1 2521:1 3440:1 3710:1 4600:1 4601:1 4602:1 4603:1 4604:1 4605:1
7 	|BT| (S (VP (VBG Blocking) (NP (NP (NN activation) (NN Notch) (NN signaling) (NN GSI34)) (VP (VBN sensitized) (NP (NP (NN cell) (NN chemotherapy) (JJ synergistic) (NN oxaliplatin)) (, ,) (NP (NN 5-FU)) (, ,) (NP (NN SN-38))))))) |ET| |BS|41:A11 69:G02.111.087.800 122:C14.280.383 151:E02.319 560:D03.383.742.698.875.404|ES| 2:1 19:1 94:1 195:1 225:1 256:1 495:1 598:1 2012:1 2308:1 2543:1 4606:1 4607:1 4608:1
7 	|BT| (NP (NP (NP (NN BTG3) (NN tumor) (NN suppressor) (NN gene) (NN promoter) (NN demethylation)) (, ,) (NP (NN histone) (NN modification) (NN cell) (NN cycle) (NN arrest)) (NP (NN genistein) (JJ renal) (NN cancer)))) |ET| |BS|206:G05.360.340.024.340.375.249 399:D12.776.660.470 773:G04.299.134.109 944:D03.383.663.283.266.450.400.375|ES| 2:1 7:1 9:1 18:1 19:1 83:1 94:1 503:1 601:1 602:1 700:1 922:1 2374:1 3312:1 3313:1 3314:1
7 	|BT| (NP (NP (PP (IN By) (NP (NN contrast))) (, ,) (NP (NP (NP (NN Ha-ras) (NN mutation) (JJ undetectable) (NN tumor) (NN mouse)) (VP (VBN treated) (NP (NP (NN DEN/PB)) (PRN (-LRB- -LRB-) (NP (CD 0/32)) (-RRB- -RRB-))))) (, ,) (NP (NP (QP (RB approximately) (CD 80)) (NN %)) (-LRB- -LRB-) (CD 37/46) (-RRB- -RRB-) (NN tumor) (NN group)) (NP (VBD showed) (NN beta-catenin) (NN mutation))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 52:E02 216:Z01.107.084.900.425 491:D27.505.259.500 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 34:1 52:1 60:1 132:1 369:1 573:1 747:1 1099:1 1392:1 1843:1 1868:1 2300:1 4183:1 4609:1 4610:1 4611:1
7 	|BT| (NP (NP (NN Calcium) (NN chloride)) (, ,) (NP (NN DFMO) (NN piroxicam)) (NP (NP (VBD increased) (NN protein) (NN mRNA) (NN level) (NN p16)) (PP (IN along) (NP (NN sulindac)))) (NP (VBD increased) (NN protein) (NN level) (NN p27)) (, ,) (NP (NN mRNA))) |ET| |BS|7:D12.776 111:D13.444.735.544 203:G05.360.340.024.340.375.249.375 251:D02.455.426.559.847.486.875 1294:D01.146.300 1295:D12.125.068.665.340 1296:D02.886.665.500|ES| 2:1 4:1 19:1 47:1 249:1 325:1 869:1 1124:1 1313:1 2666:1 2788:1 4612:1 4613:1 4614:1
7 	|BT| (NP (NP (NP (NN Calcium) (NN chloride)) (, ,) (NP (NN DFMO)) (, ,) (NP (NP (NN piroxicam) (NN sulindac)) (VP (VBN administered) (NP (CD 7) (NN day)))) (VP (VBD decreased) (SBAR (S (NP (JJ mitotic) (NN index)) (VP (VBD reduced) (NP (NN protein) (NN mRNA) (NN level) (NN c-myc) (NN colon) (NN tumor)))))))) |ET| |BS|7:D12.776 51:C04.588.274.476.411.307.180 111:D13.444.735.544 212:E01.370.225.500.385.500 251:D02.455.426.559.847.486.875 1294:D01.146.300 1295:D12.125.068.665.340 1296:D02.886.665.500|ES| 2:1 4:1 7:1 19:1 113:1 202:1 249:1 325:1 452:1 455:1 720:1 721:1 869:1 988:1 2336:1 2788:1 4078:1 4612:1 4613:1 4614:1
7 	|BT| (S (NP (NN Cdh1) (NN knockdown) (NN siRNA)) (VP (VP (VBD reversed) (NP (JJ salinomycin-induced) (NN Skp2) (NN downregulation) (NN p27Kip1) (NN upregulation)) (, ,) (S (VP (VBG indicating) (NP (NN salinomycin)))) (VP (VBZ activates) (NP (NP (NN APC)) (PRN (-LRB- -LRB-) (NP (NN Cdh1)) (-RRB- -RRB-))))) (: -) (NP (NN Skp2-p27Kip1) (NN pathway)))) |ET| |BS|3:C04.557.470.035.215.100 85:G02.111.087.225 117:D13.150.650.700 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 507:D12.776.157.743|ES| 2:1 10:1 11:1 14:1 19:1 301:1 351:1 383:1 464:1 524:1 595:1 1126:1 1785:1 2236:1 4352:1 4615:1 4616:1 4617:1 4618:1
7 	|BT| (S (S (NP (NNP Celecoxib)) (VP (VBP induce) (NP (JJ significant) (NN autophagy) (NN U87MG-PFT)))) (, ,) (NP (NP (NN U87MG-E6) (NN U373MG) (NN cell)) (, ,) (S (VP (VBP lack) (NP (JJ functional) (NN p53)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 390:G04.299.139.399 684:D02.065.884.247|ES| 2:1 12:1 19:1 94:1 135:1 243:1 415:1 1317:1 2475:1 3937:1 4619:1 4620:1 4621:1
7 	|BT| (S (NP (NN Celecoxib)) (VP (VBD induced) (NP (NP (NN G1-phase) (NN cell) (NN cycle) (NN arrest)) (, ,) (NP (VBN accompanied) (NP (NN p21) (NN activation) (NN U87MG) (NN cell)))))) |ET| |BS|41:A11 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 94:1 225:1 412:1 601:1 602:1 1135:1 2475:1 2801:1 4622:1 4623:1
7 	|BT| (S (NP (NN Celecoxib)) (VP (VBZ inhibits) (NP (NN glioblastoma) (NN cell) (NN viability) (NN induction) (NN DNA) (NN damage)) (, ,) (S (VP (VBG leading) (NP (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest)) (JJ p53-dependent) (NP (NN autophagy)) (, ,) (NP (NN apoptosis))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 86:D01.268.556.435 108:G04.299.316 122:C14.280.383 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 88:1 89:1 94:1 309:1 601:1 602:1 615:1 639:1 666:1 670:1 736:1 1317:1 1848:1 2186:1 2475:1
7 	|BT| (S (NP (NN Cell) (NN cycle) (NN analysis)) (VP (VBD showed) (SBAR (S (NP (NN MK-801)) (VP (VBD induced) (NP (NP (NN G1) (NN cell) (NN cycle) (NN arrest)) (S (NP (JJ down-regulating) (NN cyclin) (NN D1)) (VP (VBG up-regulating) (NP (NN p27)))))))))) |ET| |BS|150:Z01.542.248.960 206:G05.360.340.024.340.375.249 209:G02.111.087.847 215:D12.644.360.262.150.100 351:A17.360 353:G04.299.134 463:C23.550.210.870 1076:G04.299.134.109.249 1297:D02.455.426.559.847.181.384.380|ES| 2:1 7:1 9:1 19:1 94:1 132:1 412:1 487:1 601:1 602:1 661:1 670:1 700:1 715:1 743:1 744:1 1124:1 1256:1 1334:1 1618:1 1876:1 3097:1 3264:1 4094:1 4624:1 4625:1 4626:1 4627:1
7 	|BT| (S (NP (NN Cell) (NN proliferation)) (ADVP (RB significantly)) (VP (VBD inhibited) (, ,) (SBAR (S (NP (NN apoptosis)) (VP (VBD induced) (NP (NP (NN area) (NN GST-P) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NN focus) (NNP Valerian) (NN group)) (VP (VBN associated) (NP (NN suppression) (NN c-myc)))) (, ,) (NP (NP (NN Mafb)) (, ,) (NP (NP (NN cyclin) (NN D1) (NN induction) (NN p21)) (PRN (-LRB- -LRB-) (NP (NN Waf1/Cip1)) (-RRB- -RRB-))) (, ,) (NP (NN p53) (NN Bax) (NN mRNA) (NN expression)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 111:D13.444.735.544 122:C14.280.383 183:G04.299.233.750 215:D12.644.360.262.150.100 292:Z01 342:D12.644.360.075.718.400 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 1298:D12.776.260.108.500.061.500 1299:D12.644.360.225.500 1300:E05.318.308.112|ES| 2:1 10:1 12:1 14:1 19:1 89:1 115:1 124:1 169:1 299:1 325:1 365:1 412:1 455:1 736:1 743:1 744:1 1135:1 1431:1 2300:1 2453:1 3057:1 3058:1 3059:1 4080:1 4094:1 4628:1 4629:1 4630:1
7 	|BT| (NP (NP (JJ Chemopreventive) (NN agent)) (VP (VBD reported) (S (NP (NN mechanism) (VBG targeting) (NN epigenome)) (VBP include) (NP (NN micronutrient)) (-LRB- -LRB-) (NP (NP (NP (NN folate)) (, ,) (NP (NP (NN selenium)) (, ,) (NP (JJ retinoic) (NN acid))) (, ,) (NP (NN Vit))))))) |ET| |BS|224:D03.438.733.631.400 770:D02.455.326.271.665.202.495.818.500 833:D27.505.696.706.018 835:D27.505.696.377.605 935:D01.268.185.850|ES| 2:1 10:1 19:1 162:1 616:1 728:1 778:1 993:1 1275:1 2704:1 2973:1 3284:1 3972:1 4631:1 4632:1 4633:1
7 	|BT| (NP (NP (JJ Chemopreventive) (NN agent)) (VP (VBD reported) (S (NP (NN mechanism) (VBG targeting) (NN epigenome)) (VBP include) (NP (NN micronutrient)) (-LRB- -LRB-) (NP (NP (NP (NN folate)) (, ,) (NP (NP (NN selenium)) (, ,) (NP (JJ retinoic) (NN acid))) (, ,) (NP (NN Vit))))))) |ET| |BS|36:G02.111.087.029.538 56:D02.455.426.559.389.657.715 224:D03.438.733.631.400 399:D12.776.660.470 433:F01.470.047 595:G07.203.650.240 652:D20.215.784.249 674:B01.650.510.956 684:D02.065.884.247 692:D02.455.326.146.485.222.222 737:D04.808.105.225.272.962 741:D03.383.663.283.909 770:D02.455.326.271.665.202.495.818.500 833:D27.505.696.706.018 835:D27.505.696.377.605 935:D01.268.185.850 944:D03.383.663.283.266.450.400.375 1001:B01.650.940.800.575.100.401.750 1032:D03.383.663.283.266.450.400 1059:H01.158.703 1295:D12.125.068.665.340 1301:B01.650.940.800.575.100.842.500.444 1302:D02.455.426.559.389.140.450.582 1303:D02.455.426.559.847.562.050.650 1304:B01.650.940.800.575.100.610.100 1305:D27.505.954.122.085.255.135 1306:D27.505.954.122.085 1307:D02.241.081.114.750 1308:D10.212.302.380.410 1309:D02.241.081.114 1310:D02.033.623 1311:D12.125.068.555 1312:D02.886.489 1313:D02.092.782 1314:D08.811.913 1315:D01.875|ES| 2:1 10:1 14:1 19:1 69:1 81:1 154:1 162:1 380:1 399:1 503:1 616:1 728:1 778:1 993:1 1275:1 1380:1 1712:1 2070:1 2085:1 2379:1 2386:1 2433:1 2458:1 2498:1 2530:1 2566:1 2594:1 2630:1 2704:1 2807:1 2973:1 3219:1 3284:1 3314:1 3371:1 3598:1 3707:1 3758:1 3916:1 3924:1 3972:1 4229:1 4245:1 4613:1 4631:1 4632:1 4633:1 4634:1 4635:1 4636:1 4637:1 4638:1 4639:1 4640:1 4641:1 4642:1 4643:1 4644:1 4645:1 4646:1 4647:1 4648:1 4649:1 4650:1 4651:1 4652:1 4653:1 4654:1 4655:1 4656:1 4657:1 4658:1 4659:1 4660:1 4661:1 4662:1 4663:1 4664:1 4665:1 4666:1 4667:1 4668:1 4669:1 4670:1 4671:1 4672:1 4673:1 4674:1
7 	|BT| (S (NP (JJ Colonic) (NN adenocarcinoma)) (ADVP (RB rapidly)) (VP (VBD induced) (NP (NP (JJ combined) (NP (NN treatment) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine) (NN dextran) (NN sodium) (NN sulfate) (JJ male) (NN ICR) (NN mouse) (NN posse) (NN beta-catenin) (NN gene) (NN mutation)) (NN increase) (NN immunoreactivity) (NN beta-catenin)) (, ,) (NP (NN cyclooxygenase-2) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase))))) |ET| |BS|18:G05.365.590 22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 46:A03.556.124.526.356 84:C04.557.470.200.025 131:D09.698.365.272.300 618:E02.186 744:D03.383.725 1316:B01.050.050.199.520.520.510|ES| 2:1 9:1 19:1 34:1 40:1 52:1 60:1 61:1 63:1 64:1 65:1 66:1 164:1 255:1 406:1 407:1 412:1 546:1 1373:1 1378:1 1402:1 2638:1 2639:1 2640:1 3048:1 3300:1 3424:1 4675:1 4676:1 4677:1
7 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN curcumin)) (VP (VBZ potentiates) (NP (NP (JJ antitumor) (NN effect) (NN radiation) (NN therapy)) (JJ colorectal) (NN cancer) (VBG suppressing) (NP (NN NF-kappaB) (JJ NF-kappaB-regulated) (NN gene) (NN product))) (, ,) (NP (VBG leading) (NN inhibition) (NN proliferation) (NN angiogenesis))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 43:F01.145.544 52:E02 86:D01.268.556.435 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 693:G01.750.745|ES| 2:1 9:1 17:1 18:1 19:1 75:1 101:1 103:1 104:1 130:1 299:1 639:1 675:1 714:1 796:1 1872:1 1882:1 2244:1 2250:1 2498:1 2499:1 2500:1 2501:1 2502:1
7 	|BT| (S (NP (NN CONCLUSION) (: :)) (NP (PRP$ Our) (NN finding)) (VP (VBP reveal) (NP (NN p53) (NN increase) (JJ human) (NN glioblastoma) (NN sensitivity) (NN celecoxib)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247|ES| 12:1 19:1 36:1 40:1 104:1 607:1 658:1 927:1 1670:1 1882:1 2186:1 2807:1
7 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT Both) (NP (NN sulindac) (NN etodolac))) (VP (VBD reduced) (NP (NN occurrence) (NN ACF) (VBD induced) (NN increase) (NN APC) (NN mRNA) (NN rat) (NN colon) (NN mucosa))))) |ET| |BS|3:C04.557.470.035.215.100 12:Z01.542.049 46:A03.556.124.526.356 111:D13.444.735.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 302:A10.615.550 842:N02.278.035 1317:D03.066.288.200|ES| 11:1 19:1 40:1 104:1 113:1 239:1 325:1 412:1 452:1 579:1 849:1 869:1 2282:1 2914:1 4678:1 4679:1
7 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN FTS)) (VP (VBZ inhibits) (NP (NP (NN Ras)) (NN activation)))) (VP (VBZ prevents) (NP (NP (JJ preneoplastic) (NN liver) (NN nodule) (NN development)) (VP (VBG inducing) (NP (NP (NN apoptosis)) (VP (VBN transformed) (NP (NNS hepatocytes) (NN activation) (NN Fas/Fas) (NN ligand) (NN system)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 39:G04.299.139.160 122:C14.280.383 242:A03.620 262:A11.436.348 1318:D12.644.276.374.750.249|ES| 19:1 35:1 89:1 104:1 225:1 239:1 593:1 615:1 836:1 894:1 1438:1 1775:1 1835:1 1864:1 2718:1 4551:1 4680:1 4681:1 4682:1
7 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NP (DT The) (JJ novel) (NN effect) (NN ROS)) (VP (VBG modulating) (NP (NP (NP (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NN expression) (NN splice) (NN variant)))) (VP (MD could) (VP (VB play) (NP (JJ relevant) (NN role) (NN liver) (NN injury) (NN TNFalpha) (NN regulation)))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 142:I01.880.604 242:A03.620 259:D12.776.395.240.150.500 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 10:1 14:1 19:1 31:1 75:1 104:1 115:1 238:1 239:1 438:1 691:1 836:1 865:1 891:1 908:1 990:1 2356:1 2416:1 2435:1 4116:1 4683:1 4684:1 4685:1
7 	|BT| (S (ADVP (RB Consistently)) (, ,) (NP (NP (NN expression) (JJ oxidative-stress-inducible) (NN gene) (NN heme) (NN oxygenase-1)) (PRN (-LRB- -LRB-) (NP (NN HO-1)) (-RRB- -RRB-))) (VP (VBD upregulated) (NP (NN liver) (JJ arsenic) (NN group)))) |ET| |BS|155:G05.355.310 716:G03.495.710 1158:D01.268.513.249 1226:E01.370.372.460 1319:D08.811.682.690.708.410.500|ES| 2:1 9:1 10:1 14:1 19:1 115:1 125:1 836:1 2300:1 4106:1 4686:1 4687:1 4688:1 4689:1 4690:1
7 	|BT| (S (ADVP (RB Consistently)) (, ,) (VP (VBD found) (SBAR (S (NP (NN simvastatin)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN p21) (NN p27) (NN expression) (NN tumor) (NN section)) (VP (VBG reducing) (NP (NP (NN Skp2) (NN expression)) (VP (VBG inducing) (NP (NN AMPK) (NN activation) (NN STAT3) (NN suppression) (NN tumor) (NN tissue))))))))))) |ET| |BS|8:C04 82:D12.644.360.024.342.300 98:A10 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900|ES| 2:1 5:1 7:1 19:1 37:1 47:1 115:1 225:1 251:1 272:1 1124:1 1135:1 1785:1 1864:1 2453:1 2679:1 3331:1 4686:1 4691:1 4692:1
7 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NN IEX-1) (NN overexpression) (NN Colo320mut) (NN cell)) (VP (VBD caused) (SBAR (S (NP (NP (NN increase) (JJ basal) (NN TNFalpha)) (: -) (NP (JJ 5-FU-induced) (NN apoptosis)) (, ,) (NP (NN effect))) (VP (VBD triggered) (NP (NN G17) (NN treatment))))))) |ET| |BS|12:Z01.542.049 39:G04.299.139.160 41:A11 52:E02 560:D03.383.742.698.875.404 573:N05.715.350.200.650 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 19:1 40:1 75:1 89:1 94:1 152:1 546:1 760:1 2506:1 3398:1 3404:1 4184:1 4693:1 4694:1 4695:1 4696:1
7 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NP (NN MBO-asGCS) (NN treatment)) (VP (VBD decreased) (NP (NP (NP (NN globo) (NN series) (NNS GSLs)) (PRN (-LRB- -LRB-) (NP (NP (NN Gb3)) (, ,) (NP (NN Gb4))) (-RRB- -RRB-))) (, ,) (NP (NN cSrc) (NN kinase) (JJ nuclear) (NN beta-catenin)) (, ,)))) (VP (VBD suppressed) (NP (NN MDR-1) (NN expression) (JJ dose-dependent) (NN pattern)))) |ET| |BS|23:D12.776.091.249 52:E02 469:D08.811.913.696|ES| 2:1 10:1 14:1 19:1 60:1 115:1 202:1 260:1 307:1 470:1 546:1 1256:1 1807:1 2824:1 3404:1 4697:1 4698:1 4699:1 4700:1 4701:1 4702:1 4703:1
7 	|BT| (NP (NP (ADJP (NN Correction) (JJ malignant)) (NN behavior) (ADJP (NN tumor) (NN cell) (JJ traditional)) (JJ Chinese) (NN herb) (NN medicine) (NN restoration) (NN p53))) |ET| |BS|2:G05.360.340.024.340.375.249.385 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 788:H01.158.273.118.598.500 876:F01.145 1320:E02.190.488.585.520|ES| 7:1 12:1 19:1 94:1 802:1 2326:1 2327:1 2763:1 2764:1 4704:1 4705:1 4706:1
7 	|BT| (S (NP (NP (NN Cr)) (PRN (-LRB- -LRB-) (NP (NNP VI)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (JJ significant) (NN increase) (NN miR-21) (NN expression)) (VBN associated) (NN inhibition) (NN PDCD4) (NN expression)))) |ET| |BS|43:F01.145.544 1321:Z01.107.084.900.182|ES| 10:1 14:1 19:1 40:1 103:1 115:1 135:1 169:1 2177:1 2506:1 4707:1 4708:1 4709:1
7 	|BT| (S (NP (NP (JJ CRC-associated) (NN symptom) (NN patient)) (PP (VBG including) (NP (JJ intestinal) (NN bleeding) (NN anaemia)))) (ADVP (RB faithfully)) (VP (VBD mimicked) (NP (NP (NP (JJ AOM-treated) (NN MybER) (JJ transgenic) (NN mouse)) (VBN implicated) (NN hypoxia) (NN vessel) (NN leakage)) (VP (VBG identifying) (NP (ADJP (ADJP (JJ additional)) (ADJP (JJ pathogenic))) (NN role) (NN Myb)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 15:F01.829.316.616 47:A03.556.124 50:M01.643 52:E02 99:B01.050.050.136.500 132:D02.172.080 327:G06.930 371:A07.231 1011:C23.888.852.079 1322:C15.378.071 1323:C23.550.414|ES| 19:1 31:1 52:1 109:1 120:1 285:1 561:1 977:1 980:1 1698:1 2474:1 4710:1 4711:1 4712:1 4713:1 4714:1 4715:1 4716:1 4717:1 4718:1 4719:1 4720:1 4721:1
7 	|BT| (S (NP (NN Ctnnb1) (JJ hemizygous) (NN dose)) (VP (VP (ADVP (RB markedly)) (VBD inhibited) (NP (NN increase) (NN beta-catenin) (NN level) (NN cytoplasm) (NN nucleus)) (PP (VBG following) (NP (NN Apc) (NN inactivation) (NN colon) (NN epithelium)))) (, ,) (VP (VBD attenuated) (NP (NN expression) (JJ key) (JJ beta-catenin/TCF-regulated) (NN target) (NN gene)) (, ,) (PP (VBG including) (S (VP (VBG encoding) (NP (NP (NP (NN EphB2/B3) (NN receptor)) (, ,) (NP (NN stem) (NN cell) (NN marker) (NN Lgr5)) (, ,) (NP (NN Myc)) (, ,) (NP (VBG leading) (NN maintenance) (NN crypt) (NN compartmentalization) (NN restriction) (NN stem))) (VP (VBG proliferating) (NP (NN cell) (NN crypt) (NN base)))))))))) |ET| |BS|3:C04.557.470.035.215.100 23:D12.776.091.249 41:A11 46:A03.556.124.526.356 62:A10.272 86:D01.268.556.435 122:C14.280.383 142:I01.880.604 155:G05.355.310 158:D23.101 188:N02.628 308:A11.872 309:A18.024.937 333:D01.045 1098:A11.284.430.214 1104:A11.284.430.106 1324:D08.811.913.696.620.682.725.400.850.650|ES| 2:1 9:1 19:1 40:1 60:1 94:1 113:1 115:1 159:1 160:1 173:1 186:1 249:1 280:1 365:1 534:1 561:1 639:1 808:1 1063:1 1106:1 1314:1 1786:1 2301:1 2396:1 2865:1 2913:1 3510:1 3873:1 4032:1 4722:1 4723:1 4724:1 4725:1 4726:1 4727:1 4728:1 4729:1 4730:1
7 	|BT| (S (NP (NN Curcumin)) (VP (VBD suppressed) (NP (NP (NP (NN expression) (NN protein) (JJ related) (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NN bcl-2) (NN bcl-xL)) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D1) (NN c-myc)) (-RRB- -RRB-))) (, ,) (NP (NP (NN tumor) (NN invasion)) (NP (NP (-LRB- -LRB-) (NN MMP-9) (NN ICAM-1) (-RRB- -RRB-) (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-)))) (, ,) (NP (NN microvessel) (NN density))))) |ET| |BS|7:D12.776 8:C04 54:G05.360.340.024.340.375.500.791.150 108:G04.299.316 215:D12.644.360.262.150.100 586:D08.811.277.656.300.480.205.360 692:D02.455.326.146.485.222.222 1325:D12.776.395.550.200.450 1326:A07.231.461|ES| 2:1 4:1 7:1 10:1 14:1 19:1 94:1 115:1 151:1 274:1 299:1 307:1 419:1 455:1 620:1 743:1 744:1 2066:1 2158:1 2502:1 3429:1 4731:1 4732:1 4733:1 4734:1
7 	|BT| (S (NP (NP (NN Cyp2b20)) (, ,) (NP (NN growth) (NN arrest)) (: -) (NP (NP (JJ damage-inducible) (NN gene) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN Gadd45beta)) (-RRB- -RRB-))) (, ,) (NP (NP (ADJP (NN tumor) (NN necrosis) (NN factor) (JJ alpha-induced)) (NN protein) (CD 2) (JJ insulin-like) (NN growth) (NN factor) (NN binding) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Igfbp5)) (-RRB- -RRB-))) (NP (NN gene) (NN protein))) (VP (VP (VBD upregulated) (NP (NN oxazepam) (, ,) (NN Cyp2b20) (, ,) (NN Cyclin) (NN D1)) (, ,) (S (VP (VBG proliferating) (NP (NP (NP (NN cell) (JJ nuclear) (NN antigen)) (, ,) (NP (NN Igfbp5)) (, ,)) (NP (NP (NN Gadd45beta) (NN cell) (JJ death-inducing) (NN DNA) (NN fragmentation) (NN factor) (NN alpha) (JJ subunit-like) (NN effector)) (DT A)))))) (VP (VBD exhibited) (NP (JJR higher) (NN expression) (NN Wy-14,643) (NN treatment))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 45:G07.700.320.249 52:E02 134:G04.299.139 175:J01.897.280.500.269 198:D13.444.308 215:D12.644.360.262.150.100 583:D12.776.813 768:D12.776.660.740 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1327:D12.776.157.420.250 1328:D06.472.699.322.326.562 1329:D03.438.079.080.070.663 1330:G05.355.180.230|ES| 2:1 4:1 7:1 9:1 10:1 14:1 19:1 69:1 94:1 98:1 102:1 115:1 125:1 148:1 170:1 185:1 546:1 570:1 609:1 666:1 744:1 1030:1 1256:1 1487:1 1836:1 1972:1 2093:1 2865:1 4173:1 4257:1 4735:1 4736:1 4737:1 4738:1 4739:1 4740:1 4741:1 4742:1 4743:1 4744:1 4745:1
7 	|BT| (S (NP (NP (NNP DCA)) (, ,) (NP (NNP TCA) (JJR lesser) (NN extent)) (NN chloroform)) (VP (VBD decreased) (SBAR (S (NP (NN methylation)) (VP (VBD increased) (NP (NN mRNA) (NN expression) (NN c-myc) (NN gene))))))) |ET| |BS|36:G02.111.087.029.538 111:D13.444.735.544 155:G05.355.310 1196:D02.455.526.439.224 1331:C06.198.439 1332:Z01.107.084.900|ES| 2:1 9:1 19:1 47:1 81:1 115:1 202:1 325:1 455:1 2805:1 4179:1 4180:1 4486:1 4746:1
7 	|BT| (S (NP (JJ DHMEQ-treated) (NN cell)) (VP (VP (VBD exhibited) (NP (NN DNA) (NN damage))) (, ,) (VP (VBD evaluated) (NP (NN accumulation) (JJ nuclear) (NN focus) (NN phospho-H2AX))) (, ,) (S (ADVP (RB completely)) (VP (VBD reversed) (NP (NN NAC)))))) |ET| |BS|41:A11 52:E02 94:A11.251.210 155:G05.355.310 175:J01.897.280.500.269 225:E05.337 526:G05.355.180 1071:G04.434 1333:G02.111.087.750.700|ES| 2:1 9:1 10:1 14:1 19:1 94:1 115:1 264:1 325:1 346:1 412:1 494:1 609:1 622:1 666:1 774:1 780:1 1256:1 1431:1 1848:1 1912:1 2120:1 2522:1 2824:1 3223:1 3745:1 3746:1 4271:1 4352:1 4441:1 4747:1 4748:1 4749:1 4750:1 4751:1 4752:1 4753:1 4754:1
7 	|BT| (S (NP (NP (JJ Dietary) (NN intake) (NN pterostilbene)) (, ,) (NP (NN constituent) (NN blueberry)) (, ,)) (VP (VBZ inhibits) (NP (NN beta-catenin/p65) (JJ downstream) (NN signaling) (NN pathway) (NN colon) (NN carcinogenesis) (NN rat)))) |ET| |BS|23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 710:B01.650.940.800.575.100.343.774.249|ES| 2:1 19:1 113:1 195:1 207:1 383:1 560:1 615:1 849:1 2428:1 2457:1 2562:1 2563:1 2564:1 2565:1
7 	|BT| (S (NP (JJ Differential) (NN expression)) (VBN selected) (NP (NP (JJ beta-catenin/TCF-regulated) (NN gene)) (, ,) (NP (NN Myc)) (, ,)) (ADVP (JJ likely)) (VP (VBZ underlies) (NP (JJ context-dependent) (NN effect) (NN Ctnnb1) (NN gene) (NN dosage) (NN tumorigenesis)))) |ET| |BS|23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 142:I01.880.604 155:G05.355.310 280:G05.380.350|ES| 2:1 9:1 19:1 75:1 78:1 115:1 1328:1 1786:1 1905:1 2586:1 4032:1 4724:1 4755:1 4756:1 4757:1
7 	|BT| (S (NP (NN Down-regulation) (NN Notch) (NN signaling)) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (NP (NN induction)) (JJ prosurvival) (NN pathway)) (, ,) (NP (NP (ADJP (RB notably) (JJ phosphoinositide)) (NN kinase-3)) (: /) (NP (NNP Akt))) (, ,) (NP (NN oxaliplatin))))) |ET| |BS|69:G02.111.087.800 85:G02.111.087.225 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 2:1 5:1 19:1 195:1 256:1 383:1 736:1 1865:1 1944:1 2080:1 2543:1 3458:1 4758:1 4759:1
7 	|BT| (S (NP (NP (NN Doxorubicin) (NN treatment)) (VP (VBD induced) (NP (NP (NP (NNS GCS)) (NP (NN MDR1) (NN expression) (NN tumor))) (, ,) (NP (NN MBO-asGCS) (NN treatment))))) (VP (VBD eliminated) (NP (NP (`` ``) (JJ in-vivo) ('' '') (NN growth) (JJ drug-resistant) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN NCI/ADR-RES)) (-RRB- -RRB-))))) |ET| |BS|8:C04 45:G07.700.320.249 52:E02 67:D26 120:I01.409.418.750.600.480.150 136:D02.455.426.559.847.562.050.200.175|ES| 2:1 7:1 10:1 14:1 19:1 102:1 115:1 412:1 453:1 546:1 3247:1 3268:1 3269:1 4697:1 4760:1 4761:1 4762:1 4763:1 4764:1
7 	|BT| (NP (NP (NP (NN Effect) (JJ antisense) (NN oligodeoxy) (NN nucleotide) (NN c-Myc) (NN E2F1)) (NP (VBN studied) (NP (JJ human) (NN HCC) (NN cell) (NN line))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 104:C04.557.470.200.025.255 1334:D09.408.620|ES| 19:1 36:1 94:1 264:1 401:1 441:1 824:1 1961:1 3661:1 4765:1 4766:1 4767:1
7 	|BT| (NP (NP (NN Effect) (NN chloroform) (JJ dichloroacetic) (NN acid) (JJ trichloroacetic) (JJ acid-induced) (NN hypomethylation) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN kidney) (NN tumor) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 155:G05.355.310 242:A03.620 274:C04.588.945.947.535 1196:D02.455.526.439.224 1219:D02.241.081.018.214.500 1335:D02.241.081.018.214.750|ES| 7:1 9:1 19:1 52:1 115:1 455:1 836:1 1275:1 1717:1 2337:1 2599:1 3661:1 4107:1 4179:1 4273:1 4768:1
7 	|BT| (NP (NP (NP (VBN Enhanced) (NN sensitivity) (NN celecoxib) (JJ human) (NN glioblastoma) (NN cell)) (: :) (NP (NP (NN Induction) (NN DNA) (NN damage)) (VP (VBG leading) (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest) (NN autophagy)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 19:1 36:1 88:1 94:1 104:1 601:1 602:1 607:1 639:1 666:1 670:1 1317:1 1848:1 2020:1 2186:1 2807:1 3466:1
7 	|BT| (S (NP (NN Erlotinib)) (VP (VBZ induces) (NP (NP (JJ mitochondrial-mediated) (NN apoptosis)) (NP (NP (JJ human) (NN H3255) (JJ non-small-cell) (NN lung) (ADJP (NN cancer) (NN cell) (JJ epidermal)) (NN growth) (NN factor) (NN receptorL858R) (NN mutation)) (NP (JJ mitochondrial) (JJ oxidative) (JJ phosphorylation-dependent) (NN activation) (NN BAX) (NN BAK)))))) |ET| |BS|18:G05.365.590 39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 110:C04.588.894.797.520.109.220.249 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 923:D06.472.317.350 1336:G02.111.087.677.550|ES| 18:1 19:1 34:1 36:1 89:1 94:1 102:1 184:1 185:1 214:1 225:1 327:1 328:1 2004:1 2583:1 2596:1 4769:1 4770:1 4771:1 4772:1 4773:1 4774:1
7 	|BT| (S (NP (NN Expression) (NN profiling) (NN CC531) (NN colon) (NN carcinoma) (NN cell)) (VP (VBZ reveals) (NP (JJ similar) (NN regulation) (NN beta-catenin) (NN target) (NN gene) (NN butyrate) (NN aspirin)))) |ET| |BS|23:D12.776.091.249 41:A11 46:A03.556.124.526.356 140:G05.355.315 265:C04.557.470.200 670:D02.455.426.559.389.657.410.595.176 1307:D02.241.081.114.750 1309:D02.241.081.114|ES| 9:1 19:1 60:1 94:1 113:1 160:1 304:1 316:1 332:1 438:1 2148:1 2253:1 2487:1 3758:1 4775:1
7 	|BT| (S (S (NP (NN Flavokawain) (NN B)) (ADVP (RB also)) (VP (VBP down-regulate) (NP (ADJP (NN Bcl-2) (JJ concomitant)) (NN increase) (NN Bax) (NN level)))) (, ,) (VP (VBD resulted) (NP (NN release) (NN cytochrome) (NN c)))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 342:D12.644.360.075.718.400 351:A17.360 589:E02.204.125 1337:D08.244.286.100 1338:D08.244.286.150|ES| 2:1 5:1 19:1 40:1 158:1 249:1 594:1 763:1 1159:1 1681:1 2165:1 3788:1 4630:1 4776:1 4777:1
7 	|BT| (S (SBAR (IN For) (S (NP (NN therapy)) (VP (VBD advanced) (NP (NNP MTC))))) (, ,) (NP (NNP Food) (NNP Drug) (NNP Administration)) (ADVP (RB recently)) (VP (VBD approved) (NP (NP (NP (NN vandetanib) (NN cabozantinib) (, ,) (NN tyrosine) (NN kinase) (NN inhibitor)) (VP (VBG targeting) (NP (NNP RET)))) (, ,) (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor) (NN receptor)) (, ,) (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (CC and/or) (NP (NN c-MET))))))) |ET| |BS|52:E02 64:D08.811.913.696.620.682.725.400.009.300 633:I01.409.418.750.600.650.760 1339:D08.811.913.696.620.682.725.400.950 1340:D08.811.913.696.620.682.725|ES| 2:1 19:1 102:1 130:1 149:1 184:1 185:1 186:1 380:1 470:1 616:1 772:1 956:1 997:1 1251:1 2341:1 2343:1 2344:1 2345:1 2346:1 3092:1 3489:1 4778:1 4779:1 4780:1 4781:1
7 	|BT| (NP (NP (JJ Formalin-fixed) (, ,) (NP (NP (NP (NN paraffin) (JJ wax-embedded) (JJ pre-operative) (NN biopsy)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 14)))) (-RRB- -RRB-))) (NP (NP (NP (JJ surgical) (NN resection) (NN specimen)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 40)))) (-RRB- -RRB-))) (NP (S (NP (NP (NN patient) (JJ rectal) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (JJ clinical) (NN UICC) (NN stage) (NN II/III)) (-RRB- -RRB-))) (VP (VBG receiving) (NP (NP (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy)) (VP (VBN studied) (S (NP (NN TS) (: -))))))) (, ,) (NP (ADJP (NN TP) (: -) (, ,) (ADJP (JJ DPD-gene))) (NN expression) (JJ quantitative) (NNP TaqMan) (JJ real-time) (NN PCR) (NN laser) (NN microdissection))))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 115:E04 154:Z01.058.266.887 257:E05.393.620.500.706 333:D01.045 346:E05.393.620.500.706 347:D02.047.407 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500 1341:E01.370.225.998.221.580.500 1342:Z01.639.040 1343:D02.455.612|ES| 2:1 10:1 14:1 19:1 84:1 115:1 120:1 128:1 304:1 341:1 401:1 548:1 580:1 581:1 582:1 817:1 874:1 875:1 1129:1 1154:1 1440:1 1550:1 1984:1 1986:1 1987:1 1988:1 1989:1 3543:1 4046:1 4782:1 4783:1 4784:1 4785:1 4786:1 4787:1 4788:1 4789:1 4790:1
7 	|BT| (S (NP (NN FoxM1) (NN expression) (NN activity) (NN cancer) (NN cell)) (VP (VBN targeted) (S (VP (VBG using) (NP (NN PPARgamma) (NN agonist) (JJ anti-neoplastic) (JJ antibiotic) (NN mithramycin)))))) |ET| |BS|8:C04 41:A11 719:D12.776.826.239.588 1303:D02.455.426.559.847.562.050.650 1306:D27.505.954.122.085|ES| 16:1 18:1 19:1 94:1 115:1 350:1 399:1 2588:1 3228:1 4658:1 4659:1 4791:1 4792:1
7 	|BT| (S (S (S (NP (NN FTS)) (VP (VBZ abrogates) (NP (JJ DEN-induced) (NN Ras) (NN membrane) (NN activity)))) (, ,) (NP (NN increase) (NP (NP (NNP Tunel) (JJ positive) (NN cell)) (VP (VBN transformed)) (, ,) (NP (JJ GSTp-expressing) (NNS hepatocytes)) (, ,))) (VP (VBZ up-regulates) (NP (NN caspase) (CD 3) (CD 8) (NN activity)))) (, ,) (VP (VBZ induces) (SBAR (S (NP (NP (NN Fas)) (, ,) (NP (NN Fas) (NN ligand) (NN JNK) (NN phosphorylation))) (VP (VBZ occurs) (NP (RB independently) (NN TNFalpha) (NN Trail))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 41:A11 144:E05.393.475 150:Z01.542.248.960 262:A11.436.348 789:D12.644.276.374.500.800 790:D12.644.276.374.750 906:D08.811.277.656.262.500.126.350.300 972:G02.111.087.677 1318:D12.644.276.374.750.249 1344:A10.615|ES| 2:1 19:1 40:1 94:1 214:1 233:1 399:1 657:1 781:1 862:1 894:1 1775:1 1835:1 2149:1 2580:1 2735:1 3426:1 3622:1 4276:1 4551:1 4681:1 4685:1 4793:1 4794:1 4795:1 4796:1 4797:1 4798:1
7 	|BT| (S (NP (JJ Further) (NN study)) (VP (VBD revealed) (SBAR (S (NP (ADJP (NN TFSC) (VBD induced)) (NN HCC) (NN cell) (NN apoptosis)) (VP (VBD inhibited) (NP (NP (JJ expressional) (NN level) (NN NF-kappaB) (JJ responsive) (NN gene)) (VP (VBN transplanted) (NP (NN tumor) (NN tissue))))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 39:G04.299.139.160 41:A11 104:C04.557.470.200.025.255 122:C14.280.383 210:D12.776.260.600 1345:A01.941 1346:A01.941|ES| 7:1 9:1 19:1 89:1 94:1 131:1 249:1 272:1 275:1 330:1 365:1 412:1 441:1 714:1 4799:1 4800:1 4801:1 4802:1
7 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN calcitriol)) (PRN (-LRB- -LRB-) (NP (JJ active) (NN form) (NN vitamin) (NN D)) (-RRB- -RRB-))) (VP (VBD suppressed) (NP (NN CYP3A4) (NN expression) (VBG activating) (NN miR-627)))) |ET| |BS|189:V02.460 720:D04.808.247.222.474 721:D04.808.812.768 1347:D04.808.247.222.159.478.387.300 1348:D08.244.453.400|ES| 2:1 10:1 14:1 19:1 115:1 197:1 307:1 334:1 630:1 1958:1 2591:1 2592:1 4803:1 4804:1 4805:1
7 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN PSI) (NN treatment)) (VP (VBD increased) (NP (NN level) (NN Bax)) (, ,) (SBAR (S (NP (NP (NN cytochrome) (NN c)) (, ,) (NP (VBN activated) (NN caspase-3)) (, ,) (NP (JJ active) (NN caspase-9)) (, ,) (NP (NP (VBN cleaved) (NN poly)) (PRN (-LRB- -LRB-) (NP (NN ADP-ribose)) (-RRB- -RRB-))) (NP (NN polymerase))) (VP (VBD decreased) (NP (NP (NN Bcl-2) (NN expression) (NN level)) (NP (JJ extracellular) (JJ signal-regulated) (NN kinase-1) (: /) (CD 2) (NN activity)))))))) |ET| |BS|52:E02 54:G05.360.340.024.340.375.500.791.150 116:D08.811.913.696.620.682.700.567.249.750 342:D12.644.360.075.718.400 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1337:D08.244.286.100 1338:D08.244.286.150 1349:D08.811.277.656.262.500.126.550.900|ES| 2:1 10:1 14:1 19:1 47:1 115:1 158:1 163:1 197:1 202:1 249:1 334:1 394:1 399:1 546:1 1707:1 3788:1 4630:1 4777:1 4806:1 4807:1 4808:1 4809:1 4810:1 4811:1 4812:1 4813:1
7 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN cancer) (NN cell)) (VP (VBD showed) (SBAR (S (NP (VBN increased) (NN level) (VBN activated) (NN caspase-3)) (VP (VBD increased) (NP (NN Bax) (NN Bcl-2) (NN Bax) (NN Bcl-xL) (NN ratio)) (, ,) (S (VP (VBG suggesting) (NP (NP (NN cell)) (VP (VBG undergoing) (NP (NN apoptosis))))))))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 342:D12.644.360.075.718.400 906:D08.811.277.656.262.500.126.350.300|ES| 2:1 18:1 19:1 47:1 89:1 94:1 132:1 158:1 163:1 249:1 334:1 1009:1 2940:1 4630:1 4807:1 4814:1 4815:1
7 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN Cr)) (PRN (-LRB- -LRB-) (NP (NNP VI)) (-RRB- -RRB-))) (VP (VP (VBD induced) (SBAR (S (NP (NN inhibition) (NN PDCD4)) (VP (VBD suppressed) (NP (JJ downstream) (NN E-cadherin) (NN protein) (NN expression)))))) (, ,) (VP (VBD promoted) (NP (JJ beta-catenin/TCF-dependent) (NN transcription) (NN uPAR) (NN c-Myc))))) |ET| |BS|7:D12.776 23:D12.776.091.249 43:F01.145.544 209:G02.111.087.847 613:D12.776.395.550.200.200 1321:Z01.107.084.900.182|ES| 2:1 4:1 10:1 14:1 19:1 103:1 115:1 307:1 334:1 412:1 487:1 560:1 824:1 1912:1 2267:1 4707:1 4708:1 4709:1 4816:1 4817:1
7 	|BT| (S (NP (NN gamma-Secretase) (NN inhibitor)) (VP (VBP abrogate) (NP (NP (JJ oxaliplatin-induced) (NN activation) (NN Notch-1) (NN signaling) (NN pathway) (NN colon) (NN cancer) (NN cell)) (VP (VBG resulting) (NP (VBN enhanced) (NN chemosensitivity)))))) |ET| |BS|41:A11 69:G02.111.087.800 125:D08.811.277.656.300.032 126:G02.111.087.800|ES| 18:1 19:1 20:1 94:1 113:1 195:1 225:1 379:1 380:1 381:1 382:1 383:1 384:1 385:1 386:1
7 	|BT| (S (NP (JJ Gefitinib) (NN treatment)) (VP (VBD diminished) (NP (NP (ADJP (NP (NN phosphorylation) (NN ErbB-3)) (JJR >)) (NN EGFR)) (JJR >) (NN HER2/neu) (NN signal) (NN transducer) (NN activator) (NN transcription) (JJ dose-dependent) (NN fashion)))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 209:G02.111.087.847 250:E07.305.812 972:G02.111.087.677 1350:G05.360.340.024.340.375.500.791.295|ES| 19:1 187:1 487:1 546:1 859:1 860:1 861:1 901:1 1466:1 2824:1 3024:1 3426:1 4156:1 4754:1 4818:1
7 	|BT| (NP (NP (NP (S (NP (NP (NN Gene) (NN expression) (NN analysis) (NN Bcl-2) (NN family) (NN gene)) (NP (JJ antioxidant) (NN enzyme))) (VP (VBD revealed) (NP (NP (NN t-PTER)) (CC +) (NP (NN QUER)) (NP (NN treatment))) (SBAR (S (ADVP (RB preferentially)) (VP (VBZ promotes)))))) (, ,) (NP (NN HT-29) (NN cell)) (ADVP (VBG growing) (FW vivo)) (, ,) (-LRB- -LRB-) (NP (NP (NP (-RRB- -RRB-) (NN superoxide) (NN dismutase) (CD 2) (NN overexpression)) (PRN (-LRB- -LRB-) (NP (ADJP (ADJP (RB approximately) (JJ 5.7-fold)) (, ,) (ADJP (IN via) (NN specificity))) (NN protein) (JJ 1-dependent) (NN transcription) (NN regulation)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN b)) (-RRB- -RRB-))) (NP (NP (NN down-regulation) (NN bcl-2) (NN expression)) (PRN (-LRB- -LRB-) (ADVP (RB approximately) (RB 3.3-fold)) (, ,)))) (PP (IN via) (NP (NN inhibition) (JJ nuclear) (NN factor-kappaB) (NN activation)))) (ADJP (-RRB- -RRB-))) |ET| |BS|43:F01.145.544 44:F01.829.263 52:E02 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 142:I01.880.604 155:G05.355.310 209:G02.111.087.847 210:D12.776.260.600 700:D27.505.519.217 730:D08.811 792:A11.251.210.190.475 1050:D12.776.157.125.050.060 1052:D12.776.641.750 1224:E05.318.740.872|ES| 2:1 4:1 9:1 10:1 14:1 19:1 94:1 97:1 103:1 115:1 146:1 147:1 148:1 151:1 152:1 158:1 166:1 167:1 225:1 257:1 275:1 298:1 378:1 438:1 487:1 546:1 596:1 661:1 1233:1 1256:1 1843:1 2388:1 2521:1 2702:1 2782:1 3059:1 3532:1 4819:1 4820:1 4821:1 4822:1 4823:1 4824:1
7 	|BT| (S (NP (NP (NNS Genes)) (VP (VBG encoding) (NP (NP (NN DNA) (JJ damage-inducible) (CD 45) (-LRB- -LRB-) (NN GADD45) (-RRB- -RRB-) (NN family) (NN protein)) (, ,) (NP (NP (JJ particular) (NN GADD45g)) (PRN (-LRB- -LRB-) (NP (NN GADD45) (NN gamma)) (-RRB- -RRB-)))))) (VP (VBD down-regulated) (NP (NP (NN treatment)) (NP (CC either) (NP (NN PB) (NN CF) (CD 4) (CD 13) (NN week)))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 44:F01.829.263 52:E02 142:I01.880.604 325:Z01.058.290.100.140 351:A17.360 526:G05.355.180|ES| 2:1 4:1 10:1 14:1 19:1 39:1 97:1 319:1 485:1 546:1 666:1 783:1 1100:1 1283:1 1532:1 2389:1 3495:1 3496:1 4177:1 4725:1 4737:1 4825:1 4826:1
7 	|BT| (S (NP (NN Genistein) (NN 5Aza-C) (NN treatment)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN promoter) (NN methylation)) (, ,) (S (VP (VBG reactivating) (NP (NN BTG3) (NN expression)))))) |ET| |BS|36:G02.111.087.029.538 52:E02 944:D03.383.663.283.266.450.400.375|ES| 2:1 19:1 81:1 83:1 115:1 124:1 202:1 546:1 3312:1 4827:1 4828:1 4829:1
7 	|BT| (S (NP (NP (JJ Global) (NN gene) (NN expression) (NN analysis)) (NP (JJ subsequent) (JJ quantitative) (JJ real-time) (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction))) (VP (VBD revealed) (NP (NN BNF) (VBD induced) (`` `) (NP (NN AhR) (NN gene) (NN battery'Cyp) (NN 1a1)) (, ,) (NP (NN Cyp1a2)) (, ,) (NP (NN Cyp1b1)) (, ,) (NP (NN Nqo1)) (, ,) (NP (NN Aldh3a1) (NN Ugt1a6)) (RB also) (NP (NP (NN transcription) (NN factor) (JJ NF-E2-related) (NN factor) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Nrf2)) (-RRB- -RRB-))) (PRN (: -) (NP (NP (VBN regulated) (NN gene) (NN Gstm1) (, ,) (NN Gpx2) (, ,) (NP (NP (NN Akr7a3) (NN Yc2)) (PRN (-LRB- -LRB-) (ADVP (RB also)) (NP (NN Nqo1)) (-RRB- -RRB-))) (, ,)) (NP (RB presumably) (JJ due) (JJ adaptive) (NN response) (JJ BNF-triggered) (JJ oxidative) (NN stress) (NN response))))))) |ET| |BS|6:G05.360.340.024.340 142:I01.880.604 155:G05.355.310 197:A01.456.505.420 257:E05.393.620.500.706 346:E05.393.620.500.706 573:N05.715.350.200.650 591:G02.111.087.847.500 705:D08.244.453.040.443 716:G03.495.710 799:D12.776.260.615.249 1351:D08.244.453.040.500 1352:D08.244.453.040.332 1353:D12.776.260.262.500.750|ES| 2:1 5:1 9:1 10:1 14:1 19:1 115:1 148:1 185:1 275:1 412:1 487:1 494:1 661:1 768:1 817:1 874:1 939:1 941:1 1319:1 2522:1 2583:1 2851:1 4037:1 4355:1 4830:1 4831:1 4832:1 4833:1 4834:1 4835:1 4836:1 4837:1 4838:1 4839:1 4840:1 4841:1 4842:1 4843:1 4844:1 4845:1 4846:1 4847:1
7 	|BT| (S (NP (NN Glucosylceramide) (NN synthase)) (VP (VBZ upregulates) (NP (NN MDR1) (NN expression) (NN regulation) (NN cancer) (NN drug) (NN resistance) (NN cSrc) (NN beta-catenin) (NN signaling)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 142:I01.880.604 1354:G07.690.773.984.395|ES| 18:1 19:1 60:1 66:1 115:1 191:1 195:1 438:1 453:1 1094:1 2153:1 4702:1 4848:1
7 	|BT| (NP (NP (NP (NNP Grifolin)) (, ,) (NP (JJ potent) (NN antitumour) (JJ natural) (NN product)) (VP (VBZ upregulates) (NP (NP (JJ death-associated) (NN protein) (NN kinase) (CD 1) (NN DAPK1)) (PP (IN via) (NP (NN p53) (JJ nasopharyngeal) (NN carcinoma) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 793:D20.215 1285:D08.811.913.696.620.682.700.125.387|ES| 2:1 4:1 12:1 19:1 22:1 94:1 98:1 304:1 470:1 596:1 675:1 1178:1 2153:1 2333:1 4572:1 4849:1 4850:1 4851:1
7 	|BT| (S (NP (NP (NNS GSLs)) (, ,) (NP (JJ particular) (NN globo) (NN series) (NNS GSLs))) (VP (VBP mediate) (NP (NN gene) (NN expression) (NN MDR1) (NN cSrc) (NN beta-catenin) (NN signaling) (NN pathway)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 126:G02.111.087.800 155:G05.355.310|ES| 2:1 9:1 19:1 60:1 115:1 195:1 383:1 453:1 485:1 1601:1 1807:1 4698:1 4699:1 4702:1
7 	|BT| (S (NP (NN GST-P) (NN gene) (NN expression) (VBN linked) (NN reporter) (NN gene)) (ADVP (RB specifically)) (VP (VBD suppressed) (NP (NP (NN cotransfection) (NN PPAR) (NN alpha) (NN expression) (NN plasmid) (NN presence) (NN peroxisome) (NN proliferator)) (, ,) (NP (NN clofibrate))))) |ET| |BS|155:G05.355.310 457:G05.360.600 536:D12.776.826.239.500 910:D02.241.081.114.968.500.500.195 912:D27.888.569.100.675 1355:G05.360.340.024.340.435|ES| 2:1 9:1 19:1 115:1 288:1 307:1 346:1 1279:1 1363:1 1597:1 1836:1 1887:1 1888:1 3058:1 3200:1 3227:1 4852:1
7 	|BT| (FRAG (NP (NP (NP (NN H)) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NP (NN O) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-))) (RRC (ADVP (RB also)) (NP (VBN stimulated) (NP (NN expression) (NN Gadd45b) (VBN cultured) (NN cell)))))) |ET| |BS|94:A11.251.210 1356:D01.268.406.500 1357:A11.251|ES| 5:1 10:1 14:1 19:1 94:1 115:1 148:1 612:1 1232:1 4853:1 4854:1 4855:1
7 	|BT| (S (ADVP (RB Hence)) (, ,) (NP (NN chloroform)) (VP (VBD prevented) (SBAR (S (NP (NN hypomethylation)) (VP (VBD increased) (NP (NP (NN mRNA)) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN tumor) (NN DCA)) (, ,) (S (VP (VBG enhancing) (NP (JJ DCA-promotion) (NN kidney) (NN tumor))))))))) |ET| |BS|111:D13.444.735.544 155:G05.355.310 274:C04.588.945.947.535 515:C04.588.274.623 1196:D02.455.526.439.224|ES| 2:1 7:1 9:1 19:1 47:1 115:1 325:1 455:1 836:1 1717:1 1943:1 1944:1 2337:1 2527:1 4107:1 4179:1 4180:1 4181:1
7 	|BT| (S (VP (VP (ADVP (RB Here)) (VP (VBP show)) (S (NP (NN Sp1)) (VP (VBP bind) (NP (NP (NN FoxM1) (NN promoter) (NN region)) (ADVP (RB positively))))) (VP (VBZ regulates) (NP (NP (NN FoxM1) (NN transcription)) (, ,) (NP (NN mithramycin)) (, ,) (NP (NN chemotherapy) (NN drug)) (S (ADVP (RB specifically)) (VP (VBP bind) (SBAR (S (NP (NP (NN GC)) (JJ rich) (NN sequence) (NN DNA)) (VP (VBZ inhibits) (NP (NN activity) (NN Sp1)))))))))) (, ,) (VP (VBZ inhibits) (NP (NN expression) (NN FoxM1))))) |ET| |BS|67:D26 122:C14.280.383 151:E02.319 196:G02.111.570.080.689.675 209:G02.111.087.847 1303:D02.455.426.559.847.562.050.650 1358:G02.111.570.080.380|ES| 2:1 19:1 83:1 115:1 191:1 293:1 399:1 400:1 429:1 487:1 495:1 554:1 603:1 615:1 666:1 667:1 1279:1 3848:1 4659:1 4791:1 4856:1 4857:1 4858:1
7 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBP describe) (NP (JJ functional) (NN characterization) (JJ novel) (NN rat) (JJ mutant) (NN model) (NN MMR) (NN gene) (NN Msh6)) (SBAR (S (ADVP (RB genetically)) (VP (VBD inactivated) (NP (JJ N-ethyl-N-nitrosourea-driven) (JJ target-selected) (NN mutagenesis))))))) |ET| |BS|6:G05.360.340.024.340 66:F01.658.293 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 259:D12.776.395.240.150.500 1359:G05.355.600 1360:D02.654.692|ES| 2:1 9:1 19:1 72:1 400:1 415:1 811:1 849:1 891:1 898:1 1735:1 2134:1 4859:1 4860:1 4861:1 4862:1 4863:1 4864:1
7 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (VBD investigated) (NP (NP (NN effect) (JJ erlotinib) (JJ apoptotic) (NN signal) (NN pathway) (NN H3255) (NN cell) (NN EGFR)) (PRN (-LRB- -LRB-) (NP (NN L858R)) (-RRB- -RRB-))) (NN mutation))) |ET| |BS|18:G05.365.590 39:G04.299.139.160 41:A11 761:G02.111.087.800|ES| 2:1 10:1 14:1 19:1 34:1 75:1 94:1 187:1 383:1 400:1 403:1 859:1 2223:1 2342:1 4770:1 4865:1
7 	|BT| (S (ADVP (RB Here)) (, ,) (NP (NN report) (NN NaB)) (ADVP (RB specifically)) (VP (VBZ represses) (NP (NP (NP (NP (NN expression) (NN MUC2) (NN gene)) (, ,) (NP (NN differentiation) (NN marker) (JJ secretory) (NN goblet) (NN cell) (NN lineage)) (, ,) (NP (NN forskolin)) (: -)) (NP (NN 12-O-tetradecanoylphorbol) (JJ 13-acetate-induced) (NN HT29) (NN cell))) (, ,) (NP (NN Cl) (CD .16) (NN E) (NN cell)) (, ,) (NP (JJ clonal) (JJ derivative) (NN HT29) (NN cell))) (VP (ADVP (RB spontaneously)) (VBZ differentiates) (NP (JJ goblet) (NN cell))))) |ET| |BS|41:A11 74:G04.299.151 155:G05.355.310 158:D23.101 301:A11.251.353 792:A11.251.210.190.475 1361:D02.455.849.291.500.510.850 1362:A03.556.124.369.320 1363:D02.455.849.291.300|ES| 2:1 9:1 19:1 94:1 115:1 212:1 215:1 347:1 400:1 417:1 534:1 643:1 1069:1 1262:1 1279:1 1506:1 2473:1 2813:1 3017:1 3759:1 4866:1 4867:1 4868:1 4869:1 4870:1
7 	|BT| (S (NP (NN Hes1) (NN induction)) (VP (VBD mediated) (SBAR (S (NP (NN beta-catenin)) (VP (VBD resulted) (NP (NN induction) (NN Notch) (NN ligand/receptor) (JJ Notch-independent) (NN control) (NN Hes1) (NN promoter) (NN beta-catenin))))))) |ET| |BS|23:D12.776.091.249 170:D27.720.470.480|ES| 19:1 60:1 83:1 256:1 258:1 289:1 437:1 594:1 736:1 4871:1 4872:1
7 	|BT| (S (NP (JJ Hexavalent) (NN chromium)) (VP (VBZ induces) (NP (JJ malignant) (NN transformation) (JJ human) (NN lung) (JJ bronchial) (JJ epithelial) (NN cell)) (PP (IN via) (NP (JJ ROS-dependent) (NN activation) (NN miR-21-PDCD4) (NN signaling))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 75:A11.436 231:C04.557.465.625.600.380.590 1364:C08.127.509|ES| 19:1 36:1 94:1 127:1 195:1 214:1 225:1 328:1 596:1 802:1 1384:1 4873:1 4874:1 4875:1 4876:1 4877:1
7 	|BT| (S (NP (NN Histone) (NN deacetylase) (NN inhibitor)) (VP (VBP suppress) (SBAR (S (NP (NN thymidylate) (NN synthase) (NN gene) (NN expression)) (VP (VBP synergize) (NP (NNS fluoropyrimidines) (NP (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|41:A11 153:D27.505.519.389.360 155:G05.355.310 713:D08.811.913.555.500.862|ES| 9:1 18:1 19:1 66:1 94:1 113:1 115:1 380:1 504:1 2441:1 2578:1 3528:1 4878:1 4879:1
7 	|BT| (S (NP (NN HO-3867)) (VP (VBD induced) (NP (NN G) (S (-LRB- -LRB-) (NP (NP (CD 2) (-RRB- -RRB-) (: -)) (NP (NP (NN M) (NN cell) (NN cycle) (NN arrest) (NN A2780) (NN cell) (NN modulating) (NN cell) (NN cycle) (JJ regulatory) (NN molecule) (NN p53)) (, ,) (NP (NN p21)) (, ,) (NP (NN p27)) (, ,) (NP (JJ cyclin-dependent) (NN kinase) (CD 2)) (, ,) (NP (NN cyclin)) (, ,))) (VP (VBD promoted) (NP (NN apoptosis) (NN caspase-8) (NN caspase-3) (NN activation))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 353:G04.299.134 768:D12.776.660.740 773:G04.299.134.109 906:D08.811.277.656.262.500.126.350.300 1034:D08.811.277.656.262.500.126.550.800 1280:D12.644.360.262 1365:D08.811.913.696.620.682.700.646.500.750|ES| 2:1 10:1 12:1 14:1 19:1 89:1 94:1 148:1 180:1 225:1 412:1 470:1 601:1 602:1 743:1 1124:1 1135:1 1817:1 1912:1 2435:1 3016:1 3612:1 4546:1 4807:1 4880:1 4881:1 4882:1
7 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (NNS pretreatments) (NP (NP (JJ selective) (JJ mitogen-activated) (NN protein) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN MAPK)) (-RRB- -RRB-))) (NN inhibitor)) (, ,) (NP (NP (NP (NP (NN SB203580)) (PRN (-LRB- -LRB-) (NP (NN p38) (NN inhibitor)) (-RRB- -RRB-))) (NN PD0325901)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2) (NN inhibitor)) (-RRB- -RRB-))) (, ,)) (ADVP (RB significantly)) (VP (VBD suppressed) (NP (NN activation) (NN EGCG) (NN BTG2) (NN expression)))) |ET| |BS|116:D08.811.913.696.620.682.700.567.249.750 478:D08.811.913.696.620.682.700.567|ES| 2:1 4:1 10:1 14:1 19:1 115:1 124:1 225:1 307:1 380:1 433:1 470:1 809:1 1666:1 1749:1 2525:1 3295:1 4594:1 4883:1 4884:1 4885:1 4886:1
7 	|BT| (S (ADVP (RB Importantly)) (, ,) (NP (NN cotreatment) (JJ low) (NNS dos) (NP (NP (NNS oligoamines) (NN DNA) (NN methyltransferase) (NN inhibitor)) (ADVP (RB highly)))) (VP (VBZ induces) (SBAR (S (NP (NN reexpression)) (ADVP (RB aberrantly)) (VP (VBD silenced) (SBAR (S (NP (NN SFRP2) (NN gene)) (VP (VBP result) (NP (NP (JJ significant) (NN inhibition) (NN growth)) (VBN established) (NN tumor) (JJ human) (NN colon) (NN tumor) (NN model)) (FW vivo))))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240|ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1
7 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN reporter) (NN assay)) (VP (VBD indicated) (SBAR (S (NP (NN FXRE) (NN promoter) (NN activity)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (NN treatment) (NN ACR)) (CC plus) (NP (NN GW4064)))))))) |ET| |BS|52:E02 106:E05.091|ES| 2:1 19:1 47:1 83:1 124:1 244:1 288:1 310:1 399:1 468:1 546:1 1541:1 4503:1 4504:1 4887:1 4888:1
7 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN PIM) (NN kinase)) (VP (VBP activate) (S (NP (NN MYC) (NN signaling) (NN mRNA) (NN translation) (NN prostate) (NN cancer)) (VP (VBP cooperate) (S (NP (NN MYC)) (VP (VB accelerate) (NP (NN tumorigenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 69:G02.111.087.800 145:G02.111.087.675.871|ES| 2:1 18:1 19:1 77:1 78:1 195:1 244:1 325:1 468:1 469:1 470:1 471:1 472:1 473:1 474:1 475:1
7 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN treatment) (JJ nude) (NN mouse) (NN isochaihulactone)) (NP (VBD increased) (FW vivo) (NN NAG-1) (NN expression)) (VP (VBD examined) (NP (NN immunohistochemistry) (NN tumor) (NN biopsy)))) |ET| |BS|8:C04 52:E02 88:B01.050.150.900.649.865.635.505.500.550.500 143:E01.370.225.500.607.512 559:E01.370.225.500.384.100|ES| 2:1 7:1 19:1 47:1 52:1 115:1 244:1 266:1 324:1 378:1 468:1 546:1 833:1 1662:1 1984:1 4889:1
7 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ ursolic) (NN acid)) (VP (VBD suppressed) (NP (ADJP (NP (NP (NN EGF) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (VBD induced)) (NN p53) (NN p21) (NN expression)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 64:D08.811.913.696.620.682.725.400.009.300|ES| 2:1 10:1 12:1 14:1 19:1 115:1 186:1 187:1 244:1 307:1 412:1 468:1 1135:1 1275:1 4890:1 4891:1
7 	|BT| (S (PP (IN In) (NP (JJ AR-positive) (NN bladder) (NN cancer) (NN cell) (NN line))) (, ,) (NP (NN dihydrotestosterone) (NN treatment)) (VP (VP (VBD increased) (NP (NP (NP (NN ELK1)) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (NN mRNA)) (, ,) (NP (NN protein))) (-RRB- -RRB-))) (S (VP (JJ nuclear) (NP (NP (NN translocation)) (, ,) (NP (NN ELK1) (JJ transcriptional) (NN activity)) (, ,) (NP (NN c-fos)) (NP (NN expression)) (, ,))))) (VP (VBD restored) (NP (JJ anti-androgen) (NN hydroxyflutamide))))) |ET| |BS|7:D12.776 52:E02 94:A11.251.210 111:D13.444.735.544 165:G05.360.340.024.340.375.500.791.330 209:G02.111.087.847 463:C23.550.210.870 1287:D04.808.054.040.248 1288:D06.347.065 1366:D12.776.260.108.765|ES| 2:1 4:1 10:1 14:1 18:1 19:1 47:1 94:1 115:1 244:1 264:1 325:1 399:1 546:1 558:1 559:1 562:1 564:1 1256:1 1618:1 4578:1 4892:1 4893:1 4894:1 4895:1
7 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN study)) (VP (VBP show) (SBAR (S (NP (NN TS) (NN gene) (NN expression) (NN pretreatment) (NN biopsy)) (VP (VBZ predicts) (NP (NN response) (JJ local) (JJ rectal) (NN cancer) (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy) (JJ high) (NN percentage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 154:Z01.058.266.887 155:G05.355.310 333:D01.045 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500|ES| 2:1 9:1 18:1 19:1 115:1 131:1 178:1 244:1 429:1 494:1 509:1 1284:1 1751:1 1983:1 1984:1 1985:1 1986:1 1987:1 1988:1 1989:1 1990:1
7 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN troglitazone)) (VP (VBD attenuated) (NP (NN Skp2) (NN expression)) (, ,) (S (VP (ADVP (RB thereby)) (NP (VBG promoting) (NP (NN p27) (-LRB- -LRB-) (NN Kip1) (-RRB- -RRB-) (NN accumulation) (JJ human) (NN hepatoma) (NN cell))))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 338:D12.644.360.225.600 507:D12.776.157.743 515:C04.588.274.623|ES| 2:1 10:1 14:1 19:1 36:1 94:1 115:1 244:1 808:1 881:1 1124:1 1125:1 1284:1 1785:1 2120:1 3896:1 4508:1 4896:1
7 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBD found) (NP (NP (NN U0126) (JJ atypical) (NN PXR) (NN ligand)) (PP (IN via) (NP (NP (NP (NP (JJ direct)) (PRN (-LRB- -LRB-) (NP (NN binding) (NN activation) (NN PXR)) (-RRB- -RRB-))) (ADJP (ADJP (JJ indirect)) (PRN (-LRB- -LRB-) (NP (NN SHP) (NN dowregulation)) (-RRB- -RRB-)))) (NN mechanism)))) (PP (ADVP (RB selectively)) (VBZ restores) (NP (NN CYP3A) (NN gene) (NN HepG2) (NN cell))))) |ET| |BS|6:G05.360.340.024.340 170:D27.720.470.480 1015:A11.251.860.180.432|ES| 2:1 9:1 10:1 14:1 19:1 37:1 94:1 162:1 225:1 244:1 596:1 1284:1 1487:1 1835:1 1891:1 2382:1 3481:1 3523:1 4897:1 4898:1 4899:1 4900:1 4901:1 4902:1 4903:1
7 	|BT| (FRAG (PP (IN In) (NP (NN LNCaP) (NN cell))) (, ,) (NP (NP (JJ caspase-mediated) (NN apoptosis) (NN induction) (NN PGG)) (SBAR (S (NP (VBN associated) (JJ mediated) (JJ major) (NN part) (NN activation) (NN p53)) (VP (VBD established) (NP (JJ small) (VBG interfering) (NN RNA) (NN knockdown) (JJ dominant-negative) (JJ mutant) (NN approach))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 117:D13.150.650.700 133:D01.248.497.158.685.750.744.600 1367:D08.811.277.656.262.500.126|ES| 2:1 12:1 19:1 89:1 94:1 169:1 225:1 244:1 413:1 437:1 451:1 462:1 464:1 515:1 736:1 750:1 811:1 911:1 2115:1 2660:1 3019:1 4904:1 4905:1
7 	|BT| (S (PP (IN In) (NP (NP (NP (NN mouse) (JJ ovarian) (JJ endometrioid) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NNS OEAs)) (-RRB- -RRB-))) (VP (VBG arising) (NP (NN Apc))))) (: -) (NP (NP (NN Pten-inactivation)) (, ,) (NP (NN Ctnnb1) (JJ hemizygous) (NN dose))) (VP (VBD affected) (NP (NP (NN beta-catenin) (NN level) (NN beta-catenin/TCF) (NN target) (NN gene)) (, ,) (NP (NN Myc) (NN induction))) (VP (VBD retained) (SBAR (S (NP (NNS OEAs)) (VP (VBD arose) (NP (NP (NN fashion) (JJ akin)) (VBN seen) (JJ intact) (NN Ctnnb1) (NN gene) (NN dose)))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 213:F02.830.816.964 433:F01.470.047 1368:C04.557.470.200.025.240 1369:A05.360.319.114.630|ES| 2:1 9:1 10:1 14:1 19:1 52:1 60:1 160:1 244:1 249:1 255:1 724:1 736:1 1577:1 1763:1 1786:1 2301:1 4032:1 4422:1 4722:1 4754:1 4906:1 4907:1 4908:1 4909:1 4910:1 4911:1 4912:1 4913:1 4914:1
7 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NN SAHA)) (VP (VP (VBD inhibited) (S (NP (NN growth) (JJ human) (JJ pancreatic) (NN cancer) (NN cell)) (VP (VBG inducing) (NP (NN apoptosis))))) (, ,) (NP (NP (NN differentiation) (NN cell) (NN cycle) (NN arrest)) (, ,) (ADVP (RB well)) (NP (NN increase) (NN expression) (JJ several) (NN tumor) (NN suppressor) (NN gene))))) |ET| |BS|39:G04.299.139.160 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 122:C14.280.383 206:G05.360.340.024.340.375.249 773:G04.299.134.109|ES| 2:1 7:1 9:1 18:1 19:1 36:1 40:1 89:1 94:1 102:1 115:1 215:1 244:1 262:1 365:1 467:1 490:1 601:1 602:1 700:1 787:1 1864:1 4915:1
7 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (JJ small) (NN molecule) (NN inhibitor) (NN imatinib)) (VP (VP (VBZ attenuates) (NP (JJ stromal) (NN cell) (NN proliferation) (JJ PDGF-C-induced) (NN HCC))) (, ,) (VP (VBZ coincides) (NP (NP (VBN decreased) (NN expression) (NN CD34) (NN PDGFRalpha)) (, ,) (NP (VBN activated) (NN Akt)))))) |ET| |BS|104:C04.557.470.200.025.255 183:G04.299.233.750 378:D08.811.913.696.620.682.700.755 1370:D08.811.913.696.620.682.725.400.900.500|ES| 2:1 19:1 94:1 115:1 163:1 180:1 202:1 244:1 299:1 380:1 441:1 490:1 750:1 1289:1 2423:1 4916:1 4917:1 4918:1 4919:1 4920:1 4921:1
7 	|BT| (S (PP (IN In) (NP (NN H1373) (NN xenograft) (NN model))) (, ,) (NP (NN treatment) (NN JQ1)) (ADVP (RB significantly)) (VP (VBD reduced) (SBAR (S (NP (NN tumor) (NN growth)) (VP (VBD downregulated) (NP (NN expression) (NN c-Myc))))))) |ET| |BS|8:C04 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875|ES| 2:1 7:1 19:1 72:1 102:1 115:1 124:1 244:1 265:1 426:1 452:1 546:1 824:1 4922:1 4923:1
7 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (NP (NN report) (NN vitro) (NN treatment) (JJ primary) (NN hepatoma)) (, ,) (NP (NP (NN HepG2)) (PRN (-LRB- -LRB-) (NP (JJ wild-type) (NN p53)) (-RRB- -RRB-))) (, ,) (NP (NP (NN PLC/PRF/5)) (PRN (-LRB- -LRB-) (NP (NN p53-mutant)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Hep3B)) (PRN (-LRB- -LRB-) (ADJP (JJ p53-deleted)) (-RRB- -RRB-))) (NP (NP (NN cell) (NN 2-chloroethyl-3-sarcosinamide-1-nitrosourea)) (PRN (-LRB- -LRB-) (NP (NN SarCNU)) (-RRB- -RRB-)))) (VP (VBD resulted) (NP (NP (NN upregulation) (NN p53) (, ,) (NN p21) (-LRB- -LRB-) (NN Cip1/Waf1) (-RRB- -RRB-)) (, ,) (NP (NP (VBN phosphorylated) (NN cdc-2) (NN Tyr15) (JJ wild-type) (NN p53) (NN cell) (NN phosphorylation) (NN cdc-2) (NN Tyr15)) (NP (JJ p53-mutant) (NP (JJ p53-deleted) (NN hepatoma) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 52:E02 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880 515:C04.588.274.623 972:G02.111.087.677 1371:I01.409.418.750.600.650.225|ES| 2:1 8:1 10:1 12:1 14:1 19:1 94:1 131:1 216:1 244:1 344:1 417:1 546:1 594:1 1126:1 1135:1 1307:1 3426:1 3481:1 3896:1 4502:1 4924:1 4925:1 4926:1 4927:1 4928:1 4929:1 4930:1 4931:1 4932:1
7 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBP demonstrate) (S (NP (NP (NP (NN histone) (NN deacetylase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN HDACi)) (-RRB- -RRB-))) (NN vorinostat) (NN LBH589)) (VP (ADVP (RB significantly)) (VBP downregulate) (NP (NN TS) (NN gene) (NN expression) (NN panel) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|94:A11.251.210 153:D27.505.519.389.360 154:Z01.058.266.887 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 113:1 115:1 124:1 131:1 244:1 264:1 380:1 502:1 503:1 504:1 505:1 506:1 507:1 508:1 509:1 510:1
7 	|BT| (NP (NP (PP (IN In) (NP (NP (NN tumor) (NN mouse) (VBN treated) (NN DEN)) (ADVP (RB alone)))) (, ,) (NP (NP (NP (NN prevalence) (NN Ha-ras) (NN mutation)) (NP (ADJP (QP (RB approximately) (CD 30)) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 6/20)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN beta-catenin) (NN mutation)) (PRN (-LRB- -LRB-) (NP (CD 0/13)) (-RRB- -RRB-))) (NP (JJ detectable) (NN tumor) (NN treatment) (NN group))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 52:E02 60:E05.318.308.985.525.750 216:Z01.107.084.900.425 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 34:1 52:1 60:1 179:1 241:1 244:1 369:1 546:1 747:1 1099:1 1520:1 1843:1 1875:1 2300:1 4933:1 4934:1 4935:1
7 	|BT| (S (NP (ADJP (FW In) (FW vivo)) (NN treatment) (NN imatinib)) (ADVP (RB also)) (VP (VBP block) (NP (NN expression) (NN CD34) (NN PDGF-C) (NN Tg) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 122:C14.280.383|ES| 5:1 19:1 52:1 115:1 244:1 378:1 546:1 742:1 4916:1 4920:1 4936:1 4937:1
7 	|BT| (NP (NP (NP (NN Incubation) (NNS pro-oxidants) (JJ arachidonic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN AA)) (-RRB- -RRB-))) (, ,) (NP (NN beta-naphtoflavone)) (, ,) (NP (NN H) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (S (NP (NN O) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (VP (VBD enhanced) (NP (NP (NP (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NN splice) (NN variant)))))) |ET| |BS|636:D01.339.431 1014:D10.251.355.255.100.100 1356:D01.268.406.500|ES| 2:1 10:1 14:1 19:1 148:1 385:1 517:1 612:1 990:1 1275:1 3553:1 4116:1 4683:1 4684:1 4853:1 4938:1 4939:1 4940:1
7 	|BT| (S (NP (NN Inhibition) (NN FoxM1) (NN expression) (NNS TZDs)) (VP (VBZ provides) (SBAR (S (NP (JJ new) (NN mechanism) (NN TZD)) (VP (VBD mediated) (NP (JJ negative) (NN regulation) (NN cancer) (NN cell) (NN growth))))))) |ET| |BS|41:A11 43:F01.145.544 45:G07.700.320.249 142:I01.880.604|ES| 18:1 19:1 94:1 102:1 115:1 162:1 437:1 438:1 449:1 712:1 815:1 2703:1 3119:1 4791:1 4941:1
7 	|BT| (S (NP (NN Inhibition) (JJ functional) (NN p53) (NN glioblastoma) (NN cell)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (JJ anti-proliferative) (NN effect) (NN celecoxib)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 43:F01.145.544 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247|ES| 12:1 19:1 75:1 94:1 124:1 415:1 452:1 2186:1 2703:1 2807:1 3695:1
7 	|BT| (S (NP (NP (NN Inhibition) (JJ isochaihulactone-induced) (NN NAG-1) (NN expression) (NN EGR-1)) (ADJP (JJ small) (S (VP (VBG interfering) (NP (NN RNA)))))) (VP (VBD blocked) (NP (JJ isochaihulactone-induced) (NN apoptosis) (NN A549) (NN cell)) (, ,) (S (VP (VBG suggesting) (NP (NN induction) (NN EGR-1) (NN expression) (NN decrease) (NN survival) (NN A549) (NN cell)))))) |ET| |BS|39:G04.299.139.160 41:A11 43:F01.145.544 108:G04.299.316 117:D13.150.650.700 122:C14.280.383 580:D12.776.260.158.500|ES| 2:1 19:1 89:1 94:1 115:1 274:1 295:1 364:1 515:1 736:1 750:1 1009:1 1662:1 2703:1 2777:1 3019:1 3874:1 4942:1
7 	|BT| (S (NP (NN Inhibition) (NN JNK) (NN chemical) (JJ genetic) (NN method)) (VP (VBD attenuated) (NP (JJ NaBT-induced) (NN PTEN) (NN expression)))) |ET| |BS|43:F01.145.544 1372:E05.393|ES| 19:1 115:1 808:1 864:1 1599:1 1936:1 2124:1 2703:1 4276:1 4943:1
7 	|BT| (FRAG (ADVP (RB Interestingly)) (, ,) (NP (NP (JJ DEN-induced) (NN Pol) (CD III) (NN gene) (NN transcription) (NN H3S10ph) (NN tumor) (NN cell) (NN liver)) (NP (ADJP (RB significantly) (JJR higher)) (NP (JJ non-tumor) (NN cell))))) |ET| |BS|8:C04 41:A11 209:G02.111.087.847 515:C04.588.274.623 614:G05.360.340.024.340.364.875.667 1373:Z01.542.248.679|ES| 2:1 7:1 9:1 19:1 94:1 124:1 170:1 487:1 518:1 836:1 2280:1 2281:1 2735:1 4944:1 4945:1
7 	|BT| (S (NP (JJ Intracellular) (NN beta-catenin) (NN level)) (ADVP (RB slightly)) (VP (VBD reduced) (SBAR (S (NP (JJ NDRG2-transfected) (NN SW620) (NN cell) (NN regulation) (NN beta-catenin) (NN stability) (NN TCF/LEF) (NN activity)) (VP (VBD mediated) (NP (NP (NN modulation) (NN glycogen) (NN synthase) (NN kinase-3beta)) (NN activity) (NN NDRG2) (NN function))))))) |ET| |BS|23:D12.776.091.249 41:A11 142:I01.880.604 924:A11.284.430.214|ES| 19:1 33:1 60:1 66:1 92:1 93:1 94:1 249:1 399:1 437:1 438:1 452:1 1945:1 4946:1 4947:1 4948:1 4949:1 4950:1 4951:1 4952:1
7 	|BT| (NP (NP (NP (NP (JJ Intratumoral) (NN injection) (JJ anti-Wnt-1) (NN antibody)) (NP (VBD suppressed) (FW vivo) (NN tumor) (NN growth) (NN Huh7) (NN xenograft) (NN model))) (, ,) (NP (NP (ADVP (RB also)) (VBN associated) (NN apoptosis)) (VP (VBD reduced) (NP (NP (NN c-Myc)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (NN survivin) (NN expression))))))) |ET| |BS|8:C04 39:G04.299.139.160 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 215:D12.644.360.262.150.100 1374:E02.095.465.425.400.330|ES| 2:1 5:1 7:1 19:1 72:1 89:1 102:1 115:1 169:1 265:1 307:1 378:1 452:1 743:1 744:1 785:1 824:1 2229:1 2611:1 3482:1 4953:1 4954:1
7 	|BT| (S (NP (NN IR-5) (NN bear) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)) (VP (VP (VBZ corresponds) (SBAR (S (NP (NN L726I) (JJ ATP-binding) (NN pocket)) (VP (VBP correlate) (NP (NN log) (NN decrease) (NN sensitivity) (NN gefitinib)))))) (, ,) (NP (NP (VBD increased) (NN heterodimerization) (NN EGFR) (NN HER3)) (, ,) (NP (JJ impaired) (NN down-regulation))))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 85:G02.111.087.225 259:D12.776.395.240.150.500 438:G05.365.590.675 455:B01.050.150.900.649.147.890 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 19:1 34:1 47:1 187:1 257:1 295:1 607:1 891:1 901:1 1740:1 2003:1 2121:1 3310:1 3505:1 4281:1 4955:1 4956:1 4957:1 4958:1 4959:1 4960:1 4961:1
7 	|BT| (S (NP (NN Isochaihulactone)) (VP (VBD increased) (NP (NN EGR-1) (NN NAG-1) (NN mRNA) (NN protein) (NN expression)))) |ET| |BS|7:D12.776 111:D13.444.735.544 580:D12.776.260.158.500|ES| 4:1 19:1 47:1 115:1 325:1 1662:1 3874:1 4962:1
7 	|BT| (S (NP (NN Isochaihulactone) (NN treatment)) (VP (VBD increased) (NP (NP (NN luciferase)) (NP (NN activity) (NN NAG-1) (NN A549) (NN cell)) (NP (VBN transfected) (NN NAG-1) (NN promoter) (NN construct))))) |ET| |BS|41:A11 52:E02 1375:D08.811.682.517|ES| 19:1 47:1 83:1 94:1 364:1 399:1 479:1 546:1 1662:1 4962:1 4963:1 4964:1
7 	|BT| (S (NP (JJ Isochaihulactone-induced) (NN increase) (NN EGR-1) (NN NAG-1) (NN expression)) (VP (VBD reduced) (SBAR (S (NP (NP (NP (JJ mitogen-activated) (NN protein) (NN kinase) (NN kinase)) (CD 1/2) (NN inhibitor) (CD 2) ('' ')) (: -) (NP (NP (NN amino-3)) ('' ') (: -) (NP (NN methoxyflavone) (-LRB- -LRB-) (NN PD98059) (-RRB- -RRB-))) (, ,) (NP (NN effect))) (VP (VBD blocked) (NP (NP (NP (NP (NP (NN phosphatidylinositol) (JJ 3-kinase/protein) (NN kinase) (NN B) (NN pathway) (NN inhibitor) (CD 2)) (: -) (PRN (-LRB- -LRB-) (NP (NN 4-morpholinyl)) (-RRB- -RRB-))) (NN -8-phenyl-1)) (PRN (-LRB- -LRB-) (NP (NN 4H)) (-RRB- -RRB-))) (: -) (NP (NP (NN benzopyran-4-one) (NN hydrochloride)) (PRN (-LRB- -LRB-) (NP (NN LY294002)) (-RRB- -RRB-))))))))) |ET| |BS|122:C14.280.383 378:D08.811.913.696.620.682.700.755 580:D12.776.260.158.500 1376:D08.811.913.696.620.682.700.565.300 1377:D08.811.913.696.620.500.100|ES| 2:1 4:1 10:1 14:1 19:1 40:1 75:1 115:1 380:1 383:1 452:1 470:1 763:1 1662:1 2777:1 3295:1 3874:1 4588:1 4965:1 4966:1 4967:1 4968:1 4969:1 4970:1 4971:1 4972:1 4973:1 4974:1 4975:1 4976:1
7 	|BT| (S (NP (JJ Isochaihulactone-inducible) (NN gene)) (VP (VBD included) (S (NP (NP (JJ early) (NN growth) (NN response) (NN gene-1)) (PRN (-LRB- -LRB-) (NP (NN EGR-1)) (-RRB- -RRB-))) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (JJ drug-activated) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN NAG-1)) (-RRB- -RRB-)))))) |ET| |BS|6:G05.360.340.024.340 45:G07.700.320.249 796:D27.505.696.663.850.014.040.500|ES| 9:1 10:1 14:1 19:1 102:1 494:1 1128:1 1528:1 1662:1 1859:1 2795:1 3046:1 3874:1 4977:1 4978:1
7 	|BT| (S (NP (PRP It)) (VP (VBD augmented) (SBAR (S (NP (NN caspase-3) (NN activity)) (VP (VBD downregulated) (NP (NP (NN expression) (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN cIAP1) (NN cFLIP)))))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 906:D08.811.277.656.262.500.126.350.300|ES| 2:1 19:1 115:1 158:1 399:1 426:1 1327:1 4807:1 4814:1 4979:1 4980:1 4981:1
7 	|BT| (NP (NP (NP (NN KLF4)) (NP (ADVP (RB therefore)) (NP (JJ potential) (NN mediator) (NN antitumor) (NN effect) (NN Notch) (NN inhibitor) (NN dibenzazepine))))) |ET| |BS||ES| 19:1 75:1 218:1 256:1 380:1 827:1 1892:1 2244:1 3018:1 3351:1
7 	|BT| (FRAG (NN Ku70) (: -) (: /) (: -) (FRAG (S (NP (NNS HCCs)) (VP (VBD showed) (SBAR (S (NP (JJ high) (JJ proliferative) (NN activity)) (VP (VBD increased) (S (NP (NN cyclin) (NN D1)) (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen) (NN expression))))))))) (, ,) (NP (NP (NNP Aurora) (NNP A) (NN kinase) (NN activity)) (, ,) (VP (VP (VBD enhanced) (NP (NP (NN ataxia) (NN telangiectasia)) (NP (VBN mutated) (NN kinase) (NN ubiquitination)))) (, ,) (NP (NP (NN loss) (NN p53)) (PP (IN via) (NP (NP (JJ proteasomal) (NN degradation)) (, ,) (S (NP (NN feature)) (ADVP (RB closely)) (VP (VBP resemble) (NP (JJ human) (NN HCC))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 215:D12.644.360.262.150.100 469:D08.811.913.696 520:C10.228.140.252.190.530.060 768:D12.776.660.740 1281:D05.500.562.500 1293:G03.495 1378:D08.811.913.696.620.682.700.103.500 1379:G02.111.087.675.871.790.600.925|ES| 2:1 12:1 19:1 32:1 36:1 47:1 69:1 94:1 115:1 132:1 178:1 229:1 385:1 399:1 441:1 470:1 596:1 597:1 743:1 744:1 855:1 1030:1 1132:1 1250:1 1256:1 2865:1 4117:1 4556:1 4982:1 4983:1 4984:1 4985:1 4986:1 4987:1
7 	|BT| (S (NP (NNS Levels) (NN PGE2)) (VP (VBD correlated) (NP (NN YAP) (NN level) (JJ human) (JJ sporadic) (JJ colorectal) (NN tumor) (JJ colitis-associated) (NN tumor)))) |ET| |BS|8:C04 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 1031:C04.588.274.476.411.307 1118:D10.251.355.255.550.250.200|ES| 7:1 17:1 19:1 36:1 249:1 410:1 446:1 725:1 4988:1 4989:1 4990:1
7 	|BT| (FRAG (S (NP (NN LRAT) (NN deficiency)) (VP (VBD decreased) (SBAR (S (NP (JJ diethylnitrosamine-induced) (NN injury) (NN tumour) (NN load)) (VP (VBD increased) (NP (NN expression) (JJ retinoic) (NN acid) (JJ responsive) (NN gene) (NN Cyp26a1))))))) (, ,) (NP (NP (NN RARb) (NN p21)) (, ,) (VP (VBG suggesting) (S (NP (JJR lower) (NN tumour) (NN load) (JJ LRAT-deficient) (NN mouse) (NN result)) (VP (VBD increased) (NP (NN retinoid) (NN signalling) (JJ subsequent) (JJ p21-mediated) (NN inhibition) (NN proliferation))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 87:C18.654.521 155:G05.355.310 554:D02.654.442.200 711:D02.455.326.271.665.202.495 770:D02.455.326.271.665.202.495.818.500 1380:E05.041.124.892|ES| 2:1 9:1 19:1 47:1 52:1 101:1 103:1 115:1 117:1 202:1 253:1 299:1 1009:1 1011:1 1135:1 1275:1 1319:1 2416:1 2437:1 2573:1 2704:1 2732:1 4140:1 4801:1 4991:1 4992:1 4993:1 4994:1 4995:1
7 	|BT| (S (NP (NN MBO-asGCS)) (VP (VBD suppressed) (NP (NP (NN expression) (NN MDR1) (NNS GCS)) (NP (VBN sensitized) (NN NCI/ADR-RES) (NN tumor) (NN doxorubicin))))) |ET| |BS|8:C04 120:I01.409.418.750.600.480.150 136:D02.455.426.559.847.562.050.200.175|ES| 7:1 19:1 115:1 307:1 453:1 598:1 599:1 4697:1 4761:1 4764:1
7 	|BT| (S (S (NP (NNP Mebendazole) (JJ single) (NN agent)) (VP (VBD decreased) (NP (NN COX2) (NN expression)))) (, ,) (NP (NP (NN blood) (NN vessel) (NN formation)) (, ,) (NP (NN VEGFR2) (NN phosphorylation)) (, ,)) (VP (VBD worked) (ADVP (RB synergistically)) (S (NP (NN sulindac)) (VP (VB reduce) (NP (NP (NN overexpression) (NN MYC)) (, ,) (NP (NN BCL2)) (, ,) (NP (JJ various) (JJ pro-inflammatory) (NN cytokine))))))) |ET| |BS|20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 54:G05.360.340.024.340.375.500.791.150 251:D02.455.426.559.847.486.875 371:A07.231 445:I03.946 752:D12.644.276.374 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 972:G02.111.087.677 1185:D12.125.072.401.623 1381:D08.811.913.696.620.682.725.400.950.200 1382:D02.241.081.251.415|ES| 2:1 19:1 43:1 115:1 152:1 202:1 472:1 728:1 869:1 1096:1 1559:1 2361:1 2676:1 2846:1 3349:1 3426:1 3685:1 4118:1 4718:1 4996:1 4997:1 4998:1 4999:1
7 	|BT| (S (VP (ADVP (RB Mechanistically)) (, ,) (VP (VBD demonstrated) (SBAR (S (NP (NN EPLE)) (VP (VBD exerted) (NP (NN function) (VBG suppressing) (NN Wnt) (NN signaling) (NN pathway)))))) (, ,) (VP (VBN evidenced) (NP (NP (JJ EPLE-mediated) (NN downregulation) (NN Wnt) (NN target) (NN gene) (NN c-Myc)) (, ,) (NP (NN Axin2) (NN Survivin)))))) |ET| |BS|6:G05.360.340.024.340 85:G02.111.087.225 147:G02.149.115.800.925|ES| 2:1 9:1 19:1 33:1 160:1 195:1 308:1 383:1 595:1 824:1 877:1 1175:1 2102:1 2250:1 2489:1 3779:1 5000:1 5001:1 5002:1
7 	|BT| (S (NP (NN Meloxicam) (NN therapy)) (VP (VBD inhibited) (NP (NN cell) (NN proliferation)) (, ,) (VP (VBD induced) (NP (NP (NN cell) (NN apoptosis)) (, ,) (NP (NP (VBN reduced) (NN expression)) (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen)))) (, ,))) (NP (NP (VBD increased) (NP (NN activation) (NN caspase-3))) (, ,) (NP (VBN upregulated) (NN Bax))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 52:E02 122:C14.280.383 183:G04.299.233.750 342:D12.644.360.075.718.400 371:A07.231 768:D12.776.660.740 906:D08.811.277.656.262.500.126.350.300 1067:D12.644.276.624.120 1130:D12.644.276.390 1383:D27.505.696.377.077.077|ES| 2:1 5:1 7:1 19:1 47:1 75:1 89:1 94:1 102:1 115:1 125:1 130:1 185:1 225:1 299:1 365:1 412:1 452:1 1030:1 1251:1 1256:1 2213:1 2502:1 2865:1 3092:1 3733:1 4630:1 4807:1 4947:1 5003:1
7 	|BT| (NP (NP (NP (NNS METHODS)) (CC AND) (NP (NNS RESULTS)) (: :)) (S (NP (JJ Endogenous) (NN ROS) (NN production) (JJ CYP2E1-expressing) (NN HepG2) (NN cell)) (VP (VBD induced) (NP (NP (NP (NN mRNA) (NN protein) (NN expression) (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NN splice) (NN variant)) (S (VP (VBN compared) (NP (NN control) (NN cell))))))) |ET| |BS|7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 111:D13.444.735.544 168:E05.581 1015:A11.251.860.180.432 1218:D08.244.453.300|ES| 4:1 10:1 14:1 19:1 50:1 94:1 104:1 115:1 289:1 325:1 412:1 565:1 688:1 710:1 990:1 2356:1 2677:1 3481:1 4116:1 4683:1 4684:1 5004:1 5005:1
7 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG receiving) (NP (NN NaTC)))) (VP (VBD manifested) (NP (NP (VBN increased) (JJ intestinal) (NN expression) (JJ FXR-regulated) (NN gene)) (, ,) (NP (NP (NNP Shp)) (, ,) (NP (NNP FGF15) (NNP IBABP)) (, ,) (NP (JJ concomitant) (NN decrease) (NN cyclin) (NN D1) (NN message)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 47:A03.556.124 142:I01.880.604 155:G05.355.310 215:D12.644.360.262.150.100|ES| 2:1 9:1 19:1 47:1 109:1 115:1 295:1 548:1 583:1 743:1 744:1 1681:1 1928:1 4507:1 5006:1 5007:1 5008:1 5009:1 5010:1
7 	|BT| (S (NP (NN Microarray) (NN analysis) (NN liver) (NN sample)) (VP (VBD showed) (SBAR (S (NP (NN arsenic)) (VP (VBD induced) (NP (NP (JJ aberrant) (NN gene) (NN expression)) (PP (VBG including) (NP (NP (JJ steroid-related) (NN gene)) (, ,) (NP (NN cytokine)) (, ,) (NP (JJ apoptosis-related) (NN gene) (NN cell) (JJ cycle-related) (NN gene)))))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 155:G05.355.310 242:A03.620 718:E05.588.570 752:D12.644.276.374 996:G05.360.340.024.340.220 1158:D01.268.513.249 1384:D04.808|ES| 2:1 9:1 19:1 94:1 115:1 132:1 412:1 561:1 661:1 835:1 836:1 1725:1 2676:1 3738:1 4106:1 4542:1 4571:1 5011:1
7 	|BT| (S (NP (NN MK-801)) (VP (VBN dephosphorylated) (S (NP (NN Thr24) (NN FOXO1)) (VP (VBD induced) (NP (JJ nuclear) (NN translocation)) (, ,) (ADVP (RB thus)) (VP (VP (VBG increasing) (NP (NN transcription) (NN TXNIP))) (, ,) (NP (NN tumor) (NN suppressor) (NN gene))))))) |ET| |BS|206:G05.360.340.024.340.375.249 209:G02.111.087.847 463:C23.550.210.870 1297:D02.455.426.559.847.181.384.380|ES| 2:1 7:1 9:1 19:1 412:1 487:1 700:1 715:1 1256:1 1334:1 1618:1 3264:1 4624:1 4625:1 4626:1 4627:1
7 	|BT| (S (S (NP (NP (NN MLN8237)) (, ,) (NP (JJ investigational) (JJ small-molecule) (JJ selective) (NN inhibitor) (NN AURKA)) (, ,)) (VP (VBD reduced) (S (NP (NP (JJ nuclear) (NN staining) (JJ nuclear) (NN factor-kappaB)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-))) (VP (NN p65) (NP (JJ human) (JJ gastric) (NN cancer) (NN sample) (NN mouse) (JJ epithelial) (NN cell)))))) (, ,) (VP (VBD suppressed) (SBAR (S (NP (NP (NN NF-kappaB) (NN reporter) (NN activity)) (, ,) (NP (VBN reduced) (NN expression) (NN NF-kappaB) (NN target) (NN gene))) (VP (VBP regulate) (NP (NN inflammation) (NN cell) (NN survival))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 55:B01.050.150.900.649.801.400.112.400.400 75:A11.436 108:G04.299.316 155:G05.355.310 210:D12.776.260.600 225:E05.337 525:C23.550.470 1378:D08.811.913.696.620.682.700.103.500|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 52:1 86:1 94:1 115:1 127:1 160:1 274:1 288:1 307:1 380:1 399:1 452:1 714:1 835:1 858:1 1256:1 1605:1 1749:1 2702:1 3064:1 5012:1 5013:1 5014:1 5015:1 5016:1
7 	|BT| (S (NP (NP (NP (NN Modulation) (NN dasatinib)) (PRN (-LRB- -LRB-) (NP (NN c-Src) (NN inhibitor)) (-RRB- -RRB-))) (NN cytotoxicity) (NN STAT3) (NN knockdown)) (VP (VBN measured) (NP (NP (NNP MTT)) (, ,) (NP (NN cell) (NN cycle)) (, ,) (NP (NN apoptosis) (NN assay))))) |ET| |BS|39:G04.299.139.160 82:D12.644.360.024.342.300 106:E05.091 228:E05.978 353:G04.299.134 946:D27.888.569.213 1385:G05.360.340.024.340.375.500.791.570 1386:D02.886.675.184|ES| 2:1 10:1 14:1 19:1 89:1 94:1 251:1 310:1 380:1 464:1 601:1 789:1 2760:1 3317:1 5017:1 5018:1 5019:1
7 	|BT| (S (ADVP (RBR More) (RB importantly)) (, ,) (NP (NN ATRA)) (VP (VBD downregulated) (NP (NN expression) (NNP CSC) (NN marker) (NN CD44) (NN ALDH)) (SBAR (S (NP (ADJP (RB well) (JJ stemness)) (NN gene) (NN Klf4) (NN Sox2)) (VP (VBD induced) (NP (NN differentiation) (NNS tumorspheres))))))) |ET| |BS|6:G05.360.340.024.340 74:G04.299.151 158:D23.101 556:C11.768.175 770:D02.455.326.271.665.202.495.818.500 1387:D12.776.260.719.100|ES| 2:1 9:1 19:1 115:1 215:1 412:1 426:1 534:1 787:1 1581:1 2767:1 2768:1 3577:1 5020:1 5021:1 5022:1 5023:1 5024:1 5025:1
7 	|BT| (FRAG (ADVP (RB Moreover)) (, ,) (SBAR (IN although) (NP (NP (NP (NP (JJ sulindac-mediated) (NN induction) (NN p21)) (PRN (-LRB- -LRB-) (NP (NN cip/waf1)) (-RRB- -RRB-))) (ADJP (CD 113) (NN %)) (JJ wild-type) (NN HT-29)) (, ,) (S (NP (NN induction)) (VP (VBD alleviated) (NP (NP (NNP Csk) (NN shRNA) (NNS transfectants)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 65) (NN %)) (NN induction)) (: ;) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01))))) (-RRB- -RRB-)))))))) |ET| |BS|251:D02.455.426.559.847.486.875 792:A11.251.210.190.475 1273:D13.150.650.700|ES| 2:1 8:1 10:1 14:1 19:1 217:1 311:1 312:1 315:1 369:1 622:1 736:1 1135:1 1592:1 2782:1 4230:1 4235:1 5026:1 5027:1 5028:1 5029:1 5030:1 5031:1
7 	|BT| (S (ADVP (RB Moreover)) (, ,) (S (NP (NN curcumin)) (VP (VBD suppressed) (NP (NP (NN NF-kappaB) (NN activity) (NN expression) (JJ NF-kappaB-regulated) (NN gene) (NN product)) (PRN (-LRB- -LRB-) (NP (NP (NN cyclin) (NN D1)) (, ,) (NP (NN c-myc)) (, ,) (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (JJ cellular) (NN inhibitor) (NN apoptosis) (NN protein-1)) (, ,) (NP (NN cyclooxygenase-2)) (, ,) (NP (NN matrix) (NN metalloproteinase-9)) (, ,) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor))) (-RRB- -RRB-))))) (, ,) (NP (JJ many)) (VP (VBD induced) (SBAR (S (NP (NN radiation) (NN therapy)) (VP (VBP mediate) (NP (NN radioresistance))))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 41:A11 54:G05.360.340.024.340.375.500.791.150 142:I01.880.604 155:G05.355.310 210:D12.776.260.600 215:D12.644.360.262.150.100 281:E02.815 371:A07.231 586:D08.811.277.656.300.480.205.360 692:D02.455.326.146.485.222.222 1130:D12.644.276.390|ES| 2:1 9:1 10:1 14:1 19:1 61:1 89:1 102:1 115:1 130:1 158:1 185:1 307:1 380:1 399:1 412:1 455:1 622:1 675:1 714:1 743:1 744:1 1040:1 1251:1 1601:1 2157:1 2498:1 2500:1 2501:1 3074:1 3092:1 3491:1 4814:1 5032:1 5033:1
7 	|BT| (S (ADVP (RB Moreover)) (, ,) (VP (NP (NN DENA)) (VP (VBD decreased) (NP (NP (NN gene) (NN expression) (NN GSHPx)) (, ,) (NP (NN GST) (NN CAT)))) (VP (VBD caused) (NP (JJ severe) (JJ histopathological) (NN lesion) (NN liver) (NN tissue))))) |ET| |BS|98:A10 155:G05.355.310 242:A03.620 554:D02.654.442.200 1388:B01.050.150.900.649.147.354.250.125 1389:B01.050.150.900.649.147.354.250|ES| 2:1 9:1 19:1 115:1 202:1 272:1 622:1 836:1 1131:1 2506:1 3527:1 4413:1 5034:1 5035:1 5036:1 5037:1
7 	|BT| (S (VP (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN EIF5A) (JJ small) (S (VP (VBG interfering) (NP (NP (NP (NN RNA) (-LRB- -LRB-) (NN siRNA) (-RRB- -RRB-) (NN deoxyhypusine) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN DHPS)) (-RRB- -RRB-))) (NP (NN inhibitor) (NN GC7)))))) (, ,) (VP (VBZ inhibits) (NP (NN EIF5A2) (NN maturation))) (, ,) (VP (MD could) (ADVP (RB effectively)) (VP (VB decrease) (NP (NN cell) (NN motility)))))) |ET| |BS|43:F01.145.544 117:D13.150.650.700 122:C14.280.383|ES| 2:1 10:1 14:1 19:1 66:1 94:1 103:1 295:1 351:1 380:1 515:1 615:1 622:1 750:1 908:1 1177:1 1311:1 2977:1 3019:1 5038:1 5039:1 5040:1 5041:1 5042:1
7 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN MCC-555)) (VP (VBD increased) (NP (JJ transcriptional) (NN activity) (JJ human) (NN mouse) (NN MUC2) (NN promoter)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 209:G02.111.087.847 1390:I03|ES| 2:1 19:1 36:1 47:1 52:1 83:1 212:1 399:1 559:1 622:1 5043:1
7 	|BT| (FRAG (ADVP (RB Moreover)) (, ,) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNFalpha)) (-RRB- -RRB-))) (: -) (NP (NP (JJ 5-FU-induced) (NN apoptosis)) (VP (ADVP (RB greatly)) (VBD enhanced) (SBAR (S (NP (NN G17) (NN treatment) (NN Colo320wt) (NN cell)) (VP (VBD prevented) (SBAR (S (NP (NN IEX-1) (NN expression)) (VP (VBD repressed))))))))))) |ET| |BS|39:G04.299.139.160 41:A11 52:E02 560:D03.383.742.698.875.404 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 7:1 10:1 14:1 19:1 89:1 94:1 115:1 185:1 385:1 466:1 546:1 622:1 760:1 1836:1 1944:1 2691:1 3398:1 3984:1 4257:1 4685:1 4696:1 5044:1
7 	|BT| (NP (NP (JJ Negative) (NN regulation) (JJ oncogenic) (NN transcription) (NN factor) (NN FoxM1) (NNS thiazolidinediones) (NN mithramycin))) |ET| |BS|142:I01.880.604 166:D12.776.930 279:D27.888.569.100 862:D02.886.675.933 1303:D02.455.426.559.847.562.050.650|ES| 19:1 185:1 438:1 487:1 953:1 3118:1 4659:1 4791:1 5045:1
7 	|BT| (S (ADVP (RB Nevertheless)) (, ,) (NP (NN extent) (NN NAG-1) (NN induction)) (VP (MD could) (NP (VBN altered) (NN ERK) (NN inhibitor) (NN PD98059)))) |ET| |BS||ES| 2:1 19:1 380:1 693:1 736:1 908:1 1662:1 4486:1 4968:1 5046:1 5047:1
7 	|BT| (S (NP (NN Niclosamide)) (VP (VBD caused) (NP (NP (NN dose)) (: -) (NP (NP (NP (JJ time-dependent) (NN reduction) (NN beta-catenin) (JJ key) (NN component)) (PRN (-LRB- -LSB-) (PP (FW e.g.) (, ,) (NP (NP (NNS DVLs)) (, ,) (NP (NP (NN phospho-GSK3beta)) (PRN (-LRB- -LRB-) (NP (NN S9)) (-RRB- -RRB-))) (, ,) (NP (NN c-Myc) (NN Cyclin) (NN D1)))) (-RRB- -RSB-))) (JJ canonical) (NN Wnt/beta-catenin) (NN pathway))))) |ET| |BS|23:D12.776.091.249 105:G02.149.115.800.925 215:D12.644.360.262.150.100 322:G01.910 1391:D02.065.199.860.470|ES| 2:1 10:1 14:1 19:1 60:1 159:1 302:1 370:1 383:1 744:1 824:1 1021:1 1373:1 1378:1 1997:1 2506:1 3236:1 4742:1 5048:1 5049:1 5050:1 5051:1 5052:1 5053:1
7 	|BT| (NP (NP (JJ Nicotine-induced) (ADJP (NN survival) (NN signaling) (NN lung) (NN cancer) (NN cell) (JJ dependent)) (ADJP (NN p53) (NN status) (NN down-regulation) (NN curcumin) (JJ independent)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 69:G02.111.087.800 85:G02.111.087.225 96:I03.784 108:G04.299.316 692:D02.455.326.146.485.222.222 1392:D03.132.760.570|ES| 12:1 18:1 19:1 94:1 195:1 257:1 274:1 321:1 328:1 416:1 883:1 2498:1 5054:1
7 	|BT| (S (DT No) (NP (NP (NP (NP (NN PPARgamma/retinoid) (NN X) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN RXR)) (-RRB- -RRB-))) (NP (NN consensus) (NN DNA) (NN binding) (NN site))) (VP (VBD detected) (NP (NP (NN FoxM1) (NN promoter)) (VP (VBG extending) (NP (NP (CD -10) (NN kb)) (NP (RB upstream) (, ,) (JJ knockdown) (NN PPARgamma) (NN impact) (NN TZD))))))) (VP (VBD mediated) (NP (NN downregulation) (NN FoxM1) (NN expression)))) |ET| |BS|13:D01.339.387 85:G02.111.087.225 198:D13.444.308 719:D12.776.826.239.588 1393:D12.776.826.701.500 1394:F01.829.316.068 1395:G02.111.570.120|ES| 2:1 10:1 14:1 19:1 83:1 115:1 186:1 437:1 464:1 595:1 666:1 929:1 1003:1 1007:1 1487:1 1996:1 2588:1 3119:1 3541:1 3660:1 4791:1 5055:1 5056:1 5057:1 5058:1 5059:1 5060:1
7 	|BT| (S (NP (NN NO-ASA)) (VP (VBD reduced) (NP (NP (NN expression) (NN cyclin) (NN D1)) (, ,) (NP (NP (JJ downstream) (NN target) (NN gene) (NN play) (JJ important) (NN role)) (NN colon) (NN carcinogenesis))))) |ET| |BS|6:G05.360.340.024.340 12:Z01.542.049 15:F01.829.316.616 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 215:D12.644.360.262.150.100|ES| 2:1 9:1 19:1 31:1 113:1 115:1 160:1 207:1 238:1 452:1 560:1 743:1 744:1 902:1 3892:1
7 	|BT| (S (NP (JJ Novel) (NN oligoamine) (NN analogue)) (VP (VBP inhibit) (SBAR (S (NP (JJ lysine-specific) (NN demethylase) (CD 1)) (VP (VBP induce) (NP (NN reexpression)) (VP (ADVP (RB epigenetically)) (NP (VBN silenced) (NN gene)))))))) |ET| |BS|6:G05.360.340.024.340 122:C14.280.383 259:D12.776.395.240.150.500 1311:D12.125.068.555|ES| 9:1 19:1 98:1 243:1 1370:1 1380:1 2656:1 2658:1 5061:1 5062:1 5063:1 5064:1 5065:1
7 	|BT| (S (NP (NN Nrf2)) (VP (VBZ transactivates) (SBAR (S (NP (JJ wide) (NN variety)) (VP (VBP ARE) (PRN (-LRB- -LRB-) (NP (JJ anti-oxidant) (NN response) (NN element)) (-RRB- -RRB-)))))) (: -) (VP (VBN mediated) (NP (NN enzyme) (PP (VBG including) (NP (NN GSTP1-1)))))) |ET| |BS|730:D08.811 799:D12.776.260.615.249 1396:G02.111.570.080.689.675.700.040 1397:D08.811.913.225.500.500|ES| 10:1 14:1 19:1 494:1 561:1 952:1 2388:1 4048:1 4355:1 4522:1 5066:1 5067:1 5068:1 5069:1 5070:1
7 	|BT| (S (NP (JJ Oral) (NN administration) (NN gefitinib) (JJ able) (VBP prevent) (NP (NN outgrowth) (NN Bam1a) (NN tumor) (NN cell) (JJ palpable) (NN lesion))) (PRN (, ,) (S (VP (VB shrink) (NP (VBN established) (NN tumor)))) (, ,)) (VP (VB eliminate) (NP (NP (NN HER2) (NN HER3) (NN phosphorylation)) (, ,) (NP (NP (NN decrease) (NN MAPK) (NN Akt) (NN signaling)) (FW vivo))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 378:D08.811.913.696.620.682.700.755 385:F02.784.629.131 739:E02.319.267.100 972:G02.111.087.677|ES| 2:1 7:1 19:1 94:1 188:1 195:1 295:1 378:1 733:1 809:1 1131:1 1289:1 2575:1 2660:1 2832:1 3310:1 3426:1 4031:1 4961:1 5071:1 5072:1 5073:1 5074:1 5075:1
7 	|BT| (NP (NP (NP (NP (NNP Ornithine) (NN decarboxylase)) (PRN (-LRB- -LRB-) (NP (NN ODC)) (-RRB- -RRB-))) (, ,) (NP (JJ first) (NN enzyme) (NN polyamine) (NN synthesis)) (, ,) (NP (JJ transcriptional) (NN target) (NN c-myc) (NN modifier) (JJ APC-dependent) (NN tumorigenesis)))) |ET| |BS|3:C04.557.470.035.215.100 20:G03.495 32:C04.697.098.500 33:C04.697.098 209:G02.111.087.847 730:D08.811 1313:D02.092.782 1398:D08.811.520.224.125.425|ES| 2:1 10:1 14:1 19:1 78:1 160:1 455:1 559:1 816:1 2388:1 2697:1 3436:1 3819:1 4672:1 5076:1 5077:1 5078:1
7 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD revealed) (NP (NP (NN HBx)) (ADJP (JJ survivin-dependently) (S (VP (VBN down-regulated) (S (VP (NN miR-520b) (S (VP (VBG interacting) (NP (NN Sp1) (NN cell)))))))))))) |ET| |BS|41:A11 142:I01.880.604 351:A17.360|ES| 19:1 94:1 275:1 658:1 793:1 1283:1 2014:1 4856:1 5079:1 5080:1 5081:1
7 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN TZD)) (VP (VBD mediated) (NP (NN suppression) (NN Sp1) (JJ responsible) (NN downregulation) (NN FoxM1) (NN gene) (NN expression))))))) |ET| |BS|85:G02.111.087.225 155:G05.355.310|ES| 9:1 19:1 115:1 437:1 595:1 658:1 793:1 796:1 2132:1 2453:1 3119:1 4791:1 4856:1
7 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP support) (NP (NP (NN PGG) (JJ multitargeting) (NN agent) (NN chemoprevention) (NN therapy) (NN prostate) (NN cancer)) (VP (VBG activating) (NP (NP (NN p53) (NN tumor) (NN suppressor) (NN pathway)) (VP (VBG inhibiting) (NP (NN STAT3) (JJ oncogenic) (NN signaling)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 69:G02.111.087.800 82:D12.644.360.024.342.300 122:C14.280.383 133:D01.248.497.158.685.750.744.600 253:E02.319.162 279:D27.888.569.100 1399:D12.776.260.820|ES| 7:1 12:1 18:1 19:1 77:1 130:1 195:1 251:1 383:1 413:1 658:1 700:1 728:1 793:1 870:1 880:1 953:1 1364:1 1958:1 5082:1
7 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (NN NAG-1) (NN expression)) (VP (VBD up-regulated) (NP (NP (NN isochaihulactone) (JJ ERK-dependent) (NN pathway)) (VP (VBG involving) (NP (NN activation) (NN EGR-1))))))))) |ET| |BS|142:I01.880.604 150:Z01.542.248.960 580:D12.776.260.158.500 1400:G02.111.087.800.560|ES| 19:1 115:1 225:1 383:1 658:1 796:1 927:1 1301:1 1662:1 3874:1 4055:1 4889:1 5083:1
7 	|BT| (S (S (NP (PRP$ Our) (NN result)) (VP (VBD demonstrated) (SBAR (S (NP (NP (NN soy) (NN peptide)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (VP (ADVP (RB dramatically)) (VBZ inhibits) (NP (NN expression) (NN HSP90))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG suppressing) (NP (NN signaling) (NN pathway) (VBG leading) (NN NF-gammaB) (NN activation)))))) (: ;) (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (VP (VBZ induces) (NP (NP (NN expression) (NN p21)) (, ,) (NP (NP (NN p53)) (, ,) (NP (NN caspase-3) (NN protein))) (: ;) (S (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (VP (VBZ inhibits) (NP (NN expression) (NN VEGF)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 69:G02.111.087.800 86:D01.268.556.435 122:C14.280.383 126:G02.111.087.800 906:D08.811.277.656.262.500.126.350.300 1001:B01.650.940.800.575.100.401.750 1113:D12.776.580.216.380 1401:D12.644|ES| 2:1 4:1 10:1 12:1 14:1 19:1 98:1 101:1 115:1 148:1 195:1 214:1 217:1 225:1 383:1 615:1 639:1 645:1 658:1 862:1 1135:1 1175:1 2066:1 2250:1 4636:1 4807:1 4896:1 5084:1 5085:1 5086:1
7 	|BT| (NP (NP (PRP$ Our) (VBP result) (VBP indicate) (NN EGCG) (S (VP (VBZ attenuates) (S (NP (NN cell) (NN proliferation) (NN OSCC) (NN cell)) (VP (VBG upregulating) (NP (NN BTG2) (NN expression)) (PP (IN via) (NP (NN p38) (NN ERK) (NN pathway))))))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 183:G04.299.233.750 1400:G02.111.087.800.560|ES| 19:1 94:1 101:1 115:1 299:1 383:1 596:1 658:1 1479:1 1666:1 2423:1 3140:1 4885:1 4886:1 5047:1 5087:1
7 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (SBAR (S (NP (NNP Protandim)) (VP (VBD suppressed) (NP (JJ mitochondrial) (NN translocation) (NN p53) (JJ mitochondrial) (JJ outer) (NN membrane) (NN protein) (NN Bax))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 342:D12.644.360.075.718.400 463:C23.550.210.870 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 1402:A11.284.149.450.349|ES| 4:1 12:1 19:1 101:1 132:1 307:1 658:1 1618:1 2004:1 3622:1 4630:1 5088:1 5089:1
7 	|BT| (NP (NN Overexpression) (S (NP (NP (NN c-Jun) (JJ N-terminal) (NN kinase) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN JNK1)) (-RRB- -RRB-))) (VP (VBD resulted) (NP (NN miR-122) (NN down-regulation) (NN induction) (NN PTP1B))))) |ET| |BS|85:G02.111.087.225 469:D08.811.913.696|ES| 10:1 14:1 19:1 98:1 257:1 470:1 594:1 668:1 736:1 1686:1 1789:1 2357:1 5090:1 5091:1
7 	|BT| (S (S (NP (NN Overexpression) (NN NF-kappaB) (NN superrepressor)) (VP (VBD increased) (NP (NN PTEN) (NN expression) (NN JNK) (NN activity)))) (, ,) (IN whereas) (S (NP (NN overexpression) (NN p65) (NN NF-kappaB) (NN subunit)) (VP (VBD reduced) (NP (JJ basal) (JJ NaBT-mediated) (NN JNK) (NN activation) (NN PTEN) (NN expression))))) |ET| |BS|210:D12.776.260.600 583:D12.776.813|ES| 2:1 19:1 47:1 115:1 152:1 225:1 372:1 399:1 452:1 668:1 714:1 1936:1 2110:1 4184:1 4276:1 5016:1 5092:1 5093:1
7 	|BT| (S (NP (NN p66) (NN overexpression)) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (NN activation) (NN luciferase) (NN reporter) (NN gene)) (VP (VBN controlled) (NP (NN SOD2) (NN promoter)))) (, ,) (S (VP (VBG indicating) (S (NP (NN p66) (NN repression) (NN MnSOD)) (VP (VBZ operates) (NP (JJ transcriptional) (NN level)))))))) |ET| |BS|208:F01.393.821 209:G02.111.087.847 264:G05.355.315.800 1375:D08.811.682.517 1403:D08.811.682.881|ES| 2:1 5:1 9:1 19:1 83:1 152:1 225:1 249:1 288:1 559:1 706:1 1944:1 2236:1 4601:1 4604:1 4963:1 5094:1 5095:1 5096:1
7 	|BT| (S (NP (NN Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)) (VP (VP (VBZ induces) (SBAR (S (NP (NN p53)) (VP (VBZ inhibits) (NP (NN STAT3) (NN prostate) (NN cancer) (NN cell) (NN vitro)))))) (VP (VBZ suppresses) (NP (NN prostate) (NN xenograft) (NN tumor) (NN growth)) (FW vivo)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770|ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1
7 	|BT| (S (NP (NN Penta-O-galloyl-beta-D-glucose)) (VP (VBZ induces) (NP (NN G1) (NN arrest) (NN DNA) (JJ replicative) (NN S-phase) (NN arrest)) (NP (NP (ADJP (RB independently) (JJ cyclin-dependent)) (NN kinase) (NN inhibitor) (NN 1A)) (, ,) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1B) (NN P53) (JJ human) (NN breast) (NN cancer) (NN cell)) (NP (RB orally) (JJ active) (JJ triple) (JJ negative) (NN xenograft) (NN growth))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 198:D13.444.308 338:D12.644.360.225.600 1299:D12.644.360.225.500 1404:G02.111.087.222.880|ES| 2:1 18:1 19:1 23:1 36:1 94:1 102:1 197:1 214:1 265:1 380:1 449:1 470:1 602:1 666:1 670:1 1503:1 1916:1 2052:1 2149:1 4226:1 4546:1 5097:1 5098:1 5099:1 5100:1
7 	|BT| (S (NP (NN POX)) (ADVP (RB markedly)) (VP (VBD elevated) (SBAR (S (NP (JJ p53-induced) (NN apoptosis)) (VP (VBZ generates) (NP (JJ proline-dependent) (NP (NP (JJ reactive) (NN oxygen) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))))))) (, ,) (NP (NP (ADVP (RB specifically)) (NP (NN superoxide) (NN radical))) (, ,) (NP (VBP induce) (NN apoptosis) (JJ mitochondrial) (NN death) (NN receptor) (NN pathway))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 135:C23.550.260 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 636:D01.339.431 1185:D12.125.072.401.623 1405:D01.248.497.158.685.750.850|ES| 2:1 10:1 14:1 19:1 89:1 146:1 186:1 243:1 383:1 411:1 480:1 756:1 1279:1 2004:1 2353:1 2354:1 2355:1 2356:1 2396:1 5101:1 5102:1 5103:1 5104:1
7 	|BT| (S (NP (VBN Presented) (NNS data)) (VP (VP (VBP reveal) (S (NP (NN pterostilbene)) (ADJP (JJ novel)))) (, ,) (NP (NP (ADJP (ADJP (JJ effective)) (, ,) (ADJP (JJ anti-metastatic))) (NN agent) (NN function)) (VP (VBG downregulating) (NP (NN MMP-9) (NN gene) (NN expression)))))) |ET| |BS|155:G05.355.310 259:D12.776.395.240.150.500 586:D08.811.277.656.300.480.205.360|ES| 2:1 9:1 19:1 33:1 115:1 728:1 793:1 891:1 1639:1 1670:1 2065:1 2158:1 2428:1 5105:1 5106:1
7 	|BT| (S (S (NP (NN Pretreatment) (NN p38) (NN kinase) (NN inhibitor)) (VP (VBD blocked) (NP (JJ VES-induced) (NN increase) (NN NAG-1) (NN protein) (NN mRNA) (NN level)))) (, ,) (IN whereas) (NP (NP (NN inhibition) (NN protein) (NN kinase) (NN C)) (, ,) (NP (NN Akt)) (, ,) (FRAG (NN c-Jun) (NNP NH) (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (: -) (NP (NP (JJ terminal) (NN kinase)) (, ,) (NP (NP (NN MEK) (NN activity) (NN effect)) (JJ VES-induced) (NN NAG-1) (NN level)))))) |ET| |BS|7:D12.776 12:Z01.542.049 13:D01.339.387 43:F01.145.544 111:D13.444.735.544 122:C14.280.383 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565 378:D08.811.913.696.620.682.700.755 469:D08.811.913.696 470:C02.782.160.927 992:D08.811.913.696.620.682.700.725 1406:D02.455.526.728.650.529|ES| 2:1 4:1 10:1 14:1 19:1 40:1 75:1 103:1 148:1 249:1 325:1 372:1 380:1 399:1 470:1 1289:1 1661:1 1662:1 1666:1 1686:1 1955:1 2777:1 5107:1 5108:1 5109:1 5110:1
7 	|BT| (S (NP (NP (NN Protein) (NN analysis)) (VP (VBN treated) (NP (NN tumor) (NN biopsy)))) (VP (VBD revealed) (NP (NP (NP (JJ elevated) (NN amount) (NN cell) (NN cycle) (NN regulator)) (NP (NN p21) (NN proapoptosis) (NN factor))) (, ,) (NP (NP (NN caspase) (CD 3)) (CD 7) (VBN cleaved) (NN poly) (-LRB- -LSB-) (NN ADP-ribose) (-RRB- -RSB-) (NN polymerase)) (, ,) (VP (VBN coupled) (VP (VBN decreased) (NP (NP (NN level) (JJ antiapoptotic) (NN factor) (NN Bcl-2) (NN Bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-)))))))) |ET| |BS|52:E02 54:G05.360.340.024.340.375.500.791.150 353:G04.299.134 418:D12.644.360.075.718.937 559:E01.370.225.500.384.100 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1407:D12.776.624|ES| 2:1 7:1 10:1 14:1 19:1 94:1 158:1 185:1 202:1 235:1 249:1 275:1 394:1 601:1 661:1 709:1 756:1 862:1 988:1 1099:1 1135:1 1373:1 1378:1 1436:1 1984:1 2911:1 4796:1 4809:1 4810:1 4811:1 5111:1 5112:1 5113:1 5114:1
7 	|BT| (S (NP (NN Rapamycin)) (VP (VBZ inhibits) (SBAR (S (NP (JJ multiple) (NN stage) (NN c-Neu/ErbB2)) (VP (VBD induced) (NP (NP (NN tumor) (NN progression) (JJ transgenic) (NN mouse) (NN model)) (NP (JJ HER2-positive) (NN breast) (NN cancer)))))))) |ET| |BS|8:C04 16:C23.550.291.656 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 99:B01.050.050.136.500 122:C14.280.383 827:D02.540.505.760 1002:C04.588.180|ES| 7:1 18:1 19:1 23:1 48:1 52:1 72:1 285:1 412:1 615:1 649:1 1129:1 2225:1 5115:1 5116:1
7 	|BT| (S (NP (NP (NNS Rats)) (VP (VBN fed) (NP (JJ high-dose) (NN CP-31398) (NN combination) (JJ low-dose) (NN CP-31398) (NN celecoxib)))) (VP (VBD showed) (NP (NP (NP (NP (NP (JJ considerable) (NN enhancement) (NN p53) (NN p21)) (PRN (-LRB- -LRB-) (NP (NN WAF1/CIP)) (-RRB- -RRB-))) (NN expression)) (, ,) (NP (NN apoptosis)) (, ,)) (VP (VBN reduced) (NP (NN tumor) (NN cell) (NN proliferation) (JJ colonic) (NN tumor)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 39:G04.299.139.160 51:C04.588.274.476.411.307.180 183:G04.299.233.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 663:C16.320.565.398.500.330.500 684:D02.065.884.247|ES| 2:1 7:1 10:1 12:1 14:1 19:1 89:1 94:1 115:1 132:1 299:1 452:1 530:1 677:1 1135:1 2278:1 2426:1 2807:1 3047:1 3049:1 3664:1 5117:1 5118:1 5119:1
7 	|BT| (NP (NP (RB Regardless) (NN p53) (NN status)) (, ,) (NP (NN celecoxib)) (VP (VBD caused) (NP (NP (JJ significant) (NN difference) (NN apoptosis) (NN level) (NN U87MG)) (, ,) (NP (NN U87MG-PFT)) (, ,) (NP (NN U87MG-E6) (NN U373MG) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 13:D01.339.387 39:G04.299.139.160 41:A11 684:D02.065.884.247|ES| 2:1 12:1 19:1 89:1 94:1 135:1 249:1 416:1 1674:1 2506:1 2807:1 4619:1 4620:1 4621:1 4623:1 5120:1
7 	|BT| (NP (NP (NP (NN Regulation) (NN PTEN) (NN expression) (JJ intestinal) (JJ epithelial) (NN cell) (NN c-Jun) (JJ NH2-terminal) (NN kinase) (NN activation)) (NP (JJ nuclear) (NN factor-kappaB) (NN inhibition)))) |ET| |BS|43:F01.145.544 47:A03.556.124 75:A11.436 142:I01.880.604 210:D12.776.260.600 771:D08.811.913.696.620.682.700.567.374|ES| 19:1 94:1 103:1 109:1 115:1 127:1 225:1 470:1 699:1 1256:1 1686:1 1936:1 2702:1 2708:1
7 	|BT| (NP (NP (NP (NN Relationship) (NN CYP1A) (NN induction) (NN indole-3-carbinol) (NN flutamide) (NN liver)) (JJ tumor-promoting) (JJ potential) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1172:D02.065.199.420|ES| 19:1 736:1 827:1 836:1 849:1 3647:1 3776:1 4057:1 5121:1 5122:1
7 	|BT| (S (ADVP (RB Remarkably)) (, ,) (NP (NP (NN F-box) (NN protein) (NN FBW7)) (, ,) (NP (NN E3-ubiquitin) (NN ligase)) (, ,)) (VP (VBN controlled) (NP (NP (NN stability) (NN arm) (NN c-MYC/MXD1) (JJ push-pull) (NN network)) (, ,) (NP (NN FBW7) (NN ablation)))) (S (VP (VBD attenuated) (NP (CD 1,25) (NN D) (NN regulation) (NN c-MYC) (NN MXD1) (NN turnover))))) |ET| |BS|142:I01.880.604 588:I01.880.853.500.600 665:N04.452.677.680 1408:C04.557.450.590.550.660.665 1409:D08.811.464.938.750 1410:A01.378.800.075|ES| 2:1 4:1 19:1 91:1 438:1 625:1 808:1 2154:1 2424:1 4529:1 4533:1 4950:1 5094:1 5123:1 5124:1 5125:1 5126:1 5127:1 5128:1 5129:1 5130:1
7 	|BT| (NP (NP (NN Repression) (NN MUC2) (NN gene) (NN expression) (NN butyrate)) (, ,) (NP (JJ physiological) (NN regulator) (JJ intestinal) (NN cell) (NN maturation))) |ET| |BS|47:A03.556.124 155:G05.355.310 208:F01.393.821 230:G04 1307:D02.241.081.114.750 1309:D02.241.081.114|ES| 2:1 9:1 19:1 94:1 109:1 115:1 212:1 235:1 3758:1 3762:1 5042:1 5131:1
7 	|BT| (S (NP (NNS RESULTS) (: :)) (S (NP (NP (NN Depletion) (NN c-Src) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD sustained) (NP (NN inhibition) (NN dasatinib)))) (VP (VBD increased) (NP (NN pSTAT3)))) (, ,) (VP (MD could) (VP (VBD blocked) (NP (NN inhibition) (NN JAK))))) |ET| |BS|43:F01.145.544 117:D13.150.650.700 122:C14.280.383 1386:D02.886.675.184|ES| 2:1 19:1 47:1 103:1 104:1 515:1 710:1 750:1 908:1 1847:1 2777:1 3019:1 5017:1 5018:1 5132:1 5133:1 5134:1
7 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (NP (NN MDR1) (NNS GCS)) (ADVP (RB coincidently)) (VP (VBN overexpressed) (NP (NP (JJ drug-resistant) (NN breast)) (, ,) (NP (NN ovary)) (, ,) (NP (JJ cervical) (NN colon) (NN cancer) (NN cell))))) (FRAG (: ;) (NP (NP (NN silencing) (NNS GCS)) (VP (VBG using) (NP (NP (NP (JJ novel) (NN mixed-backbone) (NN oligonucleotide)) (PRN (-LRB- -LRB-) (NP (NN MBO-asGCS)) (-RRB- -RRB-))) (VP (VBN sensitized) (NP (CD four) (JJ drug-resistant) (NN cell) (NN line) (NN doxorubicin)))))))) |ET| |BS|10:A01.236 41:A11 67:D26 94:A11.251.210 136:D02.455.426.559.847.562.050.200.175 259:D12.776.395.240.150.500 575:V02.050 1369:A05.360.319.114.630 1411:D13.695.578.424 1412:A02.835.232.834 1413:A01.598|ES| 2:1 10:1 14:1 18:1 19:1 23:1 25:1 94:1 100:1 104:1 113:1 217:1 264:1 350:1 453:1 598:1 599:1 710:1 891:1 3247:1 4188:1 4697:1 4761:1 5135:1 5136:1 5137:1 5138:1 5139:1
7 	|BT| (S (S (NP (NN Resveratrol)) (VP (VBD induced) (NP (NP (NN cell) (NN cycle) (NN arrest)) (VP (VBG up-regulating) (NP (NN expression) (NN p21/CIP1)))))) (, ,) (S (NP (NN p27/KIP1)) (VP (VBG inhibiting) (NP (NN expression) (NN cyclin) (NN D1))))) |ET| |BS|122:C14.280.383 150:Z01.542.248.960 215:D12.644.360.262.150.100 338:D12.644.360.225.600 773:G04.299.134.109|ES| 2:1 19:1 94:1 115:1 412:1 601:1 602:1 743:1 744:1 880:1 1876:1 2946:1 5140:1 5141:1
7 	|BT| (S (NP (NNP Resveratrol)) (VP (VBZ prevents) (S (NP (NN tumorigenesis) (NN mouse) (NN model)) (VP (NNP Kras) (VP (VBD activated) (S (NP (JJ sporadic) (JJ colorectal) (NN cancer)) (VP (VBG suppressing) (NP (JJ oncogenic) (NN Kras) (NN expression))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 279:D27.888.569.100 388:G05.360.340.024.340.375.500.791.550|ES| 17:1 18:1 19:1 52:1 72:1 78:1 115:1 163:1 725:1 953:1 2250:1 2718:1 2946:1 5142:1
7 	|BT| (S (NP (NN Retinol) (NN treatment)) (VP (VP (VBD decreased) (NP (NN transcription) (NN TOPFlash) (NN reporter) (NN construct) (NN mRNA) (NN level) (JJ endogenous) (NN beta-catenin) (NN target) (NN gene))) (, ,) (NP (NN cyclin) (NN D1) (NN c-myc)))) |ET| |BS|6:G05.360.340.024.340 23:D12.776.091.249 52:E02 111:D13.444.735.544 209:G02.111.087.847 215:D12.644.360.262.150.100 1414:D02.455.326.271.665.202.495.818 1415:D02.455.326.271.665.202.495.818|ES| 2:1 9:1 19:1 60:1 160:1 202:1 249:1 288:1 325:1 455:1 487:1 546:1 743:1 744:1 3870:1 4964:1 5143:1 5144:1
7 	|BT| (NP (NP (NP (NN Role)) (NP (VBN phosphorylated) (NN histone) (NN H3) (NN serine) (CD 10) (JJ DEN-induced) (NN deregulation) (NN Pol) (CD III) (NN gene) (NN cell) (NN proliferation) (NN transformation)))) |ET| |BS|15:F01.829.316.616 183:G04.299.233.750 614:G05.360.340.024.340.364.875.667 926:D12.125.154.800 1416:D12.776.660.470|ES| 9:1 19:1 94:1 299:1 402:1 503:1 1384:1 1519:1 2187:1 2280:1 2281:1 2735:1 4930:1 5145:1 5146:1
7 	|BT| (S (NP (NNS RWPs)) (VP (VBD reduced) (NP (SBAR (S (NP (NP (NN expression) (NN VEGF)) (, ,) (NP (NP (NP (NN matrix) (NN metalloproteinase)) (PRN (-LRB- -LRB-) (NP (NN MMP)) (-RRB- -RRB-))) (CD -2) (, ,) (NN MMP-9) (, ,) (NN cyclooxygenase-2))) (VP (VBD increased) (NP (NN expression) (NN tumor) (NN suppressor) (NN gene) (NN p16) (-LRB- -LRB-) (NN INK4A) (-RRB- -RRB-))))) (, ,) (NP (NN p53) (, ,) (NN p73) (NN tumor) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 24:D08.811.600.720.750 41:A11 155:G05.355.310 203:G05.360.340.024.340.375.249.375 206:G05.360.340.024.340.375.249 586:D08.811.277.656.300.480.205.360 1417:D08.811.277.656.300.480.205.352|ES| 2:1 7:1 9:1 10:1 12:1 14:1 19:1 47:1 61:1 94:1 115:1 452:1 700:1 1313:1 2066:1 2158:1 2892:1 3182:1 3491:1 5147:1 5148:1 5149:1 5150:1
7 	|BT| (S (S (NP (NN SAHA)) (VP (VBD decreased) (NP (NN cyclin) (NN B1) (NN expression)))) (: ;) (S (NP (NN cyclin)) (ADVP (RB normally)) (VP (VBZ promotes) (NP (NN progression) (NN G2) (NN cell) (NN cycle))))) |ET| |BS|16:C23.550.291.656 353:G04.299.134 768:D12.776.660.740 979:D12.644.360.262.120.100 1280:D12.644.360.262|ES| 19:1 48:1 94:1 115:1 202:1 217:1 298:1 601:1 743:1 3455:1 4915:1 5151:1 5152:1
7 	|BT| (S (NP (NN Salinomycin)) (VP (VBD induced) (NP (NN degradation) (NN Skp2)) (ADVP (RB thus)) (VP (VBN accumulated) (NP (NN p27Kip1))))) |ET| |BS|338:D12.644.360.225.600 507:D12.776.157.743 1293:G03.495|ES| 19:1 412:1 597:1 1334:1 1785:1 4616:1 5153:1 5154:1
7 	|BT| (S (NP (NN Salinomycin)) (VP (VBZ induces) (NP (NN cell) (NN death)) (PP (IN via) (NP (NN inactivation) (NN Stat3) (NN downregulation) (NN Skp2))))) |ET| |BS|82:D12.644.360.024.342.300 85:G02.111.087.225 134:G04.299.139 507:D12.776.157.743|ES| 19:1 94:1 214:1 411:1 595:1 596:1 1314:1 1785:1 2646:1 5153:1
7 	|BT| (S (NP (NN Selenium) (NN treatment) (NN tumor) (NN promotion)) (VP (VBD increased) (S (NP (JJ hepatic) (NN GPx4) (NN expression)) (VP (VBN reduced) (NP (NN expression) (NN VEGF) (NN AP-1) (NN component) (NN c-fos)) (NP (ADJP (RB well) (JJ nodule)) (NN growth)))))) |ET| |BS|8:C04 45:G07.700.320.249 52:E02 935:D01.268.185.850 1418:D12.776.260.108.875|ES| 7:1 19:1 47:1 102:1 115:1 452:1 546:1 562:1 787:1 838:1 1021:1 2066:1 2337:1 4680:1 5155:1 5156:1 5157:1
7 	|BT| (S (NP (NNP Sesamin)) (ADVP (RB also)) (VP (VP (VBD potentiated) (SBAR (S (NP (NN tumor) (NN necrosis) (JJ factor-alpha-induced) (NN apoptosis)) (VP (VBD correlated) (SBAR (S (NP (NN suppression) (NN gene) (NN product)) (VP (VBN linked) (NP (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP (NN Bcl-2) (NN survivin))) (-RRB- -RRB-))))))))) (, ,) (PRN (NP (NN proliferation) (-LRB- -LRB-) (FW e.g.) (, ,) (NP (NN cyclin) (NN D1))) (-RRB- -RRB-) (NP (, ,) (NP (NP (NN inflammation)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP (NN cyclooxygenase-2))) (-RRB- -RRB-))) (, ,) (NP (NP (NN invasion)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP (NN matrix) (NN metalloproteinase-9)) (, ,) (NP (JJ intercellular) (NN adhesion) (NN molecule) (CD 1))) (-RRB- -RRB-))) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor))) (-RRB- -RRB-))))))) |ET| |BS|6:G05.360.340.024.340 24:D08.811.600.720.750 39:G04.299.139.160 54:G05.360.340.024.340.375.500.791.150 108:G04.299.316 215:D12.644.360.262.150.100 371:A07.231 525:C23.550.470 586:D08.811.277.656.300.480.205.360 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1130:D12.644.276.390 1325:D12.776.395.550.200.450|ES| 2:1 5:1 7:1 9:1 10:1 14:1 19:1 61:1 89:1 94:1 98:1 102:1 158:1 180:1 185:1 274:1 299:1 446:1 620:1 675:1 743:1 744:1 753:1 1251:1 1363:1 1997:1 2157:1 2229:1 2453:1 2502:1 2952:1 3064:1 3092:1 3491:1 3679:1 4257:1 5158:1 5159:1
7 	|BT| (S (NP (NN SGE)) (VP (VBD inhibited) (NP (NP (NN induction) (JJ gamma-glutamyltranspeptidase-positive) (NNS hepatocytes)) (, ,) (NP (NN lipid) (NN peroxidation)) (, ,) (NP (NN gene) (NN expression) (NN Cyp1a1)) (, ,)) (VP (VBD caused) (NP (NN DC))))) |ET| |BS|122:C14.280.383 155:G05.355.310 262:A11.436.348 648:D08.811.913.050.200.500 1247:G02.111.087.520 1352:D08.244.453.040.332|ES| 2:1 9:1 19:1 115:1 365:1 736:1 894:1 2401:1 2506:1 4384:1 5160:1 5161:1 5162:1 5163:1
7 	|BT| (S (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (VP (VBD found) (NP (NN repressor) (NN Gadd45b) (NN gene) (NN binding) (JJ upstream) (JJ regulatory) (NN element)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 149:G05.360.340.024.340.364.875.890 209:G02.111.087.847 250:E07.305.812 1419:G02.111.570.080.689|ES| 9:1 10:1 14:1 19:1 37:1 251:1 487:1 860:1 861:1 862:1 1487:1 1817:1 1996:1 2960:1 4855:1 5070:1 5164:1
7 	|BT| (NP (NP (NP (NN Silencing) (NN CXCR4) (VBG impairing) (NN MIF-CXCR4) (NN signaling) (NN pathway) (NN ISO-1)) (, ,) (NP (NN pAb) (NN FL-115)) (, ,) (NP (NN AMD-3100)) (, ,) (NP (JJ monoclonal) (NN antibody) (NN 12G5)) (, ,) (NP (NN BIM-46187)) (VP (VBD abolished) (NP (JJ aggressive) (NN phenotype))))) |ET| |BS|80:G05.695 126:G02.111.087.800 162:F01.145.126.125 1204:D12.776.543.750.100.160.500.400 1420:D12.776.124.486.485.114.224 1421:D06.472.699.327.700.500|ES| 2:1 19:1 195:1 236:1 383:1 538:1 722:1 775:1 1365:1 2611:1 4220:1 4582:1 5165:1 5166:1 5167:1 5168:1 5169:1 5170:1 5171:1
7 	|BT| (S (NP (NN Silibinin)) (ADVP (RB strongly)) (VP (VBD increased) (SBAR (S (JJ phospho-extracellular) (NP (NP (NP (JJ signal-regulated) (NN kinase) (CD 1/2)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Cip1/p21) (NN Kip1/p27)) (PRN (-LRB- -LRB-) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor)) (-RRB- -RRB-))) (NP (NN level))) (ADVP (RB moderately)) (VP (VBD decreased) (NP (NN Bcl-2) (NN survivin) (NN level))))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 919:D08.811.913.696.620.682.700.567.249.500 1279:D12.644.360.225|ES| 2:1 10:1 14:1 19:1 47:1 158:1 202:1 249:1 380:1 470:1 635:1 1706:1 1707:1 2229:1 2531:1 4546:1 4592:1 4593:1 4594:1 4966:1 5172:1
7 	|BT| (S (PP (IN Since) (NP (NP (NN fate) (JJ chemotherapy-insensitive) (NN tumor) (NN cell)) (VP (ADVP (RB rarely)) (VBN described)))) (, ,) (NP (VBN performed) (NP (JJ comparative) (NN analysis) (NN 5-FU) (NN toxicity) (JJ p53-deficient) (NN cell))) (VP (VBP conclude) (NP (NP (NN p53) (NN act) (NN facilitator)) (NP (RB rather) (NN gatekeeper) (NN cell) (NN death))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 41:A11 81:E02.095.465.425.400.330.050.400 134:G04.299.139 151:E02.319 557:D02.241.081.069.600.150 560:D03.383.742.698.875.404|ES| 2:1 7:1 12:1 19:1 94:1 246:1 411:1 458:1 634:1 661:1 851:1 1968:1 2308:1 2406:1 2535:1 3001:1 4561:1 5173:1 5174:1 5175:1 5176:1 5177:1
7 	|BT| (S (NP (NN SiRNA) (NN treatment) (NN BNL-CL.2) (NN cell) (NN Tsc-22) (NNS oligonucleotides)) (SBAR (S (NP (JJ nonspecific) (NNS oligonucleotides)) (VP (VBD decreased) (NP (NN RNA) (NN protein) (NN expression) (NN Tsc-22)) (NP (CD 80-90) (NN %))))) (, ,) (NP (NP (NN expression) (NN Gadd45b) (NN gene)) (, ,) (NP (NN Lzts2)) (, ,)) (VP (VBD increased) (S (NP (NN time)) (NP (JJ initial) (NN decrease))))) |ET| |BS|7:D12.776 41:A11 52:E02 117:D13.150.650.700 155:G05.355.310 322:G01.910 1411:D13.695.578.424 1422:D13.444.735|ES| 2:1 4:1 9:1 19:1 47:1 94:1 115:1 202:1 295:1 369:1 515:1 546:1 1081:1 4161:1 4855:1 5178:1 5179:1 5180:1 5181:1 5182:1 5183:1 5184:1
7 	|BT| (S (NP (NP (NNP Sixth)) (, ,) (NP (NN curcumin))) (VP (VBD inhibited) (NP (NP (NN expression) (NN cell) (NN survival) (NN protein) (NN B-cell) (NN lymphoma-2)) (, ,) (NP (NN B-cell) (NN leukemia) (NN protein) (NN xL)) (, ,) (NP (NP (JJ X-linked) (NN inhibitor) (NN apoptosis) (NN protein)) (, ,) (NP (NN c-FLIP))) (, ,) (NP (NP (NP (JJ cellular) (NN inhibitor) (NN apoptosis) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN cIAP)) (-RRB- -RRB-))) (CD -1)) (, ,) (NP (NP (NN cIAP-2) (NN survivin) (NN protein)) (VP (VBN linked) (NP (NN cell) (NP (NN proliferation)) (, ,) (NP (NN cyclin) (NN D1)) (NP (NN c-Myc)))))))) |ET| |BS|7:D12.776 41:A11 108:G04.299.316 122:C14.280.383 183:G04.299.233.750 215:D12.644.360.262.150.100 692:D02.455.326.146.485.222.222 1423:D12.644.360.075.437.750 1424:C04.557.386.480.150 1425:C04.557.337.428.080.125 1426:C04.557.337.428.080|ES| 2:1 4:1 10:1 14:1 19:1 89:1 94:1 115:1 274:1 299:1 365:1 380:1 743:1 744:1 824:1 1363:1 2199:1 2229:1 2498:1 3074:1 5185:1 5186:1 5187:1 5188:1 5189:1 5190:1 5191:1 5192:1 5193:1
7 	|BT| (S (NP (NN SPARC) (NN promoter) (NN hypermethylation) (JJ colorectal) (NN cancer)) (VP (VBD reversed) (S (NP (NN 5-Aza-2) (`` `) (NN deoxycytidine) (NN increase) (NN SPARC) (NN expression)) (VP (VB improve) (NP (NN therapy) (NN response)))))) |ET| |BS|4:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 37:D12.776.157.125.715 52:E02 1427:D03.383.742.680.245.500 1428:D02.886.759.111|ES| 17:1 18:1 19:1 40:1 82:1 83:1 115:1 130:1 494:1 664:1 2466:1 4352:1 5194:1
7 	|BT| (S (NP (ADVP (RB Strikingly)) (, ,) (NP (NP (NN CYR61) (NN overexpression) (JJ impaired) (NN accumulation)) (NP (NP (JJ wild-type) (NN p53)) (PP (VBG following) (NP (NN Taxol) (NN exposure))))) (, ,) (NP (NN inhibition) (NN alphavbeta3) (NN ERK1/ERK2) (NN MAPK) (NN signaling))) (ADVP (RB completely)) (VP (VBD restored) (NP (JJ Taxol-induced) (NN upregulation) (NN p53)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 43:F01.145.544 69:G02.111.087.800 116:D08.811.913.696.620.682.700.567.249.750 249:G05.355.315.800 339:G02.111.087.880 919:D08.811.913.696.620.682.700.567.249.500 1429:D02.455.426.392.368.242.888.777|ES| 2:1 8:1 12:1 19:1 103:1 152:1 195:1 809:1 1126:1 1953:1 2003:1 2120:1 3244:1 3510:1 3792:1 4271:1 4893:1 5195:1 5196:1 5197:1 5198:1
7 	|BT| (S (NP (NP (JJ Subsequent) (NN inhibition) (NN Notch-1) (NN signaling) (NN sulfonamide) (NN GSI)) (PRN (-LRB- -LRB-) (NP (NN GSI34)) (-RRB- -RRB-))) (VP (VBD prevented) (SBAR (S (NP (NN induction) (NN NICD) (NN chemotherapy)) (VP (VBD blunted) (NP (NN Hes-1) (NN activation))))))) |ET| |BS|43:F01.145.544 69:G02.111.087.800 151:E02.319 1430:D02.065.884|ES| 10:1 14:1 19:1 20:1 103:1 195:1 225:1 495:1 736:1 1867:1 1944:1 2277:1 4269:1 4607:1 5199:1 5200:1 5201:1
7 	|BT| (S (NP (NN Sugiol)) (VP (VBD induced) (SBAR (S (NP (NN cell) (NN cycle) (NN arrest)) (VP (VBD decreased) (NP (NP (NP (NN expression) (NN level) (NN STAT3) (NN target) (NN gene)) (, ,) (NP (NN cyclin) (NN D1))) (, ,) (NP (NN cyclin) (NN A)) (, ,) (NP (NN survivin)))))))) |ET| |BS|82:D12.644.360.024.342.300 155:G05.355.310 215:D12.644.360.262.150.100 773:G04.299.134.109 1431:D12.644.360.262.100|ES| 2:1 9:1 19:1 69:1 94:1 115:1 160:1 202:1 249:1 251:1 412:1 601:1 602:1 743:1 744:1 2229:1 5202:1
7 	|BT| (S (NP (NP (NP (NN Sulindac) (NN cyclooxygenase-2) (NN inhibitor)) (, ,) (NP (NN etodolac)) (, ,)) (NN increase) (NN APC) (NN mRNA) (NN colon) (NN rat)) (VP (VBN treated) (NP (NN azoxymethane)))) |ET| |BS|3:C04.557.470.035.215.100 46:A03.556.124.526.356 52:E02 111:D13.444.735.544 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 349:D27.505.519.389.310.500 683:D27.505.519.389.310 1317:D03.066.288.200|ES| 2:1 11:1 19:1 40:1 61:1 113:1 325:1 380:1 849:1 1099:1 1993:1 2965:1 4679:1
7 	|BT| (S (NP (NN TAM)) (VP (VBD increased) (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (-LRB- -LRB-) (NN ERK) (-RRB- -RRB-) (NN phosphorylation)) (, ,) (NP (JJ related) (NN proliferation) (NN regeneration) (NN liver))) (VP (VBD decreased) (NP (NN DGAT2) (NN gene) (NN expression))))) |ET| |BS|155:G05.355.310 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567 640:D02.455.426.559.389.150.700.900 925:G10.261.326.520 972:G02.111.087.677 1432:G02.111.570.060.040.750 1433:C05.651.575|ES| 2:1 9:1 10:1 14:1 19:1 47:1 115:1 202:1 299:1 419:1 470:1 836:1 1707:1 3260:1 3426:1 4812:1 5047:1 5203:1 5204:1
7 	|BT| (NP (DT The) (S (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (NN H-thymidine) (NN incorporation) (NN Western-blot) (NN assay)) (VP (VBD revealed) (SBAR (S (NP (NN cell) (NN proliferation)) (VP (VBD attenuated) (NP (NNP EGCG)) (PP (IN via) (NP (NP (NN upregulation) (NN BTG2) (NN expression)) (VP (VBG causing) (NP (NN cell) (NN cycle) (NN G1) (NN phase) (NN arrest) (NN OSCC) (NN cell))))))))))) |ET| |BS|41:A11 179:D01.248.497.300.459.700 183:G04.299.233.750 249:G05.355.315.800 255:E05.196.401.143 339:G02.111.087.880 1076:G04.299.134.109.249 1434:D03.383.742.680.705|ES| 10:1 14:1 19:1 94:1 115:1 275:1 299:1 310:1 596:1 601:1 602:1 670:1 691:1 808:1 862:1 1126:1 1491:1 2529:1 4885:1 4886:1 5087:1 5205:1 5206:1 5207:1
7 	|BT| (S (NP (DT The) (NN ability) (NN PF-03084014)) (VP (VBP inhibit) (NP (NP (NN gamma-secretase) (NN activity)) (VP (VBN shown) (NP (NP (NP (NN reduction) (JJ endogenous) (NN NICD) (NN level) (NN downregulation) (NN Notch) (NN target) (NN gene) (NN Hes-1) (NN cMyc) (NN T-cell) (JJ acute) (JJ lymphoblastic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN T-ALL)) (-RRB- -RRB-))) (NN cell) (NN line) (NN HPB-ALL)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 85:G02.111.087.225 122:C14.280.383 125:D08.811.277.656.300.032 385:F02.784.629.131 1435:C04.557.337.428.600.620|ES| 9:1 10:1 14:1 19:1 90:1 94:1 160:1 237:1 249:1 256:1 264:1 370:1 399:1 595:1 691:1 1300:1 1370:1 1866:1 2277:1 3870:1 5187:1 5200:1 5208:1 5209:1 5210:1 5211:1 5212:1 5213:1
7 	|BT| (S (NP (DT The) (NN activity) (NN PTEN)) (VP (VBD restored) (NP (VBN treated) (NN NF-kappaB) (NN inhibitor) (NN PDTC)))) |ET| |BS|52:E02 210:D12.776.260.600|ES| 19:1 380:1 399:1 691:1 714:1 1099:1 1936:1 4893:1 5214:1
7 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP investigate) (NP (NP (NP (NN contribution) (CD 2) (NN source) (NN ROS)) (, ,) (NP (NP (NN cytochrome) (NN P450) (NN 2E1)) (PRN (-LRB- -LRB-) (NP (NN CYP2E1)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP NAD)) (PRN (-LRB- -LRB-) (NP (NN P)) (-RRB- -RRB-))) (NP (NP (NN H) (NN quinone) (NN oxidoreductase)) (PRN (-LRB- -LRB-) (NP (NN NQO1)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN alcohol) (NN modulation) (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NP (NN expression))) (, ,) (NP (NN splicing) (NN KLF6) (CD _) (NN V1) (NN KLF6) (CD _) (NN V2)) (, ,) (NP (NN effect) (NN TNFalpha) (, ,) (JJ downstream) (NN target))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 751:D02.033.375 789:D12.644.276.374.500.800 790:D12.644.276.374.750 822:D02.033 1218:D08.244.453.300 1436:G02.111.087.750.700|ES| 2:1 10:1 14:1 19:1 75:1 115:1 131:1 148:1 160:1 311:1 459:1 560:1 612:1 691:1 1360:1 1567:1 1945:1 2356:1 2549:1 3710:1 3788:1 4270:1 4635:1 4683:1 4684:1 4685:1 4752:1 5215:1 5216:1 5217:1 5218:1 5219:1 5220:1 5221:1
7 	|BT| (NP (NP (DT The) (NN aim) (NN study)) (VP (VBD determine) (S (NN correlation) (NN TS) (: -) (PRN (, ,) (NN TP) (: -)) (, ,) (NP (JJ DPD-gene) (NN expression) (NN response) (JJ 5-FU-based) (JJ long-term) (JJ pre-operative) (NN chemoradiotherapy)) (VP (VBN assessed) (NP (JJ histopathological) (NN tumour) (NN regression)))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 59:E02.186.079 154:Z01.058.266.887 155:G05.355.310 333:D01.045 560:D03.383.742.698.875.404 846:F01.393.784 1342:Z01.639.040 1437:C13.703.420.491.500|ES| 2:1 19:1 74:1 115:1 131:1 494:1 691:1 1011:1 1567:1 1988:1 1989:1 3002:1 3527:1 3544:1 3546:1 3823:1 4785:1 4787:1 4788:1 4789:1
7 	|BT| (S (NP (DT The) (JJ anti-MM) (NN activity) (NN PTC-209)) (VP (VBN accompanied) (NP (NP (JJ significant) (NN decrease) (NN cyclin) (NN D1)) (PRN (-LRB- -LRB-) (NP (NN CCND1)) (-RRB- -RRB-))) (S (NP (NN v-myc) (NP (NP (JJ avian) (NN myelocytomatosis) (JJ viral) (NN oncogene) (NN homolog)) (PRN (-LRB- -LRB-) (NP (NN MYC)) (-RRB- -RRB-))) (NN expression)) (ADVP (RB well)) (VP (NN upregulation) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN CDKN1A)) (-RRB- -RRB-)) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1B)) (PRN (-LRB- -LRB-) (NP (NN CDKN1B)) (-RRB- -RRB-)))))) |ET| |BS|215:D12.644.360.262.150.100 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 1299:D12.644.360.225.500|ES| 10:1 14:1 19:1 24:1 115:1 135:1 295:1 380:1 399:1 470:1 472:1 691:1 743:1 744:1 787:1 1025:1 1126:1 2052:1 2801:1 3621:1 3969:1 4546:1 5100:1 5222:1 5223:1 5224:1 5225:1 5226:1 5227:1 5228:1
7 	|BT| (S (NP (DT The) (NN antitumor) (NN activity) (NN SRJ09)) (VP (VBD suggested) (VP (VBN mediated) (PP (IN via) (NP (NN induction) (NN p21) (NN expression) (NN suppression) (NN CDK-4) (NN expression))) (PP (IN without) (S (VP (VBG affecting) (NP (NP (NN cyclin) (NN D1) (NN trigger) (NN G1) (NN arrest)) (VP (VBG leading) (NP (NN apoptosis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 86:D01.268.556.435 215:D12.644.360.262.150.100 573:N05.715.350.200.650 978:D08.811.913.696.620.682.700.646.500|ES| 19:1 89:1 115:1 399:1 437:1 596:1 602:1 639:1 670:1 691:1 736:1 743:1 744:1 925:1 1135:1 1195:1 2015:1 2244:1 2453:1 2530:1 3763:1 5229:1
7 	|BT| (S (NP (DT The) (NN apoptosis)) (VP (VP (VBD induced) (NP (NP (NN PTX-2) (NN Hep3B) (NN cell)) (NP (NP (NP (VBN associated) (NN down-regulation) (JJ anti-apoptotic) (NN Bcl-2) (NN member)) (PRN (-LRB- -LRB-) (NP (NN Bcl-2) (NN Bcl-xL)) (-RRB- -RRB-))) (NP (NN IAP) (NN family) (NN protein))))) (, ,) (NP (NP (NP (NN up-regulation) (JJ pro-apoptotic) (NN Bax) (NN protein) (NN tumor) (NN necrosis) (JJ factor-related) (JJ apoptosis-inducing) (NN ligand)) (PRN (-LRB- -LRB-) (NP (NN TRAIL)) (-RRB- -RRB-))) (: -) (NP (NP (NP (NN receptor) (NN 1/receptor) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN DR4/DR5)) (-RRB- -RRB-))) (NP (JJ mitochondrial) (NN dysfunction)))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 142:I01.880.604 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 1272:D03.438.759.758.824.651.700 1438:D12.644.276.374.750.625 1439:D12.644.360.075.437|ES| 2:1 4:1 7:1 10:1 14:1 19:1 89:1 94:1 97:1 148:1 158:1 169:1 257:1 412:1 691:1 758:1 769:1 896:1 1695:1 1835:1 2004:1 4257:1 4502:1 4560:1 4630:1 4814:1 5230:1 5231:1 5232:1 5233:1 5234:1 5235:1 5236:1 5237:1
7 	|BT| (S (NP (DT The) (JJ apoptosis-inducing) (NN effect) (NN gastrin) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ relates) (NP (NP (VBN increased) (NP (NN IEX-1)) (NN expression)) (VP (VBG mediating) (NP (NP (NN NF-kappa) (NN B)) (NN inhibition)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600|ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1
7 	|BT| (S (NP (NP (DT The) (NN AZD6244-doxorubicin)) (NP (NP (VBN combined) (NN protocol)) (VP (VBD promoted) (NP (NN apoptosis))))) (ADVP (RB also)) (VP (VBD induced) (NP (NP (JJ synergistic) (NN effect)) (VP (VBN seen) (NP (JJ single-agent-treated) (NN tumor)))) (, ,) (PP (VBG including) (NP (VBN increased) (NN expression) (NN p130) (NN RB) (NN tumor) (NN suppressor) (NN gene))))) |ET| |BS|8:C04 39:G04.299.139.160 52:E02 136:D02.455.426.559.847.562.050.200.175 155:G05.355.310 206:G05.360.340.024.340.375.249 213:F02.830.816.964 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 2:1 5:1 7:1 9:1 19:1 47:1 75:1 89:1 115:1 164:1 412:1 561:1 691:1 700:1 724:1 1209:1 1912:1 2012:1 3216:1 5238:1 5239:1 5240:1
7 	|BT| (S (NP (DT The) (NN downregulation) (NN IRS1) (NN SOX9)) (ADVP (RB also)) (VP (VBD induced) (NP (NN sodium) (NN butyrate)))) |ET| |BS|85:G02.111.087.225 1075:D02.241.081.114.750|ES| 5:1 19:1 407:1 412:1 595:1 691:1 3758:1 5241:1 5242:1
7 	|BT| (S (NP (DT The) (JJ dual) (NN EGFR/HER2) (NN inhibitor) (NN lapatinib)) (ADVP (RB synergistically)) (VP (VBZ enhances) (NP (JJ antitumor) (NN activity) (NN histone) (NN deacetylase) (NN inhibitor) (NN panobinostat) (JJ colorectal) (NN cancer) (NN model)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 153:D27.505.519.389.360|ES| 17:1 18:1 19:1 72:1 380:1 399:1 503:1 504:1 691:1 1356:1 2067:1 2244:1 3347:1 3348:1 3349:1 5243:1
7 	|BT| (S (NP (DT The) (NN effect) (NN chloroform) (NN DCA) (JJ TCA-induced) (NN hypomethylation) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN kidney) (NN tumor)) (VP (VBD determined))) |ET| |BS|155:G05.355.310 242:A03.620 274:C04.588.945.947.535 1196:D02.455.526.439.224 1331:C06.198.439 1332:Z01.107.084.900|ES| 7:1 9:1 19:1 75:1 115:1 455:1 691:1 836:1 1582:1 1717:1 2337:1 4107:1 4179:1 4180:1 5244:1
7 	|BT| (S (NP (DT The) (NN expression) (NN HEF1)) (VP (VP (VBD upregulated) (NP (NN Wnt-3a) (, ,) (NN beta-catenin) (, ,) (NN Dvl2) (JJ dose-dependent) (NN manner))) (, ,) (VP (VBD suppressed) (PP (VBG following) (NP (NN beta-catenin) (NN downregulation) (NN shRNA)))))) |ET| |BS|23:D12.776.091.249 85:G02.111.087.225 1273:D13.150.650.700|ES| 2:1 19:1 60:1 115:1 125:1 307:1 595:1 691:1 974:1 1668:1 2824:1 3510:1 5029:1 5245:1 5246:1
7 	|BT| (S (NP (DT The) (NN expression) (NN Tsc-22)) (ADVP (RB also)) (VP (VBD repressed) (SBAR (S (NP (NN B6C3F1) (NN mouse) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ several) (NN chemical) (JJ 2-year) (NN carcinogenicity) (NN study)) (NP (ADJP (RB well) (JJ spontaneous)) (NN liver) (NN tumor)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 515:C04.588.274.623|ES| 5:1 7:1 19:1 52:1 115:1 131:1 262:1 283:1 412:1 466:1 691:1 787:1 836:1 2124:1 3583:1 3986:1 4495:1 5180:1
7 	|BT| (S (NP (DT The) (NN inhibition) (NN NAG-1) (NN expression) (JJ small) (VBG interfering) (NN RNA)) (ADVP (RB significantly)) (VP (VBD blocked) (NP (NP (NP (JJ VES-induced) (NN poly)) (PRN (-LRB- -LRB-) (NP (NN ADP-ribose)) (-RRB- -RRB-))) (NN polymerase) (NN cleavage)) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN NAG-1)) (VP (MD may) (VP (VB play) (NP (NP (JJ important) (NN role)) (NP (JJ VES-induced) (NN apoptosis))))))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 39:G04.299.139.160 43:F01.145.544 79:I03.450.642.693 117:D13.150.650.700 470:C02.782.160.927 1248:D08.811.913.400.725.115.690 1440:G04.299.134.220.250|ES| 2:1 10:1 14:1 19:1 31:1 89:1 103:1 115:1 124:1 238:1 394:1 491:1 515:1 691:1 750:1 902:1 1009:1 1661:1 1662:1 2777:1 3019:1 4810:1 4811:1 5247:1
7 	|BT| (S (NP (DT The) (NN inhibition) (NN NF-kappaB) (NN activation)) (ADVP (RB thereby)) (VP (VBD led) (NP (NP (NN down-regulation) (NN gene) (NN product)) (VBN involved) (NP (NP (NN inflammation)) (PRN (-LRB- -LRB-) (NP (NN cyclooxygenase-2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D1) (NN c-myc)) (-RRB- -RRB-))) (, ,) (NP (NP (NN invasion)) (PRN (-LRB- -LRB-) (NP (NN matrix) (NN metalloproteinase-9)) (-RRB- -RRB-))) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (-RRB- -RRB-))) (, ,) (NP (NP (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NP (NN cIAP1)) (, ,) (NP (NN cIAP2)) (, ,) (NP (NP (JJ X-linked) (NN inhibitor) (NN apoptosis) (NN protein)) (, ,) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL))))) (-RRB- -RRB-)))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 43:F01.145.544 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 86:D01.268.556.435 108:G04.299.316 210:D12.776.260.600 215:D12.644.360.262.150.100 371:A07.231 525:C23.550.470 586:D08.811.277.656.300.480.205.360 1130:D12.644.276.390|ES| 2:1 4:1 9:1 10:1 14:1 19:1 61:1 89:1 94:1 102:1 103:1 158:1 185:1 225:1 257:1 274:1 299:1 380:1 455:1 620:1 675:1 691:1 714:1 743:1 744:1 774:1 1251:1 2157:1 2228:1 2502:1 3064:1 3092:1 3491:1 4814:1 4896:1 4980:1 5189:1 5248:1
7 	|BT| (S (S (NP (DT The) (JJ knockout) (NN animal)) (VP (VBD increased) (NP (NP (NN lipid) (NN peroxidation)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ CCl4-induced) (NN liver) (NN damage)) (, ,) (PP (ADVP (RB largely)) (JJ due) (NP (NP (VBN increased) (NN CYP2E1) (NN expression) (NN diallyl) (NN sulfide)) (, ,) (NP (NN inhibitor) (NN CYP2E1)) (, ,))))))) (VP (VBD prevented) (NP (JJ CCl4-induced) (NN liver) (NN injury)))) |ET| |BS|12:Z01.542.049 19:B01.050 242:A03.620 1218:D08.244.453.300 1247:G02.111.087.520|ES| 2:1 19:1 46:1 47:1 71:1 115:1 380:1 385:1 607:1 691:1 836:1 1848:1 1944:1 2401:1 2416:1 2520:1 2595:1 2851:1 4270:1 4384:1 4385:1 4386:1
7 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBP examine) (NP (NP (NN effect) (JJ EGCG-induced) (NN BTG2) (NN expression) (JJ potential) (NN signal) (NN pathway)) (VP (VBN involved))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 415:F01.658.500 761:G02.111.087.800|ES| 19:1 75:1 115:1 131:1 383:1 691:1 774:1 827:1 859:1 960:1 2916:1 4886:1 5249:1
7 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ explores) (SBAR (S (NP (NP (NN effect) (JJ p53-modulating) (NN agent) (NN CP-31398)) (ADVP (RB alone))) (VP (VBN combined) (NP (NP (NP (NN celecoxib) (JJ azoxymethane-induced) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NN colon) (NN adenocarcinoma) (NN F344) (NN rat))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 46:A03.556.124.526.356 84:C04.557.470.200.025 132:D02.172.080 590:B01.050.050.199.520.760.200 684:D02.065.884.247 824:C04.834.020|ES| 10:1 14:1 19:1 75:1 113:1 131:1 164:1 241:1 255:1 691:1 728:1 849:1 1307:1 1431:1 1725:1 2533:1 2807:1 2913:1 2914:1 3047:1 3185:1 5250:1 5251:1
7 	|BT| (S (NP (NP (DT The) (NN Ras) (NN inhibitor) (JJ farnesylthiosalicyclic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (VP (VBZ prevents) (NP (NN nodule) (NN formation) (NN development) (JJ preneoplastic) (NN focus) (JJ altered) (NNS hepatocytes) (NN rat)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 20:G03.495 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 1062:D01.029|ES| 10:1 14:1 19:1 35:1 43:1 380:1 691:1 693:1 849:1 894:1 1275:1 1431:1 1438:1 1775:1 2718:1 4551:1 4680:1 5252:1
7 	|BT| (NP (NP (DT The) (NN Ras) (NN inhibitor) (NN S-trans)) (, ,) (NP (NP (NP (JJ trans-farnesylthiosalicylic) (NN acid) (NNS chemosensitizes)) (NP (JJ human) (NN tumor) (NN cell))) (PP (IN without) (S (VP (VBG causing) (NP (NN resistance))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 7:1 19:1 36:1 94:1 380:1 691:1 1094:1 1195:1 1275:1 1491:1 1775:1 4549:1 5253:1 5254:1
7 	|BT| (NP (NP (NP (DT The) (NN rate) (NN proliferation) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN reduced) (JJ treated) (NN gamma-secretase) (NN inhibitor) (NN dibenzazepine)) (VP (VBP inhibit) (NP (NP (NN Notch) (NN signaling) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD directed) (NP (NN Notch))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 117:D13.150.650.700 122:C14.280.383 125:D08.811.277.656.300.032 212:E01.370.225.500.385.500 792:A11.251.210.190.475|ES| 18:1 19:1 36:1 41:1 94:1 113:1 195:1 256:1 299:1 380:1 452:1 515:1 691:1 750:1 1099:1 1370:1 1866:1 3017:1 3018:1 3019:1 3020:1
7 	|BT| (S (NP (DT The) (ADJP (RB recently) (VBN completed)) (NN o-nitrotoluene) (NN study)) (VP (VBD provided) (SBAR (S (NP (JJ first) (JJ cecal) (NN tumor) (NN response) (NN opportunity)) (VP (VB evaluate) (NP (NP (NN morphology) (JJ molecular) (NN profile) (NN oncogene) (NN tumor) (NN suppressor) (NN gene) (JJ relevant)) (ADJP (JJ human)))))))) |ET| |BS|9:G05.360.340.024.340.375.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 206:G05.360.340.024.340.375.249 225:E05.337 1441:C04.588.274.476.411.184|ES| 7:1 9:1 19:1 24:1 36:1 131:1 161:1 348:1 494:1 691:1 700:1 772:1 816:1 865:1 890:1 1155:1 1711:1 4417:1 5255:1 5256:1 5257:1
7 	|BT| (NP (NP (DT The) (NN role) (NN p53) (NN mutation) (JJ anti-tumour) (NN response) (JJ selective) (NN COX-2) (NN inhibitor) (NN celecoxib) (JJ human) (NN glioblastoma) (NN cell) (NN unknown))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 15:F01.829.316.616 18:G05.365.590 41:A11 55:B01.050.150.900.649.801.400.112.400.400 349:D27.505.519.389.310.500 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247|ES| 12:1 19:1 31:1 34:1 36:1 76:1 94:1 380:1 494:1 691:1 1749:1 2182:1 2186:1 2434:1 2807:1
7 	|BT| (S (NP (DT The) (JJ tobacco-specific) (NN carcinogen) (NN NNK)) (VP (VBZ induces) (NP (NN DNA) (NN methyltransferase) (CD 1) (NN accumulation) (NN tumor) (NN suppressor) (NN gene) (NN hypermethylation) (NN mouse) (NN lung) (NN cancer) (NN patient)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 50:M01.643 206:G05.360.340.024.340.375.249 279:D27.888.569.100 459:B01.650.940.800.575.100.905.900 460:B01.650.940.800.575.100.905.900 462:J01.637.836 746:D08.811.150.240|ES| 7:1 9:1 18:1 19:1 52:1 98:1 120:1 214:1 328:1 664:1 666:1 691:1 700:1 2120:1 2125:1 2655:1 5258:1 5259:1
7 	|BT| (S (NP (NP (DT The) (NN tumor) (NN suppressor) (NN protein) (NN phosphatase) (NN tensin) (NN homologue)) (VP (VBN deleted) (S (NP (NP (NN chromosome) (CD ten)) (PRN (-LRB- -LRB-) (NP (NN PTEN)) (-RRB- -RRB-)))))) (VP (VBP play) (NP (NP (JJ important) (NN role)) (JJ intestinal) (NN cell) (NN proliferation) (NN differentiation) (NN tumor) (NN suppression)) (S (VP (VBG antagonizing) (NP (NN phosphatidylinositol) (NN 3-kinase)))))) |ET| |BS|8:C04 12:Z01.542.049 15:F01.829.316.616 47:A03.556.124 74:G04.299.151 79:I03.450.642.693 173:C07.465.864.500 183:G04.299.233.750 289:A11.284.187 1035:D08.811.277.352.650 1377:D08.811.913.696.620.500.100 1442:D12.776.624.776|ES| 4:1 7:1 10:1 14:1 19:1 31:1 94:1 109:1 215:1 226:1 238:1 299:1 574:1 691:1 700:1 902:1 1001:1 1005:1 1936:1 2453:1 3394:1 3619:1 3620:1 4969:1 5260:1
7 	|BT| (S (ADVP (RB Therefore)) (, ,) (VP (VBD investigated) (SBAR (IN whether) (S (NP (JJ lipogenic) (NN gene) (NN expression) (NN tumor) (NN cell)) (ADVP (RB differently)) (VP (VBD regulated) (NP (JJ omega-6) (NN omega-3) (NNS PUFAs))))))) |ET| |BS|41:A11 142:I01.880.604 537:G05.360.340.024.340.375 1308:D10.212.302.380.410|ES| 2:1 7:1 9:1 19:1 94:1 115:1 221:1 403:1 1620:1 1664:1 5261:1 5262:1 5263:1 5264:1 5265:1
7 	|BT| (S (NP (NP (DT These) (NN animal)) (NP (VP (VP (VBN reduced)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (JJR <) (CD 0.05))) (-RRB- -RRB-))) (NP (JJ colonic) (NN RFC1) (NN mRNA)))) (VP (VBD exhibited) (NP (JJ 2-fold) (NN reduction) (NN plasma) (NN S-adenosylmethionine/S-adenosylhomocysteine)))) |ET| |BS|19:B01.050 46:A03.556.124.526.356 111:D13.444.735.544 175:J01.897.280.500.269 232:D02.886.030.676.180 657:A12.207.152.693|ES| 10:1 14:1 19:1 46:1 311:1 312:1 325:1 370:1 452:1 609:1 677:1 792:1 2400:1 3549:1 3849:1 5266:1 5267:1
7 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (S (NP (NN resveratrol)) (VP (VBP prevent) (NP (NP (NN formation) (NN growth) (JJ colorectal) (NN tumor)) (VP (VBG downregulating) (NP (NNP Kras) (NN expression))))))))) |ET| |BS|20:G03.495 45:G07.700.320.249 388:G05.360.340.024.340.375.500.791.550 1031:C04.588.274.476.411.307|ES| 7:1 17:1 19:1 43:1 102:1 115:1 733:1 792:1 793:1 1479:1 1712:1 2065:1 5142:1
7 	|BT| (S (NP (DT These)) (VP (VBP result) (SBAR (S (NP (VBN demonstrated) (NNS SK-Hep1-NIS)) (VP (MD could) (VP (ADVP (RB selectively)) (VBN killed) (NP (JJ induced) (NN 131I) (NN 188Re-perrhenate) (NN accumulation) (NN NIS) (NN gene) (NN expression)))))))) |ET| |BS|155:G05.355.310 1443:I01.198.240.470|ES| 9:1 19:1 101:1 115:1 412:1 792:1 908:1 1175:1 2120:1 3523:1 5268:1 5269:1 5270:1 5271:1 5272:1
7 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VB establish) (SBAR (S (NP (JJ mechanistic) (NN rationale) (NN Src) (NN inhibition) (NN dasatinib) (JJ therapeutic) (NN target) (NN treatment) (JJ pancreatic) (NN cancer)) (VP (VBP identify) (NP (JJ potential) (NNS biomarkers) (NN resistance) (NN Src) (NN inhibition)))))))) |ET| |BS|43:F01.145.544 52:E02 158:D23.101 1386:D02.886.675.184|ES| 18:1 19:1 101:1 103:1 160:1 220:1 467:1 541:1 546:1 792:1 827:1 832:1 1094:1 1269:1 1495:1 1890:1 3674:1 5017:1
7 	|BT| (S (NP (DT These)) (VP (VBP result) (SBAR (S (NP (VBP suggest) (NN alteration) (NN TSLC) (NN cascade)) (VP (MD might) (NP (NN role) (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NNP DEN) (NN rat))))))))) |ET| |BS|15:F01.829.316.616 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 19:1 31:1 101:1 350:1 792:1 796:1 798:1 849:1 900:1 951:1 1875:1 5273:1 5274:1
7 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN SGE)) (VP (VBZ suppresses) (NP (NN induction) (NN Cyp1a1)) (, ,) (S (VP (VBG leading) (SBAR (S (NP (NN inhibition) (NN ROS) (NN generation)) (ADVP (RB consequently)) (VP (VBD inhibited) (NP (NN hepatocarcinogenesis)) (, ,) (NP (ADVP (RB probably)) (NP (JJ due) (NN suppression) (NN Ahr) (NN activity)))))))))))))) |ET| |BS|43:F01.145.544 86:D01.268.556.435 122:C14.280.383 506:F01.829.263.315 1352:D08.244.453.040.332|ES| 2:1 19:1 101:1 103:1 365:1 399:1 639:1 686:1 736:1 792:1 796:1 900:1 1787:1 2356:1 2453:1 2851:1 4415:1 5160:1 5162:1 5275:1 5276:1
7 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBN suggested) (SBAR (S (NP (JJ gestational) (JJ arsenic) (NN exposure)) (VP (VBZ induces) (SBAR (S (NP (NP (JJ tumor-augmenting) (NN change)) (, ,) (PP (VBG including) (NP (NP (JJ oxidative) (NN stress) (NN L1) (NN activation)) (, ,) (NP (JJ late-onset) (NN manner)) (, ,)))) (VP (MD would) (VP (ADVP (RB particularly)) (VB promote) (NP (JJ tumorigenic) (NN expansion) (NN cell) (NN C61A) (NN Ha-ras) (NN mutation)))))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 41:A11 216:Z01.107.084.900.425 716:G03.495.710 1158:D01.268.513.249 1266:G08.686.785.760.769 1444:N05.715.350.075.100|ES| 2:1 19:1 34:1 94:1 101:1 200:1 214:1 225:1 561:1 679:1 747:1 792:1 866:1 925:1 1362:1 1668:1 1809:1 1953:1 2380:1 2522:1 2583:1 3473:1 3976:1 4106:1 5277:1 5278:1 5279:1
7 	|BT| (S (NP (DT This) (JJ toxicogenomic) (NN analysis)) (VP (VBD revealed) (NP (NP (JJ several) (JJ aberrant) (NN gene) (NN expression) (NN change)) (VP (VBN associated) (NP (JJ transplacental) (JJ arsenic) (NN carcinogenesis)))))) |ET| |BS|33:C04.697.098 155:G05.355.310 1158:D01.268.513.249|ES| 9:1 19:1 115:1 169:1 200:1 207:1 262:1 275:1 661:1 807:1 1725:1 4106:1 5280:1 5281:1
7 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (CD 1,25) (NN D) (NN VDR)) (VP (VBP regulate) (NP (NN c-MYC/MXD1) (NN network)) (VP (VBP suppress) (NP (NN c-MYC) (NN function)) (, ,) (S (VP (VBG providing) (NP (JJ molecular) (NN basis) (NN cancer) (JJ preventive) (NN action) (NN vitamin) (NN D))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 588:I01.880.853.500.600 720:D04.808.247.222.474 721:D04.808.812.768|ES| 2:1 18:1 19:1 33:1 161:1 625:1 858:1 1140:1 1691:1 1883:1 2013:1 2154:1 2441:1 2591:1 2592:1 3025:1 4529:1 5129:1 5282:1
7 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (JJ final) (NN death) (NN outcome) (JJ 5-FU-treated) (NN p53)) (: -) (: /) (: -) (NP (NP (NN cell) (VBD demonstrated) (ADJP (ADJP (JJ caspase-dependent)) (, ,) (ADJP (JJ due) (JJ slow))) (NN pace)) (, ,) (NP (NN accumulation) (JJ mitochondrial) (JJ reactive) (NN oxygen) (NN specie))) (VP (VBZ contributes) (NP (JJ necrotic) (NN characteristic)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 52:E02 134:G04.299.139 135:C23.550.260 560:D03.383.742.698.875.404 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 636:D01.339.431 1216:C23.550.717 1367:D08.811.277.656.262.500.126 1445:D08.811.277.656.300.760.353|ES| 2:1 19:1 94:1 336:1 411:1 547:1 845:1 1175:1 1505:1 1691:1 2004:1 2120:1 2353:1 2354:1 2355:1 2851:1 5283:1 5284:1 5285:1 5286:1 5287:1 5288:1
7 	|BT| (NP (NP (NP (NP (NNP Thymidylate) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN TS)) (-RRB- -RRB-))) (NP (NP (NP (NN overexpression) (JJ key) (NN determinant) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NN resistance) (JJ human) (NN cancer) (NN cell))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862|ES| 10:1 14:1 18:1 19:1 36:1 66:1 94:1 152:1 159:1 509:1 1094:1 2307:1 2308:1 3081:1 4359:1
7 	|BT| (S (S (VP (TO To) (VP (VB examine) (NP (NP (JJ possible) (JJ direct) (JJ transcriptional) (NN regulation)) (NP (NN rat) (NN Bcl-2) (NN beta-catenin/Tcf)))))) (, ,) (VP (VBN cloned) (VP (VBN characterized) (SBAR (S (NP (JJ corresponding) (NN promoter) (NN region)) (VP (VBD found) (NP (NP (ADJP (CD 70.1) (NN %)) (NN similarity) (JJ human) (NN counterpart)) (, ,) (NP (NN BCL2))))))))) |ET| |BS|23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 196:G02.111.570.080.689.675 209:G02.111.087.847 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 301:A11.251.353|ES| 2:1 19:1 36:1 37:1 83:1 158:1 369:1 438:1 559:1 667:1 828:1 849:1 960:1 985:1 1048:1 1359:1 1891:1 3526:1 4231:1 4999:1 5289:1 5290:1 5291:1
7 	|BT| (S (VP (ADVP (RB Together)) (, ,) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NN silibinin)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN SW480) (NN tumor)) (VP (VBG carrying) (NP (JJ mutant) (NN APC) (NN gene) (NN down-regulating) (NN CDK8) (NN beta-catenin) (NN signaling)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (NP (JJ effective) (NN agent) (NN CRC))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 247:G01.374.676.530 351:A17.360|ES| 2:1 7:1 9:1 11:1 19:1 60:1 102:1 195:1 218:1 245:1 615:1 728:1 796:1 811:1 850:1 908:1 927:1 1639:1 2635:1 3095:1 3096:1 3097:1 3098:1
7 	|BT| (S (NP (NN TOPflash) (NN luciferase) (NN reporter) (NN assay)) (VP (VBD showed) (S (NP (NP (JJ transcriptional) (NN activity) (NN T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TCF)) (-RRB- -RRB-))) (ADJP (: /) (SBAR (S (NP (JJ lymphoid) (NN enhancer) (NN factor) (-LRB- -LRB-) (NN LEF) (-RRB- -RRB-)) (VP (VBD reduced) (SBAR (S (NP (NP (NN NDRG2) (NN introduction)) (, ,) (NP (NN introduction) (JJ mutant) (NN NDRG2))) (VP (VBD generated) (NP (NN deletion) (JJ site-directed) (NN mutagenesis)))))))))))) |ET| |BS|106:E05.091 209:G02.111.087.847 306:G05.355.600.800 1375:D08.811.682.517 1446:A11.118.637.555.567 1447:E05.393.420.601.575|ES| 2:1 10:1 14:1 19:1 73:1 132:1 185:1 288:1 310:1 399:1 452:1 559:1 811:1 972:1 1059:1 4864:1 4952:1 4963:1 5210:1 5292:1 5293:1 5294:1 5295:1 5296:1 5297:1
7 	|BT| (S (NP (NN Toxaphene)) (VP (VBD induced) (NP (NP (JJ significant) (NP (NP (NN increase) (NN expression) (JJ constitutive) (NN androstane) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN CAR)) (-RRB- -RRB-))) (NN target) (NN gene)) (PRN (-LRB- -LRB-) (NP (NP (NN Cyp2b10)) (, ,) (NP (NN Cyp3a11))) (-RRB- -RRB-))) (NP (QP (CD 32) (CD 320)) (NN ppm) (NN toxaphene)))) |ET| |BS|6:G05.360.340.024.340 1149:D02.455.526.439.913|ES| 2:1 9:1 10:1 14:1 19:1 40:1 115:1 135:1 160:1 186:1 412:1 421:1 604:1 605:1 2546:1 3233:1 3985:1 4164:1 4299:1 5298:1 5299:1
7 	|BT| (S (NP (NN Treatment) (NN HepG2) (NN cell) (NN APAP)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NN expression) (NN DAX-1) (JJ concentration-dependent) (NN manner)))) |ET| |BS|52:E02 661:D02.065.199.092.040 905:F02.830.104.214 1015:A11.251.860.180.432|ES| 19:1 94:1 115:1 124:1 452:1 1668:1 3106:1 3481:1 4193:1 4537:1 5300:1
7 	|BT| (NP (NP (NN Treatment) (NP (NP (NN rat) (NN DHEA) (NN influence) (NN expression) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN P450)) (-RRB- -RRB-))) (NN gene)) (, ,) (FRAG (VBG including) (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (-LRB- -LRB-) (NP (NP (NP (NP (NN PPAR) (NN alpha) (-RRB- -RRB-)) (: -) (NP (NP (NN pregnane) (NN X) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PXR)) (-RRB- -RRB-)))) (: -) (NP (VBN mediated) (NN induction) (NNS CYP4As) (NN CYP3A23)) (, ,) (NP (NN suppression) (NN CYP2C11)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 536:D12.776.826.239.500 740:D04.808.054.079.429.625 1079:D08.244.453 1448:D08.244.453.450|ES| 2:1 9:1 10:1 14:1 19:1 115:1 186:1 561:1 736:1 849:1 867:1 929:1 1801:1 1836:1 1887:1 2453:1 2549:1 2633:1 2691:1 3106:1 3227:1 3788:1 4048:1 4899:1 5301:1 5302:1 5303:1 5304:1
7 	|BT| (S (NP (NN Treatment) (NN cell) (NN oxazepam) (CD 48) (NN h)) (ADVP (RB also)) (VP (VBD resulted) (SBAR (S (NP (VBN decreased) (NN Tsc-22)) (VP (VBD increased) (NP (NN Gadd45b) (NN expression))))))) |ET| |BS|41:A11 52:E02 179:D01.248.497.300.459.700 1329:D03.438.079.080.070.663|ES| 5:1 19:1 47:1 94:1 115:1 202:1 594:1 3106:1 4741:1 4855:1 5180:1 5305:1 5306:1
7 	|BT| (S (NP (NN Treatment) (NN 5-AzaC)) (ADVP (RB concomitantly)) (NP (VBN upregulated) (NN expression) (NN miR-9-3) (NN miR-193a)) (, ,) (VP (VBD downregulated) (NP (JJ respective) (NN target) (NN gene) (NN NF-kappaB) (NN Mcl-1)))) |ET| |BS|6:G05.360.340.024.340 52:E02 210:D12.776.260.600|ES| 2:1 9:1 19:1 115:1 125:1 160:1 426:1 714:1 3106:1 5307:1 5308:1 5309:1 5310:1 5311:1 5312:1
7 	|BT| (S (NP (NN Troglitazone)) (VP (VBZ induces) (NP (JJ p27Kip1-associated) (NP (JJ cell-cycle) (NN arrest) (JJ down-regulating) (NN Skp2) (JJ human) (NN hepatoma) (NN cell))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 338:D12.644.360.225.600 351:A17.360 507:D12.776.157.743 515:C04.588.274.623 773:G04.299.134.109|ES| 19:1 36:1 94:1 214:1 602:1 1785:1 3097:1 3116:1 3896:1 5313:1 5314:1
7 	|BT| (S (NP (NN Troglitazone)) (ADVP (RB potently)) (VP (VBD inhibited) (SBAR (S (NP (NN proteasome) (NN activity)) (VP (VBD decreased) (NP (NN Skp2) (NN protein) (NN level))))))) |ET| |BS|122:C14.280.383 507:D12.776.157.743 1281:D05.500.562.500|ES| 4:1 19:1 202:1 249:1 365:1 399:1 1785:1 3116:1 3128:1 4559:1
7 	|BT| (S (NP (NN TS)) (ADVP (RB also)) (VP (ADVP (RB acutely)) (VBN up-regulated) (NP (NP (NN 5-FU) (NN treatment)) (, ,) (, ,) (ADVP (RB thus)) (, ,) (NP (NP (JJ novel) (NN strategy)) (VP (VBG targeting) (NP (NN TS) (NN down-regulation))))) (VP (VBP seem) (NP (JJ promising) (NN term) (VBG modulating) (NN 5-FU) (NN resistance))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 85:G02.111.087.225 142:I01.880.604 150:Z01.542.248.960 154:Z01.058.266.887 259:D12.776.395.240.150.500 560:D03.383.742.698.875.404 849:G08.686.785.760.769.490.500|ES| 2:1 5:1 19:1 257:1 509:1 546:1 616:1 891:1 995:1 1094:1 1114:1 1301:1 1334:1 1517:1 2308:1 2435:1 5315:1 5316:1
7 	|BT| (NP (NP (NP (NN Upregulation) (NN B-cell) (NN translocation) (NN gene) (CD 2) (JJ epigallocatechin-3-gallate)) (PP (IN via) (NP (NN p38) (NN ERK) (NN signaling) (NN block) (NN cell) (NN proliferation) (JJ human) (JJ oral) (JJ squamous) (NN cell) (NN carcinoma) (NN cell))))) |ET| |BS|6:G05.360.340.024.340 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 122:C14.280.383 183:G04.299.233.750 249:G05.355.315.800 310:A11.063.438 339:G02.111.087.880 463:C23.550.210.870 929:C04.557.470.200.400|ES| 9:1 19:1 36:1 94:1 148:1 195:1 299:1 304:1 596:1 742:1 1067:1 1618:1 1666:1 2199:1 2629:1 5047:1 5317:1 5318:1
7 	|BT| (S (NP (JJ Ursodeoxycholic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN Ras) (NN mutation)) (, ,) (NP (NP (JJ wild-type) (NN Ras)) (NN activation)) (, ,) (NP (NN cyclooxygenase-2) (NN expression) (NN colon) (NN cancer))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 24:D08.811.600.720.750 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 8:1 18:1 19:1 34:1 61:1 113:1 115:1 225:1 615:1 1275:1 1775:1 3121:1
7 	|BT| (S (S (VP (VBG Using) (NP (NN xenograft) (ADJP (NN tumor) (NN model) (JJ severe)) (JJ combined) (JJ immune) (NN deficiency) (NN mouse)))) (, ,) (VP (MD could) (VP (VB show) (SBAR (S (NP (NP (JJ experimental) (JJ systemic) (NN hypergastrinemia)) (VP (VBD induced) (NP (NN administration) (NN omeprazole)))) (VP (VBD led) (NP (VBN enhanced) (NN apoptosis)) (ADVP (RB well)) (NP (NP (JJ marked) (NN increase) (NN IEX-1) (NN expression) (NN Colo320wt) (NN tumor)) (, ,) (NP (NN Colo320mut) (NN tumor))))))))) |ET| |BS|8:C04 39:G04.299.139.160 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 984:D02.886.640.074.500 1449:B01.050.150.900.649.865.635.505.500.550.780|ES| 2:1 7:1 19:1 40:1 52:1 72:1 89:1 115:1 164:1 253:1 263:1 265:1 385:1 412:1 429:1 760:1 787:1 908:1 1719:1 2228:1 2575:1 2802:1 3169:1 3467:1 4693:1 5037:1 5044:1 5319:1 5320:1
7 	|BT| (S (S (VP (VBG Using) (NP (JJ several) (JJ experimental) (NN approach)))) (, ,) (VP (VBP conclude) (SBAR (S (NP (JJ RNA-rather) (JJ DNA-related) (NN stress)) (VP (VBZ follows) (NP (NP (NN caspase) (NN activation)) (RRC (ADVP (RB irrespectively)) (NP (NN p53) (NN status))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 198:D13.444.308 557:D02.241.081.069.600.150 1367:D08.811.277.656.262.500.126 1422:D13.444.735|ES| 2:1 12:1 19:1 225:1 262:1 263:1 416:1 911:1 1719:1 1968:1 2522:1 4796:1 5321:1 5322:1 5323:1 5324:1
7 	|BT| (S (NP (NN UV) (NN exposure)) (VP (VBP result) (NP (NP (NP (JJ ligand-independent) (NN activation) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (JJ subsequent) (NN activation)) (JJ mitogen-activated) (NN protein) (NN kinase) (NN phosphatidylinositol) (NN 3-kinase/Akt) (NN pathway)) (VP (VBG leading) (NP (JJ transcriptional) (NN activation) (NN COX-2) (NN gene)))))) |ET| |BS|6:G05.360.340.024.340 64:D08.811.913.696.620.682.725.400.009.300 86:D01.268.556.435 170:D27.720.470.480 209:G02.111.087.847 249:G05.355.315.800 264:G05.355.315.800 378:D08.811.913.696.620.682.700.755 478:D08.811.913.696.620.682.700.567 1377:D08.811.913.696.620.500.100 1450:G01.358.500.505.650.891 1451:Z01.058.290.190.245|ES| 4:1 9:1 19:1 76:1 101:1 102:1 184:1 185:1 186:1 225:1 383:1 470:1 559:1 639:1 1319:1 1953:1 2081:1 3295:1 4969:1 5325:1 5326:1
7 	|BT| (S (NP (NN Vitamin) (NN D)) (VP (VBZ Enhances) (NP (NNP Efficacy) (NNP Irinotecan) (JJ miR-627-Mediated) (NN Inhibition) (NNP Intratumoral) (NNP Drug) (NNP Metabolism)))) |ET| |BS|43:F01.145.544 67:D26 720:D04.808.247.222.474 721:D04.808.812.768 898:G03.495|ES| 19:1 2345:1 2592:1 2703:1 3665:1 4953:1 5327:1 5328:1 5329:1 5330:1 5331:1
7 	|BT| (S (NP (NN Vitamin) (NN D) (NN signaling)) (VP (VBP suppress) (NP (NP (NN expression) (NN gene) (VBN regulated) (NN c-MYC)) (, ,) (NP (NP (NP (NN transcription) (NN factor) (NN control)) (JJ epidermal) (NN differentiation) (NN cell) (NN proliferation)) (SBAR (WHNP (WP$ whose) (NN activity)) (S (VP (ADVP (RB frequently)) (JJ elevated) (NP (NN cancer))))))))) |ET| |BS|69:G02.111.087.800 74:G04.299.151 142:I01.880.604 155:G05.355.310 166:D12.776.930 183:G04.299.233.750 720:D04.808.247.222.474 721:D04.808.812.768 1095:A10.272.497|ES| 2:1 9:1 18:1 19:1 94:1 115:1 184:1 185:1 195:1 215:1 289:1 299:1 399:1 487:1 625:1 698:1 756:1 919:1 1664:1 2441:1 2592:1 3665:1
7 	|BT| (S (NP (NN Vitamin) (NN E) (NN succinate)) (VP (VBZ induces) (NP (NN NAG-1) (NN expression) (NN p38) (JJ kinase-dependent) (NN mechanism)))) |ET| |BS|469:D08.811.913.696 1452:D03.383.663.283.909.750.249|ES| 19:1 115:1 162:1 214:1 1662:1 1666:1 1667:1 2085:1 3665:1 5332:1
7 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD observed) (SBAR (S (NP (NN flavokawain) (NN B)) (VP (VBD caused) (NP (NP (NP (NN G2/M) (NN phase) (NN arrest) (JJ mediated) (NN reduction) (NN level) (NN cyclin) (NN A)) (, ,) (NP (NN cyclin) (NN B1))) (, ,) (NP (NN Cdc2) (NN Cdc25C) (NN increase) (NN p21/WAF1)) (, ,) (NP (NN Wee1) (NN p53) (NN level)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 122:C14.280.383 979:D12.644.360.262.120.100 1431:D12.644.360.262.100 1453:G04.299.134.500.340|ES| 2:1 5:1 12:1 19:1 40:1 69:1 249:1 261:1 370:1 437:1 602:1 743:1 763:1 843:1 2506:1 2528:1 2529:1 3455:1 5333:1 5334:1 5335:1 5336:1 5337:1
7 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD demonstrated) (S (NP (NP (NN FOXM1)) (PRN (-LRB- -LRB-) (NP (NN 1B) (NN 1C) (NNS isoforms)) (-RRB- -RRB-))) (ADVP (RB directly)) (VP (VBP bind) (ADVP (RB transcriptionally)) (VP (VBZ regulates) (NP (NP (NP (NN eEF2K) (NN gene) (NN expression) (NN chromatin) (NN immunoprecipitation)) (PRN (-LRB- -LRB-) (NP (NN ChIP)) (-RRB- -RRB-))) (NN luciferase) (NN gene) (NN reporter) (NN assay))))))) |ET| |BS|6:G05.360.340.024.340 106:E05.091 155:G05.355.310 238:D12.776.800 1375:D08.811.682.517 1454:E05.393.170|ES| 5:1 9:1 10:1 14:1 19:1 115:1 288:1 310:1 603:1 621:1 821:1 843:1 1175:1 1346:1 1854:1 4857:1 4963:1 5100:1 5338:1 5339:1 5340:1 5341:1 5342:1
7 	|BT| (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (SBAR (S (NP (NN pectolinarigenin)) (ADVP (RB significantly)) (VP (VBD suppressed) (NP (NN osteosarcoma) (NN cell) (NN proliferation))))))) (, ,) (VP (VBD induced) (NP (NP (NP (NP (NP (NN apoptosis)) (VP (VBN reduced) (NP (NN level) (NN STAT3) (JJ downstream) (NN protein) (NN cyclin) (NN D1)))) (, ,) (NP (NN Survivin)) (, ,)) (NP (NP (NN B-cell) (NN lymphoma) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Bcl-2)) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (NN B-cell) (NN lymphoma) (NN extra-large)) (PRN (-LRB- -LRB-) (NP (NN Bcl-xl)) (-RRB- -RRB-))) (NP (NP (JJ myeloid) (NN cell) (NN leukemia) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Mcl-1)) (-RRB- -RRB-))))))) |ET| |BS|39:G04.299.139.160 41:A11 82:D12.644.360.024.342.300 183:G04.299.233.750 215:D12.644.360.262.150.100 361:C04.557.337 447:C04.557.450.565.575.650 1424:C04.557.386.480.150 1455:A11.148.378.590 1456:C04.557.337.539 1457:A11.627|ES| 2:1 4:1 5:1 10:1 14:1 19:1 37:1 89:1 94:1 98:1 124:1 148:1 158:1 249:1 251:1 299:1 307:1 412:1 452:1 560:1 591:1 743:1 744:1 843:1 1562:1 2199:1 2785:1 3779:1 5187:1 5312:1 5343:1 5344:1 5345:1
7 	|BT| (FRAG (NP (PRP We)) (VBD characterized) (SBAR (S (NP (NP (NN effect) (JJ gefitinib) (NN EGFR)) (, ,) (NP (NN HER2)) (, ,) (NP (NN ErbB-3) (NN phosphorylation) (NN Western) (NN blot))) (VP (VBD determined) (NP (NN effect) (JJ downstream) (NN signaling) (NN growth))))) (, ,) (NP (NP (NN survival)) (, ,) (NP (NN stress) (NN pathway) (NN effect) (NN proliferation)) (, ,) (NP (NN cell) (NN cycle)) (, ,) (NP (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 45:G07.700.320.249 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 96:I03.784 255:E05.196.401.143 256:E05.196.401.143 353:G04.299.134 972:G02.111.087.677 1350:G05.360.340.024.340.375.500.791.295|ES| 2:1 19:1 75:1 89:1 94:1 102:1 187:1 188:1 195:1 274:1 299:1 383:1 560:1 601:1 843:1 872:1 873:1 985:1 1582:1 2522:1 3310:1 3426:1 4818:1
7 	|BT| (S (NP (PRP We)) (VP (VBD found) (NP (NP (NP (CD 7) (RB differentially) (VBN expressed) (NN gene)) (, ,) (NP (NN cyclin) (NN D1))) (, ,) (NP (NP (NN cyclin) (NN E)) (, ,) (NP (NN c-myc)) (, ,) (NP (NN Fosl1)) (, ,) (NP (NN c-fos)) (, ,) (NP (NN Cd44) (NN follistatin)) (, ,) (NP (NP (VBN known) (NN target) (NN beta-catenin)) (CC and/or) (NP (NN ra))) (NP (NN pathway)))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 6:G05.360.340.024.340 23:D12.776.091.249 165:G05.360.340.024.340.375.500.791.330 215:D12.644.360.262.150.100 1366:D12.776.260.108.765 1458:D12.644.360.262.180 1459:D12.776.157.247|ES| 2:1 6:1 9:1 19:1 37:1 60:1 149:1 160:1 383:1 455:1 556:1 562:1 743:1 744:1 843:1 988:1 1115:1 1139:1 2085:1 5346:1 5347:1 5348:1
7 	|BT| (S (NP (PRP We)) (VP (VBD found) (NP (NP (NN Tsc-22) (NN downregulation) (NN liver) (NN B6C3F1) (NN mouse)) (PP (VBG following) (NP (NP (NN treatment) (CD 2) (NN week)) (NP (NP (NP (JJ carcinogenic) (NNS dos) (JJ antianxiety) (NN drug) (NN oxazepam)) (PRN (-LRB- -LRB-) (NP (CD 2500) (NN ppm)) (-RRB- -RRB-))) (NP (NP (NP (NN peroxisome) (NN proliferator) (NN Wyeth-14,643)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN ppm)) (-RRB- -RRB-))) (NP (NP (CD two) (NN carcinogen) (NN o-nitrotoluene) (NN methyleugenol) (CD three) (NNS noncarcinogens)) (PP (VBG including) (NP (NP (NN p-nitrotoluene)) (, ,) (NP (NN eugenol)) (, ,) (NP (NN acetaminophen)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 85:G02.111.087.225 242:A03.620 279:D27.888.569.100 661:D02.065.199.092.040 912:D27.888.569.100.675 1165:D02.241.223.200.054.500 1329:D03.438.079.080.070.663 1460:D27.505.696.277.950.015|ES| 2:1 10:1 14:1 19:1 37:1 52:1 148:1 191:1 482:1 546:1 561:1 595:1 783:1 836:1 843:1 933:1 1887:1 1888:1 2125:1 2412:1 2653:1 3233:1 3346:1 3510:1 3986:1 4023:1 4293:1 4417:1 4741:1 5180:1 5349:1 5350:1 5351:1 5352:1 5353:1 5354:1
7 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NN TCE)) (VP (VBD decreased) (SBAR (S (NP (NN methylation) (NN c-jun) (NN c-myc) (NN gene)) (VP (VBD increased) (NP (NN level) (NNS mRNAs)))))))))) |ET| |BS|36:G02.111.087.029.538 111:D13.444.735.544 186:G05.360.340.024.340.375.500.791.420|ES| 9:1 19:1 47:1 81:1 202:1 249:1 447:1 455:1 843:1 993:1 1527:1 5355:1 5356:1
7 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (S (NP (JJ novel) (NN class) (NN oligoamine) (NN analogue)) (VP (MD would) (VP (ADVP (RB effectively)) (VB inhibit) (NP (NN LSD1)) (RB thus) (VP (VBP cause) (S (NP (NN reexpression)) (VP (ADVP (RB aberrantly)) (NP (VBN silenced) (NN gene))))))))))) |ET| |BS|6:G05.360.340.024.340 122:C14.280.383 259:D12.776.395.240.150.500|ES| 9:1 19:1 843:1 866:1 891:1 1334:1 1370:1 1380:1 1750:1 1779:1 2656:1 2657:1 2658:1 2814:1 2977:1 5062:1 5357:1
7 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NN function) (NN vitamin) (JJ D-regulated) (NN miR-627) (JJ intratumoral) (NN CYP3A4) (NN suppression) (NN role)) (VP (VBG enhancing) (NP (NN efficacy) (NN chemotherapy)))))) |ET| |BS|15:F01.829.316.616 142:I01.880.604 151:E02.319 720:D04.808.247.222.474 721:D04.808.812.768 1348:D08.244.453.400|ES| 19:1 31:1 33:1 403:1 495:1 843:1 2304:1 2453:1 2527:1 2591:1 4804:1 4805:1 5358:1 5359:1
7 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (JJ anti-glioblastoma) (NN response) (NN celecoxib)) (JJ p53-dependent) (, ,) (SBAR (IN whether) (FRAG (NP (NP (ADJP (NN celecoxib) (VBD induced)) (NN DNA) (NN damage)) (VP (VBG leading) (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest)))))) (, ,) (VP (VBD followed) (NP (JJ autophagy) (NN apoptosis))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 86:D01.268.556.435 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 88:1 89:1 94:1 221:1 403:1 412:1 494:1 601:1 602:1 639:1 666:1 670:1 843:1 1317:1 1848:1 2807:1 3130:1 5360:1
7 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (NP (ADJP (NP (NN induction) (NN G)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (: -)) (NN S-phase) (NN arrest) (JJ caspase-mediated) (NN apoptosis)) (NP (JJ androgen-dependent) (NP (JJ human) (NN LNCaP) (NN cell)))) (, ,) (S (VP (VBP express) (NP (JJ wild-type) (NN p53))) (, ,) (NP (JJ androgen-independent) (, ,) (NP (JJ p53-mutant) (NN DU145) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 892:D27.505.696.399.472.161 1367:D08.811.277.656.262.500.126|ES| 2:1 8:1 10:1 12:1 14:1 19:1 36:1 89:1 94:1 98:1 208:1 261:1 602:1 736:1 843:1 2691:1 3423:1 3520:1 4880:1 4904:1 4905:1 4925:1 5099:1 5361:1
7 	|BT| (S (NP (PRP We)) (VP (VBP provide) (NP (NN evidence) (NN HDACi) (NN treatment) (NN lead) (JJ potent) (JJ transcriptional) (NN repression) (NN TS) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 52:E02 86:D01.268.556.435 154:Z01.058.266.887 208:F01.393.821 209:G02.111.087.847|ES| 9:1 19:1 22:1 38:1 254:1 505:1 509:1 546:1 559:1 706:1 711:1 843:1
7 	|BT| (S (NP (PRP We)) (VP (VBP show) (ADVP (RB herein)) (NP (NN induction) (NP (NP (NN tumor) (NN suppressor) (NN gene) (JJ COOH-terminal) (NN Src) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN Csk)) (-RRB- -RRB-))) (NN NSAID) (JJ important) (JJ antiproliferative) (RB hence) (JJ chemopreventive) (NN effect)))) |ET| |BS|206:G05.360.340.024.340.375.249 469:D08.811.913.696 487:G05.355.315.800 624:D27.505.696.706.018 796:D27.505.696.663.850.014.040.500|ES| 7:1 9:1 10:1 14:1 19:1 75:1 429:1 470:1 700:1 736:1 843:1 902:1 1736:1 1946:1 3120:1 3674:1 4230:1 4499:1 5362:1 5363:1
7 	|BT| (S (NP (PRP We)) (VP (VBP show) (SBAR (S (NP (JJ individual) (JJ homozygous) (JJ minor) (NN ODC) (NN A-allele)) (VP (VBD reported) (S (VP (VBG using) (NP (NN aspirin)) (NP (NP (QP (RB approximately) (CD 0.10)) (NN time)) (NP (NP (JJ likely) (NN adenoma) (NN recurrence) (JJ non-aspirin) (NN user)) (NP (JJ homozygous) (JJ major) (NN G-allele))))))))))) |ET| |BS|12:Z01.542.049 17:C04.557.470.035 30:Z01.058.290.190.800 31:D08.811.520.224.800 77:G05.360.340.024.340.030 322:G01.910 493:M01 496:C23.550.291.937 670:D02.455.426.559.389.657.410.595.176 1108:M01.416 1283:G05.380.554 1461:E05.318.740.600|ES| 19:1 42:1 350:1 429:1 462:1 843:1 993:1 1081:1 1328:1 1843:1 2487:1 2512:1 2697:1 3881:1 4564:1 5364:1 5365:1 5366:1 5367:1 5368:1 5369:1
7 	|BT| (S (NP (PRP We)) (VP (VBD showed) (SBAR (S (ADJP (RB previously) (JJ S-trans)) (, ,) (NP (NP (JJ trans-farnesylthiosalicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (VP (VBZ disrupts) (SBAR (S (NP (NN Ras) (NN membrane) (NN anchorage) (NN disturbance)) (VP (VBZ contributes) (NP (NN inhibition) (NN cell) (NN transformation) (NN tumor) (NN growth)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 45:G07.700.320.249 1344:A10.615|ES| 2:1 7:1 10:1 14:1 19:1 94:1 102:1 103:1 132:1 843:1 845:1 1275:1 1384:1 1527:1 1775:1 3622:1 4549:1 4551:1 5253:1 5370:1 5371:1 5372:1
7 	|BT| (NP (NP (NP (NN YGK)) (NP (ADVP (RB significantly)) (VBD repressed) (NP (NN E6/E7) (NN oncogene) (JJ transcriptional) (NN level)) (, ,) (NP (NP (JJ subsequent) (NN reactivation) (NN p53) (NN p21) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 9:G05.360.340.024.340.375.500 208:F01.393.821 209:G02.111.087.847|ES| 2:1 10:1 12:1 14:1 19:1 24:1 115:1 124:1 249:1 311:1 312:1 315:1 466:1 559:1 1135:1 1319:1 1913:1 5373:1 5374:1
8 	|BT| (S (NP (JJ Other) (NN expression) (NN alteration)) (VP (VBN observed) (S (NP (JJ arsenic-treated) (JJ male) (NN mouse) (JJ newborn) (NN liver)) (VP (VBD included) (SBAR (S (NP (NP (NN overexpression) (NNS cdk-inhibitors) (NN stress) (NN response) (NN gene)) (PP (VBG including) (NP (VBN increased) (NN expression) (NN metallothionein-1)))) (VP (VBD decreased) (NP (NN expression) (NN betaine-homocysteine) (NN methyltransferase) (NN thioether) (NN S-methyltransferase))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 52:E02 242:A03.620 978:D08.811.913.696.620.682.700.646.500 1158:D01.268.513.249 1462:D08.811.913.555.500.175 1463:D08.811.913.555.500 1464:D01.248.497.158.874 1465:M01.060.703.520 1466:D12.776.556.670|ES| 9:1 19:1 47:1 52:1 115:1 152:1 202:1 261:1 494:1 561:1 836:1 951:1 1402:1 1528:1 2522:1 2655:1 5375:1 5376:1 5377:1 5378:1 5379:1 5380:1 5381:1 5382:1
8 	|BT| (S (NP (DT A) (JJ recent) (NN study)) (VP (VBD revealed) (SBAR (S (NP (NP (JJ long-term) (NN exposure)) (ADJP (RB relatively) (JJ low-dose)) (NN DEHP) (PRN (-LRB- -LRB-) (NP (CD 0.05) (NN %)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (NN liver) (NN tumor)) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (JJ hepatocellular) (NN adenoma)) (, ,) (NP (NP (NP (NP (ADJP (NP (JJ chologiocellular) (NN carcinoma)) (JJR higher)) (NN incidence) (NN Ppar) (JJ alpha-null) (NN mouse)) (PRN (-LRB- -LRB-) (NP (CD 25.8) (NN %)) (-RRB- -RRB-))) (NP (JJ wild-type) (NN mouse))) (PRN (-LRB- -LRB-) (NP (CD 10.0) (NN %)) (-RRB- -RRB-))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 104:C04.557.470.200.025.255 265:C04.557.470.200 434:E05.318.308.985.525.375 515:C04.588.274.623 536:D12.776.826.239.500 849:G08.686.785.760.769.490.500 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 2:1 7:1 8:1 10:1 14:1 19:1 42:1 52:1 69:1 131:1 170:1 275:1 303:1 304:1 369:1 561:1 659:1 836:1 1511:1 1953:1 2506:1 3049:1 3205:1 3546:1 3849:1 3924:1 5383:1 5384:1 5385:1 5386:1 5387:1
8 	|BT| (S (NP (NP (NN Activation) (JJ nonsteroidal) (JJ anti-inflammatory) (JJ drug-activated) (NN gene-1)) (PP (IN via) (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (CD 1/2) (JJ mitogen-activated) (NN protein) (NN kinase)))) (VP (VBD revealed) (NP (JJ isochaihulactone-triggered) (JJ apoptotic) (NN pathway) (NP (JJ human) (NN lung) (NN cancer) (NN A549) (NN cell))))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 264:G05.355.315.800 469:D08.811.913.696 477:D08.811.913.696.620.682.700.567.249 573:N05.715.350.200.650 796:D27.505.696.663.850.014.040.500|ES| 4:1 18:1 19:1 36:1 87:1 94:1 275:1 328:1 364:1 383:1 470:1 596:1 1707:1 1859:1 2223:1 2795:1 3046:1 3295:1 4812:1 4966:1 4978:1 5388:1
8 	|BT| (S (S (S (ADVP (RB Additionally)) (, ,) (NP (NN co-treatment) (NN RV) (NN erlotinib)) (VP (VBD repressed) (NP (NP (NN expression) (JJ anti-apoptosis) (NN protein)) (, ,) (NP (NN survivin) (NN Mcl-1)))) (, ,)) (IN whereas) (NP (VBN promoted) (NN p53) (NN PUMA) (NN expression) (NN caspase) (CD 3) (NN activity)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 906:D08.811.277.656.262.500.126.350.300 1042:Z01.107.757.284 1467:B01.050.150.900.649.147.354.630 1468:E01.370.386.700.485.750.275.650 1469:D12.644.360.075|ES| 2:1 4:1 12:1 19:1 115:1 372:1 399:1 466:1 862:1 1912:1 2229:1 2342:1 4068:1 4796:1 5312:1 5389:1 5390:1 5391:1 5392:1
8 	|BT| (NP (NP (JJ Altered) (NN expression) (NN c-myc)) (, ,) (NP (NN p16) (NN p27) (NN rat) (NN colon) (NN tumor) (NN reversal) (JJ short-term) (NN treatment) (JJ chemopreventive) (NN agent))) |ET| |BS|51:C04.588.274.476.411.307.180 52:E02 203:G05.360.340.024.340.375.249.375 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 833:D27.505.696.706.018 849:G08.686.785.760.769.490.500|ES| 2:1 7:1 19:1 113:1 115:1 455:1 546:1 728:1 849:1 971:1 1124:1 1313:1 1946:1 3022:1 3770:1
8 	|BT| (S (NP (NNP Assessment) (NN effect) (NN betaine) (NN p16) (NN c-myc) (NN DNA) (NN methylation) (NN mRNA) (NN expression) (NN chemical)) (VP (VBD induced) (NP (NN rat) (NN liver) (NN cancer) (NN model)))) |ET| |BS|111:D13.444.735.544 203:G05.360.340.024.340.375.249.375 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 366:G02.111.087.029.538.161 743:D02.092.877.883.077 838:E05.599.495|ES| 18:1 19:1 72:1 75:1 81:1 115:1 325:1 412:1 455:1 666:1 836:1 849:1 1313:1 2124:1 2636:1 5393:1
8 	|BT| (NP (NP (DT Both) (NP (NNP BaA) (NNPS MeBaAs) (JJ similar) (NN effect) (NN expression) (NN cytochrome) (NN P450) (NN 1B1) (JJ aldo-keto) (NN reductase) (NN 1C9) (NN rat) (NN liver) (JJ epithelial) (NN WB-F344) (NN cell)))) |ET| |BS|75:A11.436 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 590:B01.050.050.199.520.760.200|ES| 19:1 75:1 94:1 96:1 115:1 127:1 332:1 836:1 849:1 2549:1 3276:1 3788:1 4678:1 5394:1 5395:1 5396:1 5397:1 5398:1
8 	|BT| (S (NP (NNP CAPE) (CC plus) (NNP DEN)) (VP (VBD diminished) (NP (NP (NN expression) (NN cytochrome) (VBN involved) (NN DEN) (NN bioactivation) (NN CYP2B1)) (VP (ADVP (RB well)) (NP (NP (NN expression) (NN regulator) (JJ oxidative) (NN stress) (NN glutathione) (NN reductase)) (, ,) (NP (NN GST-kappa) (NN GST-theta)) (, ,) (NP (NN cell) (NN cycle) (NN regulator)) (NP (NN p53))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 155:G05.355.310 353:G04.299.134 716:G03.495.710 1470:D08.244.453.040.550 1471:D08.811.682.667.092 1472:D08.244|ES| 2:1 4:1 9:1 12:1 19:1 94:1 96:1 115:1 162:1 235:1 569:1 601:1 637:1 693:1 712:1 774:1 787:1 831:1 900:1 911:1 1719:1 1875:1 2332:1 2353:1 2522:1 2583:1 2744:1 3045:1 3146:1 3374:1 3788:1 4156:1 4350:1 4720:1 4888:1 5399:1 5400:1 5401:1 5402:1 5403:1 5404:1
8 	|BT| (S (NP (NN Coexpression) (NN K-rasVal12) (NN TAgWt)) (VP (VBP produce) (NP (NN dysplasia)))) |ET| |BS||ES| 19:1 203:1 1565:1 5405:1 5406:1 5407:1
8 	|BT| (S (NP (JJ Consistent) (NN finding) (, ,) (NN treatment) (NP (NP (NN protein) (NN kinase) (NN A)) (PRN (-LRB- -LRB-) (NP (NN PKA)) (-RRB- -RRB-))) (NN inhibitor)) (VP (VBD decreased) (NP (NN MMP2) (NN MMP9) (NN expression) (NN level) (JJ ADCY3-overexpressing) (NN cell)))) |ET| |BS|41:A11 52:E02 586:D08.811.277.656.300.480.205.360 1417:D08.811.277.656.300.480.205.352|ES| 2:1 4:1 10:1 14:1 19:1 69:1 94:1 115:1 202:1 249:1 380:1 470:1 546:1 927:1 3395:1 5408:1 5409:1 5410:1 5411:1
8 	|BT| (S (NP (NN Curcumin)) (VP (VBZ sensitizes) (NP (NP (JJ human) (JJ colorectal) (NN cancer) (NN xenograft) (JJ nude) (NN mouse) (NN gamma-radiation)) (VP (VBG targeting) (NP (JJ nuclear) (JJ factor-kappaB-regulated) (NN gene) (NN product)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335|ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1
8 	|BT| (S (NP (NN DEN) (NN treatment)) (VP (VP (VBD increased) (NP (NP (NN expression) (NN gene)) (VP (VBN associated) (NP (JJ oxidative) (NN stress) (NN glutathione) (NN reductase))))) (, ,) (NP (NP (NN gene) (VBN involved) (NN cell) (NN cycle) (NN regulation)) (PP (VBG including) (NP (NP (NN p53)) (, ,) (NP (VBN modified) (NN cytochrome) (NN P450))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 6:G05.360.340.024.340 52:E02 155:G05.355.310 716:G03.495.710 1079:D08.244.453 1259:G04.299.134.109 1471:D08.811.682.667.092|ES| 2:1 9:1 12:1 19:1 47:1 94:1 96:1 115:1 169:1 438:1 546:1 561:1 601:1 774:1 1875:1 2335:1 2522:1 2549:1 2583:1 2744:1 3788:1
8 	|BT| (NP (NP (NP (NN DEN) (NN treatment) (VBN modified) (NN expression) (CD 665) (NN gene)) (, ,) (NP (NP (NN CAPE)) (CC plus) (NP (NN DEN))) (VP (VBD induced) (NP (NN change) (CD 1371) (NN gene))))) |ET| |BS|6:G05.360.340.024.340 52:E02 155:G05.355.310|ES| 2:1 9:1 19:1 115:1 200:1 412:1 546:1 1875:1 2332:1 2335:1 4888:1 5412:1 5413:1
8 	|BT| (NP (NP (JJ Different) (NN mechanism) (JJ DEHP-induced) (JJ hepatocellular) (NN adenoma) (NN tumorigenesis) (JJ wild-type) (NN Ppar) (JJ alpha-null) (NN mouse))) |ET| |BS|29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 536:D12.776.826.239.500 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 8:1 19:1 42:1 52:1 78:1 162:1 303:1 5384:1 5385:1 5414:1 5415:1
8 	|BT| (S (NP (NP (NN DNA) (NN binding) (NN activity) (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-))) (VP (VBZ transactivates) (NP (NP (NP (NN miR-155) (NN gene)) (ADJP (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))) (JJ elevated) (NN liver) (JJ nuclear) (NN extract) (NN mouse)) (VBN fed) (NNP CDAA) (NN diet)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 198:D13.444.308 210:D12.776.260.600 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 1473:D20.777.351|ES| 9:1 10:1 14:1 19:1 52:1 124:1 185:1 311:1 399:1 581:1 666:1 714:1 756:1 763:1 836:1 1254:1 1256:1 1487:1 1911:1 2191:1 2426:1 2496:1 3184:1 3750:1 5066:1
8 	|BT| (FRAG (NP (NP (NP (NP (RB Early) (NN detection)) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LRB-) (JJ 4,5-b) (-RRB- -RRB-) (NN pyridine) (-LRB- -LRB-) (NN PhIP) (-RRB- -RRB-) (: -)) (VBN induced) (NN mutation)) (PP (IN within) (NP (NN Apc) (NN gene) (NN rat) (NN colon))))) |ET| |BS|18:G05.365.590 21:G05.360.340.024.340.375.249.050 46:A03.556.124.526.356 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 494:E01.390 744:D03.383.725|ES| 9:1 10:1 14:1 19:1 34:1 113:1 280:1 409:1 849:1 1023:1 2122:1 2638:1 2639:1 2640:1 2641:1 4135:1
8 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN PhIP)) (VP (VBD appeared) (NP (NP (NP (JJ carcinogenic) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NN mouse) (JJ subtoxic) (NNS dos)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 279:D27.888.569.100|ES| 2:1 10:1 14:1 19:1 45:1 52:1 1929:1 2641:1 2653:1 3346:1 3836:1 5416:1 5417:1
8 	|BT| (S (ADVP (RB Finally)) (, ,) (VP (VBP demonstrate) (NP (NP (JJ NSAID-mediated) (JJ nucleolar) (NN translocation) (NN RelA)) (VP (VBN associated) (NP (NP (NN downregulation) (JJ NF-kappaB-driven) (NN transcription) (NN NF-kappaB) (NN target) (NN gene)) (, ,) (NP (NN ICAM-1))))))) |ET| |BS|6:G05.360.340.024.340 66:F01.658.293 85:G02.111.087.225 209:G02.111.087.847 210:D12.776.260.600 463:C23.550.210.870 796:D27.505.696.663.850.014.040.500 1325:D12.776.395.550.200.450|ES| 2:1 9:1 19:1 160:1 169:1 250:1 487:1 502:1 595:1 714:1 1618:1 1929:1 4732:1 5418:1 5419:1 5420:1
8 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ stress-associated) (NN hormone)) (, ,) (NP (NN isoproterenol)) (, ,)) (VP (MD could) (VP (VP (VB increase) (NP (NN expression) (NN level) (`` ``) (NN stem) ('' ''))) (: -) (S (NP (NP (JJ related) (NN protein)) (, ,) (NP (NN CD44)) (, ,) (NP (NNP Nanog)) (, ,) (NP (NN Rex-1)) (, ,)) (VP (VBP induce) (NP (NN chemoresistance) (JJ gastric) (NN cancer) (NN cell))))))) |ET| |BS|7:D12.776 41:A11 161:D06.472 309:A18.024.937 1474:D02.033.100.291.439|ES| 2:1 4:1 18:1 19:1 40:1 86:1 94:1 115:1 182:1 243:1 249:1 334:1 542:1 908:1 1106:1 1282:1 1581:1 3268:1 3269:1 5421:1 5422:1 5423:1 5424:1
8 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN UDCA)) (VP (VBD inhibited) (NP (NP (NN Cox-2) (NN induction) (JJ Ras-dependent)) (: -) (NP (JJ independent) (NN mechanism))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 19:1 62:1 162:1 334:1 365:1 736:1 2631:1 5425:1 5426:1
8 	|BT| (NP (NP (NP (JJ Genotype-phenotype) (NN correlation) (JJ murine) (NN Apc) (NN mutation)) (: :) (NP (NN difference) (NN enterocyte) (NN migration) (NN response) (NN sulindac)))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 251:D02.455.426.559.847.486.875 1475:A03.556.124.369.290 1476:E05.393.385|ES| 19:1 34:1 104:1 280:1 494:1 514:1 627:1 869:1 1674:1 3544:1 5427:1 5428:1
8 	|BT| (S (NP (NN Hesperidin) (NN treatment)) (VP (VBD caused) (SBAR (S (NP (JJ significant) (NP (NP (NN up-regulation) (NN tumour) (NN suppressor) (NN phosphatase) (NN tensin) (NN homologue)) (PRN (-LRB- -LRB-) (NP (NN PTEN)) (-RRB- -RRB-))) (NN reduction) (NN expression) (NNP AOM)) (VP (VBD mediated) (NP (NN p-PI3K) (NN p-Akt))))))) |ET| |BS|52:E02 132:D02.172.080 142:I01.880.604 206:G05.360.340.024.340.375.249 378:D08.811.913.696.620.682.700.755 1035:D08.811.277.352.650 1290:D08.811.913.696.620.500 1477:D03.383.663.283.266.450.252.500|ES| 10:1 14:1 19:1 115:1 135:1 226:1 370:1 437:1 546:1 700:1 896:1 1011:1 1936:1 1994:1 2506:1 3619:1 3620:1 5429:1 5430:1 5431:1
8 	|BT| (S (NP (NP (ADJP (RB Highly) (JJ metastatic)) (JJ hepatocellular) (NN carcinoma)) (VP (VBD induced) (NP (NP (JJ male) (NN F344) (NN rat)) (NP (VBN treated) (NN N-nitrosomorpholine) (NN combination) (NNS hepatocarcinogens))))) (VP (VBP show) (NP (JJ high) (NN incidence) (NN p53) (NN gene) (NN mutation)) (PP (IN along) (NP (JJ altered) (NN mRNA) (NN expression) (JJ tumor-related) (NN gene))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 18:G05.365.590 52:E02 104:C04.557.470.200.025.255 111:D13.444.735.544 149:G05.360.340.024.340.364.875.890 155:G05.355.310 434:E05.318.308.985.525.375 590:B01.050.050.199.520.760.200|ES| 9:1 12:1 19:1 34:1 115:1 178:1 303:1 304:1 325:1 337:1 412:1 429:1 530:1 693:1 849:1 1099:1 1402:1 1511:1 2666:1 2705:1 3185:1 3989:1 5432:1 5433:1
8 	|BT| (NP (NP (NP (NP (NN Histogenesis) (NN role) (NN p53) (NN K-ras) (NN mutation) (NN hepatocarcinogenesis) (NN glyceryl) (NN trinitrate)) (PRN (-LRB- -LRB-) (NP (NN nitroglycerin)) (-RRB- -RRB-))) (JJ male) (NN F344) (NN rat))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 15:F01.829.316.616 18:G05.365.590 590:B01.050.050.199.520.760.200 1478:D02.033.800.421.560|ES| 10:1 12:1 14:1 19:1 31:1 34:1 849:1 900:1 1121:1 1402:1 3185:1 5434:1 5435:1 5436:1 5437:1
8 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN IBN-65)) (VP (VP (VBD induced) (NP (NP (NN apoptosis)) (NP (JJ down-regulating) (NNP Survivin)))) (, ,) (NP (NP (NN Bcl-2) (VBG up-regulating) (NN Bax)) (, ,) (VP (VBG leading) (NP (JJ sequential) (NN activation) (NN Caspase-3))) (, ,) (NP (NP (NN Caspase-9) (NN cleavage) (NN poly) (-LRB- -LRB-) (NN ADP-ribose) (-RRB- -RRB-) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN PARP)) (-RRB- -RRB-)))))) |ET| |BS|39:G04.299.139.160 54:G05.360.340.024.340.375.500.791.150 86:D01.268.556.435 150:Z01.542.248.960 342:D12.644.360.075.718.400 351:A17.360 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1349:D08.811.277.656.262.500.126.550.900 1440:G04.299.134.220.250|ES| 2:1 10:1 14:1 19:1 89:1 158:1 225:1 244:1 394:1 412:1 468:1 639:1 1876:1 3097:1 3190:1 3779:1 4630:1 4810:1 4811:1 5247:1 5438:1 5439:1 5440:1 5441:1
8 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN metformin)) (VP (VBD induced) (NP (NP (NN apoptosis) (NN OSCC) (NN cell)) (, ,) (VP (ADVP (RB significantly)) (VBG down-regulating) (NP (NP (JJ anti-apoptotic) (NN protein) (NN Bcl-2) (NN Bcl-xL)) (VP (VBG up-regulating) (NP (JJ pro-apoptotic) (NN protein) (NN Bax)))))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 150:Z01.542.248.960 342:D12.644.360.075.718.400 351:A17.360 784:D02.078.370.141.450 1469:D12.644.360.075|ES| 2:1 4:1 19:1 89:1 94:1 124:1 158:1 244:1 412:1 468:1 1876:1 3097:1 4630:1 4814:1 5087:1 5230:1 5232:1 5442:1
8 	|BT| (S (PP (IN In) (NP (NN HT-29) (NN cell))) (, ,) (NP (NN pterostilbene)) (VP (VBD reduced) (SBAR (S (NP (NP (NN protein) (NN level) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1) (NN c-MYC)) (, ,) (NP (JJ altered) (JJ cellular) (NN localization) (NN beta-catenin))) (VP (VBD inhibited) (NP (NN phosphorylation) (NN p65))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 41:A11 122:C14.280.383 215:D12.644.360.262.150.100 792:A11.251.210.190.475 972:G02.111.087.677|ES| 2:1 4:1 19:1 60:1 94:1 244:1 249:1 365:1 452:1 625:1 693:1 743:1 744:1 2428:1 2484:1 2782:1 3074:1 3426:1 5016:1
8 	|BT| (S (PP (IN In) (NP (NN HT-29) (NN cell))) (, ,) (NP (NN pterostilbene)) (VP (VBD reduced) (SBAR (S (NP (NP (NN protein) (NN level) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1) (NN c-MYC)) (, ,) (NP (JJ altered) (JJ cellular) (NN localization) (NN beta-catenin))) (VP (VBD inhibited) (NP (NN phosphorylation) (NN p65))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 41:A11 46:A03.556.124.526.356 122:C14.280.383 158:D23.101 183:G04.299.233.750 215:D12.644.360.262.150.100 792:A11.251.210.190.475 972:G02.111.087.677|ES| 2:1 4:1 18:1 19:1 60:1 78:1 94:1 113:1 159:1 216:1 244:1 249:1 299:1 365:1 378:1 452:1 534:1 625:1 658:1 693:1 743:1 744:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1 2484:1 2782:1 3074:1 3426:1 5016:1
8 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (VBN shown) (JJ first) (NN time) (NN UDCA)) (VP (VBD suppressed) (SBAR (S (NP (NN development) (NN tumor) (NN Ras) (NN mutation)) (VP (VBD blocked) (NP (NN activation) (NNP WT) (NN Ras))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 322:G01.910 737:D04.808.105.225.272.962|ES| 2:1 7:1 19:1 34:1 35:1 225:1 237:1 244:1 307:1 490:1 816:1 1081:1 1775:1 1995:1 2631:1 2777:1
8 	|BT| (FRAG (PP (IN In) (NP (NP (NNP AOM)) (ADVP (RB alone)))) (NP (NP (NN group)) (, ,) (NP (NN Cox-2)) (VP (VBD up-regulated) (SBAR (S (NP (ADJP (JJR >) (JJ 50-fold)) (NN tumor) (JJ normal) (NP (NN Ras)) (NN activity)) (VP (VBD enhanced) (NP (NN tumor) (JJ mutant) (JJ signaling-activated) (NN Ras)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 69:G02.111.087.800 132:D02.172.080 142:I01.880.604 150:Z01.542.248.960 829:M01.686|ES| 2:1 7:1 19:1 62:1 118:1 241:1 244:1 385:1 399:1 811:1 1301:1 1466:1 1775:1 1994:1 2300:1 5443:1 5444:1
8 	|BT| (FRAG (PP (IN In) (NP (NN study))) (, ,) (NP (VBN examined) (NN role) (NN Ras) (NN Cox-2) (NN inhibition) (NN UDCA))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 15:F01.829.316.616 43:F01.145.544 737:D04.808.105.225.272.962|ES| 2:1 19:1 31:1 62:1 103:1 131:1 244:1 324:1 1775:1 2631:1
8 	|BT| (S (NP (NN Induction) (NN apoptosis) (NN pectenotoxin-2)) (VP (VBD mediated) (NP (NP (NP (NN induction) (NN DR4/DR5)) (, ,) (NP (NN Egr-1) (NN NAG-1))) (, ,) (NP (NN activation) (NN caspase) (NN modulation) (NN Bcl-2) (NN family) (JJ p53-deficient) (NN Hep3B) (JJ hepatocellular) (NN carcinoma) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 44:F01.829.263 54:G05.360.340.024.340.375.500.791.150 104:C04.557.470.200.025.255 580:D12.776.260.158.500 1367:D08.811.277.656.262.500.126|ES| 2:1 19:1 89:1 94:1 97:1 158:1 225:1 303:1 304:1 437:1 736:1 1662:1 1945:1 2020:1 4498:1 4502:1 4561:1 4796:1 5236:1 5445:1
8 	|BT| (S (NP (NN Induction) (NN SPARC)) (VP (VBD demonstrated) (NP (NN treatment) (JJ demethylating) (NN agent) (NN 5Aza-dC) (CD 5) (CD 7) (NN cell) (NN line)))) |ET| |BS|37:D12.776.157.125.715 94:A11.251.210 775:E02.760.058|ES| 19:1 82:1 94:1 264:1 546:1 578:1 728:1 988:1 1175:1 2020:1 5446:1 5447:1
8 	|BT| (S (NP (NN IR-5) (NN bear) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)) (VP (VP (VBZ corresponds) (SBAR (S (NP (NN L726I) (JJ ATP-binding) (NN pocket)) (VP (VBP correlate) (NP (NN log) (NN decrease) (NN sensitivity) (NN gefitinib)))))) (, ,) (NP (NP (VBD increased) (NN heterodimerization) (NN EGFR) (NN HER3)) (, ,) (NP (JJ impaired) (NN down-regulation))))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 85:G02.111.087.225 259:D12.776.395.240.150.500 438:G05.365.590.675 455:B01.050.150.900.649.147.890 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 19:1 34:1 47:1 187:1 257:1 295:1 607:1 891:1 901:1 1740:1 2003:1 2121:1 3310:1 3505:1 4281:1 4955:1 4956:1 4957:1 4958:1 4959:1 4960:1 4961:1
8 	|BT| (S (S (S (NP (NN Levamisole)) (VP (VBD increased) (NP (NNS ECs) (JJ integrin-dependent) (NN matrix) (NN adhesion)))) (PRN (, ,) (VP (VBD inhibited) (NP (NP (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (CD -70) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN reduced) (NN expression) (NN survival) (NN factor) (NN clusterin)) (PRN (-LRB- -LRB-) (NP (CD -30) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NN endothelin-1) (PRN (-LRB- -LRB-) (NP (CD -43) (NN %)) (-RRB- -RRB-)))) (, ,) (NP (NN bcl-2) (PRN (-LRB- -LRB-) (NP (CD -34) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ endothelial) (NN NO-synthase)) (PRN (-LRB- -LRB-) (NP (CD -32) (NN %)) (-RRB- -RRB-))) (NP (NN pRb) (-LRB- -LRB-) (NN Retinoblastoma) (NN protein) (: :))) (NP (CD -89) (NN %))) (-RRB- -RRB-) (, ,)) (NP (NP (NP (NP (VBN increased) (NN growth) (NN arrest/death) (NN signal) (NN p21)) (PRN (-LRB- -LRB-) (NP (CD +73) (NN %)) (-RRB- -RRB-))) (NN bak)) (PRN (-LRB- -LRB-) (NP (CD +50) (NN %)) (-RRB- -RRB-))))) |ET| |BS|45:G07.700.320.249 54:G05.360.340.024.340.375.500.791.150 96:I03.784 122:C14.280.383 135:C23.550.260 871:D02.886.675.346 920:D12.776.543.750.705.408 1479:D12.776.260.704 1480:D08.811.682.664.500.772.750 1481:D12.644.276.400.225 1482:C23.550.355.274.840 1483:D12.776.395.207 1484:F04.570.200.583|ES| 2:1 4:1 10:1 14:1 19:1 47:1 102:1 104:1 115:1 151:1 185:1 274:1 299:1 365:1 369:1 452:1 753:1 859:1 1135:1 3088:1 3092:1 3093:1 3491:1 5448:1 5449:1 5450:1 5451:1 5452:1 5453:1 5454:1 5455:1 5456:1 5457:1 5458:1 5459:1 5460:1 5461:1 5462:1 5463:1
8 	|BT| (S (NP (JJ Long-term) (JJ pharmacological) (NN MAP) (NN kinase) (NN inhibition) (NN MEK) (NN inhibitor) (NN PD98059)) (VP (VBD induced) (NP (NP (NN expression) (JJ terminal) (NN differentiation) (NN marker) (NN ITF)) (, ,) (NP (NN sucrase-isomaltase)) (, ,) (NP (NN mucin) (NN gene) (NN MUC2))))) |ET| |BS|6:G05.360.340.024.340 43:F01.145.544 71:D12.776.395.560.631 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565 478:D08.811.913.696.620.682.700.567 849:G08.686.785.760.769.490.500 1045:D23.050.301.264 1059:H01.158.703 1485:D08.811.277.450.770 1486:V01.185.687|ES| 2:1 9:1 19:1 103:1 115:1 209:1 212:1 215:1 380:1 412:1 470:1 534:1 3707:1 4968:1 5110:1 5464:1 5465:1 5466:1 5467:1 5468:1
8 	|BT| (S (NP (NNS METHODS) (: :)) (PP (IN In) (NP (NN study))) (VP (VBD used) (NP (NP (NN p53)) (VP (VBN mutated) (VP (VB knock) (S (NP (NP (NN colon) (NN cancer) (NN cell) (NN xenograft) (NN tumour) (NN study)) (NN role) (NN p53) (NN apoptosis)) (VP (VBD mediated) (NP (NNS diaminothiazoles))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 92:E04.936.764 93:A01.941.875 168:E05.581|ES| 12:1 18:1 19:1 31:1 89:1 94:1 104:1 113:1 131:1 229:1 244:1 265:1 437:1 476:1 565:1 1011:1 5469:1 5470:1
8 	|BT| (S (NP (NN MicroRNA-122)) (VP (VBZ inhibits) (SBAR (S (NP (JJ tumorigenic) (NN property) (JJ hepatocellular) (NN carcinoma) (NN cell)) (VP (VBZ sensitizes) (NP (NN cell) (NN sorafenib))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 122:C14.280.383 184:D13.150.650.319 575:V02.050|ES| 19:1 94:1 303:1 304:1 615:1 841:1 1797:1 1809:1 2062:1 2063:1
8 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN autophagy) (NN sensitization) (NN cisplatin) (NN NAC1) (NN knockdown) (NN inactivation)) (VP (VBN accompanied) (NP (NN induction) (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 390:G04.299.139.399 498:D01.210.375|ES| 2:1 19:1 89:1 103:1 464:1 622:1 736:1 1314:1 1317:1 1761:1 2137:1 2801:1 5471:1
8 	|BT| (NP (NP (NP (NN Mutation) (NN analysis) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NP (NN mouse) (VBG carrying) (NN lacZ) (NN reporter) (NN gene)) (, ,) (S (VP (VBD indicated) (SBAR (S (NP (VBN observed) (NN toxicity) (NN PhIP)) (VP (MD might) (VP (VBD caused) (NP (JJ genotoxic) (NN effect) (JJ small) (NN intestine)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 100:G05.360.340.024.686.545 218:A03.556.124.684 247:G01.374.676.530|ES| 2:1 9:1 10:1 14:1 19:1 45:1 52:1 75:1 261:1 288:1 356:1 641:1 661:1 750:1 798:1 850:1 1541:1 2406:1 2506:1 2641:1 3329:1 5416:1 5472:1
8 	|BT| (S (NNS Mutations) (NP (NN codon) (NP (CD 13) (CD 117) (CC plus) (NP (JJ second) (NN exon) (NN insert)))) (VP (VBD contributed) (NP (CD 4) (NN %)) (NP (JJ total) (JJ H-ras) (NN frequency) (NN trichloroethylene) (NN tetrachloroethylene)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 113:C04.697.650 179:D01.248.497.300.459.700 335:D13.444.735.544.355 372:G05.360.340.024.340.137.232 1235:D02.455.526.439.939 1236:D02.455.526.439.880|ES| 19:1 319:1 369:1 1119:1 1247:1 1255:1 1410:1 1532:1 2347:1 3132:1 4416:1 4888:1 5473:1 5474:1 5475:1 5476:1 5477:1
8 	|BT| (S (NP (NNP Nestin) (NN silencing)) (VP (ADVP (RB also)) (VP (VBD upregulated) (NP (NP (NN Axin) (, ,) (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARa)) (-RRB- -RRB-))))) (, ,) (VP (VBD downregulated) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-Myc)) (, ,) (NP (NP (NN cyclin) (NN D)) (NN MMP-7) (NN expression) (NNP CSC)))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 536:D12.776.826.239.500 556:C11.768.175 937:D08.811.277.656.300.480.525.700.250 1046:D12.644.360.262.150 1047:D05.750.078.593.540|ES| 2:1 5:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 60:1 66:1 92:1 100:1 115:1 125:1 186:1 426:1 743:1 824:1 1801:1 1836:1 1887:1 1972:1 2592:1 3577:1 3650:1 3651:1 3652:1 3653:1 3654:1 3655:1
8 	|BT| (S (ADVP (RB Notably)) (, ,) (NP (NN AcEGCG)) (VP (VP (VBD inhibited) (NP (NP (NN expression) (NN p53) (, ,) (NN p21) (, ,) (NN c-Myc) (, ,) (NN cyclin) (NN B)) (, ,) (NP (NN p-CDK1) (NN Cdc25A))) (ADVP (RB also)) (VP (VBD restored) (NP (NN activation) (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (CD 1/2)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-)))))) (, ,) (VP (VBD decreased) (NP (JJ DMBA/TPA-induced) (NN increase) (NN tumor) (NN proliferation) (JJ mitotic) (NN index))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 116:D08.811.913.696.620.682.700.567.249.750 122:C14.280.383 212:E01.370.225.500.385.500 1487:D08.811.913.696.620.682.700.646.500.500.250 1488:D02.455.426.559.847.149.301 1489:D08.811.277.656.300.760.875 1490:D12.644.360.262.120|ES| 2:1 5:1 7:1 10:1 12:1 14:1 19:1 40:1 115:1 202:1 225:1 299:1 365:1 470:1 720:1 721:1 743:1 763:1 824:1 1135:1 1707:1 2798:1 4594:1 4812:1 4893:1 4966:1 5478:1 5479:1 5480:1 5481:1
8 	|BT| (S (NP (NN OBJECTIVE) (: :)) (NP (NN FBXW7)) (VP (VBZ encodes) (NP (SBAR (S (NP (JJ substrate) (NN recognition) (NN component) (NN ubiquitin) (NN ligase)) (VP (VBZ degrades) (NP (NN target) (NN Notch1))))) (, ,) (NP (NN c-Jun)) (, ,) (NP (NN c-Myc) (NN cyclin) (NN E))))) |ET| |BS|415:F01.658.500 1458:D12.644.360.262.180 1491:F02.463.425.540.706 1492:D12.776.947.500 1493:D08.811.464|ES| 2:1 19:1 104:1 160:1 651:1 743:1 824:1 1021:1 1417:1 1686:1 2085:1 2211:1 3470:1 3757:1 5127:1 5482:1 5483:1 5484:1
8 	|BT| (S (SBAR (IN Of) (S (NP (CD two) (NN gene)) (VP (VBP encode) (NP (NP (NN methionine) (NN adenosyltransferase)) (PRN (-LRB- -LRB-) (NP (NN MAT1Aand) (NN MAT2A)) (-RRB- -RRB-)))))) (, ,) (NP (NN MAT1A)) (ADVP (RB mainly)) (VP (VBD expressed) (NP (JJ adult) (NN liver)) (SBAR (IN whereas) (S (NP (NN MAT2A)) (VP (VBD expressed) (NP (JJ extrahepatic) (NN tissue))))))) |ET| |BS|6:G05.360.340.024.340 98:A10 119:M01.060.116 242:A03.620 574:D08.811.913.225.650|ES| 2:1 6:1 9:1 10:1 14:1 19:1 272:1 355:1 372:1 836:1 933:1 1429:1 1792:1 2050:1 2051:1 5485:1 5486:1 5487:1 5488:1 5489:1
8 	|BT| (S (NP (RB Only) (NN 10-MeBaA)) (VP (VBD induced) (S (NP (NP (NN apoptosis) (NN accumulation)) (VP (VBN phosphorylated) (S (NP (NN p53))))) (, ,) (VP (MD could) (NP (NP (VBN associated) (NN induction) (JJ oxidative) (NN stress)) (, ,) (NP (JJ similar) (NN DMBA))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 716:G03.495.710 1488:D02.455.426.559.847.149.301|ES| 2:1 12:1 19:1 89:1 169:1 332:1 412:1 736:1 908:1 2120:1 2522:1 2583:1 4930:1 5490:1 5491:1 5492:1
8 	|BT| (S (NP (PRP$ Our) (NN model)) (VP (VBZ predicts) (NP (NP (NP (NN 5FU) (NN sensitivity) (NN tumor)) (VP (VBN modified) (S (NP (NN aneuploidy)) (VP (VBG producing) (NP (NN copy) (NN number) (NN change) (NN TS) (NN allele) (CD one) (NN following)))))) (: :) (NP (NP (NN LOH)) (, ,) (NP (NN amplification)) (, ,) (, ,) (NP (VBN presented) (, ,) (NP (NN copy) (NN number) (NN change) (JJ due) (NN polysomy))))))) |ET| |BS|8:C04 77:G05.360.340.024.340.030 154:Z01.058.266.887 290:G05.365.590.029.530 560:D03.383.742.698.875.404 1494:C23.550.210.050|ES| 2:1 7:1 19:1 72:1 104:1 200:1 230:1 509:1 607:1 646:1 658:1 921:1 963:1 1004:1 1010:1 1751:1 2335:1 2851:1 3510:1 5493:1 5494:1 5495:1 5496:1 5497:1
8 	|BT| (S (NP (PRP$ Our) (NN study)) (ADVP (RB also)) (VP (VBP demonstrate) (NP (VBN utilized) (NN DEN/PB) (NN protocol) (NNP WT) (NN C57BL/6) (NN mouse) (JJ select) (NN beta-catenin) (NN gene) (NN mutation) (NN hepatocarcinogenesis)))) |ET| |BS|18:G05.365.590 23:D12.776.091.249 593:B01.050.050.199.520.520.420|ES| 5:1 9:1 19:1 34:1 52:1 60:1 131:1 502:1 658:1 900:1 1182:1 1995:1 2192:1 3216:1 4183:1 5498:1
8 	|BT| (S (NP (NN Panobinostat) (NN treatment)) (VP (VBD induced) (NP (NP (NP (NN downregulation) (NN EGFR)) (, ,) (NP (NN HER2)) (, ,)) (NN HER3) (ADJP (NN mRNA) (NN protein) (JJ transcriptional) (JJ posttranslational)) (NN mechanism)))) |ET| |BS|7:D12.776 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 85:G02.111.087.225 111:D13.444.735.544 209:G02.111.087.847|ES| 2:1 4:1 19:1 162:1 187:1 188:1 325:1 412:1 546:1 559:1 595:1 4961:1 5499:1 5500:1
8 	|BT| (FRAG (NP (NP (NP (NN PhIP) (NN diet)) (NP (ADJP (JJR >) (ADJP (CD 43) (NN week))) (NP (JJ present) (NN colon) (NN tumor) (JJ specific) (CD -1) (NN G) (NN mutation)))) (PP (IN within) (NP (QP (CD 5) ('' ')) (: -) (NN GGGA-3) ('' ') (NN sequence) (NN APC))) (: :)) (NP (NN gene))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 18:G05.365.590 26:G02.111.570.080 51:C04.588.274.476.411.307.180 595:G07.203.650.240 596:E02.642.249|ES| 7:1 9:1 11:1 19:1 34:1 104:1 113:1 293:1 540:1 783:1 1307:1 1466:1 1489:1 2122:1 2191:1 2641:1 5501:1 5502:1 5503:1
8 	|BT| (S (NP (NN Ras) (NN transformation)) (VP (VP (VBZ requires) (NP (NN Ras) (NN membrane) (NN anchorage))) (, ,) (VP (VBD promoted) (NP (NN farnesylcysteine) (NN carboxymethyl) (NN ester) (JJ additional) (NN sequence) (JJ specific) (NN Ras) (NN isoform))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 26:G02.111.570.080 238:D12.776.800 1344:A10.615 1495:D02.241.400|ES| 2:1 19:1 293:1 540:1 980:1 1384:1 1775:1 1912:1 2226:1 2331:1 3622:1 5371:1 5504:1 5505:1 5506:1
8 	|BT| (FRAG (ADJP (NN Reentry) (JJ dependent)) (SBAR (IN upon) (S (NP (NN ability) (NN TAg)) (VP (VBP bind) (S (NP (NN pRB)) (VP (VBN associated) (NP (JJ p53-independent) (NN apoptosis)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 385:F02.784.629.131 1479:D12.776.260.704|ES| 19:1 89:1 169:1 321:1 1300:1 1951:1 4857:1 5507:1 5508:1 5509:1 5510:1
8 	|BT| (S (NP (NN RT-PCR) (NN Western) (NN blot) (NN assay)) (NP (VBN detected) (NN expression) (VBN known) (NN target) (NN miR-372) (JJ malignant) (NN tumor)) (VP (VBD found) (SBAR (S (NP (NP (NN Cyclin) (NN A1) (JJ Cyclin-dependent) (NN Kinase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN CDK2)) (-RRB- -RRB-))) (VP (VBD downregulated) (NP (NN miR-372))))))) |ET| |BS|255:E05.196.401.143 272:E05.393.620.500.725 1365:D08.811.913.696.620.682.700.646.500.750 1496:D12.644.360.262.100.100|ES| 7:1 10:1 14:1 19:1 37:1 115:1 148:1 160:1 310:1 426:1 556:1 802:1 872:1 873:1 1007:1 1148:1 1543:1 2984:1 2992:1 4742:1 5511:1 5512:1
8 	|BT| (S (NP (NN SAHA)) (VP (VBD mediated) (NP (NP (NN acetylation) (NN histone) (NN H3)) (ADVP (RB globally))) (, ,) (ADVP (RB well)) (, ,) (S (VP (VBN associated) (NP (NP (NP (NN p21)) (PRN (-LRB- -LRB-) (NP (NN WAF1)) (-RRB- -RRB-))) (NN promoter)))) (, ,) (NP (VBN measured) (NN chromatin) (NN immunoprecipitation)))) |ET| |BS|228:E05.978 1416:D12.776.660.470 1454:E05.393.170 1497:G02.111.087.019.052|ES| 2:1 10:1 14:1 19:1 83:1 169:1 437:1 503:1 787:1 789:1 1135:1 1346:1 4915:1 5145:1 5341:1 5513:1 5514:1 5515:1
8 	|BT| (S (NP (NNP Saracatinib)) (VP (VBD enhanced) (NP (NP (NN effect) (NN lapatinib) (, ,) (NN EGFR/HER2) (JJ dual) (NN inhibitor)) (, ,) (NP (NN SNU216) (NN NCI-N87) (NN cell))))) |ET| |BS|41:A11 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 120:I01.409.418.750.600.480.150|ES| 2:1 19:1 75:1 94:1 380:1 385:1 2067:1 3347:1 5243:1 5516:1 5517:1 5518:1
8 	|BT| (S (NP (JJ Short) (JJ G-rich) (JJ repetitive) (NN sequence)) (ADVP (RB previously)) (VBN identified) (NP (NNS hot-spots) (NN frameshift) (NN mutagenesis)) (VP (VBD induced) (NP (NP (JJ large) (NN variety) (NN carcinogen)) (VP (VBG belonging) (NP (JJ several) (NN family) (JJ widespread) (JJ environmental) (NN pollutant)))))) |ET| |BS|44:F01.829.263 279:D27.888.569.100 287:G05.365.590.265 612:G02.111.570.080.708 1359:G05.355.600 1498:G01.906.595.543 1499:D27.888.284 1500:C17.800.257|ES| 19:1 97:1 262:1 293:1 412:1 623:1 952:1 1527:1 2125:1 2264:1 3446:1 4073:1 4864:1 5519:1 5520:1 5521:1 5522:1 5523:1 5524:1 5525:1
8 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NN DEHP)) (VP (MD may) (VP (VB induce) (SBAR (S (NP (NP (JJ hepatocellular) (NN adenoma)) (, ,) (NP (NN part)) (, ,) (SBAR (IN via) (S (NP (NN suppression) (NN G2/M) (NN arrest)) (VP (VBN regulated) (NP (NN Gadd45a) (NN caspase) (JJ 3-dependent) (NN apoptosis) (NN Ppar) (JJ alpha-null) (NN mouse))))) (, ,) (NP (NN gene))) (VP (MD may) (NP (VBN involved) (NN tumorigenesis) (JJ wild-type) (NN mouse)))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 142:I01.880.604 536:D12.776.826.239.500 906:D08.811.277.656.262.500.126.350.300 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 2:1 8:1 9:1 19:1 42:1 52:1 78:1 89:1 243:1 303:1 451:1 491:1 596:1 602:1 774:1 1537:1 1538:1 1664:1 2453:1 2528:1 3205:1 4796:1 5384:1 5385:1 5526:1 5527:1
8 	|BT| (FRAG (NP (NP (DT The) (JJ chemopreventive) (NN effect)) (NP (NP (NNP Protandim)) (: :) (NP (NN modulation) (NN p53) (JJ mitochondrial) (NN translocation) (NN apoptosis) (NN skin) (NN carcinogenesis))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 33:C04.697.098 39:G04.299.139.160 463:C23.550.210.870 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 624:D27.505.696.706.018 785:A17.815|ES| 12:1 19:1 75:1 89:1 104:1 207:1 691:1 1618:1 1945:1 1946:1 2004:1 2319:1 5088:1
8 	|BT| (NP (NP (NP (DT The) (ADJP (RB classically) (VBN recognized)) (NN target) (NN NSAID) (NN action)) (NP (NP (CD two) (NNS isoforms) (NP (NP (NN cyclooxygenase)) (PRN (-LRB- -LRB-) (NP (NN COX)) (-RRB- -RRB-))) (NN gene)) (, ,) (NP (JJ responsible) (NN prostaglandin) (NN production))))) |ET| |BS|6:G05.360.340.024.340 238:D12.776.800 796:D27.505.696.663.850.014.040.500 1119:D08.811.600.720.500 1501:D08.811.600.720 1502:D10.251.355.255.550|ES| 2:1 9:1 10:1 14:1 19:1 160:1 691:1 821:1 933:1 2013:1 2084:1 2132:1 2677:1 3180:1 3181:1 3237:1 4499:1 5528:1
8 	|BT| (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NP (NN TS) (NN copy) (NN number) (NN patient) (POS 's)) (NN tumor)) (VP (MD may) (VP (VBG dominating) (PP (JJ variable) (S (VP (VBG affecting) (NP (NN 5FU) (NN responsiveness))))))))))) |ET| |BS|8:C04 50:M01.643 154:Z01.058.266.887 560:D03.383.742.698.875.404|ES| 7:1 19:1 120:1 461:1 491:1 509:1 646:1 691:1 793:1 796:1 963:1 2530:1 3864:1 5493:1 5529:1 5530:1
8 	|BT| (S (NP (NP (DT The) (JJ dysplastic) (NN epithelium) (NN K-rasVal12)) (CC x) (NP (NN TAgWt) (NN mouse))) (VP (VBP develop) (NP (NN neoplasm)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 62:A10.272|ES| 19:1 52:1 173:1 648:1 691:1 1523:1 5406:1 5407:1 5531:1 5532:1
8 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
8 	|BT| (NP (NP (NP (DT The) (JJ H-ras) (NN codon) (CD 61) (NN mutation) (NN frequency) (JJ tetrachloroethylene-induced) (NN tumor)) (NP (NP (ADJP (RB significantly) (JJR lower) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (JJ combined) (NN control)) (NP (RB also) (CD two) (NN chemical))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 179:D01.248.497.300.459.700 194:G05.355.044.250.750 335:D13.444.735.544.355 1236:D02.455.526.439.880|ES| 5:1 7:1 10:1 14:1 19:1 34:1 117:1 124:1 164:1 289:1 369:1 691:1 933:1 1119:1 1247:1 2124:1 4338:1 5475:1 5533:1 5534:1
8 	|BT| (NP (NP (DT The) (JJ K-rasVal12-augmented) (NN apoptosis) (JJ unrelated) (NN dysplasia)) (: ;) (S (NP (VBN enhanced) (NN apoptosis)) (ADVP (RB also)) (VP (VBD observed) (SBAR (S (NP (NN cycling) (JJ nondysplastic) (NNS enterocytes)) (VP (VBP produce) (NP (NN K-rasVal12) (NN TAg) (JJ COOH-terminal) (NN truncation)))))))) |ET| |BS|39:G04.299.139.160 1475:A03.556.124.369.290|ES| 5:1 19:1 89:1 203:1 217:1 261:1 385:1 691:1 1565:1 5362:1 5406:1 5508:1 5535:1 5536:1 5537:1 5538:1 5539:1 5540:1
8 	|BT| (S (NP (DT The) (NN mutation) (NN spectrum) (JJ H-ras) (NN codon)) (NP (CD 61) (NN mutation)) (VP (VBD showed) (NP (NP (JJ significant) (NN decrease) (NN AAA) (NN increase) (NN CTA) (NN mutation) (JJ dichloroacetic) (NN acid)) (: -) (S (NP (JJ trichloroethylene-induced) (NN tumor)) (VP (VBN compared) (NP (JJ combined) (NN control))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 179:D01.248.497.300.459.700 335:D13.444.735.544.355 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939|ES| 7:1 19:1 34:1 40:1 50:1 132:1 135:1 164:1 289:1 295:1 691:1 1119:1 2249:1 4273:1 4336:1 5475:1 5533:1 5541:1 5542:1 5543:1
8 	|BT| (S (NP (NP (DT The) (NN result) (NN show) (NN PhIP)) (NP (NP (ADJP (RB extremely) (JJ toxic)) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-)) (NP (NN mouse)) (, ,))) (ADVP (RB even)) (VP (VBZ dos) (NP (RB 10-fold) (JJR lower) (VBN tolerated) (JJ wild-type) (NN C57BL/6) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 593:B01.050.050.199.520.520.420|ES| 2:1 8:1 10:1 14:1 19:1 45:1 52:1 101:1 117:1 429:1 691:1 1533:1 2192:1 2641:1 2653:1 5416:1 5544:1 5545:1 5546:1 5547:1
8 	|BT| (S (NP (EX There)) (ADVP (RB also)) (NP (NP (JJR higher) (NN incidence) (NN K-ras) (NN activation)) (PRN (-LRB- -LRB-) (NP (CD 13) (NN %)) (-RRB- -RRB-))) (NP (JJ tetrachloroethylene-induced) (NN tumor)) (VP (ADVP (RB chemically)) (VBN induced) (NP (NN control) (NN tumor)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 434:E05.318.308.985.525.375 1236:D02.455.526.439.880|ES| 5:1 7:1 10:1 14:1 19:1 170:1 225:1 289:1 369:1 412:1 1121:1 1511:1 1532:1 2581:1 3217:1 4338:1
8 	|BT| (S (NP (NP (DT These) (NN animal)) (NP (VP (VP (VBN reduced)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (JJR <) (CD 0.05))) (-RRB- -RRB-))) (NP (JJ colonic) (NN RFC1) (NN mRNA)))) (VP (VBD exhibited) (NP (JJ 2-fold) (NN reduction) (NN plasma) (NN S-adenosylmethionine/S-adenosylhomocysteine)))) |ET| |BS|19:B01.050 46:A03.556.124.526.356 111:D13.444.735.544 175:J01.897.280.500.269 232:D02.886.030.676.180 657:A12.207.152.693|ES| 10:1 14:1 19:1 46:1 311:1 312:1 325:1 370:1 452:1 609:1 677:1 792:1 2400:1 3549:1 3849:1 5266:1 5267:1
8 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NP (NN exposure) (JJ dichloroacetic) (NN acid)) (, ,) (NP (NN trichloroethylene) (NN tetrachloroethylene))) (VP (VBZ provides) (S (NP (JJ selective) (NN growth) (NN advantage)) (ADVP (RB spontaneously)) (VP (VBG occurring) (NP (NP (NN mutation) (NN codon) (CD 61) (NNS H-ras)) (, ,) (NP (NN time)) (, ,) (NP (NP (JJ responsible) (JJ small) (NN number) (JJ unique) (JJ molecular) (NN lesion)) (VP (JJ suggestive) (NP (CC either) (NP (JJ random) (JJ genotoxic) (NN mode) (NN action) (JJ non-specific) (NN result) (JJ secondary) (NN DNA) (NN damage)))))))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 45:G07.700.320.249 113:C04.697.650 179:D01.248.497.300.459.700 322:G01.910 335:D13.444.735.544.355 526:G05.355.180 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939 1236:D02.455.526.439.880 1503:E05.318.780.700|ES| 2:1 19:1 34:1 39:1 101:1 102:1 161:1 646:1 666:1 750:1 792:1 796:1 815:1 927:1 1081:1 1119:1 1131:1 1275:1 1469:1 1506:1 1737:1 1749:1 1848:1 1953:1 2013:1 2132:1 3329:1 4273:1 4419:1 5475:1 5476:1 5477:1 5533:1 5548:1 5549:1 5550:1 5551:1 5552:1
8 	|BT| (S (NP (DT These)) (VP (VBP result) (, ,) (NP (NP (ADVP (RB together)) (NP (NNP National) (NNP Toxicology) (NNP Program) (NN study)) (VP (VBG showing) (NP (NN evidence) (NN cytotoxicity) (NN genotoxicity) (NN oxazepam)))) (, ,) (S (VP (VBP suggest) (SBAR (S (NP (NN oxazepam)) (ADVP (RB preferentially)) (VP (VBZ promotes) (NP (NN cell) (VBG activating) (NN lesion) (NN ra)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 13:D01.339.387 41:A11 946:D27.888.569.213 1265:H01.158.891 1329:D03.438.079.080.070.663|ES| 2:1 19:1 38:1 94:1 101:1 131:1 298:1 792:1 796:1 1115:1 1131:1 1538:1 1958:1 2201:1 3317:1 3336:1 4491:1 4492:1 4493:1 4741:1 4819:1
8 	|BT| (S (NP (NP (NP (NNP Thymidylate) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN TS)) (-RRB- -RRB-))) (JJ important) (NN target) (NN 5-fluorouracil) (-LRB- -LRB-) (NN 5FU) (-RRB- -RRB-) (: -)) (VP (VBN based) (NP (NN therapy)))) |ET| |BS|52:E02 333:D01.045 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862|ES| 10:1 14:1 19:1 66:1 130:1 160:1 509:1 902:1 2307:1 2895:1 3081:1 5493:1
8 	|BT| (S (NP (NNS Tumors)) (VP (VBD isolated) (SBAR (S (NP (NP (NNS trout)) (VP (VBN treated) (NP (NP (NN DHEA)) (ADVP (RB alone))))) (VP (VBD contained) (NP (NP (NP (NN mutation) (NN Ki-ras)) (, ,) (NP (ADVP (RB primarily)) (NN codon) (CD 12) (-LRB- -LSB-) (CD 1) (-RRB- -RSB-) (NN G))) (: --) (NP (NP (JJR >) (DT A) (NN transition)) (, ,) (S (VP (VBG providing) (ADVP (JJ first)) (SBAR (S (NP (JJ suggestive) (NN evidence) (NN DHEA)) (VP (MD could) (NP (JJ genotoxic) (NN carcinogen)))))))))))))) |ET| |BS|8:C04 18:G05.365.590 52:E02 279:D27.888.569.100 335:D13.444.735.544.355 740:D04.808.054.079.429.625 1504:B01.050.150.900.493.817.750.825|ES| 2:1 19:1 34:1 38:1 53:1 69:1 98:1 241:1 552:1 816:1 908:1 1099:1 1119:1 1120:1 1373:1 1378:1 1466:1 1653:1 1970:1 2123:1 2125:1 2633:1 3025:1 3329:1 3720:1 4880:1 5549:1 5553:1 5554:1
8 	|BT| (S (NP (NN UDCA)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NP (NN Cox-2) (NN protein) (NN mRNA) (NN level)) (NP (NN tumor) (JJ normal) (NP (NN Ras)) (NN activity))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 7:D12.776 8:C04 111:D13.444.735.544 122:C14.280.383 737:D04.808.105.225.272.962|ES| 4:1 7:1 19:1 62:1 118:1 124:1 249:1 325:1 365:1 399:1 1775:1 2631:1
8 	|BT| (S (S (S (VP (VBG Using) (NP (JJ genetic) (NN engineering)))) (, ,) (NP (VBN deleted) (NP (NP (JJ short) (JJ tandem) (NN repeat)) (PRN (-LRB- -LRB-) (NP (CD two) (NN repeat)) (-RRB- -RRB-))) (NN allele)) (VP (VBD retained) (S (NP (JJ long) (PRN (-LRB- -LRB-) (NP (CD three) (NN repeat)) (-RRB- -RRB-)) (NN allele)) (VP (VBP produce) (NP (JJ artificial) (NN LOH) (NN TS) (NN gene))))) (: ;)) (S (NN TS) (-LRB- -LRB-) (NP (CC +) (: /) (: -) (-RRB- -RRB-) (NN line)) (VP (VBD reduced) (NP (NP (NN TS) (NN protein) (NN expression) (JJ hypersensitive) (NN 5FU) (NN 5-fluoro-2)) ('' ') (: -) (ADVP (FW deoxyuridine) (FW vitro))) (NP (VBN compared) (JJ syngeneic) (NN control) (NN line))))) |ET| |BS|7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 77:G05.360.340.024.340.030 154:Z01.058.266.887 290:G05.365.590.029.530 394:G02.111.570.080.708.800.500 560:D03.383.742.698.875.404 1505:G05.360.340.024.340.465 1506:E05.393.420|ES| 2:1 4:1 9:1 10:1 14:1 19:1 44:1 50:1 115:1 216:1 217:1 230:1 264:1 289:1 452:1 482:1 509:1 812:1 864:1 933:1 1001:1 1004:1 1565:1 1577:1 1719:1 2325:1 5493:1 5555:1 5556:1 5557:1 5558:1 5559:1 5560:1 5561:1
8 	|BT| (S (NP (PRP We)) (VP (VBD analyzed) (SBAR (S (NP (NP (NN matrilysin) (NN expression) (JJ benign) (JJ intestinal) (NP (NN tumor) (NN mouse) (JJ heterozygous) (NN ApcMin) (NN allele))) (PRN (-LRB- -LRB-) (NP (NN Min)) (: /) (NP (CC +)) (-RRB- -RRB-))) (VP (VBD found) (SBAR (S (NP (NN mRNA)) (VP (VBD induced) (NP (NP (NP (NN majority)) (PRN (-LRB- -LRB-) (NP (CD 88) (NN %)) (-RRB- -RRB-))) (NN adenoma)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 47:A03.556.124 77:G05.360.340.024.340.030 111:D13.444.735.544 157:G05.380.383 381:C04 937:D08.811.277.656.300.480.525.700.250|ES| 7:1 10:1 14:1 19:1 37:1 42:1 52:1 109:1 115:1 198:1 230:1 325:1 369:1 412:1 705:1 786:1 843:1 1168:1 1194:1 1288:1 3289:1 5562:1
8 	|BT| (S (NP (PRP We)) (VP (VBD explored) (NP (JJ tumor-promoting) (NN change) (JJ gestational) (JJ arsenic) (NN exposure) (NN focus) (NN Ha-ras) (NN mutation) (NN gene) (NN expression) (NN change)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 155:G05.355.310 216:Z01.107.084.900.425 1158:D01.268.513.249 1266:G08.686.785.760.769|ES| 9:1 19:1 34:1 115:1 200:1 499:1 747:1 843:1 1431:1 1953:1 3776:1 3976:1 4106:1
8 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (S (NP (NN miR-122)) (VP (VBD suppressed) (NP (NP (JJ insulin-like) (NN growth) (NN factor) (CD 1) (NN receptor) (-LRB- -LRB-) (NN IGF-1R) (-RRB- -RRB-) (NN translation)) (VP (VBD sustained) (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (NN activity))))))))) |ET| |BS|145:G02.111.087.675.871 518:D08.811.913.696.620.682.725.400.185 809:L01.178.682.920|ES| 10:1 14:1 19:1 66:1 92:1 98:1 102:1 185:1 186:1 307:1 399:1 473:1 843:1 1175:1 1789:1 1847:1 1972:1 2093:1 3652:1 3653:1 5563:1
9 	|BT| (NP (NP (NN OBJECTIVE)) (: :) (NP (NP (PRP We)) (VP (VBD aimed) (NP (NN test) (IN whether) (NP (NP (NN association) (JJ colorectal) (NN polyp) (NN intake) (NN calcium)) (, ,) (NP (NN magnesium)) (, ,) (NP (NP (NN Thr1482Ile) (NN polymorphism) (NN TRPM7) (NN gene)) (VP (VBN modified) (NP (NN Ca)))) (: :)) (NN Mg) (NN intake))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 307:G05.365.795 386:F02.463.425.069 415:F01.658.500 444:C23.300.825 1026:Z01.252.474.651 1507:A08.186.211.464.405 1508:D01.268.552.437 1509:D01.268.552.100 1510:D01.146.315|ES| 2:1 9:1 17:1 19:1 104:1 221:1 647:1 843:1 844:1 1060:1 1298:1 1417:1 1418:1 2335:1 2563:1 5564:1 5565:1 5566:1 5567:1 5568:1 5569:1
9 	|BT| (S (ADVP (RB Altogether)) (, ,) (VP (VBP result) (SBAR (S (NP (NN show) (NN identification) (JJ BET-dependent) (NN gene)) (VP (VBZ provides) (NP (NN guidance) (NN choice) (NN drug) (NN combination) (NN cancer) (NN treatment))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 374:F01.393.446 1511:F02.463.785.373.346 1512:F01.145.722.408 1513:D26.310|ES| 2:1 9:1 18:1 19:1 101:1 191:1 429:1 530:1 546:1 815:1 3469:1 5570:1 5571:1 5572:1 5573:1
9 	|BT| (S (NP (NNS Analyses) (NN xenograft)) (VP (VBD showed) (SBAR (S (NP (NP (JJ similar) (NN cell) (NN culture) (NN finding)) (, ,) (NP (NN silibinin) (NN decrease) (NN proliferation) (NN expression) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (NP (NN c-Myc)) (, ,) (NP (NN CDK8)))) (VP (VBZ induces) (NP (NN apoptosis)) (ADVP (FW vivo))))))) |ET| |BS|23:D12.776.091.249 39:G04.299.139.160 92:E04.936.764 93:A01.941.875 215:D12.644.360.262.150.100 1514:E01.370.225.500.223|ES| 2:1 19:1 60:1 89:1 94:1 115:1 132:1 214:1 265:1 295:1 299:1 332:1 378:1 743:1 744:1 824:1 927:1 2635:1 3098:1 5574:1 5575:1
9 	|BT| (FRAG (PP (IN Because) (NP (NP (NN combination) (JJ anti-EGFR) (NN 5-fluorouracil) (-LRB- -LRB-) (NP (NN 5-FU) (-RRB- -RRB-) (: -)) (VP (VBN based) (NP (NN chemotherapy) (JJ promising) (NN treatment)))) (, ,) (SBAR (S (NP (VBN analyzed) (NN effect) (NN K-Ras) (NN mutation) (NN patient)) (VP (VBD received) (NP (JJ exclusive) (NN 5-FU) (NN therapy)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 50:M01.643 52:E02 151:E02.319 333:D01.045 560:D03.383.742.698.875.404|ES| 2:1 10:1 13:1 14:1 19:1 34:1 75:1 120:1 130:1 495:1 530:1 546:1 549:1 1168:1 1517:1 1862:1 2307:1 2308:1 2895:1 4339:1 5576:1
9 	|BT| (S (S (NP (DT Both) (NNP Tyr) (-LRB- -LRB-) (CD 705) (-RRB- -RRB-) (NN phosphorylation) (NN binding) (NN STAT3) (NN MICA) (NN promoter)) (VP (VBD reduced) (NP (NN GSK3) (NN inhibitor)))) (: ;) (S (NP (NP (NN addition)) (, ,) (NP (NP (NN overexpression)) (NP (ADJP (RB constitutively) (JJ active)) (NN form) (NN STAT3)))) (ADVP (RB significantly)) (VP (VBZ inhibits) (NP (NNP MICA) (NN upregulation))))) |ET| |BS|82:D12.644.360.024.342.300 122:C14.280.383 189:V02.460 249:G05.355.315.800 339:G02.111.087.880 519:D05.500.117.875 634:D12.125.072.050.875 972:G02.111.087.677 1206:D08.811.682.690.708.125.500|ES| 2:1 10:1 14:1 19:1 83:1 124:1 152:1 196:1 197:1 217:1 251:1 380:1 452:1 468:1 615:1 630:1 1126:1 1487:1 3426:1 4232:1 4678:1 5577:1 5578:1 5579:1
9 	|BT| (SINV (PP (IN By) (NP (NN sequencing) (NN Apc) (NN Ctnnb1) (NN gene))) (, ,) (VBD found) (S (S (NP (JJ PhIP-induced) (JJ small) (JJ intestinal) (NN tumor) (JJ obese) (NN mouse)) (VP (VBD carried) (NP (JJ single) (JJ heterozygous) (NN mutation) (NN Apc)) (PP (IN By) (NP (JJ bisulfite-sequencing) (NN CpG) (NN island) (NN Apc))))) (, ,) (VP (VBD found) (NP (NP (NN DNA) (NN hypermethylation) (NN CpG) (NN cluster) (JJ located) (NN transcription) (NN initiation) (NN site)) (, ,) (SBAR (S (ADVP (JJ likely)) (VP (VBD caused) (NP (NN inactivation) (JJ wild-type) (NN Apc) (NN allele))))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 8:C04 18:G05.365.590 23:D12.776.091.249 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 38:Z01.058.290.120.180 40:Z01.542.248.700 77:G05.360.340.024.340.030 157:G05.380.383 195:G02.111.570.080.380.160 198:D13.444.308 218:A03.556.124.684 247:G01.374.676.530 765:B01.050.150.900.649.865.635.505.500.550.530 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 1515:G05.360.340.024.340.137.750.840 1516:G02.111.570.080.380.160|ES| 2:1 7:1 8:1 9:1 19:1 34:1 37:1 52:1 109:1 230:1 280:1 487:1 637:1 662:1 663:1 664:1 666:1 750:1 786:1 1003:1 1314:1 1328:1 1839:1 1868:1 2205:1 2468:1 2506:1 2846:1 4032:1 4435:1 5580:1 5581:1 5582:1
9 	|BT| (S (NNS Changes) (NP (JJ circadian) (NN cycle) (NN gene)) (: -) (S (NP (RB primarily) (NP (NN transcription) (NN factor)) (: -)) (VP (VBD showed) (SBAR (S (NP (ADJP (NP (JJ strong) (JJ concentration-related) (NN response)) (JJR higher)) (NN concentration)) (-LRB- -LRB-) (S (NP (NP (NN Arntl)) (, ,) (NP (NN Npas2)) (, ,) (NP (NN Clock))) (VP (VBD down-regulated))) (: ;) (PRN (NP (NP (NN Cry2)) (, ,) (NP (NN Wee1)) (, ,) (NP (NN Bhlhe40)) (, ,) (NP (NN Per3)) (, ,) (NP (NN Nr1d1)) (, ,) (NP (NN Nr1d2) (NN Dbp))) (-RRB- -RRB-) (S (VP (VBD up-regulated) (NP (JJ similar) (NN directionality) (NN tissue)))))))))) |ET| |BS|98:A10 142:I01.880.604 150:Z01.542.248.960 166:D12.776.930 351:A17.360 776:G01.910.645 905:F02.830.104.214|ES| 2:1 9:1 10:1 14:1 19:1 132:1 170:1 185:1 217:1 272:1 332:1 487:1 494:1 601:1 1283:1 1301:1 1970:1 2691:1 3189:1 3578:1 5337:1 5583:1 5584:1 5585:1 5586:1 5587:1 5588:1 5589:1 5590:1 5591:1 5592:1 5593:1 5594:1 5595:1
9 	|BT| (S (NP (JJ Chemopreventive) (NN activity) (NN plant) (NN flavonoid) (NN isorhamnetin) (JJ colorectal) (NN cancer)) (VP (VBN mediated) (NP (JJ oncogenic) (NN Src) (NN beta-catenin)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 279:D27.888.569.100 328:B01.650 534:D03.383.663.283.266.450|ES| 17:1 18:1 19:1 60:1 399:1 437:1 953:1 1098:1 1886:1 3673:1 3674:1 3972:1
9 	|BT| (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (JJ potential) (JJ novel) (JJ epigenetic) (NN mechanism)) (VP (VBZ underlies) (SBAR (S (NP (NP (JJ chemopreventive) (NN effect) (NN ASA)) (, ,) (NP (NN mechanism)) (VP (VBZ attenuates) (NP (NNP CAC) (JJ AOM/DSS-induced) (NN CF-1) (NN mouse)) (PP (IN via) (NP (NN inhibition) (NNS HDACs) (NN modification) (NN H3K27ac) (NN mark))))) (VP (VBP suppress) (NP (NP (NN iNOS)) (, ,) (NP (NN TNF-alpha)) (NP (NN IL-6)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 132:D02.172.080 201:D12.644.276.374.465.224 259:D12.776.395.240.150.500 624:D27.505.696.706.018 670:D02.455.426.559.389.657.410.595.176 671:G05.355.315.203 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1008:D08.811.277.087.520 1114:D08.811.277.352.827.070.250|ES| 2:1 19:1 52:1 67:1 75:1 101:1 103:1 162:1 596:1 796:1 827:1 891:1 1603:1 1872:1 1946:1 2374:1 2423:1 2441:1 2451:1 2775:1 3066:1 3148:1 4755:1 5596:1 5597:1 5598:1 5599:1 5600:1
9 	|BT| (S (ADVP (RB Consistently)) (, ,) (VP (VBD found) (SBAR (S (NP (NN simvastatin)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN p21) (NN p27) (NN expression) (NN tumor) (NN section)) (VP (VBG reducing) (NP (NP (NN Skp2) (NN expression)) (VP (VBG inducing) (NP (NN AMPK) (NN activation) (NN STAT3) (NN suppression) (NN tumor) (NN tissue))))))))))) |ET| |BS|8:C04 82:D12.644.360.024.342.300 98:A10 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900|ES| 2:1 5:1 7:1 19:1 37:1 47:1 115:1 225:1 251:1 272:1 1124:1 1135:1 1785:1 1864:1 2453:1 2679:1 3331:1 4686:1 4691:1 4692:1
9 	|BT| (S (NP (NN CpG) (NN island) (NN methylation) (NN expression) (NN ALX4)) (VP (VP (VBD evaluated) (NP (NP (JJ methylation-specific) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN PCR)) (-RRB- -RRB-)))) (, ,) (NP (NP (JJ bisulfite) (JJ genomic) (NN sequencing)) (, ,) (NP (JJ reverse-transcription) (NN PCR) (NN Western) (NN blotting))))) |ET| |BS|36:G02.111.087.029.538 195:G02.111.570.080.380.160 225:E05.337 256:E05.196.401.143 268:H01.158.273.180.350 269:G05.360.340 272:E05.393.620.500.725 448:E05.393.620.500|ES| 2:1 10:1 14:1 19:1 81:1 115:1 394:1 662:1 663:1 768:1 780:1 872:1 875:1 910:1 941:1 4584:1 5580:1 5601:1 5602:1 5603:1 5604:1
9 	|BT| (S (NP (NN Demethylation) (NN experiment)) (VP (VBD confirmed) (NP (NP (NN loss) (NN ALX4) (NN expression)) (VP (VBN regulated) (NP (NN CpG) (NN island) (NN hypermethylation)))))) |ET| |BS|142:I01.880.604 195:G02.111.570.080.380.160|ES| 19:1 32:1 115:1 662:1 663:1 664:1 938:1 1664:1 2632:1 5601:1 5605:1
9 	|BT| (S (NP (JJ DEN-induced) (NN rat)) (VP (VBD exhibited) (NP (NP (VBN increased) (NN gene) (NN expression) (NN NF-kappaB)) (, ,) (NP (NN COX-2)) (, ,) (NP (NN CYP2E1)) (, ,) (NP (NN VEGF)) (, ,) (NP (NN Bcl-2)) (, ,) (NP (NN PI3K/AKT/mTOR))) (S (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NN gene) (NN expression) (NN p53)) (, ,) (NP (NN Bax)) (, ,) (NP (NN caspase-9) (NN caspase-3))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 54:G05.360.340.024.340.375.500.791.150 155:G05.355.310 175:J01.897.280.500.269 210:D12.776.260.600 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 342:D12.644.360.075.718.400 378:D08.811.913.696.620.682.700.755 906:D08.811.277.656.262.500.126.350.300 1218:D08.244.453.300 1290:D08.811.913.696.620.500 1349:D08.811.277.656.262.500.126.550.900|ES| 2:1 9:1 12:1 19:1 47:1 76:1 115:1 124:1 158:1 202:1 609:1 714:1 849:1 2066:1 2735:1 4270:1 4630:1 4807:1 4808:1 5606:1
9 	|BT| (NP (NP (NP (NN Dependence) (NNS diaminothiazoles)) (, ,) (NP (NN compound)) (VP (VBD gained) (NP (NP (NP (NP (NN importance)) (ADJP (RB recently) (JJ due))) (JJ anticancer) (JJ anti) (JJ angiogenic) (NN activity)) (, ,) (NP (NP (VBN tested) (NN cancer) (NN model)) (VP (VBG varying) (NP (NN p53) (NN Ras/Raf) (JJ mutational) (NN status)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 18:G05.365.590 1517:F01.752.330|ES| 2:1 12:1 18:1 19:1 72:1 399:1 416:1 772:1 1244:1 1660:1 1880:1 2433:1 2851:1 2988:1 3790:1 5470:1 5607:1 5608:1 5609:1 5610:1 5611:1
9 	|BT| (FRAG (NP (NP (NP (NP (RB Early) (NN detection)) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LRB-) (JJ 4,5-b) (-RRB- -RRB-) (NN pyridine) (-LRB- -LRB-) (NN PhIP) (-RRB- -RRB-) (: -)) (VBN induced) (NN mutation)) (PP (IN within) (NP (NN Apc) (NN gene) (NN rat) (NN colon))))) |ET| |BS|18:G05.365.590 21:G05.360.340.024.340.375.249.050 46:A03.556.124.526.356 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 494:E01.390 744:D03.383.725|ES| 9:1 10:1 14:1 19:1 34:1 113:1 280:1 409:1 849:1 1023:1 2122:1 2638:1 2639:1 2640:1 2641:1 4135:1
9 	|BT| (S (NP (NNP Emodin)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NN growth) (NN lung) (NN xenograft) (NN tumor) (NN Sp1)) (, ,) (NP (VBD increased) (NN IGFBP1) (NN PPARgamma) (NN protein) (NN expression)) (ADVP (FW In) (FW vivo))))) |ET| |BS|7:D12.776 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 122:C14.280.383 237:C04.588.894.797.520 719:D12.776.826.239.588 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 4:1 5:1 7:1 19:1 47:1 102:1 115:1 244:1 265:1 328:1 365:1 378:1 2588:1 4856:1 5612:1 5613:1
9 	|BT| (S (NP (JJ Enzymatic) (NN assay)) (VP (VBD showed) (SBAR (S (NP (NN genistein) (NN 5Aza-C) (VBD decreased) (NN DNA) (NN Methyltransferase) (, ,) (JJ methyl-CpG-binding) (NN domain) (CD 2) (NN activity)) (VP (VBD increased) (NP (NN HAT) (NN activity))))))) |ET| |BS|746:D08.811.150.240 944:D03.383.663.283.266.450.400.375 1519:E05.196.427|ES| 2:1 19:1 47:1 132:1 148:1 202:1 310:1 399:1 666:1 1173:1 3314:1 4828:1 5614:1 5615:1 5616:1 5617:1
9 	|BT| (S (S (NP (NN ERK)) (VP (VBD mediated) (SBAR (S (NP (NN upregulation) (NN death) (NN receptor) (CD 5)) (VP (VBZ overcomes) (SBAR (S (NP (NN lack) (NN p53) (NN functionality) (NN diaminothiazole) (NN DAT1)) (VP (VBD induced) (NP (NN apoptosis) (NN colon) (NN cancer) (NN model)))))))))) (: :) (S (NP (NN efficiency) (NN DAT1) (NN Ras-Raf)) (NP (VBN mutated) (NN cell)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 249:G05.355.315.800 252:F02.784.692.351 339:G02.111.087.880|ES| 12:1 18:1 19:1 72:1 89:1 94:1 104:1 113:1 186:1 229:1 411:1 412:1 437:1 578:1 868:1 1126:1 3239:1 3910:1 3915:1 3937:1 5047:1 5618:1 5619:1
9 	|BT| (S (NP (NN Evodiamine)) (ADVP (RB also)) (VP (VBD suppressed) (SBAR (S (NP (NN STAT3) (NN DNA) (NN binding) (NN activity)) (VP (VBD down-regulated) (NP (NP (NN expression) (JJ STAT3-mediated) (NN gene)) (VP (VBG leading) (NP (NN suppression) (NN proliferation)))))))) (, ,) (NP (NN induction) (NN cell) (NN apoptosis) (NN cell) (NN cycle) (NN arrest))) |ET| |BS|39:G04.299.139.160 41:A11 82:D12.644.360.024.342.300 86:D01.268.556.435 142:I01.880.604 155:G05.355.310 198:D13.444.308 351:A17.360 773:G04.299.134.109|ES| 2:1 5:1 9:1 19:1 89:1 94:1 115:1 251:1 299:1 307:1 399:1 601:1 602:1 639:1 666:1 736:1 1283:1 1487:1 2453:1 5620:1 5621:1
9 	|BT| (S (NP (NN Exposure) (NN alternol)) (VP (VBD resulted) (NP (NP (NP (NP (JJ excessive) (JJ reactive) (NN oxygen) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))) (NP (NP (NN generation) (NN Jun) (JJ amino-terminal) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN JNK)) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-))) (NN p38) (NN activation))))) |ET| |BS|116:D08.811.913.696.620.682.700.567.249.750 469:D08.811.913.696 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567 506:F01.829.263.315 636:D01.339.431|ES| 2:1 10:1 14:1 19:1 225:1 470:1 594:1 1666:1 1707:1 1787:1 2353:1 2354:1 2355:1 2356:1 3982:1 4276:1 4594:1 4812:1 5622:1 5623:1 5624:1 5625:1
9 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN RNAseq) (NN analysis)) (VP (VBD indicated) (SBAR (S (NP (NP (NN p53) (NN signaling) (NN Lgr5)) (CC +) (NP (NN stem) (NN cell) (NN mouse))) (VP (VBN exposed) (NP (NNP AOM)) (ADVP (RB uniquely)) (VP (VBD upregulated) (PP (VBG following) (NP (JJ n-3) (NN PUFA) (CC +) (NN curcumin) (NN cotreatment))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 132:D02.172.080 308:A11.872 618:E02.186 692:D02.455.326.146.485.222.222 1308:D10.212.302.380.410|ES| 2:1 12:1 19:1 52:1 94:1 125:1 195:1 661:1 1106:1 1541:1 1929:1 1994:1 2652:1 3102:1 3510:1 4673:1 5626:1 5627:1 5628:1 5629:1
9 	|BT| (S (NP (NP (JJ Forced) (NN inhibition) (NN p38) (NN MAPK) (NN activity) (JJ specific) (JJ pharmacological) (NN inhibitor) (NN SB203580) (NN p38) (NN MAPK) (NN gene) (NN knockdown)) (VP (VBG using) (NP (NP (JJ small-interfering) (NN RNA)) (PRN (-LRB- -LRB-) (NP (NN siRNA)) (-RRB- -RRB-))))) (VP (VBD counteracted) (NP (NN effect) (NN FL3)) (, ,) (S (VP (VBG demonstrating) (NP (NP (JJ chemopreventive) (NN action) (JJ related) (NN growth) (NN inhibition)) (NP (NP (JJ p38-dependent) (JJ caspase-3-dependent) (NN induction) (NN apoptosis)) (NP (JJ Oct4-expressing) (NNS CSCs)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 45:G07.700.320.249 117:D13.150.650.700 400:E05.393.335.500 556:C11.768.175 906:D08.811.277.656.262.500.126.350.300 1059:H01.158.703 1520:D08.811.913.696.620.682.700.567.843 1521:D12.776.260.655.500.300|ES| 2:1 9:1 10:1 14:1 19:1 75:1 89:1 102:1 103:1 350:1 351:1 380:1 399:1 419:1 464:1 515:1 527:1 540:1 736:1 809:1 1666:1 1946:1 1966:1 2013:1 3707:1 4883:1 5630:1 5631:1 5632:1 5633:1 5634:1 5635:1 5636:1
9 	|BT| (SBAR (IN From) (S (NP (NN list)) (ADVP (RB differentially)) (VP (VBD expressed) (NP (NP (NP (NN gene) (VBN prioritized) (NN transcriptome) (NN profiling)) (, ,) (NP (NN Mmp7)) (, ,) (NP (NN S100a9)) (, ,) (NP (NP (NN Nppb) (NN Aldh1a3)) (NP (VBN defined) (NN key) (NN oncogene) (NN candidate)))) (VP (VBD downregulated) (NP (NN colon) (NN tumor) (NNP TA) (NN treatment))))))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 51:C04.588.274.476.411.307.180 52:E02 937:D08.811.277.656.300.480.525.700.250 1286:E05.393.332|ES| 2:1 6:1 7:1 9:1 19:1 24:1 113:1 159:1 426:1 546:1 680:1 1139:1 1243:1 2148:1 5637:1 5638:1 5639:1 5640:1 5641:1 5642:1 5643:1 5644:1 5645:1
9 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN exposure) (NN cell) (NN Japonicone) (NN A)) (VP (VBD caused) (NP (NN inactivation) (NN TNF-alpha-TAK1-IKK-NF-kappaB) (NN axis) (NN inhibition) (JJ TNF-alpha-stimulated) (NN NF-kappaB) (NN activity) (JJ nuclear) (NN translocation)))) (, ,) (VP (VBD followed) (NP (NP (NN downregulation) (NN NF-kappaB) (NN target) (NN gene)) (VP (VBN involved) (NP (NP (NP (NN cell) (NN apoptosis)) (PRN (-LRB- -LRB-) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN XIAP)) (, ,) (NP (NN TRAF2))) (-RRB- -RRB-))) (NP (NP (NN cell) (NN cycle) (NN growth)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D)) (, ,) (NP (NN c-Myc)) (-RRB- -RRB-)))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 41:A11 43:F01.145.544 45:G07.700.320.249 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 210:D12.776.260.600 353:G04.299.134 463:C23.550.210.870 579:A02.835.232.834.151.383 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1046:D12.644.360.262.150 1522:D12.644.360.024.500.750|ES| 2:1 9:1 10:1 14:1 19:1 69:1 89:1 94:1 102:1 103:1 158:1 160:1 334:1 399:1 595:1 601:1 714:1 743:1 774:1 824:1 1256:1 1314:1 1618:1 1953:1 2089:1 2506:1 2592:1 3130:1 4814:1 5646:1 5647:1 5648:1 5649:1 5650:1
9 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN hesperidin) (NN administration)) (VP (VBD restored) (SBAR (S (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (NN activity) (NN turn)) (VP (VBD prevented) (NP (NN accumulation) (NNS oncoproteins)) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-jun) (NN c-myc)))))))) |ET| |BS|23:D12.776.091.249 584:D12.776.624.664 1477:D03.383.663.283.266.450.252.500|ES| 2:1 10:1 14:1 19:1 60:1 66:1 92:1 334:1 399:1 455:1 1944:1 1972:1 2120:1 2575:1 3652:1 3653:1 4893:1 5356:1 5651:1 5652:1 5653:1
9 	|BT| (S (ADVP (RB Furthermore)) (, ,) (PP (IN upon) (NP (NN TQ) (NN treatment))) (, ,) (NP (NN beta-catenin)) (VP (VP (VBD retained) (SBAR (S (NP (NN membrane) (NN c-myc)) (VP (VBD decreased) (NP (NN nucleus)))))) (, ,) (S (VP (VBN associated) (NP (VBN reduced) (NN cell) (NN proliferation) (NN villus)))))) |ET| |BS|23:D12.776.091.249 52:E02 183:G04.299.233.750 1104:A11.284.430.106 1344:A10.615|ES| 2:1 19:1 60:1 94:1 169:1 202:1 299:1 334:1 452:1 455:1 460:1 546:1 1577:1 1951:1 3622:1 3873:1 5654:1
9 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (NP (NN report) (ADJP (RB inversely) (JJ related)) (NN expression) (NN miR-137) (NN CAR) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell)) (, ,) (SBAR (WHADVP (WRB wherein)) (S (NP (NN miR-137)) (VP (VBD downregulated) (NP (JJ resistant) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100|ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1
9 	|BT| (S (ADVP (RB However)) (, ,) (VP (VBZ remains) (ADJP (JJ unknown) (SBAR (IN whether) (S (NP (NP (NN neoplasia)) (VP (VBN associated) (NP (NNP Pten) (ADJP (NN loss) (JJ dependent)) (JJ upstream) (NN IGF) (NN ligand) (NN supply) (FW vivo))))))))) |ET| |BS|8:C04 170:D27.720.470.480 581:D12.644.276.937|ES| 2:1 19:1 32:1 169:1 221:1 321:1 378:1 433:1 442:1 640:1 1835:1 1996:1 2182:1 3728:1 5655:1 5656:1
9 	|BT| (S (ADVP (RB However)) (, ,) (NP (JJ combined) (NN effect) (NN mda-7) (NN sulindac)) (ADVP (RB previously)) (VP (VBN tested))) |ET| |BS|251:D02.455.426.559.847.486.875|ES| 2:1 19:1 75:1 164:1 433:1 869:1 1527:1 2988:1 5657:1
9 	|BT| (S (NP (NN Hypermethylation) (NN miR-137) (NN promoter) (JJ negative) (NN regulation) (NN miR-137) (NN CAR)) (VP (VP (VBP contribute) (NP (NP (NN part)) (VP (VBD reduced) (NP (NN miR-137) (NN expression))))) (VP (VBD increased) (NP (NN CAR) (NN MDR1) (NN expression) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 142:I01.880.604|ES| 19:1 47:1 83:1 94:1 115:1 420:1 421:1 423:1 424:1 438:1 448:1 449:1 450:1 451:1 452:1 453:1
9 	|BT| (NP (NP (NP (NN Immunohistochemistry) (NN beta-catenin)) (, ,) (NP (NN c-myc)) (, ,) (NP (NP (NN Ki-67) (NN TUNEL-staining)) (VP (VBN performed) (VP (VBP investigate) (NP (NP (NN TQ) (POS 's)) (NN effect) (JJ major) (JJ colorectal) (NN cancer) (NN pathway))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475|ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1
9 	|BT| (FRAG (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN ERK5) (NN inhibition)) (VP (VBD increased) (NP (NP (NN response) (NN HCT116) (NN p53)) (CC +) (NP (: /) (CC +) (NN cell) (NN 5-FU)))) (, ,)) (VBD failed) (VB sensitize) (NP (NP (NN HCT116) (NN p53)) (: -)) (: /) (: -) (NP (NP (NN cell) (JJ cytotoxic) (NN effect) (JJ chemotherapeutic) (NN agent)) (, ,) (VP (VBG suggesting) (NP (NP (JJ p53-dependent) (NN axis)) (VP (VBG mediating) (NP (NN 5-FU) (NN sensitization))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 560:D03.383.742.698.875.404 579:A02.835.232.834.151.383 660:D27.505.954.248 717:A11.251.210.190.380|ES| 2:1 19:1 47:1 75:1 88:1 94:1 103:1 244:1 468:1 494:1 566:1 728:1 761:1 1009:1 1457:1 1505:1 1762:1 2089:1 2308:1 5471:1 5658:1 5659:1 5660:1 5661:1
9 	|BT| (S (PP (IN In) (NP (JJ intestinal) (JJ epithelial) (NN cell) (NN IEC-6) (NN colon) (NN cancer) (NN cell) (NN HCT-116))) (, ,) (NP (NN IL-6) (NN expression) (NN signaling)) (VP (VBN assessed) (NP (NP (NNP SHH) (NN inhibitor) (NN level) (JJ inflammatory) (NN mediator)) (, ,) (NP (NP (NN proliferation)) (, ,) (NP (NN apoptosis)) (, ,) (NP (NN tumorsphere) (NN formation))) (, ,) (NP (NP (NN tumorigenesis)) (VP (ADVP (RB also)) (VBN measured)))))) |ET| |BS|20:G03.495 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 47:A03.556.124 69:G02.111.087.800 75:A11.436 201:D12.644.276.374.465.224 228:E05.978 1523:E01.370.225.625.400 1524:E04.936.225.687.500|ES| 2:1 5:1 18:1 19:1 43:1 78:1 89:1 94:1 109:1 113:1 115:1 127:1 195:1 244:1 249:1 299:1 380:1 738:1 789:1 2430:1 3148:1 3351:1 3823:1 5662:1 5663:1 5664:1
9 	|BT| (S (S (PP (IN In) (NP (NN mouse) (NN model))) (, ,) (NP (NN SHH) (NN inhibitor)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NN tumor) (NN incidence) (NN multiplicity)) (, ,) (VP (VBD decreased) (NP (NP (NN expression) (NN IL-6)) (, ,) (NP (NN TNF-alpha)) (, ,) (NP (NN COX-2)) (, ,) (NP (NN STAT3)) (, ,) (NP (NN NF-kappaB)) (, ,)))) (VP (ADVP (RB significantly)) (VBD induced) (NP (NN apoptosis)))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 210:D12.776.260.600 434:E05.318.308.985.525.375 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 7:1 19:1 52:1 72:1 76:1 89:1 115:1 124:1 202:1 244:1 251:1 380:1 412:1 452:1 714:1 1511:1 2775:1 2863:1 3148:1 5664:1
9 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD demonstrated) (NP (NP (JJ simvastatin-induced) (NN G0/G1) (NN arrest)) (VP (VBG inducing) (NP (NN p21) (NN p27) (NN accumulation) (NN HepG2) (NN Hep3B) (NN cell)))))) |ET| |BS|41:A11 754:D02.455.426.559.847.638.400.900|ES| 2:1 19:1 94:1 131:1 244:1 602:1 1124:1 1135:1 1175:1 1864:1 2120:1 3481:1 4502:1 5665:1 5666:1
9 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD identified) (NP (NP (JJ novel) (NN CEBPD) (NN activator)) (, ,) (NP (NP (LST (LS 1) (: -)) (-LRB- -LRB-) (JJ 2-hydroxy-5-methylphenyl) (-RRB- -RRB-) (NN -3-phenyl-1,3-propanedione)) (PRN (-LRB- -LRB-) (NP (NN HMDB)) (-RRB- -RRB-)))))) |ET| |BS|259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 131:1 244:1 623:1 861:1 891:1 5667:1 5668:1 5669:1 5670:1 5671:1
9 	|BT| (S (ADVP (FW In) (FW vitro)) (, ,) (VP (NP (NN TQ)) (VP (VBD activated) (NP (NN GSK-3beta))) (, ,) (VP (VBD induced) (NP (JJ membranous) (NN localization) (NN beta-catenin))) (VP (VBD reduced) (NP (JJ nuclear) (NN c-myc) (NN expression))))) |ET| |BS|23:D12.776.091.249 1344:A10.615|ES| 2:1 19:1 60:1 115:1 163:1 216:1 244:1 412:1 452:1 455:1 460:1 1256:1 2484:1 3653:1 5672:1
9 	|BT| (S (NP (NN Iso-3)) (VP (VBD induced) (NP (NP (NP (NN growth) (NN arrest) (NN cancer) (NN cell) (NN G0/G1)) (JJ concomitant)) (SBAR (S (NP (VBN increased) (NN p21) (NN p27) (NN expression)) (VP (VBD reduced) (NP (NP (NN cyclin) (NN E1)) (, ,) (NP (NN PCNA) (NN c-myc) (NN level))))))))) |ET| |BS|41:A11 45:G07.700.320.249 768:D12.776.660.740|ES| 2:1 18:1 19:1 47:1 94:1 102:1 115:1 249:1 412:1 452:1 455:1 602:1 743:1 1124:1 1135:1 1580:1 1681:1 2698:1 5666:1 5673:1
9 	|BT| (S (NP (NN Isorhamnetin)) (VP (VBD inhibited) (NP (JJ AOM/DSS-induced) (JJ oncogenic) (NN c-Src) (NN activation) (NN beta-catenin) (JJ nuclear) (NN translocation)) (, ,) (S (VP (VBG promoting) (NP (NP (NP (NN expression) (JJ C-terminal) (NN Src) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN CSK)) (-RRB- -RRB-))) (, ,) (NP (JJ negative) (NN regulator) (NN Src) (NN family) (NN tyrosine) (NN kinase))))))) |ET| |BS|23:D12.776.091.249 122:C14.280.383 132:D02.172.080 279:D27.888.569.100 463:C23.550.210.870 1525:D08.811.913.696.620.682.725.800|ES| 2:1 10:1 14:1 19:1 60:1 97:1 115:1 225:1 235:1 365:1 449:1 470:1 881:1 953:1 1256:1 1618:1 2341:1 3674:1 3676:1 5018:1 5596:1 5674:1 5675:1
9 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
9 	|BT| (NP (NP (NP (JJ K-ras) (NN mutation)) (NP (VBN assessed) (NN PCR) (NN mRNA) (NN egfr) (NN ligand) (JJ quantitative) (JJ real-time) (NN PCR)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 111:D13.444.735.544 170:D27.720.470.480 257:E05.393.620.500.706 346:E05.393.620.500.706 448:E05.393.620.500|ES| 19:1 34:1 325:1 817:1 874:1 875:1 1121:1 1835:1 3823:1 5676:1
9 	|BT| (NP (NP (NNS METHODS)) (: :) (S (NP (NP (NP (JJ Stable) (JJ transient) (NN RNA) (NN silencing) (NN GAST) (NN gene)) (VP (VBD induced) (NP (NP (JJ human) (NN tumor) (NN cell) (NN mouse)) (VP (VBG carrying) (NP (NP (JJ heterozygous) (NN Apc) (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN APCDelta14)) (-RRB- -RRB-))))))) (, ,) (VP (VBP overexpress) (NP (NN progastrin)))) (VP (VBD amidated) (NP (JJ glycine-extended) (NN gastrin))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 42:G05.355.315.203.374 55:B01.050.150.900.649.801.400.112.400.400 156:G05.355.315.203.374.790 157:G05.380.383 168:E05.581 199:D06.472.317.413 200:D06.472.317.413 247:G01.374.676.530 1003:D12.125.481 1422:D13.444.735|ES| 2:1 7:1 9:1 10:1 14:1 19:1 34:1 36:1 52:1 94:1 100:1 104:1 280:1 412:1 515:1 565:1 671:1 676:1 745:1 786:1 850:1 2513:1 5677:1 5678:1 5679:1 5680:1 5681:1
9 	|BT| (S (S (NP (NNP Mevalonate)) (VP (VBD decreased) (NP (NP (JJ simvastatin-induced) (NN AMPK) (NN activation)) (VP (VBD rescued) (NP (JJ phospho-STAT3) (NN Skp2) (NN expression) (NN HCC) (NN cell)))))) (, ,) (VP (VBD resulted) (NP (NN prevention) (NN G0/G1) (NN arrest) (NN inhibition) (NN p21) (NN p27) (NN accumulation)))) |ET| |BS|41:A11 43:F01.145.544 82:D12.644.360.024.342.300 104:C04.557.470.200.025.255 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900 1526:D02.241.511.579|ES| 2:1 19:1 94:1 103:1 115:1 202:1 225:1 441:1 594:1 602:1 1124:1 1135:1 1474:1 1785:1 2120:1 4692:1 5665:1 5666:1 5682:1 5683:1 5684:1
9 	|BT| (S (S (NP (NN miR-137) (NN overexpression)) (VP (VBD resulted) (NP (NP (NN downregulation) (NN CAR) (NN protein) (NN mRNA)) (PRN (-LRB- -LRB-) (PP (IN via) (NP (NN mRNA) (NN degradation))) (-RRB- -RRB-))))) (: ;) (S (VBN sensitized) (NP (JJ doxorubicin-resistant) (NN cell) (NN doxorubicin)) (-LRB- -LRB-) (VP (VP (VBN shown) (S (VP (VBN reduced) (NP (NN proliferation))))) (, ,) (VP (VBD increased) (NP (NN apoptosis))) (VP (VBD increased) (NP (JJ G2-phase) (NN cell) (NN cycle) (NN arrest))) (SINV (-RRB- -RRB-) (NP (VBD reduced) (FW vivo) (NN growth) (NN rate) (NN neuroblastoma) (NN xenograft)))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 45:G07.700.320.249 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 111:D13.444.735.544 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 177:G04.299.134.109.500 178:G02.111.780|ES| 2:1 4:1 10:1 14:1 19:1 41:1 47:1 89:1 94:1 102:1 152:1 217:1 237:1 265:1 299:1 325:1 378:1 420:1 421:1 423:1 424:1 452:1 594:1 595:1 596:1 597:1 598:1 599:1 600:1 601:1 602:1
9 	|BT| (S (NP (NN miR-137)) (VP (VBZ regulates) (SBAR (S (NP (JJ constitutive) (NN androstane) (NN receptor)) (VP (VBZ modulates) (NP (NN doxorubicin) (NN sensitivity) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320|ES| 19:1 94:1 186:1 420:1 422:1 423:1 424:1 599:1 603:1 604:1 605:1 606:1 607:1
9 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN SHP-1) (NN gene) (JJ small) (NN interference) (NN RNA)) (VP (VBD abolished) (SBAR (S (NP (NN ability) (NN evodiamine)) (VP (VBP inhibit) (NP (NP (NP (JJ IL-6-induced) (NN STAT3)) (PRN (-LRB- -LRB-) (NP (NP (NN Tyr)) (PRN (-LRB- -LRB-) (NP (CD 705)) (-RRB- -RRB-))) (-RRB- -RRB-))) (NN activation))))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 82:D12.644.360.024.342.300 122:C14.280.383 201:D12.644.276.374.465.224 385:F02.784.629.131 634:D12.125.072.050.875 1206:D08.811.682.690.708.125.500 1422:D13.444.735|ES| 2:1 9:1 10:1 14:1 19:1 103:1 225:1 251:1 515:1 516:1 622:1 682:1 750:1 1300:1 1370:1 4232:1 4582:1 5577:1 5685:1 5686:1
9 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN miR-221) (NN reduction)) (VP (VBD resulted) (NP (NN alteration) (JJ EMT-associated) (NN gene) (NN E-cadherin) (NN vimentin)) (NP (RB well) (ADJP (RB significantly) (JJR slower)) (NN xenograft) (NN tumor) (NN growth) (JJ nude) (NN mouse)))) |ET| |BS|8:C04 18:G05.365.590 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 820:D12.776.395.550.200.200 1527:D05.750.078.593.900|ES| 2:1 7:1 9:1 19:1 52:1 102:1 124:1 140:1 265:1 266:1 370:1 594:1 622:1 787:1 951:1 2267:1 5687:1 5688:1 5689:1
9 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN silencing) (NN IGFBP1) (NN gene)) (VP (VBD blunted) (NP (JJ emodin-induced) (NN inhibition) (NN cell) (NN growth) (NN cell) (NN cycle) (NN arrest)))) |ET| |BS|41:A11 42:G05.355.315.203.374 43:F01.145.544 45:G07.700.320.249 773:G04.299.134.109 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 9:1 19:1 94:1 100:1 102:1 103:1 601:1 602:1 622:1 5201:1 5613:1 5690:1
9 	|BT| (S (NP (JJ Natural) (JJ lipophilic) (NNS polyphenols)) (VP (JJ long-chain) (NP (NP (JJ polyunsaturated) (JJ fatty) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNS PUFAs)) (-RRB- -RRB-))) (SBAR (S (ADVP (RB generally)) (VBP suppress) (NN Wnt) (: -) (NN NF-kappaB) (: -) (-LRB- -LRB-) (NP (JJ nuclear) (NN factor-kappa) (NN light-chain) (NN enhancer)) (VP (VP (VBD activated) (NP (NN B-cell))) (-RRB- -RRB-) (NP (JJ related) (NN pathway))))))) |ET| |BS|41:A11 56:D02.455.426.559.389.657.715 210:D12.776.260.600 425:G01.358.500.505.650 1528:D10.251.355|ES| 10:1 14:1 19:1 154:1 163:1 383:1 419:1 972:1 1256:1 1275:1 2070:1 2199:1 2441:1 2780:1 3364:1 4674:1 5265:1 5691:1 5692:1 5693:1 5694:1 5695:1 5696:1
9 	|BT| (NP (NP (NP (JJ Oral) (NN administration)) (SBAR (S (NP (NP (CD 50) (NN mg/kg) (NN CX-5461)) (VP (VBD induced) (NP (NN TP53) (NN expression) (NN activity)))) (VP (VBD reduced) (NP (NP (NP (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN MKI67)) (-RRB- -RRB-))) (NN invasion)) (PRN (-LRB- -LRB-) (NP (NN loss) (JJ ductal) (NN actin)) (-RRB- -RRB-))) (NN Hi-MYC) (NN tumor))))) (, ,) (NP (NP (NN PTEN-null)) (PRN (-LRB- -LRB-) (JJ low) (NN MYC) (-RRB- -RRB-))) (NP (NN tumor)))) |ET| |BS|8:C04 739:E02.319.267.100 1025:Z01.252.100.450 1026:Z01.252.474.651 1529:C16.131.831.512.400.410 1530:Z01.107.567.875.580.375 1531:D12.776.660.625.500 1532:D05.750.078.730.250|ES| 2:1 7:1 10:1 14:1 19:1 32:1 115:1 299:1 368:1 399:1 412:1 452:1 472:1 531:1 620:1 1018:1 2575:1 3585:1 5071:1 5697:1 5698:1 5699:1 5700:1 5701:1 5702:1
9 	|BT| (S (NP (NP (JJ Other) (NN study)) (, ,) (ADVP (RB therefore)) (, ,)) (VP (VBN performed) (NP (NN SW480) (NN cell) (NN silibinin)) (SBAR (S (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (JJ beta-catenin-dependent) (NN T-cell) (NN factor-4)) (PRN (-LRB- -LRB-) (NP (NN TCF-4)) (-RRB- -RRB-))) (JJ transcriptional) (NN activity) (NN protein) (NN expression) (NN beta-catenin) (NN target) (NN gene) (NN c-Myc) (NN cyclin) (NN D1))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 41:A11 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100 1533:D12.776.260.730.875 1534:C10.597.350.400 1535:D12.776.220.145|ES| 2:1 4:1 9:1 10:1 14:1 19:1 60:1 94:1 115:1 124:1 131:1 160:1 202:1 218:1 399:1 458:1 559:1 743:1 744:1 824:1 2635:1 3096:1 5210:1 5375:1 5703:1 5704:1 5705:1
9 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (NP (NP (JJ chemoprotective) (NN effect) (NN isorhamnetin) (NN colon) (NN cancer)) (VP (VBN linked) (NP (NP (JJ anti-inflammatory) (NN activity) (NN inhibition) (JJ oncogenic) (NN Src) (NN activity) (JJ consequential) (NN loss)) (VP (JJ nuclear) (NP (NP (NN beta-catenin)) (, ,) (NP (NN activity)) (NP (JJ dependent) (NN CSK) (NN expression))))))))) |ET| |BS|23:D12.776.091.249 43:F01.145.544 279:D27.888.569.100 429:N04.761.559.590.900 430:E05.581.249 686:D27.505.954.158|ES| 2:1 18:1 19:1 32:1 60:1 75:1 103:1 113:1 115:1 321:1 399:1 658:1 796:1 953:1 1256:1 1363:1 1477:1 2795:1 3672:1 3673:1 3674:1 3675:1 3676:1
9 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (S (NP (NNP ADN) (NN time)) (NP (ADVP (RB dependently)) (NP (VBD stimulated) (NP (NN WIF1) (NN gene) (NN protein) (NN expression) (NN MDA-MB-231) (NN cell))))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 41:A11 322:G01.910 759:D02.092.471.683.152.660 760:Z01.107.084.900.600 763:Z01.542.248.540|ES| 4:1 9:1 19:1 94:1 101:1 115:1 132:1 658:1 1081:1 2689:1 4854:1 5706:1 5707:1 5708:1
9 	|BT| (S (NP (NN Overexpression) (NN PinX1)) (VP (VBD resulted) (SBAR (S (NP (NP (NN G1/S) (NN phase) (NN arrest) (NN cell) (NN growth/proliferation) (NN inhibition)) (, ,) (NP (NN silencing) (NN PinX1))) (VP (VBD led) (NP (NP (NN acceleration) (NN G1/S) (NN transition)) (, ,) (NP (NP (NN cell) (NN growth/proliferation) (NN promotion)) (VP (VBG inhibiting/enhancing) (NP (NN telomerase) (NN activity)) (PP (IN via) (NP (NN p16/cyclin) (NN D1) (NN pathway))))))))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 86:D01.268.556.435 122:C14.280.383 183:G04.299.233.750 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500 215:D12.644.360.262.150.100 1404:G02.111.087.222.880 1536:D08.811.913.696.445.308.300.750.750 1537:G01.595.560.107|ES| 2:1 19:1 94:1 100:1 103:1 383:1 399:1 552:1 594:1 596:1 602:1 668:1 744:1 2228:1 2337:1 2529:1 4430:1 5709:1 5710:1 5711:1 5712:1 5713:1 5714:1
9 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
9 	|BT| (S (NP (NN PinX1)) (VP (VBZ suppresses) (NP (NN bladder) (JJ urothelial) (NN carcinoma) (NN cell) (NN proliferation)) (PP (IN via) (NP (NN inhibition) (NN telomerase) (NN activity) (NN p16/cyclin) (NN D1) (NN pathway))))) |ET| |BS|43:F01.145.544 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500 215:D12.644.360.262.150.100 317:C04.557.470.200.430 933:A05.810.890 1536:D08.811.913.696.445.308.300.750.750|ES| 19:1 94:1 103:1 299:1 304:1 383:1 399:1 564:1 596:1 686:1 744:1 1078:1 5709:1 5713:1 5714:1
9 	|BT| (NP (NP (NN RNA) (NN interference) (JJ knockdown) (NN DRD2) (JJ pancreatic) (NN tumor) (NN cell)) (NP (NP (VBN reduced) (NN growth) (NN xenograft) (NN tumor) (NN mouse)) (, ,) (NP (NN administration) (NN DRD2) (NN inhibitor) (NN haloperidol) (NN mouse) (JJ orthotopic) (NN xenograft) (NN tumor))) (NP (VBD reduced) (JJ final) (NN tumor) (NN size) (NN metastasis))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 113:C04.697.650 156:G05.355.315.203.374.790 362:D12.776.543.750.069.300.400.500 1069:D02.522.352.506 1538:C04.588.274.761|ES| 2:1 7:1 19:1 52:1 94:1 102:1 265:1 380:1 452:1 464:1 467:1 515:1 516:1 806:1 1210:1 2142:1 2575:1 3744:1 3884:1 5283:1
9 	|BT| (NP (NP (ADVP (RB Similarly)) (, ,) (NP (NP (NN HT-29) (NN colon) (NN cancer) (NN cell)) (, ,) (NP (NN isorhamnetin)) (VP (VP (VBD inhibited) (S (NP (JJ oncogenic) (NN Src) (NN activity) (NN beta-catenin) (JJ nuclear) (NN translocation)) (VP (VBG inducing) (NP (NN expression) (NN csk))))) (, ,) (NP (VBN verified) (NN RNA) (NN interference) (NN knockdown) (NN csk)))))) |ET| |BS|23:D12.776.091.249 122:C14.280.383 156:G05.355.315.203.374.790 279:D27.888.569.100 463:C23.550.210.870 792:A11.251.210.190.475|ES| 2:1 18:1 19:1 60:1 94:1 113:1 115:1 365:1 399:1 464:1 515:1 516:1 726:1 953:1 1256:1 1618:1 1864:1 2782:1 3673:1 3674:1 5715:1 5716:1
9 	|BT| (S (NP (NNP Simvastatin)) (VP (VP (VBD decreased) (NP (NN Skp2) (NN expression) (JJ transcriptional) (NN level))) (, ,) (VP (VBD resulted) (S (NP (NN p27) (NN accumulation)) (VP (VBG preventing) (NP (JJ proteasomal) (NN degradation))))) (, ,) (NP (NN effect) (VP (VBD mediated) (NP (NP (NP (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NN inhibition)))))) |ET| |BS|43:F01.145.544 209:G02.111.087.847 250:E07.305.812 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900 1281:D05.500.562.500 1293:G03.495|ES| 2:1 10:1 14:1 19:1 75:1 103:1 115:1 202:1 249:1 251:1 437:1 487:1 559:1 594:1 597:1 859:1 860:1 861:1 862:1 1124:1 1785:1 1937:1 2120:1 2961:1 4556:1
9 	|BT| (NP (NP (ADVP (RB Specifically)) (, ,) (NP (NP (NN coregulation) (NN kinase) (NN p38) (NN ERK)) (, ,) (NP (NN translation) (NN regulator)) (NP (NN 4EBP1)) (, ,) (NP (NP (NN transcription) (NN factor) (NN CREB)) (VP (VBG proliferating) (NP (JJ normal) (NN colon) (NN cell)))) (NP (VBD lost) (NN CRC))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 46:A03.556.124.526.356 145:G02.111.087.675.871 166:D12.776.930 469:D08.811.913.696 809:L01.178.682.920|ES| 2:1 19:1 94:1 113:1 118:1 185:1 235:1 245:1 470:1 473:1 487:1 1666:1 2042:1 2865:1 5047:1 5717:1 5718:1 5719:1 5720:1
9 	|BT| (S (NP (NN Sulindac)) (VP (VBZ enhances) (NP (NP (JJ adenoviral) (NN vector)) (VP (VBG expressing) (NP (NP (NN mda-7)) (: /) (NP (NP (JJ IL-24-mediated) (NN apoptosis)) (NP (JJ human) (NN lung) (NN cancer)))))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 123:G05.360.337 251:D02.455.426.559.847.486.875 542:B04.280.030|ES| 18:1 19:1 36:1 89:1 328:1 362:1 810:1 1356:1 2965:1 5721:1 5722:1
9 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN administration) (NN SHH) (NN inhibitor)) (VP (MD could) (NP (NP (JJ effective) (NN strategy) (VBP prevent) (JJ colitis-induced) (JJ colorectal) (NN carcinogenesis)) (, ,) (VP (ADVP (RB mainly)) (VBG targeting) (NP (NP (NN IL-6)) (NN signaling))) (, ,) (NP (VBG ablating) (NNS CSCs)) (, ,) (S (VP (VBG suppressing) (NP (NP (JJ oncogenic) (NN inflammation)) (, ,) (S (VP (VBG achieving) (NP (NN chemoquiescence)) (ADVP (RB ultimately))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 53:C06.405.205.265 69:G02.111.087.800 201:D12.644.276.374.465.224 279:D27.888.569.100 525:C23.550.470 556:C11.768.175|ES| 2:1 17:1 19:1 195:1 207:1 380:1 616:1 733:1 793:1 796:1 908:1 953:1 1114:1 1537:1 1538:1 1639:1 1966:1 2250:1 2575:1 3064:1 3148:1 5488:1 5664:1 5723:1 5724:1 5725:1 5726:1 5727:1
9 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)) (, ,) (S (VP (VBG finding) (NP (JJ demonstrative) (NN existence) (JJ novel) (NN pathway) (NN simvastatin)))))) (VP (VBZ induces) (NP (NP (NN G0/G1) (NN arrest)) (VP (VBG upregulating) (NP (NP (NN p21) (NN p27) (VBG activating) (NNP AMPK)) (VP (VBG inhibiting) (NP (NN STAT3-Skp2) (NN axis)))) (, ,) (ADVP (RB respectively)))))) |ET| |BS|82:D12.644.360.024.342.300 122:C14.280.383 259:D12.776.395.240.150.500 507:D12.776.157.743 579:A02.835.232.834.151.383 754:D02.455.426.559.847.638.400.900|ES| 2:1 19:1 214:1 371:1 383:1 602:1 880:1 891:1 927:1 1124:1 1135:1 1537:1 1538:1 1958:1 2089:1 2679:1 3140:1 4692:1 5666:1 5728:1 5729:1 5730:1
9 	|BT| (NP (NP (NP (DT The) (NN colon) (JJ epithelial) (NN cell) (NN line)) (NP (NP (NN NCM460) (NN colon) (NN cancer) (NN cell) (NN line) (NN HT-29) (NN Caco-2)) (VP (VBN exposed) (NP (NN P) (NN anaerobius) (NN control) (NNS bacteria))))) (: ;) (NP (NN cell) (VBN analyzed) (NP (NN immunoblot)) (, ,) (NP (NN proliferation)) (, ,) (NP (NP (JJ bacterial) (NN attachment) (NN analysis)) (VBN compared) (NN gene) (NN expression) (VBG profiling) (NN study)))) |ET| |BS|41:A11 46:A03.556.124.526.356 94:A11.251.210 718:E05.588.570 792:A11.251.210.190.475 802:E05.478.566.320 1286:E05.393.332 1539:B03|ES| 2:1 9:1 18:1 19:1 50:1 94:1 113:1 115:1 127:1 131:1 217:1 264:1 289:1 299:1 311:1 661:1 691:1 1168:1 2148:1 2782:1 2830:1 3102:1 3355:1 5731:1 5732:1 5733:1 5734:1 5735:1
9 	|BT| (S (NP (DT The) (JJ limonoid-treated) (NN xenograft)) (VP (VP (VBD exhibited) (NP (NP (JJ significant) (NN downregulation) (NN expression) (NN protein)) (VP (VBN involved) (NP (NP (NP (NN tumor) (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN c-IAP-1)) (, ,) (NP (NN survivin)) (, ,) (NP (NN Mcl-1))) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN c-Myc) (NN cyclin) (NN D1)) (-RRB- -RRB-))) (, ,) (NP (NN invasion) (-LRB- -LRB-) (NN MMP-9) (, ,) (NN ICAM-1))))) (-RRB- -RRB-)) (, ,) (NP (NP (NN metastasis) (-LRB- -LRB-) (NN CXCR4) (-RRB- -RRB-)) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-)))))) |ET| |BS|7:D12.776 8:C04 52:E02 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 108:G04.299.316 113:C04.697.650 175:J01.897.280.500.269 215:D12.644.360.262.150.100 586:D08.811.277.656.300.480.205.360 1204:D12.776.543.750.100.160.500.400 1325:D12.776.395.550.200.450|ES| 2:1 4:1 7:1 10:1 14:1 19:1 94:1 115:1 135:1 158:1 265:1 274:1 299:1 595:1 609:1 620:1 691:1 743:1 744:1 774:1 806:1 824:1 2066:1 2158:1 2229:1 2502:1 4220:1 4732:1 4814:1 5312:1 5736:1 5737:1
9 	|BT| (S (PP (DT These) (S (VP (VBG finding) (S (VP (VBP demonstrate) (NP (NN miR-137) (JJ crucial) (NN regulator) (NN cancer) (NN response) (NN doxorubicin) (NN treatment))))))) (, ,) (VP (VBP identify) (S (NP (NN miR-137) (ADJP (RB highly) (JJ promising)) (NN target)) (VP (VB reduce) (NP (JJ CAR-driven) (NN doxorubicin) (NN resistance)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 66:F01.658.293 136:D02.455.426.559.847.562.050.200.175 139:J01.937.500.100|ES| 2:1 18:1 19:1 160:1 235:1 420:1 494:1 502:1 546:1 599:1 626:1 792:1 832:1 927:1 1094:1 1517:1 2361:1 3690:1 5738:1
9 	|BT| (S (ADVP (RB Thus)) (, ,) (S (VP (VBG signaling) (NP (NN cascade) (, ,) (JJ positive) (ADJP (NN feedback) (NN loop) (JJ cooperative)) (NN interplay) (NN transcription) (JJ factors-induced) (NN expression) (NN IGFBP1) (NN gene)))) (VP (VBP contribute) (NP (JJ overall) (NN response) (NN emodin)))) |ET| |BS|69:G02.111.087.800 83:L01.143.283.425 155:G05.355.310 166:D12.776.930 696:V02.270.500 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 9:1 19:1 115:1 195:1 233:1 247:1 248:1 450:1 487:1 494:1 1691:1 2510:1 5274:1 5613:1 5739:1 5740:1 5741:1 5742:1
9 	|BT| (S (S (VP (TO To) (VP (VB confirm) (S (VP (VBG sensitizing) (NP (NN effect) (NN NAC1) (NN inhibition) (NN cytotoxicity) (NN cisplatin))))))) (VP (VBD attributed) (NP (NN suppression) (NN autophagy)) (, ,) (NP (NP (VBN assessed) (NN effect) (NN autophagy) (NN inhibitor) (NN 3-methyladenosine) (NN chloroquine)) (, ,) (NP (NP (NP (JJ small) (VBG interfering) (NNS RNAs)) (PRN (-LRB- -LRB-) (NP (NNS siRNAs)) (-RRB- -RRB-))) (VP (VBG targeting) (NP (NN beclin) (CD 1) (NN Atg5) (NN cytotoxicity) (NN cisplatin))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 117:D13.150.650.700 390:G04.299.139.399 498:D01.210.375 946:D27.888.569.213 961:D03.438.810.050.180|ES| 2:1 10:1 14:1 19:1 75:1 98:1 103:1 380:1 616:1 750:1 828:1 1317:1 1761:1 2137:1 2453:1 3019:1 3044:1 3317:1 3378:1 3531:1 3823:1 5743:1 5744:1 5745:1 5746:1 5747:1 5748:1
9 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (JJ similar) (NN result) (JJ cellular) (NN model)) (JJ hepatocellular) (NN colon) (NN cancer)) (, ,) (S (VP (VBG indicating) (S (NP (JJ doxorubicin-sensitizing) (NN effect) (NN miR-137) (NN tumor)) (ADJP (JJ type-specific))))))) |ET| |BS|8:C04 41:A11 136:D02.455.426.559.847.562.050.200.175|ES| 2:1 7:1 18:1 19:1 72:1 75:1 101:1 113:1 261:1 303:1 332:1 420:1 843:1 2236:1 3074:1 5749:1 5750:1
